PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ALIPERTI, G; EDMUNDOWICZ, SA; SOPER, NJ; ASHLEY, SW				ALIPERTI, G; EDMUNDOWICZ, SA; SOPER, NJ; ASHLEY, SW			COMBINED ENDOSCOPIC SPHINCTEROTOMY AND LAPAROSCOPIC CHOLECYSTECTOMY IN PATIENTS WITH CHOLEDOCHOLITHIASIS AND CHOLECYSTOLITHIASIS	ANNALS OF INTERNAL MEDICINE			English	Note							COMMON BILE-DUCT; EXPLORATION	Eighteen symptomatic patients with cholecystolithiasis and choledocholithiasis were prospectively evaluated to assess the efficacy of endoscopic sphincterotomy combined with laparoscopic cholecystectomy as definitive management of simultaneous gallbladder and bile duct stones. The endoscopic management of bile duct stones was successful in all 18 patients. Seventeen patients later had laparoscopic cholecystectomy, and one required conventional cholecystectomy (5.6%; 95% CI, 0.1% to 27.3%). Mean (+/- SE) duration of postoperative hospitalization (1.6 +/- 1.0 days), total hospital stay (5.0 +/- 3.5 days), and length of convalescence (9.3 +/- 6.6 days) were significantly reduced (P < 0.01 for each) compared with similar measures from a group of 12 consecutive patients treated with conventional cholecystectomy and bile duct exploration (8.3 +/- 4.3, 14.1 +/- 12.6, and 41.7 +/- 10.9 days, respectively). Outcomes in our patients compared favorably with those in patients described in published series of cholecystectomy and bile duct exploration. We found that endoscopic sphincterotomy combined with laparoscopic cholecystectomy is effective in the treatment of patients with simultaneous gallbladder and bile duct stones. Length of hospital stay and degree of postoperative disability were significantly reduced among our patients compared with those having standard cholecystectomy and bile duct exploration.			ALIPERTI, G (corresponding author), WASHINGTON UNIV, SCH MED, GASTROENTEROL CLIN SECT, 1 BARNES HOSP PLAZA, ST LOUIS, MO 63110 USA.			Edmundowicz, Steven/0000-0002-6541-3485				COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P94, DOI 10.1016/S0016-5107(91)70637-8; CRANLEY B, 1980, BRIT J SURG, V67, P869, DOI 10.1002/bjs.1800671210; FRAZEE RC, 1989, SURG GYNECOL OBSTET, V168, P513; NORRBY S, 1988, ACTA CHIR SCAND, V154, P113; REDDICK E J, 1989, Surgical Endoscopy, V3, P131, DOI 10.1007/BF00591357; SHERIDAN WG, 1987, BRIT J SURG, V74, P1095, DOI 10.1002/bjs.1800741208; SIVAK MV, 1989, AM J SURG, V158, P228, DOI 10.1016/0002-9610(89)90256-0; SMITH PC, IN PRESS SURGERY; SOPER NJ, 1991, SURGERY, V109, P342; VELLACOTT KD, 1979, BRIT J SURG, V66, P389, DOI 10.1002/bjs.1800660605	10	60	60	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1991	115	10					783	785		10.7326/0003-4819-115-10-783	http://dx.doi.org/10.7326/0003-4819-115-10-783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP800	1834001				2022-12-24	WOS:A1991GP80000007
J	LAAKSO, M; KESANIEMI, A; KERVINEN, K; JAUHIAINEN, M; PYORALA, K				LAAKSO, M; KESANIEMI, A; KERVINEN, K; JAUHIAINEN, M; PYORALA, K			RELATION OF CORONARY HEART-DISEASE AND APOLIPOPROTEIN-E PHENOTYPE IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; E POLYMORPHISM; APOPROTEIN-E; ARTERY DISEASE; INCREASED FREQUENCY; C-PEPTIDE; SERUM; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ASSOCIATION	Objectives - To examine the relation between coronary heart disease and the apolipoprotein E phenotypes in patients with non-insulin dependent diabetes mellitus. Design - Cross sectional study. Setting - District around Kuopio University Central Hospital, East Finland. Subjects - 138 men with non-insulin dependent diabetes and 64 men without diabetes as controls. Main outcome measure - Apolipoprotein E phenotype, electrocardiographic abnormalities, other signs of coronary heart disease. Results - The prevalences of definite myocardial infarction and ischaemic electrocardiographic changes were highest in the diabetic men with the phenotypes E4/4 or E4/3 (25% (95% confidence interval 18% to 32%) and 50% (42% to 58%) respectively), although the difference between the phenotype groups was not significant. The prevalence of angina pectoris was 69% (61% to 77%) in men with the phenotypes E4/4 or E4/3 (p = 0.005 compared with other phenotypes), 41% (33% to 49%) in men with phenotype E3/3, and 47% (39% to 55%) in those with phenotypes E2/2 or E2/3. Similarly, the simultaneous presence of angina pectoris and ischaemic electrocardiographic changes was highest in the diabetic men with the phenotypes E4/4 or E4/3 (42% v 22% in those with E3/3 and 29% in those with E2/2, E2/3; p = 0.038). Overall, the prevalence of any evidence of coronary heart disease among the diabetic subjects with the phenotypes E4/4 or E4/3 was 81%(p = 0.01 compared with other phenotypes), 58% in those with phenotype E3/3, and 53% in those with phenotypes E2/2 or E3/3. Conclusion - Apolipoprotein E phenotypes E4/4 and E4/3 modulate the risk of coronary heart disease in men with non-insulin dependent diabetes.	UNIV OULU, DEPT MED, SF-90100 OULU 10, FINLAND; NATL PUBL HLTH INST, DEPT BIOCHEM, SF-00280 HELSINKI 28, FINLAND	University of Oulu; Finland National Institute for Health & Welfare	LAAKSO, M (corresponding author), KUOPIO UNIV, CENT HOSP, DEPT MED, SF-70210 KUOPIO, FINLAND.							ASSMANN G, 1984, CLIN CHEM, V30, P641; BASU SK, 1982, J BIOL CHEM, V257, P9788; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; EHNHOLM C, 1986, J LIPID RES, V27, P227; ETO M, 1986, DIABETES, V35, P1374, DOI 10.2337/diabetes.35.12.1374; ETO M, 1987, DIABETES, V36, P1301, DOI 10.2337/diabetes.36.11.1301; ETO M, 1986, CLIN GENET, V29, P477; FRIER BM, 1977, DIABETES, V26, P369; GREGG RE, 1981, SCIENCE, V211, P584, DOI 10.1126/science.7455696; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HUI DY, 1980, J BIOL CHEM, V255, P1775; IMARI Y, 1988, METABOLISM, V37, P1134, DOI 10.1016/0026-0495(88)90189-8; JAUHIAINEN M, 1983, CLIN CHEM, V29, P1731; KESANIEMI YA, 1987, J CLIN INVEST, V80, P578, DOI 10.1172/JCI113107; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; LAAKSO M, 1985, ARTERIOSCLEROSIS, V5, P653, DOI 10.1161/01.ATV.5.6.653; LAAKSO M, 1987, AM J EPIDEMIOL, V125, P611, DOI 10.1093/oxfordjournals.aje.a114574; LAAKSO M, 1988, DIABETES CARE, V11, P449, DOI 10.2337/diacare.11.6.449; LENZEN HJ, 1986, CLIN CHEM, V32, P778; LEREN TP, 1985, CLIN GENET, V27, P458; MADSBAD S, 1979, BRIT MED J, V2, P1257, DOI 10.1136/bmj.2.6200.1257; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; PENTTILA IM, 1981, SCAND J CLIN LAB INV, V41, P353, DOI 10.3109/00365518109092057; PEPE MG, 1986, J IMMUNOL, V136, P3716; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; PYORALA K, 1985, CARDIOLOGY, V72, P35, DOI 10.1159/000173839; RIEPPONEN P, 1987, SCAND J CLIN LAB INV, V47, P739; Rose G, 1982, CARDIOVASCULAR SURVE; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SING CF, 1985, AM J HUM GENET, V37, P268; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; UTERMANN G, 1984, HUM GENET, V65, P232, DOI 10.1007/BF00286508; WANG K, 1986, ACTA ACAD MED SINICA, V8, P198; 1980, WHO TECH REP SER, P646; WHOMNC821	39	71	72	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	1991	303	6811					1159	1162		10.1136/bmj.303.6811.1159	http://dx.doi.org/10.1136/bmj.303.6811.1159			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747611	Green Published, Bronze			2022-12-24	WOS:A1991GP48800020
J	HANDEL, J; TRIPP, JH				HANDEL, J; TRIPP, JH			VITAMIN-K PROPHYLAXIS AGAINST HEMORRHAGIC-DISEASE OF THE NEWBORN IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article									POSTGRAD MED SCH,DEPT CHILD HLTH,EXETER EX2 5SQ,ENGLAND	University of Exeter								Lehmann JL, 1944, LANCET, V1, P493; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; TRIPP JH, 1987, ARCH DIS CHILD, V62, P436, DOI 10.1136/adc.62.5.436	4	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1109	1109		10.1136/bmj.303.6810.1109	http://dx.doi.org/10.1136/bmj.303.6810.1109			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747579	Green Published			2022-12-24	WOS:A1991GN20900023
J	BARRETTCONNOR, E				BARRETTCONNOR, E			POSTMENOPAUSAL ESTROGEN AND PREVENTION BIAS	ANNALS OF INTERNAL MEDICINE			English	Note						ESTROGEN REPLACEMENT THERAPY; PREVENTIVE HEALTH SERVICES; HEALTH BEHAVIOR; LIPOPROTEINS, HDL CHOLESTEROL; BIAS (EPIDEMIOLOGY)	REPLACEMENT THERAPY; BREAST-CANCER; WOMEN; RISK	A mailed health survey questionnaire was returned by 1008 of 1057 (95%) previously studied older women from Rancho Bernardo, a socioeconomiclaly upper-middle-class California community where replacement estrogen use was known to be common. Women currently using estrogen had significantly healthier behaviors and more preventive services by physicians (recent cholesterol check, rectal examination, papanicolaou smear, and mammogram) than nonusers. These differences may explain some of the benefits and risks currently attributed to hormone replacement therapy.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40207] Funding Source: Medline; NIA NIH HHS [AGO 7181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; TIKKANEN MJ, 1978, LANCET, V2, P490; 1980, NEW ENGL J MED, V303, P1038	10	347	351	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					455	456		10.7326/0003-4819-115-6-455	http://dx.doi.org/10.7326/0003-4819-115-6-455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872493				2022-12-24	WOS:A1991GE81000007
J	OGAS, J; ANDREWS, BJ; HERSKOWITZ, I				OGAS, J; ANDREWS, BJ; HERSKOWITZ, I			TRANSCRIPTIONAL ACTIVATION OF CLN1, CLN2, AND A PUTATIVE NEW G1-CYCLIN (HCS26) BY SWI4, A POSITIVE REGULATOR OF G1-SPECIFIC TRANSCRIPTION	CELL			English	Article							YEAST HO GENE; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; EXPRESSION; PROTEIN; INTERCONVERSION; SEQUENCE	SWI4 of budding yeast codes for a component of a transcription factor (cell cycle box factor, or CCBF) necessary for G1-specific expression of HO. We show that SWI4 is essential for haploid cell viability at high temperature and in a/alpha-cells at all temperatures: SWI4-deficient cells arrest as large unbudded cells. Eight high copy number plasmids were identified that allow swi4- strains to grow under nonpermissive conditions. Two carry G1 cyclin genes, CLN1 and CLN2; another carries HCS26, coding for a putative cyclin. a/alpha-swi4- mutants exhibit 3- to 20-fold reductions in the levels of CLN1, CLN2, and HCS26 transcripts. The requirement of SWI4 for transcription appears to be direct: each gene contains sites similar to the CCBF-binding site; CCBF binds to the upstream region of HCS26. We propose that SWI4 participates in a positive feedback loop by which CLN1, CLN2, and possibly HCS26 promote their own transcription in G1.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA; UNIV TORONTO, DEPT MED & MOLEC GENET, TORONTO M5S 1A8, ONTARIO, CANADA	University of California System; University of California San Francisco; University of Toronto	OGAS, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA.			Ogas, Joe/0000-0002-1332-7729	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HICKS JB, 1976, GENETICS, V83, P245; HUISMAN O, 1987, GENETICS, V116, P191; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; Sherman F., 1982, METHODS YEAST GENETI; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; VAI M, 1987, EXP CELL RES, V171, P448, DOI 10.1016/0014-4827(87)90176-5; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	34	282	284	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1015	1026		10.1016/0092-8674(91)90445-5	http://dx.doi.org/10.1016/0092-8674(91)90445-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832336				2022-12-24	WOS:A1991GE46000018
J	ANNAS, GJ				ANNAS, GJ			FETAL PROTECTION AND EMPLOYMENT DISCRIMINATION - THE JOHNSON-CONTROLS CASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1988, JUDGING MED, P53; BECKER ME, 1990, JAMA-J AM MED ASSOC, V264, P2113, DOI 10.1001/jama.264.16.2113; FUCHS VR, 1986, SCIENCE, V232, P459, DOI 10.1126/science.232.4749.459; 1987, PATIENT CHOICE MATER	4	16	16	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					740	743		10.1056/NEJM199109053251020	http://dx.doi.org/10.1056/NEJM199109053251020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD497	1870647	Green Published			2022-12-24	WOS:A1991GD49700029
J	VINER, S; SZALAI, JP; HOFFSTEIN, V				VINER, S; SZALAI, JP; HOFFSTEIN, V			ARE HISTORY AND PHYSICAL-EXAMINATION A GOOD SCREENING-TEST FOR SLEEP-APNEA	ANNALS OF INTERNAL MEDICINE			English	Article							SNORERS	Objective: To determine whether presenting clinical history, pharyngeal examination, and the overall subjective impression of the clinician could serve as a sensitive screening test for sleep apnea. Design: Blinded comparison of history and physical examination with results of nocturnal polysomnography. Setting: Sleep clinic of a tertiary referral center. Patients: A total of 410 patients referred for suspected sleep apnea syndrome. Most patients reported snoring. Measurements: All patients were asked standard questions and given an examination relevant to the diagnosis of the sleep apnea syndrome, and all had full nocturnal polysomnography. Patients with more than ten episodes of apnea or hypopnea per hour of sleep were classified as having sleep apnea. Stepwise linear logistic regression was used to develop two predictive models of sleep apnea: one based on the presence of characteristic clinical features, age, sex, and body mass index; and one based on subjective clinical impression. Results: The prevalence of sleep apnea in our patients was 46%. Only age, body mass index, male sex, and snoring were found to be predictors of sleep apnea. The logistic rule discriminated between patients with and without sleep apnea (receiver operating characteristic [ROC] area, 0.77 [95% Cl, 0.73 to 0.82]). For patients with a predicted probability of apnea of less than 20%, the clinical model had 94% sensitivity and 28% specificity. Subjective impression alone identified correctly only 52% of patients with sleep apnea and had a specificity of 70%. Conclusions: In patients with a high predicted probability of the sleep apnea syndrome, subjective impression alone or any combination of clinical features cannot serve as a reliable screening test. However, in patients with a low predicted probability of sleep apnea, the model based on clinical data was sufficiently sensitive to permit about a 30% reduction in the number of unnecessary sleep studies.	ST MICHAELS HOSP, 30 BOND ST, TORONTO M5B 1W8, ONTARIO, CANADA; SUNNYBROOK HLTH SCI CTR, DEPT RES DESIGN BIOSTAT, TORONTO M4N 3M5, ONTARIO, CANADA; CALGARY GEN HOSP, BOW VALLY CTR, CALGARY T2E 0A1, ALBERTA, CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Calgary								[Anonymous], 1989, AM REV RESPIR DIS, V139, P559; BRADLEY TD, 1986, NEW ENGL J MED, V315, P1327, DOI 10.1056/NEJM198611203152105; CARSKADON MA, 1981, J GERONTOL, V36, P420, DOI 10.1093/geronj/36.4.420; GISLASON T, 1988, J CLIN EPIDEMIOL, V41, P571, DOI 10.1016/0895-4356(88)90061-3; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HAPONIK EF, 1984, AM J MED, V77, P671, DOI 10.1016/0002-9343(84)90361-9; HOFFSTEIN V, 1988, LANCET, V2, P992; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; IXON WJ, 1988, BMDP STATISTICAL SOF, P941; JEONG DU, 1989, CLIN EXP HYPERTENS A, V11, P1301, DOI 10.3109/10641968909038171; KALES A, 1985, J CHRON DIS, V38, P419, DOI 10.1016/0021-9681(85)90137-7; KAPUNIAI LE, 1988, SLEEP, V11, P430, DOI 10.1093/sleep/11.5.430; LAVIE P, 1983, SLEEP, V6, P312, DOI 10.1093/sleep/6.4.312; RIVLIN J, 1984, AM REV RESPIR DIS, V129, P355; SWETS JA, 1989, EVALUATION DIAGNOSTI; 1990, SAS P200 SAS I INC T, P175	16	210	220	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					356	359		10.7326/0003-4819-115-5-356	http://dx.doi.org/10.7326/0003-4819-115-5-356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863025				2022-12-24	WOS:A1991GC06500004
J	SCHOLER, HR; CIESIOLKA, T; GRUSS, P				SCHOLER, HR; CIESIOLKA, T; GRUSS, P			A NEXUS BETWEEN OCT-4 AND E1A - IMPLICATIONS FOR GENE-REGULATION IN EMBRYONIC STEM-CELLS	CELL			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; EARLY MOUSE EMBRYOGENESIS; F9 TERATOCARCINOMA CELLS; OCTAMER BINDING-PROTEINS; HEAVY-CHAIN ENHANCER; REGION 1A PROTEINS; CARCINOMA-CELLS; ADENOVIRUS INFECTION; CELLULAR PROTEINS; ESCHERICHIA-COLI	Oct-4 is a transcription factor expressed in the pluripotent progenitor cells of the early mouse embryo. Additional factors are required for the distal activation of genes in differentiated cells containing ectopically expressed Oct-4. Here we show that Oct-4 and E1A are sufficient for distance-independent activation of the basal transcription machinery. The ratio of Oct-4 to E1A is critical for transcriptional activation, because higher levels of either factor are less efficient. Activation depends on a transactivation domain linked to the POU domain of Oct-4 and also on the conserved domain 3 of the 289R E1A protein. This domain is required for binding to the C-terminal part of Oct-4 including the POU domain. Our results indicate that E1A can serve as a bridging factor between Oct-4 and the basal initiation complex, and we postulate that an E1A-like factor acts as a cellular bridging factor of Oct-4 in pluripotent cells.			SCHOLER, HR (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC CELL BIOL, W-3400 GOTTINGEN, GERMANY.			Scholer, Hans/0000-0003-2643-5136				BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1990, P NATL ACAD SCI USA, V87, P5878, DOI 10.1073/pnas.87.15.5878; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GULP JS, 1988, P NATL ACAD SCI USA, V85, P6450; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KELLY F, 1982, BIOCHIM BIOPHYS ACTA, V651, P105, DOI 10.1016/0304-419X(82)90009-9; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KO JL, 1986, EMBO J, V5, P1645, DOI 10.1002/j.1460-2075.1986.tb04407.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORELLO D, 1982, NATURE, V296, P260, DOI 10.1038/296260a0; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NELSON CC, 1990, P NATL ACAD SCI USA, V87, P8041, DOI 10.1073/pnas.87.20.8041; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1984, CELL, V36, P403, DOI 10.1016/0092-8674(84)90233-2; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHOLER HR, 1991, IN PRESS TRENDS GENE; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber E., 1989, TISSUE SPECIFIC GENE, P33; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SLEIGH MJ, 1985, TRENDS GENET, V1, P17, DOI 10.1016/0168-9525(85)90009-5; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1989, ONCOGENE, V4, P707; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	77	175	176	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1991	66	2					291	304		10.1016/0092-8674(91)90619-A	http://dx.doi.org/10.1016/0092-8674(91)90619-A			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1830243	hybrid			2022-12-24	WOS:A1991FY71200010
J	ZEMEL, G; KATZEN, BT; BECKER, GJ; BENENATI, JF; SALLEE, DS				ZEMEL, G; KATZEN, BT; BECKER, GJ; BENENATI, JF; SALLEE, DS			PERCUTANEOUS TRANSJUGULAR PORTOSYSTEMIC SHUNT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC PORTACAVAL-SHUNT; ENDOSCOPIC SCLEROTHERAPY; RANDOMIZED TRIAL; VARICEAL HEMORRHAGE; PORTAL-HYPERTENSION; BLEEDING VARICES; CIRRHOSIS; DISEASE; STENTS	Objective. - To determine the effectiveness of the Palmaz balloon expandable stent for the creation of a transjugular intrahepatic portosystemic shunt. The device is designed to achieve portal decompression in patients with variceal hemorrhage secondary to portal hypertension. Design. - Transjugular intrahepatic portosystemic shunting was performed in eight patients during a 9-month period. Mean follow-up was 5 months. Patients. - All patients had cirrhosis with portal hypertension and varices. Bleeding occurred in seven patients from esophageal varices and in one patient from hemorrhoids. Main Outcome Measures. - Shunt patency and recurrent variceal hemorrhage. Results. - Shunts created from a transjugular approach between a hepatic and a portal vein (diameters of 8 to 12 mm) lowered the average portosystemic pressure gradient from 36 to 11 mm Hg. Mean postoperative hospital stay was 7.7 days. Complete variceal decompression after transjugular intrahepatic portosystemic shunt placement was identified endoscopically in all eight patients. The patient treated for hemorrhoids rebled and was treated successfully by transfemoral balloon expansion of the shunt diameter from 8 to 12 mm. All shunts were patent at 1 to 9 months (mean, 5 months) of follow-up. Conclusion. - Initial results suggest that transjugular intrahepatic portosystemic shunt is a safe and effective method of portal decompression for the treatment of variceal hemorrhage.			ZEMEL, G (corresponding author), BAPTIST HOSP MIAMI,MIAMI VASC INST,8900 N KENDALL DR,MIAMI,FL 33176, USA.							CASTANEDAZUNIGA WR, 1988, INTERVENTIONAL RADIO, P167; CELLO JP, 1987, NEW ENGL J MED, V316, P11, DOI 10.1056/NEJM198701013160103; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; COLDWELL DM, 1991, RADIOLOGY, V178, P249, DOI 10.1148/radiology.178.1.1984312; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; JOHANSEN K, 1989, AM J SURG, V157, P479, DOI 10.1016/0002-9610(89)90639-9; PALMAZ JC, 1986, AM J ROENTGENOL, V147, P1251, DOI 10.2214/ajr.147.6.1251; PALMAZ JC, 1985, AJR, V145, P820; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; REYNOLDS TB, 1981, GASTROENTEROLOGY, V80, P1005; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; RIKKERS LF, 1983, SURGERY, V94, P126; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; RUEFF B, 1976, LANCET, V1, P655; RUTHERFORD RB, 1991, CIRCULATION, V83, P6; VIALLET A, 1975, GASTROENTEROLOGY, V69, P1297; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WARREN WD, 1983, AM J SURG, V145, P8, DOI 10.1016/0002-9610(83)90159-9	20	169	186	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	1991	266	3					390	393		10.1001/jama.266.3.390	http://dx.doi.org/10.1001/jama.266.3.390			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV960	1829120				2022-12-24	WOS:A1991FV96000029
J	POUNGVARIN, N; VIRIYAVEJAKUL, A; KOMONTRI, C				POUNGVARIN, N; VIRIYAVEJAKUL, A; KOMONTRI, C			SIRIRAJ STROKE SCORE AND VALIDATION-STUDY TO DISTINGUISH SUPRATENTORIAL INTRACEREBRAL HEMORRHAGE FROM INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGE	Objectives - To develop a simple, reliable, and safe diagnostic tool for acute stroke syndromes in a setting where computerised brain scanning was not readily available and to validate its accuracy with regard to pathological types of stroke. Design - 13 clinical variables that potentially might differentiate supratentorial cerebral haemorrhage from infarction were recorded and tested by multivariate analysis in a prospective study of 174 patients with acute stroke. In developing the Siriraj stroke score stepwise discriminant analysis of the variables was followed by a linear discriminant equation to differentiate between supratentorial haemorrhage and infarction. The score obtained was validated against scores in 206 other patients with stroke, computerised brain scans being used for definitive diagnosis. Setting - Siriraj Hospital Medical School, Mahidol University, Bangkok. Subjects - Prospective study: 174 consecutive patients with acute supratentorial stroke syndrome (not subarachnoid haemorrhage) admitted to Siriraj Hospital during 1984-5; validation study: 206 patients admitted to Siriraj Hospital or another hospital for supratentorial intracerebral haemorrhage or infarction. Results - The Siriraj stroke score was developed and calculated as (2.5 x level of consciousness) + (2 x vomiting) + (2 x headache) + (0.1 x diastolic blood pressure) - (3 x atheroma markers) - 12. A score above 1 indicates supratentorial intracerebral haemorrhage, while a score below -1 indicates infarction. The score between 1 and -1 represents an equivocal result needing a computerised brain scan or probability curve to verify the diagnosis. In the validation study of the Siriraj stroke score the diagnostic sensitivities of the score for cerebral haemorrhage and cerebral infarction were 89.3% and 93.2% respectively, with an overall predictive accuracy of 90.3%. Conclusion - The Siriraj stroke score is widely accepted and applied in hospitals throughout Thailand as a simple and reliable bedside method for diagnosing acute stroke.	MAHIDOL UNIV,SIRIRAJ HOSP,FAC MED,DEPT MED,CLIN EPIDEMIOL UNIT,BANGKOK 10700,THAILAND	Mahidol University	POUNGVARIN, N (corresponding author), MAHIDOL UNIV,SIRIRAJ HOSP,FAC MED,DEPT MED,DIV NEUROL,BANGKOK 10700,THAILAND.							ALLAN CMC, 1983, Q J MED, V42, P515; ALLAN CMC, 1984, THESIS U CAMBRIDGE C; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; Kurtzke J.F., 1985, CEREBROVASCULAR SURV, P1; SANDERCOCK PAG, 1985, BRIT MED J, V291, P1675, DOI 10.1136/bmj.291.6510.1675; SANDERCOCK PAG, 1986, BRIT MED J, V292, P173; SCHAAFSMA S, 1968, J NEUROL SCI, V7, P83, DOI 10.1016/0022-510X(68)90005-1; VANARBIN M, 1981, STROKE, V12, P288; VIRIYAVEJAKUL A, 1990, CLIN NEUROPHARMACOL, V13, pS26, DOI 10.1097/00002826-199013003-00003; VIRIYAVEJAKUL A, 1976, SIRIRAJ HOSP GAZETTE, V28, P1648; VIRIYAVEJAKUL A, 1982, SIRIRAJ HOSPITAL GAZ, V34, P501	11	95	98	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1565	1567		10.1136/bmj.302.6792.1565	http://dx.doi.org/10.1136/bmj.302.6792.1565			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855041	Green Published, Bronze			2022-12-24	WOS:A1991FU54900023
J	DIRICK, L; NASMYTH, K				DIRICK, L; NASMYTH, K			POSITIVE FEEDBACK IN THE ACTIVATION OF G1 CYCLINS IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HO GENE; MATING-PHEROMONE; CELL; ARREST; SIZE	YEAST cells become committed to the mitotic cell cycle at a stage during G1 called Start 1. To enter Start, cells must grow to a critical size. They also require the CDC28 protein kinase and at least one of three G1-specific cyclins encoded by CLN1, 2, and 3 (refs 2-4). It is thought that Start is triggered by the accumulation of G1 cyclins that bind to the CDC28 kinase and activate it. So what determines the accumulation of G1 cyclins? For CLN1 and CLN2, transcriptional activation could be involved because their RNAs appear transiently during the cell cycle as cells undergo Start 5. Here we report that the appearance of CLN1 and CLN2 RNAs depends on an active CDC28 kinase and is stimulated by CLN3 activity. We propose that CDC28 kinase activity due to CLN1 and CLN2 proteins arises through a positive feedback loop which allows CLN proteins to promote their own synthesis.			DIRICK, L (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				ANDREWS BJ, 1989, NATURE, V342, P803; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NASMYTH KA, IN PRESS CELL; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	19	173	176	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					754	757		10.1038/351754a0	http://dx.doi.org/10.1038/351754a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1829507				2022-12-24	WOS:A1991FU20100067
J	HAVRAN, WL; CHIEN, YH; ALLISON, JP				HAVRAN, WL; CHIEN, YH; ALLISON, JP			RECOGNITION OF SELF ANTIGENS BY SKIN-DERIVED T-CELLS WITH INVARIANT GAMMA-DELTA-ANTIGEN RECEPTORS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; MYCOBACTERIUM-TUBERCULOSIS; MURINE EPIDERMIS; PRECURSORS; PROTEINS; PRODUCT; SUBSET; MICE	Thy-1+ dendritic epidermal T cells (dECs) express invariant gamma-delta-antigen receptors and are found in intimate contact with keratinocytes in murine epidermis - thus raising the possibility that keratinocytes express a ligand for the antigen receptor of these T cells. Thy-1+ dECs were stimulated to produce lymphokines by interaction with keratinocytes in vitro. This stimulation was mediated through the dEC antigen receptor and did not appear to be restricted by the major histocompatibility complex. Thus, dECs can recognize self antigens and may participate in immune surveillance for cellular damage rather than for foreign antigens.	UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	University of California System; University of California Berkeley; Stanford University	HAVRAN, WL (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Allison, James/0000-0001-8980-5697	NATIONAL CANCER INSTITUTE [R37CA040041, R01CA040041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026942] Funding Source: NIH RePORTER; NCI NIH HHS [CA40041] Funding Source: Medline; NIAID NIH HHS [AI26942] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison J P, 1990, Semin Immunol, V2, P59; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; BERGSTRESSER PR, 1984, J INVEST DERMATOL, V83, P83, DOI 10.1111/1523-1747.ep12262587; BERGSTRESSER PR, 1983, J INVEST DERMATOL, V81, P286, DOI 10.1111/1523-1747.ep12518332; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; BORN W, 1990, IMMUNOL TODAY, V11, P40; GILLIS S, 1978, J IMMUNOL, V120, P2027; HAVRAN WL, 1989, J IMMUNOL, V142, P1422; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAVRAN WL, UNPUB; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KORMAN AJ, 1988, J EXP MED, V168, P1021, DOI 10.1084/jem.168.3.1021; KUPPER TS, 1987, J INVEST DERMATOL, V88, P501; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; SULLIVAN S, 1985, J INVEST DERMATOL, V84, P491, DOI 10.1111/1523-1747.ep12273454; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1	24	338	340	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1430	1432		10.1126/science.1828619	http://dx.doi.org/10.1126/science.1828619			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1828619				2022-12-24	WOS:A1991FP86800036
J	ALDERMAN, MH; MADHAVAN, S; OOI, WL; COHEN, H; SEALEY, JE; LARAGH, JH				ALDERMAN, MH; MADHAVAN, S; OOI, WL; COHEN, H; SEALEY, JE; LARAGH, JH			ASSOCIATION OF THE RENIN SODIUM PROFILE WITH THE RISK OF MYOCARDIAL-INFARCTION IN PATIENTS WITH HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA-RENIN; WORK SITE; ALDOSTERONE; ANGIOTENSIN; SECRETION; SYSTEM	Background. To test the prognostic value of plasma renin activity prospectively, we determined the pretreatment renin-sodium profile of 1717 subjects with mild-to-moderate hypertension (mean age, 53 years; 36 percent white; 67 percent men) in a systematic work-site treatment program. Methods. Renin profiles, obtained by plotting plasma renin activity against the urinary excretion of sodium, were classified as high (12 percent of the subjects), normal (56 percent), and low (32 percent), and there were expected variations according to age, sex, and race. Modified stepped-care treatment for hypertension, prescribed without reference to the renin profile, was similar in the three renin groups. Results. Mean (+/- SD) blood pressure at entry was 151 +/- 19/100 +/- 10 mm Hg in the subjects with a high renin profile, 151 +/- 19/97 +/- 10 mm Hg in those with a normal profile, and 151 +/- 20/96 +/- 11 mm Hg in those with a low profile. During 8.3 years of follow-up, there were 27 myocardial infarctions. As adjusted for age, sex, and race, the incidence of myocardial infarction per 1000 person-years was 14.7 among the subjects with a high renin profile, 5.6 among those with a normal profile, and 2.8 among those with a low profile (rate ratio for high vs. low, 5.3; 95 percent confidence interval, 3.4 to 8.3). The rate of mortality from all causes was 9.3 in the high-profile group, 5.3 in the normal-profile group, and 3.9 in the low-profile group. The independent association of a high renin profile with myocardial infarction (but not with stroke or noncardiovascular events) was affirmed by Cox analyses (rate ratio for high vs. normal plus low, 3.2; 95 percent confidence interval, 1.2 to 8.4) after adjustment for race, sex, age at entry, serum cholesterol level, smoking status, electrocardiographic evidence of left ventricular hypertrophy, blood glucose level, body-mass index, history of cardiovascular disease or treatment, blood pressure, and use of beta-blockers. Conclusions. In the study population, whose blood pressure before and during treatment was in a narrow range, and after other cardiovascular risk factors had been considered, the renin profile before treatment remained independently associated with the subsequent risk of myocardial infarction.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,CTR CARDIOVASC,NEW YORK,NY 10021	Cornell University	ALDERMAN, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Sealey, Jean/A-9562-2009	Cohen, Hillel/0000-0002-4524-0898	NHLBI NIH HHS [HL18323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BRUNNER HR, 1973, AM J MED, V55, P295, DOI 10.1016/0002-9343(73)90131-9; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; BUHLER FR, 1972, NEW ENGL J MED, V287, P1209, DOI 10.1056/NEJM197212142872401; COX DR, 1972, J R STAT SOC B, V34, P187; FREIS ED, 1973, AM J MED, V255, P275; GAVRAS H, 1971, LANCET, V2, P19; GAVRAS H, 1977, ARCH INTERN MED, V137, P155; HOPKINS A, 1985, BMDP STATISTICAL SOF, P576; Kannel WB, 1975, EPIDEMIOLOGY CONTROL, P553; KAPLAN NM, 1976, ANN INTERN MED, V84, P639, DOI 10.7326/0003-4819-84-6-639; KAPLAN NM, 1975, JAMA-J AM MED ASSOC, V231, P167, DOI 10.1001/jama.231.2.167; LARAGH JH, 1972, AM J MED, V52, P633, DOI 10.1016/0002-9343(72)90054-X; LARAGH JH, 1973, AM J MED, V55, P261, DOI 10.1016/0002-9343(73)90128-9; LARAGH JH, 1960, JAMA-J AM MED ASSOC, V174, P293, DOI 10.1001/jama.1960.63030030007014; Laragh JH, 1990, HYPERTENSION PATHOPH, P1329; LEDINGHAM JM, 1990, HYPERTENSION PATHOPH, P33; MEADE TW, 1983, CLIN SCI, V64, P273, DOI 10.1042/cs0640273; MEYER P, 1990, HYPERTENSION PATHOPH, P541; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Sealey J E, 1980, Endocr Rev, V1, P365; SEALEY JE, 1988, J HYPERTENS, V6, P763, DOI 10.1097/00004872-198811000-00001; SEALEY JE, 1981, CLIN BIOCHEM, V14, P273, DOI 10.1016/S0009-9120(81)91000-6; Sealey JE, 1990, HYPERTENSION PATHOPH, P1443; SHAPIRO R, 1976, J LAB CLIN MED, V88, P222; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; Winternitz M C, 1940, Yale J Biol Med, V12, P623; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1985, BMJ, V291, P97	30	687	694	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1098	1104		10.1056/NEJM199104183241605	http://dx.doi.org/10.1056/NEJM199104183241605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	1759997				2022-12-24	WOS:A1991FG91200005
J	JAP, BK; WALIAN, PJ; GEHRING, K				JAP, BK; WALIAN, PJ; GEHRING, K			STRUCTURAL ARCHITECTURE OF AN OUTER-MEMBRANE CHANNEL AS DETERMINED BY ELECTRON CRYSTALLOGRAPHY	NATURE			English	Article							ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; SENSITIVE SPECIMENS; LIPID BILAYERS; PHOE PROTEIN; PORIN; RESOLUTION; BEAM	PORINS are a family of membrane channels commonly found in the outer membranes of Gram-negative bacteria where they serve as diffusional pathways for waste products, nutrients and antibiotics, and can also be receptors for bacteriophages 1,2. Porin channels have been shown in vitro to be voltage-gated 3-6. They can exhibit slight selectivities for certain solutes; for example PhoE porin has some selectivity for anionic and phosphate-containing compounds 1,7. Unlike many known membrane proteins which often contain long stretches of hydrophobic segments that are believed to traverse the membrane in a helical conformation, porins are found to have charged residues distributed almost uniformly along their primary sequences and have most of their secondary structure in a beta-sheet conformation 8-10. We have made crystalline patches of PhoE porin embedded in a lipid bilayer and have used these to determine the structure of PhoE porin by electron crystallography to a resolution of 6 angstrom. The basic structure consists of a trimer of elliptically shaped, cylindrical walls of beta-sheet. Each cylinder has an inner lining, formed by parts of the polypeptide, that defines the channel size. The structure provides a clue as to how deletions of segments of polypeptide, which are found in certain mutants, can result in an actual increase in the channel size.			JAP, BK (corresponding author), UNIV CALIF BERKELEY LAWRENCE BERKELEY LAB,DONNER LAB,BERKELEY,CA 94720, USA.		Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BULLOUGH P, 1987, ULTRAMICROSCOPY, V21, P223, DOI 10.1016/0304-3991(87)90147-1; DARGENT B, 1986, EMBO J, V5, P773, DOI 10.1002/j.1460-2075.1986.tb04280.x; DOWNING KH, 1986, ULTRAMICROSCOPY, V20, P269, DOI 10.1016/0304-3991(86)90191-9; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOENGER A, 1990, J STRUCT BIOL, V103, P185, DOI 10.1016/1047-8477(90)90022-5; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; JAP BK, 1990, J STRUCT BIOL, V103, P57, DOI 10.1016/1047-8477(90)90086-R; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; KORTELAND J, 1982, BIOCHIM BIOPHYS ACTA, V690, P282, DOI 10.1016/0005-2736(82)90332-7; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MAURO A, 1988, P NATL ACAD SCI USA, V85, P1071, DOI 10.1073/pnas.85.4.1071; MISRA R, 1988, J BACTERIOL, V170, P3611, DOI 10.1128/jb.170.8.3611-3617.1988; NESTEL U, 1989, FEBS LETT, V242, P405, DOI 10.1016/0014-5793(89)80511-3; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; SHAW PJ, 1981, MICRON, V12, P279, DOI 10.1016/0047-7206(81)90081-9; TOMMASSEN J, 1988, NATO ASI SER, V16, P351; WALIAN PJ, 1990, J MOL BIOL, V215, P429, DOI 10.1016/S0022-2836(05)80362-6; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1989, FEBS LETT, V256, P143, DOI 10.1016/0014-5793(89)81735-1; XU GZ, 1986, BIOCHIM BIOPHYS ACTA, V862, P57, DOI 10.1016/0005-2736(86)90468-2	26	132	134	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					167	170		10.1038/350167a0	http://dx.doi.org/10.1038/350167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848682				2022-12-24	WOS:A1991FB64500064
J	KUO, HC; NASIM, FUH; GRABOWSKI, PJ				KUO, HC; NASIM, FUH; GRABOWSKI, PJ			CONTROL OF ALTERNATIVE SPLICING BY THE DIFFERENTIAL BINDING OF U1 SMALL NUCLEAR RIBONUCLEOPROTEIN PARTICLE	SCIENCE			English	Article							PRE-MESSENGER RNA; SITE SELECTION; SNRNP PROTEIN; AFFINITY-CHROMATOGRAPHY; COMPLEX; SPLICEOSOME; GENE; IDENTIFICATION; SEQUENCES; INVITRO	Cellular factors controlling alternative splicing of precursor messenger RNA are largely unknown, even though this process plays a central role in specifying the diversity of proteins in the eukaryotic cell. For the identification of such factors, a segment of the rat preprotachykinin gene was used in which differential expression of neuropeptides-gamma and K is dependent on alternative splicing of the fourth exon (E4). Sequence variants of the three-exon segment, (E3-E4-E5) were created, resulting in a sensitive assay for factors mediating the splicing switch between E4-skipping and E4-inclusion. A dinucleotide mutation in the 5' splice site of E4 that increases base-pairing of this site to U1 small nuclear RNA resulted in uniform selection of E4, whereas a control mutation that destroyed base-pairing resulted in uniform E4-skipping. Affinity selection of spliceosomes formed on these functionally distinct substrates revealed that the extreme difference in splicing was mediated by differential binding of the U1 small nuclear ribonucleoprotein particle (snRNP) to the 5' splice site of E4. These data show that, apart from its established role in selecting 5' splice sites, U1 snRNP plays a fundamental role in 3' exon selection and provides insight into possible mechanisms of alternative splicing.	BROWN UNIV, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brown University			Nasim, Faiz/F-6397-2015; Nasim, Faiz-ul Hassan/G-5799-2010	Nasim, Faiz-ul Hassan/0000-0001-9107-7449	NIGMS NIH HHS [GM-39695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BONADIO J, 1990, J BIOL CHEM, V265, P2262; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COOPER TA, 1989, NUCLEIC ACIDS RES, V17, P7905, DOI 10.1093/nar/17.19.7905; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; ETZERODT M, 1988, EMBO J, V7, P4311, DOI 10.1002/j.1460-2075.1988.tb03330.x; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FREYER GA, 1989, J BIOL CHEM, V264, P14631; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; KASHER MS, 1986, MOL CELL BIOL, V6, P3117, DOI 10.1128/MCB.6.9.3117; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAUSE JE, 1987, P NATL ACAD SCI USA, V84, P881, DOI 10.1073/pnas.84.3.881; KUIVANIEMI H, 1988, J BIOL CHEM, V263, P11407; KUO HC, UNPUB; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; NASIM FH, 1990, GENE DEV, V4, P1172, DOI 10.1101/gad.4.7.1172; NASIM FH, UNPUB; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; WEIL D, 1988, J BIOL CHEM, V263, P8561; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	63	159	159	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 1	1991	251	4997					1045	1050		10.1126/science.1825520	http://dx.doi.org/10.1126/science.1825520			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1825520				2022-12-24	WOS:A1991EZ66500041
J	KADHIM, MA; MACDONALD, DA; GOODHEAD, DT; LORIMORE, SA; MARSDEN, SJ; WRIGHT, EG				KADHIM, MA; MACDONALD, DA; GOODHEAD, DT; LORIMORE, SA; MARSDEN, SJ; WRIGHT, EG			TRANSMISSION OF CHROMOSOMAL INSTABILITY AFTER PLUTONIUM ALPHA-PARTICLE IRRADIATION	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; RADIATIONS	WHEN investigating the biological effects of ionizing radiation on the haemopoietic system, a confounding problem lies in possible differences between the biological effects of sparsely ionizing, low linear energy transfer radiation such as X-, beta- or gamma-rays, and densely ionizing, high linear energy transfer radiation such as alpha-particles. To address this problem we have developed novel techniques for studying haemopoietic cells irradiated with environmentally relevant doses of alpha-particles from a plutonium-238 source. Using a clonogenic culture system, cytogenetic aberrations in individual colonies of haemopoietic cells derived from irradiated stem cells have been studied. Exposure to alpha-particles (but not X-rays) produced a high frequency of non-clonal aberrations in the clonal descendants, compatible with alpha-emitters inducing lesions in stem cells that result in the transmission of chromosomal instability to their progeny. Such unexpected instability may have important implications for radiation leukaemogenesis.	MRC,RADIOBIOL UNIT,DIDCOT OX11 0RD,OXON,ENGLAND	MRC Harwell								AGHAMOHAMMADI SZ, 1988, INT J RADIAT BIOL, V53, P909, DOI 10.1080/09553008814551271; AMENOMORI T, 1985, INT J CELL CLONING, V3, P133, DOI 10.1002/stem.5530030301; BLACK D, 1984, INVESTIGATION POSSIB; BOBROW M, 1989, COMARE3RD COMM MED A; GOODHEAD DT, 1991, INT J RADIAT BIOL, V59, P195, DOI 10.1080/09553009114550181; GOODHEAD DT, 1989, INT J RADIAT BIOL, V56, P623, DOI 10.1080/09553008914551841; GOODHEAD DT, 1987, DOSIMETRY IONIZING R, V2, P1; Lloyd D.C., 1983, RAD INDUCED CHROMOSO, P23; LORIMORE SA, 1990, LEUKEMIA RES, V14, P481, DOI 10.1016/0145-2126(90)90036-9; PIPER J, 1989, CYTOGENET CELL GENET, V50, P111, DOI 10.1159/000132735; SINCLAIR WK, 1985, RADIAT PROT DOSIM, V13, P319; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; VANDENENGH G, 1979, EXPT HEMATOLOGY TODA, P19; VISSER J, 1977, EXPT HEMATOLOGY TODA, P21; VISSER JWM, 1990, EXP HEMATOL, V18, P248; 1988, UNSCEAR UN SCI COMMI; 1990, NCRP106 NAT COUNC RA; 1991, ICRP PUBLICATION, V60	18	535	555	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					738	740		10.1038/355738a0	http://dx.doi.org/10.1038/355738a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741061				2022-12-24	WOS:A1992HE60400068
J	ANDERSEN, WK; SILVERS, DN				ANDERSEN, WK; SILVERS, DN			MELANOMA - IT CANT BE MELANOMA - A SUBSET OF MELANOMAS THAT DEFIES CLINICAL RECOGNITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MALIGNANT-MELANOMA; DIAGNOSIS	We diagnosed histologically 178 cases of malignant melanoma in 1990. Thirteen cases were recorded in which the diagnosis of malignant melanoma was not considered by the clinician prior to biopsy or, in retrospect, following pathologic diagnosis. Eight of the 13 lesions were amelanotic. The majority were deeply invasive at the time of biopsy, implying poor prognosis. Despite improvements in early detection of malignant melanoma, a significant subcategory of melanomas escapes clinical diagnosis.	COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT DERMATOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	SILVERS, DN (corresponding author), COLUMBIA UNIV,COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,DEPT DERMATOL,NEW YORK,NY 10032, USA.							BECKER SW, 1954, AMA ARCH DERM SYPH, V69, P11, DOI 10.1001/archderm.1954.01540130013002; Clark WH., 1967, ADV BIOL SKIN, P621; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; MCMULLAN FH, 1956, ARCH DERMATOL, V74, P618, DOI 10.1001/archderm.1956.01550120038009; MIHM MC, 1971, NEW ENGL J MED, V284, P1078, DOI 10.1056/NEJM197105132841907; STEINER A, 1988, ARCH DERMATOL, V24, P1534; SWERDLOW M, 1952, AM J CLIN PATHOL, V22, P1054; THORN M, 1989, JNCI-J NATL CANCER I, V81, P611, DOI 10.1093/jnci/81.8.611; WICK MM, 1980, CANCER, V45, P2684, DOI 10.1002/1097-0142(19800515)45:10<2684::AID-CNCR2820451033>3.0.CO;2-2	9	56	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3463	3465		10.1001/jama.266.24.3463	http://dx.doi.org/10.1001/jama.266.24.3463			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744961				2022-12-24	WOS:A1991GV87800033
J	BANSAL, A; GIERASCH, LM				BANSAL, A; GIERASCH, LM			THE NPXY INTERNALIZATION SIGNAL OF THE LDL RECEPTOR ADOPTS A REVERSE-TURN CONFORMATION	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; IMMUNOGENIC PEPTIDE-FRAGMENTS; CYTOPLASMIC DOMAIN; AMINO-ACID; INSULIN-RECEPTOR; WATER SOLUTION; COATED PITS; PROTEINS; ENDOCYTOSIS; SPECTROSCOPY	Peptides corresponding to the proposed coated pit internalization signal of the native low density lipoprotein receptor, NPVY, take up in aqueous solution a reverse-turn conformation with the Asn in position i and the Tyr in position i + 3. By contrast, peptides derived from receptors that are defective for endocytosis do not adopt the reverse turn. These internalization-defective receptors include those with a nonaromatic residue substituted for the Tyr and those with Asn --> Ala or Pro --> Ala substitutions. While the tendency of an Asn-Pro sequence to induce a reverse turn was anticipated, the structural importance of an aromatic residue in position i + 3 was not. The sequences associated with the internalization signal thus appear to play a critical conformational role that is required for endocytosis, probably by enabling binding to adaptor molecules. With the results presented in the accompanying paper on lysosomal acid phosphatase, we now have direct evidence for previous proposals of a general correlation of internalization signals with a turn conformational motif.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	BANSAL, A (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.		Gierasch, Lila M/D-1494-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 27616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANSAL A, 1989, CURRENT RES PROTEIN, P331; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BROWN MS, 1976, CELL, V9, P663, DOI 10.1016/0092-8674(76)90130-6; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; RICHARDSON JS, 1988, PREDICTION PROTEIN S, P1; Stewart JM, 1984, SOLID PHASE PEPTIDE; THIES RS, 1990, J BIOL CHEM, V265, P10132; WAGNER G, 1981, EUR J BIOCHEM, V114, P375, DOI 10.1111/j.1432-1033.1981.tb05157.x; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; WUETHRICH K, 1984, J MOL BIOL, V180, P715	36	224	226	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1195	1201		10.1016/0092-8674(91)90295-A	http://dx.doi.org/10.1016/0092-8674(91)90295-A			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760844				2022-12-24	WOS:A1991GX16400017
J	SHEWELL, PC; NANCARROW, JD				SHEWELL, PC; NANCARROW, JD			DOGS THAT BITE	BRITISH MEDICAL JOURNAL			English	Article								Objective - To study the circumstances of dog bites and identify risk factors. Design - Postal questionnaire survey and case note review of victims of dog bites referred between 1982 and 1989. Setting - One referral based regional plastic surgery unit. Patients - 146 consecutive patients referred for primary treatment of dog bites, for whom current addresses were available for 133, 107 (81%) of whom returned the questionnaire. Results - The male to female ratio was 74:72; 79 (54%) patients were aged below 15 years. The commonest dogs producing bites were Staffordshire bull terriers (15 cases), Jack Russell terriers (13), medium sized mongrels (10), and Alsatians (nine). 82 of 96 (85%) dogs were male. 29 of 47 (62%) adults were bitten at home and 45 of 60 (75%) children at a friend's, neighbour's, or relative's house. 91 of 107 (85%) bites occurred in the dog's home. Bites occurred during playing with 13 (12%), petting 14 (13%), or waking 16 (15%) dogs. 45 (42%) bites were judged as unprovoked. 32 bites were identified as severe and 11 attacks as sustained. Conclusions - Most victims are bitten by male dogs which they either own or have had frequent contact with, and the bite occurs in the dog's home.	WORDSLEY HOSP,W MIDLANDS REG PLAST & JAW SURG UNIT,STOURBRIDGE,W MIDLANDS,ENGLAND		SHEWELL, PC (corresponding author), ROYAL ORTHOPAED HOSP,WOODLANDS,BIRMINGHAM B31 2AP,ENGLAND.							BAACK BR, 1989, J TRAUMA, V29, P517, DOI 10.1097/00005373-198904000-00019; BARCLAY T L, 1956, Br J Plast Surg, V9, P34, DOI 10.1016/S0007-1226(56)80006-4; CARITHERS HA, 1958, AMA J DIS CHILD, V95, P150, DOI 10.1001/archpedi.1958.02060050152007; CHUN YT, 1982, PEDIATRICS, V69, P119; HERVEY E, 1977, BRIT MED J, V2, P53; LAUER EA, 1982, AM J DIS CHILD, V136, P202, DOI 10.1001/archpedi.1982.03970390016003; PALMER J, 1983, BRIT J PLAST SURG, V36, P315; THOMAS PR, 1987, MED J AUSTRALIA, V147, P536, DOI 10.5694/j.1326-5377.1987.tb133676.x; ZAKOWSKI D, 1986, PEDIATR EMERG CARE, V2, P85	9	32	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1512	1513		10.1136/bmj.303.6816.1512	http://dx.doi.org/10.1136/bmj.303.6816.1512			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782490	Green Published, Bronze			2022-12-24	WOS:A1991GV47600022
J	SZCZEPURA, AK; FLETCHER, J; FITZPATRICK, JD				SZCZEPURA, AK; FLETCHER, J; FITZPATRICK, JD			COST-EFFECTIVENESS OF MAGNETIC-RESONANCE-IMAGING IN THE NEUROSCIENCES	BRITISH MEDICAL JOURNAL			English	Article							TECHNOLOGY	Objectives - To measure, in a service setting, the effect of magnetic resonance imaging on diagnosis, diagnostic certainty, and patient management in the neurosciences; to measure the cost per patient scanned; to estimate the marginal cost of imaging and compare this with its diagnostic impact; to measure changes in patients' quality of life; and to record the diagnostic pathway leading to magnetic resonance imaging. Design - Controlled observational study using questionnaires on diagnosis and patient management before and after imaging. Detailed costing study. Quality of life questionnaires at the time of imaging and six months later. Diagnostic pathways extracted from medical records for a representative sample. Setting - Regional superconducting 1.5 T magnetic resonance service. Subjects - 782 consecutive neuroscience patients referred by consultants for magnetic resonance imaging during June 1988-9; diagnostic pathways recorded for 158 cases. Main outcome measures - Costs of magnetic resonance imaging and preliminary investigations; changes in planned management and resulting savings; changes in principal diagnosis and diagnostic certainty; changes in patients' quality of life. Results - Average cost of magnetic resonance imaging was estimated at 206.20 pounds/patient (throughput 2250 patients/year, 1989-90 prices including contrast and upgrading). Before magnetic resonance imaging diagnostic procedures cost 164.40 pounds/patient (including inpatient stays). Management changed after imaging in 208 (27%) cases; saving an estimated 80.90 pounds/patient. Confidence in planned management increased in a further 226 (29%) referrals. Consultants' principal diagnosis changed in 159 of 782 (20%) referrals; marginal cost Per diagnostic change was 626 pounds. Confidence in diagnosis increased in 236 (30%) referrals. No improvement in patients' quality of life at six month assessment. Conclusions - Any improvement in diagnosis with magnetic resonance imaging is achieved at a higher cost. Techniques for monitoring the cost effectiveness of this technology need to be developed.	WALSGRAVE GEN HOSP,COVENTRY CV2 2DX,ENGLAND		SZCZEPURA, AK (corresponding author), UNIV WARWICK,WARWICK BUSINESS SCH RES BUREAU,HLTH SERV RES UNIT,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.			Szczepura, Ala/0000-0001-6244-9872				BOGATAY LM, 1987, HOSP TOP, V39, P12; BYDDER GM, 1988, BRIT J RADIOL, V61, P889, DOI 10.1259/0007-1285-61-730-889; CHERRYMAN GR, 1985, BRIT MED J, V291, P1437, DOI 10.1136/bmj.291.6506.1437; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; DIXON AK, 1991, BMJ, V3302, P78; DURICK AA, 1988, RADIOL TECHNOL, V59, P239; EVENS RG, 1988, RADIOLOGY, V166, P27, DOI 10.1148/radiology.166.1.3336692; EVENS RG, 1991, AM J ROENTGENOL, V157, P603, DOI 10.2214/ajr.157.3.1872246; FINEBERG HV, 1977, JAMA-J AM MED ASSOC, V238, P224, DOI 10.1001/jama.238.3.224; GUDEX C, 1988, 38 U YORK CTR HLTH E; KENT DL, 1988, ANN INTERN MED, V108, P759, DOI 10.7326/0003-4819-108-5-759; KENT DL, 1988, ANN INTERN MED, V108, P402, DOI 10.7326/0003-4819-108-3-402; Larson E B, 1989, Int J Technol Assess Health Care, V5, P195; Pribyl S, 1988, Appl Radiol, V17, P29; ROBERTS H, 1990, 33 PUBL FIN F DISC P; ROSSER R, 1983, HLTH INDICATORS; SCHERSTEN T, 1985, INT J TECHNOL ASSESS, V1; SCHUMAN WP, 1988, AJR, V151, P857; STILWELL JA, 1984, BRIT J RADIOL, V57, P647, DOI 10.1259/0007-1285-57-679-647; SZCZEPURA AK, 1988, SOC SCI MED, V26, P715, DOI 10.1016/0277-9536(88)90063-9; SZCZEPURA AK, 1991, 1 BUS SCH HLTH SERV; SZCZEPURA AK, 1990, VALUE USE BACTERIOLO; 1990, MRI ASSESSMENT PROGR; 1988, HLTH TECHNOLOGY, V2, P3; 1990, EC EVALUATION CLIN A; 1988, MRI ASSESSMENT PROGR; 1989, HLTH PERSONAL SOCIAL; 1986, MAGNET RESON MED, V6, P1; 1990, MAGNETIC RESONANCE I; 1989, MRI ASSESSMENT PROGR; 1988, ANN INTERN MED, V108, P474; 1985, DHSS141 DEP HLTH SOC	32	30	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1435	1439		10.1136/bmj.303.6815.1435	http://dx.doi.org/10.1136/bmj.303.6815.1435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1819260	Bronze, Green Published			2022-12-24	WOS:A1991GU38500022
J	FARR, BM; SLOMAN, AJ; FISCH, MJ				FARR, BM; SLOMAN, AJ; FISCH, MJ			PREDICTING DEATH IN PATIENTS HOSPITALIZED FOR COMMUNITY-ACQUIRED PNEUMONIA	ANNALS OF INTERNAL MEDICINE			English	Article						PNEUMONIA; TRIAGE; PROGNOSTIC FACTORS; HYPOTENSION; TACHYPNEA PNEUMONIA	INTENSIVE-CARE UNIT; PNEUMOCOCCAL BACTEREMIA; LOBAR PNEUMONIA; MORTALITY; DISEASE; FAILURE; INFECTIONS; ETIOLOGY; FEATURES; SURVIVAL	Objective: To validate a previously reported discriminant rule for predicting mortality in adult patients with primary community-acquired pneumonia and to determine which factors available at hospital admission predict a fatal outcome among such patients. Design: Historical cohort study. Setting: University hospital. Patients: Adults admitted to the hospital for community-acquired pneumonia. Measurements: Using stepwise logistic regression, we analyzed prognostic factors (data available at admission and recorded in the medical record) that showed a univariate association with mortality. The predictive values of three discriminant rules were measured to validate the results of a previous study. Main Results: Of 245 patients, 20 (8.2%) died. Of 42 prognostic factors identified in previous studies, 8 were associated with mortality, but only a respiratory rate of 30/min or more, a diastolic blood pressure of 60 mm Hg or less, and a blood urea nitrogen of more than 7 mmol/L remained predictive in the multivariate analysis. A discriminant rule composed of these three variables was 70% sensitive and 84% specific in predicting mortality, yielding an overall accuracy of 82%. Conclusion: Tachypnea, diastolic hypotension, and an elevated blood urea nitrogen were independently associated with death from pneumonia in our study, confirming the value of a previously reported discriminant rule from the British Thoracic Society. This rule may be useful in triage decisions because it identifies high-risk patients who may benefit from special medical attention.			FARR, BM (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, BOX 473, CHARLOTTESVILLE, VA 22908 USA.							ALLEN SC, 1984, THORAX, V39, P612, DOI 10.1136/thx.39.8.612; ANDREWS BE, 1987, Q J MED, V62, P195; ANDREWS J, 1984, GERONTOLOGY, V30, P290, DOI 10.1159/000212648; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BANKS RA, 1984, BRIT J DIS CHEST, V78, P352; BENSON H, 1970, J CLIN INVEST, V49, P791, DOI 10.1172/JCI106292; BILLE J, 1980, PNEUMONIA PNEUMONOCO; BISNO AL, 1971, AM J MED SCI, V261, P251, DOI 10.1097/00000441-197105000-00004; BURNS MW, 1976, MED J AUSTRALIA, V2, P787, DOI 10.5694/j.1326-5377.1976.tb115356.x; CALDER MA, 1970, LANCET, V1, P5; CROFTON J, 1981, RESPIRATORY DISEASES, P190; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; EBRIGHT JR, 1980, J AM GERIATR SOC, V28, P220, DOI 10.1111/j.1532-5415.1980.tb00523.x; ESPOSITO AL, 1984, ARCH INTERN MED, V144, P945, DOI 10.1001/archinte.144.5.945; FEDULLO AJ, 1985, J GERONTOL, V40, P29, DOI 10.1093/geronj/40.1.29; FEKETY RF, 1971, AM REV RESPIR DIS, V104, P499; FELDMAN C, 1989, S AFR MED J, V76, P593; FINE MJ, 1990, AM J MED, V88, pN1; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P61; GOLD MI, 1974, CHEST, V65, P388, DOI 10.1378/chest.65.4.388; GRANSDEN WR, 1985, BRIT MED J, V290, P505, DOI 10.1136/bmj.290.6467.505; HOLLAND WW, 1960, BMJ-BRIT MED J, V1, P1917, DOI 10.1136/bmj.1.5190.1917; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789; MACFARLANE JT, 1982, LANCET, V2, P255; MACFARLANE JT, 1983, THORAX, V38, P231; MARRIE TJ, 1985, J AM GERIATR SOC, V33, P671, DOI 10.1111/j.1532-5415.1985.tb01775.x; MARRIE TJ, 1988, CLIN INVEST MED, V11, P10; MCNABB WR, 1984, J ROY SOC MED, V77, P550, DOI 10.1177/014107688407700705; MOORE MA, 1977, JOHNS HOPKINS MED J, V140, P9; MUFSON MA, 1967, AM J EPIDEMIOL, V86, P526, DOI 10.1093/oxfordjournals.aje.a120763; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; MUFSON MA, 1974, ARCH INTERN MED, V134, P505, DOI 10.1001/archinte.134.3.505; ORTQVIST A, 1985, SCAND J INFECT DIS, V17, P377; POTGIETER PD, 1985, CRIT CARE MED, V13, P798, DOI 10.1097/00003246-198510000-00005; ROBERTSON L, 1958, LANCET, V2, P233; ROGERS RM, 1972, CHEST, V62, P94, DOI 10.1378/chest.62.1.94; SPENCER RC, 1976, J CLIN PATHOL, V29, P187, DOI 10.1136/jcp.29.3.187; STARCZEWSKI AR, 1988, AGE AGEING, V17, P181, DOI 10.1093/ageing/17.3.181; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935; VALENTI WM, 1978, AM REV RESPIR DIS, V117, P233; WHITE RJ, 1981, THORAX, V36, P566, DOI 10.1136/thx.36.8.566; WOODHEAD MA, 1985, J INFECTION, V10, P204, DOI 10.1016/S0163-4453(85)92463-6; [No title captured]; 1989, VITAL HLTH STATIS 13, V99	47	225	227	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					428	436		10.7326/0003-4819-115-6-428	http://dx.doi.org/10.7326/0003-4819-115-6-428			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872491				2022-12-24	WOS:A1991GE81000003
J	POTTS, WK; MANNING, CJ; WAKELAND, EK				POTTS, WK; MANNING, CJ; WAKELAND, EK			MATING PATTERNS IN SEMINATURAL POPULATIONS OF MICE INFLUENCED BY MHC GENOTYPE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MUS-MUSCULUS; HOUSE MOUSE; POLYMORPHISM; LOCI; OVERDOMINANT; PREFERENCES; RECOGNITION; SELECTION; HUMANS	BECAUSE of the central role of major histocompatibility complex (MHC) genes in immune recognition 1-3, it is often assumed that parasite-driven selection maintains the unprecedented genetic diversity of these genes 4-7. But associations between MHC genotype and specific infectious diseases have been difficult to identify 8,9 with a few exceptions such as Marek's disease 10 and malaria 11. Alternatively, MHC-related reproductive mechanisms such as selective abortion 12-15 and mating preferences 16,17 could be responsible for the diversity. To determine both the nature and strength of selection operating on MHC genes by we have studied components of selection in seminatural populations of mice (Mus musculus domesticus). Here we assess MHC-related patterns of reproduction and early (preweaning) mortality by analysing 1,139 progeny born in nine populations, and 662 progeny from laboratory matings. Reproductive mechanisms, primarily mating preferences, result in 27% fewer MHC-homozygous offspring than expected from random mating. MHC genotype had no detectable influence on neonatal (preweaning) mortality. These mating preferences are strong enough to account for most of the MHC genetic diversity found in natural populations of Mus.	UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	POTTS, WK (corresponding author), UNIV FLORIDA,DEPT PATHOL & LAB MED,MOLEC GENET LAB,GAINESVILLE,FL 32610, USA.			Potts, Wayne/0000-0003-4137-0326				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRONSON FH, 1979, Q REV BIOL, V54, P265, DOI 10.1086/411295; BROWN JL, 1983, ETHICAL QUESTIONS BR, P111; CLARKE B, 1966, NATURE, V211, P999, DOI 10.1038/211999a0; DOHERTY PC, 1975, NATURE, V256, P50, DOI 10.1038/256050a0; EGID K, 1989, ANIM BEHAV, V38, P548, DOI 10.1016/S0003-3472(89)80051-X; GILBERT AN, 1986, J COMP PSYCHOL, V100, P262, DOI 10.1037/0735-7036.100.3.262; HAMILTON M, 1978, J REPROD IMMUNOL, V19, P267; HILL AVS, 1991, NATURE, V352; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARLIN S, 1968, GENETICS, V59, P117; Klein J., 1986, NATURAL HIST MAJOR H; MCCONNELL TJ, 1988, NATURE, V332, P651, DOI 10.1038/332651a0; MELVOLD RW, 1990, TRANSGENIC MICE MUTA; NADEAU JH, 1981, GENET RES, V37, P17, DOI 10.1017/S0016672300019984; NEI M, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P222; PALM J, 1974, CANCER RES, V34, P2061; PARTRIDGE L, 1988, PHILOS T R SOC B, V319, P525, DOI 10.1098/rstb.1988.0063; PAZDERKA F, 1975, IMMUNOGENETICS, V2, P93, DOI 10.1007/BF01572279; POTTS WK, 1990, TRENDS ECOL EVOL, V5, P181, DOI 10.1016/0169-5347(90)90207-T; ROY S, 1989, SCIENCE, V244, P572, DOI 10.1126/science.2470147; SINGH PB, 1987, NATURE, V327, P161, DOI 10.1038/327161a0; TAKAHATA N, 1990, GENETICS, V124, P967; THOMAS ML, 1985, AM J OBSTET GYNECOL, V151, P1053, DOI 10.1016/0002-9378(85)90379-5; TIWARI JL, 1985, HLA DISEASE ASS; Uyenoyama M. K., 1988, EVOLUTION SEX EXAMIN, P212; WEIR BS, 1973, GENET RES, V21, P247, DOI 10.1017/S0016672300013446; WILKINSON GS, 1988, ETHOLOGY, V77, P103; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; YAMAZAKI K, 1979, J EXP MED, V150, P755, DOI 10.1084/jem.150.4.755; YOKOYAMA S, 1979, GENETICS, V91, P609	32	488	500	0	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					619	621		10.1038/352619a0	http://dx.doi.org/10.1038/352619a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865924				2022-12-24	WOS:A1991GB21100055
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR PURGING USE IN AUTOLOGOUS BONE-MARROW TRANSPLANTS FOR ACUTE MYELOGENOUS LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-24	WOS:A1991GA07300008
J	VOJTEK, A; HAARER, B; FIELD, J; GERST, J; POLLARD, TD; BROWN, S; WIGLER, M				VOJTEK, A; HAARER, B; FIELD, J; GERST, J; POLLARD, TD; BROWN, S; WIGLER, M			EVIDENCE FOR A FUNCTIONAL LINK BETWEEN PROFILIN AND CAP IN THE YEAST SACCHAROMYCES-CEREVISIAE	CELL			English	Article							ACTIN-BINDING PROTEINS; PHOSPHOLIPASE C-II; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; ACANTHAMOEBA PROFILIN; ADENYLATE-CYCLASE; A-431 CELLS; GENE	CAP is a component of the S. cerevisiae adenylyl cyclase complex. The N-terminal domain is required for cellular RAS responsiveness. Loss of the C-terminal domain is associated with morphological and nutritional defects. Here we report that cap- cells bud randomly and are defective in actin distribution. The morphological and nutritional defects associated with loss of the CAP C-terminal domain are suppressed by overexpression of PFY, the gene encoding profilin, an actin- and polyphosphoinositide-binding protein. The phenotype of cells lacking PFY resembles that of cells lacking the CAP C-terminal domain. Study of mutated yeast profilins and profilins from Acanthamoeba suggests that the ability of profilin to suppress cap- cells is dependent upon a property other than, or in addition to, its ability to bind actin. This property may be its ability to bind polyphosphoinositides. We propose that CAP and profilin provide a link between growth signals and remodeling of the cellular cytoskeleton.	UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA	University of Michigan System; University of Michigan; Johns Hopkins University	VOJTEK, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Wigler, Michael/0000-0003-4396-1971				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1991, IN PRESS CELL MOTIL; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Rose MD., 1990, METHODS YEAST GENETI; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WAHL M, 1988, J BIOL CHEM, V263, P7581; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254	35	179	180	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					497	505		10.1016/0092-8674(81)90013-1	http://dx.doi.org/10.1016/0092-8674(81)90013-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868547	Green Published			2022-12-24	WOS:A1991GA94100011
J	HAMPTON, RY; GOLENBOCK, DT; PENMAN, M; KRIEGER, M; RAETZ, CRH				HAMPTON, RY; GOLENBOCK, DT; PENMAN, M; KRIEGER, M; RAETZ, CRH			RECOGNITION AND PLASMA-CLEARANCE OF ENDOTOXIN BY SCAVENGER RECEPTORS	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; A-BINDING-SITES; CHOLESTEROL DEPOSITION; PERITONEAL-MACROPHAGES; RAT-LIVER; CELLS; PROTEIN; DEGRADATION; METABOLISM	LIPID A is the active moiety of lipopolysaccharide (LPS, also referred to as endotoxin), a surface component of Gram-negative bacteria that stimulates macrophage activation and causes endotoxic shock 1,2. Macrophages can bind, internalize and partially degrade LPS, lipid A and its bioactive precursor, lipid IV(A) (refs 3-7). We report here that lipid IV(A) binding and subsequent metabolism to a less active form by macrophage-like RAW 264.7 cells is mediated by the macrophage scavenger receptor. Scavenger-receptor ligands inhibit lipid IV(A) binding to, and metabolism by, RAW cells, and lipid IV(A) binds to type I and type II bovine scavenger receptors on transfected Chinese hamster ovary cells. Although in vitro competition studies with RAW cells indicate that scavenger receptor binding is not involved in LPS or lipid IV(A)-induced stimulation of macrophages, in vivo studies show that scavenger-receptor ligands greatly inhibit hepatic uptake of lipid IV(A) in mice. Thus, scavenger receptors expressed on macrophages may have an important role in the clearance and detoxification of endotoxin in animals.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,RAHWAY,NJ 07065; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Merck & Company; Massachusetts Institute of Technology (MIT)	HAMPTON, RY (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706, USA.							BEUTLER B, 1988, BIOCHEMISTRY-US, V27, P7575, DOI 10.1021/bi00420a001; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DRESEL HA, 1987, EMBO J, V6, P319, DOI 10.1002/j.1460-2075.1987.tb04757.x; DUNCAN RL, 1984, J IMMUNOL, V132, P1416; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FREUDENBERG MA, 1984, REV INFECT DIS, V6, P483; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLENBOCK DT, 1990, INFECT IMMUN, V58, P4069, DOI 10.1128/IAI.58.12.4069-4075.1990; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; KAPLAN HM, 1983, MOUSE BIOMEDICAL RES, V3, P248; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PETERSON AA, 1987, INFECT IMMUN, V55, P974, DOI 10.1128/IAI.55.4.974-978.1987; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; PITAS RE, 1990, J BIOL CHEM, V265, P12722; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	30	474	491	2	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					342	344		10.1038/352342a0	http://dx.doi.org/10.1038/352342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852209				2022-12-24	WOS:A1991FY28900073
J	FARLEY, CT; TAYLOR, CR				FARLEY, CT; TAYLOR, CR			A MECHANICAL TRIGGER FOR THE TROT-GALLOP TRANSITION IN HORSES	SCIENCE			English	Article							FORCE PLATFORM; LOCOMOTION; GAITS; SPEED	It is widely thought that animals switch gaits at speeds that minimize energetic cost. Horses naturally switched from a trot to a gallop at a speed where galloping required more energy than trotting, and thus, the gait transition actually increased the energetic cost of running. However, by galloping at this speed, the peak forces on the muscles, tendons, and bones, and presumably the chance of injury, are reduced. When the horses carried weights, they switched from a trot to a gallop at a lower speed but at the same critical level of force. These findings suggest that the trot-gallop transition is triggered when musculoskeletal forces reach a critical level.			FARLEY, CT (corresponding author), HARVARD UNIV,MUSEUM COMPARAT ZOOL,CONCORD FIELD STN,OLD CAUSEWAY RD,BEDFORD,MA 01730, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018140] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 18140] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDER RM, 1989, PHYSIOL REV, V69, P1199, DOI 10.1152/physrev.1989.69.4.1199; BIEWENER AA, 1989, SCIENCE, V245, P45, DOI 10.1126/science.2740914; BIEWENER AA, 1983, J BIOMECH, V16, P565, DOI 10.1016/0021-9290(83)90107-0; BIEWENER AA, 1988, J EXP BIOL, V137, P191; BIEWENER AA, 1986, J EXP BIOL, V123, P383; BIEWENER AA, 1988, J ZOOL, V214, P547, DOI 10.1111/j.1469-7998.1988.tb03759.x; CAVAGNA GA, 1977, AM J PHYSIOL, V233, pR243, DOI 10.1152/ajpregu.1977.233.5.R243; CURREY J, 1984, MECH ADAPTATIONS BON, P80; FEDAK MA, 1981, J APPL PHYSIOL, V51, P772, DOI 10.1152/jappl.1981.51.3.772; HOYT DF, 1981, NATURE, V292, P239, DOI 10.1038/292239a0; KRAM R, 1989, J APPL PHYSIOL, V67, P1692, DOI 10.1152/jappl.1989.67.4.1692; MARGARIA R, 1938, ATTI ACCAD NAZ LINCE, V6, P7; MCMAHON TA, 1985, J EXP BIOL, V115, P263; PENNYCUICK CJ, 1975, J EXP BIOL, V63, P775; RUBIN CT, 1982, J EXP BIOL, V101, P187; SEEHERMAN HJ, 1981, RESP PHYSIOL, V44, P11, DOI 10.1016/0034-5687(81)90074-8	16	214	214	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					306	308		10.1126/science.1857965	http://dx.doi.org/10.1126/science.1857965			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857965				2022-12-24	WOS:A1991FX22400037
J	GOODWIN, FK				GOODWIN, FK			CONTINGENT INEFFICACY AND TOLERANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																		WEISS SRB, 1991, EPILEPSIA, V322, P140	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1850809				2022-12-24	WOS:A1991FL98900006
J	CHAPMAN, KB; BOEKE, JD				CHAPMAN, KB; BOEKE, JD			ISOLATION AND CHARACTERIZATION OF THE GENE ENCODING YEAST DEBRANCHING ENZYME	CELL			English	Article							PRE-MESSENGER RNA; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; SPLICING INVITRO; TY ELEMENTS; INTRON; DNA; INTERMEDIATE; SEQUENCES; MUTANTS	Using a genetic screen aimed at identifying cellular factors involved in Ty1 transposition, we have identified a mutation in a host gene that reduces Ty1 transposition frequency. The mutant, dbr1, is also defective in the process of intron turnover. In dbr1 cells, excised introns derived from a variety of pre-mRNAs are remarkably stable and accumulate to levels exceeding that of the corresponding mRNA. The stable excised introns accumulate in the form of a lariat that is missing the linear sequences 3' of the branchpoint. The DBR1 gene has been isolated by complementation of the transposition phenotype. DBR1 is shown to encode debranching enzyme, an RNA processing activity that hydrolyzes the 2'-5' phosphodiester linkage at the branchpoint of excised intron lariats. In Saccharomyces cerevisiae, debranching enzyme plays a requisite role in the rapid turnover of excised introns, yet its function is not essential for viability.			CHAPMAN, KB (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,725 N WOLFE ST,BALTIMORE,MD 21205, USA.				NATIONAL CANCER INSTITUTE [T32CA009139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036481] Funding Source: NIH RePORTER; NCI NIH HHS [ET32 CA09139] Funding Source: Medline; NIGMS NIH HHS [GM-36481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENAS J, 1987, J BIOL CHEM, V262, P4274; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOEKE JD, 1989, MOBILE DNA; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FLAVELL A, 1985, NATURE, V316, P574, DOI 10.1038/316574a0; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LAMPSON BC, 1989, CELL, V56, P701, DOI 10.1016/0092-8674(89)90592-8; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SCHWINDINGER WF, 1987, J BIOL CHEM, V262, P5690; SHARP PA, 1987, COLD SPRING HARB SYM, V52, P277, DOI 10.1101/SQB.1987.052.01.033; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WESSLER SR, 1989, GENE, V82, P127, DOI 10.1016/0378-1119(89)90037-1; XU H, 1990, MOL CELL BIOL, V10, P2695, DOI 10.1128/MCB.10.6.2695; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553	34	184	188	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					483	492		10.1016/0092-8674(91)90466-C	http://dx.doi.org/10.1016/0092-8674(91)90466-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850323				2022-12-24	WOS:A1991FK18200015
J	NEBREDA, AR; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; SANTOS, E				NEBREDA, AR; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; SANTOS, E			INDUCTION BY NGF OF MEIOTIC MATURATION OF XENOPUS OOCYTES EXPRESSING THE TRK PROTOONCOGENE PRODUCT	SCIENCE			English	Article							BIOCHEMICAL-CHARACTERIZATION; RECEPTOR; PROTEINS; ACTIVATION; SEQUENCES	The effect of nerve growth factor (NGF) was assessed in Xenopus oocytes expressing the human trk proto-oncogene product, p140prototrk. Oocytes injected with trk messenger RNA expressed polypeptides recognized by antibodies to the trk gene product. Exposure of these oocytes to nanomolar amounts of NGF resulted in specific surface binding of I-125-labeled NGF, tyrosine phosphorylation of p140prototrk, and meiotic maturation, as determined by germinal vesicle breakdown and maturation promoting factor (p34cdc2) kinase activation. Thus the trk proto-oncogene product can act as a receptor for NGF in a functionally productive manner.	NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Parada, luis F/B-9400-2014; Nebreda, Angel Rodriguez/R-9594-2019					ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BONGARZONE I, 1989, ONCOGENE, V4, P1457; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SEHGAL A, 1988, MOL CELL BIOL, V8, P2242, DOI 10.1128/MCB.8.5.2242; SMITH LD, 1989, DEVELOPMENT, V107, P685; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	27	119	122	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					558	560		10.1126/science.1850550	http://dx.doi.org/10.1126/science.1850550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850550				2022-12-24	WOS:A1991FJ12700044
J	CRAWSHAW, R				CRAWSHAW, R			REQUIEM FOR AN UNKNOWN LEPER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3411	3412						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744951				2022-12-24	WOS:A1991GV87800008
J	GIRARD, F; STRAUSFELD, U; FERNANDEZ, A; LAMB, NJC				GIRARD, F; STRAUSFELD, U; FERNANDEZ, A; LAMB, NJC			CYCLIN-A IS REQUIRED FOR THE ONSET OF DNA-REPLICATION IN MAMMALIAN FIBROBLASTS	CELL			English	Article							DEPENDENT PROTEIN-KINASE; EMBRYONIC-CELL CYCLE; SEA-URCHIN EGGS; MESSENGER-RNA; TYROSINE PHOSPHORYLATION; M-PHASE; P34CDC2; CDC2; DROSOPHILA; EXTRACTS	Cyclin A protein is synthesized and localized into the nucleus at the onset of S phase in nontransformed mammalian fibroblasts. Inhibition of cyclin A synthesis or activity through microinjection of plasmids encoding antisense cyclin A cDNA or affinity-purified anti-cyclin A antibodies during G1 phase was shown to abolish the nuclear staining for cyclin A in plasmid-injected cells, and both procedures led to inhibition of DNA synthesis. No similar effect was observed with injection of other antisense vectors including antisense cyclin B, and reinjection of purified human cyclin A protein into cyclin A antisense-injected cells effectively relieved this inhibition of DNA synthesis. Taken together, these data suggest that cyclin A plays a major role in the control of DNA replication in mammalian cells.			GIRARD, F (corresponding author), CNRS, CRBM, CELL BIOL UNIT, INSERM, BP 5051, F-34033 MONTPELLIER, FRANCE.			Girard, Franck/0000-0003-2587-4495				BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McClure DB, 1982, COLD SPRING HARBOR C, V9, P345; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	47	863	876	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1169	1179		10.1016/0092-8674(91)90293-8	http://dx.doi.org/10.1016/0092-8674(91)90293-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1836977				2022-12-24	WOS:A1991GX16400015
J	STARR, DB; HAWLEY, DK				STARR, DB; HAWLEY, DK			TFIID BINDS IN THE MINOR GROOVE OF THE TATA BOX	CELL			English	Article							RNA POLYMERASE-II; ECO RI ENDONUCLEASE; TRANSCRIPTION FACTOR; PROMOTER SEQUENCES; FUNCTIONAL DOMAINS; DNA; PROTEIN; YEAST; GENE; INITIATION	We have analyzed the interaction of the general RNA polymerase II transcription factor TFIID with its DNA-binding site, the TATA box (consensus sequence TATAAAA). We have demonstrated that TFIID, unlike most sequence-specific DNA-binding proteins, interacts primarily within the minor groove of the DNA helix. This was established by a novel approach involving complete replacement of the thymines and adenines in the TATA box with cytosines and inosines, respectively. This substitution exchanged the major groove of TATAAAA for that of the sequence CGCGGGG, without altering the surface of the minor groove. The unusual DNA-binding properties of TFIID revealed by this study have important implications for TFIID specificity and function and, more generally, for sequence-specific recognition by DNA-binding proteins.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	STARR, DB (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.							ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FIRE A, 1984, J BIOL CHEM, V259, P2509; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KILPATRICK MW, 1986, J BIOL CHEM, V261, P1350; LU AL, 1981, J BIOL CHEM, V256, P3200; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PENOTTI FE, 1990, J MOL BIOL, V213, P37, DOI 10.1016/S0022-2836(05)80120-2; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIT KH, 1967, BIOCHIM BIOPHYS ACTA, V149, P344, DOI 10.1016/0005-2787(67)90162-1; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	60	187	188	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1231	1240		10.1016/0092-8674(91)90299-E	http://dx.doi.org/10.1016/0092-8674(91)90299-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760847				2022-12-24	WOS:A1991GX16400021
J	SMEAL, T; BINETRUY, B; MERCOLA, DA; BIRRER, M; KARIN, M				SMEAL, T; BINETRUY, B; MERCOLA, DA; BIRRER, M; KARIN, M			ONCOGENIC AND TRANSCRIPTIONAL COOPERATION WITH HA-RAS REQUIRES PHOSPHORYLATION OF C-JUN ON SERINE-63 AND SERINE-73	NATURE			English	Article							EXPRESSION; GENE; PEA1	RECENT advances indicate a link between tumour promoters, transformation, and AP-1 activity 1. Protein kinase C activation increases AP-1 DNA-binding activity independently of new protein synthesis 2,3. AP-1 is also stimulated by transforming oncoproteins and growth factors 4-6. These proteins are thought to participate in a signalling cascade affecting the nuclear AP-1 complex composed of the Jun and Fos proteins 1,7,8. Because c-Jun is the most potent transactivator in the AP-1 complex 9-12 and is elevated in Ha-ras-transformed cells, in which c-Fos is downregulated 13,14, we focused on it as a potential target. c-Jun could convert input from an oncogenic signalling cascade into changes in gene expression. Indeed, transformation of rat embryo fibroblasts by c-Jun requires an intact transcriptional activation domain 15 and cooperation with oncogenic Ha-ras 16. Expression of oncogenic Ha-ras augments transactivation by c-Jun and stimulates its phosphorylation 14. Here we describe the mapping of the Ha-ras-responsive phosphorylation sites to serines 63 and 73 of c-Jun. Site-directed mutagenesis indicates that phosphorylation of these serines is essential for stimulation of c-Jun activity and for cooperation with Ha-ras in ocogenic transformation.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; NCI, DIV CANC PREVENT & CONTROL, BETHESDA, MD 20814 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; University of California System; University of California San Diego	KARIN, M (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.		mercola, dan/L-4182-2013; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/AFL-7188-2022; Binetruy, Bernard/S-2062-2019	mercola, dan/0000-0002-0281-9840; Binetruy, Bernard/0000-0001-8012-7092				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, IN PRESS MOL CELL BI; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, IN PRESS METH ENZYM; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; YANG-YEN H-F, 1990, New Biologist, V2, P351	26	772	781	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					494	496		10.1038/354494a0	http://dx.doi.org/10.1038/354494a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749429				2022-12-24	WOS:A1991GV07800065
J	CHITTY, LS; HUNT, GH; MOORE, J; LOBB, MO				CHITTY, LS; HUNT, GH; MOORE, J; LOBB, MO			EFFECTIVENESS OF ROUTINE ULTRASONOGRAPHY IN DETECTING FETAL STRUCTURAL ABNORMALITIES IN A LOW-RISK POPULATION	BRITISH MEDICAL JOURNAL			English	Article							MALFORMATIONS; DIAGNOSIS	Objective - To review the efficacy of routine prenatal ultrasonography for detecting fetal structural abnormalities. Design - Retrospective study of the ultrasonographic findings and outcome of all pregnancies in women scanned in 1988-9. Setting - Maternity ultrasonography department of a district general hospital. Subjects - 8785 fetuses. Main outcome measures - Correlation of prenatal ultrasonographic findings with outcome in the neonate. Results - 8733 babies were born during 1988-9, and 52 pregnancies were terminated after a fetal malformation was identified. 8432 (95%) of the fetuses were examined by ultrasonography in the second trimester. 130 fetuses (1.5%) were found to have an abnormality at birth or after termination of pregnancy, 125 of which had been examined in the second trimester. In 93 cases the abnormality was detected before 24 weeks (sensitivity 74.4%, 95% confidence interval to 66.7% to 82.1%. Two false positive diagnoses occurred, in both cases the pregnancies were not terminated and apparently normal infants were born. This gives a specificity of 99.98% (99.9% to 99.99%). The positive predictive value of ultrasonography in the second trimester was 97.9% (92.6% to 99.7%). Of the 125 abnormalities, 87 were lethal or severely disabling; 72 of the 87 were detected by the routine screening programme (sensitivity 82.8%, 73.2% to 90.0%). Conclusion - Routine fetal examination by ultrasonography in a low risk population detects many fetal structural abnormalities but can present several dilemmas in counselling.	LUTON & DUNSTABLE HOSP,LUTON LU4 0DZ,BEDS,ENGLAND; INST CHILD HLTH,DEPT CLIN GENET,LONDON WC1 1EH,ENGLAND	University of London; University College London				chitty, lyn/0000-0002-4857-7138				ASH P, 1977, LANCET, V1, P849; BENACERRAF BR, 1988, RADIOLOGY, V169, P858, DOI 10.1148/radiology.169.3.3055042; BENACERRAF BR, 1987, AM J OBSTET GYNECOL, V156, P573, DOI 10.1016/0002-9378(87)90053-6; BENACERRAF BR, 1991, ULTRASOUND OBST GYN, V1, P66, DOI 10.1046/j.1469-0705.1991.01010066.x; CAMPBELL S, 1983, PRENATAL DIAGNOSIS, P325; CHITTY LS, 1991, ULTRASOUND OBST GYN, V1, P115, DOI 10.1046/j.1469-0705.1991.01020115.x; CHITTY LS, 1989, ARCH DIS CHILD, V64, P1036, DOI 10.1136/adc.64.7.1036; CHITTY LS, 1990, LANCET, P875; DEWALS P, 1984, EUROCAT GUIDE, P65; Gardner MJ, 1989, STAT CONFIDENCE, P28; JONES LJ, 1988, SMITHS RECOGNISABLE, P662; LEVI S, 1989, LANCET, V1, P678; NICOLAIDES KH, 1987, BAILLIERE CLIN OB GY, V1, P591, DOI 10.1016/S0950-3552(87)80008-1; PERSSON PH, 1983, AM J OBSTET GYNECOL, V146, P942, DOI 10.1016/0002-9378(83)90970-5; ROSENDAHL H, 1989, OBSTET GYNECOL, V73, P947; SAARIKEMPPAINEN A, 1990, LANCET, P387	16	221	231	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1165	1169		10.1136/bmj.303.6811.1165	http://dx.doi.org/10.1136/bmj.303.6811.1165			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747613	Bronze, Green Published			2022-12-24	WOS:A1991GP48800022
J	BELLACOSA, A; TESTA, JR; STAAL, SP; TSICHLIS, PN				BELLACOSA, A; TESTA, JR; STAAL, SP; TSICHLIS, PN			A RETROVIRAL ONCOGENE, AKT, ENCODING A SERINE-THREONINE KINASE CONTAINING AN SH2-LIKE REGION	SCIENCE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASES; CATALYTIC DOMAINS; PHOSPHOLIPASE-C; SRC; GENE; MUTAGENESIS; EXPRESSION; SIMILARITY; ACTIVATION	The v-akt oncogene codes for a 105-kilodalton fusion phosphoprotein containing Gag sequences at its amino terminus. Sequence analysis of v-akt and biochemical characterization of its product revealed that it codes for a protein kinase C-related serine-threonine kinase whose cellular homolog is expressed in most tissues, with the highest amount found in thymus. Although Akt is a serine-threonine kinase, part of its regulatory region is similar to the Src homology-2 domain, a structural motif characteristic of cytoplasmic tyrosine kinases that functions in protein-protein interactions. This suggests that Akt may form a functional link between tyrosine and serine-threonine phosphorylation pathways.	FOX CHASE CANC INST,DEPT MED ONCOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927, CA-38047] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, UNPUB; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; PAWSON T, 1988, ONCOGENE, V3, P491; REDDY EP, 1983, P NATL ACAD SCI USA, V80, P2623; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TSICHLIS PN, IN PRESS CURR TOP MI; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEISS R, 1985, RNA TUMOR VIRUSES, V2, P139	32	777	820	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					274	277		10.1126/science.1833819	http://dx.doi.org/10.1126/science.1833819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1833819				2022-12-24	WOS:A1991GJ64200035
J	FISHBEIN, DJ				FISHBEIN, DJ			DO-DNA - ALCOHOLISM IN THE SOVIET-UNION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FISHBEIN, DJ (corresponding author), UNIV MASSACHUSETTS,SCH MED,BOX 426,55 LAKE AVE N,WORCESTER,MA 01655, USA.							ADELMAN SA, IN PRESS IMPATIENT P; KIRN TF, 1987, JAMA-J AM MED ASSOC, V253, P883; KIRPICHENKO AA, 1989, PSYCHIATRY; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; SMITH H, 1989, NEW RUSSIANS; 1987, DIAGNOSTIC STATISTIC, P173	6	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1211	1212		10.1001/jama.266.9.1211	http://dx.doi.org/10.1001/jama.266.9.1211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC858	1870239				2022-12-24	WOS:A1991GC85800013
J	ORENTLICHER, D				ORENTLICHER, D			HIV-INFECTED SURGEONS - BEHRINGER V MEDICAL-CENTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ORENTLICHER, D (corresponding author), AMER MED ASSOC,ETH & HLTH POLICY COUSEL,CHICAGO,IL 60610, USA.							BARAFF LJ, 1989, ANN EMERG MED, V18, P654, DOI 10.1016/S0196-0644(89)80522-0; Barnes M, 1990, Law Med Health Care, V18, P311; BRENNAN TA, 1991, NEW ENGL J MED, V324, P1504, DOI 10.1056/NEJM199105233242112; DICKEY NW, 1991, JAMA-J AM MED ASSOC, V265, P2338, DOI 10.1001/jama.1991.03460180043023; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GERBERDING JL, 1986, NEW ENGL J MED, V315, P1562, DOI 10.1056/NEJM198612113152434; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GOSTIN L, 1991, ARCH INTERN MED, V151, P663, DOI 10.1001/archinte.151.4.663; JONSEN AR, 1991, ARCH INTERN MED, V151, P660, DOI 10.1001/archinte.151.4.660; KLEIN RS, 1991, AM J MED, V90, P141, DOI 10.1016/0002-9343(91)80152-C; RHAME FS, 1990, JAMA-J AM MED ASSOC, V264, P507, DOI 10.1001/jama.264.4.507; WONG ES, 1991, JAMA-J AM MED ASSOC, V265, P1123, DOI 10.1001/jama.265.9.1123; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1991, MMWR, V40, P1; 1991, AM ACAD ORTHOP SU S2, V39, P1; 1990, OBSTET GYNECOL, V75, P1043; 1985, MMWR, V34, P681; 1987, MMWR S2S, V36, pS3; 1991, JAMA-J AM MED ASSOC, V265, P1872; 1991, PHYSICIAN CHARACTERI, P90; 1991, MMWR, V40, P377; 1989, CURRENT OPINIONS, P32	22	16	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1134	1137		10.1001/jama.266.8.1134	http://dx.doi.org/10.1001/jama.266.8.1134			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865550				2022-12-24	WOS:A1991GB97500041
J	ROULD, MA; PERONA, JJ; STEITZ, TA				ROULD, MA; PERONA, JJ; STEITZ, TA			STRUCTURAL BASIS OF ANTICODON LOOP RECOGNITION BY GLUTAMINYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 2.8-A RESOLUTION; TRANSLATION; REFINEMENT; ATP	The refined crystal structure of Escherichia coli glutaminyl transfer RNA synthetase complexed with transfer RNA(Gln) and ATP reveals that the structure of the anticodon loop of the enzyme-bound tRNA(Gln) differs extensively from that of the known crystal structures of uncomplexed tRNA molecules. The anticodon stem is extended by two non-Watson-Crick base pairs, leaving the three anticodon bases unpaired and splayed out to bind snugly into three separate complementary pockets in the protein. These interactions suggest that the entire anticodon loop provides essential sites for glutaminyl tRNA synthetase discrimination among tRNA molecules.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06511 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06511 USA	Yale University; Howard Hughes Medical Institute; Yale University	ROULD, MA (corresponding author), YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, POB 6666, NEW HAVEN, CT 06511 USA.		Steitz, Thomas A./C-6559-2009					BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FINZEL BC, 1990, CRYSTALLOGRAPHIC MOD, P175; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; NROMANLY J, 1989, A REV BIOCH, V58, P1029; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; RAVEL JM, 1965, J BIOL CHEM, V240, P432; REDFIELD AG, 1986, STRUCTURE DYNAMICS R; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SENO T, 1974, BIOCHIM BIOPHYS ACTA, V349, P328, DOI 10.1016/0005-2787(74)90120-8; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; WESTHOF E, 1988, ACTA CRYSTALLOGR A, V44, P112, DOI 10.1107/S010876738700446X; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1986, J MOL BIOL, V192, P235, DOI 10.1016/0022-2836(86)90362-1; YARUS M, 1977, NUCLEIC ACID PROTEIN, P391	26	349	353	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					213	218		10.1038/352213a0	http://dx.doi.org/10.1038/352213a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857417				2022-12-24	WOS:A1991FX18500054
J	KENNEDY, DH; NAIR, G; ELLIOTT, L; DITTON, J				KENNEDY, DH; NAIR, G; ELLIOTT, L; DITTON, J			DRUG MISUSE AND SHARING OF NEEDLES IN SCOTTISH PRISONS	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,CTR HIV & AIDS RESOURCE,GLASGOW G12 8QQ,SCOTLAND; RUCHILL HOSP,DEPT INFECT & TROP MED,GLASGOW G20 9NB,SCOTLAND; UNIV GLASGOW,CRIMINOL RES UNIT,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; University of Glasgow								CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; DOLAN KA, 1990, HOWARD J, V29, P177; HARDING TW, 1990, HIV AIDS EUORPEAN PR; Stimson GV, 1988, INJECTING EQUIPMENT; 1990, ANSWER AIDS NEWS S	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1507	1507		10.1136/bmj.302.6791.1507	http://dx.doi.org/10.1136/bmj.302.6791.1507			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT505	1855021	Green Published, Bronze			2022-12-24	WOS:A1991FT50500024
J	WIKLER, KC; RAKIC, P				WIKLER, KC; RAKIC, P			RELATION OF AN ARRAY OF EARLY-DIFFERENTIATING CONES TO THE PHOTORECEPTOR MOSAIC IN THE PRIMATE RETINA	NATURE			English	Article							RHESUS-MONKEY RETINA; LINEAGE; GREEN; BLUE	THE retina of diurnal primates, including humans, contains a reiterative mosaic of red-, green- and blue-sensitive cones whose visual pigments are maximally sensitive to long, middle or short wavelengths, respectively 1. Although the distribution of the cone subtypes in the adult rhesus monkey has been quantified using opsin-specific antisera 2, the mechanism for the phenotypic specification of the cone subtypes and the establishment of their ratios in the retinal mosaic remain unknown. Here we present immunocytochemical evidence that a subset of cones (about 10%) express their cell-specific opsin two to three weeks before the surrounding cones. Remarkably, these precocious cones are evenly stationed throughout undifferentiated regions of the retinal surface from several weeks after their last mitotic division 3, and at least one month before the formation of their synapses with bipolar and horizontal cells 4. Use of confocal laser microscopy reveals that the inner segments of immunolabelled and surrounding unlabelled cones are transiently in apposition with one another, enabling surface mediated interactions to occur during this period. We suggest that the early maturing cones induce neighbouring undifferentiated cones to express an appropriate opsin phenotype, and therefore constitute a 'protomap' for the emergence of the species-specific retinal mosaic.			WIKLER, KC (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,POB 3333,NEW HAVEN,CT 06510, USA.							ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; CURCIO C A, 1989, Society for Neuroscience Abstracts, V15, P1206; FINLAY BL, 1989, DEV VERTEBRATE RETIN; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; Jacobs GH, 1981, COMP COLOR VISION; JOHNSON LV, 1988, INVEST OPHTH VIS SCI, V29, P550; LAVAIL M, 1983, INVEST OPHTHALMOL, V24, P7; LAVAIL MM, IN PRESS J COMP NEUR; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NISHIMURA Y, 1985, J COMP NEUROL, V241, P420, DOI 10.1002/cne.902410403; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAPAPORT DH, 1982, DEV BRAIN RES, V5, P273, DOI 10.1016/0165-3806(82)90126-2; REH TA, 1989, J NEUROSCI, V9, P417; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WATANABE T, 1990, NEURON, V2, P461; WETTS R, 1989, DEV BIOL, V136, P254, DOI 10.1016/0012-1606(89)90146-2; WIKLER KC, 1990, J COMP NEUROL, V297, P499, DOI 10.1002/cne.902970404; WIKLER KC, 1990, J NEUROSCI, V10, P3390	20	77	77	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					397	400		10.1038/351397a0	http://dx.doi.org/10.1038/351397a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1827876				2022-12-24	WOS:A1991FN85600055
J	SHARMA, HM; TRIGUNA, BD; MARTAND, AV; CHOPRA, D				SHARMA, HM; TRIGUNA, BD; MARTAND, AV; CHOPRA, D			MAHARISHI AYUR-VEDA - MODERN INSIGHTS INTO ANCIENT-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSCENDENTAL MEDITATION; ANTINEOPLASTIC PROPERTIES; CARE		ALL INDIA AYUR VEDA CONGRESS,NEW DELHI,INDIA; AMER ASSOC AYURVED MED,LANCASTER,MA		SHARMA, HM (corresponding author), OHIO STATE UNIV,COLL MED,DEPT PATHOL,ROOM M3685L,320 W 10TH AVE,COLUMBUS,OH 43210, USA.							ALEXANDER CN, 1989, J PERS SOC PSYCHOL, V57, P950, DOI 10.1037/0022-3514.57.6.950; CHOPRA D, 1990, PERFECT HLTH; Chopra Deepak, 1989, QUANTUM HEALING EXPL; Chopra R., 1982, INDIGENOUS DRUGS IND; DILEEPAN KN, 1990, BIOCHEM ARCH, V6, P267; GHISAGRANTNE KL, 1963, SUSHRUTA SAMHITA; Janssen G., 1989, NED TIJDSCHR GENEES, V5, P586; NIWA Y, 1991, INDIAN J CLIN PRACT, V1, P23; ORMEJOHNSON D, 1987, PSYCHOSOM MED, V49, P493, DOI 10.1097/00006842-198709000-00006; ORMEJOHNSON DW, 1988, J CONFLICT RESOLUT, V32, P776, DOI 10.1177/0022002788032004009; PATEL V, 1990, FASEB Journal, V4, pA637; PRASAD KN, 1990, 8TH BIENN M INT SOC; SCHNEIDER RH, 1990, J SOC BEHAV PERS, V5, P1; SHARMA HM, 1990, EUR J PHARMACOL, V183, P193, DOI 10.1016/0014-2999(90)93027-N; SHARMA HM, 1990, PHARMACOL BIOCHEM BE, V35, P767, DOI 10.1016/0091-3057(90)90356-M; SHARMA HM, 1989, CLIN TER CARDIOVAS, V8, P227; SHARMA RK, 1977, CHARAKA SAMHITA; THYAGARAJAN SP, 1988, LANCET, V2, P764; VASISHTA SD, 1983, ESSENCE PULSE DIAGNO; WALLACE RK, 1970, SCIENCE, V167, P1751, DOI 10.1126/science.167.3926.1751; Zaman H, 1974, TRADITIONAL MED, P231	21	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2633	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1817464				2022-12-24	WOS:A1991FL98900001
J	LI, R; KNIGHT, JD; JACKSON, SP; TJIAN, R; BOTCHAN, MR				LI, R; KNIGHT, JD; JACKSON, SP; TJIAN, R; BOTCHAN, MR			DIRECT INTERACTION BETWEEN SP1 AND THE BPV ENHANCER E2-PROTEIN MEDIATES SYNERGISTIC ACTIVATION OF TRANSCRIPTION	CELL			English	Article							BOVINE PAPILLOMAVIRUS TYPE-1; DNA-BINDING PROTEINS; CARBOXY-TERMINAL DOMAIN; LONG CONTROL REGION; TRANS-ACTIVATOR; MUTATIONAL ANALYSIS; GENE-EXPRESSION; MAMMALIAN-CELLS; E2 PROTEIN; PROMOTER	The physical interaction of heterologous site-specific DNA-binding proteins is an important theme in eukaryotic transcriptional regulation. In this paper, we show that the cellular transcription factor Sp1 and the BPV-1 (bovine papillomavirus type 1) enhancer protein E2 activate transcription synergistically from two papilloma viral promoters and a series of synthetic promoter constructs in transient transfection experiments. Furthermore, Sp1 can target E2 to a promoter region even in the absence of a specific E2 DNA-binding motif. Biochemical experiments establish that Sp1 enhances E2 binding to its sites and that the two proteins form a specific complex. Sp1 sequesters distally bound E2 to the promoter region by formation of stable DNA loops, visualized by electron microscopy. These experiments substantiate the notion that enhancer binding proteins are targeted to promoter regions by direct interaction with proteins that bind proximal to the transcriptional start site.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	LI, R (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.		Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937				ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BAKER CC, 1987, EMBO J, V6, P1027, DOI 10.1002/j.1460-2075.1987.tb04855.x; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOSTATNI N, 1988, EMBO J, V7, P3807, DOI 10.1002/j.1460-2075.1988.tb03265.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAUGEN TH, 1987, EMBO J, V6, P145, DOI 10.1002/j.1460-2075.1987.tb04732.x; HAUGEN TH, 1988, EMBO J, V7, P4245, DOI 10.1002/j.1460-2075.1988.tb03322.x; HEIKE T, 1989, EMBO J, V8, P1411, DOI 10.1002/j.1460-2075.1989.tb03522.x; HERMONAT PL, 1987, J VIROL, V61, P3889, DOI 10.1128/JVI.61.12.3889-3895.1987; HERMONAT PL, 1988, EMBO J, V7, P2815, DOI 10.1002/j.1460-2075.1988.tb03137.x; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; KNIGHT J, 1981, IN PRESS P NATL ACAD; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOSKALUK C, 1987, P NATL ACAD SCI USA, V84, P1215, DOI 10.1073/pnas.84.5.1215; MULLER HP, 1990, TRENDS GENET, V6, P300, DOI 10.1016/0168-9525(90)90236-Y; PRAKASH SS, 1988, J VIROL, V62, P3608, DOI 10.1128/JVI.62.10.3608-3613.1988; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBBINS P, 1985, EUKARYOTIC TRANSCRIP, P41; ROBBINS PD, 1986, MOL CELL BIOL, V6, P1283, DOI 10.1128/MCB.6.4.1283; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; SPALHOLZ BA, 1988, J VIROL, V62, P2128; STENLUND A, 1985, J MOL BIOL, V182, P541, DOI 10.1016/0022-2836(85)90240-2; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; SU W, 1991, IN PRESS GENES DEV; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VAILLANCOURT P, 1990, J VIROL, V64, P3927, DOI 10.1128/JVI.64.8.3927-3937.1990; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0	70	301	304	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					493	505		10.1016/0092-8674(91)90467-D	http://dx.doi.org/10.1016/0092-8674(91)90467-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850324				2022-12-24	WOS:A1991FK18200016
J	ACHAORBEA, H; SHAKHOV, AN; SCARPELLINO, L; KOLB, E; MULLER, V; VESSAZSHAW, A; FUCHS, R; BLOCHLINGER, K; ROLLINI, P; BILLOTTE, J; SARAFIDOU, M; MACDONALD, HR; DIGGELMANN, H				ACHAORBEA, H; SHAKHOV, AN; SCARPELLINO, L; KOLB, E; MULLER, V; VESSAZSHAW, A; FUCHS, R; BLOCHLINGER, K; ROLLINI, P; BILLOTTE, J; SARAFIDOU, M; MACDONALD, HR; DIGGELMANN, H			CLONAL DELETION OF V-BETA 14-BEARING T-CELLS IN MICE TRANSGENIC FOR MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LONG TERMINAL REPEAT; POSITIVE SELECTION; PROVIRAL DNA; MOUSE; RECEPTOR; TOLERANCE; REGION; MLSA; DETERMINANTS	Autoreactive T lymphocytes are clonally deleted during maturation in the thymus. Deletion of T cells expressing particular receptor V-beta elements is controlled by poorly defined autosomal dominant genes. A gene has now been identified by expression of transgenes in mice which causes deletion of V-beta-14+ T cells. The gene lies in the open reading frame of the long terminal repeat of the mouse mammary tumour virus.	UNIV ZURICH,INST IMMUNOL & VIROL,CH-8051 ZURICH,SWITZERLAND; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Zurich; Swiss Institute Experimental Cancer Research	ACHAORBEA, H (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.							ABE R, 1989, J EXP MED, V170, P1059, DOI 10.1084/jem.170.4.1059; BEHLKE MA, 1986, P NATL ACAD SCI USA, V83, P767, DOI 10.1073/pnas.83.3.767; BERUMEN L, 1983, EUR J IMMUNOL, V13, P292, DOI 10.1002/eji.1830130405; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BLOCHLINGER K, 1986, THESIS U LAUSANNE; BUETTI E, 1981, CELL, V23, P335, DOI 10.1016/0092-8674(81)90129-X; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; EICHER EM, 1990, GENETICS, V125, P431; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUO WL, 1988, J VIROL, V62, P2394, DOI 10.1128/JVI.62.7.2394-2402.1988; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MACDONALD HR, 1988, NATURE, V336, P471, DOI 10.1038/336471a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MACDONALD HR, 1989, PROGR IMMUNOLOGY, V7, P561; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHALIDES R, 1981, CELL, V23, P165, DOI 10.1016/0092-8674(81)90281-6; MOLINA IJ, 1989, J IMMUNOL, V143, P39; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SCHNEIDER R, 1989, J EXP MED, V169, P2149, DOI 10.1084/jem.169.6.2149; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SINGER PA, 1990, EMBO J, V9, P3641, DOI 10.1002/j.1460-2075.1990.tb07575.x; SPEISER DE, 1989, J EXP MED, V170, P595, DOI 10.1084/jem.170.2.595; TSUBURA A, 1988, CANCER RES, V48, P6555; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVERENP, 1988, J VIROL, V62, P4410; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1; WELLINGER RJ, 1986, J VIROL, V60, P1; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0	51	317	323	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1991	350	6315					207	211		10.1038/350207a0	http://dx.doi.org/10.1038/350207a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FC779	1848685				2022-12-24	WOS:A1991FC77900047
J	GERARD, NP; GERARD, C				GERARD, NP; GERARD, C			THE CHEMOTACTIC RECEPTOR FOR HUMAN-C5A ANAPHYLATOXIN	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; C5A RECEPTOR; CLONING; CDNA; C3A	HOST defence and inflammatory responses are controlled and amplified by receptor-mediated events often initiated by a chemotactic factor that directs the approach of phagocytic cells 1. Complement receptors CR1 and CR3 are responsible for the phagocytic and adhesive properties of neutrophils 2,3, whereas the C5a receptor mediates the pro-inflammatory and chemotactic actions of the complement anaphylatoxin C5a 4-6. In addition stimulating chemotaxis, granule enzyme release and superoxide anion production, this receptor stimulates upregulation of expression and activity of the adhesion molecule MAC-1, and of CR1, and a decrease in cell-surface glycoprotein 100MEL-14 on neutrophils 7-9. In vivo, the C5a receptor may participate in anaphylactoid and septic shock. The human C5a receptor was cloned from U937 and HL-60 cells and identified by high affinity binding when expressed in COS-7 cells. The deduced amino-acid sequence of the receptor reveals the expected motifs befitting its interaction with cellular GTP-binding proteins.	BETH ISRAEL HOSP, DIV PULM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	GERARD, NP (corresponding author), CHILDRENS HOSP MED CTR, INA SUE PERLMUTTER RES LAB, BOSTON, MA 02115 USA.							AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ARUFFO A, 1990, P NATL ACAD SCI USA, V265, P20455; BIRNBAUMER L, 1990, AM REV RESPIR DIS, V141, pS106, DOI 10.1164/ajrccm/141.3_Pt_2.S106; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; COTECCHIA S, 1985, LIFE SCI, V37, P2389, DOI 10.1016/0024-3205(85)90106-7; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DELBALZO U, 1989, CIRC RES, V65, P847, DOI 10.1161/01.RES.65.3.847; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FELTNER DE, 1986, J IMMUNOL, V137, P1961; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; GERARD NP, 1990, J BIOL CHEM, V265, P20455; HACK CE, 1989, AM J MED, V86, P20, DOI 10.1016/0002-9343(89)90224-6; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; JOHNSON RJ, 1985, J BIOL CHEM, V260, P7161; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; ROLLINS TE, 1985, J BIOL CHEM, V260, P7157; SNYDERMAN R, 1986, MED CLIN N AM, V70, P217, DOI 10.1016/S0025-7125(16)30951-8; STIMLERGERARD NP, 1980, AM J PATHOL, V100, P1057; WARD PA, 1974, AM J PATHOL, V77, P519	23	628	662	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					614	617		10.1038/349614a0	http://dx.doi.org/10.1038/349614a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1847994				2022-12-24	WOS:A1991EX57000061
J	MURPH, JR; BARON, JC; BROWN, CK; EBELHACK, CL; BALE, JF				MURPH, JR; BARON, JC; BROWN, CK; EBELHACK, CL; BALE, JF			THE OCCUPATIONAL RISK OF CYTOMEGALOVIRUS-INFECTION AMONG DAY-CARE PROVIDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIRUS INFECTION; MOLECULAR EPIDEMIOLOGY; CHILDREN; TRANSMISSION; PREGNANCY; CENTERS; PARENTS	We prospectively studied day-care providers at six day-care centers in southeastern Iowa to determine their occupational risk for primary cytomegalovirus infection and to define epidemiologic risk factors. Ninety-six (38%) of 252 day-care providers were seropositive for cytomegalovirus by latex agglutination at entry into the study. Among 82 seronegative providers available for follow-up, seven seroconversions occurred at only two of the six participating centers, yielding an annualized seroconversion rate of 7.9%. Median time to seroconversion among these providers was 13 months. Using Kaplan-Meier estimates of risk, we determined that the overall risk of seroconversion among providers at various centers ranged from 0% to 22% by 12 months and from 0% to 40% by 16 months. Risk of cytomegalovirus acquisition by providers was independent of race, age, education, the presence of a child at home, or caring for children younger than 2 or 3 years in the day-care center. However, the risk of seroconversion among day-care providers appeared to parallel rates of cytomegalovirus excretion and acquisition among children at each center.	UNIV IOWA,COLL MED,DIV GEN PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DIV PEDIAT NEUROL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PREVENT MED & ENVIRONM HLTH,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa	MURPH, JR (corresponding author), UNIV IOWA HOSP & CLIN,DIV GEN PEDIAT,2474 JCP,IOWA CITY,IA 52242, USA.				NICHD NIH HHS [HD 22136] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022136] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER SP, 1985, J INFECT DIS, V152, P760, DOI 10.1093/infdis/152.4.760; ADLER SP, 1988, J PEDIATR-US, V112, P366, DOI 10.1016/S0022-3476(88)80314-7; ADLER SP, 1989, NEW ENGL J MED, V321, P1290, DOI 10.1056/NEJM198911093211903; AHLFORS K, 1982, ACTA PAEDIATR SCAND, V71, P109, DOI 10.1111/j.1651-2227.1982.tb09380.x; BALCAREK KB, 1990, JAMA-J AM MED ASSOC, V263, P840, DOI 10.1001/jama.263.6.840; BALFOUR CL, 1986, JAMA-J AM MED ASSOC, V256, P1909, DOI 10.1001/jama.256.14.1909; BLACKMAN JA, 1987, PEDIATR INFECT DIS J, V6, P725, DOI 10.1097/00006454-198708000-00006; GRIFFITHS PD, 1984, BRIT J OBSTET GYNAEC, V91, P307, DOI 10.1111/j.1471-0528.1984.tb05915.x; HUTTO C, 1985, PEDIATR INFECT DIS J, V4, P149, DOI 10.1097/00006454-198503000-00008; JONES LA, 1985, J INFECT DIS, V151, P953, DOI 10.1093/infdis/151.5.953; KALBFLEISH JD, 1980, STATISTICAL ANAL FAI, P143; MCHUGH TM, 1985, J CLIN MICROBIOL, V22, P1014, DOI 10.1128/JCM.22.6.1014-1019.1985; MURPH JR, 1988, AM J DIS CHILD, V142, P843, DOI 10.1001/archpedi.1988.02150080049020; MURPH JR, 1986, J PEDIATR-US, V109, P35, DOI 10.1016/S0022-3476(86)80568-6; PASS RF, 1990, PEDIATR INFECT DIS J, V9, P465, DOI 10.1097/00006454-199007000-00003; PASS RF, 1984, PEDIATRICS, V74, P121; PASS RF, 1986, NEW ENGL J MED, V314, P1414, DOI 10.1056/NEJM198605293142204; PASS RF, 1982, NEW ENGL J MED, V307, P477, DOI 10.1056/NEJM198208193070804; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; 1987, USERS MANUAL STAT LI, P371	20	78	78	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 6	1991	265	5					603	608		10.1001/jama.265.5.603	http://dx.doi.org/10.1001/jama.265.5.603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV718	1846215				2022-12-24	WOS:A1991EV71800016
J	MILLER, NA; CARMICHAEL, HA; CALDER, BD; BEHAN, PO; BELL, EJ; MCCARTNEY, RA; HALL, FC				MILLER, NA; CARMICHAEL, HA; CALDER, BD; BEHAN, PO; BELL, EJ; MCCARTNEY, RA; HALL, FC			ANTIBODY TO COXSACKIE-B VIRUS IN DIAGNOSING POSTVIRAL FATIGUE SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYALGIC ENCEPHALOMYELITIS; INFECTIOUS-MONONUCLEOSIS; GENERAL-PRACTICE; PERSISTENT; EPIDEMIC; ILLNESS; DISEASE; MUSCLE	Objective-To study the association between coxsackie B virus infection and the postviral fatigue syndrome and to assess the immunological abnormalities associated with the syndrome. Design - Case-control study of patients with the postviral fatigue syndrome referred by local general practitioners over one year. Setting - General practioner referrals in Dunbartonshire, Scotland. Patients - 254 Patients referred with the postviral fatigue syndrome (exhaustion, myalgia, and other symptoms referable to postviral fatigue syndrome of fairly recent onset - that is, several months) and age and sex matched controls obtained from same general practitioner; 11 patients were rejected because of wrong diagnoses, resolution of symptoms, and refusal to participate, leaving 243 patients and matched controls. Main outcome measures - Detailed questionnaire (patients and controls) and clinical examination (patients) and blind analysis of blood sample at entry and after six months for determination of coxsackie B virus IgM and IgG antibodies and other variables (including lymphocyte protein synthesis, lymphocyte subsets, and immune complexes). Results - Percentage positive rates for coxsackie B virus IgM at entry were 24.4% for patients and 22.6% for controls and for coxsackie B virus IgG 56.2% and 55.3% respectively; there were no significant differences between different categories of patients according to clinical likelihood of the syndrome nor any predictive value in a fourfold rise or fall in the coxsackie B virus IgG titre in patients between entry and review at six months. The rates of positive antibody test results in patients and controls showed a strong seasonal variation. Of the numerous immunological tests performed, only a few detected significant abnormalities; in particular the mean value for immune complex concentration was much higher in 35 patients and 35 controls compared with the normal range and mean value for total IgM was also raised in 227 patients and 35 controls compared with the normal range. Conclusions - Serological tests available for detecting coxsackie B virus antibodies do not help diagnose the postviral fatigue syndrome. Percentage positive rates of the antibodies in patients simply reflect the background in the population as probably do the raised concentrations of total IgM and immune complexes.	VALE LEVEN HOSP, ALEXANDRIA G83 0UA, DUNBARTON, SCOTLAND; UNIV GLASGOW, NEUROL, GLASGOW G12 8QQ, SCOTLAND; RUCHILL HOSP, REG VIRUS LAB, GLASGOW G20 9NB, SCOTLAND	University of Glasgow								ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARCHARD LC, 1988, J EXP CLIN CANC RES, V7, P3; ARNOLD DL, 1984, LANCET, V1, P1367; BARNES DM, 1986, SCIENCE, V234, P541, DOI 10.1126/science.3020689; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BELL EJ, 1983, SCOT MED J, V28, P157, DOI 10.1177/003693308302800212; BORYSIEWICZ LK, 1986, Q J MED, V58, P111; CALDER BD, 1984, J ROY COLL GEN PRACT, V34, P15; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; DILLON MJ, 1974, BRIT MED J, V1, P301, DOI 10.1136/bmj.1.5903.301; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; FEGAN KG, 1983, J ROY COLL GEN PRACT, V33, P335; Grist N. R., 1979, DIAGNOSTIC METHODS C; HAMBLIN TJ, 1983, BRIT MED J, V287, P85, DOI 10.1136/bmj.287.6385.85; HENDERSON DA, 1959, NEW ENGL J MED, V260, P814, DOI 10.1056/NEJM195904162601606; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; JAMAL GA, 1985, J NEUROL NEUROSUR PS, V48, P691, DOI 10.1136/jnnp.48.7.691; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KADIRY WA, 1983, PROG BRAIN RES, V59, P61; KEIGHLEY BD, 1983, J ROY COLL GEN PRACT, V33, P339; MCCARTNEY RA, 1986, J MED VIROL, V19, P205, DOI 10.1002/jmv.1890190302; POOLE M, 1984, NZ MED J, V97, P351; Ramsay AM, 1986, POSTVIRAL FATIGUE SY, V1st; RICE GPA, 1984, J NEUROIMMUNOL, V6, P75, DOI 10.1016/0165-5728(84)90028-6; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; TOBI M, 1982, LANCET, V1, P61; YOUSEF GE, 1988, LANCET, V1, P146	29	70	71	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 19	1991	302	6769					140	143		10.1136/bmj.302.6769.140	http://dx.doi.org/10.1136/bmj.302.6769.140			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU020	1847316	Green Published, Bronze			2022-12-24	WOS:A1991EU02000019
J	WILENSKY, GR				WILENSKY, GR			FINANCING CARE FOR PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3404	3404						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV878	1744948				2022-12-24	WOS:A1991GV87800005
J	WONG, D; NYE, K; HOLLIS, P				WONG, D; NYE, K; HOLLIS, P			MICROBIAL-FLORA ON DOCTORS WHITE COATS	BRITISH MEDICAL JOURNAL			English	Article							NURSES	Objective - To determine the level and type of microbial contamination present on the white coats of doctors in order to assess the risk of transmission of pathogenic micro-organisms by this route in a hospital setting. Design - Cross sectional survey of the bacterial contamination of white coats in a general hospital. Setting - East Birmingham Hospital, an urban general hospital with 800 beds. Subjects - 100 doctors of different grades and specialties. Results - The cuffs and pockets of the coats were the most highly contaminated areas. The level of bacterial contamination did not vary with the length of time a coat had been in use, but it increased with the degree of usage by the individual doctor. Staphylococcus aureus was isolated from a quarter of the coats examined, more commonly from those belonging to doctors in surgical specialties than medical specialties. Pathogenic Gram negative bacilli and other pathogenic bacteria were not isolated. Conclusions - White coats are a potential source of cross infection, especially in surgical areas. Scrupulous hand washing should be observed before and after attending patients and it may be advisable to remove the white coat and put on a plastic apron before examining wounds. There is little microbiological reason for recommending a more frequent change of white coat than once a week, nor for excluding the wearing of white coats in non-clinical areas.			WONG, D (corresponding author), E BIRMINGHAM DIST GEN HOSP,PUBL HLTH LAB,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND.							AYLIFFE GAJ, 1967, J HYG-CAMB, V65, P515, DOI 10.1017/S0022172400046052; BABB JR, 1983, J HOSP INFECT, V4, P149, DOI 10.1016/0195-6701(83)90044-0; HAMBRAEUS A, 1973, J HYG-CAMBRIDGE, V71, P799, DOI 10.1017/S0022172400023068; LIDWELL OM, 1974, J APPL BACTERIOL, V37, P649, DOI 10.1111/j.1365-2672.1974.tb00489.x; NICOLES PS, 1970, AM J PUBLIC HEALTH, V60, P2175; Nystrom B, 1981, J Hosp Infect, V2, P167, DOI 10.1016/0195-6701(81)90025-6; RANSJO U, 1979, J HYG-CAMBRIDGE, V82, P369, DOI 10.1017/S0022172400053900; ROBINTON ED, 1968, AM J PUBLIC HEALTH N, V58, P1452, DOI 10.2105/AJPH.58.8.1452; SPEERS R, 1969, LANCET, V2, P233	9	115	119	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1602	1604		10.1136/bmj.303.6817.1602	http://dx.doi.org/10.1136/bmj.303.6817.1602			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773186	Green Published, Bronze			2022-12-24	WOS:A1991GX95600019
J	AARONS, EJ; BEECHING, NJ				AARONS, EJ; BEECHING, NJ			SURVEY OF DO NOT RESUSCITATE ORDERS IN A DISTRICT GENERAL-HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY RESUSCITATION; SURVIVAL	Objective - To evaluate the local use of written "Do not resuscitate" orders to designate inpatients unsuitable for cardiopulmonary resuscitation in the event of cardiac arrest. Design - Point prevalence questionnaire survey of inpatients' medical and nursing records. Setting - 10 acute medical and six acute surgical wards of a district general hospital. Participants - Questionnaires were filled in anonymously by nurses and doctors working on the wards surveyed. Main outcome measures - Responses to questionnaire items concerning details about each patient, written orders not to resuscitate in the medical case notes and nursing records, whether prognosis had been discussed with patients' relatives, whether a "crash call" was perceived as appropriate for each patient, and whether the "crash team" would be called in the event of arrest. Results - Information was obtained on 297 (93.7%) of 317 eligible patients. Prognosis had been discussed with the relatives of 32 of 88 patients perceived by doctors as unsuitable for resuscitation. Of these 88 patients, 24 had orders not to resuscitate in their medical notes, and only eight of these had similar orders in their nursing notes. Conclusions - In the absence of guidelines on decisions about resuscitation, orders not to resuscitate are rarely included in the notes of patients for whom cardiopulmonary resuscitation is thought to be inappropriate. Elective decisions not to resuscitate are not effectively communicated to nurses. There should be more discussion of patients' suitability for resuscitation between doctors, nurses, patients, and patients' relatives. Suitability for resuscitation should be reviewed on every consultant ward round.	FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND		BEECHING, NJ (corresponding author), FAZAKERLEY DIST GEN HOSP,REG INFECT DIS UNIT,LIVERPOOL L9 7AL,ENGLAND.		Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				ASPLUND K, 1990, J INTERN MED, V228, P139; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; Halligan M, 1985, Health Prog, V66, P26; HALLIGAN M, 1985, HLTH PROGR, V66, P600; KAMER RS, 1990, AM J MED, V88, P108, DOI 10.1016/0002-9343(90)90457-O; KEATINGE RM, 1989, J ROY SOC MED, V82, P402, DOI 10.1177/014107688908200711; MCCLUNG JA, 1990, NEW ENGL J MED, V323, P270, DOI 10.1056/NEJM199007263230411; PEATFIELD RC, 1977, LANCET, V1, P1223; STOLMAN CJ, 1990, ARCH INTERN MED, V150, P653, DOI 10.1001/archinte.150.3.653; URBURG M, 1987, J FAM PRACTICE, V25, P41; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1984, CODE PROFESSIONAL CO	14	45	45	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1504	1506		10.1136/bmj.303.6816.1504	http://dx.doi.org/10.1136/bmj.303.6816.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782488	Bronze, Green Published			2022-12-24	WOS:A1991GV47600019
J	SEAGROATT, V; TAN, HS; GOLDACRE, M; BULSTRODE, C; NUGENT, I; GILL, L				SEAGROATT, V; TAN, HS; GOLDACRE, M; BULSTRODE, C; NUGENT, I; GILL, L			ELECTIVE TOTAL HIP-REPLACEMENT - INCIDENCE, EMERGENCY READMISSION RATE, AND POSTOPERATIVE MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							PRIVATE SECTOR; SURGERY; ENGLAND; WALES	Objectives - To report the incidence of elective total hip replacement and postoperative mortality, emergency readmission rates, and the demographic factors associated with these rates in a large defined population. Design - Analysis of linked, routine abstracts of hospital inpatient records and death certificates. Setting - 10 hospitals in six districts in Oxford Regional Health Authority covered by the Oxford record linkage study. Subjects - Records for 11607 total hip replacements performed electively in 1976-85. Main outcome measures - Incidence of operation, postoperative mortality, relative mortality ratios, and incidence of emergency readmission. Results - NHS operation rates increased over time from 43 to 58 operations/100 000 population. Variation in operation rates between districts reduced over time. Operation rates were on average 25% higher in women than men. There were 93 deaths (11/1000 operations) within 90 days of the operation and 208 emergency readmissions (28/1000 operations) within 28 days of discharge. Postoperative mortality and emergency readmission rates increased with age. No significant trend with time was found. Mortality in the 90 days after the operation was 2.5-fold higher (1.9 to 3.0) than in the rest of the first postoperative year. This represented an estimated excess of 6.5 (4.2 to 8.8) early postoperative deaths/1000 operations. Most deaths were ascribed to cardiovascular events. Thromboembolic disease was the commonest reason for emergency readmission. Conclusions - The pronounced increase in operations in districts with initially low rates suggests a trend towards greater equity in the local provision of NHS hip arthroplasty. The early postoperative clusters of deaths attributed to cardiovascular disease and of readmissions for thromboembolic disease suggest that there is scope for investigating ways of reducing the incidence of major adverse postoperative events.	NUFFIELD ORTHOPAED CTR,NUFFIELD DEPT ORTHOPAED SURG,OXFORD OX3 7LD,ENGLAND	Nuffield Orthopaedic Centre	SEAGROATT, V (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CLIN EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.							BAKER RJ, 1978, GLIM SYSTEM; BRADY LP, 1986, CLIN ORTHOP RELAT R, V211, P51; CHANDLER HP, 1981, J BONE JOINT SURG AM, V63, P1426, DOI 10.2106/00004623-198163090-00008; CHARNLEY J, 1975, CLIN ORTHOP RELAT R, V111, P105; CORNELL CN, 1986, J BONE JOINT SURG AM, V68A, P1430, DOI 10.2106/00004623-198668090-00017; DORR LD, 1983, J BONE JOINT SURG AM, V65, P474, DOI 10.2106/00004623-198365040-00007; FRANKEL W, 1991, 2 U BRIST REP; Gustilo R B, 1982, Hip, P27; HENDERSON J, 1989, BRIT MED J, V299, P709, DOI 10.1136/bmj.299.6701.709; LASSEN MR, 1991, LANCET, P618; NICHOLL JP, 1989, BRIT MED J, V298, P243, DOI 10.1136/bmj.298.6668.243; NICHOLL JP, 1984, LANCET, V2, P89; RANAWAT CS, 1984, J BONE JOINT SURG AM, V66A, P745, DOI 10.2106/00004623-198466050-00014; SALVATI EA, 1981, J BONE JOINT SURG AM, V63, P753, DOI 10.2106/00004623-198163050-00010; TERAYAMA K, 1986, CLIN ORTHOP RELAT R, V211, P79; WELCH RB, 1988, ORTHOP CLIN N AM, V19, P551; WROBLEWSKI BM, 1986, CLIN ORTHOP RELAT R, V201, P37; [No title captured]; 1975, CLASSIFICATION SURGI; HOSPITAL PATIENT ENQ; [No title captured]	21	175	179	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1431	1435		10.1136/bmj.303.6815.1431	http://dx.doi.org/10.1136/bmj.303.6815.1431			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773147	Green Published, Bronze			2022-12-24	WOS:A1991GU38500021
J	SENTMAN, CL; SHUTTER, JR; HOCKENBERY, D; KANAGAWA, O; KORSMEYER, SJ				SENTMAN, CL; SHUTTER, JR; HOCKENBERY, D; KANAGAWA, O; KORSMEYER, SJ			BCL-2 INHIBITS MULTIPLE FORMS OF APOPTOSIS BUT NOT NEGATIVE SELECTION IN THYMOCYTES	CELL			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; ANTIGEN RECEPTOR; THYMUS; GENE; INVIVO; EXPRESSION; SURVIVAL; PROTEIN; DEATH	The vast majority of cortical thymocytes die during T cell development while those that survive this selective process accumulate in the medulla. bcl-2, an inner mitochondrial membrane protein, has been shown to inhibit apoptosis in certain cell lines. In the thymus, bcl-2 is regionally localized to the mature T cells of the medulla. To assess the role of bcl-2 in the programmed death of thymocytes, we generated transgenic mice that redirected bcl-2 expression to cortical thymocytes. bcl-2 protected immature CD4+8+ thymocytes from glucocorticoid, radiation, and anti-CD3-induced apoptosis. Moreover, bcl-2 altered T cell maturation, resulting in increased percentages of CD3hi and CD4-8+ thymocytes. Despite this, clonal deletion of T cells that recognize endogenous superantigens still occurred. This transgenic model indicates that multiple death pathways operate within the thymus that can be distinguished by their dependence on bcl-2.	WASHINGTON UNIV, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	SENTMAN, CL (corresponding author), WASHINGTON UNIV, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA.				NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49712-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; Blomgren H, 1970, Cell Immunol, V1, P545, DOI 10.1016/0008-8749(70)90041-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LUCKEHUHLE C, 1979, RADIAT RES, V79, P97, DOI 10.2307/3575025; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NETA R, 1988, J IMMUNOL, V140, P108; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PENIT C, 1986, J IMMUNOL, V137, P2115; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHI YF, 1991, J IMMUNOL, V146, P3340; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TURKA LA, 1991, J IMMUNOL, V146, P1428; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	56	1259	1313	1	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					879	888		10.1016/0092-8674(91)90361-2	http://dx.doi.org/10.1016/0092-8674(91)90361-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835668				2022-12-24	WOS:A1991GT75500007
J	WILLIAMS, RB; BURDGE, AH; JONES, SL				WILLIAMS, RB; BURDGE, AH; JONES, SL			SKIN BIOPSY IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											WILLIAMS, RB (corresponding author), MAELOR GEN HOSP,WREXHAM LL13 7TD,CLWYD,WALES.							Brundel K H, 1990, Derm Beruf Umwelt, V38, P54; Paver R D, 1990, Aust Fam Physician, V19, P699	2	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1179	1180		10.1136/bmj.303.6811.1179	http://dx.doi.org/10.1136/bmj.303.6811.1179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747617	Bronze, Green Published			2022-12-24	WOS:A1991GP48800027
J	LITTLE, JR				LITTLE, JR			STAPHYLOCOCCUS-AUREUS CARRIAGE IN THE NURSING-HOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LITTLE, JR (corresponding author), WASHINGTON UNIV, MED CTR, ST LOUIS, MO 63130 USA.							CEDERNA JE, 1990, INFECT CONT HOSP EP, V11, P13, DOI 10.1086/646072; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101; STORCH GA, 1987, INFECT CONT HOSP EP, V8, P24, DOI 10.1017/S0195941700066947; STRAUSBAUGH LJ, 1991, INFECT CONT HOSP EP, V12, P36, DOI 10.2307/30147087	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1999	2000		10.1001/jama.266.14.1999	http://dx.doi.org/10.1001/jama.266.14.1999			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1823539				2022-12-24	WOS:A1991GH40600030
J	TUNICK, PA; PEREZ, JL; KRONZON, I				TUNICK, PA; PEREZ, JL; KRONZON, I			PROTRUDING ATHEROMAS IN THE THORACIC AORTA AND SYSTEMIC EMBOLIZATION	ANNALS OF INTERNAL MEDICINE			English	Article						ATHEROSCLEROSIS; AORTA, THORACIC; ECHOCARDIOGRAPHY; CEREBROVASCULAR DISORDERS; CEREBRAL ISCHEMIA, TRANSIENT	TRANSESOPHAGEAL ECHOCARDIOGRAPHY; STROKE; ARCH	Objective: To determine whether protruding atheromas in the thoracic aorta are a risk factor for systemic embolization. Design: Case-control study. Setting: A referral hospital. Patients: A total of 122 patients with a history of stroke, transient ischemic attack, or peripheral emboli and an equal number of age- and sex-matched control patients. Measurements: Evaluation using transesophageal echocardiography was done in case patients to detect protruding atheromas in the thoracic aorta and in control patients for cardiac indications other than emboli. Main Results: Matched logistic regression showed that the presence of protruding atheromas was strongly related to the occurrence of embolic symptoms (odds ratio, 3.2; 95% Cl, 1.6 to 6.5; P < 0.001). Furthermore, atheromas with mobile components were present only in case patients. When known risk factors for stroke (hypertension and diabetes) were added to the model, the presence of protruding atheromas remained an independent risk factor for embolic symptoms (odds ratio, 3.8). Hypertension was also independently associated with embolic symptoms (odds ratio, 2.7), but diabetes was not (odds ratio, 1.0). Conclusion: Protruding atheromas in the thoracic aorta can be detected by transesophageal echocardiography and should be considered as a cause of strokes, transient ischemic attacks, and peripheral emboli.			TUNICK, PA (corresponding author), NYU MED CTR, 560 1ST AVE, SUITE 2-E, NEW YORK, NY 10016 USA.							CULLIFORD AT, 1986, ANN THORAC SURG, V41, P27, DOI 10.1016/S0003-4975(10)64492-X; DANIEL W G, 1989, European Heart Journal, V10, P204; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DIXON WJ, 1985, BMDP STATISTICAL SOF; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GOOD DC, 1986, STROKE, V17, P6, DOI 10.1161/01.STR.17.1.6; GUSSENHOVEN WJ, 1988, EUR HEART J SUPPL, V9, P1572; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; LE CT, 1988, COMPUT BIOMED RES, V21, P48, DOI 10.1016/0010-4809(88)90041-9; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; TUNICK PA, 1991, ANN INTERN MED, V114, P391, DOI 10.7326/0003-4819-114-5-391; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442; YOUNG W, 1960, AM J CARDIOL, V6, P300, DOI 10.1016/0002-9149(60)90319-2; ZENKER G, 1988, STROKE, V19, P345, DOI 10.1161/01.STR.19.3.345	16	266	270	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					423	427		10.7326/0003-4819-115-6-423	http://dx.doi.org/10.7326/0003-4819-115-6-423			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872490				2022-12-24	WOS:A1991GE81000002
J	HAMMOND, KB; ABMAN, SH; SOKOL, RJ; ACCURSO, FJ				HAMMOND, KB; ABMAN, SH; SOKOL, RJ; ACCURSO, FJ			EFFICACY OF STATEWIDE NEONATAL SCREENING FOR CYSTIC-FIBROSIS BY ASSAY OF TRYPSINOGEN CONCENTRATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFANTS; PROGRAM; AGE	Background. To evaluate the feasibility and efficacy of measuring immunoreactive trypsinogen in blood to screen for cystic fibrosis, we performed this test in 279,399 newborns in Colorado from 1982 to 1987. Methods. Immunoreactive trypsinogen was measured in dried blood spots when the infants were 1 to 4 days old; if the level was elevated (greater-than-or-equal-to 140-mu-g per liter), the measurement was repeated (mean age, 38 days); if the level was again elevated, sweat testing was performed (mean age, 49 days). For the second test, two cutoff levels (120 and 80-mu-g per liter) were evaluated. Results. We found an incidence of cystic fibrosis of 1 in 3827 (0.26 per 1000), with 3.2 newborns per 1000 requiring repeat measurement. When adjusted for race and compliance with testing, the incidence among the white infants (1 in 2521) was close to the expected incidence. The false positive rate with the initial cutoff level (92.2 percent) was similar to the rate found in neonatal screening programs for other diseases. False negative results occurred because of laboratory error or changes in procedure (three infants) and trypsinogen concentrations lower than the initial cutoff level (three infants) or lower than the remeasurement cutoff level of 120-mu-g per liter (one infant). Sweat tests were negative in 168 infants with an elevated initial trypsinogen level but a level below 80-mu-g per liter on remeasurement, confirming the value of 80-mu-g per liter as an appropriate cutoff for repeat-test results. Overall, 95.2 percent of the infants with cystic fibrosis (95 percent confidence interval, 85 to 99 percent) who did not have meconium ileus could be identified with the use of a trypsinogen cutoff level of 140-mu-g per liter on initial testing and 80-mu-g per liter on repeat testing. Conclusions. Statewide screening for cystic fibrosis based on measurements of immunoreactive trypsinogen in dried blood spots is feasible and can be implemented with acceptable rates of repeat testing and false positive and false negative results.	UNIV COLORADO, SCH MED, DIV PERINATAL MED, DENVER, CO 80262 USA; CHILDRENS HOSP, DENVER, CO 80218 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	HAMMOND, KB (corresponding author), UNIV COLORADO, SCH MED, DEPT PEDIAT, BOX C228, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00069] Funding Source: Medline; PHS HHS [MCJ-080508-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADRIAENSSENS K, 1981, LANCET, V1, P833; [Anonymous], 1983, PEDIATRICS; BOLAND C, 1990, ARCH DIS CHILD, V65, P1240, DOI 10.1136/adc.65.11.1240; BURLINA A, 1980, SCAND J GASTROENTERO, V15, P35; CROSSLEY JR, 1981, CLIN CHIM ACTA, V113, P111, DOI 10.1016/0009-8981(81)90145-5; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; Diem K., 1970, SCI TABLES, VSeventh; DIXON WJ, 1969, INTRO STATISTICAL AN, P249; DUHAMEL JF, 1984, CYSTIC FIBROSIS HORI, P208; GIBSON LE, 1973, CLIN PEDIATR, V12, P450, DOI 10.1177/000992287301200817; HAMMOND KB, 1984, LANCET, V1, P42; HAMMOND KB, 1986, GENETIC DISEASE SCRE, P81; HEELEY AF, 1982, ARCH DIS CHILD, V57, P18; KING DN, 1979, LANCET, V2, P1217; KRAMM ER, 1962, AM J PUBLIC HEALTH N, V52, P2041, DOI 10.2105/AJPH.52.12.2041; ORENSTEIN DM, 1977, AM J DIS CHILD, V131, P973, DOI 10.1001/archpedi.1977.02120220039005; REARDON MC, 1984, J PEDIATR-US, V105, P271, DOI 10.1016/S0022-3476(84)80128-6; ROCK MJ, 1990, PEDIATRICS, V85, P1001; ROCK MJ, 1989, PEDIATR PULM, V6, P42, DOI 10.1002/ppul.1950060111; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHEPHERD RW, 1989, J PEDIATR GASTR NUTR, V9, P200, DOI 10.1097/00005176-198908000-00012; SHWACHMAN H., 1967, MOD PROBL PAEDIATR, V10, P158; SOKOL RJ, 1989, AM J CLIN NUTR, V50, P1064, DOI 10.1093/ajcn/50.5.1064; SORENSON JR, 1984, PEDIATRICS, V73, P183; STEINBERG AG, 1960, AM J HUM GENET, V12, P416; WATERS DL, 1990, NEW ENGL J MED, V322, P303, DOI 10.1056/NEJM199002013220505; WILCKEN B, 1985, LANCET, V2, P1319; WILCKEN B, 1983, J PEDIATR-US, V102, P383, DOI 10.1016/S0022-3476(83)80653-2; 1990, NEW ENGL J MED, V323, P70; 1985, SAS USERS GUIDE STAT	30	125	129	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					769	774		10.1056/NEJM199109123251104	http://dx.doi.org/10.1056/NEJM199109123251104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870650	Bronze			2022-12-24	WOS:A1991GE45600004
J	STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			POSTMENOPAUSAL ESTROGEN THERAPY AND CARDIOVASCULAR-DISEASE - 10-YEAR FOLLOW-UP FROM THE NURSES HEALTH STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; PROSPECTIVE COHORT; WOMEN; REPRODUCIBILITY; QUESTIONNAIRE; MENOPAUSE; VALIDITY; CANCER; STROKE	Background. The effect of postmenopausal estrogen therapy on the risk of cardiovascular disease remains controversial. Our 1985 report in the Journal, based on four years of follow-up, suggested that estrogen therapy reduced the risk of coronary heart disease, but a report published simultaneously from the Framingham Study suggested that the risk was increased. In addition, studies of the effect of estrogens on stroke have yielded conflicting results. Methods. We followed 48,470 postmenopausal women, 30 to 63 years old, who were participants in the Nurses' Health Study and who did not have a history of cancer or cardiovascular disease at base line. During up to 10 years of follow-up (337,854 person-years), we documented 224 strokes, 405 cases of major coronary disease (nonfatal myocardial infarctions or deaths from coronary causes), and 1263 deaths from all causes. Results. After adjustment for age and other risk factors, the overall relative risk of major coronary disease in women currently taking estrogen was 0.56 (95 percent confidence interval, 0.40 to 0.80); the risk was significantly reduced among women with either natural or surgical menopause. We observed no effect of the duration of estrogen use independent of age. The findings were similar in analyese limited to women who had recently visited their physicians (relative risk, 0.45; 95 percent confidence interval, 0.31 to 0.66) and in a low-risk group that excluded women reporting current cigarette smoking, diabetes, hypertension, hypercholesterolemia, or a Quetelet index above the 90th percentile (relative risk, 0.53; 95 percent confidence interval, 0.31 to 0.91). The relative risk for current and former users of estrogen as compared with those who had never used it was 0.89 (95 percent confidence interval, 0.78 to 1.00) for total mortality and 0.72 (95 percent confidence interval, 0.55 to 0.95) for mortality from cardiovascular disease. The relative risk of stroke when current users were compared with those who had never used estrogen was 0.97 (95 percent confidence interval, 0.65 to 1.45), with no marked differences according to type of stroke. Conclusions. Current estrogen use is associated with a reduction in the incidence of coronary heart disease as well as in mortality from cardiovascular disease, but it is not associated with any change in the risk of stroke.	HARVARD UNIV, SCH MED, CHANNING LAB, DEPT PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	STAMPFER, MJ (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILAR JC, 1985, NEW ENGL J MED, V313, P1080, DOI 10.1056/NEJM198510243131709; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1986, MENOPAUSE PHYSL PHAR, P187; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COX DR, 1972, J R STAT SOC B, V34, P187; EAKER ED, 1987, CORONARY HEART DISEA, P122; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; JUDD HL, 1980, AM J OBSTET GYNECOL, V136, P859, DOI 10.1016/0002-9378(80)91043-1; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; ROTHMAN KJ, 1979, NIH791649 PHS PUBL; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; Walker AE, 1981, STROKE S1, V12, P13; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; [No title captured]	31	1872	1903	0	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					756	762		10.1056/NEJM199109123251102	http://dx.doi.org/10.1056/NEJM199109123251102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870648				2022-12-24	WOS:A1991GE45600002
J	TURKA, LA; SCHATZ, DG; OETTINGER, MA; CHUN, JJM; GORKA, C; LEE, K; MCCORMACK, WT; THOMPSON, CB				TURKA, LA; SCHATZ, DG; OETTINGER, MA; CHUN, JJM; GORKA, C; LEE, K; MCCORMACK, WT; THOMPSON, CB			THYMOCYTE EXPRESSION OF RAG-1 AND RAG-2 - TERMINATION BY T-CELL RECEPTOR CROSS-LINKING	SCIENCE			English	Article							RECOMBINATION ACTIVATING GENE; V(D)J RECOMBINATION; DEVELOPMENTAL BIOLOGY; ANTIGEN RECEPTOR; MATURE THYMOCYTES; CHAIN TRANSCRIPTS; SURFACE-ANTIGEN; ADJACENT GENES; LYMPHOCYTES-T; THYMUS	The expression of the V(D)J [variable (diversity) joining elements] recombination activating genes, RAG-1 and RAG-2, has been examined during T cell development in the thymus. In situ hybridization to intact thymus and RNA blot analysis of isolated thymic subpopulations separated on the basis of T cell receptor (TCR) expression demonstrated that both TCR- and TCR+ cortical thymocytes express RAG-1 and RAG-2 messenger RNA's. Within the TCR+ population, RAG expression was observed in immature CD4+CD8+ (double positive) cells, but not in the more mature CD4+CD8- or CD4-CD8+ (single positive) subpopulations. Thus, although cortical thymocytes that bear TCR on their surface continue to express RAG-1 and RAG-2, it appears that the expression of both genes is normally terminated during subsequent thymic maturation. Since thymocyte maturation in vivo is thought to be regulated through the interaction of the TCR complex with self major histocompatibility complex (MHC) antigens, these data suggest that signals transduced by the TCR complex might result in the termination of RAG expression. Consistent with this hypothesis, thymocyte TCR cross-linking in vitro led to rapid termination of RAG-1 and RAG-2 expression, whereas cross-linking of other T cell surface antigens such as CD4, CD8, or HLA class I had no effect.	UNIV MICHIGAN,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	TURKA, LA (corresponding author), UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176; McCormack, Wayne/0000-0002-2117-8727	NIDDK NIH HHS [DK-01899] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001899] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FINKEL TH, 1989, J IMMUNOL, V142, P3006; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; MARCHE PN, 1986, P NATL ACAD SCI USA, V83, P2190, DOI 10.1073/pnas.83.7.2190; MARRACK P, 1987, SCIENCE, V238, P1047; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; MATIS LA, 1988, J EXP MED, V168, P2379, DOI 10.1084/jem.168.6.2379; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCGHEE D, 1979, THYMUS, V1, P151; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; NIETO MA, 1990, J IMMUNOL, V145, P1364; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SAMUELSON LE, 1991, CELL, V64, P875; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCOLLAY R, 1983, THYMUS, V5, P245; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SHORTMAN K, 1987, J IMMUNOL, V138, P342; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; SPRENT J, 1989, FUNDAMENTAL IMMUNOLO, P69; STROMINGER JL, 1989, SCIENCE, V244, P943, DOI 10.1126/science.2658058; TOYONAGA B, 1987, ANNU REV IMMUNOL, V5, P585, DOI 10.1146/annurev.immunol.5.1.585; TRIEBEL F, 1988, J IMMUNOL, V140, P300; TURKA LA, 1990, J IMMUNOL, V144, P1646; TURKA LA, 1991, J IMMUNOL, V146, P1428; TURKA LA, UNPUB; VANEWIJK W, 1981, J IMMUNOL, V127, P2594; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISSMAN IL, 1973, J EXP MED, V137, P504, DOI 10.1084/jem.137.2.504; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	42	234	243	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					778	781		10.1126/science.1831564	http://dx.doi.org/10.1126/science.1831564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1831564				2022-12-24	WOS:A1991GB29500034
J	GRONENBORN, AM; FILPULA, DR; ESSIG, NZ; ACHARI, A; WHITLOW, M; WINGFIELD, PT; CLORE, GM				GRONENBORN, AM; FILPULA, DR; ESSIG, NZ; ACHARI, A; WHITLOW, M; WINGFIELD, PT; CLORE, GM			A NOVEL, HIGHLY STABLE FOLD OF THE IMMUNOGLOBULIN BINDING DOMAIN OF STREPTOCOCCAL PROTEIN-G	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURES; STAPHYLOCOCCUS-AUREUS; MOLECULAR-DYNAMICS; SPECTROSCOPY; CRYSTALLOGRAPHY; RESOLUTION; PROGRAM; CRAMBIN	The high-resolution three-dimensional structure of a single immunoglobulin binding domain (BI, which comprises 56 residues including the NH2-terminal Met) of protein G from group G Streptococcus has been determined in solution by nuclear magnetic resonance spectroscopy on the basis of 1058 experimental restraints. The average atomic root-mean-square distribution about the mean coordinate positions is 0.27 angstrom (angstrom) for the backbone atoms, 0.65 angstrom for all atoms, and 0.39 angstrom for atoms excluding disordered surface side chains. The structure has no disulfide bridges and is composed of a four-stranded 13 sheet, on top of which lies a long helix. The central two strands (beta-1 and beta-4), comprising the NH2- and COOH-termini, are parallel, and the outer two strands (beta-2 and beta-3) are connected by the helix in a +3x crossover. This novel topology (-1, +3x, -1), coupled with an extensive hydrogen-bonding network and a tightly packed and buried hydrophobic core, is probably responsible for the extreme thermal stability of this small domain (reversible melting at 87-degrees-C).	GENEX CORP, GAITHERSBURG, MD 20877 USA; NIH, PROT EXPRESS LAB, OFF DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	GRONENBORN, AM (corresponding author), NIDDKD, CHEM PHYS LAB, BLDG 2, BETHESDA, MD 20892 USA.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Wingfield, Paul/0000-0002-9515-4752; Gronenborn, Angela M/0000-0001-9072-3525				AKERSTROM B, 1986, J BIOL CHEM, V261, P240; BAX A, 1989, METHOD ENZYMOL, V176, P151; BJORCK L, 1984, J IMMUNOL, V133, P969; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1988, XPLOR MANUAL; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1987, PROTEIN ENG, V1, P275, DOI 10.1093/protein/1.4.275; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; CREIGHTON TE, 1986, METHOD ENZYMOL, V131, P157; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FAHNESTOCK S, COMMUNICATION; FAHNESTOCK SR, 1987, TRENDS BIOTECHNOL, V5, P79, DOI 10.1016/S0167-7799(87)80016-1; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB, V1, P133; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; HAVEL T, 1984, B MATH BIOL, V46, P673, DOI 10.1007/BF02459510; HAVEL TF, 1986, QUANTUM CHEM PROGRAM, V507; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Pfeil W., 1986, THERMODYNAMIC DATA B, P349; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SJOBRING U, 1991, J BIOL CHEM, V266, P399; SJOBRING U, 1989, J IMMUNOL, V143, P2948; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; Wuthrich K., 1986, NMR PROTEINS NUCL AC	47	707	728	4	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					657	661		10.1126/science.1871600	http://dx.doi.org/10.1126/science.1871600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871600				2022-12-24	WOS:A1991GA30400037
J	ROSNER, MH; VIGANO, MA; RIGBY, PWJ; ARNHEITER, H; STAUDT, LM				ROSNER, MH; VIGANO, MA; RIGBY, PWJ; ARNHEITER, H; STAUDT, LM			OCT-3 AND THE BEGINNING OF MAMMALIAN DEVELOPMENT	SCIENCE			English	Editorial Material							EMBRYONAL CARCINOMA-CELLS; DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; POU-DOMAIN; IMMUNOGLOBULIN GENES; NUCLEAR FACTOR; STEM-CELLS; MOUSE EMBRYOGENESIS; PROTEIN-BINDING; LEUKEMIA-VIRUS		NCI, METAB BRANCH, BETHESDA, MD 20892 USA; NATL INST MED RES, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND; NINCDS, VIRAL & MOLEC PATHOGENESIS LAB, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); MRC National Institute for Medical Research; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Georgetown University			Staudt, Louis/AAC-5324-2019	vigano, maria alessandra/0000-0003-2009-0384				BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DWORKIN MB, 1990, MOL REPROD DEV, V26, P261, DOI 10.1002/mrd.1080260310; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; HAAS MW, 1991, VIROLOGY, V180, P41, DOI 10.1016/0042-6822(91)90007-X; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON MH, 1981, BIOL REV, V56, P463, DOI 10.1111/j.1469-185X.1981.tb00356.x; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LOH TP, 1990, MOL CELL BIOL, V10, P4045, DOI 10.1128/MCB.10.8.4045; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; ROSNER MH, 1991, CELL, V64, P1103, DOI 10.1016/0092-8674(91)90265-Z; ROSNER MH, UNPUB; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	48	11	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 12	1991	253	5016					144	145		10.1126/science.1853199	http://dx.doi.org/10.1126/science.1853199			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853199				2022-12-24	WOS:A1991FW16000023
J	KISS, T; MARSHALLSAY, C; FILIPOWICZ, W				KISS, T; MARSHALLSAY, C; FILIPOWICZ, W			ALTERATION OF THE RNA-POLYMERASE SPECIFICITY OF U3 SNRNA GENES DURING EVOLUTION AND INVITRO	CELL			English	Article							SMALL NUCLEAR RNAS; C-MYC GENE; III PROMOTER; TATA BOX; TRANSCRIPTION; COMPONENTS; SEQUENCES; BINDING; PLANTS; VIRUS	We present evidence that the genes encoding U3 snRNA in plants are transcribed by RNA polymerase III (pol III) and not by RNA polymerase II (pol II) as in vertebrates or lower eukaryotes. The U3 gene is the only known example of a gene transcribed by different polymerases in different organisms. It is possible to convert the plant U3 gene into a functional pol II-transcribed gene by manipulating the spacing between the promoter elements and inserting a pol II-specific termination signal. Pol II-transcribed U3 RNA, containing the 5'-terminal cap different from that present in the wild-type counterpart, is packaged in transfected protoplasts into U3 snRNP precipitable with anti-fibrillarin antibodies. These findings provide further evidence for the common ancestry of the pol II and pol III transcription systems, and indicate that promoter diversification in some genes has occurred relatively recently.			KISS, T (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			Kiss, Tamas/0000-0003-0293-3093				BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; CHANDRASEKHARAPPA SC, 1983, J CELL PHYSIOL, V117, P169, DOI 10.1002/jcp.1041170206; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; England T E, 1980, Methods Enzymol, V65, P65; EPSTEIN P, 1984, BIOCHEMISTRY-US, V23, P5421, DOI 10.1021/bi00318a007; FILIPOWICZ W, 1990, MOL BIOL REP, V14, P125, DOI 10.1007/BF00360443; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GOUY M, 1989, MOL BIOL EVOL, V6, P109; GUILTINAN MJ, 1988, EUR J CELL BIOL, V46, P547; GUPTA S, 1990, J BIOL CHEM, V265, P19137; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HELLUNGLARSEN P, 1980, BIOCHIM BIOPHYS ACTA, V609, P201, DOI 10.1016/0005-2787(80)90213-0; HELLUNGLARSEN P, 1981, BIOCHEM BIOPH RES CO, V99, P1303, DOI 10.1016/0006-291X(81)90761-0; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1985, EUR J BIOCHEM, V152, P259, DOI 10.1111/j.1432-1033.1985.tb09192.x; KISS T, 1990, NUCLEIC ACIDS RES, V18, P1941, DOI 10.1093/nar/18.8.1941; KROL A, 1983, NUCLEIC ACIDS RES, V11, P8583, DOI 10.1093/nar/11.24.8583; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LUHRMANN R, 1982, NUCLEIC ACIDS RES, V10, P7103, DOI 10.1093/nar/10.22.7103; MARSHALLSAY C, 1990, NUCLEIC ACIDS RES, V18, P3451; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MEMET S, 1988, J BIOL CHEM, V263, P10048; MUHLBACH HP, 1979, NATURE, V278, P185, DOI 10.1038/278185a0; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; PORTER GL, 1988, NUCLEIC ACIDS RES, V16, P10131, DOI 10.1093/nar/16.21.10131; REDDY R, 1990, NUCLEIC ACIDS RES, V18, P2231, DOI 10.1093/nar/18.suppl.2231; REDDY R, 1988, NUCLEIC ACIDS RES, V16, pR71, DOI 10.1093/nar/16.suppl.r71; REDDY R, 1981, J BIOL CHEM, V16, P8452; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SZKUKALEK A, 1990, NUCLEIC ACIDS RES, V18, P1295, DOI 10.1093/nar/18.5.1295; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VANKAN P, 1989, EMBO J, V8, P3875, DOI 10.1002/j.1460-2075.1989.tb08566.x; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3459; WISE JA, 1981, J BIOL CHEM, V256, P956	52	98	104	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					517	526		10.1016/0092-8674(91)90469-F	http://dx.doi.org/10.1016/0092-8674(91)90469-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1826860				2022-12-24	WOS:A1991FK18200018
J	MALINOW, R				MALINOW, R			TRANSMISSION BETWEEN PAIRS OF HIPPOCAMPAL SLICE NEURONS - QUANTAL LEVELS, OSCILLATIONS, AND LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; PYRAMIDAL CELLS; RELEASE; INDUCTION; EFFICACY; INVITRO	Long-term potentiation (LTP) of synaptic transmission after coincident pre- and postsynaptic activity is considered a cellular model of changes underlying learning and memory. In intact tissue, LTP has been observed only between populations of neurons, making analysis of mechanisms difficult. Transmission between individual pre- and postsynaptic hippocampal cells was studied, suggesting quantal amplitude distributions with little variability in quantal size. LTP between such pairs is manifested by large, persistent, and synapse-specific potentiation with a shift in amplitude distribution that suggests presynaptic changes. Oscillations in amplitude of transmission, apparently of presynaptic origin, are common and can be triggered by LTP.	STANFORD UNIV, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University	MALINOW, R (corresponding author), UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA.							ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; AMARAL DG, 1990, PROG BRAIN RES, V83, P1; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T, 1988, LONG TERM POTENTIATI; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; BROWN TH, 1976, P NATL ACAD SCI USA, V73, P2913, DOI 10.1073/pnas.73.8.2913; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; FRIEDLANDER MJ, 1990, J NEUROSCI, V10, P814; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCNAUGHTON BL, 1981, J NEUROPHYSIOL, V46, P952, DOI 10.1152/jn.1981.46.5.952; MEIRI H, 1978, J PHYSIOL-LONDON, V278, P513, DOI 10.1113/jphysiol.1978.sp012321; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; PAWSON PA, 1989, PROC R SOC SER B-BIO, V237, P489, DOI 10.1098/rspb.1989.0061; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; SAYER RJ, 1989, J NEUROSCI, V9, P840; SAYER RJ, 1990, J NEUROSCI, V10, P826; SILVERMAN V, 1986, DENSITY ESTIMATE STA; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	197	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1991	252	5006					722	724		10.1126/science.1850871	http://dx.doi.org/10.1126/science.1850871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1850871				2022-12-24	WOS:A1991FK18500054
J	ADACHI, Y; LUKE, M; LAEMMLI, UK				ADACHI, Y; LUKE, M; LAEMMLI, UK			CHROMOSOME ASSEMBLY INVITRO - TOPOISOMERASE-II IS REQUIRED FOR CONDENSATION	CELL			English	Article							XENOPUS-LAEVIS; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; DNA TOPOISOMERASES; NUCLEAR SCAFFOLD; CELL-CYCLE; YEAST; LOCALIZATION; CHROMATIN; ORGANIZATION	The role of topoisomerase II (topo II) in chromosome condensation was studied in a mitotic extract derived from Xenopus eggs by specific immunodepletion. HeLa nuclei, which have a high complement of endogenous topo II, are converted to mitotic chromosomes in the topo II-depleted extract equally well as in the control. Chicken erythrocyte nuclei, however, which have a very low content of topo II, do not convert to condensed chromosomes in the depleted extract, although their condensation is normal upon addition of purified topo II. Dosage experiments support the possible notion of a structural involvement of topo II in chromosome condensation. In the topo II-depleted extract the erythrocyte nuclei progress to precondensation chromosomes, which lack the nuclear membrane-lamina complex and consist of a cluster of swollen chromatids.	UNIV GENEVA, DEPT MOLEC BIOL, CH-1211 GENEVA 4, SWITZERLAND; SUNY STONY BROOK, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA	University of Geneva; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	ADACHI, Y (corresponding author), UNIV GENEVA, DEPT BIOCHEM, CH-1211 GENEVA 4, SWITZERLAND.		Adachi, Yasuhisa/GYA-3190-2022	Galora De Mora, Raul Pavlov/0000-0001-8342-9782; Adachi, Yasuhisa/0000-0003-4197-092X				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; CHEN GL, 1984, J BIOL CHEM, V259, P3560; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; HARLOW E, 1988, ANTIBODIES; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUKE M, 1989, DEV BIOL, V136, P459, DOI 10.1016/0012-1606(89)90271-6; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; REITMAN M, 1990, CELL BIOL, V10, P2774; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMAMURA A, 1989, METHOD ENZYMOL, V170, P603; Sternglanz R, 1989, CURR OPIN CELL BIOL, V1, P533, DOI 10.1016/0955-0674(89)90016-1; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WOODLAND HR, 1977, DEV BIOL, V57, P118, DOI 10.1016/0012-1606(77)90359-1; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; ZIERLER MK, 1985, J BIOL CHEM, V260, P974	48	388	397	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					137	148		10.1016/0092-8674(91)90215-K	http://dx.doi.org/10.1016/0092-8674(91)90215-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846085				2022-12-24	WOS:A1991ET17500015
J	LANDESMAN, S; WEIBLEN, B; MENDEZ, H; WILLOUGHBY, A; GOEDERT, JJ; RUBINSTEIN, A; MINKOFF, H; MOROSO, G; HOFF, R				LANDESMAN, S; WEIBLEN, B; MENDEZ, H; WILLOUGHBY, A; GOEDERT, JJ; RUBINSTEIN, A; MINKOFF, H; MOROSO, G; HOFF, R			CLINICAL UTILITY OF HIV-IGA IMMUNOBLOT ASSAY IN THE EARLY DIAGNOSIS OF PERINATAL HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INVITRO PRODUCTION; INFANTS BORN; CHILDREN; ANTIBODY; MOTHERS; RISK	Objective. - To ascertain the sensitivity, specificity, predictive value, and clinical use of a human immunodeficiency virus (HIV)-IgA immunoblot assay for diagnosing perinatal HIV infection in infants tested at birth to 1 month, 3 months, and 6 months of age. Design. - Prospective, longitudinal cohort study of children born to HIV-infected and noninfected women. The HIV-IgA immunoblot assays were performed at birth to 1 month, 3 months, and 6 months of age and compared with the Centers for Disease Control's classification system of HIV infection in the children. Children were followed up for at least 15 months to ensure accuracy of infection status. Setting. - Municipal hospital in central Brooklyn, NY, where the prevalence of HIV infection is high. Patients. - Serum samples from 58 children, 22 with documented HIV infection, 18 noninfected children born to seropositive women, and 18 children born to noninfected women, were studied. Main Outcome Measure. - Diagnosis of HIV infection using the Centers for Disease Control's classification scheme was compared with diagnosis using the HIV-IgA immunoblot assay for children 6 months of age or younger. Results. - The HIV-IgA immunoblot assay yielded negative results at 3 and 6 months of age for all 18 infants born to seronegative women; for the 18 seroreverting, noninfected children born to infected women, the assay yielded negative results at 1 month, 3 months, and 6 months of age. The positive predictive value of the assay was 100%-no false-positive results were identified in the 88 serum samples obtained from noninfected infants. For the HIV-infected children, sensitivity was a function of age: one (5.9%) of 17 infants had an assay that yielded positive results at birth to 1 month of age, 13 (62%) of 21 infants had assays that yielded positive results at 3 months of age, and 17 (77%) of 22 infants had assays that yielded positive results at 6 months of age. The presence or absence of symptoms did not affect the sensitivity. Conclusion. - The HIV-IgA immunoblot assay can detect a significant proportion of infected children during an early asymptomatic period of their life. This relatively inexpensive, easily standardized assay may allow for institution of therapy before the onset of clinical symptoms.	NIAID,DIV AIDS,BETHESDA,MD 20892; SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,BROOKLYN,NY; THEOBALD SMITH RES INST,BOSTON,MA; NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,BETHESDA,MD 20892; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; NCI,VIRAL EPIDEMIOL BRANCH,BETHESDA,MD 20892; SUNY HLTH SCI CTR,DEPT PEDIAT,BROOKLYN,NY	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	LANDESMAN, S (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV INFECT DIS,450 CLARKSON AVE,BOX 122,BROOKLYN,NY 11203, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD082917, R01HD025714, N01HD082913] Funding Source: NIH RePORTER; NICHD NIH HHS [N0-1-HD-8-2913, N0-1-HD-8-2917, R0-HD-25714-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMADORI A, 1988, LANCET, V1, P852; AMADORI A, 1990, PEDIATR INFECT DIS J, V9, P26, DOI 10.1097/00006454-199001000-00006; BORKOWSKY W, 1989, J PEDIATR, V114, P942; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; ESCAICH S, 1991, J ACQ IMMUN DEF SYND, V4, P130; HUSSON RN, 1990, PEDIATRICS, V86, P1; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KATZ SL, 1989, NEW ENGL J MED, V320, P1687, DOI 10.1056/NEJM198906223202509; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAURE F, 1988, LANCET, V2, P538; LEE FK, 1989, AIDS RES HUM RETROV, V5, P517, DOI 10.1089/aid.1989.5.517; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MOK JQ, 1987, LANCET, V1, P1164; PALOMBA E, 1990, LANCET, V336, P940, DOI 10.1016/0140-6736(90)92310-E; PYUN KH, 1987, NEW ENGL J MED, V317, P611, DOI 10.1056/NEJM198709033171006; RAKUSAN TA, 1991, J ACQ IMMUN DEF SYND, V4, P116; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WEIBLEN BJ, 1990, J IMMUNOL METHODS, V126, P199, DOI 10.1016/0022-1759(90)90151-K; 1991, MMWR, V40, pRR2; 1991, LANCET, V337, P253; 1987, MMWR, V36, P225; 1991, NEW ENGL J MED, V325, P73	25	67	67	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3443	3446		10.1001/jama.266.24.3443	http://dx.doi.org/10.1001/jama.266.24.3443			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744958				2022-12-24	WOS:A1991GV87800029
J	GYOEVA, FK; GELFAND, VI				GYOEVA, FK; GELFAND, VI			COALIGNMENT OF VIMENTIN INTERMEDIATE FILAMENTS WITH MICROTUBULES DEPENDS ON KINESIN	NATURE			English	Article							MONOCLONAL-ANTIBODY; MICRO-INJECTION; COLLAPSE; CELLS; MOVEMENT; TUBULIN	INTERMEDIATE filaments in most types of cultured cells coalign with microtubules. Depolymerization of microtubules results in collapse of vimentin and desmin intermediate filaments to the nucleus where they form a perinuclear cap (reviewed in ref. 1). Collapse can also be induced by microinjection of antibodies against intermediate filament or microtubule proteins 2-7. Thus, two filament systems interact with each other. But the molecules mediating this interaction are unknown. One of the candidates for this role is a microtubule motor kinesin 8. Recent data showed that kinesin is involved in the plus end-directed movement of the membranous organelles along microtubules such as radial extension of lysosomes in macrophages 9 and centrifugal movement of pigment in melanophores 10. Here we report that injection of the anti-kinesin antibody into human fibroblasts results in the redistribution of intermediate filaments to a tight perinuclear aggregate but had no effect on the distribution of microtubules. Thus, kinesin is involved not only in organelle movement but also in interaction of the two major cytoskeletal systems, intermediate filaments and microtubules.	ACAD SCI USSR,INST PROT RES,PUSHCHINO 142292,USSR	Russian Academy of Sciences			Gelfand, Vladimir/M-1974-2019; Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir/0000-0002-6361-2798; Gelfand, Vladimir I/0000-0002-6361-2798				BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; GAWLITTA W, 1981, EUR J CELL BIOL, V26, P83; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL SCI, V92, P621; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; KATSUMOTO T, 1990, BIOL CELL, V68, P139, DOI 10.1016/0248-4900(90)90299-I; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KLYMKOWSKY MW, 1981, NATURE, V291, P249, DOI 10.1038/291249a0; LIN JJC, 1981, CELL, V24, P185, DOI 10.1016/0092-8674(81)90514-6; PERIDES G, 1987, J BIOL CHEM, V262, P13742; RODONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956; STACEY DW, 1977, P NATL ACAD SCI USA, V74, P1514; TOLLE HG, 1986, EXP CELL RES, V162, P462, DOI 10.1016/0014-4827(86)90350-2; TRAUB P, 1987, EUR J CELL BIOL, V43, P55; TROYANOVSKII SN, 1985, IMMUNOLOGIYA, V6, P70; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476	20	198	201	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					445	448		10.1038/353445a0	http://dx.doi.org/10.1038/353445a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1832745				2022-12-24	WOS:A1991GH60600062
J	ENGEBRECHT, J; VOELKELMEIMAN, K; ROEDER, GS				ENGEBRECHT, J; VOELKELMEIMAN, K; ROEDER, GS			MEIOSIS-SPECIFIC RNA SPLICING IN YEAST	CELL			English	Article							MEIOTIC GENE CONVERSION; SACCHAROMYCES-CEREVISIAE; SEXUAL-DIFFERENTIATION; DROSOPHILA-MELANOGASTER; CHROMOSOME SEGREGATION; BETA-GALACTOSIDASE; TRANSFORMER GENE; ESCHERICHIA-COLI; DNA-SEQUENCE; RECOMBINATION	Previous studies have suggested that the differentiated state of meiosis in yeast is regulated primarily at the transcriptional level. This study reports a case of posttranscriptional regulation of a gene whose product is essential for meiosis. The MER2 gene is transcribed in mitosis as well as meiosis; however, the transcript is spliced efficiently to generate a functional gene product only in meiosis. Meiotic levels of splicing depend on the MER1 gene product, which is also essential for meiosis and which is produced only in meiotic cells. Therefore, at least one of the functions of the MER1 protein is to mediate splicing of the MER2 transcript. Genetic data suggest that the MER1 gene may also be responsible for splicing the transcript of at least one other gene.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Yale University			Engebrecht, JoAnne/K-3355-2019	Engebrecht, JoAnne/0000-0002-2733-7506	NIGMS NIH HHS [GM28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; ATCHESON CL, 1987, P NATL ACAD SCI USA, V84, P8035, DOI 10.1073/pnas.84.22.8035; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; COLE GM, 1989, MOL CELL BIOL, V9, P3101, DOI 10.1128/MCB.9.7.3101; CONEY LR, 1988, MOL CELL BIOL, V8, P4009, DOI 10.1128/MCB.8.10.4009; DABEVA MD, 1987, J BIOL CHEM, V262, P16055; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; FARNET C, 1988, MECHANISMS CONSEQUEN, P201; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; Game J., 1983, YEAST GENETICS FUNDA, P109; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASSIR Y, 1988, CELL, V52, P853, DOI 10.1016/0092-8674(88)90427-8; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KLAPHOLZ S, 1980, GENETICS, V96, P589; KLAPHOLZ S, 1985, GENETICS, V110, P187; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAMBIE EJ, 1988, CELL, V52, P863, DOI 10.1016/0092-8674(88)90428-X; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; Maniatis T., 1982, MOL CLONING; MENEES TM, 1989, GENETICS, V123, P675; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; PERCIVALSMITH A, 1984, MOL CELL BIOL, V4, P142, DOI 10.1128/MCB.4.1.142; PERKINS DD, 1949, GENETICS, V34, P607; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1990, GENETICS, V126, P563; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH HE, 1989, MOL CELL BIOL, V9, P2142, DOI 10.1128/MCB.9.5.2142; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STEWART SE, 1989, MOL CELL BIOL, V9, P3464, DOI 10.1128/MCB.9.8.3464; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604	64	166	171	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1991	66	6					1257	1268		10.1016/0092-8674(91)90047-3	http://dx.doi.org/10.1016/0092-8674(91)90047-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1840507				2022-12-24	WOS:A1991GG55200019
J	KOFF, A; CROSS, F; FISHER, A; SCHUMACHER, J; LEGUELLEC, K; PHILIPPE, M; ROBERTS, JM				KOFF, A; CROSS, F; FISHER, A; SCHUMACHER, J; LEGUELLEC, K; PHILIPPE, M; ROBERTS, JM			HUMAN CYCLIN-E, A NEW CYCLIN THAT INTERACTS WITH 2 MEMBERS OF THE CDC2 GENE FAMILY	CELL			English	Article							MATURATION-PROMOTING FACTOR; P34CDC2 PROTEIN-KINASE; MAMMALIAN-CELL-CYCLE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; M-PHASE; DNA-REPLICATION; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE; MATING-PHEROMONE	A new human cyclin, named cyclin E, was isolated by complementation of a triple cln deletion in S. cerevisiae. Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein. Two human genes were identified that could interact with cyclin E to perform START in yeast containing a cdc28 mutation. One was CDC2-HS, and the second was the human homolog of Xenopus CDK2. Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells. The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV RENNES 1, BIOL & GENET DEV LAB, CNRS, UNITE 256, F-35042 RENNES, FRANCE	Rockefeller University; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	KOFF, A (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Schumacher, Jill/B-2932-2012; Fisher, Alfred/H-3031-2012	Fisher, Alfred/0000-0001-6451-2644				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROBERTS JM, 1988, SCIENCE, V241, P1486, DOI 10.1126/science.2843984; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zetterberg A, 1990, CURR OPIN CELL BIOL, V2, P296, DOI 10.1016/0955-0674(90)90022-7; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	77	627	683	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1217	1228		10.1016/0092-8674(91)90044-Y	http://dx.doi.org/10.1016/0092-8674(91)90044-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833068				2022-12-24	WOS:A1991GG55200016
J	TAVERNIER, J; DEVOS, R; CORNELIS, S; TUYPENS, T; VANDERHEYDEN, J; FIERS, W; PLAETINCK, G				TAVERNIER, J; DEVOS, R; CORNELIS, S; TUYPENS, T; VANDERHEYDEN, J; FIERS, W; PLAETINCK, G			A HUMAN HIGH-AFFINITY INTERLEUKIN-5 RECEPTOR (IL5R) IS COMPOSED OF AN IL5-SPECIFIC ALPHA-CHAIN AND A BETA-CHAIN SHARED WITH THE RECEPTOR FOR GM-CSF	CELL			English	Article							COLONY-STIMULATING FACTOR; EOSINOPHIL DIFFERENTIATION FACTOR; MOLECULAR-CLONING; HISTAMINE-RELEASE; SOLUBLE FORM; GENE FAMILY; HUMAN-URINE; EXPRESSION; BINDING; CELLS	cDNA clones encoding two receptor proteins involved in the binding of human interleukin 5 (hIL5) have been isolated. A first class codes for an IL5-specific chain (hIL5R-alpha). The major transcript of this receptor gene, as analyzed in both HL-60 eosinophilic cells and eosinophilic myelocytes grown from cord blood, encodes a secreted form of this receptor. This soluble hIL5R-alpha has antagonistic properties. A second component of the hIL5R is found to be identical to the beta-chain of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) high affinity receptor. The finding that IL5 and GM-CSF share a receptor subunit provides a molecular basis for the observation that these cytokines can partially interfere with each other's binding and have highly overlapping biological activities on eosinophils.	STATE UNIV GHENT, MOLEC BIOL LAB, B-9000 GHENT, BELGIUM	Ghent University	TAVERNIER, J (corresponding author), ROCHE RES GENT, PLATEAUST 22, B-9000 GHENT, BELGIUM.							ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; CLUTTERBUCK E, 1987, EUR J IMMUNOL, V17, P1743, DOI 10.1002/eji.1830171210; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEVOS R, 1991, EUR J IMMUNOL, V21, P1315, DOI 10.1002/eji.1830210533; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENOKIHARA H, 1989, BLOOD, V73, P1809; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; GAMBLE JR, 1990, SCIENCE, V249, P414; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KANAKURA Y, 1990, BLOOD, V76, P706; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIMAYE AP, 1990, J EXP MED, V172, P399, DOI 10.1084/jem.172.1.399; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1989, P NATL ACAD SCI USA, V86, P7022, DOI 10.1073/pnas.86.18.7022; MARCON L, 1988, CLIN EXP IMMUNOL, V73, P29; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MITA S, 1989, P NATL ACAD SCI USA, V86, P2311, DOI 10.1073/pnas.86.7.2311; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; OWEN WF, 1990, P NATL ACAD SCI USA, V87, P8647, DOI 10.1073/pnas.87.21.8647; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; ROLINK AG, 1989, J EXP MED, V169, P1693, DOI 10.1084/jem.169.5.1693; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERSON CJ, 1986, P NATL ACAD SCI USA, V83, P437, DOI 10.1073/pnas.83.2.437; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1990, INT J CELL CLONING, V8, P147, DOI 10.1002/stem.5530080713; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1983, NATURE, V301, P634, DOI 10.1038/301634a0; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; VANDERHEYDEN J, 1991, IN PRESS J IMMUNOL; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMAGUCHI Y, 1990, EXP HEMATOL, V18, P1152; YOKOTA T, 1987, P NATL ACAD SCI USA, V84, P7388, DOI 10.1073/pnas.84.21.7388; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	56	580	592	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1991	66	6					1175	1184		10.1016/0092-8674(91)90040-6	http://dx.doi.org/10.1016/0092-8674(91)90040-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GG552	1833065				2022-12-24	WOS:A1991GG55200012
J	BAVINCK, JNB; VERMEER, BJ; VANDERWOUDE, FJ; VANDENBROUCKE, JP; SCHREUDER, GMT; THOROGOOD, J; PERSIJN, GG; CLAAS, FHJ				BAVINCK, JNB; VERMEER, BJ; VANDERWOUDE, FJ; VANDENBROUCKE, JP; SCHREUDER, GMT; THOROGOOD, J; PERSIJN, GG; CLAAS, FHJ			RELATION BETWEEN SKIN-CANCER AND HLA ANTIGENS IN RENAL-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALLOGRAFT RECIPIENTS; SURVIVAL; INFECTION; WARTS; DNA	Background. Recipients of renal allografts are at an increased risk for skin cancer. It is also known that recipients who are homozygous for HLA antigens are at an increased risk for certain cancers, as are those who are mismatched with their donors for these antigens. In a case-control study we assessed the relation between skin cancer in renal-transplant recipients and HLA homozygosity and mismatching. Methods. Of 764 patients who received renal transplants between 1966 and 1988, 66 had squamous-cell carcinoma or basal-cell carcinoma of the skin after transplantation. HLA homozygosity was assessed in all 66 recipients, and HLA mismatching in 39; the results were compared with those in 124 recipients without skin cancer. We also investigated the relation between skin cancer and the use of immunosuppressive drugs. In separate case-control analyses we investigated the influence of exposure to the sun and keratotic skin lesions on the risk of skin cancer. Results. The risk of squamous-cell carcinoma was increased in recipients mismatched for HLA-B antigens; the relative risks were 2.6 (95 percent confidence interval, 1.1 to 6.5) and 5.0 (95 percent confidence interval, 1.3 to 19.0) with mismatching for one and two antigens, respectively, as compared with no mismatching. Mismatching for HLA-A or HLA-DR antigens had no effect on the risk of squamous-cell carcinoma, and there was no association between mismatches at any of the HLA loci and the occurrence of basal-cell carcinoma. The total doses of azathioprine and prednisone were not associated with the occurrence of skin cancer or with HLA matching. Exposure to sunlight and keratotic ski in lesions were strongly associated with skin cancer but not with HLA mismatching. Homozygosity for HLA-DR was more frequent among the patients with squamous-cell carcinoma (relative risk, 2.5; 95 percent confidence interval, 0.95 to 4.6) and among patients with 100 or more keratotic skin lesions (relative risk, 4.8; 95 percent confidence interval, 1.5 to 15.1). Conclusions. HLA-B mismatching is significantly associated with the risk of squamous-cell carcinoma in renal-transplant recipients, as is HLA-DR homozygosity. An indirect effect on the level of immunosuppression does not appear to explain these findings, nor does exposure to sunlight or the number of keratotic skin lesions account for this observation.	LEIDEN UNIV HOSP, DEPT NEPHROL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT IMMUNOHEMATOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, BLOOD BANK, 2333 AA LEIDEN, NETHERLANDS; EUROTRANSPLANT FDN, LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC	BAVINCK, JNB (corresponding author), LEIDEN UNIV HOSP, DEPT DERMATOL, RIJNSBURGERWEG 10, 2333 AA LEIDEN, NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BARR BBB, 1989, LANCET, V1, P124; BAVINCK JNB, 1990, NEW ENGL J MED, V323, P1350; BOYLE J, 1984, LANCET, V1, P702; CARPENTER CB, 1989, CONTEMP ISS NEPHROL, V19, P1; Dausset J., 1982, CANCER SURV, V1, P119; DYER PA, 1989, TRANSPLANTATION, V48, P131, DOI 10.1097/00007890-198907000-00030; FESTENSTEIN H, 1986, NATURE, V322, P502, DOI 10.1038/322502a0; FLIEDNER VEV, 1980, TISSUE ANTIGENS, V16, P399; GASSENMAIER A, 1986, ARCH DERMATOL RES, V278, P219, DOI 10.1007/BF00412927; GERKINS VR, 1974, JNCI-J NATL CANCER I, V52, P1909, DOI 10.1093/jnci/52.6.1909; GUPTA AK, 1986, ARCH DERMATOL, V122, P1288, DOI 10.1001/archderm.122.11.1288; HARDIE IR, 1980, SURGERY, V87, P177; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; Henny F C, 1986, Nephrol Dial Transplant, V1, P44; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KOOTTE AMM, 1988, NEPHROL DIAL TRANSPL, V3, P666, DOI 10.1093/oxfordjournals.ndt.a091725; LUTZNER MA, 1983, LANCET, V2, P422; OPELZ G, 1988, LANCET, V2, P61; PENN I, 1988, TRANSPLANT P, V20, P885; PERSIJN GG, 1982, NEW ENGL J MED, V307, P905, DOI 10.1056/NEJM198210073071501; RAY JG, 1979, NIH80545 DHEW PUBL; RUDLINGER R, 1986, BRIT J DERMATOL, V115, P681, DOI 10.1111/j.1365-2133.1986.tb06649.x; RUDLINGER R, 1989, LANCET, V1, P1132; SHEIL AGR, 1989, KIDNEY TRANSPLANTATI, P603; THOROGOOD J, 1990, TRANSPLANTATION, V50, P146, DOI 10.1097/00007890-199007000-00027; TING A, 1989, KIDNEY TRANSPLANTATI, P183; VANDERLEEST RJ, 1987, ARCH DERMATOL, V123, P354, DOI 10.1001/archderm.123.3.354; VANHOOFF PJ, 1980, P EUR DIAL TRANSPLAN, V17, P435; VANROOD JJ, 1985, TRANSPLANT P, V17, P681; VANROOD JJ, 1976, NATURE, V262, P795, DOI 10.1038/262795a0	30	152	155	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					843	848		10.1056/NEJM199109193251203	http://dx.doi.org/10.1056/NEJM199109193251203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875968				2022-12-24	WOS:A1991GF61600003
J	SCHWARTZ, B; SCHUCHAT, A; OXTOBY, MJ; COCHI, SL; HIGHTOWER, A; BROOME, CV				SCHWARTZ, B; SCHUCHAT, A; OXTOBY, MJ; COCHI, SL; HIGHTOWER, A; BROOME, CV			INVASIVE GROUP-B STREPTOCOCCAL DISEASE IN ADULTS - A POPULATION-BASED STUDY IN METROPOLITAN ATLANTA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACTEREMIA; POLYSACCHARIDE; INFECTIONS; COMMUNITY; VACCINE; COUNTY; WOMEN	Objective.-To define the incidence and clinical spectrum of group B streptococcus infection in adults. To characterize groups at increased risk for infection. Design.-Retrospective population-based surveillance of group B streptococcus infections occurring in adults. Patients were identified by review of microbiology records at all surveillance area hospital laboratories. Demographic and clinical data were abstracted from patient medical records. Setting.-Metropolitan Atlanta, Ga, 1982 through 1983. Patients.-We identified 70 adult patients with invasive group B streptococcus infections; 14 infections occurred in pregnant women and 56 in nonpregnant adults. Results.-The annual incidence of group B streptococcus infection in men and nonpregnant women was 2.4 cases per 100 000 population. Incidence increased with age and was higher in blacks than in whites. The case-fatality rate was 32%. Group B streptococcus was most often isolated from blood (71%) and soft tissue (16%). Common clinical presentations included skin and soft-tissue infection (36%), bacteremia without focus (34%), pneumonia (11%), arthritis (9%), and endocarditis (9%). Compared with the general population's risk of infection, the risk of infection in persons with diabetes mellitus was increased 10.5-fold (95% confidence interval [Cl], 7.8 to 14.4); in persons with cancer, it was increased 16.4-fold (95% Cl, 11.5 to 23.3). Conclusions.-Group B streptococcus infections cause serious disease in adults as well as in neonates, providing an additional rationale for vaccine development. Determining the incidence of adult disease and groups at greatest risk will help in focusing prevention efforts.	CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,STAT SERV ACTIV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ANTHONY BF, 1975, J INFECT DIS, V132, P561, DOI 10.1093/infdis/132.5.561; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1985, REV INFECT DIS, V7, P458; BAKER CJ, 1990, NEW ENGL J MED, V322, P1857, DOI 10.1056/NEJM199006283222606; BAKER CJ, 1990, INFECT DIS, P742; BAYER AS, 1976, AM J MED, V61, P498, DOI 10.1016/0002-9343(76)90329-6; DWORZACK DL, 1979, AM J MED SCI, V277, P67, DOI 10.1097/00000441-197901000-00008; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; GALLAGHER PG, 1985, AM J MED, V78, P795, DOI 10.1016/0002-9343(85)90285-2; GIBBS RS, 1981, AM J OBSTET GYNECOL, V140, P405, DOI 10.1016/0002-9378(81)90034-X; HARRIS M, 1985, NIH851468 PUBL, V8, P3; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LEDGER WJ, 1975, AM J OBSTET GYNECOL, V121, P205, DOI 10.1016/0002-9378(75)90641-9; LERNER PI, 1977, MEDICINE, V56, P457, DOI 10.1097/00005792-197711000-00001; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; SCHUCHAT A, 1990, J INFECT DIS, V162, P672, DOI 10.1093/infdis/162.3.672; VERGHESE A, 1986, REV INFECT DIS, V8, P912; 1981, J INFECTION, V3, P385; 1985, DISEASES IMPORTANCE, V1, P423	22	177	181	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1112	1114		10.1001/jama.266.8.1112	http://dx.doi.org/10.1001/jama.266.8.1112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865545				2022-12-24	WOS:A1991GB97500035
J	LANGE, C; JUGEL, A; WALTER, J; NOYERWEIDNER, M; TRAUTNER, TA				LANGE, C; JUGEL, A; WALTER, J; NOYERWEIDNER, M; TRAUTNER, TA			PSEUDO DOMAINS IN PHAGE-ENCODED DNA METHYLTRANSFERASES	NATURE			English	Article							TARGET-RECOGNIZING DOMAINS; BACILLUS-SUBTILIS PHAGES; SEQUENCE; ORGANIZATION; RESTRICTION; MOTIFS; SPR	5-Cytosine-DNA-methyltransferases, which are found in many organisms ranging from bacteriophages to mammals, transfer a methyl group from S-adenosylmethionine to the carbon-5 of a cytosine residue in specific DNA target sequences 1. Some phage-encoded methyltransferases methylate more than one sequence: these enzymes contain several independent target-recognizing domains each responsible for recognizing a different site. The amino-acid sequences of these multispecific methyltransferases reveal that some enzymes in addition carry domains that do not contribute to the enzymes' methylation potential, but strongly resemble previously identified target-recognizing domains. Here we show that introducing defined amino-acid alterations into these inactive domains endows these enzymes with additional methylation specificities. Gel retardation analysis demonstrates that these novel methylation specificities correlate with the acquisition of additional DNA-binding potential of the proteins.			LANGE, C (corresponding author), MAX PLANCK INST MOLEC GENET,IHNESTR 73,W-1000 BERLIN 33,GERMANY.							BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BEHRENS B, 1987, EMBO J, V6, P1137, DOI 10.1002/j.1460-2075.1987.tb04869.x; BUHK HJ, 1984, GENE, V29, P51; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGE C, 1991, GENE, V100, P213, DOI 10.1016/0378-1119(91)90369-M; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RATCLIFF SW, 1979, MOL GEN GENET, V168, P165, DOI 10.1007/BF00431442; RAZIN A, 1984, DNA METHYLATION BIOC; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRANBETCKE A, 1986, GENE, V42, P89, DOI 10.1016/0378-1119(86)90153-8; TRAUTNER TA, 1988, NUCLEIC ACIDS RES, V16, P6649, DOI 10.1093/nar/16.14.6649; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x	16	27	27	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					645	648		10.1038/352645a0	http://dx.doi.org/10.1038/352645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865925				2022-12-24	WOS:A1991GB21100064
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INGREDIENT LABELING PROPOSAL PUBLISHED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P28592	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-24	WOS:A1991GA07300007
J	COX, LS; LASKEY, RA				COX, LS; LASKEY, RA			DNA-REPLICATION OCCURS AT DISCRETE SITES IN PSEUDONUCLEI ASSEMBLED FROM PURIFIED DNA INVITRO	CELL			English	Article							CELL NUCLEAR ANTIGEN; XENOPUS EGGS; POLYMERASE-ALPHA; FREE-EXTRACT; CYCLE; INITIATION; PHASE	Bacteriophage-lambda DNA is assembled into pseudonuclei in Xenopus egg extract and replicated semiconservatively under temporal cell cycle control. Here, replication is shown to be regulated spatially and to occur at discrete sites that represent clustered replication forks. Clustered forks are visualized by incorporation of biotin-19-dUTP into nascent DNA. Pulse-label experiments show that discrete replication foci persist throughout S phase. We conclude that the organization of replication forks into discrete clusters, previously described in eukaryotic nuclei, is not dependent on specific eukaryotic DNA sequences or on a preexisting inherited chromosomal or nuclear structure.			COX, LS (corresponding author), WELLCOME CANC RES CAMPAIGN INST,CANC RES CAMPAIGN MOLEC EMBRYOL GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Cox, Lynne/AAT-2047-2021	Cox, Lynne/0000-0002-5306-285X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; COOK PR, 1988, J CELL SCI, V90, P1; FORBES DJ, 1983, CELL, V34, P13, DOI 10.1016/0092-8674(83)90132-0; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HUTCHISON C, 1989, J CELL SCI, V93, P605; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; MECHALI M, 1983, CELL, V35, P63, DOI 10.1016/0092-8674(83)90208-8; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Sambrook J., 1989, MOL CLONING LAB MANU; VERHEIJEN R, 1988, J CELL SCI, V90, P11	21	70	71	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					271	275		10.1016/0092-8674(91)90617-8	http://dx.doi.org/10.1016/0092-8674(91)90617-8			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1830242				2022-12-24	WOS:A1991FY71200008
J	DIETZ, HC; CUTTING, GR; PYERITZ, RE; MASLEN, CL; SAKAI, LY; CORSON, GM; PUFFENBERGER, EG; HAMOSH, A; NANTHAKUMAR, EJ; CURRISTIN, SM; STETTEN, G; MEYERS, DA; FRANCOMANO, CA				DIETZ, HC; CUTTING, GR; PYERITZ, RE; MASLEN, CL; SAKAI, LY; CORSON, GM; PUFFENBERGER, EG; HAMOSH, A; NANTHAKUMAR, EJ; CURRISTIN, SM; STETTEN, G; MEYERS, DA; FRANCOMANO, CA			MARFAN-SYNDROME CAUSED BY A RECURRENT DENOVO MISSENSE MUTATION IN THE FIBRILLIN GENE	NATURE			English	Article							DINUCLEOTIDE REPEAT POLYMORPHISM; POLYMERASE CHAIN-REACTION; DNA POLYMORPHISMS; CHROMOSOME-15; DUCHENNE; LOCUS	MARFAN syndrome is an inherited disorder of connective tissue manifested in the ocular, skeletal and cardiovascular systems. It is inherited as an autosomal dominant with high penetrance, but has great clinical variability 1. Linkage studies have mapped the Marfan locus to chromosome 15q15-21.3 (refs 2, 3). There have been no reports of genetic heterogeneity in the syndrome. Following the identification of fibrillin (a glycoprotein component of the extracellular microfibril 4), immunohistopathological quantification of the protein in skin and fibroblast culture 5, and examination of fibrillin synthesis, extracellular transport, and incorporation into the extracellular matrix (D. M. Milewicz, R.E.P., E. S. Crawford and P.H. Byers, manuscript in preparation) have demonstrated abnormalities of fibrillin metabolism in most patients. A portion of the complementary DNA encoding fibrillin has been cloned 6 and mapped by in situ hybridization to chromosome 15 (ref. 7). Here we report that the fibrillin gene is linked to the Marfan phenotYPe (theta = 0.00; logarithm of the odds (lod) = (3.9) and describe a de novo missense mutation in the fibrillin gene in two patients with sporadic disease. We thus implicate fibrillin as the protein defective in patients with the Marfan syndrome.	OREGON HLTH SCI UNIV, SHRINERS HOSP CRIPPLED CHILDREN, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, CTR MED GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT GYNECOL & OBSTET, CTR MED GENET, BALTIMORE, MD 21205 USA	Oregon Health & Science University; Oregon Health & Science University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	DIETZ, HC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, DIV PEDIAT CARDIOL, BALTIMORE, MD 21205 USA.		Pyeritz, Reed/A-1364-2010	Puffenberger, Erik/0000-0002-6388-9148				BOUDOULAS H, 1988, MITRAL VALVE PROLAPS, P161; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; DENDUNNEN JT, 1987, NATURE, V329, P640, DOI 10.1038/329640a0; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FORREST SM, 1987, NATURE, V329, P638, DOI 10.1038/329638a0; HIGUCHI M, IN PRESS P NATN ACAD; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; MAGENIS RE, IN PRESS GENOMICS; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; NAKAMURA Y, 1988, GENOMICS, V3, P342, DOI 10.1016/0888-7543(88)90125-5; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; SAIKI RK, 1988, NEW ENGL J MED, V319, P537, DOI 10.1056/NEJM198809013190903; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J., 1989, MOL CLONING; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4637, DOI 10.1093/nar/18.15.4637; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2202	22	1481	1535	3	134	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					337	339		10.1038/352337a0	http://dx.doi.org/10.1038/352337a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852208				2022-12-24	WOS:A1991FY28900071
J	QUE, L				QUE, L			OXYGEN ACTIVATION AT THE DIIRON CENTER OF RIBONUCLEOTIDE REDUCTASE	SCIENCE			English	Editorial Material							METHANE MONOOXYGENASE; HYDROGEN-PEROXIDE; IRON; COENZYME-B12; INTERMEDIATE; SPECTROSCOPY; MECHANISM; COBAMIDES; MOSSBAUER; PROTEIN				QUE, L (corresponding author), UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455, USA.							ANDERSON KK, 1991, NEW J CHEM, V15, P405; ASHLEY GW, 1986, J BIOL CHEM, V261, P3958; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, IN PRESS J AM CHEM S; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P10023; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; LEISING RA, 1991, J AM CHEM SOC, V113, P3988, DOI 10.1021/ja00010a050; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MENAGE S, 1990, J AM CHEM SOC, V112, P6423, DOI 10.1021/ja00173a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; QUE L, 1990, PROG INORG CHEM, V38, P97; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; STENKAMP RE, 1985, P NATL ACAD SCI USA, V82, P713, DOI 10.1073/pnas.82.3.713; STUBBE J, 1989, ADV ENZYMOL RELAT AR, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; TAMAO Y, 1973, BIOCHEMISTRY-US, V12, P24, DOI 10.1021/bi00725a005; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x	27	25	25	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					273	274		10.1126/science.1857963	http://dx.doi.org/10.1126/science.1857963			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857963				2022-12-24	WOS:A1991FX22400029
J	CUSICK, EL; KRUKOWSKI, ZH; MACINTOSH, CA; MATHESON, NA				CUSICK, EL; KRUKOWSKI, ZH; MACINTOSH, CA; MATHESON, NA			RISK OF NEOPLASIA AND MALIGNANCY IN DOMINANT THYROID SWELLINGS	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; DIAGNOSIS; NODULE	Objective - To determine the risk of neoplasia and malignancy in "dominant" thyroid swellings. Design - Prospective analysis during six years. Setting-Thyroid clinic serving the Grampian region. Patients-574 consecutive patients presenting with a discrete thyroid swelling, of whom 179 (31%) were classified clinically as having a dominant area of enlargement within a multinodular gland. Results-After clinical and cytological assessment 77 dominant swellings were excised. Of the excised swellings, 45 were non-neoplastic and 32 neoplastic, including 11 malignant lesions. The minimum incidence of neoplasia and malignancy in all 179 dominant swellings was therefore 18% and 6% respectively. Conclusion-Dominant thyroid swellings should be regarded with greater clinical suspicion than has been traditional.	UNIV ABERDEEN,DEPT SURG,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen								BEIERWALTES WH, 1983, ENDOCRINE SURGERY UP, P18; COLE WH, 1945, JAMA-J AM MED ASSOC, V127, P883, DOI 10.1001/jama.1945.02860140001001; COPE O, 1949, CLIN ENDOCRINOL META, V9, P1012; CUSICK EL, 1991, BRIT J SURG, V78, P94, DOI 10.1002/bjs.1800780129; CUSICK EL, 1990, BMJ-BRIT MED J, V301, P318, DOI 10.1136/bmj.301.6747.318; HOFFMAN GL, 1972, ARCH SURG-CHICAGO, V105, P379; LENNQUIST S, 1987, SURG CLIN N AM, V67, P213; ROHER HD, 1987, SURG CLIN N AM, V67, P233; THOMAS CG, 1976, ANN SURG, V183, P463, DOI 10.1097/00000658-197605000-00002	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					20	22		10.1136/bmj.303.6793.20	http://dx.doi.org/10.1136/bmj.303.6793.20			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859949	Green Published, Bronze			2022-12-24	WOS:A1991FW12800020
J	DONE, DJ; JOHNSTONE, EC; FRITH, CD; GOLDING, J; SHEPHERD, PM; CROW, TJ				DONE, DJ; JOHNSTONE, EC; FRITH, CD; GOLDING, J; SHEPHERD, PM; CROW, TJ			COMPLICATIONS OF PREGNANCY AND DELIVERY IN RELATION TO PSYCHOSIS IN ADULT LIFE - DATA FROM THE BRITISH PERINATAL-MORTALITY SURVEY SAMPLE	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRIC COMPLICATIONS; SCHIZOPHRENIC MOTHERS; EPIDEMIOLOGY; CHILDREN; ILLNESS; TWIN; RISK	Objective - To evaluate whether events occurring at or around the time of birth contribute to the onset of psychotic illness in adult life. Design - Pregnancy and birth complications as possible causes of adult mental illness were studied in the population sample of the British perinatal mortality survey. Subsequent psychiatric admissions were independently identified through the Mental Health Enquiry and records of regional and special health authorities. Logistic regression was used to compare data on perinatal deaths with those on survivors to determine factors independently associated with perinatal death, and this equation was then used to calculate the risk of perinatal death for each survivor. Subjects - 16 980 people born in a single week in 1958 (the British perinatal mortality survey sample), including 252 patients admitted to psychiatric care; case notes of 235 patients were supplied. Main outcome measures and results - Patients with a schizophrenic illness (whether defined by "broad" (n = 57) or "narrow" (n = 35) diagnostic criteria) did not have a greater mean risk of perinatal death than the population in general, but there was some evidence of increased liability (relative risk 2.43; 95% confidence interval 1.17 to 5.05) for those with affective psychosis (n = 32). Specific high risk variables for affective psychosis were decreased gestation time (273.9 v 281.2 days; mean difference 7.3 days, 95% confidence interval 3.1 to 11.5; p < 0.002) and prescription of vitamin K to the child in the first week of life (19% of patients v 5% of controls, p = 0.016). Conclusions - The findings give no support to theories that factors predicting perinatal mortality contribute significantly to causation of schizophrenic illness. Further investigation of decreased gestation length in relation to affective disorder is required.	ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1V 0BH,ENGLAND	Bristol Royal Hospital For Children; University of Bristol; City University London	DONE, DJ (corresponding author), CLIN RES CTR,DIV PSYCHIAT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.		crow, timothy J/M-8327-2014; Frith, Chris D/A-2171-2009	crow, timothy J/0000-0002-5482-6655; Frith, Chris D/0000-0002-8665-0690; Golding, Jean/0000-0003-2826-3307				BERTELSEN A, 1977, BRIT J PSYCHIAT, V130, P330, DOI 10.1192/bjp.130.4.330; BUTLER N, 1971, BMJ, V1, P127; BUTLER NR, 1969, PERINATAL PROBLEMS; DALEN P, 1965, ACTA PSYCHIAT SCAND, V41, P527, DOI 10.1111/j.1600-0447.1965.tb06169.x; DER G, 1990, LANCET, V335, P513, DOI 10.1016/0140-6736(90)90745-Q; EAGLES JM, 1990, LANCET, V336, P1139; EATON WW, 1985, EPIDEMIOL REV, V7, P105, DOI 10.1093/oxfordjournals.epirev.a036278; Gottesman I.I., 1982, SCHIZOPHRENIA EPIGEN; Gottesman I. I., 1972, SCHIZOPHRENIA GENETI; HARE EH, 1987, BRIT MED BULL, V43, P514, DOI 10.1093/oxfordjournals.bmb.a072199; JACOBSEN B, 1980, ACTA PSYCHIAT SCAND, V62, P337, DOI 10.1111/j.1600-0447.1980.tb07709.x; JOFFE M, 1985, J BIOSOC SCI, V17, P113, DOI 10.1017/S0021932000015522; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KETY SS, 1983, AM J PSYCHIAT, V140, P720; LANE EA, 1966, J PSYCHOL, V64, P227, DOI 10.1080/00223980.1966.10544847; LEWIS SW, 1989, PSYCHOL MED, V19, P5, DOI 10.1017/S0033291700010977; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; MCNEIL TF, 1973, BRIT J PSYCHIAT, V123, P341, DOI 10.1192/bjp.123.3.341; McNeil TF, 1978, NATURE SCHIZOPHRENIA, P401; MEDNICK SA, 1971, SOC BIOL, V18, P103; MEDNICK SA, 1978, NATURE SCHIZOPHRENIA, P442; MENDLEWICZ J, 1977, NATURE, V268, P327, DOI 10.1038/268327a0; MIRDAL GKM, 1974, ACTA PSYCHIAT SCAND, V50, P553; OLSON SC, 1989, BIOL PSYCHIAT, V25, pA93; OWEN MJ, 1988, PSYCHOL MED, V18, P331, DOI 10.1017/S003329170000787X; PARNAS J, 1982, BRIT J PSYCHIAT, V140, P416, DOI 10.1192/bjp.140.4.416; POLLACK M, 1966, AM J ORTHOPSYCHIAT, V36, P510, DOI 10.1111/j.1939-0025.1966.tb02394.x; POLLACK M, 1968, AM J ORTHOPSYCHIAT, V38, P94, DOI 10.1111/j.1939-0025.1968.tb00560.x; REDDY R, 1989, BIOL PSYCHIAT, V25, pA93; SHEPHERD PM, 1985, 1 CITY U SOC STAT RE; WEISSMAN MM, 1984, NEUROBIOLOGY MOOD DI, P60; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WOERNER MG, 1973, ACTA PSYCHIAT SCAND, V49, P712, DOI 10.1111/j.1600-0447.1973.tb04460.x; WREDE G, 1980, ACTA PSYCHIAT SCAND, V62, P369, DOI 10.1111/j.1600-0447.1980.tb00623.x	34	193	193	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1576	1580		10.1136/bmj.302.6792.1576	http://dx.doi.org/10.1136/bmj.302.6792.1576			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU549	1855042	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1991FU54900026
J	BAGCHI, S; WEINMANN, R; RAYCHAUDHURI, P				BAGCHI, S; WEINMANN, R; RAYCHAUDHURI, P			THE RETINOBLASTOMA PROTEIN COPURIFIES WITH E2F-I, AN E1A-REGULATED INHIBITOR OF THE TRANSCRIPTION FACTOR E2F	CELL			English	Article								Recently, we identified an inhibitory protein, E2F-I, that blocks the DNA-binding activity of the transcription factor E2F. We also showed that the adenovirus ElA protein reverses this inhibitory activity of E2F-I, thereby restoring the DNA-binding activity of E2F. We have now further purified this inhibitory activity and show that the most purified preparation of E2F-I contains a 105 kd E1A-binding protein. This 105 kd E1A-binding protein cross-reacts with two different antibodies against the retinoblastoma (RB) gene product. Moreover, the RB gene product copurifies with E2F-I activity. Taken together, we conclude that the product of the RB gene is a part of E2F-I and is involved in the regulation of E2F activity.	UNIV ILLINOIS, COLL DENT MC860, CTR RES PERIODONTAL DIS & ORAL MOLEC BIOL, CHICAGO, IL 60680 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; The Wistar Institute	BAGCHI, S (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM MC536, CHICAGO, IL 60680 USA.				NCI NIH HHS [CA 44466, CA 10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA044466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RAYCHAUDHURI P, 1991, IN PRESS GENES DEV; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; REISSMANN PT, 1989, ONCOGENE, V4, P839; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	54	424	435	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1991	65	6					1063	1072		10.1016/0092-8674(91)90558-G	http://dx.doi.org/10.1016/0092-8674(91)90558-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828393				2022-12-24	WOS:A1991FR04700017
J	COSSON, P; LANKFORD, SP; BONIFACINO, JS; KLAUSNER, RD				COSSON, P; LANKFORD, SP; BONIFACINO, JS; KLAUSNER, RD			MEMBRANE-PROTEIN ASSOCIATION BY POTENTIAL INTRAMEMBRANE CHARGE PAIRS	NATURE			English	Article							ANTIGEN RECEPTOR COMPLEX; T-CELL RECEPTOR; MOLECULAR-COMPONENTS; ANTIBODY; DEGRADATION; IGM	THE transmembrane domain of the alpha-chain of the T-cell receptor is responsible both for its assembly with the CD3 delta-chain 1 and for rapid degradation of the unassembled chain within the endoplasmic reticulum 2, 3. The determinant for both assembly and degradation is located in a segment of eight residues containing two basic amino acids (Fig. 1). We show here that placement of a single basic residue in the transmembrane domain of the Tac antigen can induce interaction with the CD3 chain, through its transmembrane acidic residue. This interaction is most favoured when the interacting residues are located at the same level in the membrane. The ability to induce protein-protein interaction by placing charge pairs within transmembrane domains suggests an approach to producing artificial dimers.			COSSON, P (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Bonifacino, Juan S./0000-0002-5673-6370				BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; VANDENELSEN P, 1985, NATURE, V314, P542, DOI 10.1038/314542a0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x	16	233	234	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1991	351	6325					414	416		10.1038/351414a0	http://dx.doi.org/10.1038/351414a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN856	1827877				2022-12-24	WOS:A1991FN85600061
J	WULCZYN, FG; KAHMANN, R				WULCZYN, FG; KAHMANN, R			TRANSLATIONAL STIMULATION - RNA SEQUENCE AND STRUCTURE REQUIREMENTS FOR BINDING OF COM PROTEIN	CELL			English	Article								Translation of the bacteriophage Mu mom gene is positively regulated by the phage Com protein. We report here that purified Com protein specifically stimulates mom gene expression in vitro. Furthermore, Com is shown to bind a site in the mom translational initiation region (TIR) in a sequence-specific manner. In vitro RNA footprint experiments have been used to define the Com-binding site and to study mRNA secondary structure in the mom TIR. Com binding is shown to correlate with a conformational change in the mom TIR both in vivo and in vitro. The role of secondary structure was further examined by testing the effects of mutations in the TIR on translation and stimulation. The results support a model for translational stimulation in which Com binding induces a conformational change in the mom mRNA, thereby enhancing ribosome binding.			WULCZYN, FG (corresponding author), BERLIN GMBH, INST GENBIOL FORSCH, IHNESTR 63, W-1000 BERLIN 33, GERMANY.							AIBA H, 1981, J BIOL CHEM, V256, P1905; ALTUVIA S, 1989, J MOL BIOL, V210, P265, DOI 10.1016/0022-2836(89)90329-X; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; BETZ JL, 1976, J MOL BIOL, V105, P293, DOI 10.1016/0022-2836(76)90113-3; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DESMIT MH, 1990, P NATL ACAD SCI USA, V87, P7668, DOI 10.1073/pnas.87.19.7668; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRALLA J, 1974, NATURE, V248, P204, DOI 10.1038/248204a0; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HATTMAN S, 1987, GENE, V55, P345, DOI 10.1016/0378-1119(87)90295-2; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAHMANN R, 1985, GENE, V39, P61, DOI 10.1016/0378-1119(85)90108-8; KAHMANN R, 1982, COLD SPRING HARB SYM, V47, P639; LEACH D, 1979, MOL GEN GENET, V172, P179, DOI 10.1007/BF00268280; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MAYFORD M, 1989, EMBO J, V8, P4307, DOI 10.1002/j.1460-2075.1989.tb08617.x; MCMULLIN TW, 1990, MOL CELL BIOL, V10, P4590, DOI 10.1128/MCB.10.9.4590; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOINE H, 1988, P NATL ACAD SCI USA, V85, P7892, DOI 10.1073/pnas.85.21.7892; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; STERN S, 1988, METHOD ENZYMOL, V164, P481; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TOUSSAINT A, 1976, VIROLOGY, V70, P17, DOI 10.1016/0042-6822(76)90232-4; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822; WULCZYN FG, 1989, CELL, V57, P1201, DOI 10.1016/0092-8674(89)90057-3; WULCZYN FG, 1987, GENE, V51, P139, DOI 10.1016/0378-1119(87)90302-7; WULCZYN FG, 1990, NATO ASI SERIES H, V49, P285; WYCKOFF E, 1986, GENE, V43, P281, DOI 10.1016/0378-1119(86)90217-9; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	56	58	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					259	269		10.1016/0092-8674(91)90160-Z	http://dx.doi.org/10.1016/0092-8674(91)90160-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1826635				2022-12-24	WOS:A1991FH09200009
J	GHIARA, JB; RICHARDSON, HE; SUGIMOTO, K; HENZE, M; LEW, DJ; WITTENBERG, C; REED, SI				GHIARA, JB; RICHARDSON, HE; SUGIMOTO, K; HENZE, M; LEW, DJ; WITTENBERG, C; REED, SI			A CYCLIN-B HOMOLOG IN SACCHAROMYCES-CEREVISIAE - CHRONIC ACTIVATION OF THE CDC28 PROTEIN-KINASE BY CYCLIN PREVENTS EXIT FROM MITOSIS	CELL			English	Article							CELL-DIVISION CYCLE; CONTROL GENE CDC2+; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; M-PHASE; SCHIZOSACCHAROMYCES-POMBE; COMPONENT; PRODUCT; MPF	A cyclin B homolog was identified in Saccharomyces cerevisiae using degenerate oligonucleotides and the polymerase chain reaction. The protein, designated Scb1, has a high degree of similarity with B-type cyclins from organisms ranging from fission yeast to human. Levels of SCB1 mRNA and protein were found to be periodic through the cell cycle, with maximum accumulation late, most likely in the G2 interval. Deletion of the gene was found not to be lethal, and subsequently other B-type cyclins have been found in yeast functionally redundant with Scb1. A mutant allele of SCB1 that removes an amino-terminal fragment of the encoded protein thought to be required for efficient degradation during mitosis confers a mitotic arrest phenotype. This arrest can be reversed by inactivation of the Cdc28 protein kinase, suggesting that cyclin-mediated arrest results from persistent protein kinase activation.			GHIARA, JB (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC BIOL, MB-7, LA JOLLA, CA 92037 USA.		Richardson, Helena E/A-8080-2013	Richardson, Helena E/0000-0003-3852-4953	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038328, R37GM038328, R01GM043487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38328, GM43487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GLOTZER M, 1991, NATURE, V349, P32; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; Maniatis T., 1982, MOL CLONING; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; RICHARDSON HE, 1989, CELL, V59, P127; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1982, METHODS YEAST GENETI; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; WITTENBERG C, 1987, J CELL BIOL, V105, P1527, DOI 10.1083/jcb.105.4.1527; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	72	277	280	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					163	174		10.1016/0092-8674(91)90417-W	http://dx.doi.org/10.1016/0092-8674(91)90417-W			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849458	Bronze			2022-12-24	WOS:A1991FF77300018
J	HSU, IC; METCALF, RA; SUN, T; WELSH, JA; WANG, NJ; HARRIS, CC				HSU, IC; METCALF, RA; SUN, T; WELSH, JA; WANG, NJ; HARRIS, CC			MUTATIONAL HOTSPOT IN THE P53 GENE IN HUMAN HEPATOCELLULAR CARCINOMAS	NATURE			English	Article							DNA; EXPOSURE	HUMAN hepatocellular carcinomas (HCC) from patients in Qidong, an area of high incidence in China, in which both hepatitis B virus and aflatoxin B1 are risk factors 1, were analysed for mutations in p53, a putative tumour-suppressor gene. Eight of the 16 HCC had a point mutation at the third base position of codon 249. The G --> T transversion in seven HCC DNA samples and the G --> C transversion in the other HCC are consistent with mutations caused by aflatoxin B1 in mutagenesis experiments 2,3. No mutations were found in exons 5, 6, 8 or the remainder of exon 7. These results contrast with p53 mutations previously reported in carcinomas and sarcomas of human lung, colon, oesophagus and breast; these are primarily scattered over four of the five evolutionarily conserved domains, which include codon 249 (refs 4-9). We suggest that the mutant p53 protein may be responsible for a selective clonal expansion of hepatocytes during carcinogenesis.	NCI,DIV CANC ETIOL,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; CHINESE ACAD MED SCI,INST CANC,BEIJING,PEOPLES R CHINA; QIDONG LIVER CANC INST,JIANGSU,PEOPLES R CHINA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; Chinese Academy of Medical Sciences - Peking Union Medical College								AUTRUP H, 1984, CHEM-BIOL INTERACT, V50, P15, DOI 10.1016/0009-2797(84)90128-5; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1978, P NATL ACAD SCI USA, V75, P2003, DOI 10.1073/pnas.75.4.2003; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; LECHNER JF, 1989, CANCER DETECT PREV, V14, P239; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SAMBAMURTI K, 1988, GENETICS, V120, P863; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSSI T, 1987, ONCOGENE, V1, P71; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; Sun T., 1986, DIET NUTRITION CANCE, P225; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WINBERG G, 1980, NUCLEIC ACIDS RES, V8, P253, DOI 10.1093/nar/8.2.253; WOGAN GN, 1989, ENVIRON HEALTH PERSP, V81, P9, DOI 10.2307/3430797; WOGAN GN, 1985, ENVIRON HEALTH PERSP, V62, P5, DOI 10.2307/3430088	25	1455	1520	1	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1991	350	6317					427	428		10.1038/350427a0	http://dx.doi.org/10.1038/350427a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1849234				2022-12-24	WOS:A1991FF04200051
J	MORI, Y; FRIEDRICH, T; KIM, MS; MIKAMI, A; NAKAI, J; RUTH, P; BOSSE, E; HOFMANN, F; FLOCKERZI, V; FURUICHI, T; MIKOSHIBA, K; IMOTO, K; TANABE, T; NUMA, S				MORI, Y; FRIEDRICH, T; KIM, MS; MIKAMI, A; NAKAI, J; RUTH, P; BOSSE, E; HOFMANN, F; FLOCKERZI, V; FURUICHI, T; MIKOSHIBA, K; IMOTO, K; TANABE, T; NUMA, S			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION FROM COMPLEMENTARY-DNA OF A BRAIN CALCIUM-CHANNEL	NATURE			English	Article							SKELETAL-MUSCLE; DIHYDROPYRIDINE RECEPTOR; CEREBELLAR SLICES; MESSENGER-RNAS; MUTANT MICE; ALPHA-1-SUBUNIT; MODULATION; CURRENTS; SEQUENCE; NEURONS	The primary structure of a voltage-dependent calcium channel from rabbit brain has been deduced by cloning and sequencing the complementary DNA. Calcium channel activity expressed from the cDNA is dramatically increased by coexpression of the alpha-2 and beta-subunits, known to be associated with the dihydropyridine receptor. This channel is a high voltage-activated calcium channel that is insensitive both to nifedipine and to omega-conotoxin. We suggest that it is expressed predominantly in cerebellar Purkinje cells and granule cells.	KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC GENET, KYOTO 606, JAPAN; UNIV SAARLAND, FAK MED, INST MED BIOCHEM, W-6650 HOMBURG, GERMANY; NATL INST BASIC BIOL, DIV BEHAV & NEUROBIOL, OKAZAKI, AICHI 444, JAPAN; OSAKA UNIV, INST PROT RES, DIV REGULAT MACROMOLEC FUNCT, SUITA, OSAKA 565, JAPAN	Kyoto University; Kyoto University; Saarland University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Osaka University			Mikoshiba, Katsuhiko/N-7943-2015; Nakai, Junichi/GQZ-6415-2022; Furuichi, Teiichi/B-5086-2014	Furuichi, Teiichi/0000-0002-9676-1888; Imoto, Keiji/0000-0002-2861-5985				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERTOLINO M, 1990, FASEB J, V4, pA1202; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOLL W, 1985, NEUROSCI LETT, V56, P335, DOI 10.1016/0304-3940(85)90265-4; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BRADLEY P, 1978, BRAIN RES, V142, P135, DOI 10.1016/0006-8993(78)90182-8; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CREPEL F, 1984, J PHYSIOL-LONDON, V346, P111, DOI 10.1113/jphysiol.1984.sp015010; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HIRANO A, 1975, J NEUROPATH EXP NEUR, V34, P1, DOI 10.1097/00005072-197501000-00001; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KASAI H, 1987, Neuroscience Research, V4, P228, DOI 10.1016/0168-0102(87)90014-9; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LIN JW, 1990, P NATL ACAD SCI USA, V87, P4538, DOI 10.1073/pnas.87.12.4538; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; NUMA S, 1986, ANN NY ACAD SCI, V479, P338, DOI 10.1111/j.1749-6632.1986.tb15580.x; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; Purves, 1985, PRINCIPLES NEURAL DE; RAKIC P, 1973, J COMP NEUROL, V152, P103, DOI 10.1002/cne.901520202; REGAN LJ, 1989, ANN NY ACAD SCI, V560, P121, DOI 10.1111/j.1749-6632.1989.tb24088.x; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAH D W Y, 1989, Society for Neuroscience Abstracts, V15, P823; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4	37	766	792	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1991	350	6317					398	402		10.1038/350398a0	http://dx.doi.org/10.1038/350398a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FF042	1849233				2022-12-24	WOS:A1991FF04200040
J	MIGNARD, M; MALPELI, JG				MIGNARD, M; MALPELI, JG			PATHS OF INFORMATION-FLOW THROUGH VISUAL-CORTEX	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; STRIATE CORTEX; CORTICAL CONNECTIONS; LAMINAR ORIGINS; AREA 17; CAT; MONKEY; CELLS; PROJECTIONS; NEURONS	The main route of information flow in the cerebral cortex is from the middle layers of cortex to upper and lower layers. However, upper layers of the cat primary visual cortex can be directly driven by inputs from secondary visual cortex when activity in middle layers is disrupted. Upper-layer activity can be driven either by middle layers or by direct corticocortical inputs. One consequence of this result is that areas of cortex thought to be carrying out low-order analysis may be able to extract considerable information from higher order areas.	UNIV ILLINOIS,DEPT PSYCHOL,603 E DANIEL ST,CHAMPAIGN,IL 61820	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL EYE INSTITUTE [R01EY002695] Funding Source: NIH RePORTER; NEI NIH HHS [EY02695] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BULLIER J, 1988, EXP BRAIN RES, V70, P90; BULLIER J, 1984, J COMP NEUROL, V228, P329, DOI 10.1002/cne.902280304; FISKEN RA, 1975, PHILOS T ROY SOC B, V272, P487, DOI 10.1098/rstb.1975.0099; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; HENRY GH, 1991, EUR J NEUROSCI, V3, P186, DOI 10.1111/j.1460-9568.1991.tb00079.x; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; Lee C., UNPUB; LEE CK, 1986, BRAIN RES, V364, P396, DOI 10.1016/0006-8993(86)90855-3; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; LEVENTHAL AG, 1979, EXP BRAIN RES, V37, P349; MALPELI JG, 1983, J NEUROPHYSIOL, V49, P595, DOI 10.1152/jn.1983.49.3.595; MALPELI JG, 1986, J NEUROPHYSIOL, V56, P1062, DOI 10.1152/jn.1986.56.4.1062; MALPELI JG, 1979, J NEUROSCI METH, V1, P143, DOI 10.1016/0165-0270(79)90011-6; MALPELI JG, 1982, NEUROSCI LETT, V32, P29, DOI 10.1016/0304-3940(82)90224-5; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; MITZDORF U, 1978, EXP BRAIN RES, V33, P371; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NAULT B, 1990, Society for Neuroscience Abstracts, V16, P1219; ORBAN GA, 1984, NEURONAL OPERATIONS, P47; OTSUKA R, 1962, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V203, P212, DOI 10.1007/BF00352744; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; ROSENQUIST AC, 1975, BRAIN RES, V80, P71; SANDELL JH, 1982, J NEUROPHYSIOL, V48, P38, DOI 10.1152/jn.1982.48.1.38; SYMONDS LL, 1984, J COMP NEUROL, V229, P39, DOI 10.1002/cne.902290104; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	25	136	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1249	1251		10.1126/science.1848727	http://dx.doi.org/10.1126/science.1848727			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FA691	1848727				2022-12-24	WOS:A1991FA69100047
J	NOREL, R; AGUR, Z				NOREL, R; AGUR, Z			A MODEL FOR THE ADJUSTMENT OF THE MITOTIC CLOCK BY CYCLIN AND MPF LEVELS	SCIENCE			English	Article							CELL-CYCLE; BIOLOGY	A mathematical model of cell cycle progression is presented, which integrates recent biochemical information on the interaction of the maturation promotion factor (MPF) and cyclin. The model retrieves the dynamics observed in early embryos and explains how multiple cycles of MPF activity can be produced and how the internal clock that determines durations and number of cycles can be adjusted by modulating the rate of change in MPF or cyclin concentrations. Experiments are suggested for verifying the role of MPF activity in determining the length of the somatic cell cycle.	WEIZMANN INST SCI,DEPT APPL MATH & COMP SCI,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Norel, Raquel/ABB-3422-2021	Norel, Raquel/0000-0001-7737-4172				CONTE SD, 1965, ELEMENTARY NUMERICAL; LIN CC, 1988, MATH APPLIED DETERMI; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NORTH G, 1989, NATURE, V339, P97, DOI 10.1038/339097a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086	11	80	83	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1076	1078		10.1126/science.1825521	http://dx.doi.org/10.1126/science.1825521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1825521				2022-12-24	WOS:A1991EZ66500052
J	BOTTARO, DP; RUBIN, JS; FALETTO, DL; CHAN, AML; KMIECIK, TE; VANDEWOUDE, GF; AARONSON, SA				BOTTARO, DP; RUBIN, JS; FALETTO, DL; CHAN, AML; KMIECIK, TE; VANDEWOUDE, GF; AARONSON, SA			IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT	SCIENCE			English	Article							MOLECULAR-CLONING; TYROSINE KINASE; CELL-LINE; PURIFICATION; GENE; PHOSPHORYLATION; ACTIVATION; SEQUENCE; SUBUNIT; CDNA	Hepatocyte growth factor (HGF) is a plasminogen-like protein thought to be a humoral mediator of liver regeneration. A 145-kilodalton tyrosyl phosphoprotein observed in rapid response to HGF treatment of intact target cells was identified by immunoblot analysis as the beta-subunit of the c-met proto-oncogene product, a membrane-spanning tyrosine kinase. Covalent cross-linking of I-125-labeled ligand to cellular proteins of appropriate size that were recognized by antibodies to c-met directly established the c-met product as the cell-surface receptor for HGF.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BOTTARO, DP (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Chan, Andrew/AAC-1145-2020; Bottaro, Donald P/AAF-3853-2020; Chan, Andrew Man-Lok/J-9497-2013; Bottaro, Donald P/F-8550-2010	Chan, Andrew/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Chan, Andrew Man-Lok/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Kmiecik, Thomas/0000-0002-1367-443X				BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, UNPUB; Chan A. H. Y., UNPUB; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FALETTO DL, UNPUB; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HORJUP P, 1985, FEBS LETT, V184, P333; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RUBIN J, UNPUB; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; WHITE MF, 1988, INSULIN RECEPTORS A, P125; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314	35	2166	2309	0	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					802	804		10.1126/science.1846706	http://dx.doi.org/10.1126/science.1846706			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846706				2022-12-24	WOS:A1991EX57500047
J	BURBULYS, D; TRACH, KA; HOCH, JA				BURBULYS, D; TRACH, KA; HOCH, JA			INITIATION OF SPORULATION IN BACILLUS-SUBTILIS IS CONTROLLED BY A MULTICOMPONENT PHOSPHORELAY	CELL			English	Article							GTP-BINDING PROTEIN; BACILLUS-SUBTILIS; REGULATORY PROTEINS; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; RESPONSE REGULATOR; DEDUCED PRODUCT; GENE; PHOSPHORYLATION; SPO0A	Stage 0 sporulation (spo0) mutants of Bacillus subtilis are defective in the signal transduction system initiating sporulation. Two of the products of these genes, Spo0A and Spo0F, are related to response regulator components of two-component regulatory systems used to control environmental responses in bacteria. The Spo0F response regulator was found to be the primary substrate for phosphorylation by the sporulation-specific protein kinase, KinA. Phosphorylated Spo0F was the phosphodonor for a phosphotransferase, Spo0B, which transferred the phosphate group to the second response regulator, the transcription regulatory protein Spo0A. This phosphorelay provides a mechanism for signal gathering from several protein kinases using Spo0F as a secondary messenger. These divergent signals are integrated through Spo0B phosphotransferase to activate the Spo0A transcription factor. This system provides for many levels of control to prevent capricious induction of sporulation.			BURBULYS, D (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV CELLULAR BIOL, LA JOLLA, CA 92037 USA.				NIGMS NIH HHS [GM39442, GM19416] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019416, R01GM039442, R37GM019416] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; BOUVIER J, 1984, P NATL ACAD SCI-BIOL, V81, P7012, DOI 10.1073/pnas.81.22.7012; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; FERRARI FA, 1985, J BACTERIOL, V161, P556, DOI 10.1128/JB.161.2.556-562.1985; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HOCH JA, 1985, J BACTERIOL, V161, P552, DOI 10.1128/JB.161.2.552-555.1985; HOCH JA, 1976, ADV GENET, V18, P69, DOI 10.1016/S0065-2660(08)60437-X; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOSHLAND DE, 1952, J AM CHEM SOC, V74, P2286, DOI 10.1021/ja01129a035; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANDELSTAM J, 1974, J BACTERIOL, V120, P38, DOI 10.1128/JB.120.1.38-42.1974; MARCH PE, 1988, ONCOGENE, V2, P539; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1987, MOL MICROBIOL, V1, P125, DOI 10.1111/j.1365-2958.1987.tb00536.x; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SPIEGELMAN G, 1990, J BACTERIOL, V172, P5011, DOI 10.1128/jb.172.9.5011-5019.1990; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; TRACH KA, 1985, P NATL ACAD SCI USA, V82, P7260, DOI 10.1073/pnas.82.21.7260; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860; ZAIN-UL-ABEDIN, 1983, Nucleosides and Nucleotides, V2, P257, DOI 10.1080/07328318308078860; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	35	728	746	2	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					545	552		10.1016/0092-8674(91)90238-T	http://dx.doi.org/10.1016/0092-8674(91)90238-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846779				2022-12-24	WOS:A1991EX36100010
J	LEAPE, LL; BRENNAN, TA; LAIRD, N; LAWTHERS, AG; LOCALIO, AR; BARNES, BA; HEBERT, L; NEWHOUSE, JP; WEILER, PC; HIATT, H				LEAPE, LL; BRENNAN, TA; LAIRD, N; LAWTHERS, AG; LOCALIO, AR; BARNES, BA; HEBERT, L; NEWHOUSE, JP; WEILER, PC; HIATT, H			THE NATURE OF ADVERSE EVENTS IN HOSPITALIZED-PATIENTS - RESULTS OF THE HARVARD MEDICAL-PRACTICE STUDY-II	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; PREVENTION; MANAGEMENT; QUALITY	Background. In a sample of 30,195 randomly selected hospital records, we identified 1133 patients (3.7 percent) with disabling injuries caused by medical treatment. We report here an analysis of these adverse events and their relation to error, negligence, and disability. Methods. Two physician-reviewers independently identified the adverse events and evaluated them with respect to negligence, errors in management, and extent of disability. One of the authors classified each event according to type of injury. We tested the significance of differences in rates of negligence and disability among categories with at least 30 adverse events. Results. Drug complications were the most common type of adverse event (19 percent), followed by wound infections (14 percent) and technical complications (13 percent). Nearly half the adverse events (48 percent) were associated with an operation. Adverse events during surgery were less likely to be caused by negligence (17 percent) than nonsurgical ones (37 percent). The proportion of adverse events due to negligence was highest for diagnostic mishaps (75 percent), noninvasive therapeutic mishaps ("errors of omission") (77 percent), and events occurring in the emergency room (70 percent). Errors in management were identified for 58 percent of the adverse events, among which nearly half were attributed to negligence. Conclusions. Although the prevention of many adverse events must await improvements in medical knowledge, the high proportion that are due to management errors suggests that many others are potentially preventable now. Reducing the incidence of these events will require identifying their causes and developing methods to prevent error or reduce its effects.	HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard Medical School	LEAPE, LL (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022					BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; BRENNAN TA, 1989, MED CARE, V27, P1148, DOI 10.1097/00005650-198912000-00006; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; DEARDEN CH, 1985, INJURY, V16, P249, DOI 10.1016/S0020-1383(85)80013-9; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; Miller RG, 1981, COMPUTER VISION, DOI [DOI 10.1007/S11263, DOI 10.1007/s11263-015-0816-y]; PERROW C, 1984, NORMAL ACCIDENTS LIV; RICKETSON DS, 1980, AVIAT SPACE ENVIR MD, V51, P1036; SHAH BV, 1981, SESUDAAN STANDARD ER; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; VINCENT CA, 1989, BMJ-BRIT MED J, V299, P1150, DOI 10.1136/bmj.299.6708.1150; 1977, REPORT MED INSURANCE	16	2452	2534	1	106	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					377	384		10.1056/NEJM199102073240605	http://dx.doi.org/10.1056/NEJM199102073240605			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1824793	Green Submitted, Green Published			2022-12-24	WOS:A1991EW29600005
J	BARLOW, DP; STOGER, R; HERRMANN, BG; SAITO, K; SCHWEIFER, N				BARLOW, DP; STOGER, R; HERRMANN, BG; SAITO, K; SCHWEIFER, N			THE MOUSE INSULIN-LIKE GROWTH-FACTOR TYPE-2 RECEPTOR IS IMPRINTED AND CLOSELY LINKED TO THE TME LOCUS	NATURE			English	Article							T-COMPLEX; CHROMOSOME-17; HAPLOTYPE; GENE	T-ASSOCIATED maternal effect (Tme) is the only known maternal-effect mutation in the mouse1,2. The defect is nuclear-encoded3 and embryos that inherit a deletion of the Tme locus from their mother die at day 15 of gestation4. There are many genomically imprinted regions known in the mouse genome5,6, but so far no imprinted genes have been cloned. The Tme locus is absent in two chromosome-17 deletion mutants, T(hp) and the t(Lub2), and its position has been localized using these deletions to a 1-cM region7-10. We report here that the genes for insulin-like growth factor type-2 receptor (Igf2r) and mitochondrial superoxide dismutase-2 (Sod-2) are absent from both deletions. Probes for these genes and for plasminogen (Plg) and T-complex peptide 1 (Tcp-1) were used in pulsed-field gel mapping to show that Tme must lie within a region of 800-1,100 kb. We also demonstrate that embryos express Igf2r only from the maternal chromosome, and that Tcp-1, Plg and Sod-2 are expressed from both chromosomes. Therefore Igf2r is imprinted and closely linked or identical to Tme.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY; VANDERBILT UNIV,NASHVILLE,TN 37232	Max Planck Society; Vanderbilt University	BARLOW, DP (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Reik, Wolf/I-6794-2012; allen, nick d/A-4336-2010	Stoger, Reinhard/0000-0002-2301-0805				BEECHEY CV, 1990, MOUSE GENOME, V87, P64; BIBBINS KB, 1989, GENOMICS, V5, P139, DOI 10.1016/0888-7543(89)90098-0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEGAN SJF, IN PRESS GENOMICS; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FIGUEROA F, 1988, IMMUNOGENETICS, V28, P260, DOI 10.1007/BF00345503; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HOLIDAY R, 1990, PHIL T R SOC B, V236, P177; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1975, GENET RES CAMB, V24, P207; LATON AK, 1982, THESIS CORNELL U MED; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; Maniatis T, 1989, DECONTAMINATION DILU; MANN EA, 1986, GENETICS, V114, P993; MCGRATH J, 1984, NATURE, V308, P550, DOI 10.1038/308550a0; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SARVETNICK N, 1986, GENETICS, V113, P723; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SILVER LM, 1985, ANNU REV GENET, V19, P179, DOI 10.1146/annurev.ge.19.120185.001143; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPENCE MA, 1989, CYTOGENET CELL GENET, V51, P149, DOI 10.1159/000132790; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MA, 1990, PHIL T R SOC B, V326, P179; WILLISON K, 1987, EMBO J, V44, P469; WINKING H, 1984, GENETICS, V108, P1013	25	739	760	4	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					84	87		10.1038/349084a0	http://dx.doi.org/10.1038/349084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845916				2022-12-24	WOS:A1991EQ60100059
J	WRIGHT, V				WRIGHT, V			IN DEFENSE OF EPONYMS	BRITISH MEDICAL JOURNAL			English	Article											WRIGHT, V (corresponding author), UNIV LEEDS,RHEUMATOL & REHABIL RES UNIT,LEEDS LS2 9NZ,ENGLAND.							[Anonymous], 1976, SERONEGATIVE POLYART; BECHTEREW VM, 1893, NEUROL ZENTRALBLAT, V12, P426; Brodie BC, 1818, PATHOLOGICAL SURGICA, P54; Crohn BB, 1932, J AMER MED ASSOC, V99, P1323, DOI 10.1001/jama.1932.02740680019005; Felty AR, 1924, B JOHNS HOPKINS HOSP, V35, P16; HUSKISSON EC, 1973, JOINT DISEASE ALL AR; KEAT AC, 1979, Q J MED, V48, P323; MARIE P, 1898, REV MED, V18, P285; MIELANTS H, 1990, Current Opinion in Rheumatology, V2, P570; Paronen I, 1948, ACTA MED SCAND  S212, V212, P1; Reiter H, 1916, DEUT MED WOCHENSCHR, V42, P1535, DOI 10.1055/s-0028-1135542; SCOTT JT, 1986, COPEMANS TXB RHEUMAT, P787; SHARP JT, ARTHRITIS ALLIED CON, P1229; Still G F, 1897, Med Chir Trans, V80, P47; Strumpell A, 1897, DTSCH Z NERVENH, V11, P338, DOI 10.1007/BF01674127; THOMPSON P, 1980, MISTER LEPROSY; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382	17	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1600	1602		10.1136/bmj.303.6817.1600	http://dx.doi.org/10.1136/bmj.303.6817.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773185	Green Published, Bronze			2022-12-24	WOS:A1991GX95600018
J	BUCHOLTZ, GA; LOCKEY, RF				BUCHOLTZ, GA; LOCKEY, RF			SEAWATER-INDUCED ITCHING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BUCHOLTZ, GA (corresponding author), UNIV S FLORIDA,COLL MED,JAMES A HALEY VET HOSP,TAMPA,FL 33612, USA.							MANDOJANA RM, 1987, CLIN DERMATOLOGY AQU, V5; SHIMODA T, 1988, J ALLERGY CLIN IMMUN, V81, P1187, DOI 10.1016/0091-6749(88)90889-5; WARIN RP, 1974, MAJOR PROBLEMS DERMA, V1, P136	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3040	3040						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820481				2022-12-24	WOS:A1991GR77500041
J	GODLEE, F				GODLEE, F			HEALTH AND THE ENVIRONMENT - DANGERS OF OZONE DEPLETION	BRITISH MEDICAL JOURNAL			English	Article																		ELWOOD MJ, 1989, OZONE DEPLETION HLTH, P179; GILES GG, 1988, BRIT MED J, V296, P13, DOI 10.1136/bmj.296.6614.13; ISAKSEN ISA, 1989, OZONE DEPLETION HLTH, P24; Jensen O M, 1980, World Health Stat Q, V33, P2; JONES RR, 1989, OZONE DEPLETION HLTH, P214; KAR RA, 1991, SCIENCE, V252, P204; SHIEL AG, 1986, WORLD J SURG, V10, P389; VANDELEUN JC, 1989, OZONE DEPLETION HLTH; WATSON RT, 1989, OZONE DEPLETION HLTH, P51; 1987, ASSESSING RISKS RACE	10	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1326	1328		10.1136/bmj.303.6813.1326	http://dx.doi.org/10.1136/bmj.303.6813.1326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747679	Green Published, Bronze			2022-12-24	WOS:A1991GT01100029
J	LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA; TORNBERG, S				LINDBERG, G; RASTAM, L; GULLBERG, B; EKLUND, GA; TORNBERG, S			SERUM SIALIC-ACID CONCENTRATION AND SMOKING - A POPULATION BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article									UNIV LUND,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT GEN ONCOL,S-10401 STOCKHOLM,SWEDEN	Lund University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	LINDBERG, G (corresponding author), CTR PUBL HLTH RES,S-65182 KARLSTAD,SWEDEN.							CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; HESS EL, 1957, J CLIN INVEST, V36, P449, DOI 10.1172/JCI103442; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; 1971, VARMLAND SURVEY	5	39	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1306	1307		10.1136/bmj.303.6813.1306	http://dx.doi.org/10.1136/bmj.303.6813.1306			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747673	Green Published, Bronze			2022-12-24	WOS:A1991GT01100022
J	WHITE, DJ; CHANG, HG; BENACH, JL; BOSLER, EM; MELDRUM, SC; MEANS, RG; DEBBIE, JG; BIRKHEAD, GS; MORSE, DL				WHITE, DJ; CHANG, HG; BENACH, JL; BOSLER, EM; MELDRUM, SC; MEANS, RG; DEBBIE, JG; BIRKHEAD, GS; MORSE, DL			THE GEOGRAPHIC SPREAD AND TEMPORAL INCREASE OF THE LYME-DISEASE EPIDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERYTHEMA CHRONICUM MIGRANS; NEW-YORK; IXODES-DAMMINI; BORRELIA-BURGDORFERI; WESTCHESTER-COUNTY; UNITED-STATES; ENDEMIC AREA; TICK BITES; ARTHRITIS; FEATURES	Objective. - To describe the temporal and geographic progression of the Lyme disease epidemic in New York State from 1977 through 1989. Design. - Communicable disease surveillance system. Setting. - Statewide. Main Outcome Measures. - The progression of the epidemic was examined by analyzing trends in Lyme disease cases reported to the state surveillance system, town and county Lyme disease incidence rates, Lyme disease hospital discharge rates, and the distribution of Ixodes dammini ticks obtained from surveillance efforts and submitted for identification. Main Results. - The number of confirmed Lyme disease cases in New York has increased with concurrent increases in the number of hospital discharges. The number of counties endemic for Lyme disease increased from four to eight between 1985 and 1989. The number of counties with documented I dammini ticks increased from four in 1985 to 22 in 1989. Incidence of the disease also increased within known endemic counties. Conclusions. - Tick surveillance indicated that the range of I dammini has expanded annually into areas up to 384 km from the original known endemic areas of Long Island, NY, and Connecticut. Cumulative data from human surveillance resources document both temporal increases and geographic expansion of the Lyme disease epidemic in New York.			WHITE, DJ (corresponding author), NEW YORK STATE DEPT HLTH, BUR COMMUNICABLE DIS CONTROL, 651 CORNING TOWER, EMPIRE STATE PLAZA, ALBANY, NY 12237 USA.		Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560	NIAID NIH HHS [AI27044] Funding Source: Medline; NIAMS NIH HHS [AR40445] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027044, R01AI027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040445] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson J F, 1989, Conn Med, V53, P343; ANDERSON JF, 1987, J PARASITOL, V73, P419, DOI 10.2307/3282102; ANDERSON JF, 1986, INFECT IMMUN, V51, P394, DOI 10.1128/IAI.51.2.394-396.1986; BENACH J L, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P477; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BENACH JL, 1988, ANN NY ACAD SCI, V539, P1; BIRKHEAD G, 1990, 4TH INT C LYM BORR S, P12; BIRKHEAD GS, 1990, 4TH INT C LYM BORR S, P67; BISHOPP FC, 1945, J PARASITOL, V31, P1, DOI 10.2307/3273061; BOSLER EM, 1984, YALE J BIOL MED, V57, P651; BOWEN GS, 1984, AM J EPIDEMIOL, V120, P387; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Cartter M L, 1989, Conn Med, V53, P320; CIESIELSKI CA, 1988, ANN NY ACAD SCI, V539, P283, DOI 10.1111/j.1749-6632.1988.tb31862.x; Cooley R. A., 1945, NATION INST HEALTH BULL, V184, P1; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; FALCO RC, 1989, AM J PUBLIC HEALTH, V79, P12, DOI 10.2105/AJPH.79.1.12; FALCO RC, 1988, AM J EPIDEMIOL, V127, P826, DOI 10.1093/oxfordjournals.aje.a114865; FISH D, 1990, J WILDLIFE DIS, V26, P339, DOI 10.7589/0090-3558-26.3.339; FISH D, 1990, 4TH INT C LYM BORR S, P50; HABICHT GS, 1987, SCI AM, V257, P78, DOI 10.1038/scientificamerican0787-78; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANRAHAN JP, 1984, YALE J BIOL MED, V57, P643; JAMNBACK H, 1969, STATE MUSEUM SCI SER, V19, P1; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; SMITH PF, 1988, ANN NY ACAD SCI, V539, P289, DOI 10.1111/j.1749-6632.1988.tb31863.x; SMITH RP, 1990, AM J PUBLIC HEALTH, V80, P333, DOI 10.2105/AJPH.80.3.333; SPIELMAN A, 1979, J MED ENTOMOL, V15, P218, DOI 10.1093/jmedent/15.3.218; STANEK G, 1987, LYME BORRELIOSIS, P1; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, 1979, ANN INTERN MED, V91, P730, DOI 10.7326/0003-4819-91-5-730; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1978, AM J EPIDEMIOL, V108, P312, DOI 10.1093/oxfordjournals.aje.a112625; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEERE AC, 1984, YALE J BIOL MED, V57, P445; Tsai T F, 1989, Conn Med, V53, P324; WALLIS RC, 1978, AM J EPIDEMIOL, V108, P322, DOI 10.1093/oxfordjournals.aje.a112626; WEINSTEIN A, 1989, NEW YORK STATE J MED, V89, P566; WEISBROD AR, 1989, APPL ENVIRON MICROB, V55, P1921, DOI 10.1128/AEM.55.8.1921-1924.1989; WILLIAMS CL, 1986, AM J PUBLIC HEALTH, V76, P62, DOI 10.2105/AJPH.76.1.62; 1985, AM HOSP ASS NEWSLETT, V2, P6; 1989, MMWR, V38, P668	48	96	96	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1230	1236		10.1001/jama.266.9.1230	http://dx.doi.org/10.1001/jama.266.9.1230			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870248				2022-12-24	WOS:A1991GC85800031
J	ADLER, M; LAZARUS, RA; DENNIS, MS; WAGNER, G				ADLER, M; LAZARUS, RA; DENNIS, MS; WAGNER, G			SOLUTION STRUCTURE OF KISTRIN, A POTENT PLATELET-AGGREGATION INHIBITOR AND GP-IIB-IIIA ANTAGONIST	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; DISTANCE GEOMETRY; AQUEOUS-SOLUTION; CELL-ADHESION; GPIIB-IIIA; INTEGRINS; FAMILY; VENOMS	The structure of kistrin, which is a member of a homologous family of glycoprotein IIb-IIIa (GP IIb-IIIa) antagonists and potent protein inhibitors of platelet aggregation, has been determined by two-dimensional nuclear magnetic resonance (NMR) spectroscopy. The 68-residue protein consists of a series of tightly packed loops held together by six disulfide bonds and has almost no regular secondary structure. Kistrin has an Arg-Gly-Asp (RGD) adhesion site recognition sequence important for binding to GP IIb-IIIa that is located at the apex of a long loop across the surface of the protein.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; GENENTECH INC, DEPT PROT ENGN, SAN FRANCISCO, CA 94080 USA	Harvard University; Harvard Medical School; Roche Holding; Genentech					NIGMS NIH HHS [GM38608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER M, UNPUB; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARKER PL, 1991, Patent No. 1331; BECKER RC, 1991, CIRCULATION, V83, P1115, DOI 10.1161/01.CIR.83.3.1115; Carter P, UNPUB; DENNIS MR, UNPUB; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; GARSKY VM, 1989, P NATL ACAD SCI USA, V86, P4022, DOI 10.1073/pnas.86.11.4022; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HAWIGER J, 1990, ATHER REV, V21, P165; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; MAZUR P, UNPUB; MONTELIONE GT, 1986, J AM CHEM SOC, V108, P6765, DOI 10.1021/ja00281a051; NICHOLS A, 1990, EUR J PHARMACOL, V183, P2019, DOI 10.1016/0014-2999(90)92378-V; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; STEIN B, 1989, J AM COLL CARDIOL, V14, P813, DOI 10.1016/0735-1097(89)90453-1; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; YASUDA T, 1991, CIRCULATION, V83, P1038, DOI 10.1161/01.CIR.83.3.1038	24	249	260	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					445	448		10.1126/science.1862345	http://dx.doi.org/10.1126/science.1862345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862345				2022-12-24	WOS:A1991FY28800040
J	WATANABE, N; HUNT, T; IKAWA, Y; SAGATA, N				WATANABE, N; HUNT, T; IKAWA, Y; SAGATA, N			INDEPENDENT INACTIVATION OF MPF AND CYTOSTATIC FACTOR (MOS) UPON FERTILIZATION OF XENOPUS EGGS	NATURE			English	Article							MATURATION-PROMOTING FACTOR; PROTO-ONCOGENE PRODUCT; CELL-CYCLE; OOCYTES; ARREST; METAPHASE; COMPONENT	IN vertebrates, mature eggs are arrested at the second meiotic metaphase by the cytostatic factor (CSF) 1, now known to be the c-mos proto-oncogene product (Mos) 2,3. Fertilization or egg activation triggers a transient increase in the cytoplasmic free calcium 4,5 and releases the meiotic arrest by inactivating maturation/mitosis-promoting factor (MPF) 6,7. CSF or Mos, which is also inactivated by the calcium transient 8,9, seems to stabilize MPF in mature eggs and CSF-injected embryos. Thus, it was assumed that CSF inactivation is the primary cause of MPF inactivation on meiotic release 2,6,8,10-14. We have directly compared the degradation kinetics of CSF (Mos) and MPF during meiotic release, using the same batch of Xenopus eggs. We report here that, at the molecular level, cyclin subunits of MPF are degraded before Mos is degraded and, at the physiological level, that MPF activity is inactivated before CSF activity during activation of Xenopus eggs. These results, in conjunction with circumstantial evidence, support the novel view that a calcium transient on fertilization induces a CSF-independent pathway for MPF inactivation, whereas CSF inactivation during meiotic release serves only to allow the fertilized egg to enter mitosis.	KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; TOKYO MED & DENT UNIV,BUNKYO KU,TOKYO 113,JAPAN	Kurume University; RIKEN; Tokyo Medical & Dental University (TMDU)			Hunt, Tim/O-8544-2019; Watanabe, Nobumoto/N-6959-2015	Hunt, Tim/0000-0001-5174-6038; Watanabe, Nobumoto/0000-0002-2130-1334				BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HUNT T, 1989, NATURE, V342, P483, DOI 10.1038/342483a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KUBOTA HY, 1987, DEV BIOL, V119, P129, DOI 10.1016/0012-1606(87)90214-4; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P319; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	24	159	164	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					247	248		10.1038/352247a0	http://dx.doi.org/10.1038/352247a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1830371				2022-12-24	WOS:A1991FX18500068
J	PONS, TP; GARRAGHTY, PE; OMMAYA, AK; KAAS, JH; TAUB, E; MISHKIN, M				PONS, TP; GARRAGHTY, PE; OMMAYA, AK; KAAS, JH; TAUB, E; MISHKIN, M			MASSIVE CORTICAL REORGANIZATION AFTER SENSORY DEAFFERENTATION IN ADULT MACAQUES	SCIENCE			English	Article							SOMATOSENSORY CORTEX; OWL MONKEYS; AREA 3B; ORGANIZATION; REPRESENTATIONS; CONNECTIONS; MAMMALS; LESIONS; HAND; BODY	After limited sensory deafferentations in adult primates, somatosensory cortical maps reorganize over a distance of 1 to 2 millimeters mediolaterally, that is, in the dimension along which different body parts are represented. This amount of reorganization was considered to be an upper limit imposed by the size of the projection zones of individual thalamocortical axons, which typically also extend a mediolateral distance of 1 to 2 millimeters. However, after extensive long-term deafferentations in adult primates, changes in cortical maps were found to be an order of magnitude greater than those previously described. These results show the need for a reevaluation of both the upper limit of cortical reorganization in adult primates and the mechanisms responsible for it.	UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294; VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240	University of Alabama System; University of Alabama Birmingham; Vanderbilt University	PONS, TP (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 9,ROOM 1N107,BETHESDA,MD 20892, USA.							CONLEY M, 1984, Society for Neuroscience Abstracts, V10, P495; Darian-Smith, 1984, HDB PHYSL 2 1, V3, P789; EL-BOHY A, 1990, Society for Neuroscience Abstracts, V16, P1162; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P323, DOI 10.1002/cne.902520304; GARRAGHTY PE, 1989, SOMATOSENS MOT RES, V6, P401, DOI 10.3109/08990228909144683; GARRAGHTY PE, 1990, J COMP NEUROL, V294, P583, DOI 10.1002/cne.902940406; GARRAGHTY PE, IN PRESS P NATL ACAD; GOLDBERGER ME, 1988, PHYSL BASIS FUNCTION, P361; HEINEN S J, 1988, Investigative Ophthalmology and Visual Science, V29, P23; JONES EG, 1978, J COMP NEUROL, V181, P297; Kaas J.H., 1988, P421; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KAAS JH, 1983, PHYSIOL REV, V63, P206, DOI 10.1152/physrev.1983.63.1.206; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Killackey H P, 1989, J Cogn Neurosci, V1, P3, DOI 10.1162/jocn.1989.1.1.3; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MERZENICH MM, 1982, TRENDS NEUROSCI, V5, P434, DOI 10.1016/0166-2236(82)90235-1; MERZENICH MM, 1988, NEUROBIOLOGY NEOCORT, P41; NELSON RJ, 1980, J COMP NEUROL, V192, P611, DOI 10.1002/cne.901920402; PONS TP, 1986, J COMP NEUROL, V248, P313, DOI 10.1002/cne.902480303; PONS TP, 1985, J COMP NEUROL, V241, P445, DOI 10.1002/cne.902410405; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; RHOADES RW, 1987, J NEUROPHYSIOL, V57, P1577, DOI 10.1152/jn.1987.57.5.1577; ROE AW, 1990, SCIENCE, V250, P818, DOI 10.1126/science.2237432; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; SUR M, 1980, J NEUROPHYSIOL, V44, P295, DOI 10.1152/jn.1980.44.2.295; Taub E., 1980, CLIN APPL, P371; WERNER G, 1968, J NEUROPHYSIOL, V31, P856, DOI 10.1152/jn.1968.31.6.856; WOOLSEY CN, 1942, B J HOPKINS HOSP, V70, P339	31	825	856	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1857	1860		10.1126/science.1843843	http://dx.doi.org/10.1126/science.1843843			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1843843				2022-12-24	WOS:A1991FU06100043
J	NICCHITTA, CV; MIGLIACCIO, G; BLOBEL, G				NICCHITTA, CV; MIGLIACCIO, G; BLOBEL, G			BIOCHEMICAL FRACTIONATION AND ASSEMBLY OF THE MEMBRANE-COMPONENTS THAT MEDIATE NASCENT CHAIN TARGETING AND TRANSLOCATION	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; SECRETORY PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; MICROSOMAL-MEMBRANES; RIBOSOME BINDING; ROUGH MICROSOMES; BOUND RIBOSOMES; RECEPTOR; COMPLEX; SEQUENCE	Fractionation of a microsomal detergent extract with ammonium sulfate allows separation of the signal recognition particle receptor (SR-alpha), which is required for targeting of the nascent chain, from other microsomal proteins, such as signal peptidase, whose activity is displayed during subsequent translocation. The reconstituted SR-alpha-enriched fraction is functional in assays of precursor targeting and elongation arrest release but lacks translocation activity. This defect can be complemented by addition, prior to reconstitution, of a separate protein subfraction. In addition, protein components necessary for translocation can be reversibly depleted from the complementary fraction, under conditions where precursor targeting is retained, by sulfhydryl-directed chromatography. Thus, precursor binding and translocation can be biochemically uncoupled, indicating that they are sequential reactions mediated by distinct components.			NICCHITTA, CV (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012899] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12899] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; KOCH GLE, 1987, J CELL SCI, V87, P491; KREIBICH G, 1983, METHOD ENZYMOL, V96, P520; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; TRUMBLE WR, 1984, BIOCHEM BIOPH RES CO, V119, P860, DOI 10.1016/0006-291X(84)90853-2; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WICKNER W, 1980, SCIENCE, V210, P861, DOI 10.1126/science.7001628; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0	41	43	44	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 17	1991	65	4					587	598		10.1016/0092-8674(91)90091-C	http://dx.doi.org/10.1016/0092-8674(91)90091-C			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1851670				2022-12-24	WOS:A1991FM03700009
J	FEATHERSTONE, C; RUSSELL, P				FEATHERSTONE, C; RUSSELL, P			FISSION YEAST P107WEE1 MITOTIC INHIBITOR IS A TYROSINE SERINE KINASE	NATURE			English	Article							EXPRESSION; PROTEINS; MITOSIS	THE fission yeast wee1+ gene product is a dose-dependent, negative regulator of entry into mitosis 1,2. wee1+ encodes a protein of relative molecular mass 107,000 (M(r) 107K), the C-terminal third of which has strong similarities with the serine/threonine protein kinase family 2,3. Here we report that p107wee1 immune complexes phosphorylate p107wee1 equally on serine and tyrosine residues, and also phosphorylate an exogenous substrate, angiotensin II, on tyrosine. Both kinase activities are attributable to p107wee1 because they are also observed when wee1+ is expressed in heterologous systems; both are abolished by a point mutation in the ATP-binding domain, and both behave like an asymmetric monomer of M(r) 114K on gel filtration and density-gradient centrifugation. Thus the wee1+ gene product is representative of a novel class of protein kinase that phosphorylates both serine and tyrosine residues.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Featherstone, Carol/0000-0002-7881-7235				BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAIZEL JV, 1969, FUNDAMENTAL TECHNIQU, P334; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; Summers MD, 1987, TEXAS AGR EXPT STATI	13	328	340	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 28	1991	349	6312					808	811		10.1038/349808a0	http://dx.doi.org/10.1038/349808a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ666	1825699				2022-12-24	WOS:A1991EZ66600062
J	TREMOLADA, F; CASARIN, C; TAGGER, A; RIBERO, ML; REALDI, G; ALBERTI, A; RUOL, A				TREMOLADA, F; CASARIN, C; TAGGER, A; RIBERO, ML; REALDI, G; ALBERTI, A; RUOL, A			ANTIBODY TO HEPATITIS-C VIRUS IN POSTTRANSFUSION HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; BLOOD	Objective: To evaluate the prevalence of antibodies to hepatitis C virus (anti-HCV), their relation to outcome, and the seroconversion rate in patients with post-transfusion non-A, non-B hepatitis. Design: Retrospective analysis of prospectively collected serum specimens. Setting: A referral-based university hospital. Patients: Sixty-three consecutive patients who developed non-A, non-B post-transfusion hepatitis after open-heart surgery. All patients had follow-up with serial serum testing and clinical evaluation. The mean ( +/- SD) duration of follow-up after hepatitis onset was 81 +/- 33 months (range, 13 to 132 months). Seventeen patients recovered after acute-phase illness, whereas 46 developed chronic disease which, in 30 cases, was confirmed histologically. Main Results: Of 32 patients tested before transfusion, 1 (3.1%) had anti-HCV. Fifty-nine (93%) patients were anti-HCV positive during acute-phase hepatitis: Patients with "early" seroconversion ( < 15 days after hepatitis onset) did not differ from those with "late" seroconversion ( > 60 days after onset) in epidemiologic, clinical, and biochemical features. The rate of anti-HCV positivity during acute-phase illness was not significantly different among patients who recovered (76%) compared with those who developed chronic disease (95%). At 6 to 12 months, patients whose disease resolved had lower antibody activity than those with progressive disease. Further, during long-term follow-up (1 to 9 years), 53% of patients whose disease resolved but only 6.9% of patients who had progressive disease became anti-HCV negative. Conclusions: Hepatitis C virus is the major cause of post-transfusion hepatitis in Italy. The time to anti-HCV seroconversion varies widely after hepatitis onset and is not significantly associated with acute-phase features or outcome of disease.	UNIV PADUA, I-35100 PADUA, ITALY; UNIV MILAN, I-20122 MILAN, ITALY	University of Padua; University of Milan				ALBERTI, ALFREDO/0000-0001-9926-2382				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1986, SEMIN LIVER DIS, V6, P67, DOI 10.1055/s-2008-1040795; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; SEEFF LB, 1988, GASTROENTEROLOGY, V95, P530; TREMOLADA F, 1988, J CLIN GASTROENTEROL, V10, P413, DOI 10.1097/00004836-198808000-00014; TREMOLADA F, 1983, VOX SANG, V44, P25, DOI 10.1111/j.1423-0410.1983.tb04099.x	8	117	117	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					277	281		10.7326/0003-4819-114-4-277	http://dx.doi.org/10.7326/0003-4819-114-4-277			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1846277				2022-12-24	WOS:A1991EX52100004
J	HANIFORD, DB; BENJAMIN, HW; KLECKNER, N				HANIFORD, DB; BENJAMIN, HW; KLECKNER, N			KINETIC AND STRUCTURAL-ANALYSIS OF A CLEAVED DONOR INTERMEDIATE AND A STRAND TRANSFER INTERMEDIATE IN TN10 TRANSPOSITION	CELL			English	Article							BACTERIOPHAGE-MU-DNA; RETROVIRAL INTEGRATION; TRANSPOSABLE ELEMENTS; INVITRO TRANSPOSITION; PROTEIN; SEQUENCES; MECHANISM; REARRANGEMENTS; ORGANIZATION; REPLICATION	Tn10 transposes by a nonreplicative "cut and paste" mechanism. We describe here two protein-DNA complexes that are reaction intermediates in the Tn10 transposition process: a cleaved donor complex whose DNA component consists of transposon sequences cleanly excised from flanking donor DNA, and a strand transfer complex whose DNA component contains transposon termini specifically joined to a target site. The kinetic behavior of the first species suggests that it is an early intermediate in the transposition reaction. These two Tn10 complexes are closely analogous to complexes identified in the pathway for replicative "cointegrate" formation by bacteriophage Mu and thus represent intermediates that may be common to both nonreplicative and replicative transposition. These and other results suggest that the Tn10 and Mu reactions are fundamentally very similar despite their very different biological outcomes. The critical difference between the two reactions is the fate of the DNA strand that is not joined to target DNA.			HANIFORD, DB (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BERG DE, 1983, P NATL ACAD SCI-BIOL, V80, P792, DOI 10.1073/pnas.80.3.792; BOEKE JD, 1989, MOBILE DNA, P335; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CHACONAS G, 1981, J MOL BIOL, V150, P341, DOI 10.1016/0022-2836(81)90551-9; COEN ES, 1989, MOBILE DNA, P413; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FAELEN M, 1978, NATURE, V271, P580, DOI 10.1038/271580a0; FEDOROFF NV, 1989, MOBILE DNA, P375; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FOSTER TJ, 1981, CELL, V23, P201, DOI 10.1016/0092-8674(81)90285-3; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; HALLING SM, 1982, P NATL ACAD SCI-BIOL, V79, P2608, DOI 10.1073/pnas.79.8.2608; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HARSHEY RM, 1983, P NATL ACAD SCI-BIOL, V80, P2012, DOI 10.1073/pnas.80.7.2012; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HUISMAN O, 1989, EMBO J, V8, P2101, DOI 10.1002/j.1460-2075.1989.tb03619.x; ISBERG RR, 1985, J MOL BIOL, V182, P69, DOI 10.1016/0022-2836(85)90028-2; JENCKS WP, 1990, BIOCH MOL BIOL, V1, P1; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KLECKNER N, 1989, MOBILE DNA, P225; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LIEBART JC, 1982, P NATL ACAD SCI-BIOL, V79, P4362, DOI 10.1073/pnas.79.14.4362; LJUNGQUIST E, 1977, P NATL ACAD SCI USA, V74, P3143, DOI 10.1073/pnas.74.8.3143; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; Miller J.H., 1972, EXPT MOL GENETICS; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MORISATO D, 1984, CELL, V39, P181, DOI 10.1016/0092-8674(84)90204-6; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHEN MM, 1987, GENETICS, V116, P359; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SZATMARI GB, 1986, GENE, V41, P315, DOI 10.1016/0378-1119(86)90113-7; VARMUS H, 1989, MOBILE DNA, P53; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WEINERT TA, 1984, COLD SPRING HARB SYM, V49, P251, DOI 10.1101/SQB.1984.049.01.029	47	78	79	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					171	179						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846088				2022-12-24	WOS:A1991ET17500018
J	HAND, R; SENER, S; IMPERATO, J; CHMIEL, JS; SYLVESTER, J; FREMGEN, A				HAND, R; SENER, S; IMPERATO, J; CHMIEL, JS; SYLVESTER, J; FREMGEN, A			HOSPITAL VARIABLES ASSOCIATED WITH QUALITY OF CARE FOR BREAST-CANCER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPARING TOTAL MASTECTOMY; COMMUNITY HOSPITALS; WOMEN; RECEPTORS; MODALITY; BLACK; AGE	Objective. - To determine the degree of compliance with clinical standards among hospitals for care of breast cancer patients and account for variations in compliance. Design. - Analysis of cancer registry data submitted to the American Cancer Society, Illinois Division, Chicago, for a concurrent prospective descriptive study of breast cancer, supplemented by other hospital data from public sources. Setting. - Ninety-nine Illinois hospitals evenly distributed among rural counties, counties with small cities outside the Chicago metropolitan area, exurban counties in the Chicago metropolitan area, suburban Cook County, and urban Chicago. Patients. - A total of 5766 newly diagnosed patients with histologically confirmed breast cancer in 1988, representing 84% of the estimated 6900 new cases in the state for that year. Main Outcome Measures. - Descriptive statistics and multiple linear regression analyses of five dependent quality variables from clinical indicators related to early diagnosis, hormone receptor determination, adjuvant therapy, radiation therapy, and axillary lymph node dissection. Results. - At the hospitals studied, (1) late stage (IIb through IV) at diagnosis was associated with urban location, higher proportion of poorly insured patients, fewer breast cancer cases treated, and lower oncology charges (proportion of variance explained, R2 = .50, P < .00001). (2) omission of hormone receptor test for stages 11 through IV was associated with urban location and higher proportion of poorly insured patients (R2 = .18, P < .00003); and (3) omission of indicated radiation therapy was associated with urban location and fewer breast cancer cases (R2 = .21, P < .00001). Omission of adjuvant therapy and omission of axillary lymph node dissection were not significantly associated with any of the hospital variables examined. Conclusions. - The findings suggest that there is a group of urban hospitals, generally small and marginally reimbursed, where comprehensive diagnosis and treatment of breast cancer are not obtained.	UNIV ILLINOIS,COLL MED,DEPT MED,CHICAGO,IL 60680; NORTHWESTERN UNIV,SCH MED,DEPT SURG,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT RADIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,CTR CANC,BIOMETRY SECT,CHICAGO,IL 60611	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Northwestern University; Northwestern University	HAND, R (corresponding author), AMER CANC SOC,CANC INCIDENCE & END RESULTS COMM,ILLINOIS DIV,77 E MONROE ST,NEW YORK,NY 10017, USA.							ANDERSSON I, 1980, RADIOLOGE, V20, P608; CADY B, 1990, CANCER, V65, P634, DOI 10.1002/1097-0142(19900201)65:3+<634::AID-CNCR2820651306>3.0.CO;2-X; CHU J, 1987, J GERONTOL, V42, P185, DOI 10.1093/geronj/42.2.185; CLARK GM, 1988, SEMIN ONCOL, V15, P20; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; Fisher E R, 1981, Breast Cancer Res Treat, V1, P37, DOI 10.1007/BF01807890; FORD LG, 1989, CANCER, V64, P219, DOI 10.1002/1097-0142(19890701)64:1+<219::AID-CNCR2820641308>3.0.CO;2-S; Gore S M, 1988, Recent Results Cancer Res, V111, P149; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; HORM JM, 1984, SEER PROGRAM CANCER; Lazarus E S, 1990, Med Anthropol, V12, P269; MAMON JA, 1990, PREV MED, V19, P363, DOI 10.1016/0091-7435(90)90036-J; MCPHEE S J, 1990, Journal of General Internal Medicine, V5, pS116, DOI 10.1007/BF02600856; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; SAWYER JA, 1990, J GEN INTERN MED, V5, P115, DOI 10.1007/BF02600510; SCANLON EF, 1991, TXB CLIN ONCOLOGY, P177; STOMPER PC, 1989, HEMATOL ONCOL CLIN N, V3, P611, DOI 10.1016/S0889-8588(18)30523-9; 1991, JAMA-J AM MED ASSOC, V265, P391; 1988, COUNTY CITY DATA BOO, pF15; 1988, MANUAL STAGING CANCE; 1989, JAMA-J AM MED ASSOC, V261, P2535; 1988, CANCER FACTS FIGURES; 1987, 1987 SURVEY PUBLIC A; 1985, CONSENSUS DEV C STAT; 1991, JOINT COMMISSION PER, V11, pA1	33	92	92	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3429	3432		10.1001/jama.266.24.3429	http://dx.doi.org/10.1001/jama.266.24.3429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744956				2022-12-24	WOS:A1991GV87800026
J	LACY, PE; HEGRE, OD; GERASIMIDIVAZEOU, A; GENTILE, FT; DIONNE, KE				LACY, PE; HEGRE, OD; GERASIMIDIVAZEOU, A; GENTILE, FT; DIONNE, KE			MAINTENANCE OF NORMOGLYCEMIA IN DIABETIC MICE BY SUBCUTANEOUS XENOGRAFTS OF ENCAPSULATED ISLETS	SCIENCE			English	Article							ARTIFICIAL ENDOCRINE PANCREAS; TISSUE REACTION; RATS; TRANSPLANTATION; IMPLANTS; INSULIN; CELLS	The goal of islet transplantation in human diabetes is to maintain the islet grafts in the recipients without the use of immunosuppression. One approach is to encapsulate the donor islets in permselective membranes. Hollow fibers fabricated from an acrylic copolymer were used to encapsulate small numbers of rat islets that were immobilized in an alginate hydrogel for transplantation in diabetic mice. The fibers were biocompatible, prevented rejection, and maintained normoglycemia when transplanted intraperitoneally; hyperglycemia returned when the fibers were removed at 60 days. Normoglycemia was also maintained by subcutaneous implants that had an appropriately constructed outer surface on the fibers.	CELLULAR TRANSPLANTS,PROVIDENCE,RI 02906		LACY, PE (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK001226] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01226] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN JJ, 1986, DIABETES, V35, P625, DOI 10.2337/diabetes.35.6.625; ARCHER J, 1980, J SURG RES, V28, P77, DOI 10.1016/0022-4804(80)90086-4; CABASSO I, 1980, KIRK OTHMERS ENCY CH, V12, P492; CHICK WL, 1977, SCIENCE, V197, P780, DOI 10.1126/science.407649; CHRISTENSON L, 1989, J BIOMED MATER RES, V23, P705, DOI 10.1002/jbm.820230704; DIONNE KE, 1991, BIOTECHNOL PROGR, V7, P359, DOI 10.1021/bp00010a011; FAN MY, 1990, DIABETES, V39, P519, DOI 10.2337/diabetes.39.4.519; KEMP CB, 1973, DIABETOLOGIA, V9, P486, DOI 10.1007/BF00461694; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LACY PE, 1972, DIABETES, V21, P987, DOI 10.2337/diab.21.10.987; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; MAZAHERI R, 1991, TRANSPLANTATION, V51, P750, DOI 10.1097/00007890-199104000-00002; SCHARP DW, 1990, DIABETES, V39, P515, DOI 10.2337/diabetes.39.4.515; SULLIVAN SJ, 1991, SCIENCE, V252, P718, DOI 10.1126/science.2024124; SUN AM, 1977, DIABETES, V26, P1136, DOI 10.2337/diabetes.26.12.1136; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; TZE WJ, 1976, NATURE, V264, P466, DOI 10.1038/264466a0; WARNOCK GL, 1989, LANCET, V2, P570; WINN SR, 1989, J BIOMED MATER RES, V23, P31, DOI 10.1002/jbm.820230104	19	296	365	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1782	1784		10.1126/science.1763328	http://dx.doi.org/10.1126/science.1763328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763328				2022-12-24	WOS:A1991GW31600040
J	BUNDRED, NJ; RATCLIFFE, WA; WALKER, RA; COLEY, S; MORRISON, JM; RATCLIFFE, JG				BUNDRED, NJ; RATCLIFFE, WA; WALKER, RA; COLEY, S; MORRISON, JM; RATCLIFFE, JG			PARATHYROID-HORMONE RELATED PROTEIN AND HYPERCALCEMIA IN BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT HYPERCALCEMIA; IMMUNOHISTOCHEMICAL LOCALIZATION; REASSESSMENT; MECHANISMS; CARCINOMA	Objective - To see whether parathyroid hormone related protein has a humoral role in breast cancer. Design - Plasma concentrations and tumour expression of parathyroid hormone related protein were determined (by two site immunoradiometric assay and immunohistochemistry respectively) in women with breast cancer and related to the presence of bone metastases and serum calcium concentrations. Subjects - Plasma concentrations of parathyroid hormone related protein were measured in 57 women with early breast cancer without apparent bone metastases, 28 women with bone metastases, and 13 women with bone metastases and hypercalcaemia. Tissue positivity for parathyroid hormone related protein was determined retrospectively in 106 primary breast tumours from women without apparent bone metastases and 72 tumours from women with bone metastases, 25 of whom subsequently developed hypercalcaemia. Results - Plasma parathyroid hormone related protein concentrations were detectable (> 0.23 pmol/l) in 12 (92%) of the 13 hypercalcaemic patients with bone metastases compared with 10 (36%) of the 28 normocalcaemic patients with bone metastases and five (9%) of the 57 normocalcaemic patients without bone metastases. Parathyroid hormone related protein concentrations were significantly higher in hypercalcaemic than normocalcaemic patients with bone metastases. Tumour staining was positive for parathyroid hormone related protein in 22 (88%) of the 25 primary breast cancers from patients with bone metastases who later developed hypercalcaemia compared with 25 (53%) of the 47 from women in this group who remained normocalcaemic and 55 (52%) of the 106 early breast cancers from women without known metastases. Conclusion - Tumour derived parathyroid hormone related protein may have an important humoral role in hypercalcaemia associated with metastatic breast cancer.	SELLY OAK HOSP,DEPT SURG,BIRMINGHAM B29 6JD,ENGLAND; QUEEN ELIZABETH MED CTR,WOLFSON RES LABS,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; ROYAL INFIRM,DEPT PATHOL,LEICESTER LE1 5WW,ENGLAND	Birmingham City University; University of Birmingham	BUNDRED, NJ (corresponding author), UNIV HOSP S MANCHESTER,DEPT SURG,TEACHING & RES BLOCK,MANCHESTER M20 8LR,LANCS,ENGLAND.							BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; COLEMAN RE, 1988, EUR J SURG ONCOL, V14, P423; DANKS JA, 1989, J BONE MINER RES, V4, P273; GALLACHER SJ, 1990, ANN CLIN BIOCHEM, V27, P551, DOI 10.1177/000456329002700605; HENDERSON JE, 1990, J BONE MINER RES, V5, P105, DOI 10.1002/jbmr.5650050203; ISALES C, 1987, AM J MED, V82, P1143, DOI 10.1016/0002-9343(87)90216-6; KRAMER S, 1991, ENDOCRINOLOGY, V128, P1927, DOI 10.1210/endo-128-4-1927; LEGHA SS, 1981, CANCER, V47, P2803, DOI 10.1002/1097-0142(19810615)47:12<2803::AID-CNCR2820471208>3.0.CO;2-A; MARTIN TJ, 1989, CLIN ENDOCRINOL, V31, P631, DOI 10.1111/j.1365-2265.1989.tb01288.x; MARTIN TJ, 1990, Q J MED, V76, P771; MUNDY GR, 1984, NEW ENGL J MED, V310, P1718; MUNDY GR, 1988, J CLIN INVEST, V82, P1, DOI 10.1172/JCI113555; PERCIVAL RC, 1985, BMJ-BRIT MED J, V291, P776, DOI 10.1136/bmj.291.6498.776; POWELL GJ, 1991, CANCER RES, V51, P3059; RALSTON SH, 1991, J CLIN PATHOL, V44, P472, DOI 10.1136/jcp.44.6.472; RATCLIFFE WA, 1991, CLIN CHEM, V37, P678; SATO K, 1988, J CLIN ENDOCR METAB, V67, P592, DOI 10.1210/jcem-67-3-592; SOUTHBY J, 1990, CANCER RES, V50, P7710; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; VANHOLTENVERZANTVOORT AT, 1987, LANCET, V2, P983	21	75	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1506	1509		10.1136/bmj.303.6816.1506	http://dx.doi.org/10.1136/bmj.303.6816.1506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782489	Green Published, Bronze			2022-12-24	WOS:A1991GV47600020
J	TRENT, JD; NIMMESGERN, E; WALL, JS; HARTL, FU; HORWICH, AL				TRENT, JD; NIMMESGERN, E; WALL, JS; HARTL, FU; HORWICH, AL			A MOLECULAR CHAPERONE FROM A THERMOPHILIC ARCHAEBACTERIUM IS RELATED TO THE EUKARYOTIC PROTEIN T-COMPLEX POLYPEPTIDE-1	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; HEAT-SHOCK; RIBULOSEBISPHOSPHATE-CARBOXYLASE; MITOCHONDRIAL PROTEIN; ATP HYDROLYSIS; GENE; CLONING; PURIFICATION; SEQUENCE	THERE is evidence to suggest that components of archaebacteria are evolutionarily related to cognates in the eukaryotic cytosol 1-7. We postulated that the major heat-shock protein of the thermophilic archaebacterium, Sulfolobus shibatae, is a molecular chaperone and that it is related to an as-yet unidentified chaperone component in the eukaryotic cytosol. Acquired thermotolerance in S. shibatae correlates with the predominant synthesis of this already abundant protein, referred to as thermophilic factor 55 (TF55; ref. 8). TF55 is a homo-oligomeric complex of two stacked 9-membered rings, closely resembling the 7-membered-ring complexes of the chaperonins, groEL, hsp60 and Rubisco-binding protein 9-15. The TF55 complex binds unfolded polypeptides in vitro and has ATPase activity-features consistent with its being a molecular chaperone 16,17. The primary structure of TF55, however, is not significantly related to the chaperonins. On the other hand, it is highly homologous (36-40% identity) to a ubiquitous eukaryotic protein, t-complex polypeptide-1 (TCP1; refs 18-20). In Saccharomyces cerevisiae, TCP1 is an essential protein that may play a part in mitotic spindle formation 21. We suggest that TF55 in archaebacteria and TCP1 in the eukaryotic cytosol are members of a new class of molecular chaperones.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LAB,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	Yale University; Memorial Sloan Kettering Cancer Center; United States Department of Energy (DOE); Brookhaven National Laboratory	TRENT, JD (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,333 CEDAR ST,NEW HAVEN,CT 06510, USA.		Hartl, F. Ulrich/Y-8206-2019					AHMAD S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P253, DOI 10.1016/0167-4781(90)90214-M; AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; CARAZO JM, 1991, J STRUCT BIOL, V106, P211, DOI 10.1016/1047-8477(91)90071-4; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, REV BIOCH, V60, P327; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RJW, 1979, J MOL BIOL, V129, P359; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HORWICH A, 1980, J VIROL, V36, P125, DOI 10.1128/JVI.36.1.125-132.1980; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; LECHNER K, 1987, MOL GEN GENET, V208, P523, DOI 10.1007/BF00328150; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SEARCY DG, 1991, BIOSYSTEMS, V25, P1, DOI 10.1016/0303-2647(91)90008-9; SHINNICK TM, 1987, J BACTERIOL, V169, P1080, DOI 10.1128/jb.169.3.1080-1088.1987; SILVER LM, 1979, CELL, V17, P275, DOI 10.1016/0092-8674(79)90153-3; SILVER LM, 1987, DEV BIOL, V119, P605, DOI 10.1016/0012-1606(87)90063-7; TRENT JD, 1990, J BACTERIOL, V172, P1478, DOI 10.1128/jb.172.3.1478-1484.1990; URSIC D, 1988, GENE, V68, P267, DOI 10.1016/0378-1119(88)90029-7; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WILLISON K, 1987, EMBO J, V6, P1967, DOI 10.1002/j.1460-2075.1987.tb02459.x; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1; ZILLIG W, 1987, ANN NY ACAD SCI, V503, P78, DOI 10.1111/j.1749-6632.1987.tb40599.x	43	293	302	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					490	493		10.1038/354490a0	http://dx.doi.org/10.1038/354490a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1836250				2022-12-24	WOS:A1991GV07800064
J	ISON, CA; BRANLEY, NS; KIRTLAND, K; EASMON, CSF				ISON, CA; BRANLEY, NS; KIRTLAND, K; EASMON, CSF			SURVEILLANCE OF ANTIBIOTIC-RESISTANCE IN CLINICAL ISOLATES OF NEISSERIA-GONORRHOEAE	BRITISH MEDICAL JOURNAL			English	Article											ISON, CA (corresponding author), ST MARYS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON W2 1PG,ENGLAND.							GILL MJ, 1988, J CLIN PATHOL, V41, P978, DOI 10.1136/jcp.41.9.978; GRANSDEN WR, 1991, J MED MICROBIOL, V34, P23, DOI 10.1099/00222615-34-1-23; JEPHCOTT AE, 1990, LANCET, V335, P165, DOI 10.1016/0140-6736(90)90035-4; LEWIN CS, 1990, J MED MICROBIOL, V31, P153, DOI 10.1099/00222615-31-3-153	4	19	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1307	1307		10.1136/bmj.303.6813.1307	http://dx.doi.org/10.1136/bmj.303.6813.1307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747674	Bronze, Green Published			2022-12-24	WOS:A1991GT01100023
J	THORNTON, JG; ONWUDE, JL				THORNTON, JG; ONWUDE, JL			PREECLAMPSIA - DISCORDANCE AMONG IDENTICAL-TWINS	BRITISH MEDICAL JOURNAL			English	Article							PREECLAMPSIA; GENETICS				THORNTON, JG (corresponding author), ST JAMES UNIV HOSP,DEPT OBSTET & GYNAECOL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.		Thornton, Jim/B-8336-2008; ONWUDE, JOSEPH LOZE/ABA-4929-2021; ONWUDE, JOSEPH Loze/AFM-0527-2022; ONWUDE, JOSEPH Loze/AAH-2903-2022; ONWUDE, JOSEPH LOZE/ABF-7876-2021	Thornton, Jim/0000-0001-9764-6876; 				ARNGRIMSSON R, 1990, BRIT J OBSTET GYNAEC, V97, P762, DOI 10.1111/j.1471-0528.1990.tb02569.x; CHESLEY LC, 1986, BRIT J OBSTET GYNAEC, V93, P898, DOI 10.1111/j.1471-0528.1986.tb08006.x; KASRIEL J, 1976, J BIOSOC SCI, V8, P263, DOI 10.1017/S0021932000010737; THOMPSON B, 1988, TWINNING TWINS, P253; THORNTON JG, 1990, LANCET, V336, P1319, DOI 10.1016/0140-6736(90)93004-9	5	65	66	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1241	1242		10.1136/bmj.303.6812.1241	http://dx.doi.org/10.1136/bmj.303.6812.1241			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ342	1747646	Bronze, Green Published			2022-12-24	WOS:A1991GQ34200025
J	CARCILLO, JA; DAVIS, AL; ZARITSKY, A				CARCILLO, JA; DAVIS, AL; ZARITSKY, A			ROLE OF EARLY FLUID RESUSCITATION IN PEDIATRIC SEPTIC SHOCK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOREPINEPHRINE THERAPY; MYOCARDIAL DEPRESSION; CARDIAC DYSFUNCTION; CANINE MODEL; SEPSIS; CHILDREN	Objective. - To examine the association of the volume of fluid administered at 1 and 6 hours after presentation, with survival and the occurrence of the adult respiratory distress syndrome, cardiogenic pulmonary edema, and persistent hypovolemia during the resuscitation of children with septic shock. Setting and Patients. - All pediatric patients with septic shock presenting to the emergency department over a 6-year period and having a pulmonary artery catheter inserted by 6 hours after presentation were identified. Methods. - Patients were analyzed together and in three groups based on fluid volume in the first hour: group 1, less than 20 mL/kg; group 2,20 to 40 mL/kg; and group 3, more than 40 mL/kg. Adult respiratory distress syndrome was diagnosed by the presence of alveolar infiltrates, hypoxemia, and a pulmonary capillary wedge pressure of 15 mm Hg or less. Cardiogenic pulmonary edema was diagnosed similarly, except the pulmonary capillary wedge pressure was greater than 15 mm Hg. Hypovolemia was diagnosed by the presence of oliguria, hypotension, and a pulmonary capillary wedge pressure of 8 mm Hg or less 6 hours after presentation. Results. - We identified 34 patients (median age, 13.5 months). At 1 and 6 hours, respectively, group 1 (n = 14) received 11 +/- 6 and 71 +/- 29 mL/kg (mean +/- SD) of fluid; group 2 received 32 +/- 5 and 108 +/- 54 mL/kg of fluid; and group 3 received 69 +/- 19 and 117 +/- 29 mL/kg of fluid. Survival in group 3 (eight of nine patients) was significantly better than in group 1 (six of 14 patients) or group 2 (four of 11 patients). Adult respiratory distress syndrome developed in 11 patients (32%) and cardiogenic pulmonary edema developed in five patients (15%). Having adult respiratory distress syndrome was associated with increased mortality, but adult respiratory distress syndrome was not increased in any group. Similarly, cardiogenic pulmonary edema was not associated with the fluid volume received or with decreased survival. Hypovolemia occurred in six patients in group 1 and two patients in group 2; all eight subsequently died. Conclusion. - Rapid fluid resuscitation in excess of 40 mL/kg in the first hour following emergency department presentation was associated with improved survival, decreased occurrence of persistent hypovolemia, and no increase in the risk of cardiogenic pulmonary edema or adult respiratory distress syndrome in this group of pediatric patients with septic shock.	GEORGE WASHINGTON UNIV,CHILDRENS HOSP,NATL MED CTR,DEPT ANESTHESIOL & CRIT CARE MED,WASHINGTON,DC 20010	Children's National Health System; George Washington University								BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOUCEK MM, 1984, J PEDIATR-US, V105, P538, DOI 10.1016/S0022-3476(84)80416-3; CARROLL GC, 1982, AM J PHYSIOL, V243, pR131, DOI 10.1152/ajpregu.1982.243.1.R131; CHAMEIDES L, 1988, TXB PEDIATRIC ADV LI, P47; CHERNOW B, 1986, CIRC SHOCK, V18, P141; DESJARS P, 1987, CRIT CARE MED, V15, P134, DOI 10.1097/00003246-198702000-00011; KAUFMAN BS, 1984, CHEST, V85, P336, DOI 10.1378/chest.85.3.336; MEADOWS D, 1988, CRIT CARE MED, V16, P663, DOI 10.1097/00003246-198807000-00003; MONSALVE F, 1984, CRIT CARE MED, V12, P1021, DOI 10.1097/00003246-198412000-00003; NATANSON C, 1986, J CLIN INVEST, V78, P259, DOI 10.1172/JCI112559; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; POWELL KR, 1990, J PEDIATR-US, V117, P515, DOI 10.1016/S0022-3476(05)80682-1; RACKOW EC, 1987, CIRC SHOCK, V22, P11; REILLY JM, 1989, CHEST, V95, P1072, DOI 10.1378/chest.95.5.1072; ROTH BL, 1959, MOL CELLULAR MECHANI, P41; WEIL M, 1977, ANN CLIN RES, V9, P181; WEIL MH, 1978, AM J MED, V64, P920, DOI 10.1016/0002-9343(78)90444-8; WILES JB, 1980, CRIT CARE MED, V8, P55, DOI 10.1097/00003246-198002000-00001; WILSON RF, 1971, ANN SURG, V174, P939, DOI 10.1097/00000658-197112000-00009; [No title captured]; [No title captured]	22	249	257	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1242	1245		10.1001/jama.266.9.1242	http://dx.doi.org/10.1001/jama.266.9.1242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870250				2022-12-24	WOS:A1991GC85800033
J	KNIGHT, MR; CAMPBELL, AK; SMITH, SM; TREWAVAS, AJ				KNIGHT, MR; CAMPBELL, AK; SMITH, SM; TREWAVAS, AJ			TRANSGENIC PLANT AEQUORIN REPORTS THE EFFECTS OF TOUCH AND COLD-SHOCK AND ELICITORS ON CYTOPLASMIC CALCIUM	NATURE			English	Article							SUSPENDED CALLUS-CULTURES; ELICITATION; EXPRESSION	METHODS for measuring plant cytoplasmic calcium using microelectrodes or microinjected fluorescent dyes are associated with extensive technical problems, so measurements have been limited to single or small groups of cells in tissue strips or protoplasts 1,2. Aequorin is a calcium-sensitive luminescent protein 3 from the coelenterate Aequorea victoria (A. forskalea) which is formed from apoaequorin, a polypeptide of relative molecular mass approximately 22,000, and coelenterazine, a hydrophobic luminophore 4. Microinjected aequorin has been widely used for intracellular calcium measurement in animal cells 4, but its use in plants has been limited to exceptionally large cells 5. We show here that aequorin can be reconstituted in transformed plants and that it reports calcium changes induced by touch, cold-shock and fungal elicitors. Reconstituted aequorin is cytoplasmic and nonperturbing; measurements can be made on whole plants and a calcium indicator can be constituted in every viable cell. Now that apoaequorin can be targeted to specific organelles, cells and tissues, with the range of coelenterazines with differing calcium sensitivities and properties available 6, this new method could be valuable for determining the role of calcium in intracellular signalling processes in plants.	UNIV WALES COLL MED, DEPT MED BIOCHEM, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University	KNIGHT, MR (corresponding author), UNIV EDINBURGH, INST CELL & MOLEC BIOL, EDINBURGH EH9 3JH, MIDLOTHIAN, SCOTLAND.		Smith, Steven M/G-7183-2015; Smith, Steven/HDM-9496-2022; Campbell, Anthony K/N-5855-2014	Smith, Steven M/0000-0001-5661-9994; Campbell, Anthony K/0000-0002-2506-5500; Knight, Marc/0000-0002-4830-8608				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Blinks J.R., 1978, Methods in Enzymology, V57, P292; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; BROOKS CJW, 1986, PHYTOCHEMISTRY, V25, P1089, DOI 10.1016/S0031-9422(00)81559-9; Campbell A.K, 1983, INTRACELLULAR CALCIU; CAMPBELL AK, 1988, BIOCHEM J, V252, P143, DOI 10.1042/bj2520143; DIXON RA, 1986, BIOL REV, V61, P239, DOI 10.1111/j.1469-185X.1986.tb00719.x; Draper J., 1988, PLANT GENETIC TRANSF; EBEL J, 1988, TRENDS BIOCHEM SCI, V13, P23, DOI 10.1016/0968-0004(88)90014-X; FRANCK A, 1980, CELL, V21, P285, DOI 10.1016/0092-8674(80)90136-1; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GILROY S, 1986, FEBS LETT, V199, P217, DOI 10.1016/0014-5793(86)80483-5; HAHN MG, 1978, PLANT PHYSIOL, V62, P107, DOI 10.1104/pp.62.1.107; HARLOW E, 1988, ANTIBODIES LABORATOR; MAUCH F, 1989, PLANT CELL, V1, P447, DOI 10.2307/3869105; MINORSKY PV, 1985, PLANT CELL ENVIRON, V8, P75, DOI 10.1111/j.1365-3040.1985.tb01226.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PRASHER D, 1985, BIOCHEM BIOPH RES CO, V126, P1259, DOI 10.1016/0006-291X(85)90321-3; PRASHER DC, 1986, BIOLUMINESCENCE CHEM; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; WATSON DG, 1985, PHYTOCHEMISTRY, V24, P2195, DOI 10.1016/S0031-9422(00)83009-5; WILLIAMSON RE, 1982, NATURE, V296, P647, DOI 10.1038/296647a0	25	921	989	3	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					524	526		10.1038/352524a0	http://dx.doi.org/10.1038/352524a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865907				2022-12-24	WOS:A1991GA22600061
J	RAMSAY, MEB; CORBEL, MJ; REDHEAD, K; ASHWORTH, LAE; BEGG, NT				RAMSAY, MEB; CORBEL, MJ; REDHEAD, K; ASHWORTH, LAE; BEGG, NT			PERSISTENCE OF ANTIBODY AFTER ACCELERATED IMMUNIZATION WITH DIPHTHERIA TETANUS PERTUSSIS-VACCINE	BRITISH MEDICAL JOURNAL			English	Article							LINKED IMMUNOSORBENT-ASSAY; TOXIN NEUTRALIZATION TEST; HUMAN-SERA; POLIOMYELITIS; ANTITOXIN; EFFICACY	Objective - To determine the persistence of antibody to diphtheria, tetanus, and pertussis in children receiving an accelerated schedule of primary immunisation. Design - Controlled study of antibody testing of blood samples from children immunised according to various schedules: three doses of triple vaccine completed at 8-13 calendar months, 6-7 calendar months, before 6 calendar months, or three doses followed by diphtheria/tetanus before age 2. Setting - Plymouth Health Authority. Subjects - 129 children aged 4 years who had received three doses of diphtheria/tetanus/pertussis vaccine with or without a diphtheria/tetanus booster. Main outcome measures-Diphtheria and tetanus antitoxin concentrations and antibody titres to pertussis toxin, filamentous haemagglutinin, and agglutinogens 2 and 3. Results - All children had protective concentrations of antitoxin to diphtheria and tetanus (greater-than-or-equal-to 0.01 IU/ml). There was no evidence of a significant difference in diphtheria or tetanus antitoxin concentrations and pertussis antibody titres in children immunised with an accelerated course (third dose of triple vaccine before 6 months) compared with those who received a longer course (third dose at 8-13 months) with no booster (geometric mean antitoxin concentration 0.411 (95% confidence interval 0.273 to 0.618) v 0.426 (0.294 to 0.616) for diphtheria and 0.358 (0.231 to 0.556) v 0.299 (0.197 to 0.453) for tetanus; geometric mean antibody titres 903 (500 to 1631) v 1386 (848 to 2266) for pertussis filamentous haemagglutinin, 179 (130 to 248) v 232 (167 to 322) for pertussis toxin, and 2002 (1276 to 3142) v 3591 (2220 to 5809) for agglutinogens 2 and 3). Conclusion - Immunisation with three doses of triple vaccine at monthly intervals completed before 6 months of age probably provides adequate protection against diphtheria, tetanus, and whooping cough which will persist until the age of the preschool booster.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,IMMUNOL & PATHOL GRP,SALISBURY SP4 0JG,WILTS,ENGLAND	Public Health England			Corbel, Michael/AAI-5520-2020; Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				AGNESE PAD, 1949, PEDIATRICS, V3, P333; BARRETT CD, 1962, PEDIATRICS, V30, P720; CANNON DA, 1960, P S IMMUNISATION CHI; CHURCH MA, 1979, LANCET, V2, P188; COLLIER LH, 1979, LANCET, V1, P1364; HALSEY N, 1985, B WORLD HEALTH ORGAN, V63, P1151; JONES AE, 1989, VACCINE, V7, P300, DOI 10.1016/0264-410X(89)90189-8; MELVILLESMITH M, 1988, J MED MICROBIOL, V25, P279, DOI 10.1099/00222615-25-4-279; MELVILLESMITH ME, 1983, J BIOL STAND, V11, P137, DOI 10.1016/S0092-1157(83)80038-9; MILLER E, 1991, LANCET, P70; MILLER JJ, 1949, PEDIATRICS, V3, P468; NOAH N, 1976, BMJ, V1, P357; SMITH JWG, 1969, BRIT MED BULL, V25, P177, DOI 10.1093/oxfordjournals.bmb.a070689; 1984, IMMUNISATION INFECTI; 1982, BMJ, V285, P357; 1990, CONTROL DIPHTHERIA E; 1990, IMMUNISATION INFECTI; 1988, IMMUNISATION INFECTI; 1951, BMJ, V1, P1463; 1968, STATE PUBLIC HLTH YE	20	31	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1489	1491		10.1136/bmj.302.6791.1489	http://dx.doi.org/10.1136/bmj.302.6791.1489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855015	Bronze, Green Published			2022-12-24	WOS:A1991FT50500017
J	HESS, JF; PARISI, MA; BENNETT, JL; CLAYTON, DA				HESS, JF; PARISI, MA; BENNETT, JL; CLAYTON, DA			IMPAIRMENT OF MITOCHONDRIAL TRANSCRIPTION TERMINATION BY A POINT MUTATION ASSOCIATED WITH THE MELAS SUBGROUP OF MITOCHONDRIAL ENCEPHALOMYOPATHIES	NATURE			English	Article							TRANSFER RNALYS; DNA-SEQUENCE; BINDING; INVITRO; PURIFICATION; SELECTION; EPILEPSY; GENOME	DEFECTS in mitochondrial DNA (mtDNA) are associated with several different human diseases, including the mitochondrial encephalomyopathies. The mutations include deletions but also duplications and point mutations 1. Individuals with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) carry a common A-to-G substitution in a highly conserved portion of the gene for transfer RNA(Leu(UUR)) (refs 2, 3). Although the MELAS mutation may be comparable to the defect in the tRNA(Lys) gene associated with MERRF (refs 4, 5) (myoclonus epilepsy associated with ragged-red fibres), it is also embedded in the middle of a tridecamer sequence necessary for the formation of the 3' ends of 16S ribosomal RNA in vitro 6. We found that the MELAS mutation results in severe impairment of 16S rRNA transcription termination, which correlates with a reduced affinity of the partially purified termination protein for the MELAS template. This suggests that the molecular defect in MELAS is the inability to produce the correct type and quantity of rRNA relative to other mitochondrial gene products.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University								ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMYN A, 1987, CURR TOP BIOENERG, V15, P295; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CHRISTIANSON TW, 1986, P NATL ACAD SCI USA, V83, P6277, DOI 10.1073/pnas.83.17.6277; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; FISHER RP, 1987, CELL, V50, P247, DOI 10.1016/0092-8674(87)90220-0; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P78; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDER ES, 1990, CELL, V61, P925, DOI 10.1016/0092-8674(90)90055-J; Maxam A M, 1980, Methods Enzymol, V65, P499; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; YONEDA M, 1990, BIOCHEM INT, V21, P789	19	217	220	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1991	351	6323					236	239		10.1038/351236a0	http://dx.doi.org/10.1038/351236a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1755869				2022-12-24	WOS:A1991FL99000058
J	SAXTON, WM; HICKS, J; GOLDSTEIN, LSB; RAFF, EC				SAXTON, WM; HICKS, J; GOLDSTEIN, LSB; RAFF, EC			KINESIN HEAVY-CHAIN IS ESSENTIAL FOR VIABILITY AND NEUROMUSCULAR FUNCTIONS IN DROSOPHILA, BUT MUTANTS SHOW NO DEFECTS IN MITOSIS	CELL			English	Article							BOVINE BRAIN KINESIN; MICROTUBULE MOTILITY; ELECTRON-MICROSCOPY; IMAGINAL DISKS; IDENTIFICATION; MELANOGASTER; LOCALIZATION; AXOPLASM; PROTEIN	The in vivo function of the microtubule motor protein kinesin was examined in Drosophila using genetics and immunolocalization. Kinesin heavy chain mutations (khc) cause abnormal behavior and lethality. Mutant larvae exhibit loss of mobility and tactile responsiveness in the most posterior segments, followed by general paralysis and death during larval or pupal development. Adults homozygous for a temperature-sensitive allele also exhibit a loss in mobility and sensory responses. The data indicate that kinesin function is essential and suggest that kinesin has an important role in the neuromuscular system, perhaps as a motor for axonal transport. The possibility of more general cellular functions remains open, but observation of embryogenesis and morphogenesis in khc mutants suggests that mitosis and the cell cycle can proceed in spite of impaired kinesin function. Immunolocalization suggests that kinesin may have some general cellular functions but that it is not a major component of mitotic spindles.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University	SAXTON, WM (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016739] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16739] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMOS LA, 1987, J CELL SCI, V87, P105; ANSTROM JA, 1987, DEVELOPMENT, V101, P255; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BONNER JJ, 1976, CHROMOSOMA, V58, P87, DOI 10.1007/BF00293443; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1982, SCIENCE, V218, P1129, DOI 10.1126/science.6183745; COHN SA, 1989, J BIOL CHEM, V264, P4290; CURTIS D, 1989, GENETICS, V122, P653; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Fischer S G, 1979, Methods Enzymol, V68, P183; FOE VE, 1983, J CELL SCI, V61, P31; FYRBERG E, 1990, J CELL BIOL, V110, P1999, DOI 10.1083/jcb.110.6.1999; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LINDSLEY DL, 1985, DROS INF SERV, V62; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; Maniatis T., 1982, MOL CLONING; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; ROBERTSON HM, 1988, GENETICS, V118, P461; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1985, CELL, V40, P455, DOI 10.1016/0092-8674(85)90160-6; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WARN RM, 1986, J CELL SCI S, V5, P311; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	43	177	180	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1093	1102		10.1016/0092-8674(91)90264-Y	http://dx.doi.org/10.1016/0092-8674(91)90264-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1825937				2022-12-24	WOS:A1991FD55800007
J	PELLICCIA, A; MARON, BJ; SPATARO, A; PROSCHAN, MA; SPIRITO, P				PELLICCIA, A; MARON, BJ; SPATARO, A; PROSCHAN, MA; SPIRITO, P			THE UPPER LIMIT OF PHYSIOLOGICAL CARDIAC-HYPERTROPHY IN HIGHLY TRAINED ELITE ATHLETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; M-MODE ECHOCARDIOGRAPHY; NON-INVASIVE EVALUATION; DOPPLER ECHOCARDIOGRAPHY; CLINICAL MANIFESTATIONS; CARDIOVASCULAR-DISEASE; DIASTOLIC FUNCTION; DISTANCE RUNNERS; PATHO-PHYSIOLOGY; CARDIOMYOPATHY	Background. In some highly trained athletes, the thickness of the left ventricular wall may increase as a consequence of exercise training and resemble that found in cardiac diseases associated with left ventricular hypertrophy, such as hypertrophic cardiomyopathy. In these athletes, the differential diagnosis between physiologic and pathologic hypertrophy may be difficult. Methods. To address this issue, we measured left ventricular dimensions with echocardiography in 947 elite, highly trained athletes who participated in a wide variety of sports. Results. The thickest left ventricular wall among the athletes measured 16 mm. Wall thicknesses within a range compatible with the diagnosis of hypertrophic cardiomyopathy (greater-than-or-equal-to 13 mm) were identified in only 16 of the 947 athletes (1.7 percent); 15 were rowers or canoeists, and 1 was a cyclist. Therefore, the wall was greater-than-or-equal-to 13 mm thick in 7 percent of 219 rowers, canoeists, and cyclists but in none of 728 participants in 22 other sports. All athletes with walls greater-than-or-equal-to 13 mm thick also had enlarged left ventricular end-diastolic cavities (dimensions, 55 to 63 mm). Conclusions. On the basis of these data, a left-ventricular-wall thickness of greater-than-or-equal-to 13 mm is very uncommon in highly trained athletes, virtually confined to athletes training in rowing sports, and associated with an enlarged left ventricular cavity. In addition, the upper limit to which the thickness of the left ventricular wall may be increased by athletic training appears to be 16 mm. Therefore, athletes with a wall thickness of more than 16 mm and a nondilated left ventricular cavity are likely to have primary forms of pathologic hypertrophy, such as hypertrophic cardiomyopathy.	NHLBI,CARDIOL BRANCH,BETHESDA,MD 20892; NHLBI,BIOSTAT RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	PELLICCIA, A (corresponding author), COMITATO OLIMPICO NAZL ITALIANO,INST SPORTS SCI,DEPT MED,VIA CAMPI SPORTIVI 46,I-00197 ROME,ITALY.			Spataro, Antonio/0000-0002-7727-665X				BEKAERT I, 1981, BRIT HEART J, V45, P213; BLAIR NL, 1980, AUST NZ J MED, V10, P540, DOI 10.1111/j.1445-5994.1980.tb04973.x; DEMARIA AN, 1978, CIRCULATION, V57, P237, DOI 10.1161/01.CIR.57.2.237; DEVEREUX RB, 1987, HYPERTENSION, V9, P19; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; EHSANI AA, 1978, AM J CARDIOL, V42, P52, DOI 10.1016/0002-9149(78)90984-0; FAGARD R, 1983, CIRCULATION, V67, P896, DOI 10.1161/01.CIR.67.4.896; FAGARD R, 1984, BRIT HEART J, V52, P124; FAGARD R, 1987, J AM COLL CARDIOL, V9, P1250, DOI 10.1016/S0735-1097(87)80463-1; FISHER AG, 1989, AM J CARDIOL, V63, P337, DOI 10.1016/0002-9149(89)90342-1; GILBERT CA, 1977, AM J CARDIOL, V40, P528, DOI 10.1016/0002-9149(77)90067-4; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; IKAHEIMO MJ, 1979, AM J CARDIOL, V44, P24, DOI 10.1016/0002-9149(79)90246-7; KEREN G, 1985, CIRCULATION, V71, P45, DOI 10.1161/01.CIR.71.1.45; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; LONGHURST JC, 1981, CIRC RES, V48, P171; LOUIE EK, 1987, ANN INTERN MED, V106, P663, DOI 10.7326/0003-4819-106-5-663; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1983, AM J CARDIOL, V51, P189, DOI 10.1016/S0002-9149(83)80034-4; MARON BJ, 1986, J AM COLL CARDIOL, V7, P190, DOI 10.1016/S0735-1097(86)80282-0; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1987, J AM COLL CARDIOL, V10, P733, DOI 10.1016/S0735-1097(87)80264-4; MARTIN WH, 1986, J AM COLL CARDIOL, V7, P982, DOI 10.1016/S0735-1097(86)80215-7; MORGANROTH J, 1975, ANN INTERN MED, V82, P521, DOI 10.7326/0003-4819-82-4-521; NETER J, 1984, APPLIED LINEAR STATI, P214; NISHIMURA T, 1980, CIRCULATION, V61, P832, DOI 10.1161/01.CIR.61.4.832; OAKLEY D, 1984, BRIT HEART J, V52, P121; PARKER BM, 1978, CHEST, V73, P376, DOI 10.1378/chest.73.3.376; ROST R, 1982, EUR HEART J, V3, P193, DOI 10.1093/eurheartj/3.suppl_A.193; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SHAPIRO LM, 1985, EUR HEART J, V6, P967, DOI 10.1093/oxfordjournals.eurheartj.a061796; SNOECKX LHEH, 1983, EUR J APPL PHYSIOL O, V52, P20, DOI 10.1007/BF00429020; SPIRITO P, 1988, ANN INTERN MED, V109, P122, DOI 10.7326/0003-4819-109-2-122; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; SPIRITO P, 1990, J AM COLL CARDIOL, V15, P1521, DOI 10.1016/0735-1097(90)92820-R; Underwood R H, 1977, Ann N Y Acad Sci, V301, P297, DOI 10.1111/j.1749-6632.1977.tb38208.x; WIELING W, 1981, BRIT HEART J, V46, P190; YAMAGUCHI H, 1979, AM J CARDIOL, V44, P401, DOI 10.1016/0002-9149(79)90388-6	42	693	706	1	35	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					295	301		10.1056/NEJM199101313240504	http://dx.doi.org/10.1056/NEJM199101313240504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1824720	Bronze			2022-12-24	WOS:A1991EU92200004
J	EARDLEY, DD; KOSHLAND, ME				EARDLEY, DD; KOSHLAND, ME			GLYCOSYLPHOSPHATIDYLINOSITOL - A CANDIDATE SYSTEM FOR INTERLEUKIN-2 SIGNAL TRANSDUCTION	SCIENCE			English	Article							PROTEIN KINASE-C; STIMULATORY FACTOR-I; MURINE B-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; DIFFERENTIATION FACTORS; IL-2 RECEPTOR; KILLER CELLS; CHAIN GENE; INSULIN; EXPRESSION	The mechanism of interleukin-2 (IL-2) signal transduction was analyzed by use of an inducible B lymphoma. Like normal antigen-activated B lymphocytes, the lymphoma cells respond to IL-2 by proliferating and differentiating into antibody-secreting cells; both responses are blocked by a second interleukin, IL-4. Analyses of the signaling pathway showed that IL-2 stimulated the rapid hydrolysis of an inositol-containing glycolipid to yield two possible second messengers, a myristylated diacylglycerol and an inositol phosphate-glycan. The myristylated diacylglycerol response exhibited the same IL-2 dose dependence as the growth and differentiative responses, and the generation of both hydrolysis products was inhibited by IL-4. These correlations implicate the glycosyl-phosphatidylinositol system in the intracellular relay of the IL-2 signal.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF SANTA BARBARA,DEPT BIOL SCI,SANTA BARBARA,CA 93106	University of California System; University of California Berkeley; University of California System; University of California Santa Barbara					PHS HHS [A107079] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BROOKS K, 1983, NATURE, V302, P325; BROOKS KH, 1986, J IMMUNOL, V137, P3205; Cambier J C, 1987, Adv Exp Med Biol, V213, P195; CHAN BL, 1989, P NATL ACAD SCI USA, V86, P1756, DOI 10.1073/pnas.86.6.1756; FRNANDEZBOTRAN R, 1989, J EXP MED, V169, P329; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; KARRAY S, 1990, J IMMUNOL, V145, P1152; KAWAKAMI Y, 1989, J IMMUNOL, V142, P3452; KELLY KL, 1987, P NATL ACAD SCI USA, V84, P6404, DOI 10.1073/pnas.84.18.6404; KELLY KL, 1987, J BIOL CHEM, V262, P15285; LEGRAVEREND C, 1989, EXP CELL RES, V181, P273, DOI 10.1016/0014-4827(89)90201-2; LOUGHNAN MS, 1989, NATURE, V340, P76, DOI 10.1038/340076a0; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; MCHUGH Y, 1981, B LYMPHOCYTES IMMUNE, P467; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAGLER A, 1988, J IMMUNOL, V141, P2349; NAKANISHI K, 1984, J EXP MED, V160, P1736, DOI 10.1084/jem.160.6.1736; NAKANISHI K, 1984, J EXP MED, V160, P1605, DOI 10.1084/jem.160.6.1605; PAUL WE, 1987, FASEB J, V1, P456, DOI 10.1096/fasebj.1.6.3315808; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5893; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SATO KL, 1987, J BIOL CHEM, V262, P2131; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPITS H, 1988, J IMMUNOL, V141, P29; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WIDMER MB, 1987, J EXP MED, V166, P1447, DOI 10.1084/jem.166.5.1447; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	39	131	134	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					78	81		10.1126/science.1824727	http://dx.doi.org/10.1126/science.1824727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824727				2022-12-24	WOS:A1991EQ60300031
J	VONMOLLARD, GF; SUDHOF, TC; JAHN, R				VONMOLLARD, GF; SUDHOF, TC; JAHN, R			A SMALL GTP-BINDING PROTEIN DISSOCIATES FROM SYNAPTIC VESICLES DURING EXOCYTOSIS	NATURE			English	Article							SECRETION; MEMBRANE; GLUTAMATE; SUGGESTS; CALCIUM; RELEASE	LOW-molecular-weight GTP-binding proteins are strong candidates for regulators of membrane traffic1-3. In yeast, mutations in the sec4 or ypt1 genes encoding small GTP-binding proteins inhibit constitutive membrane flow at the plasma membrane or Golgi complex, respectively4-6. It has been suggested that membrane fusion-fission events are regulated by cycling of small GTP-binding proteins between a membrane-bound and free state7, but although most of these small proteins are found in both soluble and tightly membrane-bound forms, there is no direct evidence to support such cycling. In rat brain a small GTP-binding protein, rab3A, is exclusively associated with synaptic vesicles, the secretory organelles of nerve terminals8,9. Here we use isolated nerve terminals to study the fate of rab3A during synaptic vesicle exocytosis. We find that rab3A dissociates quantitatively from the vesicle membrane after Ca2+-dependent exocytosis and that this dissociation is partially reversible during recovery after stimulation. These results are direct evidence for an association-dissociation cycle of a small GTP-binding protein during traffic of its host membrane.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			von Mollard, Gabriele Fischer/A-3935-2012; von Mollard, Gabriele Fischer/O-9778-2019	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Jahn, Reinhard/0000-0003-1542-3498				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; DECAMILLI P, 1990, REV PHYSL, V52, P625; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; MCMAHON HT, IN PRESS J NEUROCHEM; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9	20	303	308	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					79	81		10.1038/349079a0	http://dx.doi.org/10.1038/349079a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845915				2022-12-24	WOS:A1991EQ60100057
J	VANDERBRUGGEN, P; TRAVERSARI, C; CHOMEZ, P; LURQUIN, C; DEPLAEN, E; VANDENEYNDE, B; KNUTH, A; BOON, T				VANDERBRUGGEN, P; TRAVERSARI, C; CHOMEZ, P; LURQUIN, C; DEPLAEN, E; VANDENEYNDE, B; KNUTH, A; BOON, T			A GENE ENCODING AN ANTIGEN RECOGNIZED BY CYTOLYTIC LYMPHOCYTES-T ON A HUMAN-MELANOMA	SCIENCE			English	Article							IMMUNOGENIC TUM VARIANTS; MOUSE MASTOCYTOMA P815; MUTATED EXON ENCODES; TRANSPLANTATION ANTIGEN-P91A; CELLS; IDENTIFICATION; MUTAGENESIS; TUMOR-P815; CLONING; PEPTIDE	Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line. This gene shows no similarity to known sequences and belongs to a family of at least three genes. It is expressed by the original melanoma cells, other melanoma cell lines, and by some tumor cells of other histological types. No expression was observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the gene. Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample.	LUDWIG INST CANC RES, B-1200 BRUSSELS, BELGIUM; CATHOLIC UNIV LOUVAIN, CELLULAR GENET UNIT, B-1200 BRUSSELS, BELGIUM; UNIV MAINZ, MED KLIN & POLIKLIN 1, W-6500 MAINZ, GERMANY	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Johannes Gutenberg University of Mainz	BOON, T (corresponding author), LUDWIG INST CANC RES, B-1200 BRUSSELS, BELGIUM.		knuth, alexander/H-2608-2014; Bertrand, Mathieu J/P-6465-2016	knuth, alexander/0000-0002-9318-2784; Bertrand, Mathieu J/0000-0001-9000-0626				ANICHINI A, 1987, IMMUNOL TODAY, V8, P385, DOI 10.1016/0167-5699(87)90215-5; BOON T, 1980, J EXP MED, V152, P1184, DOI 10.1084/jem.152.5.1184; BRUNNER KT, 1981, J EXP MED, V154, P362, DOI 10.1084/jem.154.2.362; CROWLEY NJ, 1990, CANCER RES, V50, P492; DARROW TL, 1989, J IMMUNOL, V142, P3329; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DEPLAEN E, 1988, P NATL ACAD SCI USA, V85, P2274; FEARON ER, 1988, CANCER RES, V48, P2975; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; KLEIN G, 1960, CANCER RES, V20, P1561; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; LUND T, 1982, P NATL ACAD SCI-BIOL, V79, P520, DOI 10.1073/pnas.79.2.520; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PREHN RT, 1957, J NATL CANCER I, V18, P769; SIBILLE C, 1990, J EXP MED, V172, P35, DOI 10.1084/jem.172.1.35; SLOVIN SF, 1986, J IMMUNOL, V137, P3042; SZIKORA JP, 1990, EMBO J, V9, P1041, DOI 10.1002/j.1460-2075.1990.tb08208.x; TIWARI JL, 1985, HLA DISEASE ASS, P4; TRAVERSARI C, IN PRESS IMMUNOGENET; UYTTENHOVE C, 1983, J EXP MED, V157, P1040, DOI 10.1084/jem.157.3.1040; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDENEYNDE B, 1989, INT J CANCER, V44, P634; VANPEL A, 1983, J EXP MED, V157, P1992, DOI 10.1084/jem.157.6.1992; WOLFEL T, 1987, IMMUNOGENETICS, V26, P178, DOI 10.1007/BF00365909	28	2886	3179	5	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1643	1647		10.1126/science.1840703	http://dx.doi.org/10.1126/science.1840703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1840703				2022-12-24	WOS:A1991GV07300045
J	FARRAR, GJ; KENNA, P; JORDAN, SA; KUMARSINGH, R; HUMPHRIES, MM; SHARP, EM; SHEILS, DM; HUMPHRIES, P				FARRAR, GJ; KENNA, P; JORDAN, SA; KUMARSINGH, R; HUMPHRIES, MM; SHARP, EM; SHEILS, DM; HUMPHRIES, P			A 3-BASE-PAIR DELETION IN THE PERIPHERIN-RDS GENE IN ONE FORM OF RETINITIS-PIGMENTOSA	NATURE			English	Article							RHODOPSIN GENE; PREVALENCE; MUTATIONS	THE group of retinopathies termed retinitis pigmentosa (RP) greatly contribute to visual dysfunction in man with a frequency of roughly 1 in 4,000 (refs 1, 2). We mapped the first autosomal dominant RP (adRP) gene to chromosome 3q (refs 3, 4), close to the gene encoding rhodopsin, a rod photoreceptor pigment protein. Subsequently, mutations in this gene have been implicated as responsible for some forms of adRP 5-9. Another adRP gene has been mapped to chromosome 8p (ref. 10). A third adRP gene in a large Irish pedigree has been mapped to chromosome 6p (refs 11, 12), showing tight linkage with the gene for peripherin 13,14, a photoreceptor cell-specific glycoprotein, which is thus a strong candidate for the defective gene. We have now identified a three-base-pair deletion which results in the loss of one of a pair of highly conserved cysteine residues in the predicted third transmembrane domain of peripherin. This deletion segregates with the disease phenotype but is not present in unaffected controls, and suggests that mutant peripherin gives rise to retinitis pigmentosa.			FARRAR, GJ (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT GENET,LINCOLN PL GATE,DUBLIN 2,IRELAND.		Farrar, G Jane/B-9832-2011; Bateson, Jane Farrar/AAO-6147-2020	Kumar-Singh, Rajendra/0000-0002-7754-0713	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLANTON SH, IN PRESS GENOMICS; BUNDEY S, 1984, J MED GENET, V21, P417, DOI 10.1136/jmg.21.6.417; BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; FARRAR GJ, 1990, GENOMICS, V8, P35; FARRAR GJ, IN PRESS GENOMICS; INGLEHEARN CF, 1991, AM J HUM GENET, V48, P26; JORDAN SA, IN PRESS AM J HUM GE; MCWILLIAM P, 1989, GENOMICS, V5, P619, DOI 10.1016/0888-7543(89)90031-1; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0	17	348	364	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					478	480		10.1038/354478a0	http://dx.doi.org/10.1038/354478a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749427				2022-12-24	WOS:A1991GV07800060
J	KAY, GF; ASHWORTH, A; PENNY, GD; DUNLOP, M; SWIFT, S; BROCKDORFF, N; RASTAN, S				KAY, GF; ASHWORTH, A; PENNY, GD; DUNLOP, M; SWIFT, S; BROCKDORFF, N; RASTAN, S			A CANDIDATE SPERMATOGENESIS GENE ON THE MOUSE Y-CHROMOSOME IS HOMOLOGOUS TO UBIQUITIN-ACTIVATING ENZYME-E1	NATURE			English	Article							L-CELL DEFECT; X-CHROMOSOME; SEX DETERMINATION; DNA-REPLICATION; SHORT ARM; EXPRESSION; DIFFERENTIATION; COMPLEMENTS; CLONING; ANTIGEN	THE human X-linked gene A1S9 (refs 1-3) complements a temperature-sensitive cell-cycle mutation in mouse L cells 4, and encodes the ubiquitin-activating enzyme E1 (refs 5-7). The gene has been reported to escape X-chromosome inactivation 8, but there is some conflicting evidence 9. We have isolated part of the mouse A1s9 gene, mapped it to the proximal portion of the X chromosome and shown that it undergoes normal X-inactivation. We also detected two copies of the gene on the short arm of the mouse Y chromosome (A1s9Y-1 and A1s9Y-2). The functional A1s9Y gene (Als9Y-1) is expressed in testis and is lost in the deletion mutant Sxr(b) (ref. 10). Therefore A1s9Y-1 is a candidate for the spermatogenesis gene, Spy, which maps to this region. A1s9X is similar to the Zfx gene in undergoing X-inactivation 11,12, yet having homologous sequences on the short arm of the Y chromosome 13,14, which are expressed in the testis. These Y-linked genes may form part of a coregulated group of genes which function during spermatogenesis.	MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Medical Research Council Clinical Trials Unit; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	RASTAN, S (corresponding author), MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ADLER DA, 1991, P NATL ACAD SCI USA, V88, P4592, DOI 10.1073/pnas.88.11.4592; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BISHOP CE, 1988, PHILOS T ROY SOC B, V322, P119, DOI 10.1098/rstb.1988.0119; BROCKDORFF N, 1991, GENOMICS, V10, P17, DOI 10.1016/0888-7543(91)90478-W; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1989, SOMAT CELL MOLEC GEN, V15, P173, DOI 10.1007/BF01535079; BROWN CJ, 1990, AM J HUM GENET, V46, P273; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; EVANS EP, 1982, NATURE, V300, P443, DOI 10.1038/300443a0; GOODFELLOW PN, 1988, DEVELOPMENT, V102, P251; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; KAY G, IN PRESS GENOMICS; KOOPMAN P, 1991, TRENDS GENET, V7, P132, DOI 10.1016/0168-9525(91)90458-3; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; MARDON G, 1989, SCIENCE, V243, P78, DOI 10.1126/science.2563173; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MCLAREN A, 1988, TRENDS GENET, V4, P153, DOI 10.1016/0168-9525(88)90020-0; MCLAREN A, 1983, BRIT SOC DEV BIOL, P225; MONESI V, 1965, EXP CELL RES, V39, P197, DOI 10.1016/0014-4827(65)90023-6; NAGAMINE CM, 1989, SCIENCE, V243, P80, DOI 10.1126/science.2563174; REICHSTEINER M, 1988, UBUITIN; SIMPSON E, 1984, TRANSPLANTATION, V37, P17, DOI 10.1097/00007890-198401000-00007; SINGH L, 1982, CELL, V28, P205, DOI 10.1016/0092-8674(82)90338-5; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; THOMPSON LH, 1970, P NATL ACAD SCI USA, V66, P377, DOI 10.1073/pnas.66.2.377; ZACKSENHAUS E, 1988, SOMAT CELL MOLEC GEN, V14, P371, DOI 10.1007/BF01534645; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x; ZACKSENHAUS E, 1989, SOMAT CELL MOLEC GEN, V15, P545, DOI 10.1007/BF01534915	30	114	116	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1991	354	6353					486	489		10.1038/354486a0	http://dx.doi.org/10.1038/354486a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1749428				2022-12-24	WOS:A1991GV07800063
J	HJORTDAHL, P; BORCHGREVINK, CF				HJORTDAHL, P; BORCHGREVINK, CF			CONTINUITY OF CARE - INFLUENCE OF GENERAL-PRACTITIONERS KNOWLEDGE ABOUT THEIR PATIENTS ON USE OF RESOURCES IN CONSULTATIONS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To examine the relation between general practitioners' knowledge about their patients and the use of resources in consultations. Design - A cross sectional evaluation of consultations. Setting and subjects - A representative sample of 133 Norwegian general practitioners were each asked to record 30 consecutive consultations. 131 did so, and of 3990 possible registrations, 3918 (98%) were evaluated. Main outcome measures - The influence, as assessed by the doctor, of accumulated knowledge on the use of laboratory tests, expectant management, prescriptions, sickness certification, referrals, and time spent in the consultation. Results - Accumulated knowledge was a substantial factor in saving time, especially in consultations with children, the elderly, patients with psychosocial problems. and those with chronic diseases. It also influenced the overall use of laboratory tests, expectant management, sickness certification, and referrals, and to a lesser degree the use of medication. Conclusion - The findings imply strong but complex associations between accumulated knowledge and the use of resources in the consultation.			HJORTDAHL, P (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO 2,NORWAY.							ANDREWS FM, 1984, PUBLIC OPIN QUART, V48, P409, DOI 10.1086/268840; Bentsen B G, 1986, Scand J Prim Health Care, V4, P43, DOI 10.3109/02813438609013970; CARTWRIGHT A, 1976, J R COLL GEN PRACT, V26, P895; Hjortdahl P, 1990, Fam Med, V22, P361; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; MCWHINNEY I, 1982, J FAM PRACTICE, V15, P847; McWhinney IR, 1989, TXB FAMILY MED; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; Nylenna M, 1985, Scand J Prim Health Care, V3, P155, DOI 10.3109/02813438509013938; NYLENNA M, 1986, FAM PRACT, V3, P240, DOI 10.1093/fampra/3.4.240; ODOWD TC, 1988, BRIT MED J, V297, P528, DOI 10.1136/bmj.297.6647.528; Polanyi M., 1967, TACIT DIMENSION; ROSENBERG EE, 1985, FAM PRACT, V2, P23, DOI 10.1093/fampra/2.1.23; RUTLE O, 1983, 11983 STAT I FOLK RA; Schon Donald A., 1991, REFLECTIVE PRACTITIO; SHELDON M, 1985, DECISION MAKING GENE; YAFFE MJ, 1985, MED CARE, V23, P1276, DOI 10.1097/00005650-198511000-00006; 1989, WORKING PATIENTS; 1988, JAMA-J AM MED ASSOC, V260, P1272	19	119	120	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1181	1184		10.1136/bmj.303.6811.1181	http://dx.doi.org/10.1136/bmj.303.6811.1181			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP488	1747619	Bronze, Green Published			2022-12-24	WOS:A1991GP48800029
J	WEISS, DS; BATUT, J; KLOSE, KE; KEENER, J; KUSTU, S				WEISS, DS; BATUT, J; KLOSE, KE; KEENER, J; KUSTU, S			THE PHOSPHORYLATED FORM OF THE ENHANCER-BINDING PROTEIN NTRC HAS AN ATPASE ACTIVITY THAT IS ESSENTIAL FOR ACTIVATION OF TRANSCRIPTION	CELL			English	Article							RNA POLYMERASE-II; NITROGEN REGULATOR-I; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; INVITRO TRANSCRIPTION; GENE-TRANSCRIPTION; GLNA TRANSCRIPTION; ENTERIC BACTERIA; PLASMID VECTORS; LATE PROMOTER	The NTRC protein of enteric bacteria is an enhancer-binding protein that activates transcription in response to limitation of combined nitrogen. NTRC activates transcription by catalyzing formation of open complexes by RNA polymerase (sigma-54 holoenzyme form) in an ATP-dependent reaction. To catalyze open complex formation, NTRC must be phosphorylated. We show that phosphorylated NTRC has an ATPase activity, and we present biochemical and genetic evidence that NTRC must hydrolyze ATP to catalyze open complex formation. It is likely that all activators of sigma-54 holo-enzyme have an ATPase activity.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	WEISS, DS (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT PATHOL,BERKELEY,CA 94720, USA.		BATUT, Jacques/B-6506-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038361, R37GM038361] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38361] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BIEKER JJ, 1986, J BIOL CHEM, V261, P9732; BIEKER JJ, 1985, CELL, V40, P119, DOI 10.1016/0092-8674(85)90315-0; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; BUIKEMA WJ, 1985, NUCLEIC ACIDS RES, V13, P4539, DOI 10.1093/nar/13.12.4539; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; Corbin J D, 1974, Methods Enzymol, V38, P287; DEAKIN H, 1963, BIOCHEM J, V89, P296, DOI 10.1042/bj0890296; DRUMMOND M, 1986, EMBO J, V5, P441, DOI 10.1002/j.1460-2075.1986.tb04230.x; DRUMMOND MH, 1990, MOL MICROBIOL, V4, P29, DOI 10.1111/j.1365-2958.1990.tb02012.x; EBERZ G, 1991, J BACTERIOL, V173, P1845, DOI 10.1128/jb.173.6.1845-1854.1991; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GRIMM C, 1989, J BACTERIOL, V171, P5031, DOI 10.1128/jb.171.9.5031-5038.1989; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; INOUYE S, 1988, GENE, V66, P301; KASSAVETIS GA, 1983, CELL, V33, P887, DOI 10.1016/0092-8674(83)90031-4; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KOFOID EC, 1988, P NATL ACAD SCI USA, V85, P4981, DOI 10.1073/pnas.85.14.4981; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MAUPIN JA, 1990, J BACTERIOL, V172, P4798, DOI 10.1128/jb.172.9.4798-4806.1990; MINCHIN SD, 1988, MOL MICROBIOL, V2, P433, DOI 10.1111/j.1365-2958.1988.tb00049.x; MINTON AP, 1983, MOL CELL BIOCHEM, V55, P119, DOI 10.1007/BF00673707; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NARASIMHAN N, 1987, P NATL ACAD SCI USA, V84, P4078, DOI 10.1073/pnas.84.12.4078; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHLENSOG V, 1990, MOL MICROBIOL, V4, P1319, DOI 10.1111/j.1365-2958.1990.tb00711.x; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TABOR S, 1990, CURRENT PROTOCOLS MO; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WEGLENSKI P, 1989, J BACTERIOL, V171, P4479, DOI 10.1128/JB.171.8.4479-4485.1989; WEI GR, 1981, MOL GEN GENET, V183, P392, DOI 10.1007/BF00270646; WEISS DS, 1991, P NATL ACAD SCI USA, V85, P8923; WONG PK, 1987, J BACTERIOL, V169, P2876, DOI 10.1128/jb.169.6.2876-2880.1987; WOZNIAK DJ, 1991, J BACTERIOL, V173, P1406, DOI 10.1128/jb.173.4.1406-1413.1991	56	296	298	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 4	1991	67	1					155	167		10.1016/0092-8674(91)90579-N	http://dx.doi.org/10.1016/0092-8674(91)90579-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1833069				2022-12-24	WOS:A1991GJ32000014
J	WELLS, FB; GAHM, SJ; HEDRICK, SM; BLUESTONE, JA; DENT, A; MATIS, LA				WELLS, FB; GAHM, SJ; HEDRICK, SM; BLUESTONE, JA; DENT, A; MATIS, LA			REQUIREMENT FOR POSITIVE SELECTION OF GAMMA-DELTA-RECEPTOR-BEARING T-CELLS	SCIENCE			English	Article							LYMPHOCYTES-T; CYCLOSPORINE-A; STEM-CELLS; ANTIGEN; THYMUS; MICE; EXPRESSION; CD8; SPECIFICITY; RECOGNITION	The alpha-beta and gamma-delta-T cell receptors for antigen (TCR) delineate distinct T cell populations. TCR-alpha-beta-bearing thymocytes must be positively selected by binding of the TCR to major histocompatibility complex (MHC) molecules on thymic epithelium. To examine the requirement for positive selection of TCR gamma-delta-T cells, mice bearing a class I MHC-specific gamma-delta-transgene (Tg) were crossed to mice with disrupted beta-2 microglobulin (beta-2M) genes. The Tg+beta-2M- (class I MHC-) offspring had Tg+ thymocytes that did not proliferate to antigen or Tg-specific monoclonal antibody and few peripheral Tg+ cells. This is evidence for positive selection within the gamma-delta-T cell subset.	NCI, FREDERICK CANC RES & DEV CTR, MOLEC IMMUNOREGULAT LAB, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, HOWARD HUGHES MED INST, RES SCHOLARS PROGRAM, BETHESDA, MD 20892 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21701 USA; UNIV CHICAGO, BEN MAY INST, DEPT PATHOL, COMM IMMUNOL, CHICAGO, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Chicago			Hedrick, Stephen M/E-9171-2010	Hedrick, Stephen/0000-0002-6345-8751	NIAID NIH HHS [AI 26847-03, AI00602] Funding Source: Medline; PHS HHS [N01-C0-74102] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026847] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BORN W, 1990, IMMUNOL TODAY, V11, P40; BRUCE J, 1981, J IMMUNOL, V127, P2496; Bucy R P, 1991, Semin Immunol, V3, P109; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CRON RQ, 1989, J IMMUNOL, V142, P3754; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOLLER B, UNPUB; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOSUGI A, 1989, J IMMUNOL, V142, P3026; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; PARDOLL DM, 1988, J IMMUNOL, V140, P4091; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SIM GK, 1990, CELL, V61, P397, DOI 10.1016/0092-8674(90)90522-G; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WELLS FB, UNPUB; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	32	74	74	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1991	253	5022					903	905		10.1126/science.1831565	http://dx.doi.org/10.1126/science.1831565			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1831565				2022-12-24	WOS:A1991GC15200045
J	TOMALSKI, MD; MILLER, LK				TOMALSKI, MD; MILLER, LK			INSECT PARALYSIS BY BACULOVIRUS-MEDIATED EXPRESSION OF A MITE NEUROTOXIN GENE	NATURE			English	Article							PYEMOTES-TRITICI; TRANSCRIPTION; VECTORS; TOXINS	FEMALE mites of the species Pyemotes tritici inject an extremely potent venom into their insect prey that causes muscle-contraction and paralysis 1-4. These mites are able to paralyse insects 150,000 times their size 5 and their venom is effective in a broad range of insect species 4. A toxin (TxP-I) associated with the mite venom apparatus causes immediate muscle-contractive paralysis when injected into insects but not mice 6. In this report, we describe the cloning, sequencing and expression of a complementary DNA (Tox-34) encoding TxP-I. Insect cells infected with a recombinant baculovirus (vEV-Tox34) expressing Tox-34 secrete three polypeptides related to TxP-I which cause paralysis on injection. Larvae infected with vEV-Tox34 become paralysed during infection, thus reflecting the potential application of this toxin gene in insect biocontrol methods. The toxin gene expression system will also allow further exploration of the neurophysiological basis of its insect-specific effects.	UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602	University System of Georgia; University of Georgia	TOMALSKI, MD (corresponding author), UNIV GEORGIA,DEPT ENTOMOL,ATHENS,GA 30602, USA.							Battey, 1986, BASIC METHODS MOL BI; BISHOP DHL, 1988, RELEASE GENETICALLY, P143; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARBONELL LF, 1988, GENE, V73, P409, DOI 10.1016/0378-1119(88)90505-7; KRCZAL H, 1959, ACARINA, V1, P385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MILLER LK, 1983, SCIENCE, V219, P715, DOI 10.1126/science.219.4585.715; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOSER JC, 1975, T ROY ENT SOC LONDON, V127, P185; OOI BG, 1989, J MOL BIOL, V210, P721, DOI 10.1016/0022-2836(89)90105-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOMALSKI MD, 1989, TOXICON, V27, P1151, DOI 10.1016/0041-0101(89)90009-3; TOMALSKI MD, 1988, VIROLOGY, V167, P591, DOI 10.1016/S0042-6822(88)90122-5; TOMALSKI MD, 1988, TOXICON, V26, P127, DOI 10.1016/0041-0101(88)90164-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAIVANIJKUL P, 1968, P HAWAII ENTOMOL SOC, V20, P443; WANG XZ, 1991, GENE, V100, P131, DOI 10.1016/0378-1119(91)90358-I; WEISER JAROSLAV, 1964, ANN ENTOMOL SOC AMER, V57, P479	19	227	267	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					82	85		10.1038/352082a0	http://dx.doi.org/10.1038/352082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1840646				2022-12-24	WOS:A1991FV17800077
J	GOODWIN, FK				GOODWIN, FK			ARE NEUROSTEROIDS BRAINS VALIUM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1850809				2022-12-24	WOS:A1991FL98900007
J	TURSKI, L; BRESSLER, K; RETTIG, KJ; LOSCHMANN, PA; WACHTEL, H				TURSKI, L; BRESSLER, K; RETTIG, KJ; LOSCHMANN, PA; WACHTEL, H			PROTECTION OF SUBSTANTIA-NIGRA FROM MPP+ NEUROTOXICITY BY N-METHYL-D-ASPARTATE ANTAGONISTS	NATURE			English	Article							EXCITATORY AMINO-ACIDS; MOUSE-BRAIN; PARKINSONS-DISEASE; RAT; GLUTAMATE; NEURONS; MPTP; N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM	INTAKE of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) leads to symptoms of Parkinson's disease and produces degeneration of nigrostriatal dopaminergic neurons in humans, giving rise to the hypothesis that this disorder may be caused by endogenous or environmental toxins 1-3. Excitation mediated by dicarboxylic amino acids such as L-glutamate or L-aspartate, has been claimed to be involved in pathogenesis of neurodegenerative disorders 4. We therefore sought to determine whether antagonists active at the NMDA or quisqualate subtypes of L-glutamate receptors prevent toxicity of either MPP+ (1-m ethyl-4-phenyl-pyridinium ion 5, the active metabolite of MPTP 6) or the selective dopaminergic neurotoxin 6-OHDA in the rat substantia nigra pars compacta. We report here that certain selective NMDA antagonists (AP7, CPP, MK-801) 7, but not the preferential quisqualate antagonists CNQX and NBQX, 8 provided short-term (up to 24 h) protection against MPP+ toxicity when coadministered into the substantia nigra. Systemic administration of CPP or MK-801 also offered temporary protection for up to 4 h against MPP+ toxicity. Repeated systemic administration of either compound prolonged protection against MPP+ challenge. Repeated administration for at least 24 h also led to permanent protection, still evident 7 days after intranigral administration of MPP+.			TURSKI, L (corresponding author), SCHERING AG,RES LABS,W-1000 BERLIN 65,GERMANY.							BORMANN J, 1989, EUR J PHARMACOL, V166, P591, DOI 10.1016/0014-2999(89)90385-3; BRADBURY AJ, 1986, NATURE, V319, P56, DOI 10.1038/319056a0; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CHAPMAN AG, 1983, NEUROSCI LETT, V37, P75, DOI 10.1016/0304-3940(83)90507-4; CHRISTIEPOPE BC, 1989, EXP NEUROL, V104, P235, DOI 10.1016/0014-4886(89)90035-6; COMPTON RP, 1988, NEUROSCI LETT, V84, P339, DOI 10.1016/0304-3940(88)90532-0; DIMONTE D, 1988, REV NEUROSCI, V2, P67; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fallon J.H., 1985, RAT NERVOUS SYSTEM, P353; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; GIBB WRG, 1988, BRAIN RES, V461, P361, DOI 10.1016/0006-8993(88)90268-5; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; IRWIN I, 1989, NEUROSCI LETT, V101, P83, DOI 10.1016/0304-3940(89)90445-X; JOHANNESSEN JN, 1985, LIFE SCI, V36, P219, DOI 10.1016/0024-3205(85)90062-1; Konig JFR, 1963, RAT BRAIN STEREOTAXI; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; MARKEY SP, 1984, NATURE, V311, P464, DOI 10.1038/311464a0; MAWDSLEY C, 1963, LANCET, V2, P795; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OHYA Y, 1989, NEUROSCI LETT, V105, P221, DOI 10.1016/0304-3940(89)90041-4; OLNEY JW, 1987, EUR J PHARMACOL, V142, P319, DOI 10.1016/0014-2999(87)90123-3; OLNEY JW, 1988, FRONTIERS EXCITATORY, P589; OLVERMAN HJ, 1984, NATURE, V307, P460, DOI 10.1038/307460a0; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SONSALLA PK, 1989, SCIENCE, V243, P398, DOI 10.1126/science.2563176; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; SUN CJ, 1988, J NEURAL TRANSM, V74, P75, DOI 10.1007/BF01245141; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; VEZZANI A, 1989, J PHARMACOL EXP THER, V249, P278; WEISS JH, 1988, SCIENCE, V241, P973, DOI 10.1126/science.3136549	35	539	563	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					414	418		10.1038/349414a0	http://dx.doi.org/10.1038/349414a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846943				2022-12-24	WOS:A1991EV51400051
J	MUTTON, DE; ALBERMAN, E; IDE, R; BOBROW, M				MUTTON, DE; ALBERMAN, E; IDE, R; BOBROW, M			RESULTS OF 1ST YEAR (1989) OF A NATIONAL REGISTER OF DOWNS-SYNDROME IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; AGE	Objective - To examine the feasibility of a national register of Down's syndrome and its effectiveness in evaluating prenatal screening for the syndrome. Design - Information for the register was obtained from all eligible cytogenetic laboratories on relevant cytogenetic diagnoses, including date and place of birth or termination, maternal age, indication for karyotyping, and type of diagnostic test used. Setting - Cytogenetic laboratories in England and Wales. Subjects - All fetuses with trisomy 21 diagnosed prenatally and live births with Down's syndrome diagnosed at birth. Main outcome measures - Number of prenatal and postnatal diagnoses of Down's syndrome. National and maternal age specific prevalence of Down's syndrome. Results - For 1989 there were 1060 registrations-323 prenatal diagnoses and 737 postnatal diagnoses -after exclusion of postnatally diagnosed miscarriages and stillbirths. The estimated national rate of affected births for mothers resident in England and Wales was 1-4/1000 live births, assuming no terminations of affected pregnancies and after correction for natural losses which would have occurred in the absence of termination. The corrected maternal age specific rates were close to those found in previous population based studies. The proportion of affected pregnancies diagnosed prenatally in mothers aged 35 to 39 was 44%, and for those aged 40 or more it was 71%. Abnormal findings on ultrasonography played an unexpectedly important part in initiating cytogenetic investigation (13% of the prenatal diagnoses). Conclusions - The findings establish the feasibility of a national Down's syndrome register and its use in evaluating prenatal screening services. Together with information held by the Office of Population Censuses and Surveys on congenital malformations, data from the register will permit studies of environmental variables affecting the prevalence of the syndrome.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,PAEDIAT RES UNIT,LONDON SE1 9RT,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,LONDON EC1M 6BQ,ENGLAND	University of London; King's College London; University of London; Queen Mary University London	MUTTON, DE (corresponding author), LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,QMW,LONDON E1 4NS,ENGLAND.							BLACK D, 1984, INVESTIGATION POSSIB; CUCKLE H, 1991, PRENATAL DIAG, V11, P29, DOI 10.1002/pd.1970110106; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; HOOK EB, 1988, AM J HUM GENET, V42, P797; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; CONGENITAL MALFORMAT; ABORTION STATISTI AB; 1989, FM1 OFF POP CENS SUR	9	34	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1295	1297		10.1136/bmj.303.6813.1295	http://dx.doi.org/10.1136/bmj.303.6813.1295			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1836152	Bronze, Green Published			2022-12-24	WOS:A1991GT01100019
J	GILKS, CF				GILKS, CF			WHAT USE IS A CLINICAL CASE DEFINITION FOR AIDS IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							ZAIRE; TUBERCULOSIS; INFECTION		KENYA GOVT MED RES CTR,NAIROBI,KENYA	Kenya Medical Research Institute			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123				BROWN C, 1991, AIDS, V5, P89, DOI 10.1097/00002030-199101000-00013; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1988, AIDS, V2, P219; GILKES CF, IN PRESS Q J MED; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GILKS CF, 1990, AIDS, V4, P981, DOI 10.1097/00002030-199010000-00006; GILKS CF, 1991, IN PRESS TROPICAL DO; GILKS CF, IN PRESS AIDS; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; LUCAS SB, 1990, T ROY SOC TROP MED H, V84, P34, DOI 10.1016/0035-9203(90)90453-L; MANN JM, 1986, LANCET, V2, P707; REEVE PA, 1989, BRIT MED J, V298, P1567, DOI 10.1136/bmj.298.6687.1567; ROSE G, 1978, BRIT MED J, V2, P873, DOI 10.1136/bmj.2.6141.873; SWAI ABM, 1989, LANCET, V2, P976; WABWIREMANGEN F, 1989, AIDS, V3, P462, DOI 10.1097/00002030-198907000-00013; WIDIWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286; 1987, MMWR S1, V36, pS4; 1986, WEEKLY EPIDEMIOLOGIC, V61, P69	20	19	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1189	1190		10.1136/bmj.303.6811.1189	http://dx.doi.org/10.1136/bmj.303.6811.1189			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747621	Green Published, Bronze			2022-12-24	WOS:A1991GP48800031
J	DUNEA, G				DUNEA, G			BURNING DOWN THEIR HOUSES	BRITISH MEDICAL JOURNAL			English	Editorial Material											DUNEA, G (corresponding author), COOK CTY HOSP,CHICAGO,IL 60612, USA.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1141	1141						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747602				2022-12-24	WOS:A1991GN20900076
J	BENDELAC, A; SCHWARTZ, RH				BENDELAC, A; SCHWARTZ, RH			CD4+ AND CD8+ T-CELLS ACQUIRE SPECIFIC LYMPHOKINE SECRETION POTENTIALS DURING THYMIC MATURATION	NATURE			English	Article							MONOCLONAL-ANTIBODIES; MOUSE THYMOCYTES; STEM-CELLS; EXPRESSION; IL-4; SUBSETS; PRECURSORS; DEFINITION; RECEPTORS; PROFILES	PERIPHERAL CD4+ and CD8+ T lymphocytes carry out different functions during immune reactions, partly as a result of the distinct patterns of lymphokines that they secrete upon stimulation. Using thymic cells from adult and newborn mice as well as from fetal organ cultures, we show here that this functional differentiation occurs inside the thymus and is completed during the single positive stage by the time the T-cell receptor becomes fully coupled to the intracellular activation pathways leading to lymphokine secretion. Surprisingly, CD4+8- thymocytes differ from their immediate progeny, naive peripheral CD4+ cells, in that they secrete a broader range of lymphokines, including interleukins 4, 5 and 10 and gamma-interferon, and more closely resemble immunologically experienced (activated or memory) CD4+ lymphocytes.			BENDELAC, A (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AGUS DB, 1991, J EXP MED, V173, P1039, DOI 10.1084/jem.173.5.1039; BENSASSON SZ, 1990, J IMMUNOL, V145, P1127; BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BUDD RC, 1987, J IMMUNOL, V138, P3583; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CEREDIG R, 1988, J IMMUNOL, V141, P355; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; CRISPE IN, 1987, J IMMUNOL, V138, P2013; DAHL H, 1972, ACTA PATH MICRO IM B, VB 80, P863; ERNST DN, 1990, J IMMUNOL, V145, P1295; FINKEL TH, 1987, NATURE, V330, P179, DOI 10.1038/330179a0; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GROSSMANN J, 1991, J IMMUNOL, V146, P293; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HULI J, 1989, J IMMUNOL, V142, P800; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEE WT, 1990, J IMMUNOL, V144, P3288; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MICHIE SA, 1988, J EXP MED, V168, P1929, DOI 10.1084/jem.168.5.1929; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1990, J IMMUNOL, V145, P2938; NUSSENZWEIG MC, 1980, J EXP MED, V151, P1196, DOI 10.1084/jem.151.5.1196; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; ORTEGA G, 1984, J IMMUNOL, V133, P1970; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; SCHUMACHER JH, 1988, J IMMUNOL, V141, P1575; SWAIN SL, 1990, J IMMUNOL, V144, P1788; SWAIN SL, 1988, J IMMUNOL, V141, P3445	30	176	177	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					68	71		10.1038/353068a0	http://dx.doi.org/10.1038/353068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1831881				2022-12-24	WOS:A1991GD80500059
J	ANDERSON, RM; MAY, RM; BOILY, MC; GARNETT, GP; ROWLEY, JT				ANDERSON, RM; MAY, RM; BOILY, MC; GARNETT, GP; ROWLEY, JT			THE SPREAD OF HIV-1 IN AFRICA - SEXUAL CONTACT PATTERNS AND THE PREDICTED DEMOGRAPHIC-IMPACT OF AIDS	NATURE			English	Review							HUMAN IMMUNODEFICIENCY VIRUS; PREFERRED NUCLEOTIDE SUBSTITUTIONS; INTRAVENOUS DRUG-USERS; NEW-YORK-CITY; HETEROSEXUAL TRANSMISSION; TRANSMITTED DISEASES; HOUSEHOLD CONTACTS; VIRAL MIXTURES; INFECTION; CHILDREN	The spread of HIV-1 in Africa is examined here in the light of recent information on the main epidemiological and behavioural determinants of transmission. Mathematical models incorporating demographic, epidemiological and behavioural processes are used to assess the potential demographic impact of the disease AIDS. These analyses highlight the significance of patterns of sexual behaviour, and in particular networks of sexual contact, on the predicted spread of infection. Current data reveal substantial variations in the degree of spread between and in countries, but new analyses support earlier predictions that in the worst-afflicted areas AIDS is likely to change population growth rates from positive to negative values in a few decades.	UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Oxford	ANDERSON, RM (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT BIOL, PARASITE EPIDEMIOL RES GRP, LONDON SW7 2BB, ENGLAND.		Garnett, Geoffrey P/A-9312-2008	Anderson, Roy/0000-0002-9528-3175; Boily, Marie-Claude/0000-0003-3919-006X				ANDERSON RM, 1988, J ROY STAT SOC A STA, V151, P66, DOI 10.2307/2982185; ANDERSON RM, 1989, ANN NY ACAD SCI, V569, P240, DOI 10.1111/j.1749-6632.1989.tb27374.x; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; ANDERSON RM, 1988, NATURE, V332, P191; ANDIHAN WA, 1990, AIDS, V4, P758; ANDREASSON PA, 1989, 5 INT C AIDS MONTR; ANZALA A, 1989, 5 INT C AIDS MONTR; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BALDWIN JD, 1988, J SEX RES, V25, P181, DOI 10.1080/00224498809551454; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERKELY SF, 1989, 4 INT C AIDS ASS CAN; BERKLEY S, 1990, AIDS, V4, P1237, DOI 10.1097/00002030-199012000-00009; BIBERFELD G, 1986, SCAND J INFECT DIS, V18, P497, DOI 10.3109/00365548609021653; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLOWER SM, 1990, J ACQ IMMUN DEF SYND, V3, P763; BOILY MC, IN PRESS IMA J MATH; BONGAARTS J, 1989, STAT MED, V8, P103, DOI 10.1002/sim.4780080111; BROWN RC, 1990, AIDS, V4, P1267, DOI 10.1097/00002030-199012000-00014; CARAEL M, IN PRES SADIS; DECOCK KM, 1984, SCIENC, V224, P497; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; FRANCE AJ, 1988, BRIT MED J, V296, P526, DOI 10.1136/bmj.296.6621.526; GANORE E, 1990, 6 INT C AIDS MONTR; GIESECKE J, 1988, BRIT MED J, V297, P99, DOI 10.1136/bmj.297.6641.99; GLASER JB, 1989, ARCH INTERN MED, V149, P645, DOI 10.1001/archinte.149.3.645; GOEDERT JJ, 1989, LANCET, V2, P1351; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GUAY L, 1990, 6 INT C AIDS SAN FRA; GUPTA S, 1989, AIDS, V3, P807, DOI 10.1097/00002030-198912000-00005; HEWLETT IK, 1990, J ACQ IMMUN DEF SYND, V3, P714; HGSBORG M, IN PRESS ANTHR STUDI; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; HYMAN JM, 1989, MATH BIOSCI, V8, P103; JACQUEZ JA, 1988, MATH BIOSCI, V92, P119, DOI 10.1016/0025-5564(88)90031-4; JOHN JT, 1989, LANCET, V1, P160; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; KILLEWO J, 1990, AIDS, V4, P1081, DOI 10.1097/00002030-199011000-00005; KONINGS E, 1989, AIDS, V3, P245; KREISS J, 1988, GENITOURIN MED, V64, P1; LIFOON AR, 1990, 6 INT C AIDS SAN FRA; LIOMBA NG, 1989, 5 INT C AIDS MONTR; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; LPAGE P, 1989, 4 INT C AIDS ASS CAN; MAIGA MK, 1989, 5 INT C AIDS MONTR; MATI J, 1989, 6 INT C AIDS MONTR; MAY RM, 1988, MATH BIOSCI, V90, P475, DOI 10.1016/0025-5564(88)90079-X; MAY RM, 1990, PARASITOLOGY, V100, pS89, DOI 10.1017/S0031182000073042; May RM, 1989, LECT NOTES BIOMATHEM, V81, P220; MAY RM, 1989, CURRENT TOPICS AIDS, V2, P33; MELBYE M, 1986, LANCET, V2, P1113; MURLIE A, 1989, 5 INT C AIDS MONTR; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; NTOZI JPM, IN PRESS ANTHR STUDI; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PECKHAM CS, 1991, LANCET, V337, P253; PECKHAM CS, 1988, LANCET, V2, P1039; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; POTTS M, IN PRESS LANCET; REEVES GK, 1989, PHIL T R SOC B, V325, P109; REZZA G, 1989, AIDS, V3, P87, DOI 10.1097/00002030-198902000-00006; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SHARP PM, 1988, NATURE, V336, P315, DOI 10.1038/336315a0; TAYLOR JMG, 1991, J ACQ IMMUN DEF SYND, V4, P69; THANGCHARVEN P, 1989, HIV INFECTION THAILA; TOVO PA, 1988, LANCET, V2, P1043; VANDEPERRE P, 1985, LANCET, V2, P524; VANICHSENI S, 1989, 5 INT C AIDS MONTR; WARD J, 1990, 6 INT C AIDS SAN FRA; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; YOKOYAMA S, 1988, MOL BIOL EVOL, V5, P237; 1990, NATIONAL HIV SEROPRE; 1990, HIV AIDS SURVEILLANC; 1989, HIV SEROPREVALENCE B; 1987, MORBIDITY MORTALITY, V36, P593	87	261	262	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					581	589		10.1038/352581a0	http://dx.doi.org/10.1038/352581a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865922				2022-12-24	WOS:A1991GB21100044
J	WIRAK, DO; BAYNEY, R; RAMABHADRAN, TV; FRACASSO, RP; HART, JT; HAUER, PE; HSIAU, P; PEKAR, SK; SCANGOS, GA; TRAPP, BD; UNTERBECK, AJ				WIRAK, DO; BAYNEY, R; RAMABHADRAN, TV; FRACASSO, RP; HART, JT; HAUER, PE; HSIAU, P; PEKAR, SK; SCANGOS, GA; TRAPP, BD; UNTERBECK, AJ			DEPOSITS OF AMYLOID-BETA PROTEIN IN THE CENTRAL-NERVOUS-SYSTEM OF TRANSGENIC MICE	SCIENCE			English	Article							ALTERNATIVELY SPLICED FORM; PRECURSOR MESSENGER-RNAS; CELL-SURFACE RECEPTOR; ALZHEIMERS-DISEASE; SENILE PLAQUES; GENE; EXPRESSION; BRAIN; LOCALIZATION; QUANTITATION	Alzheimer's disease is characterized by widespread deposition of amyloid in the central nervous system. The 4-kilodalton amyloid beta-protein is derived from a larger amyloid precursor protein and forms amyloid deposits in the brain by an unknown pathological mechanism. Except for aged nonhuman primates, there is no animal model for Alzheimer's disease. Transgenic mice expressing amyloid beta-protein in the brain could provide such a model. To investigate this possibility, the 4-kilodalton human amyloid beta-protein was expressed under the control of the promoter of the human amyloid precursor protein in two lines of transgenic mice. Amyloid beta-protein accumulated in the dendrites of some but not all hippocampal neurons in 1-year-old transgenic mice. Aggregates of the amyloid beta-protein formed amyloid-like fibrils that are similar in appearance to those in the brains of patients with Alzheimer's disease.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University	WIRAK, DO (corresponding author), MOLEC THERAPEUT INC,MILES RES CTR,400 MORGAN LANE,W HAVEN,CT 06516, USA.							BROECKHOVEN CV, 1990, SCIENCE, V248, P1120; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CORK LC, 1990, AM J PATHOL, V137, P1383; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; LEVEY E, 1990, SCIENCE, V248, P1124; MANN DMA, 1988, NEW ENGL J MED, V318, P789; MARTIN LJ, 1991, P NATL ACAD SCI USA, V88, P1461, DOI 10.1073/pnas.88.4.1461; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; RICHARDS SJ, 1990, EMBO J, V10, P297; ROBAKIS NK, 1987, LANCET, V1, P384; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SISODIA S, 1987, NUCLEIC ACIDS RES, V15, P1999; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TRAPP BD, UNPUB; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WIRAK D, UPUB; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	36	118	151	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					323	325		10.1126/science.1857970	http://dx.doi.org/10.1126/science.1857970			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857970				2022-12-24	WOS:A1991FX22400043
J	BHATTI, N; GILSON, RJC; BEECHAM, M; WILLIAMS, P; MATTHEWS, MP; TEDDER, RS; WELLER, IVD				BHATTI, N; GILSON, RJC; BEECHAM, M; WILLIAMS, P; MATTHEWS, MP; TEDDER, RS; WELLER, IVD			FAILURE TO DELIVER HEPATITIS-B VACCINE - CONFESSIONS FROM A GENITOURINARY MEDICINE CLINIC	BRITISH MEDICAL JOURNAL			English	Article							HOMOSEXUAL MEN; VIRAL-HEPATITIS; VIRUS-INFECTION; EFFICACY; DISEASE; TRIAL; POPULATION; PREVALENCE; ANTIBODIES; CARRIERS	Objective-To audit hepatitis B immunisation of homosexual or bisexual men in a genitourinary medicine clinic. Design-Retrospective case note review of all homosexual and bisexual men presenting to a genitourinary clinic as new patients during 12 months in 1988 and follow up review of notes to May 1990. Setting-One department of genitourinary medicine, Middlesex Hospital. Patients-758 homosexual or bisexual men, of whom 207 started a course of hepatitis B vaccine in 1988. Case notes were unavailable for one patient. Main outcome measures-The proportion of patients screened for hepatitis B virus markers, the proportion of susceptible patients immunised, the proportion completing the vaccine course, and the proportion rendered immune. Results-25 men had been previously tested for hepatitis markers; of the 732 not previously tested, 440 (60.1%) were screened for hepatitis B markers. 207 (69%) of the 300 patients without hepatitis B serological markers started the vaccine course, and 141 (68%) completed it, with 75 (84%) of the 89 tested after immunisation being immune. An estimated 24% of susceptible new patients were rendered immune as a result of the immunisation policy. Patients who presented with a further episode of a sexually transmitted disease were more likely to have been screened (25% v 12%, p < 0.0001) and immunised (31% v 18% p = 0.02); those known or found to be positive for HIV antibody were more likely to have been screened (23% v 14%, p = 0.047) but less likely to have been immunised (6% v 17%, p = 0.004). Conclusions-The major failure was that in not screening; failure to immunise patients found to be susceptible and failure of compliance with the vaccine course contributed. Non-response to the vaccine was of minor importance. Improvements in vaccine delivery are required. Implications-Other providers should be encouraged to review their performance.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT MED MICROBIOL,DIV VIROL,LONDON WC1E 6BT,ENGLAND; MIDDLESEX HOSP,DEPT GENITOURINARY MED,LONDON W1N 8AA,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London			Gilson, Richard J C/C-5123-2009	Tedder, Richard/0000-0002-9672-5721				ADLER MW, 1983, BRIT MED J, V266, P1621; ANDRE FE, 1987, POSTGRAD MED J, V63, P169; BODSWORTH N, 1989, J INFECT DIS, V160, P577, DOI 10.1093/infdis/160.4.577; CARNE CA, 1987, BRIT MED J, V294, P866, DOI 10.1136/bmj.294.6576.866; CHRISTOPHER PJ, 1984, AUST NZ J MED, V14, P491, DOI 10.1111/j.1445-5994.1984.tb03624.x; COLEMAN JC, 1979, J INFECTION, V1, P61, DOI 10.1016/S0163-4453(79)80055-9; COLLIER AC, 1988, ANN INTERN MED, V109, P101, DOI 10.7326/0003-4819-109-2-101; COUTINHO RA, 1983, BRIT MED J, V286, P1305, DOI 10.1136/bmj.286.6374.1305; ELLIS WR, 1979, LANCET, V1, P903; FEFFRIES DJ, 1973, BMJ, V2, P455; FRANCIS DP, 1982, ANN INTERN MED, V97, P362, DOI 10.7326/0003-4819-97-3-362; FULFORD KWM, 1973, LANCET, V1, P1470; GILSON RJC, 1990, HEPATITIS B SEXUALLY, V919, P45; HENTZER B, 1980, SCAND J INFECT DIS, V12, P245, DOI 10.3109/inf.1980.12.issue-4.02; KANE MA, 1989, AM J MED, V87; KROGSGAARD K, 1987, HEPATOLOGY, V7, P37, DOI 10.1002/hep.1840070109; LOKE RHT, 1989, BRIT MED J, V298, P234, DOI 10.1136/bmj.298.6668.234; LOVEDAY C, 1989, BRIT MED J, V298, P419, DOI 10.1136/bmj.298.6671.419; MCCUSKER J, 1990, PUBLIC HEALTH REP, V105, P59; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; POLAKOFF S, 1990, J INFECTION, V20, P163, DOI 10.1016/0163-4453(90)93522-T; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; Taylor PE, 1988, VIRAL HEPATITIS LIVE, P198; TEDDER RS, 1980, J MED VIROL, V6, P323, DOI 10.1002/jmv.1890060407; WELLER IVD, 1986, J HEPATOL, V3, pS9, DOI 10.1016/S0168-8278(86)80095-2; 1985, MMWR, V34, P313; 1988, MMWR, V37, P429; 1987, MMWR, V36, P353; 1989, MMWR, V38, P37; 1988, IMMUNISATION INFECTI, P75	31	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					97	101		10.1136/bmj.303.6794.97	http://dx.doi.org/10.1136/bmj.303.6794.97			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1830505	Green Published, Bronze			2022-12-24	WOS:A1991FW58600024
J	NICHOLAS, AS; DEBIAS, DA; GREENE, CH				NICHOLAS, AS; DEBIAS, DA; GREENE, CH			SOMATIC COMPONENT TO MYOCARDIAL-INFARCTION - 3 YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY DISEASE; DYSFUNCTION		PHILADELPHIA COLL OSTEOPATH MED,PHYSIOL & PHARMACOL,PHILADELPHIA,PA 19131; PHILADELPHIA COLL OSTEOPATH MED,OSTEOPATH PRINCIPLES & PRACTICE,PHILADELPHIA,PA 19131; PHILADELPHIA COLL OSTEOPATH MED,PHYSIOL,PHILADELPHIA,PA 19131									BEAL MC, 1985, J AM OSTEOPATH ASSOC, V85, P302; BEAL MC, 1983, J AM OSTEOPATH ASSOC, V82, P822; COX JM, 1983, J AM OSTEOPATH ASSOC, V82, P832; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; NICHOLAS AS, 1985, BRIT MED J, V291, P13, DOI 10.1136/bmj.291.6487.13	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1581	1581		10.1136/bmj.302.6792.1581	http://dx.doi.org/10.1136/bmj.302.6792.1581			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855044	Bronze, Green Published			2022-12-24	WOS:A1991FU54900028
J	GOODWIN, FK				GOODWIN, FK			CLOZAPINE RESPONSE THRESHOLD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																		PERRY PJ, 1991, AM J PSYCHIATRY  FEB	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2657	2657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FL989	1850809				2022-12-24	WOS:A1991FL98900008
J	BRUNET, JF; SHAPIRO, E; FOSTER, SA; KANDEL, ER; IINO, Y				BRUNET, JF; SHAPIRO, E; FOSTER, SA; KANDEL, ER; IINO, Y			IDENTIFICATION OF A PEPTIDE SPECIFIC FOR APLYSIA SENSORY NEURONS BY PCR-BASED DIFFERENTIAL SCREENING	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; MECHANOAFFERENT NEURONS; SYNAPTIC CONNECTIONS; RESPONSE PROPERTIES; INNERVATING TAIL; FACILITATION; DISHABITUATION; SENSITIZATION; AMPLIFICATION; HABITUATION	In order to identify genes specific for the sensory neurons of Aplysia, a miniaturized differential screening method based on the polymerase chain reaction and applicable to small amounts of tissue was used. One messenger RNA was isolated that is expressed in every mechanoreceptor sensory cluster of the Aplysia central nervous system. This messenger RNA encodes a peptide that seems to function as an inhibitory cotransmitter. The peptide selectively inhibits certain postsynaptic cells but not others and thereby allows the sensory neurons to achieve target-specific synaptic actions.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	BRUNET, JF (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,722 W 168 ST,NEW YORK,NY 10032, USA.			Brunet, Jean-Francois/0000-0002-1985-6103				BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BEUSHAUSEN S, 1988, NEURON, V1, P853, DOI 10.1016/0896-6273(88)90133-X; BYRNE J, 1974, J NEUROPHYSIOL, V37, P1041, DOI 10.1152/jn.1974.37.5.1041; BYRNE JH, 1980, J NEUROPHYSIOL, V43, P896, DOI 10.1152/jn.1980.43.4.896; CASTELLUCCI V, 1970, SCIENCE, V167, P1745, DOI 10.1126/science.167.3926.1745; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; CROPPER EC, 1987, P NATL ACAD SCI USA, V84, P5483, DOI 10.1073/pnas.84.15.5483; CROPPER EC, 1990, P NATL ACAD SCI USA, V87, P933, DOI 10.1073/pnas.87.3.933; DUBUC B, 1991, J EXP BIOL, V156, P315; ESKIN A, 1989, P NATL ACAD SCI USA, V86, P2458, DOI 10.1073/pnas.86.7.2458; FIORE L, 1980, NEUROBIOLOGY INVERTE, P20; FREMEAU RT, 1986, SCIENCE, V234, P1265, DOI 10.1126/science.3775385; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HOKFELT T, 1987, EXPERIENTIA, V43, P768; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; HOKFELT T, 1983, SCIENCE, V221, P286; KISTLER HB, 1985, J NEUROSCI, V5, P72; Maniatis T., 1982, MOL CLONING; PINSKER H, 1970, SCIENCE, V167, P1740, DOI 10.1126/science.167.3926.1740; RAYPORT SG, 1983, J NEUROPHYSIOL, V49, P864, DOI 10.1152/jn.1983.49.4.864; ROSEN SC, 1979, J NEUROPHYSIOL, V42, P954, DOI 10.1152/jn.1979.42.4.954; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STOLTZ KP, 1987, SCIENCE, V235, P685; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543	27	82	86	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					856	859		10.1126/science.1840700	http://dx.doi.org/10.1126/science.1840700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1840700				2022-12-24	WOS:A1991FL12300051
J	BROWN, ZA; BENEDETTI, J; ASHLEY, R; BURCHETT, S; SELKE, S; BERRY, S; VONTVER, LA; COREY, L				BROWN, ZA; BENEDETTI, J; ASHLEY, R; BURCHETT, S; SELKE, S; BERRY, S; VONTVER, LA; COREY, L			NEONATAL HERPES-SIMPLEX VIRUS-INFECTION IN RELATION TO ASYMPTOMATIC MATERNAL INFECTION AT THE TIME OF LABOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLYCOPROTEIN-G; WESTERN BLOT; DELIVERY; TYPE-2; ANTIBODIES; CULTURES; RISK; HISTORY; MOTHERS; INFANTS	Background and Methods. To define the risk factors associated with neonatal acquisition of herpes simplex virus (HSV) infection, we prospectively obtained HSV cultures from the cervis and external genitalia of 15,923 pregnant women in early labor who were without symptoms or signs of genital HSV infection. Follow-up of the women with positive cultures for HSV and their HSV-exposed infants included serologic tests and serial cultures for HSV. Results. HSV was isolated from 56 of the women (0.35 percent), 18 of whom (35 percent) had serologic evidence of a recently acquired, subclinical first episode of genital HSV infection, and 34 of whom (65 percent) had reactivation of HSV. Neonatal HSV developed in 6 of 18 infants (33 percent) born to the women with a first episode of genital HSV, and in 1 of 34 infants (3 percent) born to the women with reactivation of HSV (P < 0.01); neonatal HSV also occurred in three of the infants born to the 15,867 women with negative cultures. Neonatal HSV-2 occurred in 1 of 4 infants born to mothers seronegative at delivery for both HSV-1 and HSV-2, in 4 of 12 infants exposed to HSV-2 whose mothers had only HSV-1 antibodies at delivery, and in none of the infants born to 31 women who were HSV-2-seropositive. An increased risk of neonatal HSV was associated with exposure to viral shredding from the cervix and the use of fetal-scalp electrodes. Conclusions. Of the asymptomatic women who shed HSV in early labor, about a third have recently acquired genital HSV, and their infants are 10 times more likely to have neonatal HSV than those of women with asymptomatic reactivation of HSV. The presence of maternal antibodies specific to HSV-2 but not HSV-1 appears to reduce the neonatal transmission of HSV-2. Further studies are necessary to determine whether screening and prophylactic treatment are warranted for infants of HSV-2-seronegative mothers who shed HSV-1 or HSV-2 in early labor.	CHILDRENS HOSP MED CTR, SEATTLE, WA USA; UNIV WASHINGTON, DEPT LAB MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	BROWN, ZA (corresponding author), UNIV WASHINGTON, DEPT OBSTET & GYNECOL, RH-20, SEATTLE, WA 98195 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20381] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARVIN AM, 1986, NEW ENGL J MED, V315, P796, DOI 10.1056/NEJM198609253151303; ASHLEY R, 1985, J MED VIROL, V17, P153, DOI 10.1002/jmv.1890170208; ASHLEY RL, 1989, CLIN LAB MED, V9, P405, DOI 10.1016/S0272-2712(18)30611-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1987, J VIROL METHODS, V18, P159, DOI 10.1016/0166-0934(87)90121-2; BERNSTEIN DI, 1984, AM J MED, V77, P1055, DOI 10.1016/0002-9343(84)90188-8; BOUCHER FD, 1990, PEDIATR INFECT DIS J, V9, P499, DOI 10.1097/00006454-199007000-00009; BROWN ZA, 1987, PEDIATR INFECT DIS J, V6, P1057; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; FORSGREN M, 1990, SCAND J INFECT DIS, P37; GUTMAN LT, 1986, J INFECT DIS, V154, P415, DOI 10.1093/infdis/154.3.415; HANKINS GDV, 1984, AM J OBSTET GYNECOL, V150, P100, DOI 10.1016/S0002-9378(84)80119-2; KEYSERLING HH, 1983, INFECT DIS, P636; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; NAHMIAS AJ, 1971, AM J OBSTET GYNECOL, V110, P825, DOI 10.1016/0002-9378(71)90580-1; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; SIMKOVICH JW, 1988, AM J OBSTET GYNECOL, V158, P588, DOI 10.1016/0002-9378(88)90034-8; STAGNO S, 1985, NEW ENGL J MED, V313, P1327, DOI 10.1056/NEJM198511213132105; SULLENDER WM, 1988, J INFECT DIS, V157, P164, DOI 10.1093/infdis/157.1.164; SULLIVANBOLYAI J, 1983, JAMA-J AM MED ASSOC, V250, P3059, DOI 10.1001/jama.250.22.3059; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; YEAGER AS, 1984, PEDIATRICS, V73, P188; [No title captured]	27	316	323	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1991	324	18					1247	1252		10.1056/NEJM199105023241804	http://dx.doi.org/10.1056/NEJM199105023241804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FJ823	1849612				2022-12-24	WOS:A1991FJ82300004
J	DYSON, PJ; KNIGHT, AM; FAIRCHILD, S; SIMPSON, E; TOMONARI, K				DYSON, PJ; KNIGHT, AM; FAIRCHILD, S; SIMPSON, E; TOMONARI, K			GENES ENCODING LIGANDS FOR DELETION OF V-BETA-11 T-CELLS COSEGREGATE WITH MAMMARY-TUMOR VIRUS GENOMES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLONAL DELETION; ENTEROTOXIN-B; TOLERANCE; PRODUCTS; REACTIVITY; ANTIGENS; MARKERS; MLS	THE T-cell receptor (TCR) repertoire is selected in the thymus after rearrangement of genes encoding TCR alpha and beta chains 1. Selection is based on the recognition by newly emergent T cells of self-ligands associated with molecules of the major histocompatibility complex: some combinations result in positive selection, others in negative selection. Negative selection, or clonal deletion, is an important mechanism for eliminating autoreactive T cells. A group of self-ligands involved in clonal deletion was identified because they, like exogenous superantigens 2, were recognized by almost all T cells expressing particular TCR V-beta genes. V-beta-17a T cells are deleted by a tissue-specific ligand 3,4; V-beta-6, V-beta-7, V-beta-8.1 and V-beta-9 T cells are deleted by the minor lymphocyte-stimulating (Mls) determinant Mls-1a (refs 5-8); V-beta-3 T cells by Mls-2a and Mls-3a (refs 9,10); V-beta-11 T cells 11 by ligands encoded by independently segregating genes; and V-beta-5 T cells by ligands encoded by two genes 12. Chromosomes mapping using recombinant inbred strains of mice and classic backcrosses show that Mls-1a in DBA/2 mice is encoded on chromosome 1, that one of the two ligand genes for deletion of V-beta-5 T cells maps to chromosome 12 (ref. 12) and that a ligand gene for V-beta-11 deletion is linked to the CD8 locus on chromosome 6 (ref. 11). Here we present evidence from three sets of backcross mice for concordance between V-beta-11 deletion ligand genes on chromosomes 6, 12 and 14 and endogenous mouse mammary tumour virus integrant (Mtv) genomes. Our results indicate that the V-beta-11 deletion ligands are products of Mtv genomes.			DYSON, PJ (corresponding author), CLIN RES CTR,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.			Simpson, Elizabeth/0000-0002-2118-3139				ABE R, 1989, J EXP MED, V170, P1059, DOI 10.1084/jem.170.4.1059; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; DAVISSON MT, 1989, GENETIC VARIANTS STR, P416; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GEBHARD W, 1983, J MOL BIOL, V170, P567, DOI 10.1016/S0022-2836(83)80161-2; GIBSON DM, 1983, IMMUNOGENETICS, V18, P111, DOI 10.1007/BF00368538; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KING LB, 1990, J IMMUNOL, V144, P3218; KNIGHT AM, 1990, MOL CELL PROBE, V4, P497, DOI 10.1016/0890-8508(90)90008-N; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; Maniatis T., 1982, MOL CLONING; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; OKADA CY, 1990, J IMMUNOL, V144, P3473; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; TOMONARI K, 1990, IMMUNOL REV, V116, P139, DOI 10.1111/j.1600-065X.1990.tb00808.x; TOMONARI K, 1988, IMMUNOGENETICS, V28, P445, DOI 10.1007/BF00355377; TOMONARI K, 1990, IMMUNOGENETICS, V32, P60, DOI 10.1007/BF01787331; TOMONARI K, IN PRESS IMMUNOGENET; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YANG JN, 1987, IMMUNOGENETICS, V25, P222, DOI 10.1007/BF00404691	32	329	329	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					531	532		10.1038/349531a0	http://dx.doi.org/10.1038/349531a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846950				2022-12-24	WOS:A1991EW57100069
J	MANIATIS, T				MANIATIS, T			MECHANISMS OF ALTERNATIVE PRE-MESSENGER-RNA SPLICING	SCIENCE			English	Editorial Material							BINDING PROTEINS; GENE; SEX; INTRON; LEVEL				MANIATIS, T (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; Bindereif A, 1990, Genet Eng (N Y), V12, P201; BINGHAM P, COMMUNICATION; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; DABEVA MD, 1986, P NATL ACAD SCI USA, V83, P5854, DOI 10.1073/pnas.83.16.5854; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KRAINER A, COMMUNICATION; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAINER AR, 1988, FRONTIERS MOL BIOL T, P131; LASKI FA, 1989, GENE DEV, V3, P720, DOI 10.1101/gad.3.5.720; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; McKeown M, 1990, Genet Eng (N Y), V12, P139; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROBERTSON HM, 1989, GENETICS, V123, P815; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752	35	221	222	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					33	34		10.1126/science.1824726	http://dx.doi.org/10.1126/science.1824726			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824726				2022-12-24	WOS:A1991EQ60300022
J	STEIN, PE; BOODHOO, A; TYRRELL, GJ; BRUNTON, JL; READ, RJ				STEIN, PE; BOODHOO, A; TYRRELL, GJ; BRUNTON, JL; READ, RJ			CRYSTAL-STRUCTURE OF THE CELL-BINDING B-OLIGOMER OF VEROTOXIN-1 FROM ESCHERICHIA-COLI	NATURE			English	Article							SHIGA TOXIN; PROTEIN; IDENTIFICATION; FEATURES	THE Shiga toxin family, a group of cytotoxins associated with diarrhoeal diseases and the haemolytic uraemic syndrome, includes Shiga toxin from Shigella dysenteriae type I and verotoxins 1 produced by enteropathogenic Escherichia coli. The family belongs to the A-B class of bacterial toxins, which includes the cholera toxin family, pertussis and diphtheria toxins. These toxins all have bipartite structures consisting of an enzymatic A subunit associated with a B oligomer which binds to specific cell-surface receptors, but their amino-acid sequences and pathogenic mechanisms differ. We have determined the crystal structure of the B oligomer of verotoxin-1 from E. coli. The structure unexpectedly resembles that of the B oligomer of the cholera toxin-like heat-labile enterotoxin from E. coli 2, despite the absence of detectable sequence similarity between these two proteins. This result implies a distant evolutionary relationship between the Shiga toxin and cholera toxin families. We suggest that the cell surface receptor-binding site lies in a cleft between adjacent subunits of the B pentamer, providing a potential target for drugs and vaccines to prevent toxin binding and effect.	UNIV ALBERTA, DEPT MED MICROBIOL & INFECT DIS, EDMONTON T6G 2H7, ALBERTA, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MICROBIOL, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, DEPT MED, TORONTO M5S 1A1, ONTARIO, CANADA	University of Alberta; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Read, Randy J/L-1418-2013; Tyrrell, Gregory/ABA-7203-2021	Read, Randy J/0000-0001-8273-0047; 				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOODHOO A, 1991, J MOL BIOL, V221, P729, DOI 10.1016/0022-2836(91)80166-R; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNTON JL, 1990, BACTERIA, V11, P377; DEGRANDIS S, 1989, J BIOL CHEM, V264, P12520; HART PJ, 1991, J MOL BIOL, V218, P691, DOI 10.1016/0022-2836(91)90256-6; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; JACKSON MP, 1990, J BACTERIOL, V172, P653, DOI 10.1128/jb.172.2.653-658.1990; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; OTWINOWSKI Z, 1990, 1990 AM CRYST ASS AN; PERERA LP, 1991, J BACTERIOL, V173, P1151, DOI 10.1128/jb.173.3.1151-1160.1991; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; RAMOTAR K, 1990, BIOCHEM J, V273, P805; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; TYRRELL GJ, IN PRESS P NATN ACAD; WADDELL T, 1988, BIOCHEM BIOPH RES CO, V152, P674, DOI 10.1016/S0006-291X(88)80091-3	24	265	282	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1992	355	6362					748	750		10.1038/355748a0	http://dx.doi.org/10.1038/355748a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741063				2022-12-24	WOS:A1992HE60400072
J	QUINN, TC; KLINE, RL; HALSEY, N; HUTTON, N; RUFF, A; BUTZ, A; BOULOS, R; MODLIN, JF				QUINN, TC; KLINE, RL; HALSEY, N; HUTTON, N; RUFF, A; BUTZ, A; BOULOS, R; MODLIN, JF			EARLY DIAGNOSIS OF PERINATAL HIV-INFECTION BY DETECTION OF VIRAL-SPECIFIC IGA ANTIBODIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INFANTS BORN; CHILDREN; WOMEN; MOTHERS; AIDS; TRANSMISSION; TYPE-1; BLOOD	Objectives. - To evaluate the clinical utility of a human immunodeficiency virus (HIV)-IgA serological assay for diagnosis of perinatally acquired HIV infection. Design. - Coded serum samples prospectively collected from children born to HIV-infected mothers and uninfected mothers were analyzed by HIV-IgA immunoblot. Setting. - A university hospital in Baltimore, Md, and an outpatient clinic in Port-au-Prince, Haiti. Population. - Five hundred thirty-nine serum samples were obtained sequentially from 278 children born to HIV-infected women (116 from The Johns Hopkins Hospital and 62 from Port-au-Prince) and from 42 control children born to HIV-seronegative children in Port-au-Prince. Outcome Measures. - Results from the HIV-IgA serological assays were compared with the known infection status of the child at 15 months of age as determined by the standard IgG Western blot and the clinical classification of the Centers for Disease Control. Sensitivity, specificity, and predictive values were calculated at different ages and collectively for children 3 months of age or older. Results. - The HIV-IgA assay was positive in one of six specimens from HIV-infected children under 1 month of age, six of nine specimens from infected children at 3 months of age, and 160 of 161 specimens from 47 HIV-infected children 6 months of age or older. Of 334 specimens from 243 uninfected children, 333 were negative by the HIV-IgA assay. The overall sensitivity and the specificity of the IgA assay for children older than 3 months of age were 97.6% and 99.7%, and the positive and negative predictive values were 99.4% and 98.7%, respectively. Conclusion. - Although the HIV-IgA assay had a low sensitivity within the first months of life, the high sensitivity, specificity, and predictive values of this assay demonstrate its utility for the diagnosis of perinatally acquired HIV infection after the third month of age. Early diagnosis with this relatively simple and inexpensive serological assay should aid in the implementation of antiviral therapy and provide useful information for the care of children born to HIV-infected mothers in both developing and developed countries.	CTR DEV & HLTH,PORT AU PRINCE,HAITI; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NURSING,BALTIMORE,MD 21205	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	QUINN, TC (corresponding author), JOHNS HOPKINS UNIV HOSP,BLALOCK 1111,600 N WOLFE ST,BALTIMORE,MD 21205, USA.				PHS HHS [1R01A126521] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMADORI A, 1988, LANCET, V1, P852; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; HUSSON RN, 1990, PEDIATRICS, V86, P1; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; NEWELL M-L, 1990, AIDS (London), V4, pS111; PAHWA S, 1989, P NATL ACAD SCI USA, V86, P7532, DOI 10.1073/pnas.86.19.7532; PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401; QUINN TC, 1990, AIDS, V4, P709, DOI 10.1097/00002030-199008000-00001; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WEIBLEN BJ, 1990, J IMMUNOL METHODS, V126, P199, DOI 10.1016/0022-1759(90)90151-K; 1990, MMWR, V39, P850; 1989, MMWR, V38, pS1; 1991, MMWR, V40, P195; 1990, MMWR, V39, P845; 1991, HIV AIDS SURVEILLANC, P9; 1991, LANCET, V338, P253; 1990, MMWR, V39, P1	27	81	82	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3439	3442		10.1001/jama.266.24.3439	http://dx.doi.org/10.1001/jama.266.24.3439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744957				2022-12-24	WOS:A1991GV87800028
J	COUPLAND, RM; KORVER, A				COUPLAND, RM; KORVER, A			INJURIES FROM ANTIPERSONNEL MINES - THE EXPERIENCE OF THE INTERNATIONAL-COMMITTEE OF THE RED-CROSS	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe and quantify patterns of injury from antipersonnel mines in terms of distribution of injury, drain on surgical resources, and residual disability. Design - Retrospective analysis. Setting - Two hospitals for patients injured in war. Subjects - 757 patients with injuries from antipersonnel mines. Main outcome measures - Distribution and number of injuries; number of blood transfusions; number of operations; disability. Results - Pattern 1 injury results from standing on a buried mine. These patients usually sustain traumatic amputation of the foot or leg; they use most surgical time and blood and invariably require surgical amputation of one or both lower limbs. Pattern 2 injury is a more random collection of penetrating injuries caused by multiple fragments from a mine triggered near the victim. The lower limb is injured but there is less chance of traumatic amputation or subsequent surgical amputation. Injuries to the head, neck, chest, or abdomen are common. Pattern 3 injury results from handling a mine: the victim sustains severe upper limb injuries with associated face injuries. Eye injuries are common in all groups. Conclusions - Patients who survive standing on a buried mine have greatest disability. Non-combatants are at risk from these weapons; in developing countries their social and economic prospects after recovery from amputation are poor.			COUPLAND, RM (corresponding author), RED CROSS, INT COMM, DIV MED, CH-1202 GENEVA, SWITZERLAND.							ADAMS DB, 1988, J TRAUMA, V28, pS159, DOI 10.1097/00005373-198801001-00032; CHENG XM, 1990, J TRAUMA S, V6, P169; COUPLAND RM, 1989, ANN ROY COLL SURG, V71, P404; Jones E L, 1968, Arch Surg, V97, P1; TRAVERSO LW, 1981, MIL MED, V146, P682	5	112	115	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	1991	303	6816					1509	1512		10.1136/bmj.303.6816.1509	http://dx.doi.org/10.1136/bmj.303.6816.1509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1838290	Green Published, Bronze			2022-12-24	WOS:A1991GV47600021
J	DOROZYNSKI, A				DOROZYNSKI, A			CRIMINAL CHARGES OVER HIV IN FRENCH BLOOD-TRANSFUSIONS	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1091	1091						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GN209	1747576				2022-12-24	WOS:A1991GN20900016
J	MCNINCH, AW; TRIPP, JH				MCNINCH, AW; TRIPP, JH			HEMORRHAGIC-DISEASE OF THE NEWBORN IN THE BRITISH-ISLES - 2 YEAR PROSPECTIVE-STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the incidence of haemorrhagic disease of the newborn in the British Isles, study risk factors, and examine the effect of vitamin K prophylaxis. Design - Prospective survey of all possible cases of haemoffhagic disease of the newborn as reported by consultant paediatricians using the monthly notification cards of the British Paediatric Surveillance Unit and a follow up questionnaire for each case to validate the diagnosis and accrue further data. Setting - Britain (England, Scotland, and Wales) and Ireland (Northern Ireland and the Irish Republic) during December 1987 to March 1990. Patients - 27 infants classified as having confirmed (n = 25) or probable (n = 2) haemoffhagic disease of the newborn. Results - 24 of the 27 infants were solely breast fed. 10 suffered intracranial haemorrhage; two of these died and there was clinical concern about the remainder. 20 infants had received no vitamin K prophylaxis, and seven had received oral prophylaxis. Relative risk ratios for these groups compared with babies who had received intramuscular vitamin K were 81:1 and 13:1 respectively. Six infants had hepatitis (alpha-1 antitrypsin deficiency in four), unsuspected until presentation with haemorrhagic disease of the newborn, of whom four had received oral prophylaxis. One other baby had prolonged jaundice. One mother had taken phenytoin during pregnancy. Conclusions - All newborn infants should receive vitamin K prophylaxis. Intramuscular vitamin K is more effective than oral prophylactic regimens currently used in the British Isles.	POSTGRAD MED SCH,DEPT CHILD HLTH,EXETER EX2 5SQ,ENGLAND	University of Exeter	MCNINCH, AW (corresponding author), ROYAL DEVON & EXETER HOSP,EXETER EX2 5DW,DEVON,ENGLAND.							DAM H, 1952, ADV PEDIATR, V5, P129; EKELUND H, 1991, ACTA PAEDIATR SCAND, V80, P966, DOI 10.1111/j.1651-2227.1991.tb11763.x; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; Hall S M, 1988, Arch Dis Child, V63, P344; HANAWA Y, 1990, Acta Paediatrica Japonica, V32, P51; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; MARTIN J, 1988, INFANT FEEDING 1985; MOUNTAIN KR, 1970, LANCET, V1, P265; SUTHERLAND JM, 1967, AM J DIS CHILD, V113, P524, DOI 10.1001/archpedi.1967.02090200056003; TONZ O, 1988, SCHWEIZ MED WSCHR, V118, P1747; TRIPP JH, 1987, ARCH DIS CHILD, V62, P426; VONKRIES R, 1988, EUR J PEDIATR, V147, P106; 1988, BPSU3RD BRIT PAED SU	13	132	135	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1105	1109		10.1136/bmj.303.6810.1105	http://dx.doi.org/10.1136/bmj.303.6810.1105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747578	Green Published, Bronze			2022-12-24	WOS:A1991GN20900022
J	CLEAVELAND, CR				CLEAVELAND, CR			CPR	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS; RESUSCITATION; MORTALITY; BURNOUT, PROFESSIONAL; STRESS, PSYCHOLOGICAL		A doctor, after a discouraging week at work, seeks respite in the new film version of Hamlet. However, real tragedy intervenes. In an adjoining theater, an old man collapses, the victim of an apparent cardiac arrest. The doctor responds to the appeal for medical help and does all he can to save the man. The intensity and cathartic nature of this experience lead to revelations and insights of interest to all doctors.											0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					570	571		10.7326/0003-4819-115-7-570	http://dx.doi.org/10.7326/0003-4819-115-7-570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1810284				2022-12-24	WOS:A1991GG28300011
J	TRINH, TQ; SINDEN, RR				TRINH, TQ; SINDEN, RR			PREFERENTIAL DNA SECONDARY STRUCTURE MUTAGENESIS IN THE LAGGING STRAND OF REPLICATION IN ESCHERICHIA-COLI	NATURE			English	Article							ESCHERICHIA-COLI; MUTATION; SEQUENCES; JUNCTION; REPAIR; GENE	WHEN present in single-stranded DNA, palindromic or quasipalindromic sequences have the potential to form complex secondary structures, including hairpins, which may facilitate interstrand misalignment of direct repeats and be responsible for diverse types of replication-based mutations, including deletions, additions, frameshifts and duplications 1-5. In regions of palindromic symmetry, specific deletion events may involve the formation of a hairpin or other DNA secondary structures which can stabilize the misalignment of direct repeats 1,2. One model suggests that these deletions occur during DNA replication by slippage of the template strand and misalignment with the progeny strand 6,7. The concurrent DNA replication model, involving an asymmetric dimeric DNA polymerase III complex which replicates the leading and lagging strands 8, has significant implications for mutagenesis. The intermittent looping of the lagging strand template, and the fact that the lagging strand template may contain a region of single-stranded DNA the length of an Okazaki fragment, provides an opportunity for DNA secondary-structure formation and misalignment. Here we report our design of a palindromic fragment to create an 'asymmetric palindromic insert' in the chloramphenicol acetyltransferase gene of plasmid pBR325. The frequency with which the insert was deleted in Escherichia coli depends on the orientation of the gene in the plasmid. Our results suggest that replication-dependent deletion between direct repeats may occur preferentially in the lagging strand.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,231 BETHESDA AVE,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati			Sinden, Richard/AAE-3086-2019					ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; DRAKE JW, 1983, AM SCI, V71, P621; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1990, EMBO J, V9, P1659, DOI 10.1002/j.1460-2075.1990.tb08286.x; GLICKMAN BW, 1984, P NATL ACAD SCI USA, V81, P4046; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; RIPLEY LS, 1982, P NATL ACAD SCI-BIOL, V79, P4128, DOI 10.1073/pnas.79.13.4128; RIPLEY LS, 1983, UCLA S MOL CELLULAR, V10, P521; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCOTT JR, 1984, MICROBIOL REV, V48, P1; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3	17	210	214	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					544	547		10.1038/352544a0	http://dx.doi.org/10.1038/352544a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865910				2022-12-24	WOS:A1991GA22600068
J	SHAPER, AG; PHILLIPS, AN; POCOCK, SJ; WALKER, M; MACFARLANE, PW				SHAPER, AG; PHILLIPS, AN; POCOCK, SJ; WALKER, M; MACFARLANE, PW			RISK-FACTORS FOR STROKE IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							DIASTOLIC BLOOD-PRESSURE; CIGARETTE-SMOKING; VENTRICULAR HYPERTROPHY; MORTALITY; ALCOHOL; HYPERTENSION	Objective - To determine the risk factors for stroke in a cohort representative of middle aged British men. Design - Prospective study of a cohort of men followed up for eight years. Setting - General practices in 24 towns in England, Wales, and Scotland (the British regional heart study). Subjects - 7735 men aged 40-59 at screening, selected at random from one general practice in each town. Main outcome measure - Fatal and non-fatal strokes. Results - 110 of the men had at least one stroke; there were four times as many non-fatal as fatal strokes. The relative risk of stroke was 12.1 in men who had high blood pressure (systolic blood pressure greater-than-or-equal-to 160 mm Hg) and were current smokers compared with normotensive, non-smoking men. Diastolic blood pressure yielded no additional information, and former cigarette smokers had the same risk as men who had never smoked. Heavy alcohol intake was associated with a relative risk of stroke of 3.8 in men without previously diagnosed cardiovascular disease. Men with pre-existing ischaemic heart disease had an increased risk of stroke, but only when left ventricular hypertrophy on electrocardiography was also present. Conclusions - Systolic blood pressure, cigarette smoking, and left ventricular hypertrophy on electrocardiography in men with pre-existing ischaemic heart disease were found to be the major risk factors for stroke in middle aged British men. Heavy alcohol intake seemed to increase the risk of stroke in men without previously diagnosed cardiovascular disease. A large proportion of strokes should be preventable by controlling blood pressure and stopping smoking.	ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G4 0SS,SCOTLAND	Royal Infirmary of Edinburgh	SHAPER, AG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BLACKWELDER WC, 1980, AM J MED, V68, P165; BONITA R, 1986, BRIT MED J, V293, P6, DOI 10.1136/bmj.293.6538.6; BRUCE NG, 1988, J HYPERTENS, V6, P374; COOK DG, 1989, INT J EPIDEMIOL, V18, P607, DOI 10.1093/ije/18.3.607; DALE S, 1988, STROKE; DAVEYSMITH G, 1990, J EPIDEMIOL COMMUNIT, V44, P257; DONNAN GA, 1989, LANCET, V2, P643; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; ISO H, 1989, NEW ENGL J MED, V324, P4; KANNEL WB, 1983, AM J MED, V75, P4, DOI 10.1016/0002-9343(83)90111-0; MACFARLANE PW, 1981, BRIT HEART J, V45, P402; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MACMAHON SW, 1986, J HYPERTENS, V4, pS14; MENOTTI A, 1989, J HYPERTENS, V7, P595, DOI 10.1097/00004872-198907000-00011; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; RUTAN GH, 1989, J CLIN EPIDEMIOL, V42, P663, DOI 10.1016/0895-4356(89)90010-3; SAUNDERS JB, 1981, LANCET, V2, P653; SHAPER AG, 1988, LANCET, V2, P1267; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STAMLER J, 1989, HYPERTENSION S1, V13, P12; STOKES J, 1987, CIRCULATION, V75, P56; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; VANDENBAN GC, 1989, INT J EPIDEMIOL, V18, P95, DOI 10.1093/ije/18.1.95; WALKER M, 1984, JR COLL GEN PRACT, V34, P364; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P201; 1988, BMJ, V297, P126; 1988, BMJ, V296, P1565	31	169	170	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1991	302	6785					1111	1115		10.1136/bmj.302.6785.1111	http://dx.doi.org/10.1136/bmj.302.6785.1111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL439	1828378	Green Published, Bronze			2022-12-24	WOS:A1991FL43900016
J	GILBERTSON, TA; SCOBEY, R; WILSON, M				GILBERTSON, TA; SCOBEY, R; WILSON, M			PERMEATION OF CALCIUM-IONS THROUGH NON-NMDA GLUTAMATE CHANNELS IN RETINAL BIPOLAR CELLS	SCIENCE			English	Article							MOUSE CENTRAL NEURONS; EXCITATORY AMINO-ACIDS; SPINAL-CORD NEURONS; HIPPOCAMPAL-NEURONS; NEUROMUSCULAR-JUNCTION; ACTIVATED CHANNELS; DIVALENT-CATIONS; PHOTORECEPTORS; QUISQUALATE; RECEPTORS	The conduction of calcium ions through glutamate-gated channels is important in the induction of long-term potentiation and may trigger other cellular changes. In retinal bipolar cells, which lack the N-methyl-D-aspartate (NMDA) type of glutamate-gated channel, calcium permeability through non-NMDA channels was examined. Changes in extracellular calcium concentration unexpectedly affected the reversal potential for glutamate-induced currents in a manner consistent with these channels being highly permeable to calcium. External magnesium ions promote desensitization of these non-NMDA channels in a voltage-independent way. Thus, in addition to non-NMDA channels that conduct only sodium and potassium, there is a class that is also permeable to calcium.	UNIV CALIF DAVIS, DEPT ZOOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT NEUROL, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis			Gilbertson, Timothy/G-7147-2011	Gilbertson, Timothy/0000-0003-2569-3096	NATIONAL EYE INSTITUTE [R01EY004112] Funding Source: NIH RePORTER; NEI NIH HHS [EY 04112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P227; ASCHER P, 1986, J PHYSIOL-LONDON, V377, pP34; ATTWELL D, 1987, J PHYSIOL-LONDON, V387, P125, DOI 10.1113/jphysiol.1987.sp016567; AULT B, 1980, J PHYSIOL-LONDON, V307, P413, DOI 10.1113/jphysiol.1980.sp013443; BATES RG, 1970, ANAL CHEM, V42, P867, DOI 10.1021/ac60290a006; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRANDON C, 1983, P NATL ACAD SCI-BIOL, V80, P5117, DOI 10.1073/pnas.80.16.5117; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; GILBERTSON TA, UNPUB; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; ISHIDA AT, 1985, P NATL ACAD SCI USA, V82, P1837, DOI 10.1073/pnas.82.6.1837; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JAN LY, 1976, J PHYSIOL-LONDON, V262, P215, DOI 10.1113/jphysiol.1976.sp011593; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MARC RE, 1981, P NATL ACAD SCI-BIOL, V78, P7185, DOI 10.1073/pnas.78.11.7185; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1989, NATURE, V338, P425, DOI 10.1038/338425a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MILLER AM, 1983, J PHYSIOL-LONDON, V334, P325, DOI 10.1113/jphysiol.1983.sp014497; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1989, J NEUROPHYSIOL, V61, P162, DOI 10.1152/jn.1989.61.1.162; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1988, P NATL ACAD SCI USA, V85, P4562, DOI 10.1073/pnas.85.12.4562-a	34	202	202	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	1991	251	5001					1613	1615		10.1126/science.1849316	http://dx.doi.org/10.1126/science.1849316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD890	1849316				2022-12-24	WOS:A1991FD89000039
J	ROGGE, RD; KARLOVICH, CA; BANERJEE, U				ROGGE, RD; KARLOVICH, CA; BANERJEE, U			GENETIC DISSECTION OF A NEURODEVELOPMENTAL PATHWAY - SON OF SEVENLESS FUNCTIONS DOWNSTREAM OF THE SEVENLESS AND EGF RECEPTOR TYROSINE KINASES	CELL			English	Article							FAINT-LITTLE-BALL; DROSOPHILA-MELANOGASTER; COMPOUND EYE; CELL LINEAGE; RETINA; PROTEIN; HOMOLOG; MUTATIONS; ENCODES; DOMAIN	We have isolated a dominant mutation in a gene called Son of sevenless (Sos) that is an allele-specific suppressor of the sevenless phenotype. This suppressor function is autonomously required in R7 and is sensitive to the dosage of the Sos and bride of sevenless genes. Loss-of-function alleles of Sos are recessive lethals, but in the eye Sos has a role in R cell development. Mutations in Sos also interact with the Ellipse allele of the Drosophila EGF receptor. We propose a model suggesting that the Sos product is downstream of sevenless and the EGF receptor, and that the dominant suppression results from the overexpression or increased activity of the gene product.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	ROGGE, RD (corresponding author), UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA.			Rogge, Ronald/0000-0002-1875-3938	NEI NIH HHS [1 R01 EY08152-01A1] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008152] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1987, CELL, V49, P281, DOI 10.1016/0092-8674(87)90569-1; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BONNERFRASER M, 1988, NATURE, V335, P161; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BRENNER S, 1965, NATURE, V206, P994, DOI 10.1038/206994a0; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; GRIGLIATTI T, 1986, MUTAGENESIS DROSOPHI, P39; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HARTE A, 1990, IN PRESS GENES DEV; HODGKIN J, 1989, GENETICS, V123, P301; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WOODRUFF RC, 1979, GENETICS, V92, P133	30	191	192	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					39	48		10.1016/0092-8674(91)90207-F	http://dx.doi.org/10.1016/0092-8674(91)90207-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846090				2022-12-24	WOS:A1991ET17500007
J	CRESS, WD; TRIEZENBERG, SJ				CRESS, WD; TRIEZENBERG, SJ			CRITICAL STRUCTURAL ELEMENTS OF THE VP16 TRANSCRIPTIONAL ACTIVATION DOMAIN	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; DNA-BINDING PROTEINS; FUNCTIONAL DISSECTION; MUTATIONAL ANALYSIS; REGULATORY PROTEIN; TRANS-ACTIVATOR; FUSION PROTEINS; MAMMALIAN-CELLS; FACTOR VMW65; ALPHA-GENES	Virion protein 16 (VP16) of herpes simplex virus type 1 contains an acidic transcriptional activation domain. Missense mutations within this domain have provided insights into the structural elements critical for its function. Net negative charge contributed to, but was not sufficient for, transcriptional activation by VP16. A putative amphipathic alpha helix did not appear to be an important structural component of the activation domain. A phenylalanine residue at position 442 was exquisitely sensitive to mutation. Transcriptional activators of several classes contain hydrophobic amino acids arranged in patterns resembling that of VP16. Therefore, the mechanism of transcriptional activation by VP16 and other proteins may involve both ionic and specific hydrophobic interactions with target molecules.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University				Triezenberg, Steven/0000-0003-4184-5221	NIAID NIH HHS [AI 27323] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027323, R21AI027323] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACE CI, 1988, J GEN VIROL, V69, P2595, DOI 10.1099/0022-1317-69-10-2595; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, UNPUB; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GRAVES BJ, 1985, MOL CELL BIOL, V5, P1948, DOI 10.1128/MCB.5.8.1948; GREAVES R, 1989, J VIROL, V63, P1641, DOI 10.1128/JVI.63.4.1641-1650.1989; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1988, CELL, V54, P1043; INGLES CJ, UNPUB; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KRISTIE TM, 1987, P NATL ACAD SCI USA, V84, P71, DOI 10.1073/pnas.84.1.71; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; WERSTUCK G, 1989, GENE, V75, P213, DOI 10.1016/0378-1119(89)90267-9; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	39	402	418	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					87	90		10.1126/science.1846049	http://dx.doi.org/10.1126/science.1846049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1846049				2022-12-24	WOS:A1991EQ60300034
J	DIEDERICHS, K; BOONE, T; KARPLUS, PA				DIEDERICHS, K; BOONE, T; KARPLUS, PA			NOVEL FOLD AND PUTATIVE RECEPTOR-BINDING SITE OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	SCIENCE			English	Article							MOLECULAR-CLONING; 3-DIMENSIONAL STRUCTURE; GM-CSF; IDENTIFICATION; PURIFICATION; REGIONS; MOUSE	Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the development of and the cytotoxic activity of white blood cells. Recombinant human GM-CSF has proven useful in the treatment of blood disorders. The structure of GM-CSF, which was determined at 2.4 angstrom resolution by x-ray crystallography, has a novel fold combining a two-stranded antiparallel-beta-sheet with an open bundle of four a helices. Residues implicated in receptor recognition, which are distant in the primary sequence, are on adjacent alpha-helices in the folded protein. A working model for the receptor binding site is presented.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL LAB,ITHACA,NY 14853; AMGEN INC,THOUSAND OAKS,CA 91320	Cornell University; Amgen	KARPLUS, PA (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL LAB,ITHACA,NY 14853, USA.			Karplus, Paul/0000-0001-8725-6292				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ALTMANN SW, 1991, J BIOL CHEM, V266, P5333; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURGESS AW, 1987, BLOOD, V69, P43; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLARKLEWIS I, 1988, J IMMUNOL, V141, P881; CREIGHTON TE, 1984, PROTEIN STRUCTURES M, P226; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JANIN J, 1976, J MOL BIOL, V100, P197, DOI 10.1016/S0022-2836(76)80148-9; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MOONEN P, 1987, P NATL ACAD SCI USA, V84, P4428, DOI 10.1073/pnas.84.13.4428; MOORE MAS, 1991, ANNU REV IMMUNOL, V9, P159; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAKAMOTO KM, 1991, J PEDIATR-US, V118, pS17, DOI 10.1016/S0022-3476(05)82185-7; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; SHANAFELT AB, 1989, P NATL ACAD SCI USA, V86, P4872, DOI 10.1073/pnas.86.13.4872; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	32	194	209	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1779	1782		10.1126/science.1837174	http://dx.doi.org/10.1126/science.1837174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1837174	Green Submitted			2022-12-24	WOS:A1991GW31600039
J	FRAUENFELDER, H; SLIGAR, SG; WOLYNES, PG				FRAUENFELDER, H; SLIGAR, SG; WOLYNES, PG			THE ENERGY LANDSCAPES AND MOTIONS OF PROTEINS	SCIENCE			English	Article							X-RAY-DIFFRACTION; MOLECULAR-DYNAMICS; CARBON-MONOXIDE; HEME-PROTEINS; SPIN-GLASS; LOW-TEMPERATURES; LIGAND-BINDING; MODEL; MYOGLOBIN; RELAXATION	Recent experiments, advances in theory, and analogies to other complex systems such as glasses and spin glasses yield insight into protein dynamics. The basis of the understanding is the observation that the energy landscape is complex: Proteins can assume a large number of nearly isoenergetic conformations (conformational substates). The concepts that emerge from studies of the conformational substates and the motions between them permit a quantitative discussion of one simple reaction, the binding of small ligands such as carbon monoxide to myoglobin.	UNIV ILLINOIS, BECKMAN INST, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	FRAUENFELDER, H (corresponding author), UNIV ILLINOIS, CTR ADV STUDY, URBANA, IL 61801 USA.							ADAM G, 1965, J CHEM PHYS, V43, P139, DOI 10.1063/1.1696442; AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Atkins WM, 1991, CURR OPIN STRUC BIOL, V1, P611, DOI 10.1016/S0959-440X(05)80085-5; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BINDER K, 1986, REV MOD PHYS, V58, P801, DOI 10.1103/RevModPhys.58.801; BRAWER S, 1985, RELAXATION VISCOUS L; BROOKS CL, 1988, PROTEINS THEORETICAL; BRYNGELSON JD, 1987, P NATL ACAD SCI USA, V84, P7524, DOI 10.1073/pnas.84.21.7524; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CAMPBELL BF, 1988, BIOCHEMISTRY-US, V27, P3507; CARERI G, 1979, ANNU REV BIOPHYS BIO, V8, P69, DOI 10.1146/annurev.bb.08.060179.000441; CASE DA, 1988, PROG BIOPHYS MOL BIO, V52, P39, DOI 10.1016/0079-6107(88)90007-7; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHANCE MR, 1986, J BIOL CHEM, V261, P5689; DEDOMINICIS C, 1985, J PHYS LETT-PARIS, V46, pL463, DOI 10.1051/jphyslet:019850046011046300; DERRIDA B, 1981, PHYS REV B, V24, P2613, DOI 10.1103/PhysRevB.24.2613; EATON WA, 1991, P NATL ACAD SCI USA, V88, P4472, DOI 10.1073/pnas.88.10.4472; EIGEN M, 1986, CHEM SCRIPTA, V26B, P13; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; ENGLANDER SW, 1979, Q REV BIOPHYS, V8, P521; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; FERRY JD, 1953, J APPL PHYS, V24, P911, DOI 10.1063/1.1721401; Fischer KH., 1991, SPIN GLASSES, DOI [10.1017/CBO9780511628771, DOI 10.1017/CBO9780511628771]; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; FRAUENFELDER H, 1989, INT J QUANTUM CHEM, V35, P711, DOI 10.1002/qua.560350606; FRAUENFELDER H, 1989, CHEM SCRIPTA, V29A, P145; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; GAREL T, 1988, EUROPHYS LETT, V6, P307, DOI 10.1209/0295-5075/6/4/005; GO N, 1989, CHEM SCRIPTA, V29A, P151; GOLDANSKII VI, 1983, DOKL AKAD NAUK SSSR+, V272, P978; GROSS DJ, 1984, NUCL PHYS B, V240, P431, DOI 10.1016/0550-3213(84)90237-2; GROSS DJ, 1985, PHYS REV LETT, V55, P304, DOI 10.1103/PhysRevLett.55.304; Gurd F R, 1979, Adv Protein Chem, V33, P73, DOI 10.1016/S0065-3233(08)60459-3; HARTMANN H, 1982, P NATL ACAD SCI-BIOL, V79, P4967, DOI 10.1073/pnas.79.16.4967; HENRY ER, 1985, P NATL ACAD SCI USA, V82, P2034, DOI 10.1073/pnas.82.7.2034; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6583, DOI 10.1021/bi00240a031; HONG MK, 1990, BIOPHYS J, V58, P429, DOI 10.1016/S0006-3495(90)82388-2; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; JACKLE J, 1986, REP PROG PHYS, V49, P171, DOI 10.1088/0034-4885/49/2/002; JANKOWIAK R, 1987, SCIENCE, V237, P618, DOI 10.1126/science.237.4815.618; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KIRKPATRICK TR, 1987, PHYS REV B, V36, P8552, DOI 10.1103/PhysRevB.36.8552; KIRKPATRICK TR, 1989, PHYS REV A, V40, P1045, DOI 10.1103/PhysRevA.40.1045; KNOWLES J, 1991, WORKSHOP STRUCTURE F; KOHLER W, 1989, J CHEM PHYS, V90, P1270, DOI 10.1063/1.456131; KOPER GJM, 1987, EUROPHYS LETT, V3, P1213, DOI 10.1209/0295-5075/3/11/010; KUBO R, 1966, REP PROG PHYS, V29, P255, DOI 10.1088/0034-4885/29/1/306; Landau LD, 1980, STATISTICAL PHYSICS; Leventhal C, 1969, MOSSBAUER SPECTROSCO, P22; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; LEVITT M, 1983, J MOL BIOL, V168, P621, DOI 10.1016/S0022-2836(83)80306-4; Linderstrom-Lang K, 1959, ENZYMES, P443; LYONS KB, 1982, HEMOGLOBIN OXYGEN BI, P333; MAKINEN MW, 1979, P NATL ACAD SCI USA, V76, P6042, DOI 10.1073/pnas.76.12.6042; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCCOY S, 1971, PROBES STRUCTURE FUN, V2, P323; MEZARD M, 1987, SPIN GLASS THEORY BE; Moerner W. E., 1988, PERSISTENT SPECTRAL; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; ORMOS P, 1990, BIOPHYS J, V57, P191, DOI 10.1016/S0006-3495(90)82522-4; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PETSKO GA, 1984, ANNU REV BIOPHYS BIO, V13, P331; Phillips W. A., 1981, AMORPHOUS SOLIDS; ROUSSEAU DL, 1986, P NATL ACAD SCI USA, V83, P1310, DOI 10.1073/pnas.83.5.1310; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SCHER H, 1991, PHYS TODAY, V44, P26, DOI 10.1063/1.881289; SHAKHNOVICH EI, 1989, EUROPHYS LETT, V8, P327, DOI 10.1209/0295-5075/8/4/005; SHAKHNOVICH EI, 1989, EUROPHYS LETT, V9, P569, DOI 10.1209/0295-5075/9/6/013; SINGH GP, 1984, Z PHYS B CON MAT, V55, P23, DOI 10.1007/BF01307496; SRAJER V, 1988, J AM CHEM SOC, V110, P6656, DOI 10.1021/ja00228a009; STEIN DL, 1985, P NATL ACAD SCI USA, V82, P3670, DOI 10.1073/pnas.82.11.3670; STEIN DL, 1989, SCI AM, V261, P52, DOI 10.1038/scientificamerican0789-52; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; STILLINGER FH, 1984, SCIENCE, V225, P983, DOI 10.1126/science.225.4666.983; TOULOUSE G, 1986, P NATL ACAD SCI USA, V83, P1695, DOI 10.1073/pnas.83.6.1695; WAGNER G, 1983, Q REV BIOPHYS, V16, P1, DOI 10.1017/S0033583500004911; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WOLYNES PG, IN PRESS SPIN GLASSE; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013; ZALLEN R, 1983, PHYSICS AMORPHOUS SO; ZWANZIG R, 1988, P NATL ACAD SCI USA, V85, P2029, DOI 10.1073/pnas.85.7.2029	94	2583	2608	8	389	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1991	254	5038					1598	1603		10.1126/science.1749933	http://dx.doi.org/10.1126/science.1749933			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749933				2022-12-24	WOS:A1991GV07300033
J	HARRINGTON, C; CASSEL, C; ESTES, CL; WOOLHANDLER, S; HIMMELSTEIN, DU				HARRINGTON, C; CASSEL, C; ESTES, CL; WOOLHANDLER, S; HIMMELSTEIN, DU			A NATIONAL LONG-TERM CARE PROGRAM FOR THE UNITED-STATES - A CARING VISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; FUTURE	The financing and delivery of long-term care (LTC) need substantial reform. Many cannot afford essential services; age restrictions often arbitrarily limit access for the nonelderly, although more than a third of those needing care are under 65 years old; Medicaid, the principal third-party payer for LTC, is biased toward nursing home care and discourages independent living; informal care provided by relatives and friends, the only assistance used by 70% of those needing LTC, is neither supported nor encouraged; and insurance coverage often excludes critically important services that fall outside narrow definitions of medically necessary care. We describe an LTC program designed as an integral component of the national health program advanced by Physicians for a National Health Program. Everyone would be covered for all medically and socially necessary services under a single public plan, federally mandated and funded but administered locally. An LTC payment board in each state would contract directly with providers through a network of local public agencies responsible for eligibility determination and care coordination. Nursing homes, home care agencies, and other institutional providers would be paid a global budget to cover all operating costs and would not bill on a per-patient basis. Alternatively, integrated provider organizations could receive a capitation fee to cover a broad range of LTC and acute care services. Individual practitioners could continue to be paid on a fee-for-service basis or could receive salaries from institutional providers. Support for innovation, training of LTC personnel, and monitoring of the quality of care would be greatly augmented. For-profit providers would be compensated for past investments and phased out. Our program would add between $18 billion and $23.5 billion annually to current spending on LTC. Polls indicate that a majority of Americans want such a program and are willing to pay earmarked taxes to support it.	HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,NATL HLTH PROGRAM,1493 CAMBRIDGE ST,CAMBRIDGE,MA 02139	Harvard University; Cambridge Health Alliance; Cambridge Hospital								BALL R, 1989, BECAUSE WERE ALL THI; BARKER WH, 1987, ADDING LIFE YEARS OR; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P3587, DOI 10.1001/jama.259.24.3587; BLUMENTHAL D, 1988, RENEWING PROMISE MED; BODENHEIMER T, 1990, INT J HEALTH SERV, V20, P199, DOI 10.2190/DAKX-ULL1-R1EF-X5NR; CALLAHAN JJ, 1989, J AGING SOC POLICY, V1, P181; Campbell L J, 1987, Clin Geriatr Med, V3, P99; ESTES CL, 1989, GERONTOLOGIST, V29, P587, DOI 10.1093/geront/29.5.587; ESTES CL, 1990, LONG TERM CARE REQUI; ESTES CL, 1985, INT PERSPECTIVES LON, P315; ESTES CL, 1983, FISCAL AUSTERITY AGI; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FIRMAN JP, 1988, PRIVATE LONG TERM CA; FREIDSON F, 1970, PROFESSIONAL DOMINAN; HARRINGTON C, 1985, LONG TERM CARE ELDER; HARRINGTON C, 1987, SOCIAL HLTH MAINTENA, pCH4; HARRIS L, 1988, MAJORITIES FAVOR PAS; HAWES C, 1986, FOR PROFIT ENTERPRIS, P492; HAZZARD WR, 1991, ANN INTERN MED, V115, P229, DOI 10.7326/0003-4819-115-3-229; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; HIMMELSTEIN DU, 1991, JAMA-J AM MED ASSOC, V266, P399, DOI 10.1001/jama.266.3.399; HOLAHAN J, 1989, MILBANK Q, V67, P137, DOI 10.2307/3350072; Institute of Medicine report, 1986, IMPROVING QUALITY CA; JUSTICE D, 1988, STATE LONG TERM CARE; KANE R, 1980, NEW ENGL J MED, V302, P1327, DOI 10.1056/NEJM198006123022402; Kane RA, 1987, LONG TERM CARE PRINC; KANE RL, 1991, NEW ENGL J MED, V324, P627, DOI 10.1056/NEJM199102283240910; Kane Robert L., 1985, WILL WAY WHAT US CAN; KUSSEROW RP, 1987, OA1018600010 US DEP; LAPLANTE MP, 1988, DATA DISABILITY NATI; LEVIT KR, 1988, HEALTH AFFAIR, V7, P124, DOI 10.1377/hlthaff.7.5.124; Liu K, 1985, Health Care Financ Rev, V7, P51; NEWCOMER RJ, 1989, 03283 US DEP HLTH HU; PRICE RJ, 1990, LONG TERM CARE ELDER; RIVLIN AM, 1988, CARING DISABLED ELDE; ROWE JW, 1987, NEW ENGL J MED, V316, P1425, DOI 10.1056/NEJM198705283162229; STONE R, 1987, GERONTOLOGIST, V27, P616, DOI 10.1093/geront/27.5.616; STONE R, 1986, NCHS ADV DATA, P124; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; ZAWADSKI RT, 1983, HOME HEALTH CARE SER, V4, P3; 1988, INTERSTUDYS LONG TER, P2; 1987, VITAL HLTH STAT 13, V97; 1987, MEDICARE MEDICAID ST; 1987, AM PUBLIC VIEWS LONG; 1990, CALL ACTION FINAL RE; 1989, ISSUES FINANCING DEL; 1986, HOSPITAL STATISTICS; 1989, DEV AGING 1988 REPOR, P1; 1990, HLTH MED SERVICES US; 1986, MEDIGAP INSURANCE LA; 1987, LONG TERM CARE C; 1987, NATIONAL HLTH EXPEND, V8, P1; 1988, INTERSTUDYS LONG TER, P1; 1989, PRIVATE LONG TERM CA; 1987, VITAL HLTH STAT 10, V166; 1988, SOURCE BOOK HLTH INS	56	25	25	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3023	3029		10.1001/jama.266.21.3023	http://dx.doi.org/10.1001/jama.266.21.3023			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820477				2022-12-24	WOS:A1991GR77500037
J	KINLEN, LJ; HUDSON, C				KINLEN, LJ; HUDSON, C			CHILDHOOD LEUKEMIA AND POLIOMYELITIS IN RELATION TO MILITARY ENCAMPMENTS IN ENGLAND AND WALES IN THE PERIOD OF NATIONAL MILITARY SERVICE, 1950-63	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA	Objective - To determine if any excess of childhood leukaemia was associated with the large and increasing numbers of national military servicemen in 1949 and 1950, particularly in rural districts. This would be a further test of the hypothesis that childhood leukaemia can originate in an infection, the transmission of which is facilitated by an increased number of unaccustomed contacts in the community. Design - Rural and urban districts, aggregated by county, were ranked by proportion of servicemen, and five groups containing similar numbers of children were created. In addition, individual local authority districts were ranked and grouped in tenths. Mortality from childhood leukaemia 1950-3 was examined in these groups. Data on infectious diseases were also examined, as well as data on leukaemia in later periods. Setting - England and Wales. Subjects - Children aged under 15 years. Results - In 1950-3 but not subsequently a significant excess of leukaemia in children under 15 was found in the fifth of county groupings with the highest proportions of servicemen. This was due mainly to a significant excess in children under 2 years (and especially in those under 1 year) in rural districts. It was confirmed among the tenth of local authority districts with the highest proportion of servicemen. These rural areas showed significantly more notifications of, and deaths from, poliomyelitis among children than the rural average. Conclusions - The findings support the infection hypothesis. That the excess of leukaemia was greatest in children under 1 year suggests transmission of infection among adults and thence to the fetus. The pattern of spread of poliomyelitis may also have been influenced by the presence of large numbers of servicemen.			KINLEN, LJ (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH MED,CANC RES CAMPAIGN,CANC EPIDEMIOL RES GRP,OXFORD OX2 6HE,ENGLAND.							ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BRESLOW N, 1987, IARC SCI PUBL, V82, P93; CAMPBELL D, 1984, UNSINKABLE AIRCRAFT; Coburn AFY, 1949, EPIDEMIOLOGY HEMOLYT; GLOVER JA, 1915, CEREBRO SPINAL FEVER; GREAVES MF, 1988, LEUKEMIA, V2, P120; Greaves MF, 1984, PATHOGENESIS LEUKEMI, P129; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; ROBISON LL, 1989, CANCER, V63, P1904; ROYLE T, 1986, BEST YEASTS THEIR LI; TITMUSS RM, 1950, HIST 2ND WORLD WAR, P245; Werner B., 1984, POPULATION TRENDS, V38, P18; 1958, DECENNIAL SUPPLEMENT; 1952, STATISTICAL REV EN 1; 1957, DECENNIAL SUPPLEME 2, V2; 1953, STATISTICAL REV EN 1; 1956, CENSUS 1951 ENGLAND	19	57	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1357	1362		10.1136/bmj.303.6814.1357	http://dx.doi.org/10.1136/bmj.303.6814.1357			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760600	Green Published, Bronze			2022-12-24	WOS:A1991GU38400017
J	WALKER, A				WALKER, A			HEALTH AND THE ENVIRONMENT - WASTE-DISPOSAL - FRESH LOOKS AT A ROTTING PROBLEM	BRITISH MEDICAL JOURNAL			English	Article																		CROFT B, 1990, 1990 P HARW WAST MAN; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; GUSTAVSSON P, 1989, AM J IND MED, V15, P245, DOI 10.1002/ajim.4700150302; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; LAGAKOS SW, 1986, J AM STAT ASSOC, V81, P583, DOI 10.2307/2288982; LOWRY S, 1990, BRIT MED J, V300, P177, DOI 10.1136/bmj.300.6718.177; PAIGEN B, 1987, HUM BIOL, V59, P489; WALDRON HA, 1985, BRIT MED J, V290, P1285, DOI 10.1136/bmj.290.6477.1285; 1990, SOCIAL TRENDS, V20; 1991, URBAN SOLID WASTE MA; 1985, 11TH ROYAL COMM ENV; 1988, ASSESSMENT GROUNDWAT; 1989, 2ND REPORT HOUS COMM; 1990, CODE PRACTICE SAFE U; 1991, CLIN WASTE APPRAISAL; 1989, HAZARDOUS WASTE HUMA	16	9	9	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1391	1394		10.1136/bmj.303.6814.1391	http://dx.doi.org/10.1136/bmj.303.6814.1391			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760610	Bronze, Green Published			2022-12-24	WOS:A1991GU38400027
J	SONNEX, C; SCHOLEFIELD, JH; KOCJAN, G; KELLY, G; WHATRUP, C; MINDEL, A; NORTHOVER, JMA				SONNEX, C; SCHOLEFIELD, JH; KOCJAN, G; KELLY, G; WHATRUP, C; MINDEL, A; NORTHOVER, JMA			ANAL HUMAN PAPILLOMAVIRUS INFECTION IN HETEROSEXUALS WITH GENITAL WARTS - PREVALENCE AND RELATION WITH SEXUAL-BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							MEN		UNIV COLL & MIDDLESEX HOSP SCH MED,ACAD DEPT GENITOURINARY MED,LONDON W1,ENGLAND; ST MARKS HOSP,IMPERIAL CANC RES FUND,COLORECTAL CANC UNIT,LONDON EC1,ENGLAND; UNIV COLL & MIDDLESEX HOSP SCH MED,DEPT HISTOPATHOL,LONDON W1,ENGLAND									FRAZER IH, 1986, LANCET, V2, P657; GOORNEY BP, 1987, GENITOURIN MED, V63, P216; ORIEL JD, 1971, BRIT J VENER DIS, V47, P1; ORIEL JD, 1971, BR J VENER DIS, V47, P273; SONNEX C, 1991, GENITOURIN MED, V67, P21	5	30	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1243	1243		10.1136/bmj.303.6812.1243	http://dx.doi.org/10.1136/bmj.303.6812.1243			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ342	1747648	Bronze, Green Published			2022-12-24	WOS:A1991GQ34200027
J	GOODWIN, FK				GOODWIN, FK			TELLTALE NEUROTOXIN AND DEMENTIAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							1991, ANN NEUROL, V29, P202	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1832194				2022-12-24	WOS:A1991GF41900005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC MEETING ON DIETARY-SUPPLEMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1991, FED REG         0716, V56, P32436	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-24	WOS:A1991GA07300006
J	KINGSBURY, J; KOSHLAND, D				KINGSBURY, J; KOSHLAND, D			CENTROMERE-DEPENDENT BINDING OF YEAST MINICHROMOSOMES TO MICROTUBULES INVITRO	CELL			English	Article							MITOTIC CHROMOSOME TRANSMISSION; BASE-PAIR MUTATIONS; SACCHAROMYCES-CEREVISIAE; KINETOCHORE INVITRO; S-CEREVISIAE; DNA; PROTEIN; REPLICATION; CHROMATIN; MUTANTS	We present an in vitro assay for yeast centromere function; isolated yeast minichromosomes require a functional centromere to bind to bovine microtubules and sediment with them. Centromere-bovine microtubule complexes form at physiological microtubule concentrations. Two of the three centromere DNA elements, which are necessary for centromere function in vivo, are also necessary for centromeres to bind microtubules in vitro. However, purified centromere DNA alone does not bind to microtubules. These results suggest that microtubule binding must be mediated by the two centromere DNA elements and factors that associate with one or both of them. The percent of centromeres with microtubule-binding activity is 7- to 10-fold higher in lysates made from nocodazole-arrested G2-M cells than from alpha-factor G1 cells, suggesting that this centromere activity is regulated during the cell cycle. The potential of this assay for dissecting centromere assembly, function, and regulation is discussed.			KINGSBURY, J (corresponding author), CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA.							BAKER RE, 1989, J BIOL CHEM, V264, P10843; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; CLARKE L, 1980, P NATL ACAD SCI-BIOL, V77, P2173, DOI 10.1073/pnas.77.4.2173; DEAN A, 1989, METHOD ENZYMOL, V170, P26; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FITZGERALDHAYES M, 1987, YEAST, V3, P187, DOI 10.1002/yea.320030306; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; HARTWELL LH, 1985, GENETICS, V110, P381; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; HUITOREL P, 1988, J CELL BIOL, V106, P151, DOI 10.1083/jcb.106.1.151; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MAINE GT, 1984, GENETICS, V106, P365; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; PEDERSON DS, 1986, P NATL ACAD SCI USA, V83, P7206, DOI 10.1073/pnas.83.19.7206; PETERSON JB, 1976, J CELL SCI, V22, P219; PLARR CM, 1990, NATURE, V345, P263; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; SHERO J, 1991, IN PRESS GENES DEV; SPENCER F, 1990, GENETICS, V124, P237; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Strehler B L, 1968, Methods Biochem Anal, V16, P99, DOI 10.1002/9780470110348.ch2	36	46	46	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					483	495		10.1016/0092-8674(81)90012-X	http://dx.doi.org/10.1016/0092-8674(81)90012-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868546				2022-12-24	WOS:A1991GA94100010
J	ISHIJIMA, A; DOI, T; SAKURADA, K; YANAGIDA, T				ISHIJIMA, A; DOI, T; SAKURADA, K; YANAGIDA, T			SUB-PICONEWTON FORCE FLUCTUATIONS OF ACTOMYOSIN INVITRO	NATURE			English	Article							SINGLE KINESIN MOLECULES; ACTIN-FILAMENTS; MUSCLE-CONTRACTION; SLIDING FILAMENTS; MYOSIN; MOVEMENT; MECHANISM; MOTION; DIRECTION; VELOCITY	A new system has been developed for measuring the forces produced by a small number (< 5-150) of myosin molecules interacting with a single actin filament in vitro. The technique can resolve forces of less than a piconewton and has a time resolution in the submillisecond range. It can thus detect fluctuations of force caused by individual molecular interactions. From analysis of these force fluctuations, the coupling between the enzymatic ATPase activity of actomyosin and the resulting mechanical impulses can be elucidated.	OSAKA UNIV,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; HONDA RES & DEV CO,WAKO RES CTR,WAKO,SAITAMA,JAPAN	Osaka University; Honda Motor Company			Yanagida, Toshio/D-1919-2009; Ishijima, Akihiko/F-4603-2012	Ishijima, Akihiko/0000-0002-8919-9268				BAGSHAW CR, 1990, J MUSCLE RES CELL M, V11, P533, DOI 10.1007/BF01745220; BAGSHAW CR, 1982, MUSCLE CONTRACTION; BERGER CL, 1989, P NATL ACAD SCI USA, V86, P8753, DOI 10.1073/pnas.86.22.8753; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BOREJDO J, 1977, BIOPHYS J, V20, P315, DOI 10.1016/S0006-3495(77)85552-5; BRENNER B, 1990, TOPICS MOL STRUCT BI, V13, P78; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; EBASHI S, 1991, ANNU REV PHYSIOL, V53, P1, DOI 10.1146/annurev.ph.53.030191.000245; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; FUJME S, 1985, J CELL BIOL, V101, P2335; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; IRVING M, 1985, NATURE, V316, P292, DOI 10.1038/316292a0; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KATZ B, 1971, NATURE-NEW BIOL, V232, P124, DOI 10.1038/newbio232124b0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KWAZUMI T, 1987, AM J PHYSIOL, V252, P253; LANDAU L, 1969, STATISTICAL PHYSICS, pCH4; LEE YW, 1969, STAT THEORY COMMUNIC, pCH8; MEISTER M, 1989, BIOPHYS J, V55, P904; MITSUI T, 1988, J MUSCLE RES CELL M, V9, P248, DOI 10.1007/BF01773895; OHNO T, IN PRESS J PHYOL; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SPUDICH JA, 1990, NATURE, V348, P284, DOI 10.1038/348284a0; STEVENS CF, 1972, BIOPHYS J, V12, P1028, DOI 10.1016/S0006-3495(72)86141-1; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TONOMURA Y, 1986, ENERGY TRANSDUCING A; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YAMADA A, 1990, J BIOCHEM-TOKYO, V108, P341, DOI 10.1093/oxfordjournals.jbchem.a123203; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1985, NATURE, V316, P369; YANOTOYOSHIMA Y, 1990, P NATL ACAD SCI USA, V87, P7130; YANOTOYOSHIMA Y, 1989, NATURE, V341, P154; YANOTOYOSHIMA Y, 1987, NATURE, V328, P536	49	228	230	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					301	306		10.1038/352301a0	http://dx.doi.org/10.1038/352301a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1830130				2022-12-24	WOS:A1991FY28900059
J	MUDRYJ, M; DEVOTO, SH; HIEBERT, SW; HUNTER, T; PINES, J; NEVINS, JR				MUDRYJ, M; DEVOTO, SH; HIEBERT, SW; HUNTER, T; PINES, J; NEVINS, JR			CELL-CYCLE REGULATION OF THE E2F TRANSCRIPTION FACTOR INVOLVES AN INTERACTION WITH CYCLIN-A	CELL			English	Article							DNA-BINDING ACTIVITY; ADENOVIRUS-INFECTED CELLS; SERUM RESPONSE ELEMENT; C-FOS GENE; TRANS-ACTIVATION; MESSENGER-RNA; E1A PROTEINS; E4 GENE; EXPRESSION; IDENTIFICATION	We have examined E2F binding activity in extracts of synchronized NIH 3T3 cells. During the GO to Gl transition, there is a marked increase in the level of active E2F. Subsequently, there are changes in the nature of E2F-containing complexes. A G1-specific complex increases in abundance, disappears, and is then replaced by another complex as S phase begins. Analysis of extracts of thymidine-blocked cells confirms that the complexes are cell cycle regulated. We also show that the cyclin A protein is a component of the S phase complex. Each complex can be dissociated by the adenovirus E1A 12S product, releasing free E2F. The release of E2F from the cyclin A complex coincides with the stimulation of an E2F-dependent promoter. We suggest that these interactions control the activity of E2F and that disruption of the complexes by E1A contributes to a loss of cellular proliferation control.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Salk Institute	MUDRYJ, M (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,GENET SECT,DURHAM,NC 27710, USA.			Pines, Jonathon/0000-0002-5227-6004; Devoto, Stephen/0000-0001-9513-3962	NCI NIH HHS [CA39780] Funding Source: Medline; NIGMS NIH HHS [GM26765] Funding Source: Medline; NINDS NIH HHS [NS08790] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008790] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P43532; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FELTCHER C, 1987, CELL, V51, P773; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NAGARAJAN M, 1989, EXP CELL RES, V181, P289, DOI 10.1016/0014-4827(89)90203-6; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	49	360	371	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1243	1253		10.1016/0092-8674(91)90019-U	http://dx.doi.org/10.1016/0092-8674(91)90019-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1829647				2022-12-24	WOS:A1991FU89900016
J	UENO, H; COLBERT, H; ESCOBEDO, JA; WILLIAMS, LT				UENO, H; COLBERT, H; ESCOBEDO, JA; WILLIAMS, LT			INHIBITION OF PDGF BETA-RECEPTOR SIGNAL TRANSDUCTION BY COEXPRESSION OF A TRUNCATED RECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; SWISS 3T3 CELLS; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; INSULIN-RECEPTORS; HUMAN-FIBROBLASTS; ACTIVATION; BINDING; PROTEIN	A mutated form of the platelet-derived growth factor (PDGF) beta-receptor lacking most of its cytoplasmic domain was tested for its ability to block wild-type PDGF receptor function. PDGF induced the formation of complexes consisting of wild-type and truncated receptors. Such complexes were defective in autophosphorylation. When truncated receptors were expressed in excess compared to wild-type receptors, stimulation by PDGF of receptor autophosphorylation, association of phosphatidylinositol-3 kinase with the receptor, and calcium mobilization were blocked. Thus, a truncated receptor can inactivate wild-type receptor function by forming ligand-dependent receptor complexes (probably heterodimers) that are incapable of mediating the early steps of signal transduction.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	UENO, H (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [P01 HL-43821, R01 HL-32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, P01HL043821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHU SHW, 1985, J CELL PHYSIOL, V124, P391, DOI 10.1002/jcp.1041240306; COLBERT H, UNPUB; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANTZ CN, 1985, EXP CELL RES, V158, P287, DOI 10.1016/0014-4827(85)90454-9; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1987, J BIOL CHEM, V262, P7932; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MAHAN LC, 1990, P NATL ACAD SCI USA, V87, P2196, DOI 10.1073/pnas.87.6.2196; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, UNPUB; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	39	184	201	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					844	848		10.1126/science.1851331	http://dx.doi.org/10.1126/science.1851331			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1851331				2022-12-24	WOS:A1991FL12300047
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CORRECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Correction, Addition																		NIGHTINGALE SL, 1991, JAMA-J AM MED ASSOC, V265, P847, DOI 10.1001/jama.265.7.847	1	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1802	1802		10.1001/jama.265.14.1802	http://dx.doi.org/10.1001/jama.265.14.1802			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	1848642				2022-12-24	WOS:A1991FE86200004
J	CHAKRABORTY, M; CHATTERJEE, D; KELLOKUMPU, S; RASMUSSEN, H; BARON, R				CHAKRABORTY, M; CHATTERJEE, D; KELLOKUMPU, S; RASMUSSEN, H; BARON, R			CELL-CYCLE DEPENDENT COUPLING OF THE CALCITONIN RECEPTOR TO DIFFERENT G-PROTEINS	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; SALMON-CALCITONIN; KINASE-C; ISOLATED OSTEOCLASTS; ADENYLATE-CYCLASE; BINDING-SITES; HEART-CELLS; RAT-BRAIN; K+-ATPASE; PATHWAYS	Calcitonin is a calcium regulating peptide hormone with binding sites in kidney and bone as well as in the central nervous system. The mechanisms of signal transduction by calcitonin receptors were studied in a pig kidney cell line where the hormone was found to regulate sodium pumps. Calcitonin receptors activated the cyclic adenosine monophosphate (cAMP) or the protein kinase C (PKC) pathways. The two transduction pathways required guanosine triphosphate (GTP)-binding proteins (G proteins) (the choleratoxin sensitive G(s) and the pertussis toxin sensitive G(i), respectively) and led to opposite biological responses. Moreover, selective activation of one or the other pathway was cell cycle-dependent. Therefore, calcitonin may induce different biological responses in target cells depending on their positions in the cell cycle. Such a modulation of ligand-induced responses could be of importance in rapidly growing cell populations such as during embryogenesis, growth, and tumor formation.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT ORTHOPED,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019813, R01DK019813] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-04724] Funding Source: Medline; NIDDK NIH HHS [DK-19813] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL N, 1986, AM J PHYSIOL, V251, pC825, DOI 10.1152/ajpcell.1986.251.5.C825; AITON JF, 1981, BRIT J PHARMACOL, V73, P333, DOI 10.1111/j.1476-5381.1981.tb10426.x; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; AZRIA M, 1989, CALCITONINS, P152; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1986, CELL, V46, P311, DOI 10.1016/0092-8674(86)90748-8; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BLACK NB, 1980, AM J PHYSIOL, V238, pR406; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; CAMBARDIERE C, 1990, BIOCHEM BIOPH RES CO, V168, P65; CHAKRABORTY M, UNPUB; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104; CHAMBERS TJ, 1983, J CLIN ENDOCR METAB, V57, P819, DOI 10.1210/jcem-57-4-819; CLEMENTI G, 1984, EUR J PHARMACOL, V98, P449, DOI 10.1016/0014-2999(84)90298-X; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DAYER JM, 1981, J CELL BIOL, V91, P195, DOI 10.1083/jcb.91.1.195; DOODS HN, 1987, J PHARMACOL EXP THER, V242, P257; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; ENJALBERT A, 1986, J BIOL CHEM, V261, P4071; FINDLAY DM, 1980, CANCER RES, V40, P1311; FISCHER JA, 1981, LIFE SCI, V29, P663, DOI 10.1016/0024-3205(81)90018-7; FORBUSH B, 1979, BIOCHEMISTRY-US, V18, P2308, DOI 10.1021/bi00578a027; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENKE H, 1985, BRAIN RES, V360, P165, DOI 10.1016/0006-8993(85)91232-6; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUNT NH, 1977, BRIT J CANCER, V35, P777, DOI 10.1038/bjc.1977.119; KRIEGER NS, 1980, PHARMACOL REV, V217, P586; KYTE J, 1976, J CELL BIOL, V68, P287, DOI 10.1083/jcb.68.2.287; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1989, J CELL SCI, V92, P131; MACINTYRE I, 1989, ENDOCRINOLOGY, P892; MARBACH I, 1988, EUR J BIOCHEM, V172, P239, DOI 10.1111/j.1432-1033.1988.tb13879.x; MCCALL D, 1979, AM J PHYSIOL, V236, pC87, DOI 10.1152/ajpcell.1979.236.1.C87; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MORGAN A, 1990, BIOCHEM J, V269, P521, DOI 10.1042/bj2690521; MUALLEM S, 1989, BIOCHEM J, V263, P769, DOI 10.1042/bj2630769; NAKAMUTA H, 1981, JPN J PHARMACOL, V31, P53, DOI 10.1254/jjp.31.53; NAKAMUTA H, 1987, FOLIA PHARMACOL JPN, V89, P191, DOI 10.1254/fpj.89.191; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PECILE A, 1975, EXPERIENTIA, V31, P332, DOI 10.1007/BF01922569; PRALLET B, 1988, CALCIFIED TISSUE INT, V42, pA14; RIZZO AJ, 1981, ENDOCRINOLOGY, V108, P1672, DOI 10.1210/endo-108-5-1672; SCHOFIELD PR, 1990, TRENDS NEUROSCI, V13, P8, DOI 10.1016/0166-2236(90)90052-C; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TWERY MJ, 1982, PEPTIDES, V3, P749, DOI 10.1016/0196-9781(82)90010-9; TWERY MJ, 1988, EUR J PHARMACOL, V155, P285, DOI 10.1016/0014-2999(88)90515-8; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	57	134	135	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 1	1991	251	4997					1078	1082		10.1126/science.1847755	http://dx.doi.org/10.1126/science.1847755			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EZ665	1847755				2022-12-24	WOS:A1991EZ66500053
J	LEE, TH; SOLOMON, MJ; MUMBY, MC; KIRSCHNER, MW				LEE, TH; SOLOMON, MJ; MUMBY, MC; KIRSCHNER, MW			INH, A NEGATIVE REGULATOR OF MPF, IS A FORM OF PROTEIN PHOSPHATASE-2A	CELL			English	Article							MATURATION-PROMOTING FACTOR; XENOPUS-LAEVIS OOCYTES; RABBIT SKELETAL-MUSCLE; CYCLIN MESSENGER-RNA; CELL-CYCLE; OKADAIC ACID; CDC2 PROTEIN; CYTOPLASMIC FACTOR; KINASE; PURIFICATION	MPF, a protein kinase complex consisting of cyclin and p34cdc2 subunits, promotes the G2 to M phase transition in eukaryotic cells. The pathway of activation and inactivation of MPF is not well understood, although there is strong evidence that removal of phosphate from a tyrosine residue on p34cdc2 is part of the activation process. INH was originally identified as an activity that could inhibit the posttranslational activation of a latent form of MPF, called pre-MPF, in immature (G2 phase-arrested) Xenopus oocytes. We have purified INH and demonstrated that it is a form of protein phosphatase 2A. Both INH and the catalytic subunit of protein phosphatase 2A can directly inactivate an isolated p34cdc2-cyclin complex. Both cyclin and p34cdc2 become dephosphorylated; the rate of inactivation closely parallels the removal of phosphate from a specific site on p34cdc2. We propose that INH opposes MPF activation by reversing this critical phosphorylation.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LEE, TH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL 31107] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MEIJER L, 1986, EXP CELL RES, V163, P489, DOI 10.1016/0014-4827(86)90079-0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORIA AO, 1989, CELL, V58, P193; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1989, CR ACAD SCI III-VIE, V309, P563; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	41	227	230	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 25	1991	64	2					415	423		10.1016/0092-8674(91)90649-J	http://dx.doi.org/10.1016/0092-8674(91)90649-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EV336	1846321				2022-12-24	WOS:A1991EV33600017
J	ANIKSZTEJN, L; BENARI, Y				ANIKSZTEJN, L; BENARI, Y			NOVEL FORM OF LONG-TERM POTENTIATION PRODUCED BY A K+ CHANNEL BLOCKER IN THE HIPPOCAMPUS	NATURE			English	Article							SYNAPTIC TRANSMISSION; PYRAMIDAL CELLS; NMDA RECEPTORS; AFTER-HYPERPOLARIZATION; POTASSIUM CONDUCTANCES; LASTING POTENTIATION; NEURONS; CALCIUM; ANTAGONISTS; INVITRO	LONG-term potentiation (LTP) of synaptic transmission in the hippocampus is a widely studied model of memory processes1. In the CA1 region, LTP is triggered by the entry of CA2+ through N-methyl-D-aspartate (NMDA) receptor channels and maintained by the activation of CA2+-sensitive intracellular messengers2,3. We now report that in CA1, a transient block by tetraethylammonium of I(C), I(M) and the delayed rectifier (I(K)) produces a Ca2+-dependent NMDA-independent form of LTP. Our results suggest that this new form of LTP (referred as to LTP(K)) is induced by a transient enhanced release of glutamate which generates a depolarization by way of the non-NMDA receptors and the consequent activation of voltage -dependent Ca2+ channels.			ANIKSZTEJN, L (corresponding author), HOP PORT ROYAL,INSERM,U29,123 BLVD PORT ROYAL,F-75014 PARIS,FRANCE.		Aniksztejn, Laurent/E-2072-2017	Aniksztejn, laurent/0000-0001-9215-1698; Ben-Ari, Yehezkel/0000-0001-6208-8480				ANDERSEN P, 1980, J PHYSIOL-LONDON, V302, P463; BLAKE JF, 1988, NEUROSCI LETT, V89, P182, DOI 10.1016/0304-3940(88)90378-3; BROWN DA, 1983, J PHYSIOL-LONDON, V337, P303, DOI 10.1113/jphysiol.1983.sp014625; CHERUBINI E, 1987, NATURE, V328, P70, DOI 10.1038/328070a0; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; GHO M, 1986, BRAIN RES, V385, P411, DOI 10.1016/0006-8993(86)91093-0; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HIGASHI H, 1990, NEUROSCIENCE, V34, P35, DOI 10.1016/0306-4522(90)90302-K; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KESSLER M, 1989, BRAIN RES, V489, P377, DOI 10.1016/0006-8993(89)90875-5; KRNJEVIC K, 1989, J NEUROPHYSIOL, V62, P896, DOI 10.1152/jn.1989.62.4.896; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P241; MALENKA RC, 1989, TRENDS NEUROSCI, V12, P444, DOI 10.1016/0166-2236(89)90094-5; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P262; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NEUMAN RS, 1988, NEUROSCI LETT, V92, P64, DOI 10.1016/0304-3940(88)90743-4; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; SEGAL M, 1984, J NEUROPHYSIOL, V51, P1409, DOI 10.1152/jn.1984.51.6.1409; SOTRM JF, 1990, PROG BRAIN RES, V83, P161; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; STORM JF, 1987, J PHYSIOL-LONDON, V385, P733, DOI 10.1113/jphysiol.1987.sp016517; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; STURGESS NC, 1985, LANCET, V2, P474; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x; WRIGHT J M, 1988, Society for Neuroscience Abstracts, V14, P1046	33	254	259	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					67	69		10.1038/349067a0	http://dx.doi.org/10.1038/349067a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1845914				2022-12-24	WOS:A1991EQ60100052
J	NANKHONYA, JM; TURNBULL, CJ; NEWTON, JT				NANKHONYA, JM; TURNBULL, CJ; NEWTON, JT			SOCIAL AND FUNCTIONAL IMPACT OF MINOR FRACTURES IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									ARROWE PK HOSP,DEPT GERIATR MED,WIRRAL L49 5PE,ENGLAND; SALFORD UNIV,DEPT BEHAV SCI,SALFORD M6 6PU,ENGLAND	University of Salford	NANKHONYA, JM (corresponding author), 24 COLMORE AVE,WIRRAL L63 9NL,ENGLAND.		Newton, Jonathon T/B-7015-2009					ANDREWS K, 1989, CLIN NEUROLOGY OLD A, P479; Dove A F, 1986, Health Trends, V18, P86; Roberts NA, 1990, CLIN REHABIL, V4, P37; ROWLAND K, 1990, AGE AGEING, V19, P415, DOI 10.1093/ageing/19.6.415; 1989, FRACTURED NECK FEMUR	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1514	1515		10.1136/bmj.303.6816.1514-a	http://dx.doi.org/10.1136/bmj.303.6816.1514-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782491	Bronze, Green Published			2022-12-24	WOS:A1991GV47600024
J	HAUSMANN, N; RICHARD, G				HAUSMANN, N; RICHARD, G			EFFECT OF HIGH-DOSE STEROID BOLUS ON OCCLUSION OF OCULAR CENTRAL ARTERY - ANGIOGRAPHIC STUDY	BRITISH MEDICAL JOURNAL			English	Article									UNIV MAINZ,DEPT OPHTHALMOL,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz	HAUSMANN, N (corresponding author), LANDESKRANKENHAUS FELDKIRCH,DEPT OPHTHALMOL,A-6807 FELDKIRCH,AUSTRIA.							BRAUGHLER JM, 1985, J NEUROSURG, V62, P805; HAYREH SS, 1980, BRIT J OPHTHALMOL, V64, P818, DOI 10.1136/bjo.64.11.818; MAGARGAL LE, 1977, SURG FORUM, V28, P518; NEUBAUER H, 1962, Klin Monbl Augenheilkd Augenarztl Fortbild, V141, P70; RICHARD G, 1989, FLUORESZENZANGIOGRAP, P19	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1445	1446		10.1136/bmj.303.6815.1445	http://dx.doi.org/10.1136/bmj.303.6815.1445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773152	Bronze, Green Published			2022-12-24	WOS:A1991GU38500027
J	SACKS, JJ; HOLMGREEN, P; SMITH, SM; SOSIN, DM				SACKS, JJ; HOLMGREEN, P; SMITH, SM; SOSIN, DM			BICYCLE-ASSOCIATED HEAD-INJURIES AND DEATHS IN THE UNITED-STATES FROM 1984 THROUGH 1988 - HOW MANY ARE PREVENTABLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							HELMET USE; SAFETY HELMETS; CHILDREN; ACCIDENTS; VICTORIA	Objective. - To estimate the potential benefits from more widespread bicycle safety helmet use. Design. - Review of death certificates and emergency department injury data for 1984 through 1988. Categorization of deaths and injuries as related to bicycling and head injury Using relative risks of 3.85 and 6.67 derived from a case-control study and varying helmet usage from 10% to 100%, population attributable risk was calculated to estimate preventable deaths and injuries. Setting. - Entire United States. Main Outcome Measures. - Numbers of US residents coded as dying from bicycle-related head injuries, numbers of persons presenting to emergency departments for bicycle-related head injuries, and numbers of attributable bicycle-related deaths and head injuries. Main Results. - From 1984 through 1988, bicycling accounted for 2985 head injury deaths (62% of all bicycling deaths) and 905 752 head injuries (32% of persons with bicycling injuries treated at an emergency department). Forty-one percent of head injury deaths and 76% of head injuries occurred among children less than 15 years of age. Universal use of helmets by all bicyclists could have prevented as many as 2500 deaths and 757 000 head injuries, ie, one death every day and one head injury every 4 minutes. Conclusions. - Effective community-based education programs and legislated approaches for increasing bicycle safety helmet usage have been developed and await only the resources and commitment to reduce these unnecessary deaths and injuries.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	SACKS, JJ (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH INJURY CONTROL,DIV INJURY CONTROL F36,ATLANTA,GA 30333, USA.							Bishop P J, 1984, Can J Appl Sport Sci, V9, P94; BUCCINI RV, 1987, OCT AM PUBL HLTH ASS; BUNTAIN WL, 1985, 29TH P ANN M AM ASS, P307; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; FLORA JD, 1979, J SAFETY RES, V11, P20; FRIEDE AM, 1985, PEDIATR CLIN N AM, V32, P141; Hodgson V.R., 1990, IMPACT SKID RETENTIO; LUNDAR T, 1985, CHILD NERV SYST, V1, P24, DOI 10.1007/BF00706726; MCDERMOTT FT, 1985, AUST NZ J SURG, V55, P477, DOI 10.1111/j.1445-2197.1985.tb00926.x; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P38; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WASSERMAN RC, 1988, AM J PUBLIC HEALTH, V78, P1220, DOI 10.2105/AJPH.78.9.1220; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; WEISS BD, 1986, PEDIATRICS, V77, P677; WEISS BD, 1986, AM J PUBLIC HEALTH, V76, P1022, DOI 10.2105/AJPH.76.8.1022; WEISS BD, 1987, AM J DIS CHILD, V141, P135, DOI 10.1001/archpedi.1987.04460020025018; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5; WOOD T, 1988, ACCIDENT ANAL PREV, V20, P177, DOI 10.1016/0001-4575(88)90002-4; 1984, VITAL STATISTICS MOR; 1987, MMWR, V36, P269; 1986, INTERCENSAL POPULATI, P38; 1990, CONSUMER REP     MAY, P348; 1977, MANUAL INT CLASSIFIC	29	132	132	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3016	3018		10.1001/jama.266.21.3016	http://dx.doi.org/10.1001/jama.266.21.3016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820476				2022-12-24	WOS:A1991GR77500035
J	KAPELRUD, H; BANGSTAD, HJ; DAHLJORGENSEN, K; BERG, K; HANSSEN, KF				KAPELRUD, H; BANGSTAD, HJ; DAHLJORGENSEN, K; BERG, K; HANSSEN, KF			SERUM LP(A) LIPOPROTEIN CONCENTRATIONS IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH MICROALBUMINURIA	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; URINARY ALBUMIN EXCRETION; APOLIPOPROTEIN-B; RISK-FACTORS; NEPHROPATHY; TYPE-1; PLASMA; PROTEINURIA; CHOLESTEROL; MELLITUS	Objective - To compare the serum concentrations of lipoproteins and apolipoproteins in insulin dependent diabetic patients with and without microalbuminuria. Design - Cross sectional study. Setting - Paediatric and medical outpatient clinic at a university hospital. Patients - 76 insulin dependent diabetic patients: 41 with microalbuminuria (20 males, 21 females) and 35 controls without microalbuminuria (18 males, 17 females). The two groups were similar with respect to age, duration of disease, and haemoglobin A1c concentrations before the study. Main outcome measures - Serum concentrations of Lp(a) lipoprotein, total cholesterol, high density lipoprotein cholesterol, very low density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, and apolipoproteins A-I, A-II, and B. Results - Median serum Lp(a) lipoprotein concentration was 10.0 mg/100 ml in the microalbuminuric group and 4.9 mg/100 ml in the control group (p = 0.007). 17 (41%) of the microalbuminuric patients and five (14%) of the control patients had Lp(a) lipoprotein values above the upper quartile of a normal population. Median serum triglycerides concentrations in the microalbuminuric and control groups were 1.15 mmol/l and 0.88 mmol/l respectively (p = 0.03). Median very low density lipoprotein cholesterol concentration was 0.52 mmol/l in the microalbuminuric group and 0.40 mmol/l in the control group (p = 0.03). No significant differences in serum concentrations of total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, or apolipoproteins A-I, A-II, and B were found between the groups. Conclusions - Serum concentrations of Lp(a) lipoprotein are twice as high in insulin dependent diabetic patients with microalbuminuria as in those without microalbuminuria. Increased concentrations of Lp(a) lipoprotein might partly explain the increased morbidity and mortality from cardiovascular disease observed among patients with diabetic nephropathy.	AKER UNIV HOSP,N-0514 OSLO 5,NORWAY; UNIV OSLO,INST MED GENET,N-0315 OSLO 3,NORWAY	University of Oslo; University of Oslo								ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ARAUZ C, 1990, DIABETES S1, V39, pA64; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BERG K, 1974, CLIN GENET, V6, P230; BERG K, 1990, FROM PHENOTYPE TO GENE IN COMMON DISORDERS, P138; Berg K., 1990, LIPOPROTEIN A, P1; BERG K, 1983, PROGR MED GENETICS, P35; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; COOPER ME, 1988, DIABETIC MED, V5, P361, DOI 10.1111/j.1464-5491.1988.tb01006.x; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLJORGENSEN K, 1988, ACTA ENDOCRINOL-COP, V117, P19, DOI 10.1530/acta.0.1170019; DAHLJORGENSEN K, 1990, DIABETES S1, V39, pA16; DAVIDHOFF E, 1989, DIABETES S2, V38, pA70; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FRICK MH, 1978, CHEST, V73, P62, DOI 10.1378/chest.73.1.62; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, LANCET, V1, P461; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; MASAREI JRL, 1984, AM J CLIN NUTR, V40, P468, DOI 10.1093/ajcn/40.3.468; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MORTON N E, 1985, Genetic Epidemiology, V2, P113, DOI 10.1002/gepi.1370020202; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSCHLAU P, 1974, Z KLIN CHEM KLIN BIO, V12, P403; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SCHRIEWER H, 1984, J CLIN CHEM CLIN BIO, V22, P591; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SIMON DI, 1990, CIRCULATION, V82, P599; VANNINI P, 1984, DIABETES CARE, V7, P151, DOI 10.2337/diacare.7.2.151; WAHLEFELD AW, 1974, METHOD ENZYMAT AN, P1831	38	123	127	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					675	678		10.1136/bmj.303.6804.675	http://dx.doi.org/10.1136/bmj.303.6804.675			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1833011	Green Published, Bronze			2022-12-24	WOS:A1991GG98000018
J	HILGEMANN, DW; NICOLL, DA; PHILIPSON, KD				HILGEMANN, DW; NICOLL, DA; PHILIPSON, KD			CHARGE MOVEMENT DURING NA+ TRANSLOCATION BY NATIVE AND CLONED CARDIAC NA+/CA2+ EXCHANGER	NATURE			English	Article							SODIUM-CALCIUM EXCHANGE; SARCOLEMMAL MEMBRANE PATCHES; CURRENT-VOLTAGE RELATIONSHIP; PIG VENTRICULAR MYOCYTES; CA EXCHANGE; GUINEA-PIG; NA/K PUMP; DEPENDENCE; STOICHIOMETRY; TRANSIENTS	Na+/Ca2+ EXCHANGE is electrogenic and moves one net positive charge per cycle 1,2. Although the cardiac exchanger has a three-to-one Na+/Ca2+ stoichiometry 3, details of the reaction cycle are not well defined 2,4-8. Here we associate Na+ translocation by the cardiac exchanger with positive charge movement in giant membrane patches from cardiac myocytes 9,10 and oocytes expressing the cloned cardiac Na+/Ca2+ exchanger 11. The charge movements are initiated by step increments of the cytoplasmic Na+ concentration in the absence of Ca2+. Giant patches from control oocytes lack both steady-state Na/Ca2+ exchange current (I(NaCa)) and Na+-induced charge movements. Charge movements indicate about 400 exchangers per mu-m2 in guinea-pig sarcolemma. Fully activated I(NaCa) densities (20-30-mu-A cm-2) indicate maximum turnover rates of 5,000 s-1. As has been predicted for consecutive exchange models 4-7, the apparent ion affinities of steady state I(NaCa) increase as the counterion concentrations are decreased. Consistent with an electroneutral Ca2+ translocation, we find that voltage dependence of I(NaCa) in both directions is lost as Ca2+ concentration is decreased. The principal electrogenic step seems to be at the extracellular end of the Na+ translocation pathway.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	HILGEMANN, DW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.							ALLEN TJA, 1986, J PHYSIOL-LONDON, V378, P77, DOI 10.1113/jphysiol.1986.sp016208; ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; BORLINGHAUS R, 1987, J MEMBRANE BIOL, V97, P161, DOI 10.1007/BF01869220; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; FENDLER K, 1987, FEBS LETT, V224, P83, DOI 10.1016/0014-5793(87)80427-1; FORBUSH B, 1984, P NATL ACAD SCI-BIOL, V81, P5310, DOI 10.1073/pnas.81.17.5310; GADSBY DC, 1989, J GEN PHYSIOL, V94, P511, DOI 10.1085/jgp.94.3.511; GLYNN IM, 1975, ANNU REV PHYSIOL, V37, P13, DOI 10.1146/annurev.ph.37.030175.000305; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HILGEMANN DW, 1988, PROG BIOPHYS MOL BIO, V51, P1, DOI 10.1016/0079-6107(88)90009-0; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; LAGNADO L, 1990, J MEMBRANE BIOL, V113, P177, DOI 10.1007/BF01870070; LAUGER P, 1987, J MEMBRANE BIOL, V99, P1, DOI 10.1007/BF01870617; LI JM, 1990, J GEN PHYSIOL, V96, P777, DOI 10.1085/jgp.96.4.777; LI ZP, 1991, J BIOL CHEM, V266, P1014; NAKAO M, 1989, J GEN PHYSIOL, V94, P539, DOI 10.1085/jgp.94.3.539; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994	24	191	194	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					715	718		10.1038/352715a0	http://dx.doi.org/10.1038/352715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876186				2022-12-24	WOS:A1991GC06400058
J	ROBINSON, DR; GULL, K				ROBINSON, DR; GULL, K			BASAL BODY MOVEMENTS AS A MECHANISM FOR MITOCHONDRIAL GENOME SEGREGATION IN THE TRYPANOSOME CELL-CYCLE	NATURE			English	Article							BRUCEI-BRUCEI; MICROTUBULES; INVITRO	THE mitochondrial genome of Trypanosoma brucei is organized in the form of a complex catenated network of circular DNA molecules. This mass of DNA, known as the kinetoplast, is present at a unique site in the single mitochondrion, and is replicated in a discrete, periodic S phase of the cell cycle. The single-copy nature of the kinetoplast suggests that there is a mechanism ensuring segregation fidelity of replicated copies to each daughter cell. Historically, speculation regarding the nature of this mechanism has often attributed significance to the close association between the kinetoplast and the flagellum basal body. We provide here direct evidence that this mitochondrial DNA complex is indeed linked to the basal body, and segregation of the kinetoplast DNA is dependent on a microtubule-mediated separation of the new and old flagellar basal bodies during the cell cycle. This unique system may represent the remnants of an evolutionarily archaic mechanism for genome segregation.	UNIV MANCHESTER, SCH MED, DEPT BIOCHEM & MOLEC BIOL, OXFORD RD, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								BRUN R, 1979, ACTA TROP, V36, P289; CHOW KC, 1988, MOL PHARMACOL, V34, P467; HIRUKI T, 1987, ZBL BAKT-INT J MED M, V264, P392; LEWIS DH, 1975, J PROTOZOOL, V22, P344, DOI 10.1111/j.1550-7408.1975.tb05184.x; MOLYNEUX DH, 1969, PARASITOLOGY, V59, P55, DOI 10.1017/S0031182000069821; OOTSU K, 1980, CANCER RES, V40, P1707; PATEL S, 1990, ANTI-CANCER DRUG DES, V5, P149; Robertson M, 1913, PHILOS T R SOC LON B, V203, P161, DOI 10.1098/rstb.1913.0005; SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; SIMPSON L, 1968, J PROTOZOOL, V15, P132, DOI 10.1111/j.1550-7408.1968.tb02097.x; SOUTOPADRON T, 1984, J CELL SCI, V69, P167; Steinert M., 1976, P193; VICKERMAN K., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P487, DOI 10.1016/0035-9203(62)90072-X; WOODS A, 1989, J CELL SCI, V93, P491	16	263	264	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					731	733		10.1038/352731a0	http://dx.doi.org/10.1038/352731a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876188	Green Submitted			2022-12-24	WOS:A1991GC06400064
J	GITTER, MJ; GOLDSMITH, SR; DUNBAR, DN; SHARKEY, SW				GITTER, MJ; GOLDSMITH, SR; DUNBAR, DN; SHARKEY, SW			COCAINE AND CHEST PAIN - CLINICAL-FEATURES AND OUTCOME OF PATIENTS HOSPITALIZED TO RULE OUT MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article							ABUSE; ISCHEMIA	Objective: To investigate the clinical features, electrocardiographic findings, and hospital course in patients admitted with acute chest pain temporally related to cocaine use. Design: Retrospective data analysis. Setting: A 485-bed county hospital. Patients: One hundred and one consecutive patients with cocaine-related chest pain admitted to the hospital to rule out myocardial infarction. Measurements and Main Results: The quality of the chest pain frequently suggested myocardial ischemia. Dyspnea was common (56%). The onset of chest pain occurred during cocaine use in 21% of patients, within 1 hour of use in 37%, and after 1 hour of use in 42%. Admission electrocardiographic findings were interpreted as normal in 32% of patients; as acute myocardial injury in 8%; as early repolarization variant in 32%; as left ventricular hypertrophy in 16%; and as "other" in 12%. Forty-three percent of patients had ST-segment elevation meeting the electrocardiographic criteria for use of thrombolytic therapy, but such elevation was usually due to the early repolarization variant. The initial total creatine kinase was elevated more than 3.3-mu-kat/L (200 U/L) in 43% of patients, and an elevated total creatine kinase was recorded at some time during the hospital course in 47% of patients. The creatine kinase MB fraction was less than 0.02 in all patients. Myocardial infarction was ruled out in all patients. No patient experienced in-hospital cardiovascular complications. Conclusion: The quality of acute chest pain related to cocaine use is indistinguishable from that experienced in acute myocardial ischemia. Abnormal or normal variant electrocardiographic findings are common in patients with chest pain related to cocaine use, but nevertheless the incidence of acute myocardial infarction is low. The ST-segment and T-wave changes can mimic acute myocardial injury and are most likely normal findings in young black men that can be readily recognized in the emergency department. Most of these patients do not require admission to an intensive	HENNEPIN CTY MED CTR, DIV CARDIOL, 701 PK AVE, MINNEAPOLIS, MN 55415 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities								AMIN M, 1990, AM J CARDIOL, V66, P1434, DOI 10.1016/0002-9149(90)90529-A; BLACKMAN NS, 1964, AM HEART J, V67, P304, DOI 10.1016/0002-8703(64)90004-3; BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U; CHELTON LG, 1955, AM J MED SCI, V230, P54, DOI 10.1097/00000441-195507000-00008; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; CREGLER LL, 1985, AM J CARDIOL, V56, P794, DOI 10.1016/0002-9149(85)91140-3; GOLDBERGER AL, 1980, MOD CONC CARDIOV DIS, V49, P13; GOLDBERGER AL, 1984, MYOCARDIAL INFARCTIO, P167; GOLDMAN MJ, 1953, AM HEART J, V46, P817, DOI 10.1016/0002-8703(53)90080-5; HERZLICH BC, 1988, ANN INTERN MED, V109, P335, DOI 10.7326/0003-4819-109-4-335; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LANGE RA, 1990, CARDIOLOGY, V8, P74; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; LITTMANN D, 1946, AM HEART J, V32, P370, DOI 10.1016/0002-8703(46)90797-1; MATHIAS DW, 1986, AM J MED, V81, P675, DOI 10.1016/0002-9343(86)90556-5; OSHER HL, 1953, AM J MED SCI, V226, P541, DOI 10.1097/00000441-195322650-00011; PASCUALLEONE A, 1990, NEUROLOGY, V40, P404, DOI 10.1212/WNL.40.3_Part_1.404; PASTERNACK PF, 1985, AM J CARDIOL, V55, P847, DOI 10.1016/0002-9149(85)90172-9; ROTH D, 1988, NEW ENGL J MED, V319, P673, DOI 10.1056/NEJM198809153191103; RUBIN RB, 1989, AM J MED, V86, P551, DOI 10.1016/0002-9343(89)90383-5; SMITH HWB, 1987, ANN INTERN MED, V107, P13, DOI 10.7326/0003-4819-107-1-13; THOMAS J, 1960, AM J CARDIOL, V5, P468, DOI 10.1016/0002-9149(60)90102-8; Thompson WP, 1943, AM HEART J, V25, P372, DOI 10.1016/S0002-8703(43)90831-2; TOKARSKI GF, 1990, ANN EMERG MED, V19, P1088, DOI 10.1016/S0196-0644(05)81509-4; WIENER L, 1964, AM HEART J, V67, P684, DOI 10.1016/0002-8703(64)90340-0; ZIMMERMAN FH, 1987, J AM COLL CARDIOL, V9, P964, DOI 10.1016/S0735-1097(87)80256-5	29	96	99	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					277	282		10.7326/0003-4819-115-4-277	http://dx.doi.org/10.7326/0003-4819-115-4-277			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854111				2022-12-24	WOS:A1991GA76400006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR DIDEOXYCYTIDINE (DDC)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-24	WOS:A1991GA07300009
J	HEEMSKERK, J; DINARDO, S; KOSTRIKEN, R; OFARRELL, PH				HEEMSKERK, J; DINARDO, S; KOSTRIKEN, R; OFARRELL, PH			MULTIPLE-MODES OF ENGRAILED REGULATION IN THE PROGRESSION TOWARDS CELL FATE DETERMINATION	NATURE			English	Article							SEGMENT-POLARITY GENE; DROSOPHILA EMBRYOS; DEVELOPMENTAL COMPARTMENTALIZATION; AUTO-REGULATION; WINGLESS GENE; EXPRESSION; LOCALIZATION; TRANSCRIPTS; PROTEIN; LOCUS	The engrailed gene product of Drosophila specifies the fate of a subset of cells in each segment. Our studies of engrailed regulation suggest that fate determination is an elaborate, multistep process. At the time in embryogenesis when the engrailed-dependent cell fate is probably determined, four modes of control act in an overlapping progression to govern engrailed expression. After activation by pair-rule genes, both an extracellular signal, wingless, and autoregulation are required for engrailed expression. Autoregulation graduates to wingless independence, but is transient, and is superseded by an engrailed- independent mode of maintenance.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Rockefeller University; University of California System; University of California Berkeley	HEEMSKERK, J (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			DiNardo, Stephen/0000-0003-4131-5511; O'Farrell, Patrick/0000-0003-0011-2734	NIGMS NIH HHS [R01 GM037193-10, R01 GM037193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEVELOPMENT, V103, P289; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CLINE TW, 1984, GENETICS, V107, P231; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DURA JM, 1988, DEVELOPMENT, V103, P733; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KASSIS JA, 1990, GENE DEV, V4, P433, DOI 10.1101/gad.4.3.433; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; POOLE SJ, 1988, DEVELOPMENT, V104, P85; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Slack J, 1983, EGG EMBRYO; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8	33	240	242	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					404	410		10.1038/352404a0	http://dx.doi.org/10.1038/352404a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861720	Green Accepted			2022-12-24	WOS:A1991FZ34600055
J	KOMIYAMA, NH; SHIH, DTB; LOOKER, D; TAME, J; NAGAI, K				KOMIYAMA, NH; SHIH, DTB; LOOKER, D; TAME, J; NAGAI, K			WAS THE LOSS OF THE D-HELIX IN ALPHA-GLOBIN A FUNCTIONALLY NEUTRAL MUTATION	NATURE			English	Article							ESCHERICHIA-COLI; HEMOGLOBIN; EXPRESSION; SEQUENCES; MYOGLOBIN	PROTEINS in the globin family are found in a variety of species from bacteria to man 1-3. From the many globin sequences known, evolutionary trees have been constructed showing that alpha and beta-globins diverged from a common ancestor between 425 and 500 million years ago, after vertebrate species had appeared and roughly when sharks and bony vertebrates diverged 4-6. The alpha and beta-globins assemble to form tetrameric haemoglobin, alpha-2-beta-2, which can switch between quaternary states having high and low oxygen affinity 7. This allows the protein to bind oxygen cooperatively and therefore efficiently transport oxygen from the lungs to respiring tissues. The alpha and beta-globins have closely related tertiary structures, being alpha-helical proteins with similar haem-binding sites. Most globins consist of eight helices, designated A to H from the N terminus, connected by short nonhelical segments, but all known vertebrate alpha-globins lack a D helix. Because the loss of this helix by alpha-globin occurred shortly before tetrameric haemoglobin appeared, it might be a functionally important mutation required for a tetramer assembly or allostery. We have now tested this idea by engineering human haemoglobins containing beta-subunits without a D helix and alpha-subunits with a D helix. Both of these mutations have little effect on the oxygen-binding properties of the molecule. Thus it is possible that deletion of the D helix in the alpha-subunit was caused by a neutral mutation 8.	MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201; STOMATOGEN INC,BOULDER,CO 80301	MRC Laboratory Molecular Biology; Oregon Health & Science University				Tame, Jeremy/0000-0002-9341-7280				ARUTYUNYAN EG, 1980, SOV PHYS-CRYSTALLOGR, V25, P43; ASCHAUER H, 1985, BIOL CHEM H-S, V366, P589, DOI 10.1515/bchm3.1985.366.1.589; BRAUNITZER G, 1961, H-S Z PHYSIOL CHEM, V325, P283, DOI 10.1515/bchm2.1961.325.1.283; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; DODSON G, 1988, PROTEIN ENG, V2, P233, DOI 10.1093/protein/2.3.233; FERMI G, 1981, ATLAS MOL STRUCTURES, V2; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; HUBER R, 1971, EUR J BIOCHEM, V19, P42, DOI 10.1111/j.1432-1033.1971.tb01285.x; Imai K, 1981, Methods Enzymol, V76, P438; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; KIMURA M, 1979, SCI AM, V241, P94; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LOVE WA, 1973, J MOL BIOL, V74, P331; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; PADLAN EA, 1974, J BIOL CHEM, V249, P4067; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; PERUTZ MF, 1990, MECHANISMS COOPERATI; ROYER WE, 1989, J BIOL CHEM, V264, P21052; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; 1985, HEMOGLOBIN, V9, P229	22	21	21	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					349	351		10.1038/352349a0	http://dx.doi.org/10.1038/352349a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852211				2022-12-24	WOS:A1991FY28900076
J	KRAMER, H; CAGAN, RL; ZIPURSKY, SL				KRAMER, H; CAGAN, RL; ZIPURSKY, SL			INTERACTION OF BRIDE OF SEVENLESS MEMBRANE-BOUND LIGAND AND THE SEVENLESS TYROSINE-KINASE RECEPTOR	NATURE			English	Article							HOMOPHILIC ADHESION MOLECULE; GROWTH-FACTOR RECEPTOR; DROSOPHILA RETINA; EGF RECEPTOR; CELL FATE; SIGNAL TRANSDUCTION; MESODERM INDUCTION; PUTATIVE RECEPTOR; PATTERN-FORMATION; FASCICLIN-III	During development of the Drosophila retina, the R8 photoreceptor neuron induces a neighbouring cell to assume an R7 cell fate. Genetic data suggest that the induction is mediated by two transmembrane proteins encoded by bride of sevenless and sevenless. A direct interaction between these two proteins was demonstrated by the heterotypic aggregation of cell lines expressing them. In the developing eye the sevenless-dependent internalization of bride of sevenless by the R7 precursor cell provides evidence for a direct interaction between these two proteins in vivo.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	KRAMER, H (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.		Cagan, Ross Leigh/AAV-9528-2021	Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181; Cagan, Ross/0000-0001-5297-450X				ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAGAFUCHI A, 1987, NATURE, V308, P693; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTTE AP, 1991, SCIENCE, V251, P570, DOI 10.1126/science.1990433; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SORACCIA P, 1990, J BIOL CHEM, V265, P4902; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	55	287	294	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					207	212		10.1038/352207a0	http://dx.doi.org/10.1038/352207a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857416				2022-12-24	WOS:A1991FX18500053
J	SHEIKH, KH; DAVIDSON, CJ; NEWMAN, GE; KISSLO, KB; SCHWAB, SJ				SHEIKH, KH; DAVIDSON, CJ; NEWMAN, GE; KISSLO, KB; SCHWAB, SJ			INTRAVASCULAR ULTRASOUND ASSESSMENT OF THE RENAL-ARTERY	ANNALS OF INTERNAL MEDICINE			English	Article						RENAL ARTERY; HYPERTENSION; ANGIOPLASTY; ANGIOGRAPHY; ULTRASONOGRAPHY	RENOVASCULAR HYPERTENSION; ANGIOPLASTY; DISEASE; SIZE	Objective: To determine the feasibility and diagnostic value of catheter-based intravascular ultrasound imaging compared with angiography for visualizing renal artery structure. Design: Renal artery images were obtained in patients with renal artery stenosis having percutaneous balloon angioplasty and in normal subjects by digital angiography and by a 20-MHz, mechanically driven, catheter-based, intravascular ultrasound imaging system. Setting. A referral-based university hospital. Patients: Four randomly selected normal subjects without known renal disease and four consecutive patients with known renal artery stenosis referred for percutaneous balloon angioplasty. Interventions: Digital angiograms and intravascular ultrasound images of nine renal artery segments were obtained. In patients with renal artery stenosis, imaging was done before and after balloon angioplasty. Main Results: Digital angiography and ultrasonography correlated closely in the determination of arterial lumen diameter (r = 0.81) and cross-sectional area (r = 0.83). However, ultrasonography provided structural information not shown by angiography. All normal arteries showed discrete intimal, medial, and adventitial wall layers by ultrasonography. In the five stenotic segments, angiography identified the cause of stenosis to be atherosclerosis in four patients and fibromuscular dysplasia in one patient. Ultrasound imaging, however, identified the disease process as atherosclerosis in three patients and as fibromuscular dysplasia in two patients. After renal angioplasty, ultrasonography identified three arterial dissections, only one of which was shown by angiography. Conclusions: These preliminary data indicate that catheter-based intravascular ultrasound imaging of the renal artery is feasible and correlates well with angiography in assessing renal artery size and also provides potentially important additional structural information that permits a better characterization of arterial pathology.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA	Duke University					NATIONAL CANCER INSTITUTE [R01CA037586] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DAVIDSON CJ, 1990, J AM COLL CARDIOL, V16, P633, DOI 10.1016/0735-1097(90)90354-R; FOSTER JH, 1975, JAMA-J AM MED ASSOC, V231, P1043, DOI 10.1001/jama.231.10.1043; GUSSENHOVEN EJ, 1989, J AM COLL CARDIOL, V14, P947, DOI 10.1016/0735-1097(89)90471-3; HARRISON EG, 1971, MAYO CLIN PROC, V46, P161; HARRISON JK, 1990, J AM COLL CARDIOL, V15, P906, DOI 10.1016/0735-1097(90)90291-V; MCCORMAC.LJ, 1966, AM HEART J, V72, P188, DOI 10.1016/0002-8703(66)90442-X; NICHOLS AB, 1989, J AM COLL CARDIOL, V13, P1094, DOI 10.1016/0735-1097(89)90267-2; PANDIAN NG, 1990, AM J CARDIOL, V65, P1278, DOI 10.1016/0002-9149(90)90993-B; PICKERING TG, 1984, AM J MED, V77, P61, DOI 10.1016/S0002-9343(84)80059-5; SOS TA, 1986, HYPERTENSION KIDNEY, P251; TEGTMEYER CJ, 1984, RADIOLOGY, V153, P77, DOI 10.1148/radiology.153.1.6236477	11	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					22	25		10.7326/0003-4819-115-1-22	http://dx.doi.org/10.7326/0003-4819-115-1-22			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1828655				2022-12-24	WOS:A1991FT93700005
J	VANDUIJN, CM; HOFMAN, A				VANDUIJN, CM; HOFMAN, A			RELATION BETWEEN NICOTINE INTAKE AND ALZHEIMERS-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; RISK-FACTORS; BINDING-SITES; CEREBRAL-CORTEX; HUMAN-BRAIN; DEMENTIA; SMOKING	Objective - To study the association between Alzheimer's disease and nicotine intake through smoking. Design - Population based case-control study. Setting - City of Rotterdam and four northern provinces of The Netherlands. Subjects - 198 patients with early onset Alzheimer's disease, 198 controls matched for age and sex, and families of 17 patients in whom Alzheimer's disease was apparently inherited as an autosomal dominant disorder. Main outcome measures - Age of onset of dementia, relative risk of Alzheimer's disease. Results - 89 of 193 patients with Alzheimer's disease had a history of smoking compared with 102 of 195 controls. Among the patients and controls with a family history of dementia, smoking was significantly less common in those with dementia (40/95 with dementia v 55/96 controls; relative risk 0.35; 95% confidence interval 0.16 to 0.78). The risk of Alzheimer's disease decreased with increasing daily number of cigarettes smoked before onset of disease (relative risk 0.3 in those smoking > 21/day v 1 in non-smokers). In six families in which the disease was apparently inherited as an autosomal dominant disorder, the mean age of onset was 4.17 years later in smoking patients than in non-smoking patients from the same family (p = 0.03). Conclusions - These findings suggest an inverse association between smoking and Alzheimer's disease, although smoking cannot be advocated for other health reasons. We speculate that nicotine may have a role in the aetiology of both Alzheimer's disease and Parkinson's disease.			VANDUIJN, CM (corresponding author), ERASMUS UNIV,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; APPEL SH, 1981, BRAIN NEUROTRANSMITT, P203; Barclay L, 1989, Prog Clin Biol Res, V317, P189; BARON JA, 1986, NEUROLOGY, V36, P1490, DOI 10.1212/WNL.36.11.1490; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; DITTER SM, 1987, NEUROLOGY, V37, P754, DOI 10.1212/WNL.37.5.754; FARRER LA, 1990, NEUROLOGY, V40, P395, DOI 10.1212/WNL.40.3_Part_1.395; FERRINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; GRAVES AB, IN PRESS INT J EPIDE; GROSSBERG GT, 1989, J AM GERIATR SOC, V37, P822; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HOFMAN A, 1989, NEUROLOGY, V39, P1589, DOI 10.1212/WNL.39.12.1589; HOFMAN A, 1989, NEUROEPIDEMIOLOGY, V8, P296, DOI 10.1159/000110197; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; JONES GMM, 1987, J NEUROL NEUROSUR PS, V50, P1383, DOI 10.1136/jnnp.50.10.1383; JOYA CJ, 1990, NEUROBIOL AGING, V11, P296; KELLAR KJ, 1987, BRAIN RES, V436, P62, DOI 10.1016/0006-8993(87)91556-3; LONDON ED, 1989, NEUROCHEM RES, V14, P745, DOI 10.1007/BF00964952; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NEWHOUSE PA, 1988, PSYCHOPHARMACOLOGY, V95, P171; PERRY EK, 1989, NEUROSCI RES COMMUN, V5, P117; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; PRICE DL, 1986, TRENDS NEUROSCI, V9, P29, DOI 10.1016/0166-2236(86)90011-1; SAHAKIAN B, 1989, BRIT J PSYCHIAT, V154, P797, DOI 10.1192/bjp.154.6.797; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; WHITEHOUSE PJ, 1988, NEUROLOGY, V38, P720, DOI 10.1212/WNL.38.5.720	34	161	175	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1491	1494		10.1136/bmj.302.6791.1491	http://dx.doi.org/10.1136/bmj.302.6791.1491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855016	Green Published, Bronze			2022-12-24	WOS:A1991FT50500018
J	FORSBURG, SL; NURSE, P				FORSBURG, SL; NURSE, P			IDENTIFICATION OF A G1-TYPE CYCLIN PUC1+ IN THE FISSION YEAST SCHIZOSACCHAROMYCES-POMBE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MATING-PHEROMONE; DNA-REPLICATION; MESSENGER-RNA; CONTROL GENE; M-PHASE; MITOSIS; PROTEIN; DIVISION	IN rapidly growing cells of the budding yeast Saccharomyces cerevisiae, the cell cycle is regulated chiefly at Start, just before the G1-S boundary 1, whereas in the fission yeast Schizosaccharomyces pombe, the cycle is predominantly regulated at G2-M (ref. 2). Both control points are present in both yeasts, and both require the p34cdc2 protein kinase 3-5. At G2-M, p34cdc2 kinase activity in S. pombe requires a B-type cyclin in a complex with p34cdc2 (refs 6-14); this complex is the same as MPF (maturation promoting factor 15,16). The p34cdc2 activity at the G1-S transition in S. cerevisiae may be regulated by a similar cyclin complex, using one of the product of a new class of cyclin genes (CLN1, CLN2 and WHI1 (DAF1/CLN3)) (refs 17-22). At least one is required for progression through the G1-S phase, and deletion of all three leads to G1 arrest 19. WHI1 was isolated as a dominant allele causing budding yeast cells to divide at a reduced size 21 and was later independently identified as DAF1, a dominant allele of which rendered the cells refractory to the G1-arrest induced by the mating pheromone alpha-factor 22. The dominant alleles are truncations thought to yield proteins of increased stability, and the cells are accelerated through G1 (refs 20, 22). Without WHI1 function, the cells are hypersensitive to alpha-factor 22, enlarged and delayed in G1 (refs 20, 22). Heretofore, this G1-class of cyclins has not been identified in other organisms. We have isolated a G1-type cyclin gene called puc1+ from S. pombe, using a functional assay in S. cerevisiae. Expression of puc1+ in S. pombe indicates that it has a cyclin-like role in the fission yeast distinct from the role of the B-type mitotic cyclin.			FORSBURG, SL (corresponding author), UNIV OXFORD, DEPT BIOCHEM,MICROBIOL UNIT,IMPERIAL CANC RES FUND, CELL CYCLE GRP, S PARKS RD, OXFORD OX1 3QU, ENGLAND.			Forsburg, Susan L/0000-0002-4895-8598				BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKACZ B, 1986, EMBO J, V5, P369, DOI 10.1002/j.1460-2075.1986.tb04221.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOEBL M, 1988, CELL, V54, P739; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SAZER S, 1990, J CELL SCI, V97, P509; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	32	87	88	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					245	248		10.1038/351245a0	http://dx.doi.org/10.1038/351245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1828291				2022-12-24	WOS:A1991FL99000061
J	SHAPIRO, BM				SHAPIRO, BM			THE CONTROL OF OXIDANT STRESS AT FERTILIZATION	SCIENCE			English	Article							SEA-URCHIN EGGS; PROTEIN CROSS-LINKING; GUANYLATE-CYCLASE; ACROSOME REACTION; INTRACELLULAR-PH; STRONGYLOCENTROTUS-PURPURATUS; EXTRACELLULAR-MATRIX; SPERM; MEMBRANE; ENVELOPE	Metazoan eggs alter their coats after fertilization to protect the early embryo. In sea urchins, this modification consists of a rapid, coordinated set of noncovalent macromolecular assembly steps that are stabilized by protein cross-linking. The sea urchin egg uses an oxidative cross-linking reaction that requires hydrogen peroxide and a secreted peroxidase and thus faces the challenge of oxidant stress at the beginning of its development. Protection from the deleterious effects of this oxidative mechanism is afforded by regulation of the production and utilization of oxidizing species. This regulation requires a specific protein kinase C-activated oxidase and ovothiol, an intracellular antioxidant.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98105 USA	University of Washington; University of Washington Seattle								BACKSTROM S, 1959, EXP CELL RES, V18, P347, DOI 10.1016/0014-4827(59)90013-8; BATTAGLIA DE, 1988, J CELL BIOL, V107, P2447, DOI 10.1083/jcb.107.6.2447; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; CHANDLER DE, 1986, CELL TISSUE RES, V246, P153; CHANDLER DE, 1980, J CELL BIOL, V84, P618, DOI 10.1083/jcb.84.3.618; CHRISTEN R, 1983, J BIOL CHEM, V258, P5392; CHRISTEN R, 1982, J BIOL CHEM, V257, P4881; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; DARSZON A, 1984, EUR J BIOCHEM, V144, P515, DOI 10.1111/j.1432-1033.1984.tb08496.x; DEITS T, 1984, J BIOL CHEM, V259, P3525; DEITS T, 1985, J BIOL CHEM, V260, P7882; DEITS TL, 1986, J BIOL CHEM, V261, P2159; DUBE F, 1985, CELL, V40, P657, DOI 10.1016/0092-8674(85)90214-4; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; EPEL D, 1969, EXP CELL RES, V58, P312, DOI 10.1016/0014-4827(69)90510-2; Epel D., 1978, Current Topics in Developmental Biology, V12, P185, DOI 10.1016/S0070-2153(08)60597-9; FAHEY RC, 1976, BIOCHIM BIOPHYS ACTA, V437, P445, DOI 10.1016/0304-4165(76)90013-1; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FOERDER CA, 1978, P NATL ACAD SCI USA, V75, P3183, DOI 10.1073/pnas.75.7.3183; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GUERRERO A, 1989, J BIOL CHEM, V264, P19593; HALL HG, 1978, CELL, V15, P343, DOI 10.1016/0092-8674(78)90003-X; Harvey EN, 1910, J EXP ZOOL, V8, P355, DOI 10.1002/jez.1400080402; HEINECKE JW, 1989, P NATL ACAD SCI USA, V86, P1259, DOI 10.1073/pnas.86.4.1259; HEINECKE JW, 1990, J BIOL CHEM, V265, P7717; HOLLER TP, 1988, J AM CHEM SOC, V110, P4837, DOI 10.1021/ja00222a057; HOLLER TP, 1990, BIOCHEMISTRY-US, V29, P1953, DOI 10.1021/bi00459a042; ISONO N, 1968, EXP CELL RES, V50, P616, DOI 10.1016/0014-4827(68)90423-0; Isono N., 1963, Journal of the Faculty of Science Tokyo University Zoology, V10, P67; JAFFE LA, 1976, NATURE, V261, P68, DOI 10.1038/261068a0; JAFFE LA, 1986, ANNU REV PHYSIOL, V48, P191, DOI 10.1146/annurev.ph.48.030186.001203; JAFFE LA, 1985, DEV BIOL, V99, P265; KAMEL LC, 1985, LIPIDS, V20, P350, DOI 10.1007/BF02534201; KAY E, 1982, CELL, V29, P867, DOI 10.1016/0092-8674(82)90448-2; KAY ES, 1987, DEV BIOL, V121, P325, DOI 10.1016/0012-1606(87)90168-0; KAY ES, 1985, BIOL FERTILIZATION, V3, P45; KLEBANOFF SJ, 1979, J EXP MED, V149, P938, DOI 10.1084/jem.149.4.938; KRANE SM, 1960, BIOCHIM BIOPHYS ACTA, V43, P369, DOI 10.1016/0006-3002(60)90461-3; LALLIER R, 1971, EXPERIENTIA, V27, P1323, DOI 10.1007/BF02136716; LALLIER R A, 1970, Experimental Cell Research, V63, P460; LASER H., 1939, PROC ROY SOC [LONDON] SER B, V126, P539, DOI 10.1098/rspb.1939.0007; LEE HC, 1983, DEV BIOL, V95, P31, DOI 10.1016/0012-1606(83)90004-0; LEE HC, 1986, J BIOL CHEM, V261, P6026; PALUMBO A, 1982, TETRAHEDRON LETT, V23, P3207, DOI 10.1016/S0040-4039(00)88597-4; PALUMBO A, 1984, COMP BIOCHEM PHYS B, V78, P81, DOI 10.1016/0305-0491(84)90149-4; PETASNE RG, 1987, NATURE, V325, P516, DOI 10.1038/325516a0; RUNNSTROM J, 1966, ADV MORPHOL, V5, P231; SCHACKMANN RW, 1984, J BIOL CHEM, V259, P3914; SCHATTEN H, 1988, CELL BIOL FERTILIZAT; SCHULZ S, 1989, FASEB J, V3, P2026, DOI 10.1096/fasebj.3.9.2568301; SHAPIRO B M, 1988, Biofactors, V1, P85; SHAPIRO BM, 1987, CELL, V49, P293, DOI 10.1016/0092-8674(87)90276-5; SHAPIRO BM, 1988, CELL BIOL FERTILIZAT, P251; Shearer C, 1922, P R SOC LOND B-CONTA, V93, P213, DOI 10.1098/rspb.1922.0016; Sies H., 1985, OXIDATIVE STRESS; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SOMERS CE, 1989, DEV BIOL, V131, P226, DOI 10.1016/S0012-1606(89)80054-5; SOMERS CE, IN PRESS J BIOL CHEM; SWEZEY RR, 1986, J CELL BIOL, V103, P1509, DOI 10.1083/jcb.103.4.1509; TAYLOR AE, 1986, PHYSL OXYGEN RADICAL; TOMBES RM, 1987, BIOPHYS J, V52, P75, DOI 10.1016/S0006-3495(87)83190-9; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; TRIMMER JS, 1986, ANNU REV CELL BIOL, V2, P1; TURNER E, 1986, J BIOL CHEM, V261, P3056; TURNER E, 1988, SCIENCE, V242, P939, DOI 10.1126/science.3187533; TURNER E, 1987, BIOCHEMISTRY-US, V26, P4028, DOI 10.1021/bi00387a043; TURNER E, 1988, RESPIRATORY BURST IT, P385; TURNER PR, 1984, NATURE, V310, P414, DOI 10.1038/310414a0; VANBAALE.C, 1966, NATURE, V211, P951; VERON M, 1977, CELL, V10, P321, DOI 10.1016/0092-8674(77)90226-4; Warburg O, 1908, H-S Z PHYSIOL CHEM, V57, P1, DOI 10.1515/bchm2.1908.57.1-2.1; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WEIDMAN PJ, 1987, J BIOL CHEM, V262, P15076; WEIDMAN PJ, 1985, J CELL BIOL, V100, P938, DOI 10.1083/jcb.100.3.938; WEIDMAN PJ, 1987, J CELL BIOL, V105, P561, DOI 10.1083/jcb.105.1.561; WHITAKER MJ, 1982, QUANT REV BIOPHYS, V15, P4; WHITAKER MJ, 1985, FERTILIZATION RESPON, V3, P168; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203	80	132	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1991	252	5005					533	536		10.1126/science.1850548	http://dx.doi.org/10.1126/science.1850548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850548				2022-12-24	WOS:A1991FJ12700037
J	FERRARI, G; ROSSINI, S; GIAVAZZI, R; MAGGIONI, D; NOBILI, N; SOLDATI, M; UNGERS, G; MAVILIO, F; GILBOA, E; BORDIGNON, C				FERRARI, G; ROSSINI, S; GIAVAZZI, R; MAGGIONI, D; NOBILI, N; SOLDATI, M; UNGERS, G; MAVILIO, F; GILBOA, E; BORDIGNON, C			AN INVIVO MODEL OF SOMATIC-CELL GENE-THERAPY FOR HUMAN SEVERE COMBINED IMMUNODEFICIENCY	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; HUMAN ADENOSINE-DEAMINASE; RETROVIRUS-MEDIATED TRANSFER; STEM-CELLS; B-CELLS; EXPRESSION; MICE; DEFICIENCY; VECTOR; CULTURE	Deficiency of adenosine deaminase (ADA) results in severe combined immunodeficiency (SCID), a candidate genetic disorder for somatic cell gene therapy. Peripheral blood lymphocytes from patients affected by ADA- SCID were transduced with a retroviral vector for human ADA and injected into immunodeficient mice. Long-term survival of vector-transduced human cells was demonstrated in recipient animals. Expression of vector-derived ADA restored immune functions, as indicated by the presence in reconstituted animals of human immunoglobulin and antigen-specific T cells. Retroviral vector gene transfer, therefore, is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.	IST SCI HS RAFFAELE,HEMATOL SERV,HEMATOL LAB,VIA OLGETTINA 60,I-20132 MILAN,ITALY; IST RIC MARIO NEGRI BERGAMO,BERGAMO,ITALY; MEM SLOAN KETTERING CANC CTR,DEPT MOLEC BIOL,NEW YORK,NY 10021	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Memorial Sloan Kettering Cancer Center			Giavazzi, Raffaella/ABB-9768-2020; Ferrari, Giuliana/AAB-5546-2019; Daniela, Maggioni/AAN-6553-2020; Giavazzi, Raffaella/J-7424-2018	Giavazzi, Raffaella/0000-0001-5249-8208; Ferrari, Giuliana/0000-0003-0790-3133; Daniela, Maggioni/0000-0001-9894-6387; Mavilio, Fulvio/0000-0003-0459-4320				ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; ARREDONDOVEGA FX, 1990, J CLIN INVEST, V86, P444, DOI 10.1172/JCI114730; BELMONT JW, 1988, MOL CELL BIOL, V8, P5116, DOI 10.1128/MCB.8.12.5116; BELMONT JW, 1986, NATURE, V322, P385, DOI 10.1038/322385a0; BENDER MA, 1989, MOL CELL BIOL, V9, P1426, DOI 10.1128/MCB.9.4.1426; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; BORDIGNON C, 1989, P NATL ACAD SCI USA, V86, P6748, DOI 10.1073/pnas.86.17.6748; BORDIGNON C, UNPUB; COLLINS SJ, 1983, P NATL ACAD SCI USA, V80, P4831; CULLITON BJ, 1989, SCIENCE, V246, P751, DOI 10.1126/science.2814495; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DISEGNI C, 1981, NUCLEIC ACIDS RES, V9, P6709; EGLITIS MA, 1985, SCIENCE, V230, P1395, DOI 10.1126/science.2999985; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GERSHON D, 1990, NATURE, V346, P402, DOI 10.1038/346402a0; GRUBER HE, 1985, SCIENCE, V230, P1057, DOI 10.1126/science.3864246; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HOCK RA, 1986, NATURE, V320, P275, DOI 10.1038/320275a0; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KANTOFF PW, 1986, P NATL ACAD SCI USA, V83, P6563, DOI 10.1073/pnas.83.17.6563; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KHAN PM, 1971, ARCH BIOCHEM BIOPHYS, V145, P470, DOI 10.1016/S0003-9861(71)80007-3; KWOK WW, 1986, P NATL ACAD SCI USA, V83, P4552, DOI 10.1073/pnas.83.12.4552; LEVY Y, 1988, J PEDIATR-US, V113, P312, DOI 10.1016/S0022-3476(88)80271-3; MARTINI A, 1985, INT J CLIN PHARM RES, V5, P149; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; ROSEN A, 1983, J IMMUNOL, V130, P2899; Sambrook J., 1989, MOL CLONING LAB MANU; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VANDERWEYDEN MB, 1978, CLIN CHIM ACTA, V82, P179, DOI 10.1016/0009-8981(78)90041-4; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877	39	113	125	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1991	251	4999					1363	1366		10.1126/science.1848369	http://dx.doi.org/10.1126/science.1848369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB733	1848369				2022-12-24	WOS:A1991FB73300046
J	BOYLE, WJ; SMEAL, T; DEFIZE, LHK; ANGEL, P; WOODGETT, JR; KARIN, M; HUNTER, T				BOYLE, WJ; SMEAL, T; DEFIZE, LHK; ANGEL, P; WOODGETT, JR; KARIN, M; HUNTER, T			ACTIVATION OF PROTEIN-KINASE-C DECREASES PHOSPHORYLATION OF C-JUN AT SITES THAT NEGATIVELY REGULATE ITS DNA-BINDING ACTIVITY	CELL			English	Article							LEUCINE ZIPPER; TRANSCRIPTION FACTOR; ONCOGENE JUN; METALLOTHIONEIN GENE; GROWTH-FACTORS; FOS PROTEINS; 3T3 CELLS; V-JUN; AP-1; PRODUCT	In resting human epithelial and fibroblastic cells, c-Jun is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 (GSK-3). These three sites are nested within a single tryptic peptide located just upstream of the basic region of the c-Jun DNA-binding domain (residues 227-252). Activation of protein kinase C results in rapid, site-specific dephosphorylation of c-Jun at one or more of these three sites and is coincident with increased AP-1-binding activity. Phosphorylation of recombinant human c-Jun proteins in vitro by GSK-3 decreases their DNA-binding activity. Mutation of serine 243 to phenylalanine blocks phosphorylation of all three sites in vivo and increases the inherent trans-activation ability of c-Jun at least 10-fold. We propose that c-Jun is present in resting cells in a latent, phosphorylated form that can be activated by site-specific dephosphorylation in response to protein kinase C activation.	SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Ludwig Institute for Cancer Research			Messier, Claude/A-2322-2008; Woodgett, Jim/F-1087-2010	Messier, Claude/0000-0002-4791-1763; Woodgett, Jim/0000-0003-3731-5797	NCI NIH HHS [CA39780, CA50528, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195, P01CA050528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, IN PRESS METH ENZYMO; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1984, CELL, V36, P259; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MULLER R, 1987, ONCOGENE RES, V2, P19; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	70	1016	1025	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					573	584		10.1016/0092-8674(91)90241-P	http://dx.doi.org/10.1016/0092-8674(91)90241-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846781				2022-12-24	WOS:A1991EX36100013
J	ZHOU, RP; OSKARSSON, M; PAULES, RS; SCHULZ, N; CLEVELAND, D; VANDEWOUDE, GF				ZHOU, RP; OSKARSSON, M; PAULES, RS; SCHULZ, N; CLEVELAND, D; VANDEWOUDE, GF			ABILITY OF THE C-MOS PRODUCT TO ASSOCIATE WITH AND PHOSPHORYLATE TUBULIN	SCIENCE			English	Article							PROTO-ONCOGENE PRODUCT; CELL-CYCLE; MEIOTIC MATURATION; XENOPUS OOCYTES; GERM-CELLS; EXPRESSION; EGGS; OOGENESIS; CLEAVAGE; PROTEINS	The mos proto-oncogene product, pp39mos, is a protein kinase and has been equated with cytostatic factor (CSF), an activity in unfertilized eggs that is thought to be responsible for the arrest of meiosis at metaphase II. The biochemical properties and potential substrates of pp39mos were examined in unfertilized eggs and in transformed cells in order to study how the protein functions both as CSF and in transformation. The pp39mos protein associated with polymers under conditions that favor tubulin oligomerization and was present in an approximately 500-kilodalton "core" complex under conditions that favor depolymerization. beta-Tubulin was preferentially coprecipitated in pp39mos immunoprecipitates and was the major phosphorylated product in a pp39mos-dependent immune complex kinase assay. Immunofluorescence analysis of NIH 3T3 cells transformed with Xenopus c-mos showed that pp39mos colocalizes with tubulin in the spindle during metaphase and in the midbody and asters during telophase. Disruption of microtubules with nocodazole affected tubulin and pp39mos organization in the same way. It therefore appears that pp39mos is a tubulin-associated protein kinase and may thus participate in the modification of microtubules and contribute to the formation of the spindle. This activity expressed during interphase in somatic cells may be responsible for the transforming activity of pp39mos.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University	ZHOU, RP (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.		Cleveland, Don/AAN-9783-2021	Paules, Richard S/0000-0001-9106-7486	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GRAETTA G, 1989, CELL, V56, P829; HEIDEMANN SR, 1980, DEV BIOL, V80, P489, DOI 10.1016/0012-1606(80)90421-2; KATZ W, 1990, MOL CELL BIOL, V10, P5286, DOI 10.1128/MCB.10.10.5286; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHIFF PB, 1979, NATURE, V277, P605; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; YEW N, IN PRESS MOL CELL BI	40	138	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					671	675		10.1126/science.1825142	http://dx.doi.org/10.1126/science.1825142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1825142				2022-12-24	WOS:A1991EW39900045
J	JACK, DB; SOPPITT, AJ				JACK, DB; SOPPITT, AJ			GIVE A DRUG A BAD NAME	BRITISH MEDICAL JOURNAL			English	Article									DUDLEY RD GEN HOSP,DEPT GASTROENTEROL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND		JACK, DB (corresponding author), FIDIA RES LABS,SCI INFORMAT SERV,I-35031 ABANO TERME,ITALY.							BLAIN J, 1990, REV PRESCRIRE    OCT; Eliot T. S., 1939, OLD POSSUMS BOOK PRA; FABER J, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92954-Z; Heller J., 1962, CATCH 22; HOFFMAN JP, 1990, NEW ENGL J MED, V323, P1428; KURTH MC, 1990, NEW ENGL J MED, V323, P1776; TOLSTOI LN, 1954, ANNA KARENINA; 1990, INDEX NOMINUM; 1991, BRIT NATIONAL FORMUL, V21	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1606	1608		10.1136/bmj.303.6817.1606	http://dx.doi.org/10.1136/bmj.303.6817.1606			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773189	Green Published, Bronze			2022-12-24	WOS:A1991GX95600022
J	ENGELMAN, A; MIZUUCHI, K; CRAIGIE, R				ENGELMAN, A; MIZUUCHI, K; CRAIGIE, R			HIV-1 DNA INTEGRATION - MECHANISM OF VIRAL-DNA CLEAVAGE AND DNA STRAND TRANSFER	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLIC DIGUANYLIC ACID; RETROVIRAL DNA; ACETOBACTER-XYLINUM; CELLULOSE SYNTHESIS; CHEMICAL SYNTHESIS; PROTEIN; INVITRO; RECOMBINATION; SEQUENCES	Retroviral DNA integration involves a coordinated set of DNA cutting and joining reactions. Linear viral DNA is cleaved at each 3' end to generate the precursor ends for integration. The resulting recessed 3' ends are inserted into target DNA by a subsequent DNA strand transfer reaction. Purified HIV-1 integration protein carries out both of these steps in vitro. Two novel forms of the dinucleotide cleaved from HIV-1 DNA were identified and one, a cyclic dinucleotide, was used to analyze the stereochemical course of viral DNA cleavage. Both viral DNA cleavage and DNA strand transfer display inversion at chiral phosphorothioates during the course of the reaction. These results suggest that both reactions occur by a one-step mechanism without involvement of a covalent protein-DNA intermediate.			ENGELMAN, A (corresponding author), NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							Berg D. E., 1989, MOBILE DNA; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BURGERS PMJ, 1979, BIOCHEMISTRY-US, V18, P592, DOI 10.1021/bi00571a007; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FUJIWARA T, 1989, P NATL ACAD SCI USA, V86, P3065, DOI 10.1073/pnas.86.9.3065; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; HONG T, 1991, J VIROL, V65, P551, DOI 10.1128/JVI.65.1.551-555.1991; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1991, P NATL ACAD SCI USA, V88, P4695, DOI 10.1073/pnas.88.11.4695; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; PAUZA CD, 1990, VIROLOGY, V179, P886; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; ROMANIUK PJ, 1982, J BIOL CHEM, V257, P7684; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; ROSS P, 1990, J BIOL CHEM, V265, P18933; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SMITH JS, 1990, J VIROL, V64, P6286, DOI 10.1128/JVI.64.12.6286-6290.1990; VARMUS H, 1989, MOBILE DNA, P53; VORA AC, 1990, J VIROL, V64, P5656, DOI 10.1128/JVI.64.11.5656-5659.1990; WHITCOMB JM, 1990, J VIROL, V64, P4903, DOI 10.1128/JVI.64.10.4903-4906.1990	43	550	568	2	42	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1211	1221		10.1016/0092-8674(91)90297-C	http://dx.doi.org/10.1016/0092-8674(91)90297-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760846				2022-12-24	WOS:A1991GX16400019
J	STROBEL, SA; DOUCETTESTAMM, LA; RIBA, L; HOUSMAN, DE; DERVAN, PB				STROBEL, SA; DOUCETTESTAMM, LA; RIBA, L; HOUSMAN, DE; DERVAN, PB			SITE-SPECIFIC CLEAVAGE OF HUMAN CHROMOSOME-4 MEDIATED BY TRIPLE-HELIX FORMATION	SCIENCE			English	Article							HUNTINGTONS-DISEASE GENE; LARGE DNA-MOLECULES; GEL-ELECTROPHORESIS; YEAST CHROMOSOME; SINGLE SITE; G8 PROBE; FIELD; MARKERS; D4S10; BINDING	Direct physical isolation of specific DNA segments from the human genome is a necessary goal in human genetics. For testing whether triple-helix mediated enzymatic cleavage can liberate a specific segment of a human chromosome, the tip of human chromosome 4, which contains the entire candidate region for the Huntington's disease gene, was chosen as a target. A 16-base pyrimidine oligodeoxyribonucleotide was able to locate a 16-base pair purine target site within more than 10 gigabase pairs of genomic DNA and mediate the exact enzymatic cleavage at that site in more than 80 percent yield. The recognition motif is sufficiently generalizable that most cosmids should contain a sequence targetable by triple-helix formation. This method may facilitate the orchestrated dissection of human chromosomes from normal and affected individuals into megabase sized fragments and facilitate the isolation of candidate gene loci.	CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	California Institute of Technology; Massachusetts Institute of Technology (MIT)	DERVAN, PB (corresponding author), CALTECH,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000329] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00098, HG00329] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BATES GP, 1991, AM J HUM GENET, V49, P7; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BIRREN BW, 1988, NUCLEIC ACIDS RES, V16, P7563, DOI 10.1093/nar/16.15.7563; BUCAN M, 1990, GENOMICS, V6, P1; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CLARK SM, 1988, SCIENCE, V241, P1203, DOI 10.1126/science.3045968; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DERVAN PB, 1988, NUCLEIC ACIDS MOL BI, V2, P49; DOUCETTESTAMM LA, IN PRESS SOMATIC CEL; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FOLSTEIN SE, 1985, SCIENCE, V229, P776, DOI 10.1126/science.2992086; GILLIAM TC, 1987, CELL, V50, P565, DOI 10.1016/0092-8674(87)90029-8; GILLIAM TC, 1987, SCIENCE, V238, P950, DOI 10.1126/science.2890209; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; GUSELLA JF, 1986, COLD SPRING HARB SYM, V51, P359, DOI 10.1101/SQB.1986.051.01.043; GUSELLA JF, IN PRESS GENOMICS; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LANDEGENT JE, 1986, HUM GENET, V73, P354, DOI 10.1007/BF00279100; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; POHL TM, 1988, NUCLEIC ACIDS RES, V16, P9185, DOI 10.1093/nar/16.19.9185; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; PRITCHARD CA, 1989, GENOMICS, V4, P408, DOI 10.1016/0888-7543(89)90348-0; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; RICHARDS B, 1991, GENOMICS, V9, P235, DOI 10.1016/0888-7543(91)90247-C; RICHARDS JE, 1988, P NATL ACAD SCI USA, V85, P6437, DOI 10.1073/pnas.85.17.6437; Saiki R.K., 1989, PCR TECHNOLOGY, P7; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SKRAASTAD MI, 1989, AM J HUM GENET, V44, P560; Smith C.L., 1988, P41; STAPLETON PM, 1988, NUCLEIC ACIDS RES, V16, P2735, DOI 10.1093/nar/16.6.2735; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; THEUNE S, 1991, GENOMICS, V9, P511, DOI 10.1016/0888-7543(91)90418-E; WASMUTH JJ, 1988, NATURE, V332, P734, DOI 10.1038/332734a0; YOUNGMAN S, 1989, GENOMICS, V5, P802, DOI 10.1016/0888-7543(89)90122-5	48	195	212	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1639	1642		10.1126/science.1836279	http://dx.doi.org/10.1126/science.1836279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1836279				2022-12-24	WOS:A1991GV07300044
J	STEIN, HF				STEIN, HF			PUPILS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2941	2942						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820456				2022-12-24	WOS:A1991GR77500001
J	RALSTON, R				RALSTON, R			COMPLEMENTATION OF TRANSFORMING DOMAINS IN E1A/MYC CHIMERAS	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; C-MYC; LARGE-T; ONCOGENES; PRODUCTS; REGIONS; GENE; CELLS; E7	THE myc oncogene is functionally similar to adenovirus E1a in its ability to collaborate with activated ras oncogenes to transform primary fibroblasts 1,2. The transforming functions of E1a and myc have been mapped to two distinct regions in each protein 3,4. I investigated the functional similarities between E1a and myc by constructing E1a/myc chimaeras to discover whether the individual transforming domains of E1a could complement individual myc-transforming domains. Transformation assays in rat embryo fibroblasts demonstrated that the N-terminal transforming domain of E1a (CR1; ref. 5) could complement the C-terminal transforming domain of myc in cis, and that the reciprocal chimaera (N-terminal myc/C-terminal E1a) was also active. Chimaeras constructed using domains from transformation-defective mutants of either E1a or myc were inactive, indicating that both E1a and myc domains contribute to function. These experiments suggest that transformation by myc and E1a may involve interactions with common substrates.			RALSTON, R (corresponding author), CHIRON CORP, 4560 HORTON ST, EMERYVILLE, CA 94608 USA.		Ralston, Robert O/A-6924-2009					ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; JONES NC, 1983, MOL CELL BIOL, V3, P2131, DOI 10.1128/MCB.3.12.2131; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	24	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 31	1991	353	6347					866	868		10.1038/353866a0	http://dx.doi.org/10.1038/353866a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1834947				2022-12-24	WOS:A1991GM73200067
J	PORAT, R; CLARK, BD; WOLFF, SM; DINARELLO, CA				PORAT, R; CLARK, BD; WOLFF, SM; DINARELLO, CA			ENHANCEMENT OF GROWTH OF VIRULENT-STRAINS OF ESCHERICHIA-COLI BY INTERLEUKIN-1	SCIENCE			English	Article							RECEPTOR ANTAGONIST; EXPRESSION; UROMODULIN; INHIBITOR; CLONING; PROTEIN; SHOCK; SERUM; BINDS; IL-1	Interleukin-1 (IL-1) is a polypeptide cytokine that mediates many physiological responses to infection and inflammation and is a growth factor for certain mammalian cells. Virulent and avirulent clinical isolates of Escherichia coli were grown in culture media in the presence of human IL-1. IL-1-beta, but not tumor necrosis factor or IL-4, enhanced the growth of virulent, but not avirulent, E. coli. This enhancement was blocked by the IL-1 receptor antagonist (IL-lra). Radiolabeled IL-1 bound to virulent but not avirulent E. coli in a specific and saturable fashion; IL-lra inhibited this binding. Thus, human IL-1 may recognize a functional IL-1-like receptor structure on virulent E. coli and may be a virulence factor for bacterial pathogenicity.	TUFTS UNIV,NEW ENGLAND MED CTR HOSP,DEPT MED,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111	Tufts Medical Center; Tufts University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI015614, R01AI015614, R37AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AREND WP, 1985, J IMMUNOL, V134, P3868; BJORNSON BH, 1988, INFECT IMMUN, V56, P1602, DOI 10.1128/IAI.56.6.1602-1607.1988; BRODY DT, 1989, J IMMUNOL, V143, P1183; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, COMMUNICATION; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; MANCILLA J, 1989, CYTOKINE, V1, P95; MCCABE WR, 1978, J INFECT DIS, V138, P33, DOI 10.1093/infdis/138.1.33; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; MUCHMORE AV, 1986, J BIOL CHEM, V261, P3404; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PORAT R, 1987, INFECT IMMUN, V55, P320, DOI 10.1128/IAI.55.2.320-328.1987; PORAT R, UNPUB; ROANTREE RJ, 1960, J CLIN INVEST, V39, P72, DOI 10.1172/JCI104029; Savage N, 1989, Cytokine, V1, P23, DOI 10.1016/1043-4666(89)91045-4; SECKINGER P, 1987, J IMMUNOL, V139, P1546; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; Sipe J D, 1988, Adv Exp Med Biol, V243, P193; STROM TB, 1988, INFECT IMMUN, V56, P1593; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816	24	159	163	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1991	254	5030					430	432		10.1126/science.1833820	http://dx.doi.org/10.1126/science.1833820			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GK729	1833820				2022-12-24	WOS:A1991GK72900049
J	CLARKE, ND; BEAMER, LJ; GOLDBERG, HR; BERKOWER, C; PABO, CO				CLARKE, ND; BEAMER, LJ; GOLDBERG, HR; BERKOWER, C; PABO, CO			THE DNA-BINDING ARM OF LAMBDA-REPRESSOR - CRITICAL CONTACTS FROM A FLEXIBLE REGION	SCIENCE			English	Article							OPERATOR; DOMAIN; OR1; CRO	Segments of protein that do not adopt a well-ordered conformation in the absence of DNA can still contribute to site-specific recognition of DNA. The first six residues (NH2-Ser1-Thr2-Lys3-Lys4-Lys5-Pro6-) of phage-lambda repressor are flexible but are important for site-specific binding. Low-temperature x-ray crystallography and codon-directed saturation mutagenesis were used to study the role of this segment. All of the functional sequences have the form [X]1-[X]2-[Lys or Arg]3-[Lys]4-[Lys or Arg]5-[X]6. A high-resolution (1.8 angstrom) crystal structure shows that Lys3 and Lys4 each make multiple hydrogen bonds with guanines and that Lys5 interacts with the phosphate backbone. The symmetry of the complex breaks down near the center of the site, and these results suggest a revision in the traditional alignment of the six lambda-operator sites.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Clarke, Neil/D-9613-2014		NIGMS NIH HHS [GM31471] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAMER L, UNPUB; BEAMER LJ, 1991, THESIS J HOPKINS U B; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; ELIASON JL, 1985, P NATL ACAD SCI USA, V82, P2339, DOI 10.1073/pnas.82.8.2339; HOCHSCHILD A, 1986, CELL, V47, P807, DOI 10.1016/0092-8674(86)90523-4; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PABO CO, 1982, NATURE, V298, P441, DOI 10.1038/298441a0; Ptashne M., 1986, A GENETIC SWITCH; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P6019, DOI 10.1073/pnas.81.19.6019	13	100	101	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1991	254	5029					267	270		10.1126/science.1833818	http://dx.doi.org/10.1126/science.1833818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GJ642	1833818				2022-12-24	WOS:A1991GJ64200033
J	GELERNTER, J; OMALLEY, S; RISCH, N; KRANZLER, HR; KRYSTAL, J; MERIKANGAS, K; KENNEDY, JL; KIDD, KK				GELERNTER, J; OMALLEY, S; RISCH, N; KRANZLER, HR; KRYSTAL, J; MERIKANGAS, K; KENNEDY, JL; KIDD, KK			NO ASSOCIATION BETWEEN AN ALLELE AT THE D2-DOPAMINE RECEPTOR GENE (DRD2) AND ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEHYDROGENASE; DEFICIENCY; JAPANESE; DISEASE; LIVER	Objective. - We attempted to replicate a positive allelic association between the A1 allele of DRD2 (the D2 dopamine receptor locus) and alcoholism that has been reported. Design. - We compared allele frequencies at the previously described Taq I restriction fragment length polymorphism system of DRD2 in alcoholics and random population controls. Subjects. - The alcoholic subjects were 44 unrelated white individuals, diagnosed by direct structured interview to have alcohol dependence (by the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition, criteria). The subjects in our random population control group (N = 68) were also white. Results. - For the control group, allele frequencies at DRD2 were 0.20 (A1) and 0.80 (A2). For the alcoholic group overall, allele frequencies were 0.23 (A1) and 0.77 (A2). There were no significant differences in allele frequencies at the DRD2 locus between alcoholics and controls. The allele frequencies in both groups agreed closely with those observed in most previously described control populations. Subtyping the alcoholic group according to presence or absence of family history of alcoholism, presence or absence of antisocial personality disorder, age of onset, presence or absence of physical withdrawal symptoms, or recent alcohol consumption (as a measure of severity) did not in any case reveal significant differences in allele frequencies. Conclusion. - We were not able to replicate the results previously reported. We conclude that our data do not support an allelic association between the A1 allele at DRD2 and alcoholism.	YALE UNIV,SCH MED,DEPT PSYCHIAT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510; UNIV CONNECTICUT,SCH MED,FARMINGTON,CT 06032; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510	Yale University; Yale University; University of Connecticut; Yale University	GELERNTER, J (corresponding author), DEPT VET AFFAIRS MED CTR,950 CAMPBELL AVE,W HAVEN,CT 06516, USA.		kranzler, henry/AAS-1113-2020	kranzler, henry/0000-0002-1018-0450; Gelernter, Joel/0000-0002-4067-1859	NIAAA NIH HHS [5RO1AA08033, P50AA03510] Funding Source: Medline; NIMH NIH HHS [MH30929] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH030929, P50MH030929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008033, P50AA003510] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; Bowcock A M, 1987, Gene Geogr, V1, P47; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BREG WR, 1980, TRISOMY 21 DOWN SYND, P205; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; COMINGS DE, 1990, AM J HUM GENET S, V47, P52; CONNEALLY PM, 1991, ARCH GEN PSYCHIAT, V48, P664; FINEMAN RM, 1976, NATURE, V260, P320, DOI 10.1038/260320a0; GELERNTER J, 1990, ARCH GEN PSYCHIAT, V47, P1073; GELERNTER J, 1990, AM J HUM GENET S, V447, P179; GOEDDE HW, 1979, HUM GENET, V51, P331; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRANDY DK, 1989, AM J HUM GENET, V45, P778; HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2; HARADA S, 1981, LANCET, V2, P982; HAUGE XY, 1991, GENOMICS, V10, P527, DOI 10.1016/0888-7543(91)90431-D; LI TK, 1977, P NATL ACAD SCI USA, V74, P4378, DOI 10.1073/pnas.74.10.4378; MERIKANGAS KR, 1990, PSYCHIAT CLIN N AM, V13, P613; MERIKANGAS KR, 1990, PSYCHOL MED, V20, P11, DOI 10.1017/S0033291700013192; Modell J G, 1990, J Neuropsychiatry Clin Neurosci, V2, P123; MOISES HW, 1991, ARCH GEN PSYCHIAT, V48, P643; NOBLE EP, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047016; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; RISCH N, 1987, AM J HUM GENET, V40, P1; Robins LN, 1985, EPIDEMIOLOGIC FIELD, P143; Sambrook J., 1989, MOL CLONING LAB MANU; SHIBUYA A, 1988, AM J HUM GENET, V43, P744; SMITH SS, 1991, JAMA-J AM MED ASSOC, V265, P2667, DOI 10.1001/jama.1991.03460200047017; Sobell M. B., 1980, EVALUATING ALCOHOL D, P129, DOI DOI 10.1016/B978-0-08-022997-3.50013-2; Spitzer R., 1985, STRUCTURED CLIN INTE; Spitzer R.L., 1975, SCHEDULE AFFECTIVE D; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; WEISSMAN MM, 1986, ARCH GEN PSYCHIAT, V43, P1104; WISE RA, 1988, J ABNORM PSYCHOL, V97, P118, DOI 10.1037/0021-843X.97.2.118; WISE RA, 1982, PHARMACOL BIOCHEM BE, V17, P239, DOI 10.1016/0091-3057(82)90076-4; WU JS, 1990, AM J HUM GENET, V46, P624; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; 1980, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC	42	223	228	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1801	1807		10.1001/jama.266.13.1801	http://dx.doi.org/10.1001/jama.266.13.1801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG551	1832467				2022-12-24	WOS:A1991GG55100032
J	GOODWIN, FK				GOODWIN, FK			STRESS OF CARING FOR THE DEMENTED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; DIAGNOSTIC STATISTIC	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1832194				2022-12-24	WOS:A1991GF41900006
J	KNOWLES, MR; CLARKE, LL; BOUCHER, RC				KNOWLES, MR; CLARKE, LL; BOUCHER, RC			ACTIVATION BY EXTRACELLULAR NUCLEOTIDES OF CHLORIDE SECRETION IN THE AIRWAY EPITHELIA OF PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEIN-KINASE-C; RESPIRATORY EPITHELIA; LUNG-DISEASE; CHANNELS; PERMEABILITY; TRANSPORT; AMILORIDE	Background. Cystic fibrosis is characterized by abnormal electrolyte transport across the epithelia of the airways. In particular, there is excessive sodium absorption and deficient chloride secretion. Drugs that block excessive sodium absorption may provide clinical benefit in cystic fibrosis, but there are no available therapeutic agents to improve chloride secretion. In vitro studies in cultured human-airway epithelia indicate that triphosphate nucleotides (ATP and UTP) induce chloride secretion through apical-membrane purinergic receptors. Methods. We tested the ability of nucleotides to induce chloride secretion in vivo in 9 normal subjects and 12 patients with cystic fibrosis by measuring responses of nasal transepithelial potential difference (PD) to superfusion of nucleotides. Changes in transepithelial bioelectric properties and the permeability of the apical membrane to chloride in response to extracellular (apical) UTP were determined with ion-selective microelectrodes in cultured nasal epithelia. Results. ATP and UTP induced chloride secretion in vivo in both groups. At their maximal effective concentrations of 10(-4) M, ATP and UTP were more effective chloride secretagogues in the patients with cystic fibrosis (mean [+/- SE] change in PD, -19.8 +/- 1.4 mV and -15.0 +/- 1.7 mV, respectively) than in the normal subjects (-6.9 +/- 0.6 mV and -8.1 +/- 0.9 mV, respectively). Microelectrode studies established that extracellular UTP stimulated a larger increase in PD and chloride secretory current in epithelial cells from patients with cystic fibrosis than in cells from normal subjects, by actions localized to the apical membrane. Conclusions. Extracellular nucleotides are effective in vivo chloride secretagogues in the nasal epithelia of patients with cystic fibrosis. The equipotency of ATP and UTP suggests that the effect is mediated by P2 nucleotide receptors. Selected nucleotides, such as UTP or nucleotide analogues, should be investigated as therapeutic agents for lung disease in cystic fibrosis.			KNOWLES, MR (corresponding author), UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CB 7020,724 BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322, P50HL019171] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-000046] Funding Source: Medline; NHLBI NIH HHS [HL-19171, HL-34322] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; Bean B P, 1990, Ion Channels, V2, P169; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; BURNS RF, 1990, ANN NY ACAD SCI, V603, P211; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHINET T, 1991, FASEB J, V5, pA1763; CLARKE L, 1991, FASEB J, V5, pA1018; CLARKE LL, 1990, PEDIATR PULM S, V5, P216; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; RIORDAN JR, 1989, SCIENCE, V245, P1066; WALTNER WE, 1987, TRENDS PHARMACOL SCI, V8, P316, DOI 10.1016/0165-6147(87)90127-1; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1045, DOI 10.1152/ajpcell.1989.256.5.C1045; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Willumsen NJ, 1989, AM J PHYSIOL, V256, pC1054, DOI 10.1152/ajpcell.1989.256.5.C1054; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P181; 1990, ANN NY ACAD SCI, V603, P1	34	475	498	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					533	538		10.1056/NEJM199108223250802	http://dx.doi.org/10.1056/NEJM199108223250802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857389	Green Submitted, Bronze			2022-12-24	WOS:A1991GB44700002
J	BINGHAM, S				BINGHAM, S			DIETARY ASPECTS OF A HEALTH STRATEGY FOR ENGLAND	BRITISH MEDICAL JOURNAL			English	Article											BINGHAM, S (corresponding author), MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 1QL,ENGLAND.							BINGHAM S, 1990, DIET CANCER BRIEFING; BRETT A, 1986, HUM NUTR-APPL NUTR, V40A, P217; BUSS DH, 1988, P NUTR SOC, V47, P295, DOI 10.1079/PNS19880047; Doll R, 1981, J NATL CANCER I, V66, P1192; Gregory F., 1990, DIETARY NUTR SURVEY; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEAN MEJ, 1988, INT J OBESITY, V12, P15; SHAPER AG, 1988, CORONARY HEART DISEA; Willett W, 1990, NUTRITIONAL EPIDEMIO; 1991, DIETARY REFERENCE VA; 1988, DHHS8850210 DEP HLTH; 1990, WHO TECH REP SER, V797; 1991, HLTH NATION; 1988, MONOGRAPH EVALUATION, V44	15	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					353	355		10.1136/bmj.303.6798.353	http://dx.doi.org/10.1136/bmj.303.6798.353			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1823133	Green Published, Bronze			2022-12-24	WOS:A1991GA60600027
J	CHUNG, SK; REINHART, PH; MARTIN, BL; BRAUTIGAN, D; LEVITAN, IB				CHUNG, SK; REINHART, PH; MARTIN, BL; BRAUTIGAN, D; LEVITAN, IB			PROTEIN-KINASE ACTIVITY CLOSELY ASSOCIATED WITH A RECONSTITUTED CALCIUM-ACTIVATED POTASSIUM CHANNEL	SCIENCE			English	Article							K+ CHANNELS; PHOSPHORYLATION; MODULATION; NEURONS; CONDUCTANCE; CELLS; BRAIN; FAMILY	Modulation of the activity of potassium and other ion channels is an essential feature of nervous system function. The open probability of a large conductance Ca2+-activated K+ channel from rat brain, incorporated into planar lipid bilayers, is increased by the addition of adenosine triphosphate (ATP) to the cytoplasmic side of the channel. This modulation takes place without the addition of protein kinase, requires Mg2+, and is mimicked by an ATP analog that serves as a substrate for protein kinases but not by a nonhydrolyzable ATP analog. Addition of protein phosphatase 1 reverses the modulation by MgATP. Thus, there may be an endogenous protein kinase activity firmly associated with this K+ channel. Some ion channels may exist in a complex that contains regulatory protein kinases and phosphatases.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA; BROWN UNIV, DIV BIOL & MED, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brandeis University; Brandeis University; Brown University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017910] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31374] Funding Source: Medline; NINDS NIH HHS [NS17910] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BARABAN JM, 1985, P NATL ACAD SCI USA, V82, P2538, DOI 10.1073/pnas.82.8.2538; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; DEPEYER JE, 1982, P NATL ACAD SCI-BIOL, V79, P4207; DOERNER D, 1988, J NEUROSCI, V8, P4069; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; GRAY MA, 1990, J MEMBRANE BIOL, V115, P203, DOI 10.1007/BF01868636; HAUNG K, 1988, J BIOL CHEM, V263, P14839; HSIAO KJ, 1978, J BIOL CHEM, V253, P6901; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LECHLEITER JD, 1988, NEURON, V1, P227, DOI 10.1016/0896-6273(88)90143-2; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; MEISLER MH, 1969, J BIOL CHEM, V244, P4961; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; SADOSHIMA JI, 1988, AM J PHYSIOL, V255, pH754, DOI 10.1152/ajpheart.1988.255.4.H754; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; TANK DW, 1982, J CELL BIOL, V92, P207, DOI 10.1083/jcb.92.1.207; WHITTAKER VP, 1964, BIOCHEM J, V90, P293, DOI 10.1042/bj0900293	28	181	186	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					560	562		10.1126/science.1857986	http://dx.doi.org/10.1126/science.1857986			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857986				2022-12-24	WOS:A1991FZ34700038
J	PINKER, S				PINKER, S			RULES OF LANGUAGE	SCIENCE			English	Article							IMPAIRMENT; WORDS	Language and cognition have been explained as the products of a homogeneous associative memory structure or alternatively, of a set of genetically determined computational modules in which rules manipulate symbolic representations. Intensive study of one phenomenon of English grammar and how it is processed and acquired suggests that both theories are partly right. Regular verbs (walk-walked) are computed by a suffixation rule in a neural system for grammatical processing; irregular verbs (run-ran) are retrieved from an associative memory.			PINKER, S (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA.		Pinker, Steven/GPX-7942-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018381] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson S. R., 1988, LINGUISTICS CAMBRIDG, VI, P146; Ariew Roger, 1989, PHILOS ESSAYS; ARONOFF M, 1983, ANNU REV ANTHROPOL, V12, P355, DOI 10.1146/annurev.an.12.100183.002035; BELLUGI U, 1990, AM J MED GENET, P115; BERKO J, 1958, WORD, V14, P150, DOI 10.1080/00437956.1958.11659661; BROWN R, 1973, 1ST LANGUAGE; BYBEE JL, 1983, LANGUAGE, V59, P251, DOI 10.2307/413574; BYBEE JL, 1982, LANGUAGE, V58, P265, DOI 10.2307/414099; Bybee JoanL., 1985, MORPHOLOGY; Chomsky N, 1980, RULES REPRESENTATION; CHOMSKY N, 1990, SOUND PATTERN ENGLIS; CURTISS S, 1988, EXCEPTIONAL BRAIN; EGEDI D, UNPUB; Fodor J. A, 1983, MODULARITY MIND; FRANCIS WN, 1982, FREQUENCY ANAL ENGLI; GOPNIK M, 1990, NATURE, V344, P715, DOI 10.1038/344715a0; GOPNIK M, IN PRESS COGNITION; GOPNIK M, 1990, LANG ACQUIS, V1, P139; GORDON P, 1985, COGNITION, V21, P73, DOI 10.1016/0010-0277(85)90046-0; HEBB DO, 1949, ORG BEHAVIOR; HICKOK G, UNPUB; Hume D., 1955, INQUIRY HUMAN UNDERS; Jespersen Otto., 1961, MODERN ENGLISH GRAMM; KEMPLEY ST, 1982, BRIT J PSYCHOL, V73, P441, DOI 10.1111/j.2044-8295.1982.tb01826.x; KIM J, IN PRESS PAP REP CHI; KIM JJ, 1991, COGNITIVE SCI, V15, P173, DOI 10.1207/s15516709cog1502_1; Kiparsky Paul, 1982, STRUCTURE PHONOLOGIC, P93; KLIMA E, UNPUB; KUCZAJ SA, 1977, J VERB LEARN VERB BE, V16, P589, DOI 10.1016/S0022-5371(77)80021-2; LACHTER J, 1988, COGNITION, V28, P195, DOI 10.1016/0010-0277(88)90033-9; LENNEBERG EH, 1967, BIOL F LANGUAGE; MARCUS G, 1990, MIT41 CTR COG SCI OC; MARIN OSM, 1976, ANN NY ACAD SCI, V280, P868, DOI 10.1111/j.1749-6632.1976.tb25550.x; MENCKEN HL, 1936, AM LANGUAGE; NEWELL A, 1961, SCIENCE, V134, P2011, DOI 10.1126/science.134.3495.2011; PINKER S, 1988, COGNITION, V28, P73, DOI 10.1016/0010-0277(88)90032-7; PRASADA S, 1990, 31ST ANN M PSYCH SOC; PRASADA S, UNPUB; Rumelhart D.E., 1986, LEARNING INTERNAL RE, V1, P318, DOI 10.1016/b978-1-4832-1446-7.50035-2; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, DOI DOI 10.7551/MITPRESS/5237.001.0001; STANNERS RF, 1979, J VERB LEARN VERB BE, V18, P399, DOI 10.1016/S0022-5371(79)90219-6; TALLAL P, 1989, J SPEECH HEAR DISORD, V54, P167, DOI 10.1044/jshd.5402.167; TOMBLIN J, UNPUB; TOMBLIN JB, 1989, J SPEECH HEAR DISORD, V54, P287, DOI 10.1044/jshd.5402.287; ULLMAN M, 1991, MAR SPRING S AAAI ST	45	564	572	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					530	535		10.1126/science.1857983	http://dx.doi.org/10.1126/science.1857983			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	FZ347	1857983				2022-12-24	WOS:A1991FZ34700029
J	KEMP, DS; BOYD, JG; MUENDEL, CC				KEMP, DS; BOYD, JG; MUENDEL, CC			THE HELICAL S-CONSTANT FOR ALANINE IN WATER DERIVED FROM TEMPLATE-NUCLEATED HELICES	NATURE			English	Article							IMMUNOGENIC PEPTIDE-FRAGMENTS; ROTATING-FRAME; ALPHA-HELIX; PROTEINS; H-1-NMR; SPECTROSCOPY	FORMATION of alpha-helices from disordered polypeptides depends on the degree to which amino acids favour the helical state. The folding of helical oligopeptides can be modelled by two parameters: sigma which reflects helix initiation and s which reflects propagation of a pre-existing helix and measures helical bias 1,2. Scheraga has reported s values for oligopeptides of about 1.1, implying a weak helical bias for amino-acid residues 3. By contrast, certain helical peptides studied by Baldwin seem to require much larger s values for alanine 4. Resolution of this inconsistency requires experiments that disentangle the ease of propagation from that of initiation. In this study varying lengths of polyalanine are linked to a 'template' that initiates helical structure and permits study solely of propagation. We report here that the s value for alanine in water is close to 1, supporting the earlier results of Scheraga but not the more recent results of Baldwin.			KEMP, DS (corresponding author), MIT,DEPT CHEM,ROOM 18-584,CAMBRIDGE,MA 02139, USA.							BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ESPOSITO G, 1987, BIOCHEMISTRY-US, V26, P1043, DOI 10.1021/bi00378a010; KARLE IL, 1987, P NATL ACAD SCI USA, V84, P5087, DOI 10.1073/pnas.84.15.5087; KEMP DS, 1988, TETRAHEDRON LETT, V29, P4931, DOI 10.1016/S0040-4039(00)80644-9; KEMP DS, IN PRESS J ORG CHEM; KEMP DS, 1990, PEPT P AM PEPT S, V11, P677; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; POLARD D, 1970, THEORY HELIX COLI TR; SCHERAGA HA, 1978, PURE APPL CHEM, V50, P315, DOI 10.1351/pac197850040315; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; WAGNER G, 1983, J AM CHEM SOC, V105, P5948, DOI 10.1021/ja00356a056; WUETHRICH K, 1984, J MOL BIOL, V180, P715; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	21	132	133	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					451	454		10.1038/352451a0	http://dx.doi.org/10.1038/352451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861726				2022-12-24	WOS:A1991FZ34600072
J	JAHN, M; ROGERS, MJ; SOLL, D				JAHN, M; ROGERS, MJ; SOLL, D			ANTICODON AND ACCEPTOR STEM NUCLEOTIDES IN TRANSFER RNAGLN ARE MAJOR RECOGNITION ELEMENTS FOR ESCHERICHIA-COLI GLUTAMINYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							IDENTITY; AMINOACYLATION; METHIONINE; INVITRO; SPECIFICITY; PARAMETERS; INVIVO; GLN	THE correct attachment of amino acids to their corresponding (cognate) transfer RNA catalysed by aminoacyl-tRNA synthetases is a key factor in ensuring the fidelity of protein biosynthesis. Previous studies have demonstrated that the interaction of Escherichia coli tRNA(Gln) with glutaminyl-tRNA synthetase (GlnRS) provides an excellent system 1 to study this highly specific recognition process, also referred to as 'tRNA identity' 2. Accurate acylation of tRNA depends mainly on two principles: a set of nucleotides in the tRNA molecule (identity elements) responsible for proper discrimination by aminoacyl-tRNA synthetases 1-3 and competition between different synthetases for tRNAs 4-6. Elements of glutamine identity are located in the anticodon 2,7-9 and in the acceptor stem region, including the discriminator base 5,10-13. We report here the production of more than 20 tRNA2Gln mutants at positions likely to be involved in tRNA discrimination by the enzyme. Unmodified tRNA, containing the wild-type anticodon and U or G at its 5'-terminus, can be aminocylated by GlnRS with similar kinetic parameters to native tRNA2Gln. By in vitro aminoacylation the mutant tRNAs showed decreases of up to 3 x 10(5)-fold in the specificity constant (k(cat)/K(M)) 14 with the major contribution of k(cat). Despite these large changes, some of these mutant tRNAs are efficient amber suppressors in vivo. Our results show that strong elements for glutamine identity reside in the anticodon region and in positions 2 and 3 of the acceptor stem, and that the contribution of different identity elements to the overall discrimination varies significantly. We discuss our data in the light of the crystal structure of the GlnRS:tRNA(Gln) complex 15,16.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University								CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; Fersht A., 1985, ENZYME STRUCTURE MEC; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOBEN PJ, 1984, THESIS YALE U; HOOPER ML, 1972, FEBS LETT, V22, P149, DOI 10.1016/0014-5793(72)80241-2; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; INOKUCHI H, 1984, P NATL ACAD SCI-BIOL, V81, P5076, DOI 10.1073/pnas.81.16.5076; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PERONA JJ, 1988, J MOL BIOL, V202, P121, DOI 10.1016/0022-2836(88)90524-4; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; REDFIELD AG, 1986, STRUCTURE DYNAMICS R, P99; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SENO T, 1974, BIOCHIM BIOPHYS ACTA, V349, P328, DOI 10.1016/0005-2787(74)90120-8; SEONG BL, 1989, J BIOL CHEM, V246, P6504; SHIMURA Y, 1972, FEBS LETT, V22, P144, DOI 10.1016/0014-5793(72)80240-0; SOLL D, 1990, EXPERIENTIA, V46, P1089; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1988, CELL, V55, P739, DOI 10.1016/0092-8674(88)90127-4	35	189	191	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					258	260		10.1038/352258a0	http://dx.doi.org/10.1038/352258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857423				2022-12-24	WOS:A1991FX18500072
J	SHIPLEY, MJ; POCOCK, SJ; MARMOT, MG				SHIPLEY, MJ; POCOCK, SJ; MARMOT, MG			DOES PLASMA-CHOLESTEROL CONCENTRATION PREDICT MORTALITY FROM CORONARY HEART-DISEASE IN ELDERLY PEOPLE - 18 YEAR FOLLOW-UP IN WHITEHALL STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To explore the extent to which the relation between plasma cholesterol concentration and risk of death from coronary heart disease in men persists into old age. Design - 18 year follow up of male Whitehall civil servants. Plasma cholesterol concentrations and other risk factors were determined at first examination in 1967-9 when they were aged 40-69. Death of men up to 31 january 1987 was recorded. Subjects-18296 male civil servants, 4155 of whom died during follow up. Main outcome measures - Cause and age of death. Cholesterol concentration in 1967-9 and number of years elapsed between testing and death. Results - 1676 men died of coronary heart disease. The mean cholesterol concentration in these men was 0.32 mmol/l higher than that in all other men (95% confidence interval 0.26 to 0.37 mmol/l). This difference in cholesterol concentrations fell 0.15 mmol/l with every 10 years' increase in age at screening. The risk of raised cholesterol concentration fell with age at death. Compared with other men cholesterol concentration in those who died of coronary heart disease was 0.44 mmol/l higher in those who died aged < 60 and 0.26 mmol/l higher in those aged 60-79 (p = 0.03). For a given age at death the longer the gap between cholesterol measurement and death the more predictive the cholesterol concentration, both for coronary heart disease and all cause mortality (trend test p = 0.06 and 0.03 respectively). Conclusion-Reducing plasma cholesterol concentrations in middle age may influence the risk of death from coronary heart disease in old age.	UCL, DEPT COMMUNITY MED, LONDON WC1E 6EA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BLOCK WD, 1966, CLIN CHEM, V10, P681; COX DR, 1972, J R STAT SOC B, V34, P187; MARMOT MG, 1986, LANCET, V2, P274; REID DD, 1974, LANCET, V1, P469; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; ROSE G, 1980, LANCET, V1, P523; 1982, JAMA-J AM MED ASSOC, V248, P2853	9	86	86	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					89	92		10.1136/bmj.303.6794.89	http://dx.doi.org/10.1136/bmj.303.6794.89			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860009	Bronze, Green Published			2022-12-24	WOS:A1991FW58600020
J	BROWNER, WS; WESTENHOUSE, J; TICE, JA				BROWNER, WS; WESTENHOUSE, J; TICE, JA			WHAT IF AMERICANS ATE LESS FAT - A QUANTITATIVE ESTIMATE OF THE EFFECT ON MORTALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MAMMARY CARCINOGENESIS; SERUM-CHOLESTEROL; RISK-FACTORS; DIETARY-FAT; BREAST-CANCER; FOLLOW-UP; CARDIOVASCULAR-DISEASE; PROSTATE-CANCER; PLASMA-LIPIDS	Americans consume an average of 37% of their energy intake as fat. Many authorities recommend restricting fat intake to 30% of energy intake to reduce the rates of coronary heart disease and perhaps of cancers of the breast, colon, and prostate. Based on the assumptions that underlie those recommendations, we estimated the effect of this dietary change on mortality. If all Americans restricted their intake of dietary fat by reducing consumption of saturated fat and accompanying dietary cholesterol, the corresponding reductions in serum cholesterol levels could reduce coronary heart disease mortality rates by 5% to 20%, depending on age. If the relationship between dietary fat and cancer is as strong as has been observed in some studies, the proportional effects on mortality from fat-related cancers could be even greater, although the absolute effects - given the lower mortality rates - would be smaller. Overall, if the assumptions are correct, about 42 000 of the 2.3 million deaths that would have occurred in adults each year in the United States could be deferred. This 2% benefit, equivalent to an increase in average life expectancy of 3 to 4 months, would accrue chiefly to people over the age of 65 years. If recent concerns about the possibly harmful effects of cholesterol lowering on mortality from noncardiovascular causes - which mainly affect younger persons - are valid, these relatively modest benefits would be overestimates of the actual effect.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT EPIDEMIOL & BIOSTAT, DIV CLIN EPIDEMIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BROWNER, WS (corresponding author), VET AFFAIRS MED CTR, DEPT MED, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA.			Tice, Jeffrey/0000-0002-9857-2028				ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BANSAL BR, 1978, CANCER RES, V38, P3293; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BRADEN LM, 1986, LIPIDS, V21, P285, DOI 10.1007/BF02536414; BROWNER WS, 1986, AM J EPIDEMIOL, V123, P143, DOI 10.1093/oxfordjournals.aje.a114208; BULL AW, 1979, CANCER RES, V39, P4956; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHAN PC, 1983, CANCER RES, V43, P1079; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DAO TL, 1983, J NATL CANCER I, V71, P201; ERNST N, 1980, LANCET, V2, P111; FISHER M, 1989, ARCH INTERN MED, V149, P1726, DOI 10.1001/archinte.149.8.1726; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709; GRAHAM S, 1983, JNCI-J NATL CANCER I, V70, P687; GRAY GE, 1979, BRIT J CANCER, V39, P1, DOI 10.1038/bjc.1979.1; HAENSZEL W, 1973, J NATL CANCER I, V51, P1765, DOI 10.1093/jnci/51.6.1765; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HESHMAT MY, 1985, PROSTATE, V6, P7, DOI 10.1002/pros.2990060103; HIATT RA, 1986, J CHRON DIS, V39, P861, DOI 10.1016/0021-9681(86)90034-2; HILL AB, 1971, PRINCIPLES MED STATI, P220; HOPKINS GJ, 1981, J NATL CANCER I, V66, P517; INGRAM D M, 1981, Nutrition and Cancer, V3, P75; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JAIN M, 1980, INT J CANCER, V26, P757, DOI 10.1002/ijc.2910260609; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; JONES DY, 1987, AM J CLIN NUTR, V45, P1451, DOI 10.1093/ajcn/45.6.1451; KANNEL WB, 1988, CLIN CHEM, V34, pB53; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KEYS A, 1974, AM J CLIN NUTR, V27, P188, DOI 10.1093/ajcn/27.2.188; KEYS A, 1965, METABOLIS, V14, P759, DOI 10.1016/0026-0495(65)90002-8; KNEKT P, 1988, J CLIN EPIDEMIOL, V41, P519, DOI 10.1016/0895-4356(88)90056-X; KRITCHEVSKY D, 1984, CANCER RES, V44, P3174; MACQUARTMOULIN G, 1986, INT J CANCER, V38, P183, DOI 10.1002/ijc.2910380207; MARTIN MJ, 1986, LANCET, V2, P933; MILLER AB, 1978, AM J EPIDEMIOL, V107, P499, DOI 10.1093/oxfordjournals.aje.a112569; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; PAGE IH, 1961, CIRCULATION, V23, P133, DOI 10.1161/01.CIR.23.1.133; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; POTTER JD, 1986, JNCI-J NATL CANCER I, V76, P557, DOI 10.1093/jnci/76.4.557; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; Ravenholt R T, 1985, Am J Prev Med, V1, P4; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROBERTSON L, 1983, INJUIRES CAUSES CONT, P9; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SNOWDON DA, 1984, AM J EPIDEMIOL, V120, P244, DOI 10.1093/oxfordjournals.aje.a113886; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; VANTVEER P, 1990, INT J EPIDEMIOL, V19, P12, DOI 10.1093/ije/19.1.12; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILLETT WC, 1984, NEW ENGL J MED, V310, P633, DOI 10.1056/NEJM198403083101006; WILLETT WC, 1984, NEW ENGL J MED, V310, P697, DOI 10.1056/NEJM198403153101106; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; 1988, NCI NIH882789 US DEP; 1966, DIETARY FAT HUMAN HL; 1988, SURGEON GENERALS REP; 1984, NUTRITION CANCER CAU; 1988, US BUREAU CENSUS P25, V1000; 1984, NCI NIH842671 US DEP; 1985, KJAMA, V253, P2080; [No title captured]; 1983, DHHHS PHS831681 US D; 1977, 052070039132 PUBL; 1985, INJURY AM CONTINUING, P23; 1979, DHEW PHS7955071 PUBL; 1984, CIRCULATION, V70, pA153; 1988, VITAL STATISTICS U A, V2	77	79	81	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3285	3291		10.1001/jama.265.24.3285	http://dx.doi.org/10.1001/jama.265.24.3285			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1801770				2022-12-24	WOS:A1991FR83500036
J	MARTUZA, RL; MALICK, A; MARKERT, JM; RUFFNER, KL; COEN, DM				MARTUZA, RL; MALICK, A; MARKERT, JM; RUFFNER, KL; COEN, DM			EXPERIMENTAL-THERAPY OF HUMAN GLIOMA BY MEANS OF A GENETICALLY ENGINEERED VIRUS MUTANT	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; ACYCLOVIR-RESISTANT HERPES; ACQUIRED IMMUNODEFICIENCY SYNDROME; RADIATION-THERAPY; MALIGNANT GLIOMA; INFECTIONS; RADIOTHERAPY; FOSCARNET; GLIOBLASTOMA; THYMIDINE	Malignant gliomas are the most common malignant brain tumors and are almost always fatal. A thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas. In cell culture, dlsptk killed two long-term human glioma lines and three short-term human glioma cell populations. In nude mice with implanted subcutaneous and subrenal U87 human gliomas, intraneoplastic inoculation of dlsptk caused growth inhibition. In nude mice with intracranial U87 gliomas, intraneoplastic inoculation of dlsptk prolonged survival. Genetically engineered viruses such as dlsptk merit further evaluation as novel antineoplastic agents.	HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,DEPT SURG NEUROSURG,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; UNIV MICHIGAN,MED CTR,DIV NEUROSURG,ANN ARBOR,MI 48109	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan	MARTUZA, RL (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,MOLEC NEUROGENET LAB,BOSTON,MA 02129, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7RRO5381] Funding Source: Medline; NIAID NIH HHS [R01-AI26126] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Austin F C, 1979, Adv Cancer Res, V30, P301, DOI 10.1016/S0065-230X(08)60900-8; BURDICK KH, 1964, CANCER, V17, P708, DOI 10.1002/1097-0142(196406)17:6<708::AID-CNCR2820170604>3.0.CO;2-3; CASSEL WA, 1983, CANCER, V52, P856, DOI 10.1002/1097-0142(19830901)52:5<856::AID-CNCR2820520519>3.0.CO;2-4; CHATIS PA, 1989, NEW ENGL J MED, V320, P297, DOI 10.1056/NEJM198902023200507; COEN DM, 1985, J VIROL, V53, P477, DOI 10.1128/JVI.53.2.477-488.1985; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; ERLICH KS, 1989, ANN INTERN MED, V110, P710, DOI 10.7326/0003-4819-110-9-710; FIELD HJ, 1978, J HYG-CAMBRIDGE, V81, P267, DOI 10.1017/S0022172400025109; FIELD HJ, 1980, ANTIMICROB AGENTS CH, V17, P209, DOI 10.1128/AAC.17.2.209; HIRSCH MS, 1983, NEW ENGL J MED, V309, P963; HIRSCH MS, 1983, NEW ENGL J MED, V309, P1034; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; JAMIESON AT, 1974, J GEN VIROL, V24, P465, DOI 10.1099/0022-1317-24-3-465; KIM TS, IN PRESS J NEUROSURG; Kobayashi H, 1979, Adv Cancer Res, V30, P279; LEE JK, 1990, NEUROSURGERY, V26, P598, DOI 10.1227/00006123-199004000-00007; LEVIN AL, 1989, CANC PRINCIPLES PRAC, V2, P1557; Luna LG, 1968, MANUAL HISTOLOGIC ST; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MEDHKOUR A, 1989, J NEUROSURG, V71, P545, DOI 10.3171/jns.1989.71.4.0545; MOORE A. E., 1960, PROGR EXPTL TUMOR RES, V1, P411; ONOYAMA Y, 1976, AM J ROENTGENOL, V126, P481, DOI 10.2214/ajr.126.3.481; PEARSON HE, 1956, P SOC EXP BIOL MED, V92, P551; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SALAZAR OM, 1979, INT J RADIAT ONCOL, V5, P1733, DOI 10.1016/0360-3016(79)90554-6; SAUTER C, 1978, CURRENT CHEMOTHERAPY, P1112; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; SHAPIRO WR, 1989, J NEUROSURG, V71, P1, DOI 10.3171/jns.1989.71.1.0001; SIGEL MM, 1955, J IMMUNOL, V75, P386; SOUTHAM CHESTER M., 1960, TRANS NEW YORK ACAD SCI, V22, P657; TENSER RB, 1979, SCIENCE, V205, P915, DOI 10.1126/science.224454; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; YOULE MM, 1988, LANCET, V2, P341	36	741	815	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					854	856		10.1126/science.1851332	http://dx.doi.org/10.1126/science.1851332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1851332				2022-12-24	WOS:A1991FL12300050
J	ADAMS, SR; HAROOTUNIAN, AT; BUECHLER, YJ; TAYLOR, SS; TSIEN, RY				ADAMS, SR; HAROOTUNIAN, AT; BUECHLER, YJ; TAYLOR, SS; TSIEN, RY			FLUORESCENCE RATIO IMAGING OF CYCLIC-AMP IN SINGLE CELLS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; RESONANCE ENERGY-TRANSFER; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; TRANSFER MICROSCOPY; SKELETAL-MUSCLE; EXPRESSION; COMPARTMENTS; RECEPTOR; PROBES	FLUORESCENCE imaging is perhaps the most powerful technique currently available for continuously observing the dynamic intracellular biochemistry of single living cells 1. However, fluorescent indicator dyes have been available only for simple inorganic ions such as Ca2+, H+, Na+, K+, Mg2+ and Cl-. We now report a fluorescent indicator for the adenosine 3',5'-cyclic monophosphate (cAMP) signalling pathway. The sensor consists of cAMP-dependent protein kinase 2 in which the catalytic (C) and regulatory (R) subunits are each labelled with a different fluorescent dye such as fluorescein or rhodamine capable of fluorescence resonance energy transfer in the holoenzyme complex R2C2. When cAMP molecules bind to the R subunits, the C subunits dissociate, thereby eliminating energy transfer. The change in shape of the fluorescence emission spectrum allows cAMP concentrations and the activation of the kinase to be nondestructively visualized in single living cells microinjected with the labelled holoenzyme.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST M-047, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM M-054, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego								BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; BUCHLER W, 1990, EUR J BIOCHEM, V188, P253, DOI 10.1111/j.1432-1033.1990.tb15397.x; CARDULLO RA, 1988, P NATL ACAD SCI USA, V85, P8790, DOI 10.1073/pnas.85.23.8790; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P32; HAYES JS, 1982, J CYCLIC NUCL PROT, V8, P1; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; HUGHES RJ, 1982, MOL PHARMACOL, V22, P258; JOHNSON DA, 1984, J BIOL CHEM, V259, P5717; JOVIN TM, 1989, ANNU REV BIOPHYS BIO, V18, P271, DOI 10.1146/annurev.bb.18.060189.001415; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MURRAY KJ, 1989, MOL CELL BIOCHEM, V89, P175; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SLICE LW, 1989, J BIOL CHEM, V264, P20940; TAYLOR SS, 1978, J BIOL CHEM, V253, P2284; TAYLOR SS, 1990, REV BIOCH, V59, P971; TERASAKI WL, 1977, J BIOL CHEM, V252, P1041; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.ne.12.030189.001303; USTER PS, 1986, J CELL BIOL, V103, P1221, DOI 10.1083/jcb.103.4.1221; WILLIAMS DA, 1990, CELL CALCIUM, V11, P55, DOI 10.1016/0143-4160(90)90058-3; WU FYH, 1974, BIOCHEMISTRY-US, V13, P2567, DOI 10.1021/bi00709a015; YAMASHITA T, 1986, J BIOL CHEM, V261, P6878	30	549	580	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					694	697		10.1038/349694a0	http://dx.doi.org/10.1038/349694a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1847505				2022-12-24	WOS:A1991EY62700047
J	BRUGGEMEIER, U; KALFF, M; FRANKE, S; SCHEIDEREIT, C; BEATO, M				BRUGGEMEIER, U; KALFF, M; FRANKE, S; SCHEIDEREIT, C; BEATO, M			UBIQUITOUS TRANSCRIPTION FACTOR OTF-1 MEDIATES INDUCTION OF THE MMTV PROMOTER THROUGH SYNERGISTIC INTERACTION WITH HORMONE RECEPTORS	CELL			English	Article							MAMMARY-TUMOR VIRUS; RNA POLYMERASE-II; HEAVY-CHAIN PROMOTER; HISTONE H2B GENE; GLUCOCORTICOID RECEPTOR; BINDING-PROTEIN; ADENOVIRUS ORIGIN; STEROID-HORMONES; DNA-REPLICATION; OCTAMER MOTIF	Steroid hormones induce transcription from the mouse mammary tumor virus (MMTV) promoter by complex mechanisms requiring binding of the hormone receptors to the hormone responsive element (HRE) of the long terminal repeat region. Here we show that the MMTV promoter contains two degenerated octamer motifs immediately upstream of the TATA box that together bind OTF-1 (Oct-1, NFIII) with an affinity similar to the octamer consensus. In transfection experiments, mutation of these octamer motifs interferes with the hormonal response of the MMTV promoter. In vitro, these mutations do not influence basal transcription but completely abolish the stimulatory effect of purified progesterone receptor. Progesterone receptor and glucocorticoid receptor bound to the HRE facilitate binding of OTF-1 to the two octamer motifs. Thus, OTF-1 is a natural mediator of hormonal induction of the MMTV promoter and acts through cooperation with the hormone receptors for binding to DNA.	MAX PLANCK INST MOLEC GENET, W-1000 BERLIN, GERMANY	Max Planck Society	BRUGGEMEIER, U (corresponding author), INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, W-3550 MARBURG, GERMANY.		Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GODING CR, 1989, VIROLOGY, V173, P363; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	49	207	209	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 8	1991	64	3					565	572		10.1016/0092-8674(91)90240-Y	http://dx.doi.org/10.1016/0092-8674(91)90240-Y			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1846780				2022-12-24	WOS:A1991EX36100012
J	HALLER, RG; LEWIS, SF				HALLER, RG; LEWIS, SF			GLUCOSE-INDUCED EXERTIONAL FATIGUE IN MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCLEAR MAGNETIC-RESONANCE; MCARDLES DISEASE; CARDIAC-OUTPUT; EXERCISE; METABOLISM; SPECTROSCOPY	Background. The exercise capacity of patients with muscle phosphofructokinase deficiency is low and fluctuates from day to day. The basis of this variable exercise tolerance is unknown, but out patients with this disorder report that fatigue of active muscles is more rapid after a high-carbohydrate meal. Methods and Results. To determine the effect of carbohydrate on exercise performance, we asked four patients with muscle phosphofructokinase deficiency to perform cycle exercise under conditions of differing availability of substrate - i.e., after an overnight fast, and during an infusion of glucose or triglyceride (with 10 U of heparin per kilogram of body weight) after an overnight fast. As compared with fasting and the infusion of triglyceride with heparin, the glucose infusion lowered plasma levels of free fatty acids and ketones, reduced maximal work capacity by 60 to 70 percent, and lowered maximal oxygen consumption by 30 to 40 percent. Glucose also increased the relative intensity of submaximal exercise, as indicated by a higher heart rate at a given workload during exercise. The maximal cardiac output (i.e., oxygen delivery) was not affected by varying substrate availability, but the maximal systemic arteriovenous oxygen difference was significantly lower during glucose infusion (mean +/- SE, 5.5 +/- 0.3 ml per deciliter) than after fasting (7.6 +/- 0.4 ml per deciliter, P < 0.05) or during the infusion of triglyceride with heparin (8.9 +/- 1.3 ml per deciliter, P < 0.05). Conclusions. In muscle phosphofructokinase deficiency, the oxidative capacity of muscle and the capacity for aerobic exercise vary according to the availability of blood-borne fuels. We believe that glucose infusion lowers exercise tolerance by inhibiting lipolysis and thus depriving muscle of oxidative substrate (plasma free fatty acids and ketones); this impairs the capacity of working muscle to extract oxygen and lowers maximal oxygen consumption.	DEPT VET AFFAIRS MED CTR, DEPT PHYSIOL, DALLAS, TX USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA; DEPT VET AFFAIRS MED CTR, DEPT NEUROL, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCRR NIH HHS [M01-RR-00633] Funding Source: Medline; NHLBI NIH HHS [HL-01581, HL-06296] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296, K04HL001581] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGAMANOLIS DP, 1980, MUSCLE NERVE, V3, P456, DOI 10.1002/mus.880030602; ARGOV Z, 1987, ANN NEUROL, V22, P46, DOI 10.1002/ana.410220112; DIMAURO S, 1986, MYOLOGY, P1585; DUBOC D, 1987, NEUROLOGY, V37, P663, DOI 10.1212/WNL.37.4.663; EDWARDS RHT, 1982, LANCET, V1, P725; GOLLNICK PD, 1985, FED PROC, V44, P353; HALLER RG, 1986, NEUROLOGY, V36, P716, DOI 10.1212/WNL.36.5.716; HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135; HALLER RG, 1985, ANN NEUROL, V17, P196, DOI 10.1002/ana.410170216; LAUWERYS RR, 1969, ANAL BIOCHEM, V32, P331, DOI 10.1016/0003-2697(69)90093-1; LAYZER RB, 1967, ARCH NEUROL-CHICAGO, V17, P512, DOI 10.1001/archneur.1967.00470290066009; LEWIS SF, 1985, J APPL PHYSIOL, V59, P1991, DOI 10.1152/jappl.1985.59.6.1991; LEWIS SF, 1986, J APPL PHYSIOL, V61, P391, DOI 10.1152/jappl.1986.61.2.391; LEWIS SF, 1984, J APPL PHYSIOL, V57, P1749, DOI 10.1152/jappl.1984.57.6.1749; LEWIS SF, 1989, EXERCISE SPORT SCI R, V17, P67; MINEO I, 1984, MUSCLE NERVE, V7, P552, DOI 10.1002/mus.880070706; PEARSON CM, 1961, AM J MED, V30, P502, DOI 10.1016/0002-9343(61)90075-4; PERNOW BB, 1967, ACTA MED SCAND, VS, P294; PORTE D, 1966, NEW ENGL J MED, V275, P406, DOI 10.1056/NEJM196608252750802; ROWLAND LP, 1986, MYOLOGY, P1603; Sahlin K., 1986, BIOCH EXERCISE, VVI, P323; SCHMID R, 1959, J CLIN INVEST, V38, P2044, DOI 10.1172/JCI103983; TARUI S, 1984, NEUROMUSCULAR DISEAS, P71; TRIEBWASSER JH, 1977, AVIAT SPACE ENVIR MD, V48, P203; VORA S, 1983, J CLIN INVEST, V72, P1995, DOI 10.1172/JCI111164; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090	26	63	63	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 7	1991	324	6					364	369		10.1056/NEJM199102073240603	http://dx.doi.org/10.1056/NEJM199102073240603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EW296	1824792	Bronze			2022-12-24	WOS:A1991EW29600003
J	BOKOCH, GM; QUILLIAM, LA; BOHL, BP; JESAITIS, AJ; QUINN, MT				BOKOCH, GM; QUILLIAM, LA; BOHL, BP; JESAITIS, AJ; QUINN, MT			INHIBITION OF RAP1A BINDING TO CYTOCHROME-B558 OF NADPH OXIDASE BY PHOSPHORYLATION OF RAP1A	SCIENCE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; RAS-RELATED PROTEIN; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; RAS-P21 GTPASE; COMPONENTS; ACTIVATION; GENE; CELL	Rap1A is a low molecular weight guanosine triphosphate (GTP)-binding protein in human neutrophil membranes whose cellular function is unknown. Rap1A was found to form stoichiometric complexes with the cytochrome b558 component of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system. The (guanosine-5'-O-(3-thiotriphosphate) (GTP-gamma-S)-bound form of Rap1A bound more tightly to cytochrome b558 than did the guanosine diphosphate-bound form. No complex formation was observed between cytochrome b558 and H-Ras-GTP-gamma-S or Rap1A-GTP-gamma-S that had been heat-inactivated, nor between Rap1A-GTP-gamma-S and hydrophobic proteins serving as controls. Complex formation between Rap1A-GTP-gamma-S and cytochrome b558 was inhibited by phosphorylation of Rap1A with cyclic adenosine monophosphate (cAMP)-dependent protein kinase. These observations suggest that Rap1A may participate in the structure or regulation of the NADPH oxidase system and that this function of the Rap1A protein may be altered by phosphorylation.	MONTANA STATE UNIV, DEPT CHEM, BOZEMAN, MT 59717 USA; MONTANA STATE UNIV, DEPT BIOCHEM, BOZEMAN, MT 59717 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Scripps Research Institute	BOKOCH, GM (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Jesaitis, Algirdas/0000-0001-9001-5617	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44428, GM39434] Funding Source: Medline; PHS HHS [5RO126711] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOKOCH GM, UNPUB; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; DER CJ, 1989, ONCOGENES, P73; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GABIG TG, 1987, J BIOL CHEM, V262, P1685; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; IGNARRO LJ, 1974, J EXP MED, V139, P1398; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MUELLER H, 1988, MOL PHARMACOL, V34, P347; MUELLER H, 1989, J CELL BIOCHEM, V40, P27; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PEVERI P, 1989, BLOOD, V74, P397; PIZON V, 1988, ONCOGENE, V3, P201; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; RIVKIR I, 1975, J IMMUNOL, V115, P112; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SEGAL AW, 1983, NEW ENGL J MED, V308, P245, DOI 10.1056/NEJM198302033080503; SMITH RM, 1989, J BIOL CHEM, V264, P1958; TAKAI Y, IN PRESS SIGNAL TRAN, V3; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; YATANI Y, 1991, IN PRESS J BIOL CHEM; ZURIER RB, 1973, J CELL BIOL, V58, P27, DOI 10.1083/jcb.58.1.27	42	109	111	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1794	1796		10.1126/science.1763330	http://dx.doi.org/10.1126/science.1763330			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763330				2022-12-24	WOS:A1991GW31600044
J	POWER, RF; MANI, SK; CODINA, J; CONNEELY, OM; OMALLEY, BW				POWER, RF; MANI, SK; CODINA, J; CONNEELY, OM; OMALLEY, BW			DOPAMINERGIC AND LIGAND-INDEPENDENT ACTIVATION OF STEROID-HORMONE RECEPTORS	SCIENCE			English	Article							CHICKEN PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; MOLECULAR-CLONING; RAT-BRAIN; COMPLEMENTARY-DNA; ADENYLATE-CYCLASE; RESPONSE ELEMENT; ESTROGEN; GENE; TRANSCRIPTION	The current view of how steroid hormone receptors affect gene transcription is that these receptors, on binding ligand, change to a state in which they can interact with chromatin and regulate transcription of target genes. Receptor activation is believed to be dependent only on this ligand-binding event. Selected steroid hormone receptors can be activated in a ligand-independent manner by a membrane receptor agonist, the neurotransmitter dopamine. In vitro, dopamine faithfully mimicked the effect of progesterone by causing a translocation of chicken progesterone receptor (cPR) from cytoplasm to nucleus. Dual activation by progesterone and dopamine was dissociable, and a serine residue in the cPR was identified that is not necessary for progesterone-dependent activation of cPR, but is essential for dopamine activation of this receptor.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	OMALLEY, BW (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							APERIA A, 1990, AM J HYPERTENS, V3, pS11, DOI 10.1093/ajh/3.6.11S; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEYER C, 1981, PHYSIOL BEHAV, V26, P249, DOI 10.1016/0031-9384(81)90019-6; BLAUSTEIN JD, 1980, NEUROENDOCRINOLOGY, V31, P403, DOI 10.1159/000123110; BOGIC L, 1988, ENDOCRINOLOGY, V122, P2735, DOI 10.1210/endo-122-6-2735; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CONNEELY OM, 1987, BIOCHEM BIOPH RES CO, V149, P493, DOI 10.1016/0006-291X(87)90395-0; CONNEELY OM, 1989, J BIOL CHEM, V264, P14062; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DEKLOFT ER, 1985, EUR J PHARMACOL, V118, P185, DOI 10.1016/0014-2999(85)90679-X; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DENNER LA, UNPUB; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELDER CC, 1989, J BIOL CHEM, V264, P8739; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gorski J, 1968, Recent Prog Horm Res, V24, P45; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUICHONMANTEL A, 1989, CELL, V57, P1147; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; MOBLEY PL, 1983, J PHARMACOL EXP THER, V226, P71; MOBLEY PL, 1980, NATURE, V286, P608, DOI 10.1038/286608a0; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; O'Malley B W, 1969, Recent Prog Horm Res, V25, P105; OKULICZ WC, 1989, ENDOCRINOLOGY, V125, P930, DOI 10.1210/endo-125-2-930; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PARSONS B, 1980, ENDOCRINOLOGY, V107, P774, DOI 10.1210/endo-107-3-774; POWER R, UNPUB; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; REKER CE, 1987, J STEROID BIOCHEM, V26, P653, DOI 10.1016/0022-4731(87)91037-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER M, 1990, TRENDS NEUROSCI, V13, P359, DOI 10.1016/0166-2236(90)90016-4; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHOLL SA, 1986, ENDOCRINOLOGY, V119, P1625, DOI 10.1210/endo-119-4-1625; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEIMER T, 1981, NATURE, V292, P345, DOI 10.1038/292345a0; STRALFORS P, 1989, EUR J BIOCHEM, V180, P143, DOI 10.1111/j.1432-1033.1989.tb14624.x; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SULSER F, 1986, J CLIN PSYCHIAT, V10, P13; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TORO MJ, 1987, MOL ENDOCRINOL, V1, P669, DOI 10.1210/mend-1-10-669; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEIGEL N, UNPUB; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	56	528	538	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1636	1639		10.1126/science.1749936	http://dx.doi.org/10.1126/science.1749936			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749936				2022-12-24	WOS:A1991GV07300043
J	LINGNER, J; KELLERMANN, J; KELLER, W				LINGNER, J; KELLERMANN, J; KELLER, W			CLONING AND EXPRESSION OF THE ESSENTIAL GENE FOR POLY(A) POLYMERASE FROM SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							BINDING-PROTEIN; YEAST; IDENTIFICATION; SEQUENCE; INVITRO; MOTIFS	POLY(A) polymerase is essential for the maturation of messenger RNA, adding tracts of adenosine residues to the 3' end of precursor RNA generated by endonucleolytic cleavage. This mechanism of MRNA 3' processing seems to be similar in yeast and in higher eucaryotes 1, although there are differences in the recognition signals in the pre-mRNA 2. Here we describe the cloning of the gene for yeast poly(A) polymerase. The enzyme is encoded by a single and essential gene located near the centromere on the left arm of chromosome 11. Poly(A) polymerase purified from recombinant Escherichia coli has the same physical and biochemical properties as the yeast enzyme. The yeast poly(A) polymerase shares features of sequence with its mammalian homologue 3,4.	MAX PLANCK INST BIOCHEM, GENZENTRUM, W-8033 MARTINSRIED, GERMANY	Max Planck Society	LINGNER, J (corresponding author), UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND.			Lingner, Joachim/0000-0002-2853-5803				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LUNDBLAD V, 1990, CELL, V60, P529; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, IN PRESS EMBO J; YEH E, 1986, MOL CELL BIOL, V6, P158, DOI 10.1128/MCB.6.1.158; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	30	113	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1991	354	6353					496	498		10.1038/354496a0	http://dx.doi.org/10.1038/354496a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV078	1840648				2022-12-24	WOS:A1991GV07800066
J	HANCOCK, SL; COX, RS; MCDOUGALL, IR				HANCOCK, SL; COX, RS; MCDOUGALL, IR			THYROID-DISEASES AFTER TREATMENT OF HODGKINS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECK IRRADIATION; GRAVES-DISEASE; RADIATION-THERAPY; MANTLE IRRADIATION; FOLLICULAR CARCINOMA; RADIOTHERAPY; DYSFUNCTION; HYPOTHYROIDISM; HYPERTHYROIDISM; OPHTHALMOPATHY	Background and Methods. Thyroid disease, especially hypothyroidism, is common in patients with Hodgkin's disease who have been treated with irradiation. We reviewed the records of 1787 patients (740 women and 1047 men) with Hodgkin's disease who were treated with radiation therapy alone (810 patients), radiation and chemotherapy (920 patients), or chemotherapy alone (57 patients) at Stanford University between 1961 and 1989. Among these patients, 1533 were alive at the last follow-up, and 254 had died of causes other than Hodgkin's disease. Four other patients were excluded from the analysis because they had undergone thyroidectomy before treatment for Hodgkin's disease. The thyroid was irradiated in 1677 patients. Follow-up averaged 9.9 years. Results. A total of 573 patients had clinical or biochemical evidence of thyroid disease. Among the 1677 patients whose thyroid was irradiated, the actuarial risk of thyroid disease 20 years after treatment was 52 percent, and it was 67 percent at 26 years. Hypothyroidism was found in 513 patients. A total of 486 patients received thyroxine therapy for elevated serum thyrotropin concentrations and either low free thyroxine (208 patients) or normal free thyroxine values (278 patients); 27 had transient elevations of the serum thyrotropin level that were not treated. Graves' hyperthyroidism developed in 30 patients (2 of whom had not undergone thyroid irradiation), and ophthalmopathy developed in 17 of these patients. Ophthalmopathy developed in four other patients with Graves' disease during a period of hypothyroidism (n = 3) or euthyroidism (n = 1). The risk of Graves disease was 7.2 to 20.4 times that for normal subjects. Silent thyroiditis with thyrotoxicosis developed in six patients. Forty-four patients were found to have single or multiple thyroid nodules, 26 of whom underwent thyroidectomy. Six of the 44 had papillary or follicular cancers. Among the patients who did not undergo operation, 12 had small functioning nodules, 4 had cysts, and 2 had multinodular goiters. The actuarial risk of thyroid cancer was 1.7 percent. The risk of thyroid cancer was 15.6 times the expected risk. Conclusions. High risks of thyroid disease persist more than 25 years after patients have received radiation therapy for Hodgkin's disease, reinforcing the need for continued clinical and biochemical evaluation. Prolonged follow-up confirms an elevated risk of thyroid cancer and Graves' disease as well as hypothyroidism in these patients.	STANFORD UNIV, MED CTR, SCH MED, DEPT DIAGNOST RADIOL & NUCL MED, STANFORD, CA 94305 USA	Stanford University	HANCOCK, SL (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT RADIAT ONCOL, A089, STANFORD, CA 94305 USA.				NCI NIH HHS [CA-34233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN R, 1983, BRIT J RADIOL, V56, P768, DOI 10.1259/0007-1285-56-670-768; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BAKRI K, 1983, CANCER, V52, P465, DOI 10.1002/1097-0142(19830801)52:3<465::AID-CNCR2820520315>3.0.CO;2-6; BANTLE JP, 1985, INT J RADIAT ONCOL, V11, P1999, DOI 10.1016/0360-3016(85)90283-4; BERGLUND J, 1990, J INTERN MED, V227, P137, DOI 10.1111/j.1365-2796.1990.tb00132.x; BLITZER JB, 1985, ARCH INTERN MED, V145, P1734, DOI 10.1001/archinte.145.9.1734; CONSTINE LS, 1984, CANCER-AM CANCER SOC, V53, P878, DOI 10.1002/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO;2-J; CONSTINE LS, 1982, CLIN NUCL MED, V7, P69, DOI 10.1097/00003072-198202000-00006; COX DR, 1972, J R STAT SOC B, V34, P187; DEAN JW, 1985, BRIT MED J, V290, P1555, DOI 10.1136/bmj.290.6481.1555; EINHORN J, 1967, RADIOLOGY, V88, P326, DOI 10.1148/88.2.326; FURSZYFER J, 1970, MAYO CLIN PROC, V45, P636; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GHANDOUR C, 1985, ACTA HAEMATOL-BASEL, V74, P137, DOI 10.1159/000206189; Greene M H, 1985, Natl Cancer Inst Monogr, V68, P191; Groover TA, 1929, J AMER MED ASSOC, V92, P1730, DOI 10.1001/jama.1929.02700470006003; JACKSON R, 1979, CANCER TREAT REP, V63, P1393; JACOBSON DR, 1984, AM J MED SCI, V288, P217, DOI 10.1097/00000441-198412000-00005; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN MM, 1983, AM J MED, V74, P272, DOI 10.1016/0002-9343(83)90626-5; KINSELLA TJ, 1982, CANCER TREAT REP, V66, P991; LOEFFLER JS, 1988, INT J RADIAT ONCOL, V14, P175, DOI 10.1016/0360-3016(88)90065-X; MARCIALVEGA VA, 1990, INT J RADIAT ONCOL, V18, P613, DOI 10.1016/0360-3016(90)90068-U; MARKSON JL, 1965, BRIT MED J, V1, P1228, DOI 10.1136/bmj.1.5444.1228; MAUCH PM, 1983, CANCER-AM CANCER SOC, V51, P925, DOI 10.1002/1097-0142(19830301)51:5<925::AID-CNCR2820510527>3.0.CO;2-O; MCDOUGALL IR, 1980, CANCER-AM CANCER SOC, V45, P2056, DOI 10.1002/1097-0142(19800415)45:8<2056::AID-CNCR2820450812>3.0.CO;2-M; MCHARDYY.S, 1965, BRIT MED J, V2, P230, DOI 10.1136/bmj.2.5455.230-a; MEYER O O, 1971, Wisconsin Medical Journal, V70, P129; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MOROFF SV, 1986, MED PEDIATR ONCOL, V14, P216, DOI 10.1002/mpo.2950140406; MORTIMER RH, 1986, AUST NZ J MED, V16, P347, DOI 10.1111/j.1445-5994.1986.tb01184.x; NELSON DF, 1978, CANCER-AM CANCER SOC, V42, P2553, DOI 10.1002/1097-0142(197812)42:6<2553::AID-CNCR2820420608>3.0.CO;2-H; NICOL F, 1982, POSTGRAD MED J, V58, P180, DOI 10.1136/pgmj.58.677.180; PETERSEN M, 1989, J NUCL MED, V30, P255; PILEPICH MV, 1978, JAMA-J AM MED ASSOC, V240, P1381, DOI 10.1001/jama.240.13.1381; PORTER AT, 1988, J ROY SOC MED, V81, P45, DOI 10.1177/014107688808100119; SCHIMPFF SC, 1980, ANN INTERN MED, V92, P91, DOI 10.7326/0003-4819-92-1-91; SERIES JJ, 1988, CLIN CHIM ACTA, V172, P217, DOI 10.1016/0009-8981(88)90326-9; SHALET SM, 1977, CLIN RADIOL, V28, P511, DOI 10.1016/S0009-9260(77)80066-4; SLATSTEI.E, 1971, J CLIN ENDOCR METAB, V32, P833, DOI 10.1210/jcem-32-6-833; SMITH RE, 1981, JAMA-J AM MED ASSOC, V245, P46, DOI 10.1001/jama.245.1.46; Storm H H, 1985, Natl Cancer Inst Monogr, V68, P389; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; WASNICH RD, 1973, J CLIN ENDOCR METAB, V37, P703, DOI 10.1210/jcem-37-5-703; WESHLER Z, 1978, ACTA RADIOL ONCOL, V17, P383, DOI 10.3109/02841867809128248; YOUNG RC, 1990, J NCI MONOGR, V10, P55; 1986, NATL CANCER I MONOGR, V70, P84	48	368	376	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					599	605		10.1056/NEJM199108293250902	http://dx.doi.org/10.1056/NEJM199108293250902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1861693	Bronze			2022-12-24	WOS:A1991GC32800002
J	BOZZETTE, SA; LARSEN, RA; CHIU, J; LEAL, MAE; TILLES, JG; RICHMAN, DD; LEEDOM, JM; MCCUTCHAN, JA				BOZZETTE, SA; LARSEN, RA; CHIU, J; LEAL, MAE; TILLES, JG; RICHMAN, DD; LEEDOM, JM; MCCUTCHAN, JA			FLUCONAZOLE TREATMENT OF PERSISTENT CRYPTOCOCCUS-NEOFORMANS PROSTATIC INFECTION IN AIDS	ANNALS OF INTERNAL MEDICINE			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; MENINGITIS		UNIV CALIF IRVINE, IRVINE, CA 92717 USA	University of California System; University of California Irvine	BOZZETTE, SA (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DIV INFECT DIS, H-208, 225 DICKINSON, SAN DIEGO, CA 92103 USA.							BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DIAMOND RD, 1974, ANN INTERN MED, V80, P176, DOI 10.7326/0003-4819-80-2-176; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LARSEN RA, 1990, ANN INTERN MED, V113, P183, DOI 10.7326/0003-4819-113-3-183; LARSEN RA, 1989, ANN INTERN MED, V111, P125, DOI 10.7326/0003-4819-111-2-125; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; STERN JJ, 1988, AM J MED, V85, P477, DOI 10.1016/S0002-9343(88)80081-0; ZUGER A, 1988, ANN INTERN MED, V109, P592, DOI 10.7326/0003-4819-109-7-592; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	10	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1991	115	4					285	286		10.7326/0003-4819-115-4-285	http://dx.doi.org/10.7326/0003-4819-115-4-285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA764	1854112				2022-12-24	WOS:A1991GA76400008
J	GOODNOW, CC; BRINK, R; ADAMS, E				GOODNOW, CC; BRINK, R; ADAMS, E			BREAKDOWN OF SELF-TOLERANCE IN ANERGIC LYMPHOCYTES-B	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; T-CELL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSGENIC MICE; CLONAL ANERGY; RECEPTOR; INACTIVATION; EXPRESSION; INDUCTION; DELETION	PRODUCTION of autoantibodies, which characterizes most autoimmune diseases, is normally avoided by active elimination 1-7 or functional inactivation (anergy) 8-15 of B and T lymphocytes bearing receptors for self antigens. The mechanisms leading to the escape of self-reactive clones from these normal tolerance mechanisms in autoimmune diseases nevertheless remain obscure. Here, we demonstrate that clonal anergy in B lymphocytes is a reversible process, and that silenced self-reactive B cells can be reactivated under particular conditions to give rise to vigorous antibody responses. Reactivation of anergic lymphocytes may explain many examples of transient autoimmune reactions in normal individuals, and may under pathological conditions be important in the development of chronic autoimmune disease.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	GOODNOW, CC (corresponding author), UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA.		Brink, Robert/B-7910-2010; Goodnow, Christopher C/V-8108-2018	Brink, Robert/0000-0002-9586-3655; Goodnow, Christopher C/0000-0001-5296-6155				ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BONNEVILLE M, 1990, NATURE, V344, P163, DOI 10.1038/344163a0; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; GLEICHMANN E, 1982, EUR J IMMUNOL, V12, P152, DOI 10.1002/eji.1830120210; GLEICHMANN E, 1976, EUR J IMMUNOL, V6, P899, DOI 10.1002/eji.1830061212; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HANG L, 1983, J EXP MED, V157, P874, DOI 10.1084/jem.157.3.874; IZUI S, 1977, J EXP MED, V145, P1115, DOI 10.1084/jem.145.5.1115; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; PRIMI D, 1977, J EXP MED, V145, P21, DOI 10.1084/jem.145.1.21; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Weigle W O, 1980, Adv Immunol, V30, P159	24	223	223	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					532	536		10.1038/352532a0	http://dx.doi.org/10.1038/352532a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1830923				2022-12-24	WOS:A1991GA22600064
J	BENITO, M; PORRAS, A; NEBREDA, AR; SANTOS, E				BENITO, M; PORRAS, A; NEBREDA, AR; SANTOS, E			DIFFERENTIATION OF 3T3-L1 FIBROBLASTS TO ADIPOCYTES INDUCED BY TRANSFECTION OF RAS ONCOGENES	SCIENCE			English	Article							GROWTH FACTOR-I; FATTY-ACID SYNTHASE; ADIPOSE CELL LINE; H-RAS; MOLECULAR-CLONING; MESSENGER-RNAS; NEURONAL DIFFERENTIATION; RESPONSIVENESS INVITRO; SIGNAL TRANSDUCTION; POTENTIAL MEDIATOR	Mammalian 3T3-L1 cells differentiate into adipocytes after continuous exposure to pharmacological doses of insulin or physiological doses of insulin-like growth factor I (IGF-1). Expression of transfected ras oncogenes led to differentiation of these cells into adipocytes in the absence of externally added insulin or IGF-I. Cells transfected with normal ras genes or the tyrosine kinase trk oncogene did not differentiate. Transfection with a dominant inhibitory ras mutant resulted in inhibition of differentiation. Exposure of untransfected 3T3-L1 cells to insulin stimulated formation of the active Ras.GTP complex. These observations indicate that Ras proteins participate in signal transduction pathways initiated by insulin and IGF-I in these cells.	NIAID, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Porras, Almudena/N-2121-2015; Nebreda, Angel Rodriguez/R-9594-2019; Benito, Manuel/J-5637-2014	Porras, Almudena/0000-0002-6495-3308; Benito, Manuel/0000-0002-7218-406X				AILHAUD G, 1982, MOL CELL BIOCHEM, V49, P17; ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZAK LP, 1983, P NATL ACAD SCI-BIOL, V80, P3020, DOI 10.1073/pnas.80.10.3020; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCCORMICK F, 1990, ONCOGENE, V5, P1281; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OGISO Y, 1990, CELL GROWTH DIFFER, V1, P217; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PEARSE AGE, 1968, HISTOCHEMISTRY, P697; PINTZAS A, 1989, GENE ANAL TECH, V6, P125, DOI 10.1016/0735-0651(89)90003-4; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TOSCANI A, 1990, J BIOL CHEM, V265, P5722	45	167	169	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					565	568		10.1126/science.1857988	http://dx.doi.org/10.1126/science.1857988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857988				2022-12-24	WOS:A1991FZ34700040
J	HIGUCHI, H; GOLDMAN, YE				HIGUCHI, H; GOLDMAN, YE			SLIDING DISTANCE BETWEEN ACTIN AND MYOSIN-FILAMENTS PER ATP MOLECULE HYDROLYZED IN SKINNED MUSCLE-FIBERS	NATURE			English	Article							FROG-MUSCLE; STEP SIZE; FIBERS; RABBIT; ADENOSINE-5'-TRIPHOSPHATE; GENERATION; MOVEMENT; FORCE; ASSAY; RIGOR	MUSCLE contraction is generally thought to be driven by tilting 1,2 of the 19-nm-long myosin head 3, part of the thick filament, while attached to actin, part of the thin filament. This motion would produce about 12 nm of filament sliding 4,5. Recent estimates of the sliding distance per ATP molecule hydrolysed by actomyosin in vitro vary widely from 8 nm (ref. 6) to greater-than-or-equal-to 200 nm (ref. 7). The latter value is incompatible with a power stroke incorporating a single tilting motion of the head. We have measured the isotonic sliding distance per ATP molecule hydrolysed during the interaction between myosin and actin in skinned muscle fibres. We directly estimated the proportion of simultaneously attached actomyosin complexes and their ATP use. We report here that at low loads the interaction distance is at least 40 nm. This distance corresponds to the length of the power stroke plus the filament sliding while actomyosin crossbridges bear negative drag forces 5,8. If the power stroke is 12 nm, then our results indicate the drag distance to be at least 28 nm. Our results could also be explained by multiple power strokes per ATP molecule hydrolysed.	UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania								Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; FERENCZI MA, 1984, J PHYSIOL-LONDON, V352, P575, DOI 10.1113/jphysiol.1984.sp015311; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P605, DOI 10.1113/jphysiol.1984.sp015395; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; GOLDMAN YE, 1987, BIOPHYS J, V52, P57, DOI 10.1016/S0006-3495(87)83188-0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1973, COLD SPRING HARB SYM, V37, P669, DOI 10.1101/SQB.1973.037.01.081; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; TAWADA K, 1984, BIOPHYS J, V45, P593, DOI 10.1016/S0006-3495(84)84197-1; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	20	92	92	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					352	354		10.1038/352352a0	http://dx.doi.org/10.1038/352352a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852212				2022-12-24	WOS:A1991FY28900077
J	UYEDA, TQP; WARRICK, HM; KRON, SJ; SPUDICH, JA				UYEDA, TQP; WARRICK, HM; KRON, SJ; SPUDICH, JA			QUANTIZED VELOCITIES AT LOW MYOSIN DENSITIES IN AN INVITRO MOTILITY ASSAY	NATURE			English	Article							SINGLE KINESIN MOLECULES; STEP SIZE; ACTIN; MOVEMENT; MUSCLE	An in vitro motility assay has been developed in which single actin filaments move on one or a few heavy meromyosin (HMM) molecules. This movement is slower than when many HMM molecules are involved, in contrast to analogous experiments with microtubules and kinesin. Frequency analysis shows that sliding speeds distribute around integral multiples of a unitary velocity. This discreteness may be due to differences in the numbers of HMM molecules interacting with each actin filament, where the unitary velocity reflects the activity of one HMM molecule. The value of the unitary velocity predicts a step size of 5-20 nm per ATP, which is consistent with the conventional swinging crossbridge model for myosin function.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,FAIRCHILD CTR,STANFORD,CA 94305	Stanford University	UYEDA, TQP (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,FAIRCHILD CTR,STANFORD,CA 94305, USA.			Kron, Stephen/0000-0003-1518-2436				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KRON SJ, 1991, J CELL SCI S, V14, P129; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SHIMMEN T, 1988, BOT MAG TOKYO, V101, P533, DOI 10.1007/BF02488095; Taylor E W, 1989, Prog Clin Biol Res, V315, P9; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	19	164	164	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					307	311		10.1038/352307a0	http://dx.doi.org/10.1038/352307a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852205				2022-12-24	WOS:A1991FY28900060
J	NAGAFUCHI, S; KASHIWAGI, S; OKADA, K; ANZAI, K; NAKAMURA, M; NISHIMURA, Y; SASAZUKI, T; NIHO, Y				NAGAFUCHI, S; KASHIWAGI, S; OKADA, K; ANZAI, K; NAKAMURA, M; NISHIMURA, Y; SASAZUKI, T; NIHO, Y			REVERSAL OF NONRESPONDERS AND POSTEXPOSURE PROPHYLAXIS BY INTRADERMAL HEPATITIS-B VACCINATION IN JAPANESE MEDICAL PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DTH SKIN REACTION; IMMUNE GLOBULIN; FINAL REPORT; VIRUS-INFECTION; SURFACE-ANTIGEN; HEPTAVAX-B; IMMUNOGENICITY; EFFICACY; HBSAG; IMMUNOPROPHYLAXIS	Thirty-one Japanese nonresponders to subcutaneous hepatitis B vaccination and 15 medical personnel who were accidentally exposed to specimens positive for hepatitis B e antigen and were given hepatitis B immunoglobulin were intradermally immunized with 5-mu-g of plasma-derived hepatitis B vaccine every 2 weeks until delayed type hypeersensitivity skin reaction to hepatitis B surface antigen became positive. Thirty (97%) of the 31 nonresponders developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen after 2.3 +/- 1.2 (mean +/- SD) revaccinations. Twenty-nine (94%) of the 31 nonresponders had anti-hepatitis B surface antigen antibody levels greater than 10 IU/L. The immunoglobulin subclass of the antibody to hepatitis B surface antigen was mainly IgG1. After 1 year, 23 (74%) of the 31 nonresponders continued to have anti-hepatitis B surface antigen antibody levels greater than 10 IU/L. Persons accidentally exposed to specimens positive for hepatitis B e antigen developed delayed type hypersensitivity skin reactions to hepatitis B surface antigen following 3.1 +/- 1.1 revaccinations. None developed clinical hepatitis. There was no production of anti-hepatitis B core antigen antibody 1 year after exposure, indicating that protection was 100%. Intradermal hepatitis B vaccination is useful in reversing nonresponsiveness to hepatitis B surface antigen and for prophylaxis after exposure.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT GENET,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DEPT PEDIAT,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC MED,DEPT GEN MED,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University; Kyushu University	NAGAFUCHI, S (corresponding author), KYUSHU UNIV,FAC MED,DEPT INTERNAL MED 1,FUKUOKA 812,JAPAN.							ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103; CASALI P, 1986, SCIENCE, V234, P476, DOI 10.1126/science.3020687; CHUTIVONGSE S, 1990, LANCET, V335, P896, DOI 10.1016/0140-6736(90)90488-Q; CLARKE JA, 1989, JAMA-J AM MED ASSOC, V262, P2567, DOI 10.1001/jama.262.18.2567; CRAVEN DE, 1986, ANN INTERN MED, V105, P356, DOI 10.7326/0003-4819-105-3-356; DIENSTAG JL, 1989, HEPATOLOGY, V10, P385, DOI 10.1002/hep.1840100323; GRADY GF, 1978, J INFECT DIS, V138, P625, DOI 10.1093/infdis/138.5.625; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HAYASHI J, 1989, J INFECTION, V19, P119, DOI 10.1016/S0163-4453(89)91839-2; HEIJTINK RA, 1989, J MED VIROL, V27, P151, DOI 10.1002/jmv.1890270216; HOOFNAGLE JH, 1979, ANN INTERN MED, V91, P813, DOI 10.7326/0003-4819-91-6-813; IRVING WL, 1987, LANCET, V2, P561; KAPLAN PM, 1973, J VIROL, V12, P995, DOI 10.1128/JVI.12.5.995-1005.1973; KARASAWA T, 1983, J INFECT DIS, V147, P327, DOI 10.1093/infdis/147.2.327; KASHIWAGI S, 1984, MICROBIOL IMMUNOL, V28, P1355, DOI 10.1111/j.1348-0421.1984.tb00793.x; MASUKO K, 1985, GASTROENTEROLOGY, V88, P151, DOI 10.1016/S0016-5085(85)80147-5; MATHIESEN T, 1989, J NEUROL, V236, P238, DOI 10.1007/BF00314506; MILLER KD, 1983, LANCET, V2, P1454, DOI 10.1016/S0140-6736(83)90800-0; MITSUI T, 1989, HEPATOLOGY, V10, P324, DOI 10.1002/hep.1840100312; NAGAFUCHI S, 1987, LANCET, V2, P1522; NAGAFUCHI S, 1984, MICROBIOL IMMUNOL, V28, P257, DOI 10.1111/j.1348-0421.1984.tb00678.x; NAGAFUCHI S, 1989, MICROBIOL IMMUNOL, V33, P539, DOI 10.1111/j.1348-0421.1989.tb02004.x; NAGAFUCHI S, 1985, CLIN EXP IMMUNOL, V61, P569; NAKAMURA M, 1988, J IMMUNOL, V141, P4165; Paul W.E., 1989, FUNDAMENTAL IMMUNOLO, P95; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P3203, DOI 10.1001/jama.254.22.3203; SEEFF LB, 1978, ANN INTERN MED, V88, P285, DOI 10.7326/0003-4819-88-3-285; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; VANDVIK B, 1977, SCAND J IMMUNOL, V6, P651, DOI 10.1111/j.1365-3083.1977.tb02145.x; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WATANABE H, 1988, HUM IMMUNOL, V22, P9, DOI 10.1016/0198-8859(88)90047-X; WEISSMAN JY, 1988, JAMA-J AM MED ASSOC, V260, P1734, DOI 10.1001/jama.260.12.1734; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; ZOULEK G, 1984, J MED VIROL, V14, P27, DOI 10.1002/jmv.1890140105; ZUCKERMAN AJ, 1988, CURR OPIN INFECT DIS, V1, P829, DOI 10.1097/00001432-198811000-00002; 1985, MMWR, V34, P313	37	39	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1991	265	20					2679	2683		10.1001/jama.265.20.2679	http://dx.doi.org/10.1001/jama.265.20.2679			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL989	1827167				2022-12-24	WOS:A1991FL98900031
J	KHUSMITH, S; CHAROENVIT, Y; KUMAR, S; SEDEGAH, M; BEAUDOIN, RL; HOFFMAN, SL				KHUSMITH, S; CHAROENVIT, Y; KUMAR, S; SEDEGAH, M; BEAUDOIN, RL; HOFFMAN, SL			PROTECTION AGAINST MALARIA BY VACCINATION WITH SPOROZOITE SURFACE PROTEIN-2 PLUS CS PROTEIN	SCIENCE			English	Article							CIRCUMSPOROZOITE PROTEIN; MONOCLONAL-ANTIBODIES; PLASMODIUM-YOELII; MAMMALIAN-CELLS; MURINE MALARIA; EXPRESSION; EFFICIENT; VACCINES; ANTIGENS; SYSTEM	The circumsporozoite (CS) protein has been the target for development of malaria sporozoite vaccines for a decade. However, immunization with subunit vaccines based on the CS protein has never given the complete protection found after immunization with irradiated sporozoites. BALB/c mice immunized with irradiated Plasmodium yoelii sporozoites produced antibodies and cytotoxic T cells against a 140-kilodalton protein, sporozoite surface protein 2 (SSP2). Mice immunized with P815 cells that had been transfected with either SSP2 or CS genes were partially protected, and those immunized with a mixture of SSP2 and CS transfectants were completely protected against malaria. These studies emphasize the importance of vaccine delivery systems in achieving protection and define a multi-antigen sporozoite vaccine.	USN,MED RES INST,MALARIA PROGRAM,BETHESDA,MD 20889; NIH,PARASIT DIS LAB,BETHESDA,MD 20892	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA								AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; [Anonymous], COMMUNICATION; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHAROENVIT Y, 1991, J IMMUNOL, V146, P1020; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLYDE DF, 1973, AM J MED SCI, V266, P160; EGAN JE, 1987, SCIENCE, V236, P453, DOI 10.1126/science.3551073; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; HAMMERLING GJ, 1979, J EXP MED, V150, P108, DOI 10.1084/jem.150.1.108; HEDSTROM RC, 1990, B WORLD HEALTH ORGAN, V68, P152; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; KHUSMITH S, UNPUB; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; LAL AA, 1987, J BIOL CHEM, V262, P2937; LAL AA, 1987, P NATL ACAD SCI USA, V84, P8647, DOI 10.1073/pnas.84.23.8647; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; Rieckmann K H, 1979, Bull World Health Organ, V57 Suppl 1, P261; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SADOFF JC, 1988, SCIENCE, V240, P336, DOI 10.1126/science.3281260; Sedegah M., 1988, Technological Advances in Vaccine Development  (Proceedings of a Genentech, Ortho, Smith Kline & French-UCLA Symposium, 30 Jan.-6 Feb. 1988, Park City, Utah, USA)., P295; SEDEGAH M, 1990, B WORLD HEALTH ORGAN, V68, P109; SEDEGAH M, UNPUB; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591	33	181	189	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1991	252	5006					715	718		10.1126/science.1827210	http://dx.doi.org/10.1126/science.1827210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK185	1827210				2022-12-24	WOS:A1991FK18500052
J	PFALLER, R; SMYTHE, C; NEWPORT, JW				PFALLER, R; SMYTHE, C; NEWPORT, JW			ASSEMBLY DISASSEMBLY OF THE NUCLEAR-ENVELOPE MEMBRANE - CELL-CYCLE DEPENDENT BINDING OF NUCLEAR-MEMBRANE VESICLES TO CHROMATIN INVITRO	CELL			English	Article							XENOPUS CDC2 PROTEIN; CHROMOSOME CONDENSATION; GOLGI-APPARATUS; FREE SYSTEM; COMPONENT; MITOSIS; LAMINA; LAEVIS; KINASE; MATURATION	Dissociation and association of membranes with chromatin at the beginning and end of mitosis are critical in controlling nuclear dynamics during these stages of the cell cycle. Employing purified membrane and cytosolic fractions from Xenopus eggs, a simple assay was developed for the reversible binding of nuclear membrane vesicles to chromatin. We have shown, using phosphatase and kinase inhibitors, that membrane-chromatin association is regulated by a phosphatase/kinase system. In interphase, the balance in this system favors dephosphorylation, possibly of a membrane receptor, which then mediates chromatin binding. At mitosis the membrane receptor is phosphorylated, causing release of chromatin-bound membrane. Purified MPF kinase does not directly cause membranes to dissociate from chromatin. Rather, binding of membranes to chromatin at mitosis appears to be regulated indirectly by MPF through its action on a phosphatase/kinase system that directly modulates the phosphorylation state of a nuclear membrane component.			PFALLER, R (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,B-022,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GM 33523-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BENAVENTE R, 1985, CELL, V41, P177, DOI 10.1016/0092-8674(85)90072-8; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; CHALY N, 1984, J CELL BIOL, V99, P661, DOI 10.1083/jcb.99.2.661; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DOERING V, 1990, EMBO (European Molecular Biology Organization) Journal, V9, P4073; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; FIELDS AP, 1988, J CELL BIOL, V107, P833, DOI 10.1083/jcb.107.3.833; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEAF DS, 1990, DEV BIOL, V141, P1, DOI 10.1016/0012-1606(90)90097-3; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MCKEON FD, 1984, CELL, V36, P83, DOI 10.1016/0092-8674(84)90076-X; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, NATURE, V339, P287; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; PADAN R, 1990, J BIOL CHEM, V265, P7808; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	46	119	119	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					209	217		10.1016/0092-8674(91)90155-R	http://dx.doi.org/10.1016/0092-8674(91)90155-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849796				2022-12-24	WOS:A1991FH09200004
J	KUMAGAI, A; DUNPHY, WG				KUMAGAI, A; DUNPHY, WG			THE CDC25 PROTEIN CONTROLS TYROSINE DEPHOSPHORYLATION OF THE CDC2 PROTEIN IN A CELL-FREE SYSTEM	CELL			English	Article							ACTIVATED XENOPUS EGGS; CYCLIN MESSENGER-RNA; SEA-URCHIN EGGS; FISSION YEAST; PROMOTING FACTOR; MITOTIC CONTROL; KINASE; MITOSIS; MPF; DIVISION	As a prerequisite for the activation of MPF, the cdc2 protein kinase must undergo tyrosine dephosphorylation. Genetic studies have demonstrated that the cdc25 protein activates the cdc2 protein kinase once DNA replication has been completed. We have produced the cdc25 protein in bacteria and shown that it activates MPF in Xenopus extracts. In extracts that normally cannot enter mitosis owing to inhibition of DNA synthesis, the addition of active cdc25 protein efficiently elicits the mitotic state by inducing premature dephosphorylation of tyrosine on the cdc2 protein. The cdc25-dependent activation reaction can be reconstituted in a partially purified system lacking ATP. These biochemical experiments demonstrate that the cdc25 protein actively drives tyrosine dephosphorylation of the cdc2 protein and offer the prospect for characterizing the individual factors that regulate the activation of MPF during the progression from S phase to mitosis.			KUMAGAI, A (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.							BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1989, J CELL SCI, V92, P131; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WASSERMAN WJ, 1975, EXP CELL RES, V91, P381, DOI 10.1016/0014-4827(75)90118-4	56	444	456	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					903	914		10.1016/0092-8674(91)90315-P	http://dx.doi.org/10.1016/0092-8674(91)90315-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1825803				2022-12-24	WOS:A1991FA94000008
J	SMRCKA, AV; HEPLER, JR; BROWN, KO; STERNWEIS, PC				SMRCKA, AV; HEPLER, JR; BROWN, KO; STERNWEIS, PC			REGULATION OF POLYPHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C ACTIVITY BY PURIFIED GQ	SCIENCE			English	Article							PROTEIN ALPHA-SUBUNIT; BETA-GAMMA-SUBUNITS; GUANINE-NUCLEOTIDE; PERTUSSIS TOXIN; BOVINE BRAIN; MEMBRANES; AFFINITY; CALCIUM; CELLS	The hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C yields the second messengers inositol 1,4,5-trisphosphate (InsP3) and 1,2-diacylglycerol. This activity is regulated by a variety of hormones through G protein pathways. However, the specific G protein or proteins involved has not been identified. The alpha-subunit of a newly discovered pertussis toxin-insensitive G protein (G(q)) has recently been isolated and is now shown to stimulate the activity of polyphosphoinositide-specific phospholipase C (PI-PLC) from bovine brain. Both the maximal activity and the affinity of PI-PLC for calcium ion were affected. These results identify G(q) as a G protein that regulates PI-PLC.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM31954, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497, R01GM031954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOYER JL, 1989, J BIOL CHEM, V264, P13917; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, UNPUB; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HARDENTK, 1989, INOSITOL LIPIDS CELL, P113; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MARTIN TFJ, 1986, J BIOL CHEM, V261, P10041; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SHAFFNER W, 1973, ANAL BIOCHEM, V56, P502; SMRCKA AV, UNPUB; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; Taylor Suzanne, COMMUNICATION; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254	34	841	847	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					804	807		10.1126/science.1846707	http://dx.doi.org/10.1126/science.1846707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846707				2022-12-24	WOS:A1991EX57500048
J	SUNG, P; PRAKASH, L; PRAKASH, S				SUNG, P; PRAKASH, L; PRAKASH, S			RENATURATION OF DNA CATALYZED BY YEAST DNA-REPAIR AND RECOMBINATION PROTEIN RAD10	NATURE			English	Article							EXCHANGE STIMULATORY FACTOR; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; UNWINDING PROTEIN; GENE; EXCISION; INCISION; BINDING; PRODUCT; STRAND	THE RAD10 gene of Saccharomyces cerevisiae is required for the incision step of excision repair of ultraviolet-damaged DNA (refs 1, 2), and it functions in mitotic recombination 3. RAD10 has homology to the human excision repair gene ERCC-1 (ref. 4). Here we describe the purification of the protein encoded by RAD10 and show that it is a DNA-binding protein with a strong preference for single-stranded DNA. We also show that RAD10 promotes the renaturation of complementary DNA strands.	UNIV ROCHESTER,DEPT BIOL,RIVER CAMPUS STN,ROCHESTER,NY 14627; UNIV ROCHESTER,SCH MED,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444				ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; HINTON DM, 1986, J BIOL CHEM, V261, P5663; Kowalczykowski S.C., 1981, ENZYMES, V14, P373; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MCPHERSON A, 1979, J MOL BIOL, V134, P379, DOI 10.1016/0022-2836(79)90359-0; MORANELLI F, 1980, P NATL ACAD SCI-BIOL, V77, P3201, DOI 10.1073/pnas.77.6.3201; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; REYNOLDS P, 1985, EMBO J, V4, P3549, DOI 10.1002/j.1460-2075.1985.tb04115.x; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P5450, DOI 10.1073/pnas.78.9.5450; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SCHIESTL RH, 1990, MOL CELL BIOL, V10, P2485, DOI 10.1128/MCB.10.6.2485; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; VANDUIN M, 1986, CELL, V44, P912; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	25	40	42	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					743	745		10.1038/355743a0	http://dx.doi.org/10.1038/355743a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741062				2022-12-24	WOS:A1992HE60400070
J	VANVACTOR, DL; CAGAN, RL; KRAMER, H; ZIPURSKY, SL				VANVACTOR, DL; CAGAN, RL; KRAMER, H; ZIPURSKY, SL			INDUCTION IN THE DEVELOPING COMPOUND EYE OF DROSOPHILA - MULTIPLE MECHANISMS RESTRICT R7 INDUCTION TO A SINGLE RETINAL PRECURSOR CELL	CELL			English	Article							RECEPTOR TYROSINE KINASE; PATTERN-FORMATION; ECTOPIC EXPRESSION; SEVENLESS PROTEIN; PUTATIVE RECEPTOR; GENE; ENCODES; MELANOGASTER; DOMAIN; ROUGH	The development of the Drosophila R7 photoreceptor cell is determined by a specific inductive interaction between the R8 photoreceptor cell and a single neighboring precursor cell. This process is mediated by bride of sevenless (boss), a cell-surface bound ligand, and the sevenless (sev) tyrosine kinase receptor. The boss ligand is expressed specifically on the surface of the R8 cell, whereas the sev receptor is expressed on 5 cells contacting the developing R8 cell and other cells not in contact with R8. By altering the spatial and temporal expression of boss, we demonstrate that sev-expressing cells that do not contact R8 can assume an R7 cell fate. By contrast, the sev-expressing precursor cells to the R1-R6 photoreceptor cells that do contact R8 are nonresponsive to the inductive cue. Using the rough and N(spl) mutations, we demonstrate that an early commitment to an R1-R6 cell fate blocks the pathway of sev activation in these cells.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, HOWARD HUGHES MED INST, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Cagan, Ross Leigh/AAV-9528-2021	Kramer, Helmut/0000-0002-1167-2676; Cagan, Ross/0000-0001-5297-450X; Van Vactor, Jr., David L./0000-0001-8156-9482; Zipursky, Stephen/0000-0001-5630-7181				AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAGAN RL, 1992, DETERMINANTS NEURONA; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LIPOSITS Z, 1984, NEUROSCIENCE, V13, P513, DOI 10.1016/0306-4522(84)90245-8; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Spemann H., 1938, EMBRYONIC DEV INDUCT; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; WARING DA, 1991, NATURE, V350, P712, DOI 10.1038/350712a0	42	145	145	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 20	1991	67	6					1145	1155		10.1016/0092-8674(91)90291-6	http://dx.doi.org/10.1016/0092-8674(91)90291-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760842				2022-12-24	WOS:A1991GX16400013
J	ROUBENOFF, R; KLAG, MJ; MEAD, LA; LIANG, KY; SEIDLER, AJ; HOCHBERG, MC				ROUBENOFF, R; KLAG, MJ; MEAD, LA; LIANG, KY; SEIDLER, AJ; HOCHBERG, MC			INCIDENCE AND RISK-FACTORS FOR GOUT IN WHITE MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - To identify potentially modifiable risk factors for the development of gout. Design. - Longitudinal cohort study (The Johns Hopkins Precursors Study). Participants. - Of 1337 eligible medical students, 1271 (95%) received a standardized medical examination and questionnaire during medical school. The participants were predominantly male (91%), white (97%), and young (median age, 22 years) at cohort entry. Outcome Measure. - The development of gout. Results. - Sixty cases of gout (47 primary and 13 secondary) were identified among 1216 men; none occurred among 121 women (P = .01). The cumulative incidence of all gout was 8.6% among men (95% confidence interval, 5.9% to 11.3%). Body mass index at age 35 years (P = .01), excessive weight gain (> 1.88 kg/m2) between cohort entry and age 35 years (P = .007), and development of hypertension (P = .004) were significant risk factors for all gout in univariate analysis. Multivariate Cox proportional hazards models confirmed the association of body mass index at age 35 years (relative risk [RR] = 1.12; P = .02), excessive weight gain (RR = 2.07; P = .02), and hypertension (RR = 3.26; P = .002) as risk factors for all gout. Hypertension, however, was not a significant risk factor for primary gout. Conclusions. - Obesity, excessive weight gain in young adulthood, and hypertension are risk factors for the development of gout. Prevention of obesity and hypertension may decrease the incidence of and morbidity from gout; studies of weight reduction in the primary and secondary prevention of gout are indicated.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV MOLEC & CLIN RHEUMATOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV INTERNAL MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Liang, Kung-Yee/F-8299-2011	Roubenoff, Ronenn/0000-0002-3959-3179	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001760] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00722] Funding Source: Medline; NHLBI NIH HHS [HL42734] Funding Source: Medline; NIA NIH HHS [AG01760] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOTT RD, 1988, J CLIN EPIDEMIOL, V41, P237, DOI 10.1016/0895-4356(88)90127-8; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; COX DR, 1972, J R STAT SOC B, V34, P187; GLYNN RJ, 1983, ARTHRITIS RHEUM-US, V26, P87, DOI 10.1002/art.1780260115; HALL AP, 1967, AM J MED, V42, P27, DOI 10.1016/0002-9343(67)90004-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAWRENCE RC, 1989, J RHEUMATOL, V16, P427; LEE ET, 1980, STATISTICAL METHODS, P122; MANUEL MA, 1974, AM J MED, V57, P741, DOI 10.1016/0002-9343(74)90847-X; ROUBENOFF R, 1990, RHEUM DIS CLIN N AM, V16, P539; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; [No title captured]; [No title captured]	13	183	193	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3004	3007		10.1001/jama.266.21.3004	http://dx.doi.org/10.1001/jama.266.21.3004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820473				2022-12-24	WOS:A1991GR77500032
J	FARISH, E; ROLTON, HA; BARNES, JF; HART, DM				FARISH, E; ROLTON, HA; BARNES, JF; HART, DM			LIPOPROTEIN (A) CONCENTRATIONS IN POSTMENOPAUSAL WOMEN TAKING NORETHISTERONE	BRITISH MEDICAL JOURNAL			English	Article							LP(A) LIPOPROTEIN		STOBHILL GEN HOSP,DEPT OBSTET & GYNAECOL,GLASGOW G21 3UW,SCOTLAND		FARISH, E (corresponding author), STOBHILL GEN HOSP,DEPT BIOCHEM,GLASGOW G21 3UW,SCOTLAND.							ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789; ALBERS JJ, 1984, BIOCHIM BIOPHYS ACTA, V795, P293, DOI 10.1016/0005-2760(84)90078-X; ALBERS JJ, 1975, METABOLISM, V24, P1047, DOI 10.1016/0026-0495(75)90098-0; FARISH E, 1986, CLIN CHIM ACTA, V159, P147; MBEWU AD, 1990, ATHEROSCLEROSIS, V85, P1, DOI 10.1016/0021-9150(90)90177-K	5	125	125	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1991	303	6804					694	694		10.1136/bmj.303.6804.694	http://dx.doi.org/10.1136/bmj.303.6804.694			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG980	1833013	Green Published, Bronze			2022-12-24	WOS:A1991GG98000023
J	DALONZO, GE; BARST, RJ; AYRES, SM; BERGOFSKY, EH; BRUNDAGE, BH; DETRE, KM; FISHMAN, AP; GOLDRING, RM; GROVES, BM; KERNIS, JT; LEVY, PS; PIETRA, GG; REID, LM; REEVES, JT; RICH, S; VREIM, CE; WILLIAMS, GW; WU, M				DALONZO, GE; BARST, RJ; AYRES, SM; BERGOFSKY, EH; BRUNDAGE, BH; DETRE, KM; FISHMAN, AP; GOLDRING, RM; GROVES, BM; KERNIS, JT; LEVY, PS; PIETRA, GG; REID, LM; REEVES, JT; RICH, S; VREIM, CE; WILLIAMS, GW; WU, M			SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION, PULMONARY; VENTRICULAR FUNCTION, RIGHT; ATRIAL FUNCTION, RIGHT; RAYNAUDS DISEASE; HEART-LUNG TRANSPLANTATION	UNUSUALLY LONG DURATION; NATURAL-HISTORY	Objective: To characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival. Design: Registry with prospective follow-up. Setting: Thirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart, Lung, and Blood Institute. Patients: Patients (194) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988. Measurements: At diagnosis, measurements of hemodynamic variables, pulmonary function, and gas exchange variables were taken in addition to information on demographic variables, medical history, and life-style. Patients were followed for survival at 6-month intervals. Main Results: The estimated median survival of these patients was 2.8 years (95% Cl, 1.9 to 3.7 years). Estimated single-year survival rates were as follows: at 1 year, 68% (Cl, 61% to 75%); at 3 years, 48% (Cl, 41% to 55%); and at 5 years, 34% (Cl, 24% to 44%). Variables associated with poor survival included a New York Heart Association (NYHA) functional class of III or IV, presence of Raynaud phenomenon, elevated mean right atrial pressure, elevated mean pulmonary artery pressure, decreased cardiac index, and decreased diffusing capacity for carbon monoxide (DL(CO)). Drug therapy at entry or discharge was not associated with survival duration. Conclusions: Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. Such an equation, once validated prospectively, could be used as an adjunct in planning treatment strategies and allocating medical resources.	NHLBI, DIV LUNG DIS, WESTWOOD BLDG, ROOM 6A09, BETHESDA, MD 20892 USA; UNIV TEXAS, MED CTR, DIV PULM, HOUSTON, TX 77030 USA; BABYS HOSP S, NEW YORK, NY 10032 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA; SUNY STONY BROOK, HLTH SCI CTR, DIV PULM CRIT CARE, STONY BROOK, NY 11794 USA; UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR, TORRANCE, CA 90509 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15261 USA; UNIV PENN, DEPT PHYS MED & REHABIL, PHILADELPHIA, PA 19104 USA; NYU, DEPT MED, NEW YORK, NY 10016 USA; UNIV HOSP DENVER, DIV CARDIOL, DENVER, CO 80262 USA; UNIV ILLINOIS, SCH PUBL HLTH, CHICAGO, IL 60680 USA; HOSP UNIV PENN, DEPT PATHOL & MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP MED CTR, MED CTR, DEPT PATHOL, BOSTON, MA 02115 USA; UNIV COLORADO, HLTH SCI CTR, CARDIOVASC PULM RES LAB, DENVER, CO 80262 USA; UNIV ILLINOIS, DEPT MED, CARDIOL SECT, CHICAGO, IL 60680 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; NIH, DIV HEART LUNG & BLOOD INST, MATH & STAT BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; Virginia Commonwealth University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; New York University; University of Colorado System; University of Colorado Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Boston Children's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA				goldring, roberta/0000-0003-3319-4932	DIVISION OF LUNG DISEASES [N01HR014000] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR-14000] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham M T, 1981, Indian Heart J, V33, P5; BOURDILLON PDV, 1976, BRIT HEART J, V38, P264; CHARTERS AD, 1970, BRIT HEART J, V32, P130; FUJII A, 1981, BRIT HEART J, V46, P574; FUSTER V, 1981, AM J CARDIOL, V47, P422, DOI 10.1016/0002-9149(81)90761-X; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GLANVILLE AR, 1987, CHEST, V91, P675, DOI 10.1378/chest.91.5.675; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANEMOTO N, 1979, JPN HEART J, V20, P395; KLEIGER RE, 1976, CHEST, V69, P143, DOI 10.1378/chest.69.2.143; LEE ET, 1980, STATISTICAL METHODS; MCCAFFREY R M, 1964, Obstet Gynecol Surv, V19, P567, DOI 10.1097/00006254-196408000-00001; NELSON DM, 1983, OBSTET GYNECOL, V62, pS58; OAKLEY C, 1968, LANCET, V1, P890; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1984, AM J MED, V76, P573, DOI 10.1016/0002-9343(84)90279-1; ROZKOVEC A, 1986, BRIT HEART J, V55, P449; SUAREZ LD, 1979, BRIT HEART J, V41, P702; TRELL E, 1973, ACTA MED SCAND, V193, P137; VOELKEL N, 1979, PULMONARY VASCULAR D, V14, P573; WALCOTT G, 1970, AM J MED, V49, P70, DOI 10.1016/S0002-9343(70)80115-2; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; ZAHAVI I, 1984, ARCH INTERN MED, V144, P742, DOI 10.1001/archinte.144.4.742	24	2615	2741	0	70	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					343	349		10.7326/0003-4819-115-5-343	http://dx.doi.org/10.7326/0003-4819-115-5-343			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863023				2022-12-24	WOS:A1991GC06500002
J	LEE, C; LEVITT, M				LEE, C; LEVITT, M			ACCURATE PREDICTION OF THE STABILITY AND ACTIVITY EFFECTS OF SITE-DIRECTED MUTAGENESIS ON A PROTEIN CORE	NATURE			English	Article							FREE-ENERGY CALCULATIONS; T4 LYSOZYME; STAPHYLOCOCCAL NUCLEASE; HYDROPHOBIC CORE; PACKING; THERMOSTABILITY; REPRESSOR	THEORETICAL prediction of the structure, stability and activity of proteins, an important unsolved problem in molecular biology, would be of use for guiding site-directed mutagenesis and other protein-engineering techniques. X-ray diffraction studies have provided extensive structural information for many proteins, challenging theorists to develop reliable techniques able to use such knowledge as a base for prediction of mutants' characteristics. Here we report theoretical calculation of stabilization energies for 78 triple-site sequence variants of lambda-repressor characterized experimentally by Lim and Sauer 1. The calculated energies correlate with the mutants' measured activities; active and inactive mutations are discriminated with 92% reliability. They correlate even more directly with the mutants' thermostabilities, correctly identifying two of the mutants to be more stable than the wild type.			LEE, C (corresponding author), STANFORD UNIV,MED CTR,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305, USA.		Levitt, Michael/E-4582-2012	Levitt, Michael/0000-0002-8414-7397				BASH PA, 1987, SCIENCE, V236, P564, DOI 10.1126/science.3576184; DAGGETT V, IN PRESS PROTEIN ENG; DANG LX, 1989, J AM CHEM SOC, V111, P8505, DOI 10.1021/ja00204a027; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; McCammon JA, 1991, CURR OPIN STRUC BIOL, V1, P196; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SHORTLE D, 1989, ARCH BIOCHEM BIOPHYS, V272, P103, DOI 10.1016/0003-9861(89)90200-2; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SHORTLE D, 1986, Proteins Structure Function and Genetics, V1, P81, DOI 10.1002/prot.340010113; TIDOR B, 1991, BIOCHEMISTRY-US, V30, P3217, DOI 10.1021/bi00227a009	19	161	172	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					448	451		10.1038/352448a0	http://dx.doi.org/10.1038/352448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861725				2022-12-24	WOS:A1991FZ34600071
J	PIEKEN, WA; OLSEN, DB; BENSELER, F; AURUP, H; ECKSTEIN, F				PIEKEN, WA; OLSEN, DB; BENSELER, F; AURUP, H; ECKSTEIN, F			KINETIC CHARACTERIZATION OF RIBONUCLEASE-RESISTANT 2'-MODIFIED HAMMERHEAD RIBOZYMES	SCIENCE			English	Article							SELF-CLEAVAGE; RNA; OLIGORIBONUCLEOTIDES	The incorporation of 2'-fluoro- and 2'-aminonucleotides into a hammerhead ribozyme was accomplished by automated chemical synthesis. The presence of 2'-fluorouridines, 2'-fluorocytidines, or 2'-aminouridines did not appreciably decrease catalytic efficiency. Incorporation of 2'-aminocytidines decreased ribozyme activity approximately by a factor of 20. The replacement of all adenosines with 2'-fluoroadenosines abolished catalysis in the presence of MgCl2 within the limits of detection, but some activity was retained in the presence of MnCl2. This effect on catalysis was localized to a specific group of adenines within the conserved single-stranded region of the ribozyme. The decrease in catalytic efficiency was caused by a decrease in the rate constant; the Michaelis constant was unaltered. The 2'-fluoro and 2'-amino modifications conferred resistance toward ribonuclease degradation. Ribozymes containing 2'-fluoro- or 2'-aminonucleotides at all uridine and cytidine positions were stabilized against degradation in rabbit serum by a factor of at least 10(3) compared to unmodified ribozyme.	MAX PLANCK INST EXPTL MED,CHEM ABT,HERMANN REIN STR 3,W-3400 GOTTINGEN,GERMANY	Max Planck Society				olsen, david/0000-0001-5521-0206				BEIJER B, 1990, NUCLEIC ACIDS RES, V18, P5143, DOI 10.1093/nar/18.17.5143; BENSELER F, UNPUB; CODINGTON JF, 1964, J ORG CHEM, V29, P558, DOI 10.1021/jo01026a009; COTTEN M, 1990, TRENDS BIOTECHNOL, V8, P174, DOI 10.1016/0167-7799(90)90168-W; DOERR IL, 1967, J ORG CHEM, V32, P1462, DOI 10.1021/jo01280a035; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; HOBBS J, 1973, BIOCHEMISTRY-US, V12, P5138, DOI 10.1021/bi00749a018; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; IKEHARA M, 1978, CHEM PHARM BULL, V26, P2449; IMAZAWA M, 1979, J ORG CHEM, V44, P2039, DOI 10.1021/jo01326a037; JANIK B, 1972, BIOCHEM BIOPH RES CO, V46, P1153, DOI 10.1016/S0006-291X(72)80095-0; Mengel R., 1978, ANGEW CHEM, V90, P557; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PIEKEN WA, UNPUB; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VERHEYDEN JP, 1971, J ORG CHEM, V36, P250; WILLIAMS DM, 1991, BIOCHEMISTRY-US, V30, P4001, DOI 10.1021/bi00230a027	27	407	552	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					314	317		10.1126/science.1857967	http://dx.doi.org/10.1126/science.1857967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857967				2022-12-24	WOS:A1991FX22400040
J	PINOLROMA, S; DREYFUSS, G				PINOLROMA, S; DREYFUSS, G			TRANSCRIPTION-DEPENDENT AND TRANSCRIPTION-INDEPENDENT NUCLEAR TRANSPORT OF HNRNP PROTEINS	SCIENCE			English	Article							RNA-BINDING PROTEINS; HELIX-DESTABILIZING PROTEIN; RIBONUCLEOPROTEIN-PARTICLES; MONOCLONAL-ANTIBODIES; CDNA CLONING; COMPLEXES; ENVELOPE; REVEALS; CELLS; SNRNA	Heterogeneous nuclear RNAs and specific nuclear proteins form heterogeneous nuclear ribonucleoprotein complexes (hnRNPs), one of the most abundant components of the nucleus. In mitosis, as the nuclear envelope breaks down, hnRNPs disperse throughout the cell. At the end of mitosis, hnRNPs dissociate and their proteins are transported into the daughter cell nuclei separately. Some are transported immediately (early group), white others are transported later (late group). Transport of the late group appears to require transcription by RNA polymerase II, in that inhibitors of this polymerase cause the late proteins to remain in the cytoplasm. Thus, there are two modes, transcription-dependent and transcription-independent, for the transport of nuclear proteins.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania	PINOLROMA, S (corresponding author), UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104, USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; CHOI YD, 1984, J CELL BIOL, V99, P1997; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DEROBERTIS EM, 1982, NATURE, V295, P572, DOI 10.1038/295572a0; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EGYHAZI E, 1982, EUR J BIOCHEM, V122, P445; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HARLOW E, 1988, ANTIBODIES LABORATOR; LAHIRI DK, 1985, J BIOL CHEM, V260, P598; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LESER GP, 1987, J CELL BIOL, V105, P2083, DOI 10.1083/jcb.105.5.2083; MARTIN TE, 1981, CELL NUCLEUS, V9, P119; MCKEON FD, 1983, P NATL ACAD SCI-BIOL, V80, P4374, DOI 10.1073/pnas.80.14.4374; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PINOLROMA S, 1990, METHOD ENZYMOL, V181, P317; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, UNPUB; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2; ZIEVE GW, 1986, J CELL PHYSIOL, V128, P85, DOI 10.1002/jcp.1041280114; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	31	188	189	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					312	314		10.1126/science.1857966	http://dx.doi.org/10.1126/science.1857966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857966				2022-12-24	WOS:A1991FX22400039
J	BARROW, CJ; ZAGORSKI, MG				BARROW, CJ; ZAGORSKI, MG			SOLUTION STRUCTURES OF BETA PEPTIDE AND ITS CONSTITUENT FRAGMENTS - RELATION TO AMYLOID DEPOSITION	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; X-RAY-DIFFRACTION; ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; MESSENGER-RNA; SENILE PLAQUES; BRAIN; INHIBITOR; IDENTIFICATION; LOCALIZATION	The secondary structures in solution of the synthetic, naturally occurring, amyloid beta-peptides, residues 1 to 42 [beta(1-42)] and beta(1-39), and related fragments, beta(1-28) and beta(29-42), have been studied by circular dichroism and two-dimensional nuclear magnetic resonance spectroscopy. In patients with Alzheimer's disease, extracellular amyloid plaque core is primarily composed of beta(1-42), whereas cerebrovascular amyloid contains the more soluble beta(1-39). In aqueous trifluoroethanol solution, the beta(1-28), beta(1-39), and beta(1-42) peptides adopt monomeric alpha-helical structures at both low and high pH, whereas at intermediate pH (4 to 7) an oligomeric beta-structure (the probable structure in plaques) predominates. Thus, beta-peptide is not by itself an insoluble protein (as originally thought), and localized or normal age-related alterations of pH may be necessary for the self-assembly and deposition of beta-peptide. The hydrophobic carboxyl-terminal segment, beta(29-42), exists exclusively as an oligomeric beta-sheet in solution, regardless of differences in solvent, pH, or temperature, suggesting that this segment directs the folding of the complete beta(1-42) peptide to produce the beta-pleated sheet found in amyloid plaques.	SUNTORY INST BIOORGAN RES,SHIMAMOTO,OSAKA 618,JAPAN	Suntory Holdings Ltd								BAX A, 1989, ANNU REV BIOCHEM, V58, P223; BEHROUZ N, 1989, LAB INVEST, V61, P576; BEYREUTHER K, 1988, ETIOLOGY DEMENTIA AL, P125; CANDY JM, 1986, LANCET, V1, P354; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; EANES ED, 1968, J HISTOCHEM CYTOCHEM, V16, P673, DOI 10.1177/16.11.673; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GILBOE DD, 1986, PHARM CEREBRAL ISCHE, P119; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRONENBORN AM, 1990, ANAL CHEM, V62, P2, DOI 10.1021/ac00200a003; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Hollosi M, 1989, Pept Res, V2, P109; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEWIS PN, 1971, P NATL ACAD SCI USA, V68, P2293, DOI 10.1073/pnas.68.9.2293; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; MUNCKATA K, 1987, STROKE, V18, P412; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P75; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WISNIEWSKI HM, 1976, J NEUROL SCI, V27, P173, DOI 10.1016/0022-510X(76)90059-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x; ZHANG H, 1989, P NATL ACAD SCI USA, V86, P8045, DOI 10.1073/pnas.86.20.8045	53	554	575	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					179	182		10.1126/science.1853202	http://dx.doi.org/10.1126/science.1853202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853202				2022-12-24	WOS:A1991FW16000031
J	DYE, S; ISAACS, C				DYE, S; ISAACS, C			INTRAVENOUS DRUG MISUSE AMONG PRISON-INMATES - IMPLICATIONS FOR SPREAD OF HIV	BRITISH MEDICAL JOURNAL			English	Article											DYE, S (corresponding author), ST MARYS HOSP,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND.			Dye, Stephen/0000-0002-0535-5332				CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219; 1989, HIV AIDS PRISONS; 1988, HIV AIDS PRISONS	4	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1506	1506		10.1136/bmj.302.6791.1506	http://dx.doi.org/10.1136/bmj.302.6791.1506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT505	1855020	Bronze, Green Published			2022-12-24	WOS:A1991FT50500023
J	SMITH, RA; LING, S; ALEXANDER, FW				SMITH, RA; LING, S; ALEXANDER, FW			GOLF RELATED HEAD-INJURIES IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									NEWCASTLE GEN HOSP,DEPT PAEDIAT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital								JENNETT B, 1977, Lancet, V2, P696; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MILLER JD, 1968, LANCET, V2, P991; STRANG I, 1978, INJURY, V10, P154	4	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1505	1506		10.1136/bmj.302.6791.1505	http://dx.doi.org/10.1136/bmj.302.6791.1505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855019	Green Published, Bronze			2022-12-24	WOS:A1991FT50500022
J	MAGUIRE, HF; HOEFFLER, JP; SIDDIQUI, A				MAGUIRE, HF; HOEFFLER, JP; SIDDIQUI, A			HBV X-PROTEIN ALTERS THE DNA-BINDING SPECIFICITY OF CREB AND ATF-2 BY PROTEIN-PROTEIN INTERACTIONS	SCIENCE			English	Article							HEPATITIS-B VIRUS; LONG TERMINAL REPEAT; CYCLIC-AMP; RESPONSE ELEMENT; TRANS-ACTIVATION; VIRAL ENHANCERS; MAMMALIAN-CELLS; GENE; TRANSCRIPTION; TRANSACTIVATOR	The hepatitis B virus (HBV) X gene product trans-activates viral and cellular genes. The X protein (pX) does not bind independently to nucleic acids. The data presented here demonstrate that pX entered into a protein-protein complex with the cellular transcriptional factors CREB and ATF-2 and altered their DNA binding specificities. Although CREB and ATF-2 alone did not bind to the HBV enhancer element, a pX-CREB or pX-ATF-2 complex did bind to the HBV enhancer. Thus, the ability of pX to interact with cellular factors broadened the DNA binding specificity of these regulatory proteins and provides a mechanism for pX to participate in transcriptional regulation. This strategy of altered binding specificity may modify the repertoire of genes that can be regulated by transcriptional factors during viral infection.	UNIV COLORADO,SCH MED,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,CTR CANC,DENVER,CO 80262; UNIV COLORADO,SCH MED,DIV MED ONCOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA33135, P30-CA46934-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033135, P30CA046934] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FACTOR O, 1990, ONCOGENE, V5, P867; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GODING CR, 1989, VIROLOGY, V173, P363; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, IN PRESS MOL ENDOCRI; HOEFFLER JP, 1990, TRENDS ENDOCRINOL ME, V1, P151; HOEFFLER JP, UNPUB; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7144; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; JAMEEL S, 1990, J VIROL, V64, P3963, DOI 10.1128/JVI.64.8.3963-3966.1990; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGUIRE HG, UNPUB; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TOGNONI A, 1986, NUCLEIC ACIDS RES, V13, P7357; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; WU J, 1990, CELL, V63, P673; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	41	404	420	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1991	252	5007					842	844		10.1126/science.1827531	http://dx.doi.org/10.1126/science.1827531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL123	1827531				2022-12-24	WOS:A1991FL12300046
J	GERBERT, B; BLEECKER, T; MIYASAKI, C; MAGUIRE, BT				GERBERT, B; BLEECKER, T; MIYASAKI, C; MAGUIRE, BT			POSSIBLE HEALTH-CARE PROFESSIONAL-TO-PATIENT HIV TRANSMISSION - DENTISTS REACTIONS TO A CENTERS-FOR-DISEASE-CONTROL REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								On July 27, 1990, the Centers for Disease Control reported possible transmission of the human immunodeficiency virus (HIV) from a dentist to a patient as a result of patient care. We surveyed a random national probability sample of 300 dentists with a 26-item survey in August and September 1990 to assess reactions to the report (response rate, 59%). Respondents tended not to believe the report (mean was 3.2, median 3.0, where 1 indicated "do not believe" and 7 indicated "believe"). Our sample also tended to believe that transmission of HIV from dentists to patients was unlikely in the future (mean was 2.0, median 2.0, where 1 indicated "not at all likely" and 7 indicated "very likely"). Fifty-one percent of our sample recommended that dentists infected with HIV should discontinue practice, while 38% recommended continuing practice with changes in procedures. Seventy-four percent believed patients should be told if their dentist was infected with HIV. In summary, dentists doubted the possibility of dentist-to-patient transmission of HIV and did not believe the Centers for Disease Control case report, but they did believe infected dentists should refrain from clinical work or modify their practice.	UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	GERBERT, B (corresponding author), UNIV CALIF SAN FRANCISCO,SCH DENT,DEPT DENT PUBL HLTH & HYG,DIV BEHAV SCI,707 PARNASUS,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Babbie ER, 1973, SURVEY RES METHODS, P165; BLAND A, 1990, AIDS ALERT, V5, P161; BREO DL, 1990, JAMA-J AM MED ASSOC, V264, P1464, DOI 10.1001/jama.264.11.1464; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V264, P1079; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; RELMAN AS, 1987, SEARCH MODERN HIPPOC, P198; Shilts R., 1987, BAND PLAYED POLITICS; 1991, MMWR, V40, P33; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1987, MMWR S2S, V36, pS1; 1986, FACTS AIDS DENTAL TE; 1990, MMWR, V39, P489; 1991, MMWR, V40, P21	14	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1991	265	14					1845	1848		10.1001/jama.265.14.1845	http://dx.doi.org/10.1001/jama.265.14.1845			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE862	1848643				2022-12-24	WOS:A1991FE86200025
J	CHADWICK, DJ; GILLATT, DA; GINGELL, JC				CHADWICK, DJ; GILLATT, DA; GINGELL, JC			MEDICAL OR SURGICAL ORCHIECTOMY - THE PATIENTS CHOICE	BRITISH MEDICAL JOURNAL			English	Article							PROSTATIC-CARCINOMA; ORCHIECTOMY				CHADWICK, DJ (corresponding author), SOUTHMEAD GEN HOSP,DEPT UROL,BRISTOL BS10 5NB,AVON,ENGLAND.							CASSILETH BR, 1989, UROLOGY, V33, P57, DOI 10.1016/0090-4295(89)90108-8; LUNGLMAYR G, 1987, INT C S SERIES, V125, P47; MCCLINTON S, 1989, BRIT J UROL, V63, P309, DOI 10.1111/j.1464-410X.1989.tb05195.x; PEELING WB, 1989, UROLOGY, V33, P45, DOI 10.1016/0090-4295(89)90106-4; 1990, MIMS             DEC, P248	5	33	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 9	1991	302	6776					572	572		10.1136/bmj.302.6776.572	http://dx.doi.org/10.1136/bmj.302.6776.572			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB936	1827036	Green Published, Bronze			2022-12-24	WOS:A1991FB93600023
J	YEH, E; DRISCOLL, R; COLTRERA, M; OLINS, A; BLOOM, K				YEH, E; DRISCOLL, R; COLTRERA, M; OLINS, A; BLOOM, K			A DYNAMIN-LIKE PROTEIN ENCODED BY THE YEAST SPORULATION GENE SPO15	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MICROTUBULES	THE tightly centromere-linked gene SPO15 is essential for meiotic cell division in the yeast Saccharomyces cerevisiae. Diploid cells without the intact SPO15 gene product are able to complete premeiotic DNA synthesis and genetic recombination, but are unable to traverse the division cycles. Electron microscopy of blocked cells reveals a duplicated but unseparated spindle-pole body. Thus cells are unable to form a bipolar spindle. Sequence analysis of SPO15 DNA reveals an open reading frame that predicts a protein of 704 amino acids. This protein is identical to VPS1, a gene involved in vacuolar protein sorting in yeast which has significant sequence homology (45% overall, 66% over 300 amino acids) to the microtubule bundling-protein, dynamin. The SPO15 gene product expressed in Escherichia coli can be affinity-purified with microtubules. SPO15 encodes a protein that is likely to be involved in a microtubule-dependent process required for the timely separation of spindle-pole bodies in meiosis	UNIV WASHINGTON,DEPT OTOLARYNGOL,SEATTLE,WA 98195; UNIV TENNESSEE,GRAD SCH BIOMED SCI,DIV BIOL,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831	University of Washington; University of Washington Seattle; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville	YEH, E (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.		Bloom, Kerry/AAE-5336-2019	Bloom, Kerry/0000-0002-3457-004X				BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TABOR S, 1990, CURRENT PROTOCOLS MO; YEH E, 1986, MOL CELL BIOL, V6, P158, DOI 10.1128/MCB.6.1.158	11	78	79	1	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 21	1991	349	6311					713	715		10.1038/349713a0	http://dx.doi.org/10.1038/349713a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1825352				2022-12-24	WOS:A1991EY62700053
J	XIE, XM; SMART, TG				XIE, XM; SMART, TG			A PHYSIOLOGICAL-ROLE FOR ENDOGENOUS ZINC IN RAT HIPPOCAMPAL SYNAPTIC NEUROTRANSMISSION	NATURE			English	Article							PYRAMIDAL CELLS; BRAIN; LOCALIZATION; RELEASE; NEURONS; ZN-2+; RESPONSES	THE mammalian central nervous system (CNS) contains an abundance of the transition metal zinc, which is highly localized in the neuronal parenchyma 1-4. Zinc is actively taken up 5,6 and stored in synaptic vesicles in nerve terminals 7-10, and stimulation of nerve fibre tracts that contain large amounts of zinc, such as the hippocampal mossy fibre system 4, can induce its release 11-13, suggesting that it may act as a neuromodulator. The known interaction of zinc with the major excitatory and inhibitory amino-acid neurotransmitter receptors in the CNS supports this notion 14-16. That zinc has a role in CNS synaptic transmission, however, has so far not been shown. Here we report a physiological role for zinc in the young rat hippocampus (postnatal, P3-P14 days). Our results indicate that naturally occurring spontaneous giant depolarizing synaptic potentials (GDPs) in young CA3 pyramidal neurones, mediated by the release of GABA (gamma-aminobutyric acid) 17, are induced by endogenously released zinc. These synaptic potentials are inhibited by specific zinc-chelating agents. GDPs are apparently generated by an inhibitory action of zinc on both pre- and postsynaptic GABA(B) receptors in the hippocampus. Our study implies that zinc modulates synaptic transmission in the immature hippocampus, a finding that may have implications for understanding benign postnatal seizures in young children suffering with acute zinc deficiency 18.	UNIV LONDON, DEPT PHARMACOL, 29-39 BRUNSWICK SQ, LONDON WC1N 1AX, ENGLAND	University of London				Xie, Xinmin Simon/0000-0002-4049-6499	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; CHARTON G, 1985, EXP BRAIN RES, V58, P202; CRAWFORD IL, 1975, J ORTHOMOL MED, V4, P39; CRAWFORD IL, 1972, J NEUROCHEM, V19, P1451, DOI 10.1111/j.1471-4159.1972.tb05088.x; DANSCHER G, 1975, BRAIN RES, V85, P522, DOI 10.1016/0006-8993(75)90825-2; DANSCHER G, 1984, NEUROBIOLOGY ZINC, VA, P227; DOLLER HJ, 1984, NEUROBIOLOGY ZINC, VB, P163; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FRIEDMAN B, 1984, J COMP NEUROL, V223, P88, DOI 10.1002/cne.902230108; GOLDBERG HJ, 1982, ARCH DIS CHILD, V57, P633, DOI 10.1136/adc.57.8.633; HESSE GW, 1979, SCIENCE, V205, P1005, DOI 10.1126/science.224456; HIDER RC, 1990, BIOCHEM PHARMACOL, V39, P1005, DOI 10.1016/0006-2952(90)90278-S; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HOLM IE, 1988, HISTOCHEMISTRY, V89, P289, DOI 10.1007/BF00493154; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; IBATA Y, 1969, J HISTOCHEM CYTOCHEM, V17, P171, DOI 10.1177/17.3.171; MCLAUGHLIN BJ, 1975, BRAIN RES, V85, P355, DOI 10.1016/0006-8993(75)90813-6; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SCHWARTZKROIN PA, 1981, DEV BRAIN RES, V2, P469, DOI 10.1016/0165-3806(81)90017-1; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; WENSINK J, 1988, J NEUROCHEM, V50, P782, DOI 10.1111/j.1471-4159.1988.tb02982.x; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WOLF G, 1984, NEUROSCI LETT, V51, P277, DOI 10.1016/0304-3940(84)90564-0	30	372	381	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 7	1991	349	6309					521	524		10.1038/349521a0	http://dx.doi.org/10.1038/349521a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846946				2022-12-24	WOS:A1991EW57100065
J	VONKRIES, JP; BUHRMESTER, H; STRATLING, WH				VONKRIES, JP; BUHRMESTER, H; STRATLING, WH			A MATRIX SCAFFOLD ATTACHMENT REGION BINDING-PROTEIN - IDENTIFICATION, PURIFICATION, AND MODE OF BINDING	CELL			English	Article							CHROMOSOMAL LOOP ANCHORAGE; DNA TOPOISOMERASE-II; HEAT-SHOCK GENE; INTERPHASE NUCLEI; CHROMATIN DOMAIN; XENOPUS OOCYTES; TRANSCRIPTION; METAPHASE; INVITRO; SITES	Matrix/scaffold attachment regions (MARs/SARs) partition chromatin into functional loop domains. Here we have identified a chicken protein that selectively binds to MARs from the chicken lysozyme locus and to MARs from Drosophila, mouse, and human genes. This protein, named ARBP (for attachment region binding protein), was purified to homogeneity and shown to bind to MARs in a cooperative fashion. ARBP is an abundant nuclear protein and a component of the internal nuclear network. Deletion mutants indicate that multiple AT-rich sequences, if contained in a minimal approximately 350 bp MAR fragment, can lead to efficient binding of ARBP. Furthermore, dimerization mutants show that, to bind ARBP efficiently, MAR sequences can act synergistically over large distances, apparently with the intervening DNA looping out. The binding characteristics of ARBP to MARs reproduce those of unfractionated matrix preparations, suggesting that ARBP is an important nuclear element for the generation of functional chromatin loops.			VONKRIES, JP (corresponding author), UNIV HAMBURG, KRANKENHAUS EPPENDORF, INST PHYSIOL CHEM, MARTINISTR 52, W-2000 HAMBURG 20, GERMANY.							ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COCKERILL PN, 1986, FEBS LETT, V204, P5, DOI 10.1016/0014-5793(86)81377-1; COOK PR, 1978, EUR J BIOCHEM, V84, P465, DOI 10.1111/j.1432-1033.1978.tb12188.x; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HUNG MC, 1984, NUCLEIC ACIDS RES, V12, P1863, DOI 10.1093/nar/12.4.1863; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P309, DOI 10.1016/0022-2836(82)90331-X; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUCHNIK AN, 1985, NUCLEIC ACIDS RES, V13, P1135, DOI 10.1093/nar/13.4.1135; MALKAS LH, 1989, P NATL ACAD SCI USA, V86, P70, DOI 10.1073/pnas.86.1.70; Maniatis T., 1982, MOL CLONING; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PETERS KE, 1982, EUR J BIOCHEM, V129, P221, DOI 10.1111/j.1432-1033.1982.tb07043.x; PETRYNIAK B, 1987, CELL, V48, P289, DOI 10.1016/0092-8674(87)90432-6; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAZIN SV, 1981, CELL, V27, P65, DOI 10.1016/0092-8674(81)90361-5; RENZ M, 1976, BIOCHEMISTRY-US, V15, P3220, DOI 10.1021/bi00660a010; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RYOJI M, 1984, CELL, V37, P21, DOI 10.1016/0092-8674(84)90297-6; SCALENGHE F, 1978, CHROMOSOMA, V66, P299, DOI 10.1007/BF00328531; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILLEPONTEAU B, 1984, CELL, V39, P469, DOI 10.1016/0092-8674(84)90454-9; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VOELLMY R, 1982, P NATL ACAD SCI-BIOL, V79, P1776, DOI 10.1073/pnas.79.6.1776; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WLASCHEK M, 1988, CHROMOSOMA, V96, P145, DOI 10.1007/BF00331047	61	204	215	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					123	135		10.1016/0092-8674(91)90214-J	http://dx.doi.org/10.1016/0092-8674(91)90214-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846084				2022-12-24	WOS:A1991ET17500014
J	MORRIS, CD; MENASHE, VD				MORRIS, CD; MENASHE, VD			25-YEAR MORTALITY AFTER SURGICAL REPAIR OF CONGENITAL HEART DEFECT IN CHILDHOOD - A POPULATION-BASED COHORT STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR SEPTAL-DEFECT; TERM FOLLOW-UP; GREAT-ARTERIES; SUDDEN-DEATH; TETRALOGY; FALLOT; TRANSPOSITION; COARCTATION; MUSTARD; DYSRHYTHMIAS	Objective. - To determine long-term survival and the cause of death after repair of one of eight congenital heart defects in childhood. Design. - Cohort study. Setting. - General community. Participants. - All Oregon residents with one of eight congenital heart defects, which was repaired surgically between 1958 and 1989 when the patient was aged 18 years or younger, including (1) tetralogy of Fallot; (2) isolated ventricular septal defect; (3) isolated atrial septal defect; (4) coarctation of the aorta; (5) aortic valvular stenosis; (6) pulmonary valvular stenosis; (7) transposition of the great arteries; and (8) patent ductus arteriosus. Follow-up of this cohort of 2701 individuals was obtained from 94%. Main Outcome Measure. - Mortality from cardiac and noncardiac causes. Results. - Age at surgery and operative mortality have decreased significantly over the last 30 years. Late cardiac mortality at 25 years after surgery was 5% for tetralogy of Fallot and isolated ventricular septal defect, 1 0% for coarctation of the aorta, 17% for aortic stenosis, 5% for pulmonic stenosis,and less than 1% for patent ductus arteriosus; there were no late cardiac deaths after atrial septal defect repair. For transposition, late cardiac mortality was 15% at 15 years after the Mustard operation and was 2% at 10 years after the Senning operation. Conclusion. - Surgical repair of most congenital heart defects is associated with lingering cardiac mortality, particularly for aortic stenosis, coarctation, and transposition.	OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201	Oregon Health & Science University	MORRIS, CD (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,DIV CARDIOL,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036856, R29HL039052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R23 HL36856, R29 HL39052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN HD, 1974, CIRCULATION, V50, P465, DOI 10.1161/01.CIR.50.3.465; BEHL PR, 1987, THORAX, V42, P309, DOI 10.1136/thx.42.4.309; BENDER HW, 1989, ANN THORAC SURG, V47, P218, DOI 10.1016/0003-4975(89)90272-5; CARPENTER MA, 1985, J AM COLL CARDIOL, V6, P879, DOI 10.1016/S0735-1097(85)80498-8; CHANDAR JS, 1990, AM J CARDIOL, V65, P655, DOI 10.1016/0002-9149(90)91047-A; CLARKSON PM, 1976, CIRCULATION, V53, P519, DOI 10.1161/01.CIR.53.3.519; DEANFIELD J, 1988, J THORAC CARDIOV SUR, V96, P569; DEANFIELD JE, 1983, CIRCULATION, V67, P626, DOI 10.1161/01.CIR.67.3.626; DUSTER MC, 1985, AM HEART J, V109, P1323, DOI 10.1016/0002-8703(85)90359-X; FRIEDLI B, 1974, AM J CARDIOL, V33, P403, DOI 10.1016/0002-9149(74)90323-3; FUSTER V, 1980, AM J CARDIOL, V46, P635, DOI 10.1016/0002-9149(80)90514-7; HOFFMAN JIE, 1978, AM J CARDIOL, V42, P641, DOI 10.1016/0002-9149(78)90635-5; JAMES FW, 1975, CIRCULATION, V52, P691, DOI 10.1161/01.CIR.52.4.691; KIRKLIN JW, 1977, CIRCULATION, V56, P612, DOI 10.1161/01.CIR.56.4.612; KOPECKY SL, 1988, CIRCULATION, V78, P1150, DOI 10.1161/01.CIR.78.5.1150; LILLEHEI CW, 1986, ANN THORAC SURG, V41, P4, DOI 10.1016/S0003-4975(10)64489-X; LILLEHEI CW, 1986, ANN SURG, V204, P490, DOI 10.1097/00000658-198610000-00017; MANNING JA, 1980, CARDIOVASC CLIN, V11, P117; MARX GR, 1983, J AM COLL CARDIOL, V1, P476, DOI 10.1016/S0735-1097(83)80076-X; MATSUDA H, 1986, JPN CIRC J, V50, P1040, DOI 10.1253/jcj.50.1040; MURPHY JG, 1990, NEW ENGL J MED, V323, P1645, DOI 10.1056/NEJM199012133232401; MURPHY JG, 1989, CIRCULATION S2, V80, P490; PARSONS JM, 1989, BRIT HEART J, V62, P65; QUATTLEBAUM TG, 1976, CIRCULATION, V54, P289, DOI 10.1161/01.CIR.54.2.289; SIMSOLO R, 1988, AM HEART J, V115, P1268, DOI 10.1016/0002-8703(88)90020-8; 1988, PHS881147 DEP HLTH H; 1977, CIRCULATION S1, V55, P87; 1980, PEDIATRICS, V63, P377	28	105	107	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 25	1991	266	24					3447	3452		10.1001/jama.266.24.3447	http://dx.doi.org/10.1001/jama.266.24.3447			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV878	1744959				2022-12-24	WOS:A1991GV87800030
J	WILLIAMS, TM; MOOLTEN, D; BURLEIN, J; ROMANO, J; BHAERMAN, R; GODILLOT, A; MELLON, M; RAUSCHER, FJ; KANT, JA				WILLIAMS, TM; MOOLTEN, D; BURLEIN, J; ROMANO, J; BHAERMAN, R; GODILLOT, A; MELLON, M; RAUSCHER, FJ; KANT, JA			IDENTIFICATION OF A ZINC FINGER PROTEIN THAT INHIBITS IL-2 GENE-EXPRESSION	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 GENE; DNA-BINDING PROTEINS; MESSENGER-RNA; LYMPHOCYTES-T; CHLORAMPHENICOL ACETYLTRANSFERASE; FIREFLY LUCIFERASE; ANTIGEN RECEPTOR; MAMMALIAN-CELLS; PROMOTER; ACTIVATION	Transient activation of the interleukin-2 (IL-2) gene after antigen recognition by T lymphocytes is crucial for subsequent T cell proliferation and differentiation. Several IL-2 gene regulatory elements and binding factors necessary for activation of the IL-2 gene have been defined. However, little is known about negative regulation of IL-2 expression, which is likely to be important in the rapid shut-off of IL-2 transcription. A nucleotide sequence element (NRE-A) that negatively regulates IL-2 expression has been identified within the IL-2 gene. T cell nuclear extracts contained an NRE-A binding activity. A complementary DNA was isolated that encodes a zinc finger-containing protein that suppressed IL-2 gene expression. The observation of negative regulation of the immunoglobulin heavy chain gene enhancer by an element similar to NRE-A suggests that related proteins may regulate multiple immune response genes.	WISTAR INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania	WILLIAMS, TM (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131, USA.				NCI NIH HHS [CA54428, CA23413] Funding Source: Medline; NIAID NIH HHS [AI23879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA023413, R29CA054428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1987, CELL, V729; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH4; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EFRAT S, 1984, P NATL ACAD SCI-BIOL, V81, P2601, DOI 10.1073/pnas.81.9.2601; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KANT JA, 1989, C INSERM, V179, P53; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHAW J, 1988, J IMMUNOL, V140, P2243; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Williams T. J., UNPUB; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WILLIAMS TM, 1988, J IMMUNOL, V141, P662; ZUBIAGA AM, 1991, J IMMUNOL, V146, P3857	43	177	181	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1791	1794		10.1126/science.1840704	http://dx.doi.org/10.1126/science.1840704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1840704				2022-12-24	WOS:A1991GW31600043
J	ROUSSEL, MF; CLEVELAND, JL; SHURTLEFF, SA; SHERR, CJ				ROUSSEL, MF; CLEVELAND, JL; SHURTLEFF, SA; SHERR, CJ			MYC RESCUE OF A MUTANT CSF-1 RECEPTOR IMPAIRED IN MITOGENIC SIGNALING	NATURE			English	Article							RECOMBINANT MURINE RETROVIRUS; FACTOR-I RECEPTOR; NIH 3T3 CELLS; C-MYC; GROWTH-FACTOR; BONE-MARROW; TRANSCRIPTION; KINASE; FOS; MACROPHAGES	THE colony-stimulating factor-1 receptor (CSF-1R) mediates its pleiotropic effects through the coupling of its ligand-activated tyrosine kinase to multiple intracellular effector proteins, whose combined actions determine the magnitude and specificity of the biological response. The interaction of cytoplasmic signalling molecules with CSF-1R is mediated in part by sequence motifs flanking sites of receptor tyrosine phosphorylation 1. Mutation of an autophosphorylation site at tyrosine 809 in the cytoplasmic domain of human CSF-1R does not significantly reduce its ligand-stimulated tyrosine kinase activity, binding to phosphatidylinositol 3-kinase, or induction of the immediate early response genes, c-fos and junB (ref. 2). Unlike cells bearing wild-type receptors, mouse NIH3T3 cells expressing mutant CSF-1R(Phe 809) were unable to grow in serum-free medium containing human recombinant CSF-1 and did not form colonies in semi-solid medium in its presence. CSF-1 induction of c-myc messenger RNA in these cells was impaired, but enforced expression of an exogenous c-myc gene restored their ability to proliferate in response to the growth factor. These studies demonstrate a receptor-mediated bifurcation of intracellular signal transduction pathways during the immediate early response and assign a central role for c-myc in CSF-1-induced mitogenesis.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DEAN M, 1987, ONCOGENE RES, V1, P279; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073	24	170	171	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	1991	353	6342					361	363		10.1038/353361a0	http://dx.doi.org/10.1038/353361a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG654	1833648				2022-12-24	WOS:A1991GG65400064
J	BOSHART, M; WEIH, F; NICHOLS, M; SCHUTZ, G				BOSHART, M; WEIH, F; NICHOLS, M; SCHUTZ, G			THE TISSUE-SPECIFIC EXTINGUISHER LOCUS TSE1 ENCODES A REGULATORY SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE	CELL			English	Article							SOMATIC-CELL HYBRIDS; LIVER-SPECIFIC GENES; AMINO-ACID SEQUENCE; NUCLEAR FACTOR CREB; CYCLIC-AMP; MESSENGER-RNA; MOLECULAR-CLONING; CDNA STRUCTURE; HUMAN TESTIS; TRANSCRIPTION FACTOR	The tissue-specific extinguisher locus TSE1, a dominant negative regulator of transcription in somatic cell hybrids, acts via a cAMP response element (CRE) to repress activity of a hepatocyte-specific enhancer. Guided by the antagonism between TSE1 and cAMP-mediated signal transduction, we identified the regulatory subunit RI-alpha of protein kinase A (PKA) as the product of the TSE1 locus. The evidence derives from concordant expression of RI-alpha mRNA and TSE1 genetic activity, high resolution mapping of the RI-alpha gene and TSE1 on human chromosome 17, and the ability of a transfected RI-alpha cDNA to generate a phenocopy of TSE1-mediated extinction. The mechanism of TSE1/RI-alpha-mediated extinction involves repression of basal PKA activity, reduced phosphorylation of CREB at Ser-133, and a corresponding reduction of in vivo protein binding at the target CRE.			BOSHART, M (corresponding author), GERMAN CANC RES CTR, INST CELL & TUMOR BIOL, NEUENHEIMER FELD 280, W-6900 HEIDELBERG, GERMANY.		Boshart, Michael/A-2700-2011	Boshart, Michael/0000-0002-5070-2663				BECKER PB, 1988, GENETIC ENG, V10, P1; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BOLTON ET, 1962, P NATL ACAD SCI USA, V48, P1390, DOI 10.1073/pnas.48.8.1390; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHIN AC, 1987, P NATL ACAD SCI USA, V84, P1614, DOI 10.1073/pnas.84.6.1614; CHIN AC, 1989, MOL CELL BIOL, V9, P3736, DOI 10.1128/MCB.9.9.3736; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DAVIDSON RL, 1974, ANNU REV GENET, V8, P195, DOI 10.1146/annurev.ge.08.120174.001211; DAVIS FM, 1973, BACTERIOL REV, V37, P197, DOI 10.1128/MMBR.37.2.197-214.1973; DAY RN, 1989, J BIOL CHEM, V264, P431; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; GOURDEAU H, 1989, MOL CELL BIOL, V9, P1813, DOI 10.1128/MCB.9.5.1813; GREENGARD O, 1970, BIOCHEMICAL ACTIONS, V1, P53; GROVE JR, 1989, J BIOL CHEM, V264, P19506; GROVE JR, 1987, SCIENCE, V238, P530; JUNKER S, 1988, EMBO J, V7, P3093, DOI 10.1002/j.1460-2075.1988.tb03175.x; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEM J, 1988, P NATL ACAD SCI USA, V85, P7302, DOI 10.1073/pnas.85.19.7302; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MCKNIGHT GS, 1988, COLD SPRING HARB SYM, V53, P111, DOI 10.1101/SQB.1988.053.01.017; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PETERSON TC, 1989, MOL BIOL MED, V6, P109; PETIT C, 1986, P NATL ACAD SCI USA, V83, P2561, DOI 10.1073/pnas.83.8.2561; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RUIZBRAVO N, 1982, P NATL ACAD SCI-BIOL, V79, P365, DOI 10.1073/pnas.79.2.365; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; Sambrook J., 1989, MOL CLONING LAB MANU; SANDBERG M, 1988, BIOCHEM BIOPH RES CO, V154, P705, DOI 10.1016/0006-291X(88)90197-0; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCAMBLER P, 1987, AM J HUM GENET, V41, P925; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; SVOBODA J, 1960, NATURE, V186, P980, DOI 10.1038/186980b0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; THAYER MJ, 1989, MOL CELL BIOL, V9, P2837, DOI 10.1128/MCB.9.7.2837; THAYER MJ, 1990, MOL CELL BIOL, V10, P2660, DOI 10.1128/MCB.10.6.2660; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WEIH F, 1988, NUCLEIC ACIDS RES, V16, P1628, DOI 10.1093/nar/16.4.1628; WEIH F, 1990, GENE DEV, V4, P1437, DOI 10.1101/gad.4.8.1437; WITTMAACK FM, 1983, EUR J BIOCHEM, V129, P669; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZALLER DM, 1988, MOL CELL BIOL, V8, P1932, DOI 10.1128/MCB.8.5.1932	70	183	185	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					849	859		10.1016/0092-8674(91)90432-X	http://dx.doi.org/10.1016/0092-8674(91)90432-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832337	Green Published			2022-12-24	WOS:A1991GE46000005
J	IGARASHI, M; NAGATA, A; JINNO, S; SUTO, K; OKAYAMA, H				IGARASHI, M; NAGATA, A; JINNO, S; SUTO, K; OKAYAMA, H			WEE1+-LIKE GENE IN HUMAN-CELLS	NATURE			English	Article							HIGH-EFFICIENCY TRANSFORMATION; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; HUMAN HOMOLOG; INDUCER; DNA	THE wee1+ gene is a mitotic inhibitor controlling the G2 to M transition of the fission yeast Schizosaccharomyces pombe 1 and encodes a protein kinase with both serine- and tyrosine-phosphorylating activities 2. We have cloned a human gene (WEE1Hu) similar to wee1+ by transcomplementation of a yeast mutant 3,4. WEE1Hu encodes a protein homologous to the S. pombe wee1+ and mik1+ (a functionally redundant sibling of wee1+) 5 kinases and effectively rescues a wee1 mutation. We report here that overexpression of WEE1Hu in fission yeast generates very elongated cells as a result of inhibition of the G2-M transition in the cell cycle. In addition, we detected a 3-kilobase-long WEE1Hu messenger RNA in all the human cell lines we examined. We conclude that a wee1+-like gene exists and is expressed in human cells.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,3-1 YAMADAOKA,SUITA,OSAKA 565,JAPAN	Osaka University								CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Gutz H., 1974, HDB GENETICS, V1, P395; HANKS SK, 1988, SCIENCE, V241, P24; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Rothstein R., 1985, DNA CLONING, VII, P45; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOYAMA R, 1990, FEBS LETT, V268, P217, DOI 10.1016/0014-5793(90)81012-D	16	182	191	1	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					80	83		10.1038/353080a0	http://dx.doi.org/10.1038/353080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1840647				2022-12-24	WOS:A1991GD80500064
J	WU, J; MANLEY, JL				WU, J; MANLEY, JL			BASE-PAIRING BETWEEN U2 AND U6 SNRNAS IS NECESSARY FOR SPLICING OF A MAMMALIAN PRE-MESSENGER-RNA	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; BRANCH SITE SELECTION; GENES EVEN THOUGH; U1 SNRNA; EFFICIENT TRANSCRIPTION; DIFFERENT POLYMERASE; 2'-OME RNA; YEAST; PARTICLES; ELEMENTS	SPLICING of pre-messenger RNA in eukaryotic cells occurs in a multicomponent complex termed the spliceosome, which contains small nuclear ribonucleoprotein particles (snRNPs), protein factors and substrate pre-mRNA 1-3. Assembly of the spliceosome involves the stepwise binding of snRNPs and protein factors to the pre-mRNA through a poorly understood mechanism which probably involves specific RNA-RNA, RNA-protein and protein-protein interactions. Of particular interest are the interactions between snRNPs, which are likely to be important not only for assembly of the spliceosome but also for catalysis. U1 snRNP interacts with the 5' splice site and U2 snRNP with the branch site of the pre-mRNA; both of these interactions involve Watson-Crick base pairing 4-9. But very little is known about how other factors such as the U4/U6 and U5 snRNPs reach the spliceosome and function in splicing. Here we report evidence that U6 snRNA interacts directly with U2 snRNA by a mechanism involving base-pairing, and that this interaction can be necessary for splicing of a mammalian pre-mRNA in vivo.			WU, J (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LIAO XL, 1990, GENE DEV, V4, P1766, DOI 10.1101/gad.4.10.1766; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NOBLE JCS, 1988, GENE DEV, V2, P1460, DOI 10.1101/gad.2.11.1460; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5462; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	32	160	161	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					818	821		10.1038/352818a0	http://dx.doi.org/10.1038/352818a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1831878				2022-12-24	WOS:A1991GC96400065
J	ELLISEN, LW; BIRD, J; WEST, DC; SORENG, AL; REYNOLDS, TC; SMITH, SD; SKLAR, J				ELLISEN, LW; BIRD, J; WEST, DC; SORENG, AL; REYNOLDS, TC; SMITH, SD; SKLAR, J			TAN-1, THE HUMAN HOMOLOG OF THE DROSOPHILA NOTCH GENE, IS BROKEN BY CHROMOSOMAL TRANSLOCATIONS IN T-LYMPHOBLASTIC NEOPLASMS	CELL			English	Article							HAMSTER OVARY CELLS; CDNA CLONES; PROTEIN; RECEPTOR; LOCUS; NEUROGENESIS; SIMILARITY; SEQUENCES; LEUKEMIA; GROWTH	Previously we described joining of DNA in the beta-T cell receptor gene to DNA of an uncharacterized locus in a t(7;9)(q34;q34.3) chromosomal translocation from a case of human T lymphoblastic leukemia (T-ALL). We now show that the locus on chromosome 9 contains a gene highly homologous to the Drosophila gene Notch. Transcripts of the human gene, for which we propose the name TAN-1, and its murine counterpart are present in many normal human fetal and adult mouse tissues, but are most abundant in lymphoid tissues. In t(7;9)(q34;q34.3) translocations from three cases of T-ALL, the breakpoints occur within 100 bp of an intron in TAN-1, resulting in truncation of TAN-1 transcripts. These observations suggest that TAN-1 may be important for normal lymphocyte function and that alteration of TAN-1 may play a role in the pathogenesis of some T cell neoplasms.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV DIAGNOST MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Ellisen, Leif W/AAA-6572-2022; West, Daniel/AAW-3111-2020	Ellisen, Leif W/0000-0003-0444-7910; West, Daniel/0000-0002-0909-4213	NCI NIH HHS [CA38621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Battey, 1986, BASIC METHODS MOL BI; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOI S, 1987, BLOOD, V70, P1619; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILLARD S, 1986, P NATL ACAD SCI USA, V83, P5573, DOI 10.1073/pnas.83.15.5573; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GOETZL DJ, 1990, ADV IMMUNOL, V48, P161; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T., 1982, MOL CLONING; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RAIMONDI SC, 1987, BLOOD, V69, P131; REYNOLDS TC, 1987, CELL, V50, P107, DOI 10.1016/0092-8674(87)90667-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWENK HU, 1975, BLUT, V31, P229; SMITH SD, 1988, BLOOD, V71, P395; SMITH SD, 1989, BLOOD, V73, P2182; SMITH TF, 1985, NUCLEIC ACIDS RES, V13, P645, DOI 10.1093/nar/13.2.645; SPEHNER D, 1988, J VIROL, V62, P1297, DOI 10.1128/JVI.62.4.1297-1304.1988; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; TYCKO B, 1989, J EXP MED, V169, P3369; TYCKO B, 1991, IN PRESS J EXP MED; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	50	1454	1576	1	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					649	661		10.1016/0092-8674(91)90111-B	http://dx.doi.org/10.1016/0092-8674(91)90111-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1831692				2022-12-24	WOS:A1991GC74500006
J	HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; TWUMASI, P; ROWE, PA; BENNETT, S; BREWSTER, D; MCMICHAEL, AJ; GREENWOOD, BM				HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; TWUMASI, P; ROWE, PA; BENNETT, S; BREWSTER, D; MCMICHAEL, AJ; GREENWOOD, BM			COMMON WEST AFRICAN HLA ANTIGENS ARE ASSOCIATED WITH PROTECTION FROM SEVERE MALARIA	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; FRAGMENT-LENGTH-POLYMORPHISM; CD8+ T-CELLS; MHC POLYMORPHISM; MIXED ANCESTRY; DQ ANTIGENS; SELECTION; SUBSTITUTION; HAPLOTYPES; ALLELES	A large case-control study of malaria in West African children shows that a human leucocyte class I antigen (HLA-Bw53) and an HLA class II haplotype (DRB1*1302-DQB1*0501), common in West Africans but rare in other racial groups, are independently associated with protection from severe malaria. In this population they account for as great a reduction in disease incidence as the sickle-cell haemoglobin variant. These data support the hypothesis that the extraordinary polymorphism of major histocompatibility complex genes has evolved primarily through natural selection by infectious pathogens.	MRC LABS, FAJARA, SENEGAMBIA; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND; ROYAL VICTORIA HOSP, BANJUL, SENEGAMBIA	University of London; London School of Hygiene & Tropical Medicine	HILL, AVS (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIZAWA M, 1986, HLA ASIA OCEANIA; ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137, DOI 10.1101/SQB.1964.029.01.018; ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BAUR MP, 1984, HISTOCOMPATIBILITY T, P333; BENGTSSON BO, 1981, TISSUE ANTIGENS, V18, P356, DOI 10.1111/j.1399-0039.1981.tb01404.x; BIDWELL J, 1988, IMMUNOL TODAY, V9, P18, DOI 10.1016/0167-5699(88)91351-5; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1991, TISSUE ANTIGENS, V37, P97, DOI 10.1111/j.1399-0039.1991.tb01853.x; BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; BRILES WE, 1977, SCIENCE, V195, P193, DOI 10.1126/science.831269; BROWN PJ, 1981, HUM BIOL, V53, P367; Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1; CARLSSON B, 1987, HUM IMMUNOL, V20, P95, DOI 10.1016/0198-8859(87)90025-5; CLARKE B, 1966, NATURE, V211, P999, DOI 10.1038/211999a0; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; COLOMBO B, 1985, J MED GENET, V22, P291, DOI 10.1136/jmg.22.4.291; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; Dupont B, 1989, IMMUNOBIOLOGY HLA, V1st; DUTOIT ED, 1990, TISSUE ANTIGENS, V36, P122, DOI 10.1111/j.1399-0039.1990.tb01812.x; DUTOIT ED, 1988, TISSUE ANTIGENS, V31, P109; FAREWELL VT, 1984, BIOMETRICS, V40, P547, DOI 10.2307/2531409; FERNANDEZVINA M, 1990, HUM IMMUNOL, V28, P51, DOI 10.1016/0198-8859(90)90102-U; FESTENSTEIN H, 1972, HISTOCOMPATIBILITY T, P175; FIGUEROA F, 1988, NATURE, V335, P265, DOI 10.1038/335265a0; GILLESPIE JH, 1985, THEOR POPUL BIOL, V27, P222, DOI 10.1016/0040-5809(85)90011-5; GORSKI J, 1989, J EXP MED, V170, P1027, DOI 10.1084/jem.170.3.1027; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; GREENWOOD BM, 1990, PARASITOL TODAY, V6, P188, DOI 10.1016/0169-4758(90)90351-4; GREENWOOD BM, IN PRESS PARASITOL T; GYLLENSTEN UB, 1990, P NATL ACAD SCI USA, V87, P1835, DOI 10.1073/pnas.87.5.1835; Haldane J. B. S., 1963, Journal of Genetics, V58, P237, DOI 10.1007/BF02986143; HAYASHI H, 1990, IMMUNOGENETICS, V32, P195, DOI 10.1007/BF02114973; HEDRICK PW, 1983, GENETICS, V104, P449; HEDRICK PW, 1988, GENETICS, V119, P205; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; HILL AVS, IN PRESS MOL EVOLUTI; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; KLEIN J, 1987, HUM IMMUNOL, V19, P155, DOI 10.1016/0198-8859(87)90066-8; KLITZ W, 1986, AM J HUM GENET, V39, P340; KWIATKOWSKI D, 1991, P NATL ACAD SCI USA, V88, P5111, DOI 10.1073/pnas.88.12.5111; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; LEE KW, 1990, HUM IMMUNOL, V29, P202; LEE KW, 1990, J IMMUNOL, V145, P3119; LEE TD, 1990, TISSUE ANTIGENS, V35, P64, DOI 10.1111/j.1399-0039.1990.tb01758.x; MARTELL RW, 1989, HUM IMMUNOL, V26, P237, DOI 10.1016/0198-8859(89)90002-5; MARTELL RW, 1990, HUM IMMUNOL, V28, P32, DOI 10.1016/0198-8859(90)90100-4; MCPHERSON GG, 1988, AM J PATHOL, V119, P385; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MOLYNEUX ME, 1989, Q J MED, V71, P441; OKOYE RC, 1985, TISSUE ANTIGENS, V25, P142; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PIAZZA A, 1985, ANN HUM GENET, V49, P47, DOI 10.1111/j.1469-1809.1985.tb01675.x; PLAYFAIR JHL, 1982, BRIT MED BULL, V38, P153, DOI 10.1093/oxfordjournals.bmb.a071752; RESTREPO M, 1988, REV I MED TROP, V30, P323, DOI 10.1590/S0036-46651988000500001; RILEY EM, 1991, PARASITOL TODAY, V7, P5, DOI 10.1016/0169-4758(91)90076-Z; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; RONNINGEN KS, 1990, HUM IMMUNOL, V29, P275, DOI 10.1016/0198-8859(90)90041-M; SCHARF SJ, 1989, P NATL ACAD SCI USA, V86, P6215, DOI 10.1073/pnas.86.16.6215; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SCHREUDER GMT, 1989, IMMUNOBIOLOGY HLA, V1, P252; SERJEANTSON SW, 1989, TRANSPL P, V21, P598; SERJEANTSON SW, 1989, COLONIZATION PACIFIC, P120; SNELL GD, 1968, FOLIA BIOL-PRAGUE, V14, P335; Sy N E, 1984, Southeast Asian J Trop Med Public Health, V15, P1; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1981, GENETICS, V98, P427; TIWARI JL, 1985, HLA DISEASE ASS; VRIES RRPD, 1979, J IMMUNOGENET, V6, P271; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WORDSWORTH BP, 1990, IMMUNOGENETICS, V32, P413; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; [No title captured]	75	1238	1263	1	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					595	600		10.1038/352595a0	http://dx.doi.org/10.1038/352595a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865923	Bronze			2022-12-24	WOS:A1991GB21100046
J	HOOFNAGLE, JH				HOOFNAGLE, JH			THROMBOCYTOPENIA DURING INTERFERON ALFA THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CHRONIC HEPATITIS; ALPHA-INTERFERON				HOOFNAGLE, JH (corresponding author), NIH,BETHESDA,MD 20892, USA.							ALEXANDER GJM, 1987, LANCET, V2, P66; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; PERRILLO RP, 1990, NEW ENGL J MED, V323, P337	4	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					849	849		10.1001/jama.266.6.849	http://dx.doi.org/10.1001/jama.266.6.849			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865526				2022-12-24	WOS:A1991GA07300042
J	MASLEN, CL; CORSON, GM; MADDOX, BK; GLANVILLE, RW; SAKAI, LY				MASLEN, CL; CORSON, GM; MADDOX, BK; GLANVILLE, RW; SAKAI, LY			PARTIAL SEQUENCE OF A CANDIDATE GENE FOR THE MARFAN-SYNDROME	NATURE			English	Article							MICROFIBRILS; FIBRILLIN; COMPONENT; PROTEINS; COMPLEX	FIBRILLIN is a large (relative molecular mass 350,000) glycoprotein which can be isolated from fibroblast cell cultures and is a component of the microfibrils that are ubiquitous in the connective tissue space 1. The microfibrils of the suspensory ligament of the lens as well as the elastic fibre microfibrils of the blood vessel wall are composed of fibrillin. The ocular and cardiovascular manifestations of the Marfan syndrome are consistent with a defect in the gene coding for a structural constituent of these connective tissues. Immunohistological experiments have recently implicated fibrillin microfibrils in the pathogenesis of the Marfan syndrome 2. Genetic linkage data 3,4 localizing the Marfan gene to chromosome 15 and the in situ hybridization of fibrillin complementary DNA to 15q21.1 (ref. 5) together support fibrillin as a candidate Marfan gene. As a first step towards investigating the function of fibrillin in the architecture and development of connective tissues and its relationship to the Marfan syndrome, we report the cloning and partial sequencing of fibrillin cDNA.	SHRINERS HOSP CRIPPLED CHILDREN,3101 SW SAM JACKSON PK RD,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University								DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MAGENIS RE, IN PRESS GENOMICS; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SAKAI LY, IN PRESS J BIOL CHEM; STENFLO J, 1988, J BIOL CHEM, V263, P21; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	14	290	299	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					334	337		10.1038/352334a0	http://dx.doi.org/10.1038/352334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852207				2022-12-24	WOS:A1991FY28900070
J	BANDARA, LR; ADAMCZEWSKI, JP; HUNT, T; LATHANGUE, NB				BANDARA, LR; ADAMCZEWSKI, JP; HUNT, T; LATHANGUE, NB			CYCLIN-A AND THE RETINOBLASTOMA GENE-PRODUCT COMPLEX WITH A COMMON TRANSCRIPTION FACTOR	NATURE			English	Article							SV40 LARGE-T; E1A PROTEINS; CELL-CYCLE; BINDING; POLYPEPTIDES; ASSOCIATION; ANTIGEN	THE retinoblastoma gene (Rb) product is a negative regulator of cellular proliferation 1 an effect that could be mediated in part at the transcriptional level through its ability to complex with the sequence-specific transcription factor DRTF1 (ref. 2). This interaction is modulated by adenovirus E1a, which sequesters the Rb protein 3 and several other cellular proteins 3, including cyclin A (refs 4, 5), a molecule that undergoes cyclical accumulation and destruction during each cell cycle 6,7 and which is required for cell cycle progression 8. Cyclin A, which also complexes with DRTF1, facilitates the efficient assembly of the Rb protein into the complex. This suggests a role for cyclin A in regulating transcription and defines a transcription factor through which molecules that regulate the cell cycle in a negative fashion, such as Rb, and in a positive fashion, such as cyclin A, interact. Mutant loss-of-function Rb alleles, which occur in a variety of tumour cells, also fail to complex with E1a and large T antigen 9,10. Here we report on a naturally occurring loss-of-function Rb allele encoding a protein that fails to complex with DRTF1. This might explain how mutation in the Rb gene prevents negative growth control.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,POTTERS BAR EN6 3LD,HERTS,ENGLAND	MRC National Institute for Medical Research			Hunt, Tim/O-8544-2019	Hunt, Tim/0000-0001-5174-6038				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	22	287	298	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					249	251		10.1038/352249a0	http://dx.doi.org/10.1038/352249a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1830372				2022-12-24	WOS:A1991FX18500069
J	DEDOMBAL, FT; DALLOS, V; MCADAM, WAF				DEDOMBAL, FT; DALLOS, V; MCADAM, WAF			CAN COMPUTER-AIDED TEACHING PACKAGES IMPROVE CLINICAL CARE IN PATIENTS WITH ACUTE ABDOMINAL-PAIN	BRITISH MEDICAL JOURNAL			English	Article							ACUTE ABDOMEN; DIAGNOSIS	Objective - To compare three methods of support for inexperienced staff in their diagnosis and management of patients with acute abdominal pain -namely, with (a) structured data collection forms, (b) real time computer aided decision support, and (c) computer based teaching packages. Design - Prospective assessment of effects of methods of support on groups of doctors in one. urban hospital and one rural hospital. Setting - Accident and emergency department at Whipps Cross Hospital, London, and surgical wards of Airedale General Hospital, West Yorkshire. Patients - Consecutive prospective series of all patients presenting to each hospital in specified time periods with acute abdominal pain; total patients in the various periods were 12 506. Main outcome measures - Diagnostic accuracy of participating doctors, admission rates of patients with non-specific abdominal pain, perforation rates in patients with appendicitis, negative laparotomy rates. Results - Use of any one modality resulted in improved diagnostic accuracy and decision making performance. Use of structured forms plus computer feedback resulted in better performance than use of forms alone. Use of structured forms plus a computer teaching package gave results at least as good as those with direct feedback by computer. Conclusions - The results confirm earlier studies in suggesting that the use of computer aided decision support improves diagnostic and decision making performance when dealing with patients suffering from acute abdominal pain. That use of the computer for teaching gave results at least as good as with its use for direct feedback may be highly relevant for those who are apprehensive about the real time use of diagnostic computers in a clinical setting.	WHIPPS CROSS HOSP & CHEST CLIN,DEPT ACCID & EMERGENCY,LONDON E11,ENGLAND; AIREDALE DIST GEN HOSP,STEETON BD20 6TD,W YORKSHIRE,ENGLAND		DEDOMBAL, FT (corresponding author), UNIV LEEDS,CLIN INFORMAT SCI UNIT,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.							ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BALLA JI, 1989, BRIT MED J, V298, P579, DOI 10.1136/bmj.298.6673.579; BOOM R, 1980, P MEDINFO 80 AMSTERD, P1760; CLIFFORD PC, 1986, ANN ROY COLL SURG, V68, P182; DEDOMBAL FT, 1988, SCAND J GASTROENTERO, V23, P35; DEDOMBAL FT, 1972, BMJ-BRIT MED J, V2, P9, DOI 10.1136/bmj.2.5804.9; Gunn A A, 1976, J R Coll Surg Edinb, V21, P170; Hancock DM, 1987, THEOR SURG, V2, P99; HEWETT DJ, 1990, HOSPITAL UPDATE, V16, P283; HOFFMANN J, 1989, BRIT J SURG, V76, P774, DOI 10.1002/bjs.1800760803; LEAPER DJ, 1973, BMJ-BRIT MED J, V3, P569, DOI 10.1136/bmj.3.5880.569; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; MCADAM WAF, 1990, ANN ROY COLL SURG, V72, P140; MCADAM WAF, 1981, 6 YEARS EXPERIENCE C; MORRIS F, 1990, BRIT MED J, V300, P165, DOI 10.1136/bmj.300.6718.165; PATERSONBROWN S, 1990, BRIT J SURG, V77, P13, DOI 10.1002/bjs.1800770105; ROWSELL KV, IN PRESS THEORETICAL; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; STANILAND JR, 1972, BMJ-BRIT MED J, V3, P393, DOI 10.1136/bmj.3.5823.393; WILSON PD, 1975, BMJ-BRIT MED J, V2, P73, DOI 10.1136/bmj.2.5962.73	20	50	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1495	1497		10.1136/bmj.302.6791.1495	http://dx.doi.org/10.1136/bmj.302.6791.1495			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855017	Green Published, Bronze			2022-12-24	WOS:A1991FT50500019
J	YAN, H; SCHLESSINGER, J; CHAO, MV				YAN, H; SCHLESSINGER, J; CHAO, MV			CHIMERIC NGF-EGF RECEPTORS DEFINE DOMAINS RESPONSIBLE FOR NEURONAL DIFFERENTIATION	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PC12 CELLS; GENE-TRANSFER; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; EXPRESSION; STIMULATION; INDUCTION; MUTANTS	To determine the domains of the low-affinity nerve growth factor (NGF) receptor required for appropriate signal transduction, a series of hybrid receptors were constructed that consisted of the extracellular ligand-binding domain of the human epidermal growth factor (EGF) receptor (EGFR) fused to the transmembrane and cytoplasmic domains of the human low-affinity NGF receptor (NGFR). Transfection of these chimeric receptors into rat pheochromocytoma PC12 cells resulted in appropriate cell surface expression. Biological activity mediated by the EGF-NGF chimeric receptor was assayed by the induction of neurite outgrowth in response to EGF in stably transfected cells. Furthermore, the chimeric receptor mediated nuclear signaling, as evidenced by the specific induction of transin messenger RNA, an NGF-responsive gene. Neurite outgrowth was not observed with chimeric receptors that contained the transmembrane domain from the EGFR, suggesting that the membrane-spanning region and cytoplasmic domain of the low-affinity NGFR are necessary for signal transduction.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	YAN, H (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,NEW YORK,NY 10021, USA.			Chao, Moses/0000-0002-6969-3744				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; Berg M.D., UNPUB; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P4730; HOSANG M, 1985, J BIOL CHEM, V260, P655; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; POLLOCK D, 1990, NEUROSCIENCE, V10, P2626; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; YAN H, UNPUB	27	111	118	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					561	563		10.1126/science.1850551	http://dx.doi.org/10.1126/science.1850551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850551				2022-12-24	WOS:A1991FJ12700045
J	SCHONRICH, G; KALINKE, U; MOMBURG, F; MALISSEN, M; SCHMITTVERHULST, AM; MALISSEN, B; HAMMERLING, GJ; ARNOLD, B				SCHONRICH, G; KALINKE, U; MOMBURG, F; MALISSEN, M; SCHMITTVERHULST, AM; MALISSEN, B; HAMMERLING, GJ; ARNOLD, B			DOWN-REGULATION OF T-CELL RECEPTORS ON SELF-REACTIVE T-CELLS AS A NOVEL MECHANISM FOR EXTRATHYMIC TOLERANCE INDUCTION	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREATIC BETA-CELLS; CLASS-II MHC; CENTRAL NERVOUS-SYSTEM; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; ANTIGENS; EXPRESSION; MOLECULES; GENES	By generating two types of transgenic mice we have investigated how extrathymic events can contribute to self tolerance. The major histocompatibility complex class I gene K(b) was expressed under the control of the glial fibrillary acidic protein promoter in cells of neuroectodermal origin outside the thymus. These mice were tolerant to K(b). When crossed to transgenic mice expressing a K(b)-specific T cell receptor (TCR), clonotype+, CD8+CD4- mature T cells could be detected in normal numbers in the thymus of the double-transgenic mice but were strongly reduced in spleen and lymph nodes in comparison with TCR single-transgenic mice. After isolation of clonotype negative splenic T cells and activation in vitro, reappearance of the clonotype+, CD8+CD4- cells was observed. These results indicate that down-regulation of TCR and CD8 molecules on the antigen-specific T cells is a novel mechanism, by which peripheral tolerance to this antigen can occur.	CTR IMMUNOL MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	SCHONRICH, G (corresponding author), GERMAN CANC RES CTR,INST IMMUNOL & GENET,IM NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.		; Malissen, Bernard/AAK-4659-2020	Schmitt-Verhulst, Anne-Marie/0000-0002-1296-2739; Malissen, Marie/0000-0003-2331-1445; Malissen, Bernard/0000-0003-1340-9342; Schonrich, Gunther/0000-0002-5346-5704; Kalinke, Ulrich/0000-0003-0503-9564				ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ALBERT F, 1982, IMMUNOGENETICS, V76, P533; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; ARNOLD B, 1984, CELL, V38, P79, DOI 10.1016/0092-8674(84)90528-2; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRADBURY M, 1981, TRENDS NEUROSCI, V4, P100, DOI 10.1016/0166-2236(81)90032-1; BURKLY LC, 1989, NATURE, V342, P564, DOI 10.1038/342564a0; BURNET FM, 1959, CLONAL SELECTION THE; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; COWING C, 1985, IMMUNOL TODAY, V6, P72, DOI 10.1016/0167-5699(85)90018-0; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; HAFLER DA, 1987, IMMUNOL REV, V100, P307, DOI 10.1111/j.1600-065X.1987.tb00537.x; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; Hogan B., 1986, MANIPULATING MOUSE E; HUA C, 1986, J IMMUNOL, V136, P1937; HUE I, 1990, J IMMUNOL, V144, P4410; JONESYOUNGBLOOD SL, 1990, J IMMUNOL, V144, P1187; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOCH S, 1983, TRANSPLANTATION, V36, P177, DOI 10.1097/00007890-198308000-00013; KOURILSKY P, 1987, P NATL ACAD SCI USA, V84, P3400, DOI 10.1073/pnas.84.10.3400; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; KUHLMANNKRIEG S, 1988, DEV BRAIN RES, V39, P269, DOI 10.1016/0165-3806(88)90031-4; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; KYEWSKI BA, 1984, NATURE, V308, P196, DOI 10.1038/308196a0; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; Maniatis T, 1989, DECONTAMINATION DILU; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARSHAKROTHSTEIN A, 1979, J IMMUNOL, V122, P2491; Miller J F, 1989, Autoimmunity, V4, P299, DOI 10.3109/08916938909014706; MIYADA CG, 1985, P NATL ACAD SCI USA, V82, P2890, DOI 10.1073/pnas.82.9.2890; MOMBURG F, 1989, J IMMUNOL, V142, P352; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SPRENT J, 1989, IMMUNOL TODAY, V10, P17, DOI 10.1016/0167-5699(89)90060-1; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROTTER J, 1989, DEV BRAIN RES, V46, P115, DOI 10.1016/0165-3806(89)90148-X; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x	60	520	523	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					293	304		10.1016/0092-8674(91)90163-S	http://dx.doi.org/10.1016/0092-8674(91)90163-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849799				2022-12-24	WOS:A1991FH09200012
J	ESCOBEDO, JA; NAVANKASATTUSAS, S; KAVANAUGH, WM; MILFAY, D; FRIED, VA; WILLIAMS, LT				ESCOBEDO, JA; NAVANKASATTUSAS, S; KAVANAUGH, WM; MILFAY, D; FRIED, VA; WILLIAMS, LT			CDNA CLONING OF A NOVEL 85KD PROTEIN THAT HAS SH2 DOMAINS AND REGULATES BINDING OF PI3-KINASE TO THE PDGF BETA-RECEPTOR	CELL			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PHOSPHOLIPASE-C-GAMMA; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; TRANSFORMATION; ASSOCIATION; ACTIVATION; ELEMENTS	Using immobilized PDGF receptor as an affinity reagent, we purified an 85 kd protein (p85) from cell lysates and we cloned its cDNA. The protein contains an SH3 domain and two SH2 domains that are homologous to domains found in several receptor-associated enzymes. Recombinant p85 overexpressed in mammalian cells inhibited the binding of endogenous p85 and a 110 kd protein to the receptor and also blocked the association of PI3-kinase activity with the receptor. Experiments with receptor mutants and with short peptides derived from the kinase insert region of the PDGF receptor showed that the recombinant p85 binds to a well-defined phosphotyrosine-containing sequence of the receptor. p85 appears to be the subunit of PI3-kinase that links the enzyme to the ligand-activated receptor.	UNIV CALIF SAN FRANCISCO,SCH MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; NEW YORK MED COLL,DEPT ANAT & CELL BIOL,VALHALLA,NY 10595	University of California System; University of California San Francisco; New York Medical College	ESCOBEDO, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-32898] Funding Source: Medline; PHS HHS [K11-H102410] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER LC, 1990, J BIOL CHEM, V265, P19704; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P362; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PAWSON T, 1988, ONCOGENE, V3, P491; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Summers MD, 1987, MANUAL METHODS BACUL; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	517	541	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					75	82		10.1016/0092-8674(91)90409-R	http://dx.doi.org/10.1016/0092-8674(91)90409-R			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849460	Bronze			2022-12-24	WOS:A1991FF77300010
J	SURANA, U; ROBITSCH, H; PRICE, C; SCHUSTER, T; FITCH, I; FUTCHER, AB; NASMYTH, K				SURANA, U; ROBITSCH, H; PRICE, C; SCHUSTER, T; FITCH, I; FUTCHER, AB; NASMYTH, K			THE ROLE OF CDC28 AND CYCLINS DURING MITOSIS IN THE BUDDING YEAST SACCHAROMYCES-CEREVISIAE	CELL			English	Article							CELL-DIVISION CYCLE; P34CDC2 PROTEIN-KINASE; CONTROL GENE CDC2+; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; M-PHASE; MITOTIC CONTROL; MESSENGER-RNA; COMPONENT	cdc28-1N is a conditional allele that has normal G1 (Start) function but confers a mitotic defect. We have isolated seven genes that in high dosage suppress the growth defect of cdc28-1N cells but not of Start-defective cdc28-4 cells. Three of these (CLB1, CLB2, and CLB4) encode proteins strongly homologous to G2-specific B-type cyclins. Another gene, CLB3, was cloned using PCR. CLB1 and CLB2 encode a pair of closely related proteins; CLB3 and CLB4 encode a second pair. Neither CLB1 nor CLB2 is essential; however, disruption of both is lethal and causes a mitotic defect. Furthermore, the double mutant cdc28-1N clb2::LEU2 is nonviable, whereas cdc28-4 clb2::LEU2 is viable, suggesting that the cdc28-1N protein may be defective in its interaction with B-type cyclins. Our results are consistent with CDC28 function being required in both G1 and mitosis. Its mitotic role, we believe, involves interaction with a family of at least four G2-specific cyclins.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory	SURANA, U (corresponding author), RES INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.		Surana, Uttam/H-1142-2011	Nasmyth, Kim/0000-0001-7030-4403; Surana, Uttam/0000-0002-4785-6514				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CARTER LA, 1978, EXP CELL RES, V112, P15; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GOEBL M, 1988, CELL, V54, P739; GORDON CN, 1977, J CELL SCI, V24, P81; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGAN I, 1988, J CELL SCI, V91, P587; HAGAN IM, 1988, J CELL SCI, V89, P343; HARTIG A, 1981, CURR GENET, V4, P29, DOI 10.1007/BF00376783; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1989, J CELL SCI, V92, P131; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; Maniatis T., 1982, MOL CLONING; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WEINERT T, 1989, J CELL SCI, P145; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064	64	428	440	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					145	161		10.1016/0092-8674(91)90416-V	http://dx.doi.org/10.1016/0092-8674(91)90416-V			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849457	Bronze			2022-12-24	WOS:A1991FF77300017
J	PATTERSON, B; GUTHRIE, C				PATTERSON, B; GUTHRIE, C			A U-RICH TRACT ENHANCES USAGE OF AN ALTERNATIVE 3' SPLICE SITE IN YEAST	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; MESSENGER-RNA INTRONS; SACCHAROMYCES-CEREVISIAE; SEQUENCES; PROTEIN; GENES; RECOGNIZES; MUTATIONS; SELECTION	There has been a long-standing belief that the mechanisms of mammalian and yeast splicing differ fundamentally in their requirement for a pyrimidine-rich motif preceding the 3' splice site. Using an in vivo assay, we have tested the influence of uridine content on competition between alternative 3' splice sites in yeast. We find that a uridine-rich tract preceding a PyAG greatly enhances its ability to compete as a splice acceptor. Moreover, a proximal PyAG is often overlooked if a more distal PyAG occurs in a superior sequence context; this observation cannot be accounted for by simple scanning models. Finally, we show that a distal (> 30 nucleotide) 3' splice site that is not preceded be uridines is a poor substrate for the second step of splicing; this argues that recognition of a uridine-rich motif is required for effective identification and utilization of distant splice sites.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1984, MOL CELL BIOL, V4, P1871, DOI 10.1128/MCB.4.9.1871; CASADABAN M, 1983, RECOMBINANT DNA METH, P293; CELLINI A, 1985, EMBO J, V5, P1023; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DOMDEY H, 1984, CELL, V39, P611, DOI 10.1016/0092-8674(84)90468-9; FOUSER LA, 1987, MOL CELL BIOL, V7, P3511; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEER RJ, 1982, NUCLEIC ACIDS RES, V10, P5869, DOI 10.1093/nar/10.19.5869; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; PADGETT RA, 1986, ANN REV BIOCH, V55, P199; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PIKIELNY CW, 1983, CELL, V34, P395, DOI 10.1016/0092-8674(83)90373-2; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RODRIGUEZ JR, 1984, CELL, V39, P603, DOI 10.1016/0092-8674(84)90467-7; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1	32	106	106	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					181	187		10.1016/0092-8674(91)90219-O	http://dx.doi.org/10.1016/0092-8674(91)90219-O			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1846089				2022-12-24	WOS:A1991ET17500019
J	EBERLE, W; SANDER, C; KLAUS, W; SCHMIDT, B; VONFIGURA, K; PETERS, C				EBERLE, W; SANDER, C; KLAUS, W; SCHMIDT, B; VONFIGURA, K; PETERS, C			THE ESSENTIAL TYROSINE OF THE INTERNALIZATION SIGNAL IN LYSOSOMAL ACID-PHOSPHATASE IS PART OF A BETA-TURN	CELL			English	Article							TRANSFERRIN RECEPTOR INTERNALIZATION; DENSITY-LIPOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; ENDOCYTOSIS; SEQUENCE; LOCALIZATION; RESOLUTION; TRYPSIN; PROTEIN	For rapid endocytosis lysosomal acid phosphatase requires a Tyr-containing signal in its cytoplasmic domain, as do cell surface receptors mediating endocytosis and clustering in coated pits. To determine the structure of the internalization signal an 18 amino acid peptide representing the cytoplasmic tail of lysosomal acid phosphatase was analyzed by two-dimensional nuclear magnetic resonance spectroscopy. Part of the peptide, 5-PPGY-8, forms a well-ordered beta-turn of type I in solution. Our result and data on the structure of the endocytosis signal of the low density lipoprotein receptor reported by Bansal and Gierasch in the accompanying paper represent experimental determinations of the three-dimensional structure of protein transport signals and suggest that the essential aromatic amino acid of internalization signals is recognized by a putative cytoplasmic receptor in the structural context of a tight turn.	GESELL BIOL FORSCH,O-3300 BRAUNSCHWEIG,GERMANY; UNIV GOTTINGEN,W-3400 GOTTINGEN,GERMANY	University of Gottingen	EBERLE, W (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Sander, Chris/H-1452-2011	Sander, Chris/0000-0001-6059-6270				BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BRUNGER AT, 1987, METHODS CRYSTALLOGRA; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOTTSCHALK S, 1989, EMBO J, V8, P3215, DOI 10.1002/j.1460-2075.1989.tb08480.x; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEHRMAN MA, 1985, CELL, V41, P735, DOI 10.1016/S0092-8674(85)80054-4; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; SUMNER SCJ, 1990, J BIOMOL STRUCT DYN, V8, P687, DOI 10.1080/07391102.1990.10507836; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WRIGHT CS, 1987, J MOL BIOL, V194, P501, DOI 10.1016/0022-2836(87)90678-4	32	154	155	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1203	1209		10.1016/0092-8674(91)90296-B	http://dx.doi.org/10.1016/0092-8674(91)90296-B			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760845				2022-12-24	WOS:A1991GX16400018
J	BROCHIER, B; KIENY, MP; COSTY, F; COPPENS, P; BAUDUIN, B; LECOCQ, JP; LANGUET, B; CHAPPUIS, G; DESMETTRE, P; AFIADEMANYO, K; LIBOIS, R; PASTORET, PP				BROCHIER, B; KIENY, MP; COSTY, F; COPPENS, P; BAUDUIN, B; LECOCQ, JP; LANGUET, B; CHAPPUIS, G; DESMETTRE, P; AFIADEMANYO, K; LIBOIS, R; PASTORET, PP			LARGE-SCALE ERADICATION OF RABIES USING RECOMBINANT VACCINIA RABIES VACCINE	NATURE			English	Article							ORAL VACCINATION; FIELD TRIAL; VIRUS GLYCOPROTEIN; FOX RABIES; IMMUNIZATION; WILDLIFE; PROTECTION; EXPRESSION; EFFICACY; SAFETY	RABIES infection of domestic and wild animals is a serious problem throughout the world. The major disease vector in Europe is the red fox (Vulpes vulpes) and rabies control has focused on vaccinating and/or culling foxes. Culling has not been effective, and the distribution of live vaccine baits is the only appropriate method for the vaccination of wild foxes 1. Although some European countries have conducted field vaccination campaigns using attenuated rabies virus strains 2-5, their use has not been extensively approved because they retain pathogenicity for rodents and can revert to virulence 6,7. These strains cannot be used in North America because they are pathogenic for the striped skunk (Mephitis mephitis) 8 and are ineffective in the racoon (Procyon lotor) 9. We have constructed a recombinant vaccinia virus 10, VVTGgRAB, expressing the surface glycoprotein (G) of rabies virus (ERA strain) 11-13. The recombinant was a highly effective vaccine in experimental animals 11-13, in captive foxes 14,15 and in racoons 9. We report here the results of a large-scale campaign of fox vaccination in a 2,200 km2 region of southern Belgium, an area in which rabies is prevalent. After distribution, 81% of foxes inspected were positive for tetracycline, a biomarker included in the vaccine bait and, other than one rabid fox detected close to the periphery of the treated area, no case of rabies, either in foxes or in domestic livestock, has been reported in the area.	TRANSGENE SA,F-67000 STRASBOURG,FRANCE; PASTEUR INST BRABANT,DEPT RABIES,B-1180 BRUSSELS,BELGIUM; RHONE MERIEUX LAB IFFA,F-69342 LYONS,FRANCE; STATE UNIV LIEGE,FAC SCI,INST ZOOL,B-4020 LIEGE,BELGIUM	Transgene SA; University of Liege	BROCHIER, B (corresponding author), STATE UNIV LIEGE,FAC VET MED,DEPT VIROL,45 RUE VET,B-1070 BRUSSELS,BELGIUM.		Kieny, Marie-Paule/Q-1238-2019; Kieny, Marie-Paule/N-3914-2017	Kieny, Marie-Paule/0000-0002-5943-6488				ANDERSON RM, 1986, NATURE, V322, P304, DOI 10.1038/322304a0; ANDERSON RM, 1981, NATURE, V289, P765, DOI 10.1038/289765a0; BAER GM, 1975, NATURAL HIST RABIES, V2, P261; BALTAZAR RS, 1987, ANN MED VET, V131, P481; BLANCOU J, 1989, ANN RECH VET, V20, P195; BLANCOU J, 1986, NATURE, V322, P373, DOI 10.1038/322373a0; BROCHIER B, 1990, VACCINE, V8, P101, DOI 10.1016/0264-410X(90)90129-A; BROCHIER B, 1989, J WILDLIFE DIS, V25, P540, DOI 10.7589/0090-3558-25.4.540; BROCHIER B, 1988, VET REC, V123, P618; BROCHIER BM, 1988, VET MICROBIOL, V18, P103, DOI 10.1016/0378-1135(88)90055-7; BROCHIER BM, 1990, VET REC, V127, P165; DEAN DJ, 1974, LABORATORY TECHNIQUE, P75; DESMETTRE P, 1990, VET MICROBIOL, V23, P227, DOI 10.1016/0378-1135(90)90153-M; HARRIS S, 1986, J ANIM ECOL, V55, P575, DOI 10.2307/4740; KAPPELER A, 1988, VACCINATION CONTROL, P55; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; Leblois H., 1988, EUR Publication, Commission of the European Communities, P101; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; NEWMARK P, 1988, NATURE, V336, P416, DOI 10.1038/336416a0; PASTORET PP, 1988, VET REC, V123, P481, DOI 10.1136/vr.123.19.481; RUPPRECHT CE, 1986, P NATL ACAD SCI USA, V83, P7947, DOI 10.1073/pnas.83.20.7947; RUPPRECHT CE, 1990, J WILDLIFE DIS, V26, P99, DOI 10.7589/0090-3558-26.1.99; SCHNEIDER LG, 1983, TIERARZTL UMSCHAU, V38, P315; STECK F, 1982, ZBL VET MED B, V29, P372; THOMAS I, 1990, J GEN VIROL, V71, P37, DOI 10.1099/0022-1317-71-1-37; TOLSON ND, 1988, ARCH VIROL, V102, P297, DOI 10.1007/BF01310835; WANDELER AI, 1982, COMP IMMUNOL MICROB, V5, P173, DOI 10.1016/0147-9571(82)90032-7; WIKTOR TJ, 1984, P NATL ACAD SCI-BIOL, V81, P7194, DOI 10.1073/pnas.81.22.7194; WIKTOR TJ, 1985, ANN INST PASTEUR VIR, V136E, P405, DOI 10.1016/S0769-2617(85)80132-5; Wiktor TJ, 1988, APPLIED VIROLOGY RES, V1, P69; 1989, CONSULTATION REQUIRE	31	219	244	1	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 19	1991	354	6354					520	522		10.1038/354520a0	http://dx.doi.org/10.1038/354520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW751	1758494	Green Submitted			2022-12-24	WOS:A1991GW75100013
J	NOVELLO, AC; CLINTON, JJ; WISE, PH; MITCHELL, WI				NOVELLO, AC; CLINTON, JJ; WISE, PH; MITCHELL, WI			CARING FOR CHILDREN WITH HIV-INFECTION - THE NEED FOR A COMMON EMBRACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									OFF SURGEON GEN,HUBERT H HUMPHREY BLDG,ROOM 718-E,WASHINGTON,DC 20201									NOVELLO AC, GUIDE FAMILY CTR COM	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					770	770						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865514				2022-12-24	WOS:A1991GA07300010
J	RESNICK, NM; MALOY, WL; GUY, HR; ZASLOFF, M				RESNICK, NM; MALOY, WL; GUY, HR; ZASLOFF, M			A NOVEL ENDOPEPTIDASE FROM XENOPUS THAT RECOGNIZES ALPHA-HELICAL SECONDARY STRUCTURE	CELL			English	Article							EUKARYOTIC SIGNAL PEPTIDASE; CLEAVAGE SITE; SECRETORY GRANULES; HORMONE PRECURSORS; SINGLE ARGININE; LIPID BILAYERS; LAEVIS SKIN; SUBSTRATE; SEQUENCE; FORMS	The magainin peptides of Xenopus laevis are broad-spectrum antimicrobial agents. Upon discharge from the skin glands, these basic, amphipathic peptides are each further processed at a single Xaa-Lys bond into half-peptides by a cosecreted protease. We describe the characterization and purification to homogeneity of this endopeptidase from Xenopus skin. The enzyme is a metalloprotease 110 kd in size. Analyses of substrate specificity revealed that the endopeptidase recognizes peptides that share the ability to adopt an amphipathic, alpha-helical motif composed of at least 12 residues, with one face strongly hydrophobic. Cleavage occurs on the amino side of a specific lysine that must be precisely positioned relative to the hydrophobic face of the alpha-helix. This enzyme, which we propose to call "magaininase," represents a novel class of endopeptidases that hydrolyzes peptides on the basis of specific secondary structure rather than primary amino acid sequence.	UNIV PENN,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; MAGAININ SCI INC,PLYMOUTH MEETING,PA 19462; NCI,MATH BIOL LAB,BETHESDA,MD 20892	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	RESNICK, NM (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET,PHILADELPHIA,PA 19104, USA.							BECHINGER B, 1991, IN PRESS J BIOMOL NM; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1989, J BIOL CHEM, V264, P5852; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BRAKCH N, 1989, J BIOL CHEM, V264, P15912; CAULFIELD MP, 1989, J BIOL CHEM, V264, P15813; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DARBY NJ, 1991, EUR J BIOCHEM, V195, P65, DOI 10.1111/j.1432-1033.1991.tb15676.x; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOCKRAY GJ, 1975, J CELL BIOL, V64, P724, DOI 10.1083/jcb.64.3.724; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; Gabriel, 1971, METHOD ENZYMOL, V22, P565, DOI 10.1016/0076-6879(71)22041-3; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; GLUSCHANKOF P, 1988, FEBS LETT, V234, P149, DOI 10.1016/0014-5793(88)81322-X; GLUSCHANKOF P, 1987, NEUROCHEM RES, V12, P951, DOI 10.1007/BF00966318; GOMEZ S, 1989, EMBO J, V8, P2911, DOI 10.1002/j.1460-2075.1989.tb08440.x; HURT EC, 1987, J BIOL CHEM, V262, P1420; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; KAISER ET, 1987, ANN REV BIOPHYS CHEM, V16, P562; KUKS PFM, 1989, J BIOL CHEM, V264, P14609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH YP, 1988, MOL MECHANISMS SECRE, P525; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MIZUNO K, 1986, BIOCHEM BIOPH RES CO, V137, P984, DOI 10.1016/0006-291X(86)90322-0; MOLLAY C, 1986, EUR J BIOCHEM, V160, P31, DOI 10.1111/j.1432-1033.1986.tb09935.x; OCHS D, 1983, ANAL BIOCHEM, V135, P470, DOI 10.1016/0003-2697(83)90714-5; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATEL YC, 1981, ENDOCRINOLOGY, V109, P1943, DOI 10.1210/endo-109-6-1943; PLEVRAKIS I, 1989, BIOCHEMISTRY-US, V28, P2705, DOI 10.1021/bi00432a051; POULTER L, 1988, J BIOL CHEM, V263, P3279; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; RICHTER K, 1986, J BIOL CHEM, V261, P3676; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SURES I, 1984, P NATL ACAD SCI-BIOL, V81, P380, DOI 10.1073/pnas.81.2.380; TATEMOTO K, 1978, P NATL ACAD SCI USA, V75, P4115, DOI 10.1073/pnas.75.9.4115; THORNE BA, 1990, J BIOL CHEM, V265, P8436; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; ZAKARIAN S, 1982, BIOCHEM J, V202, P561, DOI 10.1042/bj2020561; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	52	76	78	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					541	554		10.1016/0092-8674(81)90017-9	http://dx.doi.org/10.1016/0092-8674(81)90017-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868549				2022-12-24	WOS:A1991GA94100015
J	HSU, VW; YUAN, LC; NUCHTERN, JG; LIPPINCOTTSCHWARTZ, J; HAMMERLING, GJ; KLAUSNER, RD				HSU, VW; YUAN, LC; NUCHTERN, JG; LIPPINCOTTSCHWARTZ, J; HAMMERLING, GJ; KLAUSNER, RD			A RECYCLING PATHWAY BETWEEN THE ENDOPLASMIC-RETICULUM AND THE GOLGI-APPARATUS FOR RETENTION OF UNASSEMBLED MHC CLASS-I MOLECULES	NATURE			English	Article							HEAVY-CHAINS; BREFELDIN-A; PROTEINS; ER; ANTIBODIES; RECEPTOR; COMPLEX	ASSEMBLY of Class I major histocompatibility complex (MHC) molecules involves the interaction of two distinct polypeptides (the heavy and light chains) with peptide antigen. Cell lines synthesizing both chains but expressing low levels of MHC class I molecules on their surface as a result of a failure in assembly and transport have been identified 1. We now report that although the apparent steady-state distribution in these cells of class I molecules is in the endoplasmic reticulum (ER), the molecules in fact are recycled between the ER and Golgi, rather than retained in the ER. This explains the failure of class I molecules to negotiate the secretory pathway. Class I molecules do not seem to be modified by Golgi enzymes, suggesting that the proteins do not reach the Golgi apparatus during recycling. But morphological and subcellular fractionation evidence indicates that they pass through the cis Golgi or a Golgi-associated organelle, which we postulate to be the recycling organelle. This compartment, which we call the 'cis-Golgi network', would thereby be a sorting organelle that selects proteins for return to the ER.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	HSU, VW (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; JAMIESON JD, 1968, J CELL BIOL, V39, P589, DOI 10.1083/jcb.39.3.589; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189	14	161	161	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					441	444		10.1038/352441a0	http://dx.doi.org/10.1038/352441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861723				2022-12-24	WOS:A1991FZ34600069
J	KOLETZKO, S; GRIFFITHS, A; COREY, M; SMITH, C; SHERMAN, P				KOLETZKO, S; GRIFFITHS, A; COREY, M; SMITH, C; SHERMAN, P			INFANT-FEEDING PRACTICES AND ULCERATIVE-COLITIS IN CHILDHOOD	BRITISH MEDICAL JOURNAL			English	Article							CROHNS-DISEASE		UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DIV GASTROENTEROL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PAEDIAT,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT NURSING,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Sherman, Philip/0000-0002-4733-6690				ACHESON ED, 1961, BRIT MED J, V2, P929, DOI 10.1136/bmj.2.5257.929; CHANDRA RK, 1989, NUTR RES, V9, P1, DOI 10.1016/S0271-5317(89)80098-3; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; KOLETZKO S, 1989, BRIT MED J, V298, P1617, DOI 10.1136/bmj.298.6688.1617; WHORWELL PJ, 1979, BRIT MED J, V1, P382, DOI 10.1136/bmj.1.6160.382	5	49	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1580	1581		10.1136/bmj.302.6792.1580	http://dx.doi.org/10.1136/bmj.302.6792.1580			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855043	Green Published, Bronze			2022-12-24	WOS:A1991FU54900027
J	NOJI, S; NOHNO, T; KOYAMA, E; MUTO, K; OHYAMA, K; AOKI, Y; TAMURA, K; OHSUGI, K; IDE, H; TANIGUCHI, S; SAITO, T				NOJI, S; NOHNO, T; KOYAMA, E; MUTO, K; OHYAMA, K; AOKI, Y; TAMURA, K; OHSUGI, K; IDE, H; TANIGUCHI, S; SAITO, T			RETINOIC ACID INDUCES POLARIZING ACTIVITY BUT IS UNLIKELY TO BE A MORPHOGEN IN THE CHICK LIMB BUD	NATURE			English	Article							RECEPTOR GENES; DIFFERENTIAL EXPRESSION; POSITIONAL INFORMATION; LOCAL APPLICATION; HOMEOBOX GENE; PATTERN; CELLS; IDENTIFICATION; ELEMENT; ALPHA	RETINOIC acid is a putative morphogen in limb formation in the chick and other vertebrates 1-5. In chick limb formation, it is thought that retinoic acid is released from the zone of polarizing activity (ZPA) and the concentration gradient of retinoic acid formed from the posterior to the anterior provides positional cues for digit formation 1-4,6. Implantation of a bead containing retinoic acid at the anterior margin of the limb bud induces a mirror-image symmetrical duplication of the digit pattern similar to that observed when the ZPA is grafted into the anterior margin of the host limb bud 7,8. Also, the level of endogenous retinoic acid (25 nM on average) is higher in the posterior one third of the limb bud 1,6. We found that when the bead containing either retinoic acid or an analogue but not the ZPA, was implanted in the anterior margin of the chick limb bud, expression of the retinoic acid receptor type-beta gene was induced around the bead within 4 h. These results indicate that exogenous retinoic acid is not identical with the ZPA morphogen. As the anterior tissue exposed to retinoic acid has polarizing activity 9, we conclude that the primary function of exogenous retinoic acid is to induce polarizing activity in the limb bud.	OKAYAMA UNIV, SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG 1, OKAYAMA 700, JAPAN; OKAYAMA UNIV, SCH DENT,DEPT ORAL & MAXILLOFACIAL SURG 2, OKAYAMA 700, JAPAN; KAWASAKI MED SCH, DEPT PHARMACOL, KURASHIKI, OKAYAMA 70101, JAPAN; TOHOKU UNIV, INST BIOL, SENDAI, MIYAGI 980, JAPAN	Okayama University; Okayama University; Kawasaki Medical School; Tohoku University	NOJI, S (corresponding author), OKAYAMA UNIV, SCH DENT, DEPT BIOCHEM, 2-5-1 SHIKATA CHO, OKAYAMA 700, JAPAN.		Nohno, Tsutomu/B-6923-2008	Nohno, Tsutomu/0000-0002-0351-5603				BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EICHELE G, 1987, J CELL BIOL, V105, P1917, DOI 10.1083/jcb.105.4.1917; EICHELE G, 1984, ANAL BIOCHEM, V142, P542, DOI 10.1016/0003-2697(84)90504-9; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IDE H, 1990, DEV GROWTH DIFFER, V32, P1; NOJI S, 1989, FEBS LETT, V257, P93, DOI 10.1016/0014-5793(89)81794-6; NOJI S, 1990, ACTA HISTOCHEM CYTOC, V23, P353, DOI 10.1267/ahc.23.353; NOJI S, 1989, FEBS LETT, V259, P86, DOI 10.1016/0014-5793(89)81501-7; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; OSUMIYAMASHITA N, 1990, FEBS LETT, V264, P71, DOI 10.1016/0014-5793(90)80767-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P227; Summerbell D, 1983, Prog Clin Biol Res, V110 Pt A, P109; TAMURA K, 1990, CELL DIFFER DEV, V32, P17, DOI 10.1016/0922-3371(90)90095-E; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WOLPERT L, 1989, DEVELOPMENT, V107, P3; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	29	248	254	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					83	86		10.1038/350083a0	http://dx.doi.org/10.1038/350083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1848357				2022-12-24	WOS:A1991FA69300072
J	FAUSTMAN, D; LI, XP; LIN, HY; FU, YE; EISENBARTH, G; AVRUCH, J; GUO, J				FAUSTMAN, D; LI, XP; LIN, HY; FU, YE; EISENBARTH, G; AVRUCH, J; GUO, J			LINKAGE OF FAULTY MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I TO AUTOIMMUNE DIABETES	SCIENCE			English	Article							ISLET-CELL ANTIBODIES; INSULIN-DEPENDENT DIABETICS; VIRAL PEPTIDES; PROTEIN-A; T-CELLS; MELLITUS; GENE; SUSCEPTIBILITY; ASSAY; MICE	Pancreatic islet cells are the targets of an autoimmune response in type I diabetes. In the nonobese diabetic (NOD) mouse model of autoimmune diabetes, expression of major histocompatibility complex (MHC) class I proteins was inversely correlated with diabetes; in this mouse a mutation in the MHC class II-linked gene for the putative MHC class I peptide transporter was also present. Mice deficient in MHC class I expression because they do not produce beta-2-microglobulin also developed late onset autoimmune diabetes. In cells from humans with type I diabetes expression of MHC class I was decreased; subsets of prediabetics categorized as most likely to become hyperglycemic also had low MHC class I. T cell responses to self antigens are faulty in diabetics. In sets of genetically identical twins that are discordant for diabetes, the defect appeared to reside with the antigen presenting cell. Thus, a lack of surface MHC class I protein is associated with autoimmune diabetes; the concomitant defect in antigen presentation may impair the development of self tolerance, which could result in autoimmune disease.	MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,DIABET UNIT,IMMUNOBIOL LAB,BOSTON,MA 02129; JOSLIN DIABET CTR,BOSTON,MA 02115; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Joslin Diabetes Center, Inc.; Massachusetts Institute of Technology (MIT); Whitehead Institute	FAUSTMAN, D (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115, USA.							BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAISCH JM, 1990, NEW ENGL J MED, V322, P1836, DOI 10.1056/NEJM199006283222602; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; COLMAN PG, 1988, DIABETES CARE, V11, P367, DOI 10.2337/diacare.11.4.367; ERLICH HA, 1990, DIABETES, V39, P96, DOI 10.2337/diabetes.39.1.96; FAUSTMAN D, 1989, DIABETES, V38, P1462, DOI 10.2337/diabetes.38.11.1462; FESTENSTEIN H, 1986, NATURE, V322, P64, DOI 10.1038/322064a0; GANDA OP, 1984, DIABETES, V33, P516, DOI 10.2337/diabetes.33.6.516; GLEICHMANN H, 1987, DIABETES, V36, P578, DOI 10.2337/diabetes.36.5.578; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; LERNMARK A, 1978, NEW ENGL J MED, V299, P375, DOI 10.1056/NEJM197808242990802; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777; MACCUISH AC, 1974, LANCET, V2, P1529; MAKINO S, 1985, EXP ANIM TOKYO, V34, P425, DOI 10.1538/expanim1978.34.4_425; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOREL PA, 1988, P NATL ACAD SCI USA, V85, P8111, DOI 10.1073/pnas.85.21.8111; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; ROSSINI AA, 1985, ANNU REV IMMUNOL, V3, P289; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Sambrook J., 1989, MOL CLONING LAB MANU; SERREZE DV, 1988, J IMMUNOL, V140, P3801; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SRIKANTA S, 1985, DIABETES, V34, P300, DOI 10.2337/diabetes.34.3.300; SRIKANTA S, 1985, NEW ENGL J MED, V313, P461, DOI 10.1056/NEJM198508223130801; STERKERS G, 1988, P NATL ACAD SCI USA, V85, P6473, DOI 10.1073/pnas.85.17.6473; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TODD JA, 1989, NATURE, V338, P587, DOI 10.1038/338587a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VARDI P, 1987, DIABETES, V36, P1286, DOI 10.2337/diabetes.36.11.1286; von Meyenburg H., 1940, SCHWEIZ MED WSCHR, V21, P554; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	37	191	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1756	1761		10.1126/science.1763324	http://dx.doi.org/10.1126/science.1763324			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763324				2022-12-24	WOS:A1991GW31600033
J	LAETZ, T; SILBERMAN, G				LAETZ, T; SILBERMAN, G			REIMBURSEMENT POLICIES CONSTRAIN THE PRACTICE OF ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. -To determine the prevalence of off-label anticancer drug use (ie, using drugs to treat conditions other than those listed on the Food and Drug Administration's approved drug label), the extent of reimbursement denials for these uses, and the effect of denials on the treatment of cancer patients. Design, Setting, and Participants. - A three-part questionnaire was sent to a randomized sample of oncologists taken from the 1990 membership of the American Society of Clinical Oncology in March 1990. A response rate of 56% yielded information from 681 oncologists on the drugs they prescribed to 2018 new cancer patients and on those they frequently use in treating 11 specific types of cancer. Main Outcome Measures. - The labeled uses of the drugs prescribed and frequently used in chemotherapies were checked against the indications treated to determine whether they were prescribed for off-label uses. Three drug compendia were used as cited sources of off-label drug uses. The extent of reimbursement denials over the last 12 months and their effects on treatments were based on respondent opinions. Main Results. - Off-label drug use is prevalent and dominates the chemotherapy regimens of cancers that are more difficult to treat and for which there are no cures or agreements on standardized treatment. Most oncologists reported frustration with shifting reimbursement policies in general and with an increasing rate of denials for some off-label drug uses. Indeed, a surprising number of oncologists claimed that these policies caused them to alter preferred treatments and site of care. Conclusion. - These findings suggest the need for public discussion of off-label drug use issues so that appropriate policies can be developed.	US GEN ACCOUNTING OFF,PROGRAM EVALUAT & METHODOL,441 G ST NW,WASHINGTON,DC 20548									DEVITA VT, 1985, PRINCIPLES PRACTICE, P282; 1991, PEMD9114 US GEN ACC; 1989, FED REG         0130, V54, P4302	3	51	53	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2996	2999		10.1001/jama.266.21.2996	http://dx.doi.org/10.1001/jama.266.21.2996			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820471				2022-12-24	WOS:A1991GR77500030
J	DECOCK, KM; SELIK, RM; SORO, B; GAYLE, H; COLEBUNDERS, RL				DECOCK, KM; SELIK, RM; SORO, B; GAYLE, H; COLEBUNDERS, RL			FOR DEBATE - AIDS SURVEILLANCE IN AFRICA - A REAPPRAISAL OF CASE DEFINITIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL CASE-DEFINITION; HIV INFECTION; IVORY-COAST; TUBERCULOSIS; ABIDJAN; UGANDA; EPIDEMIC; KINSHASA; FOLLOW; ZAIRE		PROJET RETRO CI, ABIDJAN, COTE IVOIRE; INST NATL SANTE PUBL, ABIDJAN, COTE IVOIRE; ROYAL INST TROP MED, ANTWERP, BELGIUM	Institute of Tropical Medicine (ITM)	DECOCK, KM (corresponding author), CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, MAIL STOP E-50, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BRAUN MM, 1990, IN PRESS AM REV RESP; CHIN J, 1990, AIDS (London), V4, pS277, DOI 10.1097/00002030-199001001-00045; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; COLEBUNDERS RL, 1989, J INFECT DIS, V160, P902, DOI 10.1093/infdis/160.5.902; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DECOCK KM, 1989, LANCET, V2, P408; DONDERO TJ, 1988, PUBLIC HEALTH REP, V103, P213; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; HOWLETT WP, 1989, AIDS, V3, P289, DOI 10.1097/00002030-198905000-00007; LAST JM, 1989, DICT EPIDEMIOLOGY, P9; MAMUN KZ, 1989, AIDS, V3, P323, DOI 10.1097/00002030-198905000-00017; NUNN P, 1990, 6TH INT C AIDS SAN F; PETERMAN TA, 1990, AM J PUBLIC HEALTH, V80, P401, DOI 10.2105/AJPH.80.4.401; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SORO B, 1990, 6TH INT C AIDS SAN F; WABWIREMANGEN F, 1989, AIDS, V3, P462, DOI 10.1097/00002030-198907000-00013; WEYER J, 1987, INFECTION, V15, P413, DOI 10.1007/BF01647217; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1987, MMWR, V36, pS1; 1986, WKLY EPIDEMIOL REC, V61, P69; 1990, EPIDEMIOLOGICAL B, V4, P9; 1986, WKLY EPIDEMIOL REC, V61, P72; 1989, MMWR, V38, P561; 1988, MMWR, V37, pS1	32	38	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	1991	303	6811					1185	1188		10.1136/bmj.303.6811.1185	http://dx.doi.org/10.1136/bmj.303.6811.1185			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747620	Bronze, Green Published			2022-12-24	WOS:A1991GP48800030
J	THRON, CD				THRON, CD			MATHEMATICAL-ANALYSIS OF A MODEL OF THE MITOTIC CLOCK	SCIENCE			English	Article											THRON, CD (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03756, USA.							HIGGINS J, 1967, IND ENG CHEM, V59, P18, DOI 10.1021/ie50689a006; NOREL R, 1991, SCIENCE, V251, P1076, DOI 10.1126/science.1825521	2	20	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					122	123		10.1126/science.1833817	http://dx.doi.org/10.1126/science.1833817			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1833817				2022-12-24	WOS:A1991GH60500044
J	BOWTON, DL; SCUDERI, PE; HARRIS, L; HAPONIK, EF				BOWTON, DL; SCUDERI, PE; HARRIS, L; HAPONIK, EF			PULSE OXIMETRY MONITORING OUTSIDE THE INTENSIVE-CARE UNIT - PROGRESS OF PROBLEM	ANNALS OF INTERNAL MEDICINE			English	Article						OXIMETRY; ANOXEMIA; RESPIRATORY THERAPY; MONITORING, PHYSIOLOGICAL; ARRHYTHMIAS	VENTRICULAR ECTOPY; OXYGEN-SATURATION; DESATURATION	Objective: To evaluate the use of continuous pulse oximetry monitoring in general care units. Design: Hemoglobin oxygen saturation data collected prospectively by use of pulse oximetry with concurrent review of the medical record. Setting: General medical-surgical nursing units in a large, tertiary care university hospital. Patients: Forty patients on two nursing units monitored with continuous, bedside pulse oximetry at the request of their primary physicians. Measurements: All patients had continuous pulse oximetry monitoring. A research associate visited the bedside two or three times daily and recorded saturation compared with time data from the previous 8.75 hours. Patients were studied for 36 hours or until pulse oximetry monitoring was discontinued. Episodes of desaturation were counted. Patient charts were reviewed for documentation of desaturation in either nursing or physician notes. Orders adjusting oxygen therapy or other respiratory therapy within 12 hours of any desaturation episode were also recorded. Main Results: Thirty of the 40 patients (75%) had at least one episode of desaturation to less than 90%; 23 (58%) had at least one episode to less than 85%. Desaturation episodes were documented in nursing notes for only 33% of those patients who desaturated to less than 90% and in physician notes in only 7% of cases. Changes in respiratory therapy were ordered in 20% of patients who desaturated to less than 90% and in only 26% who desaturated to less than 85%. Conclusions: Despite their repeated occurrence, episodes of hypoxemia were rarely documented in either nursing or physician notes. Further, even in patients who had episodic desaturation, pulse oximetry monitoring had little effect on changes in physician-directed respiratory care.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT ANESTHESIA, CRIT CARE SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	BOWTON, DL (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, PULM & CRIT CARE MED SECT, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.		Bowton, David/AAZ-2916-2020					DODSON SR, 1988, CHEST, V94, P28, DOI 10.1378/chest.94.1.28; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; MCKAY WPS, 1988, CAN J ANAESTH, V35, P265, DOI 10.1007/BF03010621; MIHM FG, 1985, ANESTHESIOLOGY, V62, P85, DOI 10.1097/00000542-198501000-00020; NEFF TA, 1988, CHEST, V94, P227, DOI 10.1378/chest.94.2.227a; PROUGH DS, 1990, CRITICAL CARE STATE, P271; SCHNAPP LM, 1990, CHEST, V98, P1244, DOI 10.1378/chest.98.5.1244; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; SHEPARD JW, 1985, AM J MED, V78, P28, DOI 10.1016/0002-9343(85)90457-7; TRASK CH, 1962, NEW ENGL J MED, V266, P639, DOI 10.1056/NEJM196203292661303; TREMPER KK, 1989, ANESTHESIOLOGY, V70, P98, DOI 10.1097/00000542-198901000-00019; TYLER IL, 1985, ANESTH ANALG, V64, P1108	12	24	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					450	454		10.7326/0003-4819-115-6-450	http://dx.doi.org/10.7326/0003-4819-115-6-450			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872492				2022-12-24	WOS:A1991GE81000006
J	BARRETT, SCH; CHARLESWORTH, D				BARRETT, SCH; CHARLESWORTH, D			EFFECTS OF A CHANGE IN THE LEVEL OF INBREEDING ON THE GENETIC LOAD	NATURE			English	Article							PLANT-POPULATIONS; DELETERIOUS MUTATIONS; DEPRESSION; EVOLUTION; RATES; LOCUS	"THE effects of inbreeding may not be as noticeable in the first generation as the invigoration immediately apparent after crossing" 1. This statement, published in 1919, has received little attention, and has apparently never been tested empirically, although the reduction of the genetic load of populations by inbreeding is well known in theoretical terms 2-5. Because inbreeding increases homozygosity, and hence the effectiveness of selection against recessive or partially recessive detrimental alleles, changes in levels of inbreeding can lead to a reduction in the frequencies of such mutant alleles. This results in equilibration at higher population mean fitness 6 and is referred to as 'purging' populations of their genetic load. Severe inbreeding can also reduce genetic load due to overdominant alleles, provided selection coefficients are not symmetrical at all loci, because alleles giving lower fitness will be reduced in frequency at equilibrium 7-8. With either fitness model, however, reduction in genetic load takes time, and the initial effect of an increase in inbreeding is reduced fitness due to homozygosity. There are few data relating to the extent to which fitness is reduced during inbreeding in a set of lines and to how long the reduction lasts before increasing again to the initial level, or higher. Inbreeding experiments involving sib mating in mice and Drosophila subobscura 10, and successive bottlenecks in house flies 11 have yielded some evidence consistent with the purging hypothesis. Here, we report results of an experiment demonstrating a prolonged time-course of recovery of mean fitness under self-fertilization of a naturally outcrossing plant, and also compare our results with expectations derived by computer calculations. Our results show that the genetic load present in an outcrossing population can be explained only with a high mutation rate to partially recessive deleterious alleles, and that inbreeding purges the population of mutant alleles.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637	University of Chicago	BARRETT, SCH (corresponding author), UNIV TORONTO,DEPT BOT,25 WILLCOCKS ST,TORONTO M5S 3B2,ONTARIO,CANADA.		Barrett, Spencer CH/M-3751-2013; Barrett, Spencer C.H./S-5782-2019; Charlesworth, Deborah/F-3071-2011	Barrett, Spencer C.H./0000-0002-7762-3455; 				BARRETT S C H, 1990, Plant Species Biology, V5, P41, DOI 10.1111/j.1442-1984.1990.tb00191.x; BROWN AHD, 1979, THEOR POPUL BIOL, V15, P1, DOI 10.1016/0040-5809(79)90025-X; BRYANT EH, 1990, AM NAT, V136, P542, DOI 10.1086/285112; CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.ecolsys.18.1.237; CHARLESWORTH D, 1990, EVOLUTION, V44, P870, DOI 10.1111/j.1558-5646.1990.tb03811.x; CHARLESWORTH D, 1990, EVOLUTION, V44, P1469, DOI [10.2307/2409330, 10.1111/j.1558-5646.1990.tb03839.x]; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; CROW JF, 1948, GENETICS, V33, P477; EAST EM, 1919, INBREEDING OUTBREEDI, P147; FALCONER DS, 1972, GENET RES CAMB, V17, P215; GLOVER DE, 1987, HEREDITY, V59, P7, DOI 10.1038/hdy.1987.91; GRIFFIN AR, 1985, THEOR APPL GENET, V71, P334, DOI 10.1007/BF00252077; HOLLINGSWORTH M. J., 1955, JOUR GENETICS, V53, P295, DOI 10.1007/BF02993984; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1985, GENETICS, V111, P635; LANDE R, 1985, EVOLUTION, V39, P24, DOI 10.1111/j.1558-5646.1985.tb04077.x; OHTA T, 1974, GENET RES, V23, P191, DOI 10.1017/S0016672300014816; SHULL GH, 1950, HETEROSIS, P14; SING CF, 1973, GENETICS, V75, P381; TEMPLETON AR, 1984, ZOO BIOL, V3, P177, DOI 10.1002/zoo.1430030302; WILTON AN, 1989, GENET RES, V54, P129; Wright S., 1977, EVOLUTION GENETICS P, V3; ZIEHE M, 1989, GENETICS, V121, P861	24	343	348	0	86	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					522	524		10.1038/352522a0	http://dx.doi.org/10.1038/352522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865906				2022-12-24	WOS:A1991GA22600060
J	WILLIAMS, DA; RIOS, M; STEPHENS, C; PATEL, VP				WILLIAMS, DA; RIOS, M; STEPHENS, C; PATEL, VP			FIBRONECTIN AND VLA-4 IN HEMATOPOIETIC STEM-CELL MICROENVIRONMENT INTERACTIONS	NATURE			English	Article							HUMAN-PLASMA FIBRONECTIN; BONE-MARROW; GROWTH-FACTOR; PRECURSOR CELLS; ADHERENT CELLS; ADHESION; PROLIFERATION; IDENTIFICATION; HEMATOPOIESIS; RECEPTOR	THE self-renewal and differentiation of haematopoietic stem cells occurs in vivo and in vitro in direct contact with cells making up the haematopoietic microenvironment 1-4. In this study we used adhesive ligands and blocking antibodies to identify stromal cell-derived extracellular matrix proteins involved in promoting attachment of murine haematopoietic stem cells. Here we report that day-12 colony-forming-unit spleen (CFU-S12) 5 cells and reconstituting haematopoietic stem cells attach to the C-terminal, heparin-binding fragment of fibronectin by recognizing the CS-1 peptide of the alternatively spliced non-type III connecting segment (IIICS) of human plasma fibronectin. Furthermore, CFU-S12 stem cells express the alpha-4 subunit of the VLA-4 integrin receptor, which is known to be a receptor for the CS-1 sequence, and monoclonal antibodies against the integrin alpha-4 subunit of VLA-4 block adhesion of CFU-S12 stem cells to plates coated with the C-terminal fibronectin fragment. Finally, polyclonal antibodies against the integrin beta-1 subunit of VLA-4 inhibit the formation of CFU-S12-derived spleen colonies and medullary haematopoiesis in vivo following intravenous infusion of antibody-treated bone marrow cells.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School								AIZAWA S, 1988, P NATL ACAD SCI USA, V85, P3180, DOI 10.1073/pnas.85.9.3180; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; GORDON MY, 1989, BONE MARROW TRANSPL, V4, P335; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HO MK, 1982, J IMMUNOL, V128, P2281; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KENNETT RH, 1980, MONOCLONAL ANTIBODIE; LAMAR EE, 1984, CELL, V37, P171, DOI 10.1016/0092-8674(84)90312-X; LAMBERTSEN RH, 1984, BLOOD, V63, P287; LORD BI, 1975, BLOOD, V46, P65; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; RIOS M, 1990, J CELL PHYSIOL, V145, P434, DOI 10.1002/jcp.1041450307; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TRENTIN JJ, 1967, PROLIFERATION SPREAD, V713; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; ZIPORI D, 1988, HEMATOPOIESIS LONG T, P27; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZUCKERMAN KS, 1983, BLOOD, V61, P540	34	452	472	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					438	441		10.1038/352438a0	http://dx.doi.org/10.1038/352438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861722				2022-12-24	WOS:A1991FZ34600068
J	JOHNSON, EF				JOHNSON, EF			A PARTNERSHIP BETWEEN THE DIOXIN RECEPTOR AND A BASIC HELIX-LOOP-HELIX PROTEIN	SCIENCE			English	Editorial Material							HEAT-SHOCK PROTEIN; XENOBIOTIC RESPONSIVE ELEMENTS; DNA-BINDING ACTIVITY; AH RECEPTOR; PEROXISOME PROLIFERATORS; AROMATIC-HYDROCARBONS; P-450C GENE; SUPERFAMILY; ENHANCER; CYTOCHROME-P-450				JOHNSON, EF (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.							BARINAGA M, 1991, SCIENCE, V251, P1176, DOI 10.1126/science.1848724; CONNEY AH, 1982, CANCER RES, V42, P4875; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN B M, 1990, New Biologist, V2, P587; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GILLETTE JR, 1979, DRUG METAB REV, V10, P59, DOI 10.3109/03602537908993901; GREENLEE WF, 1990, PROG CLIN BIOL RES, V331, P177; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOHNSON EF, 1980, CANCER RES, V40, P4456; JONES PBC, 1986, J BIOL CHEM, V261, P6647; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEMOTO T, 1990, J BIOL CHEM, V265, P2269; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; REDDY JK, 1989, MUTAT RES, V214, P63, DOI 10.1016/0027-5107(89)90198-X; REDDY JK, 1990, BIOCHEM SOC T, V18, P92, DOI 10.1042/bst0180092; ROBERTS L, 1991, SCIENCE, V251, P624, DOI 10.1126/science.1846976; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	28	16	16	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 17	1991	252	5008					924	925		10.1126/science.1852074	http://dx.doi.org/10.1126/science.1852074			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM040	1852074				2022-12-24	WOS:A1991FM04000025
J	STOORVOGEL, W; STROUS, GJ; GEUZE, HJ; OORSCHOT, V; SCHWARTZ, AL				STOORVOGEL, W; STROUS, GJ; GEUZE, HJ; OORSCHOT, V; SCHWARTZ, AL			LATE ENDOSOMES DERIVE FROM EARLY ENDOSOMES BY MATURATION	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MANNOSE 6-PHOSPHATE RECEPTOR; HEPATOMA-CELL LINE; HUMAN ASIALOTRANSFERRIN TYPE-3; ASIALOGLYCOPROTEIN RECEPTOR; IMMUNOELECTRON MICROSCOPY; LYSOSOMAL-ENZYME; RAT HEPATOCYTES; TRANSFERRIN RECEPTORS; FREE SYSTEM	Endocytosed proteins destined for degradation in lysosomes are targeted mainly to early endosomes following uptake. Late endosomes are the major site for entry of newly synthesized lysosomal hydrolases via the cation-independent mannose 6-phosphate receptor into the degradative pathway. No consensus exists as to the mechanism of transport from early to late endosomes. We used asialoorosomucoid and transferrin to label selected parts of the degradative and receptor-recycling pathways, respectively, in the human hepatoma cell line HepG2. Intracellular mixing of sequentially endocytosed I-125- and HRP-labeled ligands was monitored by using 3,3'-diaminobenzidine-mediated density perturbation. The entire endocytic pathway of asialoorosomucoid, except for the lysosomes, remained fully accessible to subsequently endocytosed transferrin conjugated to HRP with unchanged kinetics. These results together with immunoelectron microscopic data support a model in which early endosomes gradually mature into late endosomes.	ST LOUIS CHILDRENS HOSP, DEPT HEMATOL ONCOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, EDWARD MALLINKRODT DEPT PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	STOORVOGEL, W (corresponding author), STATE UNIV UTRECHT, SCH MED, DEPT CELL BIOL, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS.							AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BENVENISTE M, 1989, J CELL BIOL, V109, P2105, DOI 10.1083/jcb.109.5.2105; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; BRETSCHER MS, 1984, CELL, V38, P3, DOI 10.1016/0092-8674(84)90519-1; BRIDGES K, 1982, P NATL ACAD SCI-BIOL, V79, P350, DOI 10.1073/pnas.79.2.350; CIECHANOVER A, 1983, CELL, V32, P267, DOI 10.1016/0092-8674(83)90517-2; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; PASTAN IH, 1981, ANNU REV PHYSIOL, V43, P239, DOI 10.1146/annurev.ph.43.030181.001323; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; REGOECZI E, 1985, EXP CELL RES, V160, P1, DOI 10.1016/0014-4827(85)90230-7; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SCHWARTZ AL, 1980, J BIOL CHEM, V255, P9033; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SIMMONS CF, 1984, MOL PHARMACOL, V26, P509; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1991, IN PRESS J CELL BIOL; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; TASSIN MT, 1990, EUR J CELL BIOL, V52, P219; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WARD DM, 1989, J BIOL CHEM, V264, P8164; WATTS C, 1984, EMBO J, V3, P1965, DOI 10.1002/j.1460-2075.1984.tb02077.x; WEIGEL PH, 1984, J BIOL CHEM, V259, P1150; WILLINGHAM MC, 1984, P NATL ACAD SCI-BIOL, V81, P175, DOI 10.1073/pnas.81.1.175; WILLINGHAM MC, 1980, CELL, V21, P67, DOI 10.1016/0092-8674(80)90115-4; WILLINGHAM MC, 1981, P NATL ACAD SCI-BIOL, V78, P6967, DOI 10.1073/pnas.78.11.6967; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375	56	258	261	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1991	65	3					417	427		10.1016/0092-8674(91)90459-C	http://dx.doi.org/10.1016/0092-8674(91)90459-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850321				2022-12-24	WOS:A1991FK18200008
J	HUGIN, AW; VACCHIO, MS; MORSE, HC				HUGIN, AW; VACCHIO, MS; MORSE, HC			A VIRUS-ENCODED SUPERANTIGEN IN A RETROVIRUS-INDUCED IMMUNODEFICIENCY SYNDROME OF MICE	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MURINE LEUKEMIA VIRUSES; T-CELLS; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDES; CLONAL DELETION; C57BL/6 MICE; I-E; MLS; RECEPTOR	The development of an immunodeficiency syndrome of mice caused by a replication-defective murine leukemia virus (MuLV) is paradoxically associated with a rapid activation and proliferation of CD4+ T cells that are dependent on the presence of B cells. The responses of normal spleen cells to B cell lines that express the defective virus indicated that these lines express a cell surface determinant that shares "superantigenic" properties with some microbial antigens and Mls-like self antigens. This antigen elicited a potent proliferative response that was dependent on the presence of CD4+ T cells and was associated with selective expansion of cells bearing V-beta-5. This response was markedly inhibited by a monoclonal antibody specific for the MuLV gag-encoded p30 antigen.	NIAID,IMMUNOPATHOL LAB,BLDG 7,ROOM 304,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Morse, Herbert/0000-0002-9331-3705	NIAID NIH HHS [N01-AI-72622] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072622] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE R, 1987, J EXP MED, V166, P1150, DOI 10.1084/jem.166.4.1150; ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; ABE R, 1988, IMMUNOL TODAY, V9, P230, DOI 10.1016/0167-5699(88)91221-2; ABRIGNANI S, 1990, P NATL ACAD SCI USA, V87, P6136, DOI 10.1073/pnas.87.16.6136; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; BULLER RML, 1987, J VIROL, V61, P383, DOI 10.1128/JVI.61.2.383-387.1987; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CERNY A, 1990, J EXP MED, V171, P315, DOI 10.1084/jem.171.1.315; CERNY A, 1990, EUR J IMMUNOL, V20, P1577, DOI 10.1002/eji.1830200725; CERNY A, UNPUB; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHATTOPADHYAY SK, UNPUB; CHESEBRO B, 1983, VIROLOGY, V127, P134, DOI 10.1016/0042-6822(83)90378-1; CHEUNG SC, 1991, J VIROL, V65, P823, DOI 10.1128/JVI.65.2.823-828.1991; CHEUNG SC, 1991, J IMMUNOL, V146, P121; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; COLE BC, 1989, J IMMUNOL, V142, P4131; COLE BC, 1990, J IMMUNOL, V144, P425; COLE BC, 1990, J IMMUNOL, V144, P20; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FISCHER H, 1989, J IMMUNOL, V142, P3151; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; HAMELINBOURASSA D, 1989, IMMUNOGENETICS, V30, P266, DOI 10.1007/BF02421330; HARTLEY JW, 1989, J VIROL, V63, P1223, DOI 10.1128/JVI.63.3.1223-1231.1989; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; HUANG M, 1990, J VIROL, V64, P5764, DOI 10.1128/JVI.64.12.5764-5772.1990; HUGIN AW, UNPUB; JANEWAY CA, 1985, J IMMUNOL, V134, P2057; JANEWAY CA, 1988, J IMMUNOGENET, V15, P161; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; KLINMAN DM, 1989, J IMMUNOL, V142, P1144; KROWKA J, 1990, J IMMUNOL, V144, P2535; LEGRAND E, 1981, LEUKEMIA RES, V5, P223, DOI 10.1016/0145-2126(81)90107-7; LIAO NS, 1990, J IMMUNOL, V144, P844; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAKINO M, 1990, J IMMUNOL, V144, P4347; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MORSE HC, 1989, J IMMUNOL, V143, P844; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; NAIR MPN, 1988, P NATL ACAD SCI USA, V85, P6498, DOI 10.1073/pnas.85.17.6498; NORTON SD, 1990, J IMMUNOL, V144, P2089; OKADA CY, 1989, J EXP MED, V169, P1703, DOI 10.1084/jem.169.5.1703; PECK AB, 1977, NATURE, V266, P840, DOI 10.1038/266840a0; PITHA PM, 1988, J IMMUNOL, V141, P3611; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; ROSENBERG AS, 1991, TRANSPLANT P, V23, P167; SCHNEIDER R, 1989, J EXP MED, V169, P2149, DOI 10.1084/jem.169.6.2149; SCHRIER RD, 1989, J IMMUNOL, V142, P1166; SICILIANO RF, 1989, J IMMUNOL, V142, P1506; STAERZ UD, 1985, J IMMUNOL, V134, P3994; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YETTER RA, 1988, J EXP MED, V168, P623, DOI 10.1084/jem.168.2.623; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943	63	209	220	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					424	427		10.1126/science.1850169	http://dx.doi.org/10.1126/science.1850169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1850169				2022-12-24	WOS:A1991FH10300038
J	BUCK, L; AXEL, R				BUCK, L; AXEL, R			A NOVEL MULTIGENE FAMILY MAY ENCODE ODORANT RECEPTORS - A MOLECULAR-BASIS FOR ODOR RECOGNITION	CELL			English	Article							SENSITIVE ADENYLATE-CYCLASE; TROUT OLFACTORY ROSETTES; BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; SPATIAL-DISTRIBUTION; BINDING-SPECIFICITY; LIGAND-BINDING; GENES; CILIA; IDENTIFICATION	The mammalian olfactory system can recognize and discriminate a large number of different odorant molecules. The detection of chemically distinct odorants presumably results from the association of odorous ligands with specific receptors on olfactory sensory neurons. To address the problem of olfactory perception at a molecular level, we have cloned and characterized 18 different members of an extremely large multigene family that encodes seven transmembrane domain proteins whose expression is restricted to the olfactory epithelium. The members of this novel gene family are likely to encode a diverse family of odorant receptors.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	BUCK, L (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.			Axel, Richard/0000-0002-3141-4076	NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA 23767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amoore JE., 1982, FRAGRANCE CHEM SCI S, P27; BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRONSHTEIN AA, 1977, TSITOLOGIYA+, V19, P33; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DOVING KB, 1980, ACTA PHYSIOL SCAND, V108, P123, DOI 10.1111/j.1748-1716.1980.tb06509.x; EGEL R, 1981, NATURE, V290, P191, DOI 10.1038/290191a0; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MAEDA N, 1986, ANNU REV GENET, V20, P81; Maniatis T., 1982, MOL CLONING; MOULTON DG, 1967, PHYSIOL REV, V47, P1, DOI 10.1152/physrev.1967.47.1.1; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; REED RR, 1990, CELL, V60, P1, DOI 10.1016/0092-8674(90)90706-K; RHEIN LD, 1983, J NEUROCHEM, V41, P569, DOI 10.1111/j.1471-4159.1983.tb04777.x; RHEIN LD, 1980, P NATL ACAD SCI-BIOL, V77, P4412, DOI 10.1073/pnas.77.8.4412; RUSHTON W A, 1955, J Physiol, V129, P41; RUSHTON WAH, 1965, J PHYSIOL-LONDON, V176, P24, DOI 10.1113/jphysiol.1965.sp007532; Sambrook J., 1989, MOL CLONING LAB MANU; SHEPHERD GM, 1985, TASTE OLFACTION CENT, P307; SICARD G, 1985, BRAIN RES, V326, P203, DOI 10.1016/0006-8993(85)90029-0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; THOMMESEN G, 1978, ACTA PHYSIOL SCAND, V102, P205, DOI 10.1111/j.1748-1716.1978.tb06064.x; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANDERPLOEG L, 1991, GENE REARRANGEMENT, P51; WALD G, 1955, J GEN PHYSIOL, V38, P623, DOI 10.1085/jgp.38.5.623	44	3438	3644	25	502	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					175	187		10.1016/0092-8674(91)90418-X	http://dx.doi.org/10.1016/0092-8674(91)90418-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1840504	Bronze			2022-12-24	WOS:A1991FF77300019
J	DAVIES, CH; STARKEY, SJ; POZZA, MF; COLLINGRIDGE, GL				DAVIES, CH; STARKEY, SJ; POZZA, MF; COLLINGRIDGE, GL			GABA-B AUTORECEPTORS REGULATE THE INDUCTION OF LTP	NATURE			English	Article							D-ASPARTATE RECEPTORS; COLLATERAL-COMMISSURAL PATHWAY; SYNAPTIC TRANSMISSION; RAT HIPPOCAMPUS; DEPENDENT DEPRESSION; POTENTIATION; INHIBITION; INVITRO; NEURONS; CULTURE	UNDERSTANDING the mechanisms involved in long-term potentiation (LTP) should provide insights into the cellular and molecular basis of learning and memory in vertebrates 1. It has been established that in the CA1 region of the hippocampus the induction of LTP requires the transient activation of the N-methyl-D-aspartate (NMDA) receptor system 21. During low-frequency transmission, significant activation of this system is prevented by gamma-aminobutyric acid (GABA) mediated synaptic inhibition 3,4 which hyperpolarizes neurons into a region where NMDA receptor-operated channels are substantially blocked by Mg2+ (refs. 5, 6). But during high-frequency transmission, mechanisms are evoked that provide sufficient depolarization of the postsynaptic membrane to reduce this block 7 and thereby permit the induction of LTP. We now report that this critical depolarization is enabled because during high-frequency transmission GABA depresses its own release by an action on GABA(B) autoreceptors, which permits sufficient NMDA receptor activation for the induction of LTP. These findings demonstrate a role for GABA(B) receptors in synaptic plasticity.	UNIV BIRMINGHAM, SCH MED, DEPT INTERNAL MED, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BRISTOL, SCH MED SCI, DEPT PHARMACOL, BRISTOL BS8 1TD, AVON, ENGLAND	University of Birmingham; University of Bristol			Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020	Collingridge, Graham L/0000-0002-9572-5359; 				ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BENARI Y, 1979, CAN J PHYSIOL PHARM, V57, P1462, DOI 10.1139/y79-218; BLISS TVP, 1988, NEUROLOGY NEUROBIOLO, V35, P3; COAN EJ, 1985, NEUROSCI LETT, V53, P21, DOI 10.1016/0304-3940(85)90091-6; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P283; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P301; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; DINGLEDINE R, 1986, J PHYSIOL-LONDON, V380, P175, DOI 10.1113/jphysiol.1986.sp016279; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; LANTHORN TH, 1981, BRAIN RES, V225, P171, DOI 10.1016/0006-8993(81)90326-7; LARSON J, 1988, BRAIN RES, V441, P111, DOI 10.1016/0006-8993(88)91388-1; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; MOTT DD, 1990, NEUROSCI LETT, V113, P222, DOI 10.1016/0304-3940(90)90307-U; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; OLPE HR, 1990, N-S ARCH PHARMACOL, V342, P194, DOI 10.1007/BF00166964; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; RANDALL AD, 1990, J PHYSIOL-LONDON, V426, pP51; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0	25	491	495	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 14	1991	349	6310					609	611		10.1038/349609a0	http://dx.doi.org/10.1038/349609a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX570	1847993				2022-12-24	WOS:A1991EX57000059
J	MASON, JO				MASON, JO			PROTECTING PHYSICIANS FROM VACCINE LIABILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MASON, JO (corresponding author), US PHS,WASHINGTON,DC 20201, USA.							1991, JAMA-J AM MED ASSOC, V266, P2958; 1991, JAMA-J AM MED ASSOC, V266, P2959	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					2951	2951						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GR775	1820459				2022-12-24	WOS:A1991GR77500005
J	DATTA, B; WEINER, AM				DATTA, B; WEINER, AM			GENETIC-EVIDENCE FOR BASE-PAIRING BETWEEN U2 AND U6 SNRNA IN MAMMALIAN MESSENGER-RNA SPLICING	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; 2'-OME RNA; YEAST; U1; OLIGONUCLEOTIDES; PARTICLES; SELECTION; INVITRO; U4	REMOVAL of introns from eukaryotic nuclear messenger RNA precursors is catalysed by a large ribonucleoprotein complex called the spliceosome, which consists of four small nuclear ribonucleoprotein particles (U1, U2, U5, and U4/U6 snRNPs) and auxiliary protein factors 1,2. We have begun a genetic analysis of mammalian U2 snRNA by making second-site mutations in a suppressor U2 snRNA 3. Here we find that several mutations in the 5' end of U2 (nucleotides 3-8) are deleterious and that one of these can be rescued by compensatory base changes in the 3' end of U6 (nucleotides 92-95). The results demonstrate genetically that the base-pairing interaction between U2 (nucleotides 3-11) and U6 snRNA (nucleotides 87-95), originally proposed on the basis of psoralen photocrosslinking experiments 4, can influence the efficiency of mRNA splicing in mammals. The U2/U6 interaction in yeast, however, is fairly tolerant to mutation 5 (D. J. Field and J. D. Friesen, personal communication), emphasizing the potential for facultative RNA interactions within the spliceosome.			DATTA, B (corresponding author), YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510, USA.							BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LUCIA JS, IN PRESS BIOCHEMISTR; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; PAN ZQ, 1989, GENE DEV, V3, P1887, DOI 10.1101/gad.3.12a.1887; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; YUO CY, 1989, GENE DEV, V3, P697, DOI 10.1101/gad.3.5.697; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	29	158	160	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					821	824		10.1038/352821a0	http://dx.doi.org/10.1038/352821a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1831879				2022-12-24	WOS:A1991GC96400066
J	RILEY, WA; SCHNECKENBURGER, WA				RILEY, WA; SCHNECKENBURGER, WA			THE MARYLAND EXPERIENCE AND A PRACTICAL PROPOSAL TO EXPAND EXISTING MODELS IN AMBULATORY PRIMARY CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Two unique models for caring for the uninsured and underinsured are operating in Maryland. The first is a group practice, primary care model with a unique ambulatory Medicare waiver that has had a positive impact on patients and physicians. The second is a financial model - an all-payer prospective rate-setting system for all critical care inpatient hospitals that, during a 13-year period from 1977 through 1989, has saved the citizens of the state approximately $5.361 billion, has allowed hospitals to provide $1.657 billion of charity care and bad debts, and has earned $517 million in net profits. The reasons for the success of each of the models are discussed and form the basis for a practical and politically feasible proposal: merge the best aspects of each model into an ambulatory primary care - based model financed through an all-payer prospective charge system.			RILEY, WA (corresponding author), GREATER BALTIMORE MED CTR,DEPT MED,6701 N CHARLES ST,BALTIMORE,MD 21204, USA.							1986, 5 CITY PROGRAM IMPRO, V1, P13; 1989, HOSPITAL STATISTICS	2	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1118	1122		10.1001/jama.266.8.1118	http://dx.doi.org/10.1001/jama.266.8.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865546				2022-12-24	WOS:A1991GB97500037
J	WILLIAMS, DRR; BYRNE, C; CLARK, PMS; COX, L; DAY, NE; RAYMAN, G; WANG, T; HALES, CN				WILLIAMS, DRR; BYRNE, C; CLARK, PMS; COX, L; DAY, NE; RAYMAN, G; WANG, T; HALES, CN			RAISED PROINSULIN CONCENTRATION AS EARLY INDICATOR OF BETA-CELL DYSFUNCTION	BRITISH MEDICAL JOURNAL			English	Article							INSULIN		ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge	WILLIAMS, DRR (corresponding author), ADDENBROOKES HOSP,DEPT COMMUNITY MED,CAMBRIDGE CB2 2QQ,ENGLAND.			Byrne, Christopher D/0000-0001-6322-7753				SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397; 1985, WHO TECH REP SER, V727	4	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					95	96		10.1136/bmj.303.6794.95-a	http://dx.doi.org/10.1136/bmj.303.6794.95-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860012	Green Published, Bronze			2022-12-24	WOS:A1991FW58600023
J	SAMBHARA, SR; MILLER, RG				SAMBHARA, SR; MILLER, RG			PROGRAMMED CELL-DEATH OF T-CELLS SIGNALED BY THE T-CELL RECEPTOR AND THE ALPHA-3 DOMAIN OF CLASS-I MHC	SCIENCE			English	Article							CYTO-TOXIC RESPONSES; LYMPHOCYTES-T; BONE-MARROW; CYTOTOXIC LYMPHOCYTES; MONOCLONAL-ANTIBODIES; SELF ANTIGENS; EXPRESSION; VETO; CD8; RECOGNITION	As well as being activated or rendered unresponsive, mature T lymphocytes can be deleted, depending on the signals received by the cell. Deletion by programmed cell death (apoptosis) is triggered if a T cell that has received a signal through its T cell receptor complex also receives a signal through the alpha-3 domain of its class I major histocompatibility complex (MHC) molecule. Such a signal can be delivered by a CD8 molecule, which recognizes the alpha-3 domain, or by an antibody to this domain. Precursors of both cytotoxic T lymphocytes (CTL's) and T helper cells are sensitive to this signal but become resistant at some point before completing differentiation into functioning CTL's or T helper cells. Because CTL's carry CD8, they can induce cell death in T cells that recognize them. This pathway may be important in both removal of autoreactive T cells and immunoregulation.	UNIV TORONTO,DEPT IMMUNOL,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto			Sambhara, Suryaprakash/AAC-4428-2021					ALLEN H, 1984, NATURE, V309, P279, DOI 10.1038/309279a0; ALTEVOGT P, 1980, EUR J IMMUNOL, V10, P908, DOI 10.1002/eji.1830101204; AZUMA E, 1988, J IMMUNOL, V141, P2601; BEVAN MJ, 1975, J IMMUNOL, V114, P559; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; CASSELL DJ, 1990, J IMMUNOL, V144, P4075; CHARRON D, 1980, J EXP MED, V152, P1275; CLAESSON MH, 1984, J EXP MED, V160, P1702, DOI 10.1084/jem.160.6.1702; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; FINK PJ, 1984, J IMMUNOL, V133, P1775; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FINK PJ, 1984, J IMMUNOL, V133, P1769; GRAF L, 1985, MOL IMMUNOL, V22, P1371, DOI 10.1016/0161-5890(85)90059-8; HAMBOR JE, 1990, J IMMUNOL, V145, P1646; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEUER J, 1985, J IMMUNOL, V134, P4031; KANAGAWA O, 1989, J EXP MED, V170, P901, DOI 10.1084/jem.170.3.901; KAPLAN DR, 1989, P NATL ACAD SCI USA, V86, P8512, DOI 10.1073/pnas.86.21.8512; KIZIROGLU F, 1991, J IMMUNOL, V146, P1104; KO HS, 1979, J EXP MED, V150, P246, DOI 10.1084/jem.150.2.246; KOCH N, 1983, IMMUNOGENETICS, V17, P497, DOI 10.1007/BF00696873; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P119; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MILLER RG, 1986, IMMUNOL TODAY, V7, P112, DOI 10.1016/0167-5699(86)90151-9; MILLER RG, 1979, J IMMUNOL, V122, P1502; MILLER RG, 1980, NATURE, V287, P544, DOI 10.1038/287544a0; MILLER RG, 1974, CELL IMMUNOL, V14, P284, DOI 10.1016/0008-8749(74)90212-3; MILLER RG, 1980, STRATEGIES IMMUNE RE, P507; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MURAOKA S, 1980, J EXP MED, V152, P54, DOI 10.1084/jem.152.1.54; NAKAMURA H, 1990, TRANSPLANTATION, V49, P931, DOI 10.1097/00007890-199005000-00020; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; RAMMENSEE HG, 1989, INT REV IMMUNOL, V4, P177; RESKEKUNZ AB, 1986, J IMMUNOL, V136, P2033; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAMBHARA SR, UNPUB; Sambrooke J., 1989, MOL CLONING LAB MANU, pE3; SHAPIRO HM, 1988, PRACTICAL FLOW CYTOM, P168; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHASHI T, 1990, J EXP MED, V172, P901, DOI 10.1084/jem.172.3.901; WALLACE VA, 1991, EUR J IMMUNOL, V20, P2471	46	200	211	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1424	1427						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1828618				2022-12-24	WOS:A1991FP86800034
J	MOTOKURA, T; BLOOM, T; KIM, HG; JUPPNER, H; RUDERMAN, JV; KRONENBERG, HM; ARNOLD, A				MOTOKURA, T; BLOOM, T; KIM, HG; JUPPNER, H; RUDERMAN, JV; KRONENBERG, HM; ARNOLD, A			A NOVEL CYCLIN ENCODED BY A BCL1-LINKED CANDIDATE ONCOGENE	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; MESSENGER-RNA; GENE; AMPLIFICATION; DIVISION; KINETICS; MEIOSIS; BCL-1	WE have previously identified a candidate oncogene (PRAD1 or D11S287E) on chromosome 11q13 which is clonally rearranged with the parathyroid hormone locus in a subset of benign parathyroid tumours 1,2. We now report that a cloned human placental PRAD1 complementary DNA encodes a protein of 295 amino acids with sequence similarities to the cyclins. Cyclins can form a complex with and activate p34 cdc2 protein kinase, thereby regulating progress through the cell cycle (reviewed in refs 3-5). PRAD1 messenger RNA levels vary dramatically across the cell cycle in HeLa cells. Addition of the PRAD1 protein to interphase clam embryo lysates containing inactive p34cdc2 kinase and lacking endogenous cyclins allows it to be isolated using beads bearing p13suc1, a yeast protein that binds cdc2 and related kinases with high affinity and coprecipitates kinase-associated proteins. Addition of PRAD1 also induces phosphorylation of histone H1, a preferred substrate of cdc2. These data suggest that PRAD1 encodes a novel cyclin whose overexpression may play an important part in the development of various tumours with abnormalities in 11q13.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School			Motokura, Toru/X-3682-2019	Bloom, Theodora/0000-0002-0222-4177				ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Battey, 1986, BASIC METHODS MOL BI; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FRIEDMAN E, 1990, J CLIN ENDOCR METAB, V71, P293, DOI 10.1210/jcem-71-2-293; GARDELLA TJ, 1990, J BIOL CHEM, V265, P15854; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LAMMIE GA, 1991, ONCOGENE, V6, P439; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBERG CL, 1991, ONCOGENE, V6, P449; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THEILLET C, 1990, ONCOGENE, V5, P147; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431	33	1285	1350	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					512	515		10.1038/350512a0	http://dx.doi.org/10.1038/350512a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1826542				2022-12-24	WOS:A1991FG14300055
J	ANTONARAKIS, SE				ANTONARAKIS, SE			PARENTAL ORIGIN OF THE EXTRA CHROMOSOME IN TRISOMY-21 AS INDICATED BY ANALYSIS OF DNA POLYMORPHISMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONDISJUNCTION; SEQUENCES; RECOMBINATION; PROBES	Background. Over the past 20 years, the parental origin of the extra chromosome in children with trisomy 21 has been investigated with cytogenetic methods of identifying morphologic variations in chromosome 21. These studies have concluded that the origin of the extra chromosome 21 was maternal in approximately 80 percent of cases and paternal in about 20 percent. Methods. We studied 200 families, each with a single child with trisomy 21, using DNA polymorphisms as markers to determine the parental origin of the nondisjunction causing the extra chromosome 21. These polymorphisms spanned a region of about 120 centimorgans on the long arm of chromosome 21, from the D21S13 locus (the most centromeric) to the COL6A1 gene (the most telomeric). Results. The parental origin of nondisjunction could be determined for all but 7 of the 200 children. It was maternal in 184 children (proportion [+/- SE], 95.3 +/- 1.5 percent) and paternal in 9 (4.7 +/- 1.5 percent). In a subgroup of 31 families, we compared the results of DNA analysis with those of traditional cytogenetic analysis. According to the cytogenetic analyses, nondisjunction originated in the mother in 26 cases (84 percent) and in the father in 5 (16 percent). DNA analysis demonstrated the origin as maternal in 29 (94 percent) and paternal in 2 (6 percent). With the cytogenetic analyses, there were three false determinations of paternal origin. Conclusions. In trisomy 21 the extra chromosome 21 is maternal in origin in about 95 percent of the cases, and paternal in only about 5 percent - considerably less than has been reported with cytogenetic methods. DNA polymorphic analysis is now the method of choice for establishing the parental origin of nondisjunction.			ANTONARAKIS, SE (corresponding author), JOHNS HOPKINS UNIV HOSP,CTR MED GENET,DEPT PEDIAT,CMSC 1003,BALTIMORE,MD 21205, USA.		Petersen, Michael Bjørn B/D-1483-2017; Antonarakis, Stylianos/N-8866-2014	Petersen, Michael Bjørn B/0000-0003-0316-8207; Antonarakis, Stylianos/0000-0001-8907-5823	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024605, K04HD000774, R01HD019591] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD19591, P01HD24605, HD00774] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTONARAKIS SE, 1985, P NATL ACAD SCI USA, V82, P3360, DOI 10.1073/pnas.82.10.3360; CAROTHERS AD, 1987, AM J HUM GENET, V40, P147; CHAKRAVARTI A, 1989, AM J HUM GENET, V44, P639; DAVIES KE, 1984, HUM GENET, V66, P54, DOI 10.1007/BF00275186; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; Jacobs P A, 1977, Prog Med Genet, V2, P251; JUBERG RC, 1970, NEW ENGL J MED, V282, P292, DOI 10.1056/NEJM197002052820602; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEWIS JG, 1990, GENOMICS, V8, P400, DOI 10.1016/0888-7543(90)90300-J; MIKKELSEN M, 1980, ANN HUM GENET, V44, P17, DOI 10.1111/j.1469-1809.1980.tb00942.x; PETERSEN MB, 1990, GENOMICS, V7, P136, DOI 10.1016/0888-7543(90)90531-X; PETERSEN MB, 1991, AM J HUM GENET, V48, P65; PETERSEN MB, IN PRESS GENOMICS; RUDD NL, 1988, HUM GENET, V78, P175, DOI 10.1007/BF00278191; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART GD, 1988, AM J HUM GENET, V42, P227; STEWART GD, 1985, NUCLEIC ACIDS RES, V13, P4125, DOI 10.1093/nar/13.11.4125; WARREN AC, 1987, SCIENCE, V237, P652, DOI 10.1126/science.2955519; 1972, CYTOGENET CELL GENET, V11, P313	22	202	209	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 28	1991	324	13					872	876		10.1056/NEJM199103283241302	http://dx.doi.org/10.1056/NEJM199103283241302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD111	1825697	Bronze			2022-12-24	WOS:A1991FD11100002
J	LARKMAN, A; STRATFORD, K; JACK, J				LARKMAN, A; STRATFORD, K; JACK, J			QUANTAL ANALYSIS OF EXCITATORY SYNAPTIC ACTION AND DEPRESSION IN HIPPOCAMPAL SLICES	NATURE			English	Article							LONG-TERM POTENTIATION; TRANSMISSION; RELEASE; GLUTAMATE; SYNAPSES; NEURONS; CALCIUM	QUANTAL analysis can provide a quantitative description of important aspects of chemical synaptic transmission and its modification 1-3. The technique has recently been applied to excitatory synapses within the hippocampus 4-10, especially the form of synaptic plasticity known as long-term potentiation 11-13. However, these attempts have met with only limited success, in that the individual quantal amplitudes making up the synaptic response generally could not be resolved. Here we have paid attention to the possible instability of the quantal fluctuation pattern over time. We were able to resolve individual quantal component amplitudes for a high proportion of the experiments, and so demonstrate the quantal nature of excitatory transmission in the CA1 region of the hippocampus. Mean quantal amplitudes for individual excitatory postsynaptic potentials were 84-197-mu-V, with a mean of 131 +/- 29-mu-V. For periods during which the fluctuation pattern was stable, the variance associated with individual quantal amplitudes was low. We have also used quantal analysis to show that synaptic depression following prolonged stimulation at these synapses is primarily a presynaptic phenomenon.			LARKMAN, A (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BENNETT MR, 1989, J PHYSIOL-LONDON, V418, P219, DOI 10.1113/jphysiol.1989.sp017836; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P574, DOI 10.1113/jphysiol.1954.sp005130; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FRIEDLANDER MJ, 1990, J NEUROSCI, V10, P814; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P65, DOI 10.1113/jphysiol.1981.sp013972; JACK JJB, IN PRESS COLD SPRING; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KORN H, 1984, J NEUROSCI, V4, P125; KULLMANN DM, 1989, J NEUROSCI METH, V30, P231, DOI 10.1016/0165-0270(89)90134-9; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MARTIN AR, 1977, HDB PHYSL          1, V1, P329; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; RAHAMIMOFF R, 1973, J PHYSIOL-LONDON, V228, P241, DOI 10.1113/jphysiol.1973.sp010084; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RIVEROS N, 1986, BRAIN RES, V386, P405, DOI 10.1016/0006-8993(86)90181-2; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SAYER RJ, 1989, J NEUROSCI, V9, P840; SAYER RJ, 1990, J NEUROSCI, V10, P826; SCHWARTZKROIN PA, 1987, CEREB CORTEX, V6, P295; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; THIES RE, 1965, J NEUROPHYSIOL, V28, P427, DOI 10.1152/jn.1965.28.3.427; TITTERINGTON DM, 1985, STATISTICAL ANAL FIN, P52; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VILLANUEVA S, 1990, NEUROSCIENCE, V37, P23, DOI 10.1016/0306-4522(90)90188-A; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889; WALMSLEY B, 1987, J NEUROSCI, V7, P1037; YAMAMOTO C, 1982, EXP BRAIN RES, V46, P170	34	165	166	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1991	350	6316					344	347		10.1038/350344a0	http://dx.doi.org/10.1038/350344a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1848922				2022-12-24	WOS:A1991FD83800094
J	FRASER, JD; IRVING, BA; CRABTREE, GR; WEISS, A				FRASER, JD; IRVING, BA; CRABTREE, GR; WEISS, A			REGULATION OF INTERLEUKIN-2 GENE ENHANCER ACTIVITY BY THE T-CELL ACCESSORY MOLECULE CD28	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; ANTIGEN RECEPTOR COMPLEX; ACTIVATION PATHWAY; CHROMOSOMAL GENE; LYMPHOCYTES-T; EXPRESSION; INDUCTION; PROMOTER; EVENTS; REGION	The mechanism by which cell surface molecules regulate T cell production of lymphokines is poorly understood. Production of interleukin-2 (IL-2) can be regulated by signal transduction pathways distinct from those induced by the T cell antigen receptor. Stimulation of CD28, a molecule expressed on most human T cells, induced the formation of a protein complex that bound to a site on the IL-2 gene distinct from previously described binding sites and increased IL-2 enhancer activity fivefold. The CD28-responsive complex bound to the IL-2 gene between - 164 and - 154 base pairs from the transcription start site. The sequence of this element is similar to regions conserved in the 5' flanking regions of several other lymphokine genes.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	FRASER, JD (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FRASER JD, UNPUB; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; HARA T, 1985, J EXP MED, V161, P1513, DOI 10.1084/jem.161.6.1513; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JENKINS MK, 1987, P NATL ACAD SCI USA, V84, P5409, DOI 10.1073/pnas.84.15.5409; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NAGATA S, 1986, EMBO J, V5, P575, DOI 10.1002/j.1460-2075.1986.tb04249.x; QUILL H, 1987, J IMMUNOL, V138, P3704; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TSUCHIYA M, 1987, EUR J BIOCHEM, V165, P7, DOI 10.1111/j.1432-1033.1987.tb11187.x; WEISS A, 1986, J IMMUNOL, V137, P819; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; YANG YC, 1987, LYMPHOKINES, V15, P375	34	652	700	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 18	1991	251	4991					313	316		10.1126/science.1846244	http://dx.doi.org/10.1126/science.1846244			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET678	1846244				2022-12-24	WOS:A1991ET67800034
J	MIKI, T; FLEMING, TP; BOTTARO, DP; RUBIN, JS; RON, D; AARONSON, SA				MIKI, T; FLEMING, TP; BOTTARO, DP; RUBIN, JS; RON, D; AARONSON, SA			EXPRESSION CDNA CLONING OF THE KGF RECEPTOR BY CREATION OF A TRANSFORMING AUTOCRINE LOOP	SCIENCE			English	Article							GROWTH-FACTOR; CELLS; DIFFERENTIATION; PURIFICATION; LIBRARIES; INSERTS; SYSTEM	An expression cloning strategy was devised to isolate the keratinocyte growth factor (KGF) receptor complementary DNA. NIH/3T3 fibroblasts, which secrete this epithelial cell-specific mitogen, were transfected with a keratinocyte expression complementary DNA library. Among several transformed foci identified, one demonstrated the acquisition of specific high-affinity KGF binding sites. The pattern of binding competition by related fibroblast growth factors (FGFs) indicated that this receptor had high affinity for acidic FGF as well as KGF. The rescued 4.2-kilobase complementary DNA was shown to encode a predicted membrane-spanning tyrosine kinase related to but distinct from the basic FGF receptor. This expression cloning approach may be generally applicable to the isolation of genes that constitute limiting steps in mitogenic signaling pathways.			MIKI, T (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, UNPUB; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GUROFF G, 1987, ONCOGENES GENES GROW, P191; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAHN P, 1986, ONCOGENES GROWTH CON; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; Miki T., UNPUB; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P8722; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUBIN J, UNPUB; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1988, ONCOGENE, V3, P9; RUTA M, 1989, P NATL ACAD SCI USA, V86, P5449; SAFRAN A, 1990, ONCOGENE, V5, P635; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8	35	448	475	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 4	1991	251	4989					72	75		10.1126/science.1846048	http://dx.doi.org/10.1126/science.1846048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1846048				2022-12-24	WOS:A1991EQ60300029
J	BURNS, DA				BURNS, DA			A POTPOURRI OF PARASITES IN POETRY AND PROVERB	BRITISH MEDICAL JOURNAL			English	Article											BURNS, DA (corresponding author), LEICESTER ROYAL INFIRM,LEICESTER LE1 5WW,ENGLAND.							BOTTOMLEY G, 1925, POEMS 30 YEARS, P106; DONNE J, 1986, J DONNE POETRY, P48; GUYS PRM, 1972, ST JOHNS HOSPITAL DE, V58, P113; KINGSLEY J, 1968, POEMS SONGS R BURNS, V1, P193; LEHANE B, 1969, COMPLEAT FLEA, P94; Mellanby K, 1941, Br Med J, V2, P405; MELLANBY K, 1945, HUMAN GUINEA PIGS; MILLIGAN S, 1991, PUFFIN BOOK 20TH CEN, P162; SILCOCK A, 1969, VERSE WORSE, P242; STEVENSON B, 1967, STEVENSONS BOOK QUOT, P1171; SWIFT J, 1967, SWIFT POETICAL WORKS, P578; 1964, PLAGUE PHILISTINES, P146	12	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1611	1614		10.1136/bmj.303.6817.1611	http://dx.doi.org/10.1136/bmj.303.6817.1611			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	GX956	1773193	Green Published, Bronze			2022-12-24	WOS:A1991GX95600026
J	FEAVER, WJ; GILEADI, O; LI, Y; KORNBERG, RD				FEAVER, WJ; GILEADI, O; LI, Y; KORNBERG, RD			CTD KINASE ASSOCIATED WITH YEAST RNA POLYMERASE-II INITIATION FACTOR-B	CELL			English	Article							TRANSCRIPTION FACTOR; SUBUNIT COMPOSITION; PURIFICATION; PHOSPHORYLATION; PROMOTER; REQUIREMENT; ELONGATION; INVITRO; SYSTEM; REPEAT	A kinase activity specific for the C-terminal repeat domain (CTD) of RNA polymerase II is associated with nearly homogeneous yeast general initiation factor b by three criteria: cofractionation on the basis of size and charge and coinactivation by mild heat treatment. The kinase phosphorylates the CTD at multiple sites in a processive manner. Factor b may possess a DNA-dependent ATPase activity as well. Both kinase and DNA-dependent ATPase activities exhibit the same nucleotide requirements as previously demonstrated for the initiation of transcription. These results support the idea that phosphorylation of the CTD lies on the pathway of transcription initiation and identify a catalytic activity of a general factor essential for the initiation process.			FEAVER, WJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.		Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X	NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, IN PRESS J BIOL CHEM; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1990, J BIOL CHEM, V265, P5629; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; KIM WY, 1989, J BIOL CHEM, V264, P3169; KIM WY, 1988, J BIOL CHEM, V263, P18880; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SOPTA M, 1985, J BIOL CHEM, V260, P353; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZHANG J, 1991, J BIOL CHEM, V266, P2290	34	189	193	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1223	1230		10.1016/0092-8674(91)90298-D	http://dx.doi.org/10.1016/0092-8674(91)90298-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1836979				2022-12-24	WOS:A1991GX16400020
J	MENDEL, DB; KHAVARI, PA; CONLEY, PB; GRAVES, MK; HANSEN, LP; ADMON, A; CRABTREE, GR				MENDEL, DB; KHAVARI, PA; CONLEY, PB; GRAVES, MK; HANSEN, LP; ADMON, A; CRABTREE, GR			CHARACTERIZATION OF A COFACTOR THAT REGULATES DIMERIZATION OF A MAMMALIAN HOMEODOMAIN PROTEIN	SCIENCE			English	Article							NUCLEAR FACTOR-I; DNA-BINDING PROTEINS; ALBUMIN TRANSCRIPTION DIFFERS; POU DOMAIN PROTEINS; RAT HEPATOMA-CELLS; 3 SEQUENCE MOTIFS; CHROMOSOMAL LOCALIZATION; FUNCTIONAL DOMAINS; ACTIVATION DOMAIN; OVERLAP EXTENSION	Dimerization among transcription factors has become a recurrent theme in the regulation of eukaryotic gene expression. Hepatocyte nuclear factor-let (HNF-1-alpha) is a homeodomain-containing protein that functions as a dimer. A dimerization cofactor of HNF-1-alpha (DCoH) was identified that displayed a restricted tissue distribution and did not bind to DNA, but, rather, selectively stabilized HNF-1-alpha-dimers. The formation of a stable tetrameric DCoH-HNF-1-alpha-complex, which required the dimerization domain of HNF-1-alpha did not change the DNA binding characteristics of HNF-1-alpha but enhanced its transcriptional activity. However, DCoH did not confer transcriptional activation to the GAL4 DNA binding domain. These results indicate that DCoH regulates formation of transcriptionally active tetrameric complexes and may contribute to the developmental specificity of the complex.	UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	MENDEL, DB (corresponding author), STANFORD UNIV,BECKMAN CTR MOLEC & GENET MED,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Admon, Arie/0000-0003-0504-3950	NCI NIH HHS [CA 09302] Funding Source: Medline; NHLBI NIH HHS [HL 33942] Funding Source: Medline; NICHD NIH HHS [HD 07201] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH I, 1990, GENOMICS, V8, P155, DOI 10.1016/0888-7543(90)90238-P; BAUMHEUTER S, UNPUB; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CONLEY P, UNPUB; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL D, UNPUB; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309	62	215	219	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1762	1767		10.1126/science.1763325	http://dx.doi.org/10.1126/science.1763325			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763325				2022-12-24	WOS:A1991GW31600034
J	CHENG, SWC; LYNCH, EC; LEASON, KR; COURT, DL; SHAPIRO, BA; FRIEDMAN, DI				CHENG, SWC; LYNCH, EC; LEASON, KR; COURT, DL; SHAPIRO, BA; FRIEDMAN, DI			FUNCTIONAL IMPORTANCE OF SEQUENCE IN THE STEM-LOOP OF A TRANSCRIPTION TERMINATOR	SCIENCE			English	Article							ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; OPERON ATTENUATOR; GENE-EXPRESSION; RNA-POLYMERASE; NINR REGION; EFFICIENCY; PROMOTERS; PROTEIN; SITES	Intrinsic transcription terminators of prokaryotes are distinguished by a common RNA motif: a stem-loop structure high in guanine and cytosine content, followed by multiple uridine residues. Models explaining intrinsic terminators postulate that the stem-loop sequence is necessary only to form structure. In the tR2 terminator of coliphage lambda, single-nucleotide changes reducing potential RNA stem stability eliminated tR2 activity, and a compensatory change that restored the stem structure restored terminator activity. However, multiple changes in the stem sequence that should have either maintained or increased stability reduced terminator activity. These results suggest that the ability of the stem-loop structure to signal transcription termination depends on sequence specificity and secondary structure.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,CHROMOSOME BIOL,FREDERICK,MD 21701; NCI,FREDERICK CANC RES & DEV CTR,MATH BIOL LAB,IMAGING PROC SECT,FREDERICK,MD 21701	University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Friedman, David/G-3198-2015	Friedman, David/0000-0002-2741-4671	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIAID NIH HHS [AI1459-10] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; CARAFA YD, 1991, J MOL BIOL, V21, P835; Cheng S.-F., UNPUB; COSTANTINO N, 1990, J BACTERIOL, V172, P4610, DOI 10.1128/jb.172.8.4610-4615.1990; COURT D, 1969, VIROLOGY, V39, P348, DOI 10.1016/0042-6822(69)90060-9; Daniels D., 1983, LAMBDA, P469; Fiandt M., 1971, BACTERIOPHAGE LAMBDA, P329; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GREENBLATT J, 1981, NATURE, V292, P215, DOI 10.1038/292215a0; JOHNSTON HM, 1981, J MOL BIOL, V145, P725; KRINKE L, 1990, NUCLEIC ACIDS RES, V18, P4809, DOI 10.1093/nar/18.16.4809; KROGER M, 1982, GENE, V20, P25, DOI 10.1016/0378-1119(82)90084-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDICK R, 1987, CELLULAR MOL BIOL, P1276; LEASON KR, 1988, J BACTERIOL, V170, P5051, DOI 10.1128/jb.170.11.5051-5058.1988; LYNN SP, 1988, J BIOL CHEM, V263, P472; LYNN SP, 1985, J MOL BIOL, V183, P529, DOI 10.1016/0022-2836(85)90169-X; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; McKenney K, 1981, Gene Amplif Anal, V2, P383; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAY DS, 1981, INITIATION DNA REPLI, P169; REYNOLDS R, IN PRESS J MOL BIOL; REYNOLDS R, IN PRESS J MOL BIOLJ; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; SPENCER CA, 1990, ONCOGENE, V5, P777; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	41	61	61	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1991	254	5035					1205	1207		10.1126/science.1835546	http://dx.doi.org/10.1126/science.1835546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GQ834	1835546				2022-12-24	WOS:A1991GQ83400048
J	MCMILLAN, SA; HAUGHTON, DJ; BIGGART, JD; EDGAR, JD; PORTER, KG; MCNEILL, TA				MCMILLAN, SA; HAUGHTON, DJ; BIGGART, JD; EDGAR, JD; PORTER, KG; MCNEILL, TA			PREDICTIVE VALUE FOR CELIAC-DISEASE OF ANTIBODIES TO GLIADIN, ENDOMYSIUM, AND JEJUNUM IN PATIENTS ATTENDING FOR JEJUNAL BIOPSY	BRITISH MEDICAL JOURNAL			English	Article							CELIAC-DISEASE; DERMATITIS-HERPETIFORMIS; ANTIGLIADIN ANTIBODIES; SCREENING-TEST; IGA; DIAGNOSIS; GLUTEN; SENSITIVITY; MULTICENTER; CHILDREN	Objective - To investigate the extent to which the detection of antibodies to gliadin, endomysium, and jejunum predicts the eventual diagnosis of coeliac disease according to the revised ESPGAN diagnostic criteria in a group of patients in whom there is a high suspicion of coeliac disease. Design - Clinical assessment and laboratory analysis of patients with suspected coeliac disease. Setting - Gastroenterology department of teaching hospital. Patients - 96 adults with suspected coeliac disease attending for jejunal biopsy. Main outcome measures - Diagnosis of coeliac disease with the revised criteria of the European Society of Paediatric Gastroenterology and Nutrition in patients with and without antibodies associated with coeliac disease. Results - 28 patients had a clinical diagnosis of coeliac disease, seven of other gastrointestinal diseases, and 12 of miscellaneous diseases; 49 had no diagnosis. Gliadin IgA detected by ELISA was found in all patients with coeliac disease and none of those without, giving a sensitivity, specificity, positive and negative predictive values, and predictive efficiency of 100% for diagnosing coeliac disease within the group. Endomysial IgA was found in 25 (89%) patients with coeliac disease and jejunal IgA in 21 (75%); neither IgA was found in patients without coeliac disease. Conclusion - Detection of gliadin IgA by ELISA and to a lesser extent the endomysial IgA should allow better selection of patients for jejunal biopsy and thus make diagnosing coeliac disease simpler and more efficient.	QUEENS UNIV BELFAST,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	Queens University Belfast	MCMILLAN, SA (corresponding author), BELFAST CITY HOSP,REG IMMUNOL LAB,BELFAST BT9 7AD,ANTRIM,NORTH IRELAND.			Edgar, John David Moore/0000-0003-2969-4475				ASCHER H, 1990, J PEDIATR GASTR NUTR, V10, P443, DOI 10.1097/00005176-199005000-00005; BURGINWOLFF A, 1989, EUR J PEDIATR, V148, P496, DOI 10.1007/BF00441541; CHORZELSKI TP, 1984, BRIT J DERMATOL, V111, P395, DOI 10.1111/j.1365-2133.1984.tb06601.x; DIAS J, 1987, LANCET, V2, P157; ELEWAUT A, 1989, CLIN CHIM ACTA, V183, P285, DOI 10.1016/0009-8981(89)90362-8; GALLEN RS, 1986, MANUAL CLIN LABORATO, P966; GRODZINSKY E, 1990, INT ARCH ALLER A IMM, V92, P119, DOI 10.1159/000235201; GUANDALINI S, 1989, ARCH DIS CHILD, V64, P1320, DOI 10.1136/adc.64.9.1320; HALLSTROM O, 1989, GUT, V30, P1225, DOI 10.1136/gut.30.9.1225; KARPATI S, 1990, LANCET, P1335; KELLY J, 1987, ARCH DIS CHILD, V62, P469, DOI 10.1136/adc.62.5.469; KOLETZKO S, 1988, EUR J PEDIATR, V148, P113, DOI 10.1007/BF00445915; KUMAR V, 1989, IMMUNOL INVEST, V18, P533, DOI 10.3109/08820138909112261; MCNEISH AS, 1979, ARCH DIS CHILD, V54, P783, DOI 10.1136/adc.54.10.783; SCOTT H, 1990, SCAND J GASTROENTERO, V25, P287, DOI 10.1080/00365521.1990.12067105; UNSWORTH DJ, 1981, ARCH DIS CHILD, V56, P864, DOI 10.1136/adc.56.11.864; VOLTA U, 1990, CLIN EXP IMMUNOL, V80, P192, DOI 10.1111/j.1365-2249.1990.tb05232.x; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; WATSON RGP, 1986, ULSTER MED J, V55, P160; 1991, LANCET, P590	20	122	122	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1163	1165		10.1136/bmj.303.6811.1163	http://dx.doi.org/10.1136/bmj.303.6811.1163			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747612	Green Published, Bronze			2022-12-24	WOS:A1991GP48800021
J	FLYNN, GC; POHL, J; FLOCCO, MT; ROTHMAN, JE				FLYNN, GC; POHL, J; FLOCCO, MT; ROTHMAN, JE			PEPTIDE-BINDING SPECIFICITY OF THE MOLECULAR CHAPERONE BIP	NATURE			English	Article							NEWLY SYNTHESIZED PROTEINS; HEAT-SHOCK; CELLS; HYDROPHOBICITY; TRANSLOCATION; DEGRADATION; CATALYSTS; CORE; ATP	Members of the heat-shock protein family (hsp70s) can distinguish folded from unfolded proteins. This property is crucial to the role of hsp70s as molecular chaperones and is attributable to the amino-acid specificity of the peptide-binding site. The specificity for peptide ligands is investigated using a set of peptides of random sequence but defined chain length. The peptide-binding site selects for aliphatic residues and accommodates them in an environment energetically equivalent to the interior of a folded protein.	EMORY UNIV, SCH MED, MICROCHEM FACIL, ATLANTA, GA 30322 USA; PRINCETON UNIV, DEPT MOLEC BIOL, MICROCHEM CORE FACIL, PRINCETON, NJ 08544 USA	Emory University; Princeton University	FLYNN, GC (corresponding author), SLOAN KETTERING MEM CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA.							BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P618; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLAJNIK MF, 1991, P NATL ACAD SCI USA, V88, P537, DOI 10.1073/pnas.88.2.537; FLAJNIK MF, IN PRESS IMMUNOGENET; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; POHL J, 1990, FEBS LETT, V272, P200, DOI 10.1016/0014-5793(90)80484-Z; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; TACK BF, 1980, J BIOL CHEM, V255, P8842; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009	35	680	705	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	1991	353	6346					726	730		10.1038/353726a0	http://dx.doi.org/10.1038/353726a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GL696	1834945				2022-12-24	WOS:A1991GL69600057
J	JULIAN, BA; LASKOW, DA; DUBOVSKY, J; DUBOVSKY, EV; CURTIS, JJ; QUARLES, LD				JULIAN, BA; LASKOW, DA; DUBOVSKY, J; DUBOVSKY, EV; CURTIS, JJ; QUARLES, LD			RAPID LOSS OF VERTEBRAL MINERAL DENSITY AFTER RENAL-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE HISTOMORPHOMETRIC DATA; INDUCED OSTEOPOROSIS; ILIAC BONE; OSTEOMALACIA; RESORPTION; OSTEOPENIA; ALUMINUM	Background. Osteopenia is a major complication of renal transplantation. Immunosuppressive regimens including cyclosporine, which permit the use of lower doses of glucocorticoids, may reduce glucocorticoid-induced osteopenia. Methods. We prospectively studied the magnitude, distribution, and mechanism of bone loss in 20 adults who received renal allografts from living related donors, who had good renal function, and who were treated with azathioprine, cyclosporine, and low doses of prednisone. We measured serum biochemical markers of bone metabolism, determined the bone mineral density of the second, third, and fourth lumbar vertebrae and the shaft of the radius, and analyzed the histomorphometric features of iliac bone at the time of transplantation and six months later. Measurements of vertebral mineral density were repeated 18 months after transplantation in 17 of the patients. Results. After transplantation, the mean serum concentrations of Parathyroid hormone, phosphorus, and alkaline phosphatase decreased and the serum calcitriol concentration increased. The mean (+/- SD) bone mineral density of the vertebrae had decreased 6.8 +/- 5.6 percent 6 months after transplantation (P < 0.05) and 8.8 +/- 7.0 percent 18 months after transplantation. In contrast, the bone mineral density of the radius had increased six months after transplantation (P < 0.05). The histomorphometric studies showed that the rate of bone formation decreased from 50.5 +/- 44.8 to 23.1 +/- 13.8-mu-m3 per square micrometer per year (P < 0.05), and the formation period lengthened from 70 +/- 42 to 146 +/- 144 days (P < 0.05). Consequently, the amount of bone replaced during a remodeling cycle diminished. Conclusions. Osteopenia associated with renal transplantation remains a problem in the cyclosporine era. The loss of vertebral bone in our subjects was due to an imbalance in bone remodeling consistent with a toxic effect of glucocorticoids.	UNIV ALABAMA, DEPT SURG, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT RADIOL, BIRMINGHAM, AL 35294 USA; DUKE UNIV, DEPT MED, DURHAM, NC 27706 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Duke University	JULIAN, BA (corresponding author), UNIV ALABAMA, DEPT MED, DIV NEPHROL, THT 643, UAB STN, BIRMINGHAM, AL 35294 USA.			Quarles, L. Darryl/0000-0002-5082-7896	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037308] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00032] Funding Source: Medline; NIAMS NIH HHS [2 ROI AR 37308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BONOMINI V, 1975, J UROL NEPHROL, V81, P941; BRINER V, 1987, KIDNEY INT, V32, P431; DEMPSTER DW, 1983, CALCIFIED TISSUE INT, V35, P410, DOI 10.1007/BF02405069; DUBOVSKY J, 1987, OSTEOPOROSIS 1987, V1, P60; EASTELL R, 1990, J BONE MINER RES, V5, P1237; EISMAN JA, 1976, ARCH BIOCHEM BIOPHYS, V176, P235, DOI 10.1016/0003-9861(76)90161-2; HADDAD JG, 1971, J CLIN ENDOCR METAB, V33, P992, DOI 10.1210/jcem-33-6-992; KANIS JA, 1990, J BONE MINER RES, V5, P209, DOI 10.1002/jbmr.5650050302; KIMMEL DB, 1990, BONE MINER, V11, P217, DOI 10.1016/0169-6009(90)90061-J; KLEEREKOPER M, 1983, INT C SERIES, V617, P200; LOERTSCHER R, 1983, TRANSPLANTATION, V36, P115; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; LYLES KW, 1982, CALCIFIED TISSUE INT, V34, P125, DOI 10.1007/BF02411222; MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P449, DOI 10.1007/BF02411283; MALONEY NA, 1982, J LAB CLIN MED, V99, P206; MCCARRON DA, 1982, KIDNEY INT, V22, P662, DOI 10.1038/ki.1982.227; MOORHEAD JF, 1974, LANCET, V1, P694; MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo-123-5-2571; NETER J, 1974, APPLIED LINEAR STATI; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PARFITT AM, 1986, CPC SERIES CASES MET, P1; PECK WA, 1967, P NATL ACAD SCI USA, V57, P1599, DOI 10.1073/pnas.57.6.1599; POCOCK NA, 1987, ANN INTERN MED, V107, P319, DOI 10.7326/0003-4819-107-2-319; QUARLES LD, 1989, J BONE MINER RES, V4, P671; QUARLES LD, 1988, J CLIN INVEST, V81, P1056, DOI 10.1172/JCI113417; RECKER RR, 1988, J BONE MINER RES, V3, P133; SCHWARTZ MP, 1981, CALCIFIED TISSUE INT, V33, P561, DOI 10.1007/BF02409492; SKJODT H, 1984, Calcified Tissue International, V36, pS50; SLATOPOLSKY E, 1984, ADV EXP MED BIOL, V171, P353; STEIN B, 1991, ENDOCRINOLOGY, V128, P1369, DOI 10.1210/endo-128-3-1369; STEWART PJ, 1986, J BONE MINER RES, V1, P285; STEWART PJ, 1989, CALCIFIED TISSUE INT, V45, P222, DOI 10.1007/BF02556041; VILLANUEVA AR, 1974, STAIN TECHNOL, V49, P1, DOI 10.3109/10520297409116928	34	556	568	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					544	550		10.1056/NEJM199108223250804	http://dx.doi.org/10.1056/NEJM199108223250804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857390	Bronze			2022-12-24	WOS:A1991GB44700004
J	WANK, R; THOMSSEN, C				WANK, R; THOMSSEN, C			HIGH-RISK OF SQUAMOUS-CELL CARCINOMA OF THE CERVIX FOR WOMEN WITH HLA-DQW3	NATURE			English	Article							HERPES-SIMPLEX VIRUS; CLASS-II MOLECULES; HLA-DR ANTIGEN; ANKYLOSING-SPONDYLITIS; ASSOCIATION; SPECIFICITIES; H-2-COMPLEX; COMPLEX; LOCUS	MANY immune responses are controlled by genes of the major histocompatibility complex (MHC) 1. In man these include the loci encoding the HLA-A, -B, -C, -DR, -DQ and -DP antigens, and many diseases have been linked with these 2-5. But attempts to identify HLA genes in man that might explain why an immune response against malignant tumours should be ineffective have so far been disappointing, apart from the association reported between the HLA-DRI antigen and a susceptibility to a rare carcinoma of the thyroid gland 6. Here we describe another strong connection between a common malignant tumour and an HLA antigen, namely between HLA-DQw3 and squamous cell carcinoma of the cervix: from the 1988 United States tumour registry, 1 in every 63 newborn girls will develop this invasive cancer 7. We found that 88% of 66 patients had the leukocyte antigen HLA-DQw3 when it would normally be expected in only 50% of individuals. In animals the immune system and the MHC act in defence against virally induced tumours, but until now there has been no evidence that they do so in humans 8: as squamous cell carcinoma is probably virally induced, our discovery of its association with an HLA antigen will be important to the understanding of the immunogenetic basis of a susceptibility to this tumour.	TECH UNIV MUNICH, DEPT OBSTET & GYNAECOL, W-8000 MUNICH 80, GERMANY	Technical University of Munich	WANK, R (corresponding author), UNIV MUNICH, DEPT IMMUNOL, GOETHESTR 31, W-8000 MUNICH 2, GERMANY.		Thomssen, Christoph/ABC-3102-2021					BARBER HRK, 1989, MANUAL GYNAECOLOGIC, P212; BAUR MP, 1984, HISTOCOMPATIBILITY T, P333; BODMER JG, 1990, TISSUE ANTIGENS, V35, P1, DOI 10.1111/j.1399-0039.1990.tb01749.x; Bodmer W. F., 1989, IMMUNOBIOLOGY HLA, V1, P72; BOYUM A, 1968, SCAND J CLIN LAB I S, V97, P21; BREWERTON DA, 1973, LANCET, V1, P904; CHESEBRO B, 1974, J EXP MED, V140, P1457, DOI 10.1084/jem.140.6.1457; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; FESTENSTEIN H, 1986, NATURE, V322, P64, DOI 10.1038/322064a0; GISSMANN L, 1986, ORIGINS FEMALE GENIT, P217; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; JOHNSON JP, 1987, TISSUE ANTIGENS, V29, P26; JOHNSON JP, 1984, J EXP MED, V160, P1350, DOI 10.1084/jem.160.5.1350; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KAMPGEN E, 1988, ARCH DERMATOL, V124, P1372, DOI 10.1001/archderm.124.9.1372; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KJAER SK, 1988, INT J CANCER, V41, P518, DOI 10.1002/ijc.2910410408; KLEIN J, 1981, NATURE, V291, P455, DOI 10.1038/291455a0; KNOWLES RW, 1989, IMMUNOBIOLOGY HLA, V1, P365; KOENIG UD, 1976, LANCET, V2, P857; LACHMAN PJ, 1982, CLIN ASPECTS IMMUNOL, P1263; Lilly F., 1973, Advances in Cancer Research, V17, P231, DOI 10.1016/S0065-230X(08)60532-1; LONAI P, 1980, IMMUNOGENETICS, V11, P21, DOI 10.1007/BF01567766; MAEDA H, 1984, TISSUE ANTIGENS, V23, P163; MILFORD EL, 1989, IMMUNOBIOLOGY HLA HI, V1, P93; PANZA N, 1982, TISSUE ANTIGENS, V20, P155; PARK MS, 1978, TRANSPLANT P, V10, P823; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; TAIT BD, 1989, IMMUNOBIOLOGY HLA, V1, P269; TERMIJTELEN A, 1980, TISSUE ANTIGENS, V16, P140; TIWARI JL, 1985, HLA DISEASE ASS; VEGA MA, 1986, J IMMUNOL, V137, P3557; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9	33	240	248	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					723	725		10.1038/352723a0	http://dx.doi.org/10.1038/352723a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876187				2022-12-24	WOS:A1991GC06400061
J	HUESMANN, M; SCOTT, B; KISIELOW, P; VONBOEHMER, H				HUESMANN, M; SCOTT, B; KISIELOW, P; VONBOEHMER, H			KINETICS AND EFFICACY OF POSITIVE SELECTION IN THE THYMUS OF NORMAL AND T-CELL RECEPTOR TRANSGENIC MICE	CELL			English	Article							RESTRICTED ANTIGEN RECEPTOR; IMMATURE THYMOCYTES; DIFFERENTIATION; EXPRESSION; PROLIFERATION	DNA-labeling studies in alpha-beta T cell receptor (TCR) transgenic mice show that the lifespan of immature CD4+8+ thymocytes is 3.5 days irrespective of whether they are selected for maturation or not. While nonselected cells die, the binding of the TCR to thymic major histocompatibility complex molecules rescues CD4+8+ cells from programmed cell death and induces first upregulation of the TCR level and then differentiation into CD4+8- or CD4-8+ cells in the absence of any cell division. When most CD4+8+ thymocytes express a selectable transgenic TCR the formation of mature cells with high TCR levels is 10-20 times as efficient as observed in normal mice, yet still only 20% of the CD4+8+ cells become mature. This is due to the limited availability of selecting 'niches': most CD4+8+ thymocytes with a selectable transgenic TCR will undergo maturation when they represent only 5% or less of all CD4+8+ cells.			HUESMANN, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.							BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CEREDIG R, 1990, INT IMMUNOL, V2, P859, DOI 10.1093/intimm/2.9.859; CRISTANTI A, 1986, EMBO J, V5, P2837, DOI 10.1002/j.1460-2075.1986.tb04577.x; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GONCHOROFF NJ, 1985, CYTOMETRY, V6, P506, DOI 10.1002/cyto.990060604; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MATSUYAMA M, 1966, J EXP MED, V123, P559, DOI 10.1084/jem.123.3.559; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P1957, DOI 10.1002/eji.1830191030; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8663; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PENIT C, 1990, INT IMMUNOL, V2, P629, DOI 10.1093/intimm/2.7.629; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; SCOLLAY R, 1978, NATURE, V276, P79, DOI 10.1038/276079a0; SCOTT B, 1989, NATURE, V338, P595; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1974, CELL IMMUNOL, V12, P230, DOI 10.1016/0008-8749(74)90075-6; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VANEWIJK W, 1990, EUR J IMMUNOL, V20, P129, DOI 10.1002/eji.1830200119; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZIJSTRA M, 1990, NATURE, V344, P742	34	352	354	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					533	540		10.1016/0092-8674(81)90016-7	http://dx.doi.org/10.1016/0092-8674(81)90016-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868548				2022-12-24	WOS:A1991GA94100014
J	HAROUSE, JM; BHAT, S; SPITALNIK, SL; LAUGHLIN, M; STEFANO, K; SILBERBERG, DH; GONZALEZSCARANO, F				HAROUSE, JM; BHAT, S; SPITALNIK, SL; LAUGHLIN, M; STEFANO, K; SILBERBERG, DH; GONZALEZSCARANO, F			INHIBITION OF ENTRY OF HIV-1 IN NEURAL CELL-LINES BY ANTIBODIES AGAINST GALACTOSYL CERAMIDE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; PRODUCTIVE INFECTION; HTLV-III/LAV; MONOCLONAL-ANTIBODIES; ENVELOPE GLYCOPROTEIN; AIDS RETROVIRUS; CD4 RECEPTOR; T4 MOLECULE; SOLUBLE CD4	Although the CD4 molecule is the principal cellular receptor for the human immunodeficiency virus (HIV), several CD4-negative cell lines are susceptible to infection with one or more HIV strains. These findings indicate that there are alternate modes of viral entry, perhaps involving one or more receptor molecules. Antibodies against galactosyl ceramide (galactocerebroside, or GalC) inhibited viral internalization and infection in two CD4-negative cell lines derived from the nervous system: U373-MG and SK-N-MC. Furthermore, recombinant HIV surface glycoprotein gp120 bound to GalC but not to other glycolipids. These results suggest a role for GalC or a highly related molecule in HIV entry into neural cells.	UNIV PENN,MED CTR,DEPT NEUROL,CLIN RES BLDG,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania				Spitalnik, Steven/0000-0002-8528-4561	NCI NIH HHS [CA-45690] Funding Source: Medline; NINDS NIH HHS [NS-11037, NS-27405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011037, F32NS011037, P01NS027405, P50NS027405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANSAL R, 1989, J NEUROSCI RES, V24, P548, DOI 10.1002/jnr.490240413; BENJAMINS JA, 1987, J NEUROIMMUNOL, V14, P325, DOI 10.1016/0165-5728(87)90019-1; BERGER JR, 1989, NEUROLOGY, V39, P324, DOI 10.1212/WNL.39.3.324; BERMAN PW, 1985, SCIENCE, V227, P1490, DOI 10.1126/science.2983428; BHAT S, 1991, T AM SOC NEUROCHEM, V22, P183; BHAT S, IN PRESS P NATL ACAD; BHAT SA, UNPUB; CHIODI F, 1987, J VIROL, V61, P1244, DOI 10.1128/JVI.61.4.1244-1247.1987; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; DYER CA, 1988, J NEUROSCI, V8, P4307; GABUZDA DH, 1986, ANN NEUROL, V20, P289, DOI 10.1002/ana.410200304; GRAY F, 1991, NEUROLOGY, V41, P105, DOI 10.1212/WNL.41.1.105; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, UNPUB; JAMESON BA, 1988, SCIENCE, V240, P1335, DOI 10.1126/science.2453925; JANSSEN RS, 1988, SCIENCE, V239, P586; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JOHNSON RT, 1986, TRENDS NEUROSCI, V9, P91, DOI 10.1016/0166-2236(86)90030-5; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003; LASKY LA, 1984, BIO-TECHNOL, V2, P527, DOI 10.1038/nbt0684-527; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAGNANI JL, 1987, METHOD ENZYMOL, V138, P195; MCCUNE JM, 1988, CELL, V55; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; RAFF M, 1978, NATURE, V276, P813; RANCHST B, 1982, P NATL ACAD SCI USA, V79, P2709; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SHARPE AH, 1990, NATURE, V346, P181, DOI 10.1038/346181a0; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SPITALNIK SL, 1985, BLOOD, V66, P319; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WERNER A, 1990, AIDS, V4, P537, DOI 10.1097/00002030-199006000-00007; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZURBRIGGEN A, 1987, ACTA NEUROPATHOL, V74, P366, DOI 10.1007/BF00687214	51	497	514	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					320	323		10.1126/science.1857969	http://dx.doi.org/10.1126/science.1857969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857969				2022-12-24	WOS:A1991FX22400042
J	ASHBY, J; MORROD, RS				ASHBY, J; MORROD, RS			DETECTION OF HUMAN CARCINOGENS	NATURE			English	Editorial Material							RODENT CARCINOGENS; CHEMICALS; BIOASSAYS; MUTAGENS; TOO				ASHBY, J (corresponding author), ICI PLC,CENT TOXICOL LAB,MACCLESFIELD SK10 4TJ,ENGLAND.							AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E; ASHBY J, 1986, MUTAGENESIS, V1, P3, DOI 10.1093/mutage/1.1.3; BARTSCH H, 1989, CELL BIOL TOXICOL, V5, P115, DOI 10.1007/BF00122647; BRIDGES BA, 1976, MUTAT RES, V41, P71, DOI 10.1016/0027-5107(76)90075-0; BUTTERWORTH BE, 1990, MUTAT RES, V239, P117, DOI 10.1016/0165-1110(90)90033-8; CAGLIANO VJ, 1991, SCIENCE, V251, P606; CLAYSON DB, 1991, MUTAT RES, V257, P91, DOI 10.1016/0165-1110(91)90020-V; CLAYSON DB, 1989, MUTAT RES, V221, P53, DOI 10.1016/0165-1110(89)90045-6; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DIETRICH DR, 1991, MUTAT RES, V248, P239, DOI 10.1016/0027-5107(91)90060-2; GRIESEMER RA, 1991, MUTAT RES, V257, P207, DOI 10.1016/0165-1110(91)90001-C; HASEMAN JK, 1987, CANCER LETT, V37, P125, DOI 10.1016/0304-3835(87)90154-6; HAY A, 1991, NATURE, V350, P555, DOI 10.1038/350555a0; HILL RN, 1989, FUND APPL TOXICOL, V12, P629, DOI 10.1016/0272-0590(89)90001-8; HUGG JE, 1991, CELL BIOL TOXIC, V7, P67; MALLING HV, 1974, CHEM CARCINOGENESIS; PETO R, 1985, ASSESSMENT RISK LOW, P3; ROBERTS L, 1991, SCIENCE, V252, P911, DOI 10.1126/science.2035022; SHELBY MD, 1990, MUTAT RES, V234, P257, DOI 10.1016/0165-1161(90)90022-G; TENNANT RW, 1990, MUTAGENESIS, V5, P3, DOI 10.1093/mutage/5.1.3; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; WEISBURGER JH, 1981, FOOD COSMET TOXICOL, V19, P561, DOI 10.1016/0015-6264(81)90506-X; YAMASAKI H, 1988, TUMOUR PROMOTERS	25	89	89	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					185	186		10.1038/352185a0	http://dx.doi.org/10.1038/352185a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857407				2022-12-24	WOS:A1991FX18500022
J	CHELLAPPAN, SP; HIEBERT, S; MUDRYJ, M; HOROWITZ, JM; NEVINS, JR				CHELLAPPAN, SP; HIEBERT, S; MUDRYJ, M; HOROWITZ, JM; NEVINS, JR			THE E2F TRANSCRIPTION FACTOR IS A CELLULAR TARGET FOR THE RB PROTEIN	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; TRANS-ACTIVATION; ENCODED PROTEIN; PRODUCT; EXPRESSION; CYCLE; PHOSPHORYLATION; ASSOCIATION	Although it is generally believed that the product of the retinoblastoma susceptibility gene (RB1) is an important regulator of cell proliferation, the biochemical mechanism for its action is unclear. We now show that the RB protein is found in a complex with the E2F transcription factor and that only the underphosphorylated form of RB is in the E2F complex. Moreover, the adenovirus E1A protein can dissociate the E2F-RB complex, dependent on E1A sequence also critical for E1A to bind to RB. These sequences are also critical for E1A to immortalize primary cell cultures and to transform in conjunction with other oncogenes. Taken together, these results suggest that the interaction of RB with E2F is an important event in the control of cellular proliferation and that the dissociation of the complex is part of the mechanism by which E1A inactivates RB function.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,CELL GROWTH REGULAT & ONCOGENESIS SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,GENET SECT,DURHAM,NC 27710	Duke University; Duke University	CHELLAPPAN, SP (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.		Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026765] Funding Source: NIH RePORTER; NCI NIH HHS [CA53248] Funding Source: Medline; NIGMS NIH HHS [GM26765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EGAN C, 1989, ONCOGENE, V4, P383; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MUDRYJ M, 1991, IN PRESS CELL; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RAYCHAUDHURI P, 1991, IN PRESS GENES DEV; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; VARLEY JM, 1989, ONCOGENE, V4, P725; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOKOTA J, 1988, ONCOGENE, V3, P471; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	52	1304	1328	2	53	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1053	1061		10.1016/0092-8674(91)90557-F	http://dx.doi.org/10.1016/0092-8674(91)90557-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828392				2022-12-24	WOS:A1991FR04700016
J	CAPSON, TL; BENKOVIC, SJ; NOSSAL, NG				CAPSON, TL; BENKOVIC, SJ; NOSSAL, NG			PROTEIN DNA CROSS-LINKING DEMONSTRATES STEPWISE ATP-DEPENDENT ASSEMBLY OF T4-DNA POLYMERASE AND ITS ACCESSORY PROTEINS ON THE PRIMER-TEMPLATE	CELL			English	Article								T4 DNA polymerase, the 44/62 and 45 polymerase accessory proteins, and 32 single-stranded DNA-binding protein catalyze ATP-dependent DNA synthesis. Using DNA primers with cross-linkable residues at specific positions, we obtained structural data that reveal how these proteins assemble on the primer-template. With the nonhydrolyzable ATP analog ATP-gamma-S, assembly of the 44/62 and 45 proteins on the primer requires 32 protein but not polymerase. ATP hydrolysis changes the position and intensity of cross-linking to each of the accessory proteins and allows cross-linking of polymerase. Our data indicate that the initial binding of the three accessory proteins and ATP to a 32 protein-covered primer-template is followed by ATP hydrolysis, binding of polymerase, and movement of the accessory proteins to yield a complex capable of processive DNA synthesis.	PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	CAPSON, TL (corresponding author), NIDDKD, NUCL ACID BIOCHEM SECT, BIOCHEM PHARMACOL LAB, BLDG 8, ROOM 2A-15, BETHESDA, MD 20892 USA.				NIGMS NIH HHS [GM 12011, GM 13306] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012011] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; BARTHOLOMEW B, 1990, J BIOL CHEM, V265, P3731; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; Bayley H, 1977, Methods Enzymol, V46, P69; BAYLEY H, 1983, LABORATORY TECHNIQUE, V12; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DISSINGER S, 1990, J BIOL CHEM, V265, P7662; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GIBSON KJ, 1987, NUCLEIC ACIDS RES, V15, P6455, DOI 10.1093/nar/15.16.6455; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; JARVIS TC, 1990, UCLA SYM BI, V127, P261; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MUNN M, 1986, THESIS U CALIFORNIA; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; RUSH J, 1989, J BIOL CHEM, V264, P10943; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WOLD MS, 1989, J BIOL CHEM, V264, P2801	42	91	91	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1991	65	2					249	258		10.1016/0092-8674(91)90159-V	http://dx.doi.org/10.1016/0092-8674(91)90159-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849797				2022-12-24	WOS:A1991FH09200008
J	BERNANDER, R; DASGUPTA, S; NORDSTROM, K				BERNANDER, R; DASGUPTA, S; NORDSTROM, K			THE ESCHERICHIA-COLI CELL-CYCLE AND THE PLASMID R1 REPLICATION CYCLE IN THE ABSENCE OF THE DNAA PROTEIN	CELL			English	Article							ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; MINICHROMOSOME REPLICATION; INITIATION; GENE; ORIGIN; EXPRESSION; MUTANTS; OVERPRODUCTION; SUPPRESSION	In E. coli strain EC::71CW chromosome replication is under the control of the R1 miniplasmid pOU71. A dnaA850::Tn10 derivative of EC::71CW was viable, which confirmed that R1 can replicate in the absence of the DnaA protein. The frequency of initiation of replication was, however, lowered and cell division was severely disturbed due to underreplication of the chromosome. Both replication and cell division could be restored to normal by increasing the production of RepA, the rate-limiting protein for initiation of replication from the integrated R1 origin. Therefore, the RepA protein seems to compensate for the absence of DnaA in the initiation of replication and assembly of replisomes. The role of the DnaA protein in the initiation of DNA replication, and as an overall regulator of the chromosome replication and cell division cycles of E. coli, is discussed in view of these results.			BERNANDER, R (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT MICROBIOL,BOX 581,S-75123 UPPSALA,SWEDEN.							ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ANDERSON P, 1981, P NATL ACAD SCI-BIOL, V78, P3113, DOI 10.1073/pnas.78.5.3113; ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BERNANDER R, 1989, J BACTERIOL, V171, P674, DOI 10.1128/jb.171.2.674-683.1989; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BREMER H, 1985, J BACTERIOL, V164, P922, DOI 10.1128/JB.164.2.922-924.1985; CHANDLER M, 1977, J BACTERIOL, V131, P421, DOI 10.1128/JB.131.2.421-430.1977; CHIARAMELLO AE, 1989, J BACTERIOL, V171, P4272, DOI 10.1128/JB.171.8.4272-4280.1989; CHURCHWARD G, 1983, MOL GEN GENET, V192, P506, DOI 10.1007/BF00392197; DONACHIE WD, 1989, J BACTERIOL, V171, P4633, DOI 10.1128/jb.171.9.4633-4639.1989; DONACHIE WD, 1984, MICROBIAL DEV, P27; GEORGOPOULOS C, 1989, TRENDS GENET, V5, P319, DOI 10.1016/0168-9525(89)90118-2; GUSTAFSSON P, 1978, PLASMID, V1, P187, DOI 10.1016/0147-619X(78)90038-0; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; KOGOMA T, 1983, EMBO J, V2, P463, DOI 10.1002/j.1460-2075.1983.tb01445.x; KOPPES L, 1986, CELL, V44, P117, DOI 10.1016/0092-8674(86)90490-3; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; Maniatis T., 1982, MOL CLONING; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MASAI H, 1983, P NATL ACAD SCI USA, V80, P6841; MESSER W, 1988, BIOCHIM BIOPHYS ACTA, V951, P351, DOI 10.1016/0167-4781(88)90106-6; Miller J.H., 1972, EXPT MOL GENETICS; MORIYA S, 1990, EMBO J, V9, P2905, DOI 10.1002/j.1460-2075.1990.tb07481.x; NAGATA T, 1988, MOL GEN GENET, V213, P163, DOI 10.1007/BF00333414; NORDSTROM K, 1980, PLASMID, V4, P215, DOI 10.1016/0147-619X(80)90011-6; NORDSTROM K, 1991, IN PRESS MOL MICROBI; ORTEGA S, 1986, NUCLEIC ACIDS RES, V14, P4865, DOI 10.1093/nar/14.12.4865; PIERUCCI O, 1987, J BACTERIOL, V169, P1871, DOI 10.1128/jb.169.5.1871-1877.1987; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; TANG XB, 1989, J BACTERIOL, V171, P5290, DOI 10.1128/jb.171.10.5290-5295.1989; XU YC, 1988, MOL GEN GENET, V211, P138, DOI 10.1007/BF00338404	40	38	38	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1991	64	6					1145	1153		10.1016/0092-8674(91)90269-5	http://dx.doi.org/10.1016/0092-8674(91)90269-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FD558	1848482				2022-12-24	WOS:A1991FD55800012
J	GILLESGONZALEZ, MA; DITTA, GS; HELINSKI, DR				GILLESGONZALEZ, MA; DITTA, GS; HELINSKI, DR			A HEMOPROTEIN WITH KINASE-ACTIVITY ENCODED BY THE OXYGEN SENSOR OF RHIZOBIUM-MELILOTI	NATURE			English	Article							ESCHERICHIA-COLI; PHOSPHORYLATION; EXPRESSION; GENES; NIFA	THE expression of the nitrogen-fixation genes of Rhizobium meliloti is controlled by oxygen 1,2. These genes are induced when the free oxygen concentration is reduced to microaerobic levels. Two regulator proteins, FixL and FixJ, initiate the oxygen-response cascade, and the genes that encode them have been cloned 2,3. The fixL product seems to be a transmembrane sensor that modulates the activity of the fixJ product, a cytoplasmic regulator 3. FixL and FixJ are homologous to a family of bacterial two-component regulators 4, for which the mode of signal transduction is phosphorylation (reviewed in refs 5-9). We report here the purification of both FixJ and a soluble truncated FixL (FixL*), overproduced from a single plasmid construct. FixL* catalyses its own phosphorylation and the transfer of the gamma-phosphate of ATP to FixJ. The resulting FixJ-phosphate linkage is sensitive to base, as are the aspartyl phosphates of homologous systems. Visible spectra of purified FixL* show that it is an oxygen-binding haemoprotein. We propose that FixL senses oxygen through its haem moiety and transduces this signal by controlling the phosphorylation of FixJ.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	GILLESGONZALEZ, MA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,0634,LA JOLLA,CA 92093, USA.							ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DITTA G, 1987, J BACTERIOL, V169, P3217, DOI 10.1128/jb.169.7.3217-3223.1987; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Gibson T.J., 1984, THESIS CAMBRIDGE U U; GROSS R, 1989, MOL MICROBIOL, V3, P1661, DOI 10.1111/j.1365-2958.1989.tb00152.x; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; MELCHERS LS, 1989, EMBO J, V8, P1919, DOI 10.1002/j.1460-2075.1989.tb03595.x; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; VIRTS EL, 1988, P NATL ACAD SCI USA, V85, P3062, DOI 10.1073/pnas.85.9.3062; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	16	435	440	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					170	172		10.1038/350170a0	http://dx.doi.org/10.1038/350170a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848683				2022-12-24	WOS:A1991FB64500065
J	SCHIEBEL, E; DRIESSEN, AJM; HARTL, FU; WICKNER, W				SCHIEBEL, E; DRIESSEN, AJM; HARTL, FU; WICKNER, W			DELTA-MU-H+ AND ATP FUNCTION AT DIFFERENT STEPS OF THE CATALYTIC CYCLE OF PREPROTEIN TRANSLOCASE	CELL			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI SECB; PURIFIED PRECURSOR PROTEIN; BACTERIAL LEADER PEPTIDASE; ENDOPLASMIC-RETICULUM; TRIGGER FACTOR; COAT PROTEIN; PRO-OMPA; MEMBRANE TRANSLOCATION; CYTOPLASMIC MEMBRANE	Preprotein translocation in E. coli requires ATP, the membrane electrochemical potential DELTA-mu-H+, and translocase, an enzyme with an ATPase domain (SecA) and the membrane-embedded SecY/E. Studies of translocase and proOmpA reveal a five-step catalytic cycle: First, proOmpA binds to the SecA domain. Second, SecA binds ATP. Third, ATP-binding energy permits translocation of approximately 20 residues of proOmpA. Fourth, ATP hydrolysis releases proOmpA. ProOmpA may then rebind to SecA and reenter this cycle, allowing progress through a series of transmembrane intermediates. In the absence of DELTA-mu-H+ or association with SecA, proOmpA passes backward through the membrane, but moves forward when either ATP and SecA or a membrane electrochemical potential is supplied. However, in the presence of DELTA-mu-H+ (fifth step), proOmpA rapidly completes translocation. DELTA-mu-H+ - driven translocation is blocked by SecA plus nonhydrolyzable ATP analogs, indicating that DELTA-mu-H+ drives translocation when ATP and proOmpA are not bound to SecA.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	SCHIEBEL, E (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.		Hartl, F. Ulrich/Y-8206-2019; Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CHEN LL, 1986, J BACTERIOL, V168, P828, DOI 10.1128/jb.168.2.828-832.1986; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DRIESSEN AJM, 1991, IN PRESS P NATL ACAD; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GELLER BL, 1989, J BIOL CHEM, V264, P16465; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; ITO K, 1980, J BIOL CHEM, V255, P2123; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUHN A, 1987, EMBO J, V6, P501, DOI 10.1002/j.1460-2075.1987.tb04781.x; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1895; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESTWEBER D, 1988, J CELL BIOL, V107, P2045, DOI 10.1083/jcb.107.6.2045; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WILSON C, 1988, J CELL BIOL, V107, P69, DOI 10.1083/jcb.107.1.69; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	58	402	408	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1991	64	5					927	939		10.1016/0092-8674(91)90317-R	http://dx.doi.org/10.1016/0092-8674(91)90317-R			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1825804				2022-12-24	WOS:A1991FA94000010
J	FRANKEL, WN; RUDY, C; COFFIN, JM; HUBER, BT				FRANKEL, WN; RUDY, C; COFFIN, JM; HUBER, BT			LINKAGE OF MLS GENES TO ENDOGENOUS MAMMARY-TUMOR VIRUSES OF INBRED MICE	NATURE			English	Article							INDUCED IMMUNODEFICIENCY SYNDROME; CHROMOSOMAL DISTRIBUTION; MOUSE CHROMOSOME-1; RETROVIRUS; LOCI; GR; DETERMINANTS; SEGREGATION; EXPRESSION; INDUCTION	T CELLS that recognize self antigen are clonally deleted in the thymus-a maturation process that occurs in the context of histocompatibility molecules and the T-cell receptor. The minor lymphocyte stimulation antigens (Mls) effect these deletions through interactions with the V-beta portion of the T-cell receptor, thus mimicking bacterial 'superantigens'. Intrigued by the fact that each known Mls gene maps to the same chromosomal region as an endogenous mouse mammary tumour virus (Mtv), we reevaluated the linkage relationships between the two gene families. Here we report perfect concordance in inbred and recombinant inbred mice between the presence of four Mtv proviruses with the expression of Mls gene products. These data suggest a general model in which mammary tumour virus gene products themselves are the ligands that shape a considerable portion of the immunological repertoire of common laboratory mice.	TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MOLEC BIOL,BOSTON,MA 02111	Tufts University; Tufts University								ABE R, 1987, J EXP MED, V165, P1113, DOI 10.1084/jem.165.4.1113; ABE R, IN PRESS IMMUNOGENET; ABROMSONLEEMAN SR, 1988, J IMMUNOL, V140, P1726; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BALL JK, 1985, VIROLOGY, V140, P159, DOI 10.1016/0042-6822(85)90455-6; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; CHO M, IN PRESS MAMM GENOME; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; EICHER EM, 1990, GENETICS, V125, P431; FESTENSTEIN H, 1977, IMMUNOGENETICS, V5, P357, DOI 10.1007/BF01570493; FRANKEL WN, 1990, GENETICS, V124, P221; GRAY DA, 1986, VIROLOGY, V148, P237, DOI 10.1016/0042-6822(86)90421-6; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KAPPLER JW, 1989, COLD SPRING HARB SYM, V54, P401; KING LB, 1990, J IMMUNOL, V144, P3218; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MACINNES JI, 1984, VIROLOGY, V132, P12, DOI 10.1016/0042-6822(84)90087-4; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; Maniatis T., 1982, MOL CLONING; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MICHALIDES R, 1985, VIROLOGY, V142, P278, DOI 10.1016/0042-6822(85)90336-8; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; MORSE HC, 1989, J IMMUNOL, V143, P844; MORSE HC, 1981, MOUSE BIOMEDICAL RES; PAULEY RJ, 1984, VIRUS RES, V1, P381, DOI 10.1016/0168-1702(84)90025-X; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PROCHAZKA M, 1990, MOUSE GENOME, V87, P111; PULLEN AM, 1989, J IMMUNOL, V142, P3033; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RYAN JJ, 1990, J IMMUNOL, V144, P2506; SELDIN MF, 1988, J IMMUNOGENET, V15, P59; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SILVER J, 1985, J HERED, V76, P436, DOI 10.1093/oxfordjournals.jhered.a110140; STOYE J, 1985, RNA TUMOR VIRUSES, P357; TRAINA VL, 1981, J VIROL, V40, P735, DOI 10.1128/JVI.40.3.735-744.1981; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	41	367	368	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					526	528		10.1038/349526a0	http://dx.doi.org/10.1038/349526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846948				2022-12-24	WOS:A1991EW57100067
J	POTTER, E; BEHAN, DP; FISCHER, WH; LINTON, EA; LOWRY, PJ; VALE, WW				POTTER, E; BEHAN, DP; FISCHER, WH; LINTON, EA; LOWRY, PJ; VALE, WW			CLONING AND CHARACTERIZATION OF THE CDNAS FOR HUMAN AND RAT CORTICOTROPIN RELEASING FACTOR-BINDING PROTEINS	NATURE			English	Article							AMINO-ACID SEQUENCE; HUMAN-PLASMA; MATERNAL PLASMA; HUMAN-PLACENTA; PREGNANCY; HORMONE; ACTH; ADRENALECTOMY; SECRETION; OXYTOCIN	CORTICOTROPIN-releasing factor (CRF)1, is a potent stimulator of synthesis and secretion of preopiomelanocortin-derived peptides. Although CRF concentrations in the human peripheral circulation are normally low 2-4, they increase throughout pregnancy 4-8 and fall rapidly after parturition. Maternal plasma CRF probably originates from the placenta, which responds to the bioactive peptide 5, 9, 10 and produces the peptide 9 and its messenger RNA 11. Even though CRF concentrations in late gestational maternal plasma are similar to those in rat hypothalamic portal blood 12,13 and to those that can stimulate release of adrenocorticotropic hormone (ACTH) in vitro, maternal plasma ACTH concentrations increase only slightly with advancing gestation and remain within the normal range 14. Several groups have now reported the existence of a CRF-binding protein in human plasma which inactivates CRF 15-20 and which has been proposed to prevent inappropriate pituitary-adrenal stimulation in pregnancy. The binding protein was recently purified from human plasma 19. We have now isolated and partially sequenced the binding protein, allowing us to clone and characterize its complementary DNA from human liver and rat brain. Expression of the cDNAs for human and rat binding protein in COS7 cells showed that these proteins bind CRF with the same affinity as the native human protein 15. Both rat and human recombinant binding proteins inhibit CRF binding to a CRF antibody and inhibit CRF-induced ACTH release by pituitary cells in vitro.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92037; UNIV READING,SCH ANIM & MICROBIAL SCI,DEPT BIOCHEM & PHYSIOL,READING RG6 2AJ,BERKS,ENGLAND	University of California System; University of California San Diego; University of Reading	POTTER, E (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN PEPTIDE BIOL,LA JOLLA,CA 92138, USA.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BEHAN DP, 1989, J ENDOCRINOL, V122, P23, DOI 10.1677/joe.0.1220023; CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054, DOI 10.1210/jcem-64-5-1054; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNAH D, 1987, J ENDOCRINOL, V113, P123, DOI 10.1677/joe.0.1130123; DESOUZA EB, 1990, CORTICOTROPIN RELEAS; ELLIS MJ, 1988, J ENDOCRINOL, V117, P299, DOI 10.1677/joe.0.1170299; FINK G, 1988, J PHYSIOL-LONDON, V401, P329, DOI 10.1113/jphysiol.1988.sp017165; FISCHER WH, IN PRESS METH NEUROS; GOLAND RS, 1986, J CLIN ENDOCR METAB, V63, P1199, DOI 10.1210/jcem-63-5-1199; GRINO M, 1987, BIOCHEM BIOPH RES CO, V148, P1208, DOI 10.1016/S0006-291X(87)80261-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAATIKAINEN T, 1987, NEUROPEPTIDES, V10, P343, DOI 10.1016/S0143-4179(87)90101-6; LINTON EA, 1987, J CLIN ENDOCR METAB, V64, P1047, DOI 10.1210/jcem-64-5-1047; LINTON EA, 1988, CLIN ENDOCRINOL, V28, P315, DOI 10.1111/j.1365-2265.1988.tb01218.x; LINTON EA, 1989, J CLIN ENDOCR METAB, V70, P174; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; ORTH DN, 1987, BIOCHEM BIOPH RES CO, V143, P411, DOI 10.1016/0006-291X(87)91369-6; PETRAGLIA F, 1987, NATURE, V328, P717, DOI 10.1038/328717a0; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; REES LH, 1975, NATURE, V254, P620, DOI 10.1038/254620b0; Sambrook J., 1989, MOL CLONING LAB MANU; SASAKI A, 1984, J CLIN ENDOCR METAB, V59, P812; SHIBASAKI T, 1982, J CLIN ENDOCR METAB, V55, P384, DOI 10.1210/jcem-55-2-384; SUDA T, 1988, J CLIN ENDOCR METAB, V67, P1278, DOI 10.1210/jcem-67-6-1278; SUDA T, 1985, J CLIN INVEST, V76, P2026, DOI 10.1172/JCI112204; SUDA T, 1989, BIOCHEM BIOPH RES CO, V165, P703, DOI 10.1016/S0006-291X(89)80023-3; Vale W, 1986, Methods Enzymol, V124, P389; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699	33	320	328	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					423	426		10.1038/349423a0	http://dx.doi.org/10.1038/349423a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846945				2022-12-24	WOS:A1991EV51400054
J	OEHEN, S; HENGARTNER, H; ZINKERNAGEL, RM				OEHEN, S; HENGARTNER, H; ZINKERNAGEL, RM			VACCINATION FOR DISEASE	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TOXIC T-CELLS; RESPIRATORY SYNCYTIAL VIRUS; RECOMBINANT VACCINIA VIRUS; MURINE MODEL; HOST DISEASE; HEPATITIS-B; MICE; IMMUNIZATION; INFECTIONS	Recombinant virus vaccines that express a limited number of epitopes are currently being developed to prevent disease by changing the relative balance between viral spread and the immune response. Some circumstances, however, were found in infections with a noncytopathic virus in which vaccination caused disease; sensitive parameters included the genetic background of the host, the time or dose of infection, and the constituents of the vaccine. Thus, immunopathologic damage by T cells may be an unwanted consequence of vaccination with the new types of peptide or recombinant vaccines that are being investigated for the human immunodeficiency viruses and other pathogens.	UNIV ZURICH, INST PATHOL, EXPTL PATHOL LAB, CH-8091 ZURICH, SWITZERLAND	University of Zurich								AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BIANCHI L, 1981, SPRINGER SEMIN IMMUN, V3, P421, DOI 10.1007/BF01951491; BOLOGNESI DP, 1989, NATURE, V340, P431, DOI 10.1038/340431a0; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Cerottini J C, 1974, Adv Immunol, V18, P67, DOI 10.1016/S0065-2776(08)60308-9; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COLE GA, 1972, NATURE, V238, P335, DOI 10.1038/238335a0; DOHERTY PC, 1974, TRANSPLANT REV-DENMA, V19, P89; DOHERTY PC, 1988, CLIN IMMUNOL IMMUNOP, V47, P19, DOI 10.1016/0090-1229(88)90141-9; EZZELL C, 1987, NATURE, V328, P747, DOI 10.1038/328747a0; FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075; GOLLINS SW, 1986, NATURE, V321, P244, DOI 10.1038/321244a0; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647; HOTCHIN J, 1962, COLD SPRING HARB SYM, V27, P479, DOI 10.1101/SQB.1962.027.001.046; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; LEHMANNGRUBE F, 1977, J GEN VIROL, V37, P85, DOI 10.1099/0022-1317-37-1-85; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEIST TP, 1988, J EXP MED, V167, P1749, DOI 10.1084/jem.167.5.1749; Mackett M., 1985, DNA CLONING PRACTICA, P191; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MICHEL F, 1988, EUR J IMMUNOL, V18, P1917, DOI 10.1002/eji.1830181208; MIMS CA, 1968, J IMMUNOL, V101, P717; MIMS CA, 1982, PATHOGENESIS INFECTI, P1; MOLLER G, 1983, IMMUNOL REV, V70, P5; MONDELLI M, 1984, SEMIN LIVER DIS, V4, P47, DOI 10.1055/s-2008-1040645; MUSTAFA AS, 1986, NATURE, V319, P63, DOI 10.1038/319063a0; NOTKINS AL, 1975, VIRAL IMMUNOLOGY IMM, P1; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; PANICALI D, 1983, P NATL ACAD SCI-BIOL, V80, P5364, DOI 10.1073/pnas.80.17.5364; PFAU CJ, 1982, J EXP MED, V156, P79, DOI 10.1084/jem.156.1.79; PFAU CJ, 1983, J GEN VIROL, V64, P1827, DOI 10.1099/0022-1317-64-8-1827; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SMITH GL, 1983, NATURE, V302, P490, DOI 10.1038/302490a0; STOTT EJ, 1985, ARCH VIROL, V84, P1, DOI 10.1007/BF01310552; VIA CS, 1987, J IMMUNOL, V139, P1840; VIA CS, 1988, IMMUNOL TODAY, V9, P207, DOI 10.1016/0167-5699(88)91215-7; ZAGURY D, 1987, NATURE, V326, P249, DOI 10.1038/326249a0; ZINKERNAGEL RM, 1986, J EXP MED, V164, P1075, DOI 10.1084/jem.164.4.1075; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0	49	102	104	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 11	1991	251	4990					195	198		10.1126/science.1824801	http://dx.doi.org/10.1126/science.1824801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET173	1824801				2022-12-24	WOS:A1991ET17300040
J	HOOTON, TM; HILLIER, S; JOHNSON, C; ROBERTS, PL; STAMM, WE				HOOTON, TM; HILLIER, S; JOHNSON, C; ROBERTS, PL; STAMM, WE			ESCHERICHIA-COLI BACTERIURIA AND CONTRACEPTIVE METHOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTION; SEXUAL INTERCOURSE; DIAPHRAGM USE; RISK-FACTORS; YOUNG-WOMEN; COLONIZATION; ASSOCIATION; FLORA	We evaluated the effects of contraceptive method on the occurrence of bacteriuria and vaginal colonization with Escherichia coli in 104 women who were evaluated prior to having sexual intercourse, the morning after intercourse, and 24 hours later. After intercourse, the prevalence of E coli bacteriuria increased slightly in oral contraceptive users but dramatically in both foam and condom users and diaphragm-spermicide users. Twenty-four hours later, the prevalence of bacteriuria remained significantly elevated only in the latter two groups. Similarly, vaginal colonization with E coli was more dramatic and persistent in users of diaphragm-spermicide and foam and condoms. Vaginal colonization with Candida species, enterococci, and staphylococci also increased significantly in diaphragm-spermicide users after intercourse. We conclude that use of the diaphragm with spermicidal jelly or use of a spermicidal foam with a condom markedly alters normal vaginal flora and strongly predisposes users to the development of vaginal colonization and bacteriuria with E coli.	UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98104	Harborview Medical Center; University of Washington; University of Washington Seattle	HOOTON, TM (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT MED,325 9TH AVE,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI012192] Funding Source: NIH RePORTER; NIAID NIH HHS [AI12192] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADATTO K, 1979, JAMA-J AM MED ASSOC, V241, P2525, DOI 10.1001/jama.241.23.2525; BUCKLEY RM, 1978, NEW ENGL J MED, V298, P321, DOI 10.1056/NEJM197802092980607; ELSTER AB, 1981, SOUTHERN MED J, V74, P704, DOI 10.1097/00007611-198106000-00018; EVANS DA, 1978, NEW ENGL J MED, V299, P536, DOI 10.1056/NEJM197809072991009; FIHN SD, 1986, J UROLOGY, V136, P853, DOI 10.1016/S0022-5347(17)45104-4; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; HSIAO V, 1986, J ADOLESCENT HEALTH, V7, P381, DOI 10.1016/S0197-0070(86)80238-8; KROHN MA, 1989, J CLIN MICROBIOL, V27, P1266, DOI 10.1128/JCM.27.6.1266-1271.1989; KUNIN CM, 1968, NEW ENGL J MED, V278, P635, DOI 10.1056/NEJM196803212781201; KUNIN CM, 1980, JAMA-J AM MED ASSOC, V243, P134; LEIBOVICI L, 1987, ARCH INTERN MED, V147, P345, DOI 10.1001/archinte.147.2.345; MCGROARTY JA, 1990, CURR MICROBIOL, V21, P219, DOI 10.1007/BF02092159; NICOLLE LE, 1982, J INFECT DIS, V146, P579, DOI 10.1093/infdis/146.5.579; PEDDIE BA, 1984, AUST NZ J OBSTET GYN, V24, P217, DOI 10.1111/j.1479-828X.1984.tb01494.x; PERCIVALSMITH R, 1983, CONTRACEPTION, V27, P497, DOI 10.1016/0010-7824(83)90046-X; REMIS RS, 1987, AM J EPIDEMIOL, V126, P685, DOI 10.1093/oxfordjournals.aje.a114708; Sobel J D, 1987, Infect Dis Clin North Am, V1, P751; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STONE KM, 1986, AM J OBSTET GYNECOL, V155, P180, DOI 10.1016/0002-9378(86)90108-0; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; Svanborg Eden C, 1987, Infect Dis Clin North Am, V1, P731; VESSEY MP, 1987, INT J EPIDEMIOL, V16, P441, DOI 10.1093/ije/16.3.441; 1988, MMWR, V37, P133; 1985, ADV DATA, V128, P1	25	102	104	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					64	69		10.1001/jama.265.1.64	http://dx.doi.org/10.1001/jama.265.1.64			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1859519				2022-12-24	WOS:A1991EP55500029
J	STERN, RS; BOUDREAUX, C; ARNDT, KA				STERN, RS; BOUDREAUX, C; ARNDT, KA			DIAGNOSTIC-ACCURACY AND APPROPRIATENESS OF CARE FOR SEBORRHEIC KERATOSES - A PILOT-STUDY OF AN APPROACH TO QUALITY ASSURANCE FOR CUTANEOUS SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In 1985 there were more than 40 million visits for ambulatory surgical procedures in the United States. Although benign cutaneous lesions are among the most frequent conditions to receive surgical treatment in ambulatory settings, their treatment is seldom subject to peer review. In this pilot study we assessed diagnostic accuracy and appropriateness of care using information available from the surgical pathology laboratory. We assessed these two measures of physician performance of 527 seborrheic keratoses removed by 133 clinicians affiliated with four different institutions. Overall, a correct preoperative diagnosis was provided in only 49% of cases. Dermatologists had the highest diagnostic accuracy (61% vs 35% for all other physicians). An appropriate procedure for the actual pathological diagnosis was performed in only 50% of cases. Lesions with a correct preoperative diagnosis were more than eight times more likely to receive appropriate care. Our data suggest that many clinicians fail to note a correct diagnosis of common cutaneous lesions before surgical removal, and many patients are treated with procedures that are more invasive than necessary for the final pathological diagnosis. Because the approach used in this pilot study relies on data already available, it has promise as a low-cost method of monitoring the quality of care of ambulatory surgery.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, CHARLES DANA RES INST, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	STERN, RS (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT DERMATOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ARNDT KA, 1989, MANUAL DERMATOLOGIC, P106; CARO WA, 1985, DERMATOLOGY, P1533; CASHMORE RW, 1985, GERIATRICS, V40, P69; CLARK RA, 1983, J AM ACAD DERMATOL, V9, P787, DOI 10.1016/S0190-9622(83)70193-3; EPSTEIN E, 1969, J AMER MED ASSOC, V208, P1369; LEADER S, 1989, HEALTH AFFAIR, V8, P158, DOI 10.1377/hlthaff.8.1.158; LEDERMAN JS, 1985, J AM ACAD DERMATOL, V13, P983, DOI 10.1016/S0190-9622(85)70249-6; MOHS FE, 1970, J AMER MED ASSOC, V212, P1956; NORMAN GR, 1989, ARCH DERMATOL, V125, P1063, DOI 10.1001/archderm.125.8.1063; PALMER RH, 1988, INQUIRY-J HEALTH CAR, V25, P119; SRZEWIECKI KT, 1980, SCAND J PLAST RECONS, V14, P141; THOMPSON MS, 1984, AM J PUBLIC HEALTH, V74, P1244, DOI 10.2105/AJPH.74.11.1244; 1990, B AM ACAD DERMATOL S, V8, P12	13	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					74	77		10.1001/jama.265.1.74	http://dx.doi.org/10.1001/jama.265.1.74			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1824572				2022-12-24	WOS:A1991EP55500031
J	FORD, C; ILIFFE, S; FRANKLIN, O				FORD, C; ILIFFE, S; FRANKLIN, O			OUTCOME OF PLANNED HOME BIRTHS IN AN INNER-CITY PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; PERINATAL-MORTALITY; MATERNITY UNITS; BRADFORD	Objective - To assess the outcome of pregnancy for women booking for home births in an inner London practice between 1977 and 1989. Design - Retrospective review of practice obstetric records. Setting - A general practice in London. Subjects - 285 women registered with the practice or referred by neighbouring general practitioners or local community midwives. Main outcome measures - Place of birth and number of cases transferred to specialist care before, during, and after labour. Results - Of 285 women who booked for home births, eight left the practice area before the onset of labour, giving a study population of 277 women. Six had spontaneous abortions, 26 were transferred to specialist care during pregnancy, another 26 were transferred during labour, and four were transferred in the postpartum period. 215 women (77.6%, 95% confidence interval 72.7 to 82.5) had normal births at home without needing specialist help. Transfer to specialist care during pregnancy was not significantly related to parity, but nulliparous women were significantly more likely to require transfer during labour (p = 0.00002). Postnatal complications requiring specialist attention were uncommon among mothers delivered at home (four cases) and rare among their babies (three cases). Conclusions - Birth at home is practical and safe for a self selected population of multiparous women, but nulliparous women are more likely to require transfer to hospital during labour because of delay in labour. Close cooperation between the general practitioner and both community midwives and hospital obstetricians is important in minimising the risks of trial of labour at home.	WHITTINGTON HOSP,DEPT PRIMARY HLTH CARE,LONDON N19 5NF,ENGLAND	University of London; University College London	FORD, C (corresponding author), 97 BRONDESBURY RD,LONDON NW6 6RY,ENGLAND.		Iliffe, Steve/L-8379-2019	Iliffe, Stephen/0000-0003-2806-3997				BALLA JI, 1989, BRIT MED J, V298, P579, DOI 10.1136/bmj.298.6673.579; BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; BRYCE FC, 1990, BRIT MED J, V300, P725, DOI 10.1136/bmj.300.6726.725; CAMBELL R, 1984, BMJ, V289, P721; CHAMBERLAIN G, 1988, PRACTITIONER, V232, P771; DIXON EA, 1982, BRIT MED J, V284, P1753, DOI 10.1136/bmj.284.6331.1753; FRANCIS RB, 1984, AM J NEPHROL, V4, P43; JENKINSON S, 1990, BRIT MED J, V301, P664; JEWELL D, 1989, BRIT MED J, V298, P690, DOI 10.1136/bmj.298.6675.690; JEWELL D, 1990, BRIT MED J, V300, P1140, DOI 10.1136/bmj.300.6732.1140; LILFORD RJ, 1987, BRIT MED J, V295, P1298, DOI 10.1136/bmj.295.6609.1298; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MARSH GN, 1989, BRIT MED J, V298, P1077, DOI 10.1136/bmj.298.6680.1077; RHODES JD, 1990, BRIT MED J, V300, P1140, DOI 10.1136/bmj.300.6732.1140-a; ROSS M, 1990, BRIT MED J, V300, P1139; RYAN TDR, 1989, BRIT MED J, V299, P1383, DOI 10.1136/bmj.299.6712.1383; SANGALA V, 1990, BRIT MED J, V301, P418, DOI 10.1136/bmj.301.6749.418; TEW M, 1985, J ROY COLL GEN PRACT, V35, P390; ZANDER L, 1984, PREGNANCY CARE 1980S, P126; 1970, DOMICILIARY MEDWIFER; 1980, PERINATAL NEONATAL M; 1984, MATERNITY CARE ACTIO, V2; 1982, REPORT RCOG WORKING	23	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1517	1519		10.1136/bmj.303.6816.1517	http://dx.doi.org/10.1136/bmj.303.6816.1517			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782494	Bronze, Green Published			2022-12-24	WOS:A1991GV47600027
J	FACCHINI, F; CHEN, YDI; HOLLENBECK, CB; REAVEN, GM				FACCHINI, F; CHEN, YDI; HOLLENBECK, CB; REAVEN, GM			RELATIONSHIP BETWEEN RESISTANCE TO INSULIN-MEDIATED GLUCOSE-UPTAKE, URINARY URIC-ACID CLEARANCE, AND PLASMA URIC-ACID CONCENTRATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; RISK FACTOR	Objective. - To define the relationship, if any, between insulin-mediated glucose disposal and serum uric acid. Design. - Cross-sectional study of healthy volunteers. Setting. - General Clinical Research Center, Stanford (Calif) University Medical Center. Participants. - Thirty-six presumably healthy individuals, nondiabetic, without a history of gout. Measurements. - Obesity (overall and regional), plasma glucose and insulin responses to a 75-g oral glucose load, fasting uric acid concentrations, plasma triglyceride and high-density lipoprotein-cholesterol concentrations, systolic and diastolic blood pressure, insulin-mediated glucose disposal, and urinary uric acid clearance. Results. - Magnitude of insulin resistance and serum uric acid concentration were significantly related (r = .69; P < .001), and the relationship persisted when differences in age, sex, overall obesity, and abdominal obesity were taken into account (r = .57; P < .001). Insulin resistance was also inversely related to urinary uric acid clearance (r= -.49; P < .002), and, in addition, urinary uric acid clearance was inversely related to serum uric acid concentration (r = -.61; P < .001). Conclusions. - Urinary uric acid clearance appears to decrease in proportion to increases in insulin resistance in normal volunteers, leading to an increase in serum uric acid concentration. Thus, it appears that modulation of serum uric concentration by insulin resistance is exerted at the level of the kidney.	VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,3801 MIRANDA AVE,PALO ALTO,CA 94304; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NCRR NIH HHS [RR-00070] Funding Source: Medline; NHLBI NIH HHS [HL-08506] Funding Source: Medline; NIDDK NIH HHS [DK-07217] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007217] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAND FN, 1985, AM J EPIDEMIOL, V121, P11, DOI 10.1093/oxfordjournals.aje.a113972; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421; GOLAY A, 1990, J CLIN ENDOCR METAB, V71, P1299, DOI 10.1210/jcem-71-5-1299; GREENFIELD MS, 1981, DIABETES, V30, P387, DOI 10.2337/diabetes.30.5.387; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; HOLLENBECK CB, 1984, DIABETES, V33, P460, DOI 10.2337/diabetes.33.5.460; HOLMES EW, 1972, KIDNEY INT, V2, P115, DOI 10.1038/ki.1972.81; KADISH AH, 1968, CLIN CHEM, V14, P116; KAGAN A, 1975, INT J EPIDEMIOL, V4, P271, DOI 10.1093/ije/4.4.271; KAPLAN AL, 1989, CLIN CHEM, P1016; KLEIN R, 1973, ARCH INTERN MED, V132, P401, DOI 10.1001/archinte.132.3.401; MODAN M, 1987, DIABETOLOGIA, V30, P713, DOI 10.1007/BF00296994; MYERS AR, 1968, AM J MED, V45, P520, DOI 10.1016/0002-9343(68)90168-X; PERSKY VW, 1979, CIRCULATION, V59, P969, DOI 10.1161/01.CIR.59.5.969; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Takkunen H, 1977, Adv Exp Med Biol, V76B, P238; TRIVEDI RC, 1978, CLIN CHEM, V24, P1908; WYNGAARDEN JB, 1976, GOUT HYPEURICEMIA; Wyngaarden JB, 1983, METABOLIC BASIS INHE, P1043; 1976, J CHRON DIS, V29, P557	21	620	655	0	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1991	266	21					3008	3011		10.1001/jama.266.21.3008	http://dx.doi.org/10.1001/jama.266.21.3008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR775	1820474				2022-12-24	WOS:A1991GR77500033
J	VERITY, CM; GOLDING, J				VERITY, CM; GOLDING, J			RISK OF EPILEPSY AFTER FEBRILE CONVULSIONS - A NATIONAL COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEIZURES; CHILDHOOD; BIRTH; FEVER	Objective - To identify children with febrile convulsions, classify their febrile convulsions into simple and complex, and determine the number and type of subsequent afebrile seizures in those children. Design - National population based study. Setting - United Kingdom. Subjects - 16004 neonatal survivors born during one week in April 1970. Main outcome measures - Information about febrile and afebrile seizures obtained from questionnaires at 5 and 10 years of age and from hospital records. Results - Information was available for 14676 of the cohort children. 398 (2.7%) of them had had at least one febrile convulsion. 16 children were known to be neurologically or developmentally abnormal before the first attack. Of the remaining 382 children, 305 had had a simple first febrile convulsion and 77 a complex first febrile convulsion. Thirteen of the 382 had had one or more afebrile seizures, nine of whom had developed epilepsy (recurrent afebrile seizures). A higher proportion of children with complex febrile convulsions (6/95) rather than simple febrile convulsions (3/287) developed epilepsy, the risk being highest for those who had had focal febrile convulsions (5/17; chi-2 = 39.9, p < 0.001). Three of the 32 children who had prolonged febrile convulsions developed afebrile complex partial seizures. Conclusions - The risk of epilepsy after febrile convulsions is much less than reported in many hospital studies, and if febrile convulsions cause brain damage that leads to later epilepsy this is a rare occurrence.	UNIV BRISTOL, INST CHILD HLTH, BRISTOL BS8 1TH, AVON, ENGLAND	University of Bristol	VERITY, CM (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Golding, Jean/0000-0003-2826-3307				ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1979, NEUROLOGY, V29, P297, DOI 10.1212/WNL.29.3.297; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1980, BMJ, V281, P277; CHAMBERLAIN R, 1975, BRITH BIRTHS 1970, V1; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; LEE K, 1981, ACTA NEUROL SCAND, V63, P231; LEVITON A, 1981, FEBRILE SEIZURES, P65; MELDRUM B S, 1976, P213; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; REYNOLDS EH, 1987, EPILEPSIA, V28, P97, DOI 10.1111/j.1528-1157.1987.tb03633.x; ROCCA WA, 1987, NEUROLOGY, V37, P1315, DOI 10.1212/WNL.37.8.1315; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; TAYLOR DC, 1971, EPILEPSIA, V12, P33, DOI 10.1111/j.1528-1157.1971.tb03913.x; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1985, BMJ-BRIT MED J, V290, P1311, DOI 10.1136/bmj.290.6478.1311; WALLACE SJ, 1975, ARCH DIS CHILD, V50, P943, DOI 10.1136/adc.50.12.943; WALLACE SJ, 1977, ARCH DIS CHILD, V52, P192, DOI 10.1136/adc.52.3.192; Wallace SJ, 1988, CHILD FEBRILE SEIZUR, P109	19	201	205	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1991	303	6814					1373	1376		10.1136/bmj.303.6814.1373	http://dx.doi.org/10.1136/bmj.303.6814.1373			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760604	Bronze, Green Published			2022-12-24	WOS:A1991GU38400021
J	WARDROPE, J; RYAN, F; CLARK, G; VENABLES, G; CROSBY, AC; REDGRAVE, P				WARDROPE, J; RYAN, F; CLARK, G; VENABLES, G; CROSBY, AC; REDGRAVE, P			THE HILLSBOROUGH TRAGEDY	BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC ASPHYXIA		ROYAL HALLAMSHIRE HOSP,ACCID & EMERGENCY MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	WARDROPE, J (corresponding author), NO GEN HOSP,ACCID & EMERGENCY MED,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							[Anonymous], 1989, BMJ, V298, P651; CHANNER KS, 1989, BRIT MED J, V299, P1379, DOI 10.1136/bmj.299.6712.1379; FRED HL, 1960, AM J MED, V29, P508, DOI 10.1016/0002-9343(60)90046-2; GORENSTEIN L, 1986, J PEDIATR SURG, V21, P753, DOI 10.1016/S0022-3468(86)80358-X; LANCE JW, 1963, BRAIN, V86, P111, DOI 10.1093/brain/86.1.111; LANDERCASPER J, 1985, J TRAUMA, V25, P838, DOI 10.1097/00005373-198509000-00005; OLLIVIER D, 1837, ANN HYGIENE, V18, P486; PLUM F, 1962, ARCH INTERN MED, V110, P18, DOI 10.1001/archinte.1962.03620190020003; PLUM F, 1981, DIAGNOSIS STUPOR COM; SANDIFORD JA, 1974, J TRAUMA, V14, P805, DOI 10.1097/00005373-197409000-00011; SHAPIRO HM, 1986, ANAESTHESIA, V2, P1573; SHARPE DT, 1985, BRIT MED J, V291, P945, DOI 10.1136/bmj.291.6500.945; Taylor P., 1989, HILLSBOROUGH STADIUM; THOMPSON A, 1989, ANN THORAC SURG, V47, P247, DOI 10.1016/0003-4975(89)90279-8; WILLIAMS JS, 1968, ANN SURG, V167, P384, DOI 10.1097/00000658-196803000-00012; 1990, EMERGENCY PLANNING N	16	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1381	1385		10.1136/bmj.303.6814.1381	http://dx.doi.org/10.1136/bmj.303.6814.1381			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760607	Green Published, Bronze			2022-12-24	WOS:A1991GU38400024
J	THOMAS, KR; MUSCI, TS; NEUMANN, PE; CAPECCHI, MR				THOMAS, KR; MUSCI, TS; NEUMANN, PE; CAPECCHI, MR			SWAYING IS A MUTANT ALLELE OF THE PROTOONCOGENE WNT-1	CELL			English	Article							MOUSE MAMMARY ONCOGENE; SEGMENT POLARITY GENE; EMBRYONIC-DEVELOPMENT; NUCLEOTIDE-SEQUENCE; RAT CEREBELLUM; INT-1 PROTOONCOGENE; MOLECULAR-CLONING; WINGLESS GENE; TUMOR VIRUS; EXPRESSION	Mice homozygous for the recessive mutation swaying (sw) am characterized by ataxia and hypertonia, attributed to the malformation of anterior regions of the cerebellum. We show that sw is a deletion of a single base pair from the proto-oncogene Wnt-1. The deletion is Predicted to cause premature termination of translation, eliminating the carboxy-terminal half of the Wnt-1 Protein. Histological examination shows that sw is phenotypically identical to a previously described wnt-1 mutation introduced into mice by gene targeting. Although both mutations in Wnt-1 disrupt primarily the development of the anterior cerebellum, they also exhibit a variability in expressivity such that rostrally adjacent structures in the midbrain and caudally adjacent structures in the posterior cerebellum can also be affected.	CHILDRENS HOSP MED CTR, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	THOMAS, KR (corresponding author), UNIV UTAH, MED CTR, COLL MED, HOWARD HUGHES MED INST, ECCLES INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA.			Neumann, Paul/0000-0002-8480-4799				ALTMAN J, 1985, J COMP NEUROL, V231, P1, DOI 10.1002/cne.902310103; ALTMAN J, 1985, J COMP NEUROL, V231, P42, DOI 10.1002/cne.902310105; ALTMAN J, 1985, J COMP NEUROL, V231, P27, DOI 10.1002/cne.902310104; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BURGESS AW, 1988, BIOESSAYS, V8, P40, DOI 10.1002/bies.950080111; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HERRUP K, 1982, NEUROSCIENCE, V7, P2185, DOI 10.1016/0306-4522(82)90129-4; HESS EJ, 1991, NEURON, V6, P123, DOI 10.1016/0896-6273(91)90127-L; Hogan B., 1986, MANIPULATING MOUSE E; Jacobson M., 2013, DEV NEUROBIOL; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; Lane P. W., 1967, MOUSE NEWS LETT, V36, P40; Lane PW, 1990, MOUSE GENOME, V86, P237; LANE PW, 1970, MOUSE NEWS LETT, V42, P30; Lyon M., 1989, GENETIC VARIANTS STR; MARTINEZ S, 1989, EUR J NEUROSCI, V1, P549, DOI 10.1111/j.1460-9568.1989.tb00362.x; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MERUELO D, 1987, IMMUNOGENETICS, V25, P361, DOI 10.1007/BF00396102; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; Mullen R. J., 1984, Chimeras in developmental biology., P353; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROSS ME, 1990, P NATL ACAD SCI USA, V87, P4189, DOI 10.1073/pnas.87.11.4189; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIDMAN R L, 1968, PHYSIOLOGICAL AND BIOCHEMICAL ASPECTS OF NERVOUS INTEGRATION, P163; Sidman RL., 1965, CATALOG NEUROLOGICAL, DOI [10.4159/harvard.9780674424326, DOI 10.4159/HARVARD.9780674424326]; SIDMAN RL, 1983, GENETICS NEUROLOGICA, P19; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	53	217	221	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1991	67	5					969	976		10.1016/0092-8674(91)90369-A	http://dx.doi.org/10.1016/0092-8674(91)90369-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835670				2022-12-24	WOS:A1991GT75500015
J	BERKELEY, MIKB; MOFFAT, MAJ; RUSSELL, D				BERKELEY, MIKB; MOFFAT, MAJ; RUSSELL, D			SURVEILLANCE OF ANTIBODY TO RUBELLA-VIRUS IN GRAMPIAN - CLOSING THE IMMUNITY GAP	BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY	Objectives - To identify causes for the continuing deficit of rubella immunity in women of childbearing age with a view to further reducing the risk of the congenital rubella syndrome. Design - A questionnaire was sent to the general practitioner and a laboratory follow up study conducted in a one year cohort of women found on screening to have inadequate protection against rubella. Setting - Virus laboratory of the department of medical microbiology, Aberdeen, serving the health board areas of Grampian, Orkney, and Shetland. Patients - 239 women whose concentration of antibodies to rubella virus was either absent or below standard (15 000 IU/l) and whose general practitioner could be contacted to supply a history of infection, immunisation, pregnancy, and antibody testing. Main outcome measures - Whether rubella vaccination was given and whether those vaccinated were tested for seroconversion. Results - Only 122 (55%) of the women for whom information was available received the recommended vaccine; only 74 (61%) of these were tested for seroconversion. Oversight was the reason given for not vaccinating 64 (65%) of the women who remained at risk. Women who were pregnant when tested were significantly less likely to receive vaccine (odds ratio 3.36) than women who were not pregnant, and even if vaccinated were less likely to have a follow up antibody test (odds ratio 1.94). Conclusion - Once women are identified as being unprotected against rubella they are often over-looked and not vaccinated. Prompting mechanisms aimed at general practitioners, such as the one recently set up in Grampian, should reduce the immunity gap and help to eradicate rubella in pregnancy.	UNIV ABERDEEN,DEPT MED MICROBIOL,MED BLDG,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen; University of Aberdeen								COOK GA, 1987, COMMUNITY MED, V9, P254; EDMOND E, 1986, BRIT J OBSTET GYNAEC, V93, P563, DOI 10.1111/j.1471-0528.1986.tb07954.x; FREESTONE DS, 1972, POSTGRAD MED J, V48, P30; MILLER CL, 1985, BRIT MED J, V291, P1398, DOI 10.1136/bmj.291.6506.1398; MILLER E, 1991, REV COMMUNICABLE DIS, V4, pR33; Morgan-Capner P, 1991, CDR (Lond Engl Rev), V1, pR57; TOOKEY PA, 1988, PUBLIC HLTH, V102, P58; 1988, DHSS PLCMO8819 DEP H; 1972, DHSS1772 DEP HLTH SO; 1983, CMO838 CHIEF MED OFF; 1970, DHSS970 DEP HLTH SOC	11	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1991	303	6811					1174	1176		10.1136/bmj.303.6811.1174	http://dx.doi.org/10.1136/bmj.303.6811.1174			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GP488	1747615	Green Published, Bronze			2022-12-24	WOS:A1991GP48800024
J	HAGAR, JM; RAHIMTOOLA, SH				HAGAR, JM; RAHIMTOOLA, SH			CHAGAS HEART-DISEASE IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN IMMIGRANTS	Background and Methods. Chagas' heart disease is believed to be rare in the United States, although many persons from countries where the disease is endemic reside here. We performed a retrospective case review and prospective follow-up of 25 patients with Chagas' heart disease and no obstructive coronary artery disease on angiography. Results. The patients mainly presented with symptomatic atrioventricular block, congestive heart failure, anginal chest pain, sudden death averted by resuscitation, or sustained ventricular tachycardia. Of the 25 patients, 18 had been treated for coronary artery disease or idiopathic dilated cardiomyopathy for up to 108 months before the diagnosis of Chagas' disease was considered. The electrocardiograms frequently suggested coronary artery disease. Six of the seven patients who had exercise thallium-perfusion scans had abnormalities suggesting ischemia or infarction. A left ventricular aneurysm was found in 14 of the 25 patients, segmental akinesia or hypokinesia in 5, and diffuse hypokinesia in 3. Programmed ventricular stimulation performed in 13 patients induced sustained ventricular tachycardia in 9 and nonsustained ventricular tachycardia in 2. Actuarial survival (mean +/- SE) after four years for the entire group was 56 +/- 12 percent; it was 32 +/- 16 percent among those with global left ventricular dysfunction, and 78 +/- 14 percent among those without such dysfunction (P = 0.03). Only patients with left ventricular dysfunction or an aneurysm died (four-year survival, 45 +/- 14 percent, as compared with 100 percent for the remaining patients; P = 0.0002). Heart failu8re and left ventricular aneurysm or dysfunction were the only independent predictors of death. Nine patients required permanent pacemakers. Conclusions. In the United States, Chagas' heart disease commonly mimics coronary artery disease or idiopathic dilated cardiomyopathy. The prognosis is poor for patients with heart failure or left ventricular aneurysm or dysfunction. The disease may be underdiagnosed in the United States.	UNIV SO CALIF, LOS ANGELES CTY MED CTR,DEPT MED,DIV CARDIOL, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California				Hagar, Mohamed Esam/0000-0003-0169-7738				ACQUATELLA H, 1987, CIRCULATION, V76, P556, DOI 10.1161/01.CIR.76.3.556; ACQUATELLA H, 1980, CIRCULATION, V62, P787, DOI 10.1161/01.CIR.62.4.787; AMORIM DS, 1979, PROGR CARDIOLOGY, V8, P235; ANSELMI A, 1966, AM HEART J, V72, P469, DOI 10.1016/0002-8703(66)90104-9; ANSELMI A, 1974, CIBA F S, V20, P125; CAMARGO ME, 1988, LABORATORY DIAGNOSIS, V1, P744; COURA JR, 1976, SCI PUBLICATION PAN, V318, P378; DEOLIVEIRA JAM, 1972, ARQ BRAS CARDIOL, V25, P17; DEPAOLA AAV, 1990, AM J CARDIOL, V65, P360, DOI 10.1016/0002-9149(90)90302-H; EARLAM RJ, 1972, AM J DIG DIS, V17, P559, DOI 10.1007/BF02231217; EDMISTON WA, 1978, WESTERN J MED, V128, P248; ESPINOSA R, 1985, INT J CARDIOL, V8, P45, DOI 10.1016/0167-5273(85)90262-1; FEIT A, 1983, ARCH INTERN MED, V143, P144, DOI 10.1001/archinte.143.1.144; KIRCHHOFF LV, 1987, AM J MED, V82, P915, DOI 10.1016/0002-9343(87)90152-5; KIRCHHOFF LV, 1985, JAMA-J AM MED ASSOC, V254, P3058, DOI 10.1001/jama.254.21.3058; LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035; LORENZAN.R, 1967, AM J CLIN PATHOL, V48, P39; MAGUIRE JH, 1987, CIRCULATION, V75, P1140, DOI 10.1161/01.CIR.75.6.1140; MAHMOUD AAF, 1975, J INFECT DIS, V132, P121, DOI 10.1093/infdis/132.1.121; Marsden P D, 1971, Int Rev Trop Med, V4, P97; MARSDEN PD, 1984, REV INFECT DIS, V6, P855; MASSUMI RA, 1965, ARCH INTERN MED, V116, P531, DOI 10.1001/archinte.116.4.531; MORRIS SA, 1990, CIRCULATION, V82, P1900, DOI 10.1161/01.CIR.82.6.1900; OLIVEIRA JSM, 1985, AM HEART J, V110, P1092, DOI 10.1016/0002-8703(85)90222-4; OLIVEIRA JSM, 1981, BRIT HEART J, V46, P432, DOI 10.1136/hrt.46.4.432; PEARLMAN JD, 1983, AM J MED, V75, P1057, DOI 10.1016/0002-9343(83)90888-4; Prata A, 1986, Rev Soc Bras Med Trop, V19, P9, DOI 10.1590/S0037-86821986000100003; PRATA AR, 1976, SCI PUBLICATION PAN, V318, P191; PUIGBO JJ, 1968, B WORLD HEALTH ORGAN, V39, P341; PUIGBO JJ, 1966, B WORLD HEALTH ORGAN, V34, P655; ROSENBAUM MB, 1964, PROG CARDIOVASC DIS, V7, P199, DOI 10.1016/S0033-0620(64)80020-7; ROSENBAUM MB, 1955, AM HEART J, V50, P492, DOI 10.1016/0002-8703(55)90296-9; SHAFII A, 1977, NEW YORK STATE J MED, V77, P418; TAKLE GB, 1989, CURR TOP MICROBIOL, V145, P79; 1990, SCI PUBLICATION 524, V1, P160; 1990, BUREAU CENSUS STATIS, P41	36	123	134	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					763	768		10.1056/NEJM199109123251103	http://dx.doi.org/10.1056/NEJM199109123251103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870649				2022-12-24	WOS:A1991GE45600003
J	RAHEMTULLA, A; FUNGLEUNG, WP; SCHILHAM, MW; KUNDIG, TM; SAMBHARA, SR; NARENDRAN, A; ARABIAN, A; WAKEHAM, A; PAIGE, CJ; ZINKERNAGEL, RM; MILLER, RG; MAK, TW				RAHEMTULLA, A; FUNGLEUNG, WP; SCHILHAM, MW; KUNDIG, TM; SAMBHARA, SR; NARENDRAN, A; ARABIAN, A; WAKEHAM, A; PAIGE, CJ; ZINKERNAGEL, RM; MILLER, RG; MAK, TW			NORMAL DEVELOPMENT AND FUNCTION OF CD8+ CELLS BUT MARKEDLY DECREASED HELPER-CELL ACTIVITY IN MICE LACKING CD4	NATURE			English	Article							EMBRYONIC STEM-CELLS; TOXIC T-CELL; HOMOLOGOUS RECOMBINATION; ANTIGEN EXPRESSION; PRECURSOR CELLS; VIRUS-INFECTION; SUBSETS; THYMOCYTES; RESPONSES; INVIVO	T CELLs express T-cell antigen receptors (TCR) for the recognition of antigen in conjunction with the products of the major histocompatibility complex 1,2. They also express two key surface coreceptors, CD4 and CD8, which are involved in the interaction with their ligands 3,4. As CD4 is expressed on the early haemopoietic progenitor 5 as well as the early thymic precursor cells 6, a role for CD4 in haemopoiesis and T-cell development is implicated. Thymocytes undergo a series of differentiation 7 and selection steps 8,9 to become mature CD4+8- or CD4-8+ (single positive) T cells 10,11. Studies of the role of CD4+ T cells in vivo have been based on adoptive transfer of selected or depleted lymphocytes, or in vivo treatment of thymectomized mice with monoclonal antibodies causing depletion of CD4+ T cells 12-14. In order to study the role of the CD4 molecule in the development and function of lymphocytes, we have disrupted the CD4 gene in embryonic stem cells 15,16 by homologous recombination 17,18. Germ-like transmission 19,20 of the mutation produces mutant mouse strains that do not express CD4 on the cell surface. In these mice, the development of CD8+ T cells and myeloid components is unaltered, indicating that expression of CD4 on progenitor cells and CD4+ CD8+ (double positive) thymocytes is not obligatory. Here we report that these mice have markedly decreased helper cell activity for antibody responses, although cytotoxic T-cell activity against viruses is in the normal range. This differential requirement for CD4+ helper T cells is important to our understanding of immune disorders, including AIDS, in which CD4+ cells are reduced or absent.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ZURICH, INST PATHOL, CH-8091 ZURICH, SWITZERLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Zurich			Schilham, Marco W./AAL-7223-2021; Sambhara, Suryaprakash/AAC-4428-2021	Schilham, Marco W./0000-0003-4391-6003; Fung-Leung, Wai-Ping/0000-0001-7013-8855				AHMED R, 1988, J VIROL, V62, P2102, DOI 10.1128/JVI.62.6.2102-2106.1988; ASHMAN RB, 1979, J EXP MED, V150, P1277, DOI 10.1084/jem.150.5.1277; BENNINK JR, 1978, NATURE, V276, P829, DOI 10.1038/276829a0; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; CANTOR H, 1975, J EXP MED, V141, P1376, DOI 10.1084/jem.141.6.1376; COBBOLD S, 1986, TRANSPLANTATION, V41, P634, DOI 10.1097/00007890-198605000-00016; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GILLIS S, 1978, J IMMUNOL, V120, P2027; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HUDSON L, 1989, PRACTICAL IMMUNOLOGY; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LEIST TP, 1987, J IMMUNOL, V138, P2278; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; NASH AA, 1987, J GEN VIROL, V68, P825, DOI 10.1099/0022-1317-68-3-825; PARNES JR, 1989, ADV IMMUNOL, V44, P265; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P897, DOI 10.1084/jem.147.3.897	34	643	658	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					180	184		10.1038/353180a0	http://dx.doi.org/10.1038/353180a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1832488				2022-12-24	WOS:A1991GE73100058
J	VANDEPERRE, P; SIMONON, A; MSELLATI, P; HITIMANA, DG; VAIRA, D; BAZUBAGIRA, A; VANGOETHEM, C; STEVENS, AM; KARITA, E; SONDAGTHULL, D; DABIS, F; LEPAGE, P				VANDEPERRE, P; SIMONON, A; MSELLATI, P; HITIMANA, DG; VAIRA, D; BAZUBAGIRA, A; VANGOETHEM, C; STEVENS, AM; KARITA, E; SONDAGTHULL, D; DABIS, F; LEPAGE, P			POSTNATAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM MOTHER TO INFANT - A PROSPECTIVE COHORT STUDY IN KIGALI, RWANDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-MILK; HIV-INFECTION; AIDS; SHEEP; CELL	Background. Although transmission of human immunodeficiency virus type 1 (HIV-1) from mother to infant has been well documented during pregnancy and delivery, little is known about the possible transmission of HIV-1 during the postnatal period. Methods. We conducted a prospective cohort study in Kigali, Rwanda, of 212 mother-infant pairs who were seronegative for HIV-1 at delivery. All the infants were breast-fed. The subjects were followed at three-month intervals, with Western blot assays for antibodies to HIV-1 and testing of mononuclear cells by a double polymerase chain reaction (PCR) using three sets of primers. To evaluate potential risk factors, each mother who seroconverted was matched with three seronegative control women. Results. After a mean follow-up of 16.6 months, 16 of the 212 mothers became seropositive for HIV-1. Of their 16 infants, 9 became seropositive. One infant was excluded from the analysis because of a positive test by PCR on the blood sample obtained at birth. Postnatal seroconversion to HIV-1 occurred in four of the five infants born to the mothers who seroconverted during the first 3 months post partum, and in four infants of the 10 mothers who seroconverted between month 4 and month 21. In all cases, the infant seroconverted during the same three-month period as the mother. The main risk factor for maternal seroconversion was being single. Conclusions. HIV-1 infection can be transmitted from mothers to infants during the postnatal period. Colostrum and breast milk may be efficient routes for the transmission of HIV-1 from recently infected mothers to their infants.	CTR HOSP,DEPT PEDIAT,KIGALI,RWANDA; UNIV BORDEAUX 2,INSERM,U330,F-33076 BORDEAUX,FRANCE; STATE UNIV LIEGE,CTR TRANSFUS,B-4000 LIEGE,BELGIUM	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Liege	VANDEPERRE, P (corresponding author), NATL AIDS CONTROL PROGRAM,AIDS REFERENCE LAB,BP 780,KIGALI,RWANDA.		DABIS, FRANCOIS/S-9298-2019; Van de Perre, Philippe/B-9692-2008	DABIS, FRANCOIS/0000-0002-1614-8857; Van de Perre, Philippe/0000-0002-3912-0427				ALLEN S, 1990, 6TH INT C AIDS SAN F, V3, P104; BUCENS M, 1988, 4TH P INT C AIDS STO, V1; COMMEAU A, 1990, GENETIC SCREENING NE, P159; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; GOLDMAN AS, 1982, J PEDIATR-US, V100, P563, DOI 10.1016/S0022-3476(82)80753-1; GOUDSMIT J, 1986, LANCET, V2, P177; HINO S, 1989, Acta Paediatrica Japonica, V31, P428; HIRA SK, 1990, J PEDIATR-US, V117, P421, DOI 10.1016/S0022-3476(05)81084-4; LAWTON JWM, 1977, LANCET, V1, P253; LEPAGE P, 1991, AIDS, V5, P295, DOI 10.1097/00002030-199103000-00008; LEPAGE P, 1981, LANCET, V2, P409; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; NARAYAN O, 1985, REV INFECT DIS, V7, P89; NATHANSON N, 1985, REV INFECT DIS, V7, P75; OXTOBY MJ, 1988, PEDIATR INFECT DIS J, V7, P825, DOI 10.1097/00006454-198807120-00001; OXTOBY MJ, 1990, PEDIATR INFECT DIS J, V9, P609; POKROVSKY VV, 1990, 6TH INT C AIDS SAN F, V1, P145; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; THIRY L, 1985, LANCET, V2, P891; TUDORWILLIAMS G, 1991, AIDS, V5, P103, DOI 10.1097/00002030-199101000-00017; VOGT MW, 1986, LANCET, V1, P525; WELSH JK, 1979, J PEDIATR-US, V94, P1, DOI 10.1016/S0022-3476(79)80340-6; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003; 1986, MMWR, V35, P76; 1985, OCT WORKSH AIDS CENT; 1989, MMWR, V38, P1	26	288	292	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					593	598		10.1056/NEJM199108293250901	http://dx.doi.org/10.1056/NEJM199108293250901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1812850	Bronze			2022-12-24	WOS:A1991GC32800001
J	KATZ, SJ; MIZGALA, HF; WELCH, HG				KATZ, SJ; MIZGALA, HF; WELCH, HG			BRITISH-COLUMBIA SENDS PATIENTS TO SEATTLE FOR CORONARY-ARTERY SURGERY - BYPASSING THE QUEUE IN CANADA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVIVAL	Concern about waiting lists for elective procedures has become a highly visible challenge to the universal health insurance program in Canada. In response to lengthening queues for patients waiting for cardiac surgery, British Columbia made contracts with four Seattle hospitals to send a total of 200 patients for coronary artery bypass surgery This article examines the cause of the queue for cardiac surgery in British Columbia and the events that led to outside contracting. Global hospital budgets and restrictions on capital expansion have limited hospital capacity for cardiac surgery This constrained supply, combined with periodic shortages in critical care nurses and cardiac perfusion technologists, has resulted in a rapid increase in the waiting list. Reducing wide variations in the lengths of queues for individual surgeons may afford an opportunity to reduce long waits. While the patient queue for cardiac surgery has sparked a public debate about budget limits and health care needs, its clinical impact remains uncertain.	UNIV BRITISH COLUMBIA,DIV CARDIOL,VANCOUVER V6T 1W5,BC,CANADA; VANCOUVER GEN HOSP,VANCOUVER V5Z 1M9,BC,CANADA; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756; DEPT VET AFFAIRS MED CTR,WHITE RIVER JCT,VT; UNIV WASHINGTON,SEATTLE,WA 98195	University of British Columbia; University of British Columbia; Dartmouth College; Dartmouth College; University of Washington; University of Washington Seattle	KATZ, SJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV GEN MED,3116 TAUBMAN,BOX 0376,ANN ARBOR,MI 48109, USA.		KATZ, STEVEN/ABH-8886-2020					ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; EVANS RG, 1982, RESOURCES HLTH TECHN; LEBOURDAIS E, 1990, CAN MED ASSOC J, V143, P306; NAYLOR CD, 1990, AM J PUBLIC HEALTH, V80, P1246, DOI 10.2105/AJPH.80.10.1246; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; WHALEN RE, 1982, CIRCULATION, V65, P49, DOI 10.1161/01.CIR.65.7.49; 1988, REPORT MINISTRY HLTH; 1984, NEW ENGL J MED, V311, P1333	8	52	52	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1108	1111		10.1001/jama.266.8.1108	http://dx.doi.org/10.1001/jama.266.8.1108			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865544				2022-12-24	WOS:A1991GB97500034
J	SCHORLE, H; HOLTSCHKE, T; HUNIG, T; SCHIMPL, A; HORAK, I				SCHORLE, H; HOLTSCHKE, T; HUNIG, T; SCHIMPL, A; HORAK, I			DEVELOPMENT AND FUNCTION OF T-CELLS IN MICE RENDERED INTERLEUKIN-2 DEFICIENT BY GENE TARGETING	NATURE			English	Article							EMBRYONIC STEM-CELLS; SEVERE COMBINED IMMUNODEFICIENCY; GERM-LINE TRANSMISSION; MOUSE INTERLEUKIN-2; HPRT GENE; RECEPTOR; ANTIBODY; DIFFERENTIATION; CULTURE	INTERLEUKIN-2 (IL-2) is a lymphocytotropic hormone which is thought to have a key role in the immune response of mammalian cells. It is produced by a subpopulation of activated T-lymphocytes and acts in vitro as the principal auto- and paracrine T-cell growth factor (for reviews see refs 1-3). IL-2 is, however, not the sole T-cell growth factor 4,5, nor does it act exclusively on T cells, also promoting growth of NK cells 6 and differentiation of B cells 7. A role for IL-2 in T-cell development has been postulated but remains controversial 8-12. Here we test the requirement for IL using IL-2-deficient mice generated by targeted recombination. We find that mice homozygous for the IL-2 gene mutation are normal with regard to thymocyte and peripheral T-cell subset composition, but that a dysregulation of the immune system is manifested by reduced polyclonal in vitro T-cell responses and by dramatic changes in the isotype levels of serum immunoglobulins.	UNIV WURZBURG, INST VIROL & IMMUNOBIOL, VERSBACHERSTR 7, W-8700 WURZBURG, GERMANY	University of Wurzburg			Schorle, Hubert/M-5001-2016; Schorle, Hubert/S-1713-2019	Schorle, Hubert/0000-0001-8272-0076; 				CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; CHENBETTECKEN U, 1985, P NATL ACAD SCI USA, V82, P7384, DOI 10.1073/pnas.82.21.7384; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FUSE A, 1984, NUCLEIC ACIDS RES, V12, P9323, DOI 10.1093/nar/12.24.9323; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JENKINSON EJ, 1987, NATURE, V329, P160, DOI 10.1038/329160a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; MACDONALD HR, 1988, IMMUNOL REV, V104, P157, DOI 10.1111/j.1600-065X.1988.tb00762.x; MOLINARO GA, 1975, EUR J IMMUNOL, V5, P771, DOI 10.1002/eji.1830051108; MOSMANN TR, 1989, PROG IMMUNOL, V7, P611; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PLUM J, 1988, EUR J IMMUNOL, V18, P795, DOI 10.1002/eji.1830180521; Shortman K, 1990, Semin Immunol, V2, P3; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TAKACS L, 1984, EUR J IMMUNOL, V14, P1152, DOI 10.1002/eji.1830141217; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZURAWSKI SM, 1988, EMBO J, V7, P1061, DOI 10.1002/j.1460-2075.1988.tb02914.x	29	780	788	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					621	624		10.1038/352621a0	http://dx.doi.org/10.1038/352621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830926				2022-12-24	WOS:A1991GB21100056
J	RAJU, U; KOUMENIS, C; NUNEZREGUEIRO, M; ESKIN, A				RAJU, U; KOUMENIS, C; NUNEZREGUEIRO, M; ESKIN, A			ALTERATION OF THE PHASE AND PERIOD OF A CIRCADIAN OSCILLATOR BY A REVERSIBLE TRANSCRIPTION INHIBITOR	SCIENCE			English	Article							PROTEIN-SYNTHESIS; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; APLYSIA EYE; RHYTHM; PACEMAKER; INVOLVEMENT; SEROTONIN; SHIFTS; CAMP	A function for transcription in the mechanism of a circadian oscillator was investigated with the reversible transcription inhibitor 5,6-dichloro-1-beta-D-ribobenzimidazole (DRB). Two-hour treatments with DR-B shifted the phase of the circadian rhythm of the isolated eye of Aplysia, and continuous treatments of DRB lengthened the free running period of this rhythm. Camptothecin, an inhibitor of transcription that is structurally unrelated to DRB, had similar effects on the circadian rhythm. These results suggest that transcription may be part of the circadian oscillating mechanism.	UNIV HOUSTON, DEPT BIOCHEM & BIOPHYS SCI, HOUSTON, TX 77204 USA	University of Houston System; University of Houston			Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	NIMH NIH HHS [MH41979] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041979, R37MH041979] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ESKIN A, 1977, J COMP PHYSIOL, V117, P1, DOI 10.1007/BF00605521; ESKIN A, 1983, SCIENCE, V220, P82, DOI 10.1126/science.6298939; ESKIN A, 1984, P NATL ACAD SCI-BIOL, V81, P7637, DOI 10.1073/pnas.81.23.7637; ESKIN A, 1982, P NATL ACAD SCI-BIOL, V79, P660, DOI 10.1073/pnas.79.2.660; FELDMAN JF, 1967, P NATL ACAD SCI USA, V57, P1080, DOI 10.1073/pnas.57.4.1080; GRANICK D, 1975, J CELL BIOL, V65, P398, DOI 10.1083/jcb.65.2.398; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARTWIG R, 1985, P NATL ACAD SCI USA, V82, P6899, DOI 10.1073/pnas.82.20.6899; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JACKLET JW, 1977, SCIENCE, V198, P69, DOI 10.1126/science.897685; JACKLET JW, 1984, INT REV CYTOL, V89, P251, DOI 10.1016/S0074-7696(08)61305-4; JACKLET JW, 1979, J EXP BIOL, V63, P222; KARAKASHIAN MW, 1962, P NATL ACAD SCI USA, V48, P2130, DOI 10.1073/pnas.48.12.2130; KHALSA SBS, 1988, J COMP PHYSIOL A, V164, P195, DOI 10.1007/BF00603950; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; KOUMENIS C, IN PRESS SOC NEUR AB; MILOS P, 1990, NATURWISSENSCHAFTEN, V77, P87, DOI 10.1007/BF01131782; NAKASHIMA J, 1986, J BIOL RHYTHM, V1, P163; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6812, DOI 10.1073/pnas.86.17.6812; RAJU U, 1990, AM J PHYSIOL, V258, pR256, DOI 10.1152/ajpregu.1990.258.1.R256; ROBERTS MH, 1989, BRAIN RES, V504, P211, DOI 10.1016/0006-8993(89)91359-0; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROTHMAN BS, 1976, J GEN PHYSIOL, V68, P359, DOI 10.1085/jgp.68.4.359; ROTHMAN BS, 1977, FED PROC, V36, P2050; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; STRUMWASSER F, 1988, J PHYSIOLOGY PARIS, V83, P246; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TAMM I, 1978, ADV VIRUS RES, V22, P188; TECHEL D, 1990, J COMP PHYSIOL B, V159, P695, DOI 10.1007/BF00691715; WOOLUM JC, 1983, J COMP PHYSIOL, V151, P253, DOI 10.1007/BF00623902; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YEUNG SJ, 1987, P NATL ACAD SCI USA, V84, P279, DOI 10.1073/pnas.84.1.279; YEUNG SJ, 1988, J BIOL RHYTHM, V3, P225, DOI 10.1177/074873048800300301; ZWARTJES RE, 1990, J NEUROBIOL, V21, P376, DOI 10.1002/neu.480210210	39	72	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					673	675		10.1126/science.1871602	http://dx.doi.org/10.1126/science.1871602			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871602				2022-12-24	WOS:A1991GA30400041
J	SZCZYLIK, C; SKORSKI, T; NICOLAIDES, NC; MANZELLA, L; MALAGUARNERA, L; VENTURELLI, D; GEWIRTZ, AM; CALABRETTA, B				SZCZYLIK, C; SKORSKI, T; NICOLAIDES, NC; MANZELLA, L; MALAGUARNERA, L; VENTURELLI, D; GEWIRTZ, AM; CALABRETTA, B			SELECTIVE-INHIBITION OF LEUKEMIA-CELL PROLIFERATION BY BCR-ABL ANTISENSE OLIGODEOXYNUCLEOTIDES	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; NORMAL HUMAN HEMATOPOIESIS; PHILADELPHIA-CHROMOSOME; SYNTHETIC OLIGONUCLEOTIDES; KINASE-ACTIVITY; PROTEIN; MICE; RNA; TRANSFORMATION	To determine the role of the BCR-ABL gene in the proliferation of blast cells of patients with chronic myelogenous leukemia, leukemia blast cells were exposed to synthetic 18-mer oligodeoxynucleotides complementary to two identified BCR-ABL junctions. Leukemia colony formation was suppressed, whereas granulocyte-macrophage colony formation from normal marrow progenitors was unaffected. When equal proportions of normal marrow progenitors and blast cells were mixed, exposed to the oligodeoxynucleotides, and assayed for residual colony formation, the majority of residual cells were normal. These findings demonstrate the requirement for a functional BCR-ABL gene in maintaining the leukemic phenotype and the feasibility of gene-targeted selective killing of neoplastic cells.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV PENN,DEPT PATHOL & MED,PHILADELPHIA,PA 19103; INST REGINA ELENA STUDIO & CURA TUMORI,I-00165 ROME,ITALY; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Malaguarnera, Lucia/K-5530-2018	Malaguarnera, Lucia/0000-0002-4516-7571; MANZELLA, Livia/0000-0002-9908-6443	NATIONAL CANCER INSTITUTE [R23CA036896, T32CA009644, R01CA036896, R01CA046782] Funding Source: NIH RePORTER; NCI NIH HHS [CA36896, CA46782, CA09644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1201, DOI 10.1056/NEJM198105143042004; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P316; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; NOWELL PC, 1960, SCIENCE, V132, P1497; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROSENTHAL S, 1977, AM J MED, V63, P542, DOI 10.1016/0002-9343(77)90199-1; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1980, ANNU REV GENET, V14, P17, DOI 10.1146/annurev.ge.14.120180.000313; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; SZCZYLIK C, UNPUB; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	34	322	353	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					562	565		10.1126/science.1857987	http://dx.doi.org/10.1126/science.1857987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857987				2022-12-24	WOS:A1991FZ34700039
J	DAAR, I; NEBREDA, AR; YEW, N; SASS, P; PAULES, R; SANTOS, E; WIGLER, M; VANDEWOUDE, GF				DAAR, I; NEBREDA, AR; YEW, N; SASS, P; PAULES, R; SANTOS, E; WIGLER, M; VANDEWOUDE, GF			THE RAS ONCOPROTEIN AND M-PHASE ACTIVITY	SCIENCE			English	Article							MOS PROTO-ONCOGENE; MATURATION-PROMOTING FACTOR; MURINE SARCOMA-VIRUS; XENOPUS OOCYTES; CELL-CYCLE; MEIOTIC MATURATION; GENE-PRODUCT; ARREST; P21; EGGS	The endogenous mos proto-oncogene product (Mos) is required for meiotic maturation In Xenopus oocytes, the ras oncogene product (Ras) can induce meiotic maturation and high levels of M-phase-promoting factor (MPF) independent of endogenous Mos, indicating that a parallel pathway to metaphase exists. In addition, Ras, like Mos and cytostatic factor, can arrest Xenopus embryonic cell cleavage in mitosis and maintain high levels of MPF. Thus, in the Xenopus oocyte and embryo systems Ras functions in the M phase of the cell cycle. The embryonic cleavage arrest assay is a rapid and sensitive test for Ras function.	NCI,FREDERIK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,FREDERICK,MD 21701; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892; LEDERLE LAB,PEARL RIVER,NY 10965; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Cold Spring Harbor Laboratory			Nebreda, Angel Rodriguez/R-9594-2019	Paules, Richard S/0000-0001-9106-7486; Daar, Ira/0000-0003-2657-526X; Wigler, Michael/0000-0003-4396-1971	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHAKALAPARAMPIL I, 1988, CELL, V52, P801; DAAR IO, UNPUB; DESPHANDE AK, 1987, MOL CELL BIOL, V7, P1285; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURKIN JP, 1987, MOL CELL BIOL, V7, P444, DOI 10.1128/MCB.7.1.444; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAYAG N, 1990, ONCOGENE, V5, P1481; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEBREDA AR, UNPUB; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARK M, 1989, METABOLIC BASIS INHE, V1, P251; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SHIBUYA E, 1989, DEVELOPMENT CAMBRIDG, V106, P779; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	42	73	73	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					74	76		10.1126/science.1829549	http://dx.doi.org/10.1126/science.1829549			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1829549				2022-12-24	WOS:A1991FV17700037
J	WARRELL, RP; FRANKEL, SR; MILLER, WH; SCHEINBERG, DA; ITRI, LM; HITTELMAN, WN; VYAS, R; ANDREEFF, M; TAFURI, A; JAKUBOWSKI, A; GABRILOVE, J; GORDON, MS; DMITROVSKY, E				WARRELL, RP; FRANKEL, SR; MILLER, WH; SCHEINBERG, DA; ITRI, LM; HITTELMAN, WN; VYAS, R; ANDREEFF, M; TAFURI, A; JAKUBOWSKI, A; GABRILOVE, J; GORDON, MS; DMITROVSKY, E			DIFFERENTIATION THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA WITH TRETINOIN (ALL-TRANS-RETINOIC ACID)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREMATURE CHROMOSOME CONDENSATION; ACUTE MYELOID-LEUKEMIA; RECEPTOR-ALPHA GENE; T(15-17) TRANSLOCATION; CELL-DIFFERENTIATION; CYTOGENETIC ANALYSIS; 15-17 TRANSLOCATION; REMISSION INDUCTION; INVITRO; PATIENT	Background and Methods. Patients with acute promyelocytic leukemia have a characteristic (15;17) translocation, with a breakpoint on chromosome 17 in the region of the retinoic acid receptor-alpha (RAR-alpha). Since this receptor has been shown to be involved with growth and differentiation of myeloid cells in vitro, and since recent clinical studies have reported that tretinoin (all-trans-retinoic acid) induces complete remission in patients with acute promyelocytic leukemia, we studied the effects of tretinoin on cellular maturation and molecular abnormalities in patients undergoing the induction of remission with this agent. Results. Eleven patients with acute promyelocytic leukemia were treated with tretinoin administered orally at a dose of 45 mg per square meter of body-surface area per day. Nine of the 11 patients entered complete remission. In two patients, complete remission was preceded by striking leukocytosis that then resolved despite continued drug treatment. Serial studies of cellular morphologic features, cell-surface immunophenotypic analysis, and fluorescence in situ hybridization with a chromosome 17 probe revealed that clinical response was associated with maturation of the leukemic clone. All patients who responded to treatment who were tested by Northern blot analysis had expression of aberrant RAR-alpha. As patients entered complete remission,the expression of the abnormal RAR-alpha message decreased markedly; however, it was still detectable in several patients after complete morphologic and cytogenetic remission had been achieved. Conclusions. Tretinoin is a safe and highly effective agent for inducing complete remission in patients with acute promyelocytic leukemia. Clinical response to this agent is associated with leukemic-cell differentiation and is linked to the expression of an aberrant RAR-alpha nuclear receptor. Molecular detection of the aberrant receptor may serve as a useful marker for residual leukemia in patients with this disease.	MEM SLOAN KETTERING CANC CTR, HEMATOPOIET CANC IMMUNOCHEM LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, LEUKOCYTE BIOL LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, MOLEC MED LAB, NEW YORK, NY 10021 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MED ONCOL, HOUSTON, TX 77030 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	WARRELL, RP (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT MED, LEUKEMIA & DEV CHEMOTHERAPY SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Tafuri, Agostino/AAC-2186-2019	Tafuri, Agostino/0000-0001-7911-9263	NCI NIH HHS [CA-09207-14] Funding Source: Medline; FDA HHS [FD-R-000674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREEFF M, 1980, BLOOD, V55, P282; ANDREEFF M, 1985, TUMOR ANEUPLOIDY, P81; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CHOMIENNE C, 1989, LANCET, V2, P746, DOI 10.1016/S0140-6736(89)90812-X; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DAENEN S, 1986, BLOOD, V67, P559; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FLYNN PJ, 1983, BLOOD, V62, P1211; FONTANA JA, 1986, CANCER-AM CANCER SOC, V57, P209, DOI 10.1002/1097-0142(19860115)57:2<209::AID-CNCR2820570204>3.0.CO;2-K; GROOPMAN J, 1979, AM J HEMATOL, V7, P395, DOI 10.1002/ajh.2830070412; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HITTELMAN WN, 1988, CANCER GENET CYTOGEN, V30, P301, DOI 10.1016/0165-4608(88)90199-9; HITTELMAN WN, 1988, BLOOD, V72, P1950; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KANTARJIAN HM, 1985, J CLIN ONCOL, V3, P793, DOI 10.1200/JCO.1985.3.6.793; KESSLER JF, 1983, LANCET, V1, P1345; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LICHTMAN MA, 1982, BLOOD, V60, P279; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MILLER WH, IN PRESS CLIN RES; MOHAMED AN, 1986, CANCER GENET CYTOGEN, V20, P209, DOI 10.1016/0165-4608(86)90076-2; MUINDI J, IN PRESS P AM SOC CL; NILSSON B, 1984, BRIT J HAEMATOL, V57, P365, DOI 10.1111/j.1365-2141.1984.tb02910.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRATT, 1990, MOL CELLULAR BIOL, V0010; SCHEINBERG DA, 1989, LEUKEMIA, V3, P440; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE RM, 1988, BLOOD, V71, P690; TERSTAPPEN LWMM, 1990, LEUKEMIA, V4, P657; TKACHUK DC, 1990, SCIENCE, V250, P559, DOI 10.1126/science.2237408; TOBLER A, 1986, J CLIN INVEST, V78, P303, DOI 10.1172/JCI112565; WALLACE PJ, 1989, AM J HEMATOL, V31, P266, DOI 10.1002/ajh.2830310410; WIJERMANS PW, 1989, BLOOD, V73, P800	48	1229	1271	2	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1991	324	20					1385	1393		10.1056/NEJM199105163242002	http://dx.doi.org/10.1056/NEJM199105163242002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL125	1850498				2022-12-24	WOS:A1991FL12500002
J	GOW, JW; BEHAN, WMH; CLEMENTS, GB; WOODALL, C; RIDING, M; BEHAN, PO				GOW, JW; BEHAN, WMH; CLEMENTS, GB; WOODALL, C; RIDING, M; BEHAN, PO			ENTEROVIRAL RNA SEQUENCES DETECTED BY POLYMERASE CHAIN-REACTION IN MUSCLE OF PATIENTS WITH POSTVIRAL FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							VIRUSES	Objective-To determine the presence of enteroviral sequences in muscle of patients with the postviral fatigue syndrome. Design-Detection of sequences with the polymerase chain reaction in a well defined group of patients with the syndrome and controls over the same period. Setting-Institute of Neurological Sciences, Glasgow. Subjects-60 consecutive patients admitted to the institute with the postviral fatigue syndrome who had undergone extensive investigation to exclude other conditions. 41 controls from the same catchment area without evidence of fatigue, all undergoing routine surgery. Main outcome measures-Routine investigations, serological screen for antibodies to a range of viruses, and presence of enteroviral RNA sequences in muscle biopsy specimens. Results-15 (25%) patients and 10 (24.4%) controls had important serological findings. 12 patients had neutralising antibody titres of greater-than-or-equal-to 256 to coxsackieviruses B1-5 (six positive for enteroviral RNA sequences, six negative); three were positive for Epstein-Barr virus specific IgM (two positive, one negative). Six controls had similar neutralising antibody titres to coxsackieviruses (all negative); one was positive for Epstein-Barr virus specific IgM (negative); and three had titres of complement fixing antibody greater-than-or-equal-to 256 to cytomegalovirus (all negative). Overall, significantly more patients than controls had enteroviral RNA sequences in muscle (32/60, 53% v 6/41, 15%; odds ratio 6.7, 95% confidence interval 2.4 to 18.2). This was not correlated with duration of disease, patient and age, or to raised titres of antibodies to coxsackieviruses B1-5. Conclusions-Persistent enteroviral infection of muscle may occur in some patients with postviral fatigue syndrome and may have an aetiological role.	UNIV GLASGOW,DEPT NEUROL,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT PATHOL,GLASGOW G12 8QQ,SCOTLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,SCOTLAND; RUCHILL HOSP,SCOTTISH SERUM BANK,GLASGOW G20 9NB,SCOTLAND	University of Glasgow; University of Glasgow								ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; CALDER BD, 1987, J ROY COLL GEN PRACT, V37, P11; CHAPMAN NM, 1990, J CLIN MICROBIOL, V28, P843, DOI 10.1128/JCM.28.5.843-850.1990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM L, 1990, J GEN VIROL, V71, P1399, DOI 10.1099/0022-1317-71-6-1399; DUBOWITZ V, 1985, MUSCLE BIOPSY PRACTI, P3; EISENSTEIN BI, 1990, NEW ENGL J MED, V322, P178; FEGAN KG, 1983, J ROY COLL GEN PRACT, V33, P335; HENDERSON DA, 1959, NEW ENGL J MED, V260, P757, DOI 10.1056/NEJM195904092601506; HERMANS A, 1988, LEUKEMIA, V2, P628; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261; JAMAL GA, 1989, EUR NEUROL, V29, P272; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; OLDSTONE MBA, 1989, J INFECT DIS, V159, P384, DOI 10.1093/infdis/159.3.384; WILFERT CM, 1977, NEW ENGL J MED, V296, P1485, DOI 10.1056/NEJM197706302962601; YOUSEF GE, 1988, LANCET, V1, P146	21	157	158	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					692	696		10.1136/bmj.302.6778.692	http://dx.doi.org/10.1136/bmj.302.6778.692			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FE333	1850635	Bronze, Green Published			2022-12-24	WOS:A1991FE33300022
J	ESCALANTE, B; ERLIJ, D; FALCK, JR; MCGIFF, JC				ESCALANTE, B; ERLIJ, D; FALCK, JR; MCGIFF, JC			EFFECT OF CYTOCHROME-P450 ARACHIDONATE METABOLITES ON ION-TRANSPORT IN RABBIT KIDNEY LOOP OF HENLE	SCIENCE			English	Article							THICK ASCENDING LIMB; ACID METABOLISM; ATPASE; SODIUM; CELLS; SUSPENSION; PUMP	In the medullary segment of the thick ascending limb of the loop of Henle (mTALH), arachidonic acid (AA) is metabolized by a cytochrome P450-dependent monooxygenase to products that affect ion transport. The linkage between changes in ion transport and AA metabolism in isolated cells of the mTALH was examined. AA produced a concentration-dependent inhibition of Rb-86 uptake - an effect that was prevented by selective blockade of cytochrome P450 monooxygenases. Inhibition by cytochrome P450 blockade of the effect of AA on Rb-86 uptake could be circumvented by addition of the principal products of AA metabolism in the mTALH.	SUNY DOWNSTATE MED CTR,DEPT PHYSIOL,BROOKLYN,NY 11203; UNIV TEXAS,HLTH SCI CTR,DEPT MOLEC GENET,DALLAS,TX 75235	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Texas System; University of Texas Dallas	ESCALANTE, B (corresponding author), NEW YORK MED COLL,DEPT PHARMACOL,VALHALLA,NY 10595, USA.			Falck, John/0000-0002-9219-7845	NHLBI NIH HHS [HL34300, R01 HL25394] Funding Source: Medline; NIDDK NIH HHS [R01 DK33612] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025394, P01HL034300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN ML, 1988, AM J PHYSIOL, V255, pF704, DOI 10.1152/ajprenal.1988.255.4.F704; CANTIELLO HF, 1988, AM J PHYSIOL, V255, pF574, DOI 10.1152/ajprenal.1988.255.4.F574; CHAMBERLIN ME, 1984, AM J PHYSIOL, V247, pF955, DOI 10.1152/ajprenal.1984.247.6.F955; DOWNING DT, 1970, BIOCHEM BIOPH RES CO, V40, P218, DOI 10.1016/0006-291X(70)91069-7; EVELOFF J, 1981, PFLUG ARCH EUR J PHY, V389, P263, DOI 10.1007/BF00584788; FERRERI NR, 1984, J PHARMACOL EXP THER, V231, P441; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; KATZ AI, 1982, AM J PHYSIOL, V242, pF207, DOI 10.1152/ajprenal.1982.242.3.F207; KINNE R, 1985, RENAL BIOCH CELLS ME, P99; MAINES MD, 1977, J BIOL CHEM, V252, P5900; Overbeck HW, 1976, CIRC RES, V38, P48, DOI 10.1161/01.RES.38.6.48; ROMERO MF, 1990, ADV PROSTAGLANDIN TH, P205; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SCHWARTZMAN ML, 1986, BIOCHEM J, V238, P283, DOI 10.1042/bj2380283; SERI I, 1988, AM J PHYSIOL, V255, pF666, DOI 10.1152/ajprenal.1988.255.4.F666; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781	16	223	225	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 15	1991	251	4995					799	802		10.1126/science.1846705	http://dx.doi.org/10.1126/science.1846705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX575	1846705				2022-12-24	WOS:A1991EX57500046
J	LEE, CC; PEARLMAN, JA; CHAMBERLAIN, JS; CASKEY, CT				LEE, CC; PEARLMAN, JA; CHAMBERLAIN, JS; CASKEY, CT			EXPRESSION OF RECOMBINANT DYSTROPHIN AND ITS LOCALIZATION TO THE CELL-MEMBRANE	NATURE			English	Article							PROTEIN PRODUCT; MUSCLE; GENE; MYOFIBERS; EFFICIENT; MICE	DUCHENNE'S muscular dystrophy (DMD) is an X-linked progressive myopathy caused by a defect in the DMD gene locus 1,2. The gene corresponding to the DMD locus produces a 14-kilobase (kb) messenger RNA that codes for a large cytoskeletal membrane protein, dystrophin 3,4. DMD and Becker's muscular dystrophy are the consequences of dystrophin mutations 4,5. The exact biological function of dystrophin remains unknown but it has been demonstrated that it is localized to the cytoplasmic face of the cell membrane and has direct interaction with several other membrane proteins 6,7. We report here the synthesis of a 14-kb full-length complementary DNA for the mouse muscle dystrophin mRNA and the expression of this cDNA in COS cells. The recombinant dystrophin is indistinguishable from mouse muscle dystrophin by western blot analysis with anti-dystrophin antibodies and was shown by an immunofluorescent technique to be localized in the cell membrane. Our successful construction of a functional full-length cDNA opens opportunities for the study of structure and function of dystrophin and provides an opportunity to initiate gene therapy studies.	BAYLOR UNIV,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR UNIV,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor University; Baylor University; Howard Hughes Medical Institute				Chamberlain, Jeffrey/0000-0001-5299-0059				CHAMBERLAIN JS, 1990, CURRENT NEUROLOGY, V10, pCH2; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; EMERGY AEH, 1987, OXFORD MONOGRAPHS ME, V15; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; MONACO AP, 1989, TRENDS BIOCHEM SCI, V14, P412, DOI 10.1016/0968-0004(89)90290-9; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	20	78	80	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					334	336		10.1038/349334a0	http://dx.doi.org/10.1038/349334a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1824797				2022-12-24	WOS:A1991EU50100054
J	MATSUI, K; BONIFACE, JJ; REAY, PA; SCHILD, H; FAZEKAS DE ST GROTH, B; DAVIS, MM				MATSUI, K; BONIFACE, JJ; REAY, PA; SCHILD, H; FAZEKAS DE ST GROTH, B; DAVIS, MM			LOW AFFINITY INTERACTION OF PEPTIDE-MHC COMPLEXES WITH T-CELL RECEPTORS	SCIENCE			English	Article							PIGEON CYTOCHROME-C; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODIES; POSITIVE SELECTION; ADHESION RECEPTORS; RECOGNITION; SPECIFICITY; PROTEINS; BIOLOGY; IA	The interaction of antigen-specific T cell receptors (TCRs) with their ligands, peptides bound to molecules of the major histocompatibility complex (MHC), is central to most immune responses, yet little is known about its chemical characteristics. The binding to T cells of a labeled monoclonal antibody to the TCR was inhibited by soluble class 11 MHC heterodimers complexed to different peptides. Inhibition was both peptide- and TCR-specific and of low affinity, with a K(D) = 4 x 10(-5) to 6 x 10(-5) M, orders of magnitude weaker than comparable antibody-antigen interactions. This finding is consistent with the scanning nature of T cell recognition and suggests that antigen-independent adhesion precedes TCR engagement.	STANFORD UNIV, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Stanford University	MATSUI, K (corresponding author), STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.		de St Groth, Barbara Fazekas/O-3017-2017	de St Groth, Barbara Fazekas/0000-0001-6817-9690; Davis, Mark/0000-0001-6868-657X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19512] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BONIFACE J, UNPUB; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CARBONE FR, 1987, J IMMUNOL, V138, P1838; CHANG TW, 1982, J IMMUNOL, V128, P585; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; DAVIS M, UNPUB; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; ELLIOT EW, UNPUB; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; GOLDSTEIN A, 1987, MOL PHARMACOL, V31, P603; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JACOBS S, 1975, BIOCHEM BIOPH RES CO, V66, P687, DOI 10.1016/0006-291X(75)90564-1; JANEWAY CA, 1989, IMMUNOL REV, V109, P77, DOI 10.1111/j.1600-065X.1989.tb00020.x; JORGENSEN JL, 1991, IN PRESS NATURE; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KRENSKY AM, 1984, J IMMUNOL, V132, P2180; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1, pCH38; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PARHAM P, 1986, HDB EXPT IMMUNOLOGY, V1, pCH14; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PINCUS MR, 1983, P NATL ACAD SCI-BIOL, V80, P3297, DOI 10.1073/pnas.80.11.3297; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REAY PA, UNPUB; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; ROCK EP, UNPUB; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SETTE A, 1989, J IMMUNOL, V143, P3289; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; Singer A., 1986, PROG IMMUNOL, V6, P60; SPITS H, 1986, SCIENCE, V232, P403, DOI 10.1126/science.3485822; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; WEISS A, 1984, J IMMUNOL, V133, P123; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	55	348	362	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1991	254	5039					1788	1791		10.1126/science.1763329	http://dx.doi.org/10.1126/science.1763329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763329				2022-12-24	WOS:A1991GW31600042
J	ODIN, JA; EDBERG, JC; PAINTER, CJ; KIMBERLY, RP; UNKELESS, JC				ODIN, JA; EDBERG, JC; PAINTER, CJ; KIMBERLY, RP; UNKELESS, JC			REGULATION OF PHAGOCYTOSIS AND [CA2+]I FLUX BY DISTINCT REGIONS OF AN FC RECEPTOR	SCIENCE			English	Article							MEDIATED PHAGOCYTOSIS; HUMAN NEUTROPHIL; ACTIVATION; EXPRESSION; HETEROGENEITY; FLUORESCENCE; GENERATION; PROTEIN; IGG	The binding of multivalent immunoglobulin G complexes to Fc receptors (Fc-gamma-Rs) on macrophages activates multiple immune functions. A murine macrophage cell fine, but not a fibroblast cell line, that was transfected with human Fc-gamma-RIIA mediated phagocytosis and an intracellular Ca2+ concentration ([Ca2+]i) flux upon cross-linking of human Fc-gamma-RIIA. Transfected macrophages that expressed a truncated receptor lacking 17 carboxy-terminal amino acids phagocytosed small antibody complexes. However, only wild-type transfectants phagocytosed labeled erythrocytes and fluxed [Ca2+]i. Thus, the cytoplasmic domain of human Fc-gamma-RIIA contains distinct functional regions.	MT SINAI MED CTR,DEPT BIOCHEM,NEW YORK,NY 10029; CORNELL UNIV,MED CTR,DEPT MED,NEW YORK,NY 10021	Icahn School of Medicine at Mount Sinai; Cornell University	UNKELESS, JC (corresponding author), MT SINAI MED CTR,DEPT BIOCHEM,NEW YORK,NY 10029, USA.			Kimberly, Robert/0000-0002-5330-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671, R01AI024322, R37AI024322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033062] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 24671, AI 24322] Funding Source: Medline; NIAMS NIH HHS [AR 33062] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSSON T, 1988, FEBS LETT, V239, P371, DOI 10.1016/0014-5793(88)80954-2; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; EDBERG JC, UNPUB; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRESHAM HD, 1990, J BIOL CHEM, V265, P7819; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOLTZMAN E, 1989, LYSOSOMES, pCH2; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; MACINTYRE EA, 1988, J IMMUNOL, V141, P4333; MARTIN MM, 1975, J LUMIN, V10, P381, DOI 10.1016/0022-2313(75)90003-4; MIDOUX P, 1987, CYTOMETRY, V8, P327, DOI 10.1002/cyto.990080314; MILLER J, 1985, J IMMUNOL, V134, P4212; MUNN DH, 1991, CANCER RES, V51, P1117; ODIN JA, 1990, RECEPTORS INFLAMMATO, V1, P1; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; Sambrook J., 1989, MOL CLONING LAB MANU; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P216; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	24	159	160	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1785	1788		10.1126/science.1837175	http://dx.doi.org/10.1126/science.1837175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1837175				2022-12-24	WOS:A1991GW31600041
J	VARTY, K; VANDORPE, J; STJOHNSTON, JA; CAMPBELL, WB				VARTY, K; VANDORPE, J; STJOHNSTON, JA; CAMPBELL, WB			WHAT HAPPENS TO PATIENTS WITH NONVASCULAR LEG PAIN	BRITISH MEDICAL JOURNAL			English	Article							NEUROGENIC CLAUDICATION; DIFFERENTIATION		ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter	CAMPBELL, WB (corresponding author), ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND.							CARTER SA, 1972, NEW ENGL J MED, V287, P749; GOODREAU JJ, 1978, SURGERY, V84, P749; SMIGIEL M, 1985, GERIATRIC CLIN N AM, V1, P373; STANTON PE, 1987, AM SURGEON, V53, P71; TAIT WF, 1985, BRIT J SURG, V72, P315, DOI 10.1002/bjs.1800720425	5	1	1	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1516	1516		10.1136/bmj.303.6816.1516	http://dx.doi.org/10.1136/bmj.303.6816.1516			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV476	1782493	Bronze, Green Published			2022-12-24	WOS:A1991GV47600026
J	BALARAJAN, R; RALEIGH, VS; YUEN, P; WHEELER, D; MACHIN, D; CARTWRIGHT, R				BALARAJAN, R; RALEIGH, VS; YUEN, P; WHEELER, D; MACHIN, D; CARTWRIGHT, R			HEALTH RISKS ASSOCIATED WITH BATHING IN SEA-WATER	BRITISH MEDICAL JOURNAL			English	Article									PUBL HLTH LAB SERV,GUILDFORD,ENGLAND		BALARAJAN, R (corresponding author), UNIV SURREY,INST PUBL HLTH,GUILDFORD GU2 5XH,SURREY,ENGLAND.			Wheeler, David/0000-0002-4058-7286				EYKIN SJ, 1988, BMJ, V296, P1484; 1990, HLTH RISKS ASS BATHI; 1990, 4TH HOUS COMM ENV CO; 1976, OFFICIAL J EURO 0205	4	48	51	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 7	1991	303	6815					1444	1445		10.1136/bmj.303.6815.1444	http://dx.doi.org/10.1136/bmj.303.6815.1444			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU385	1773151	Bronze, Green Published			2022-12-24	WOS:A1991GU38500026
J	LEE, WS; KAO, CC; BRYANT, GO; LIU, X; BERK, AJ				LEE, WS; KAO, CC; BRYANT, GO; LIU, X; BERK, AJ			ADENOVIRUS E1A ACTIVATION DOMAIN BINDS THE BASIC REPEAT IN THE TATA BOX TRANSCRIPTION FACTOR	CELL			English	Article							FUNCTIONAL DOMAINS; CELLULAR TARGETS; ESCHERICHIA-COLI; EARLY REGION-1A; INFECTED CELLS; DNA-SYNTHESIS; PROTEIN; GENE; TRANSACTIVATION; CLONING	The adenovirus large E1A protein is a potent activator of transcription. We use several different experimental approaches to demonstrate that the large E1A protein binds specifically and stably to the TATA box-binding factor (TFIID), the general polymerase II transcription factor that initiates assembly of transcription complexes. Sedimentation velocity centrifugation revealed that TFIID and E1A form a heterodimer in vitro. We demonstrate that the activation domain of E1A (conserved region 3) binds to TFIID. E1A interacts with a 51 residue region from the conserved C-terminal domain of TFIID that includes a repeat of basic residues between the homologous direct repeats of TFIID. Analysis of TFIID binding by various E1A mutants indicates that TFIID binding is necessary, although not sufficient, for E1A transactivation.			LEE, WS (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA.		BERK, ARNOLD/AAF-7052-2020		NATIONAL CANCER INSTITUTE [R37CA025235, R01CA025235] Funding Source: NIH RePORTER; NCI NIH HHS [CA25235] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DASMAHAPATRA B, 1987, NUCLEIC ACIDS RES, V15, P3933, DOI 10.1093/nar/15.9.3933; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOEIJMAKERS JHJ, 1990, NATURE, V343, P417, DOI 10.1038/343417b0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIEBERMAN PM, 1990, J VIROL, V64, P2560, DOI 10.1128/JVI.64.6.2560-2568.1990; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; NAGAI K, 1990, NATURE, V343, P418, DOI 10.1038/343418a0; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; PENNINGTON TH, 1974, J GEN VIROL, V25, P433, DOI 10.1099/0022-1317-25-3-433; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	54	376	378	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					365	376		10.1016/0092-8674(91)90188-5	http://dx.doi.org/10.1016/0092-8674(91)90188-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1833071				2022-12-24	WOS:A1991GL47000016
J	RUSTGI, AK; DYSON, N; BERNARDS, R				RUSTGI, AK; DYSON, N; BERNARDS, R			AMINO-TERMINAL DOMAINS OF C-MYC AND N-MYC PROTEINS MEDIATE BINDING TO THE RETINOBLASTOMA GENE-PRODUCT	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; DNA-BINDING; SUSCEPTIBILITY GENE; TRANSFORMATION; ONCOPROTEINS; MUTATIONS; ONCOGENES; REGIONS	THE proteins encoded by the myc gene family are involved in the control of cell proliferation and differentiation, and aberrant expression of myc proteins has been implicated in the genesis of a variety of neoplasms 1. In the carboxyl terminus, myc proteins have two domains that encode a basic domain/helix-loop-helix and a leucine zipper motif, respectively. These motifs are involved both in DNA binding and in protein dimerization 2-5. In addition, myc protein family members share several regions of highly conserved amino acids in their amino termini that are essential for transformation 6,7. We report here that an N-terminal domain present in both the c-myc and N-myc proteins mediates binding to the retinoblastoma gene product, pRb. We show that the human papilloma virus E7 protein competes with c-myc for binding to pRb, indicating that these proteins share overlapping binding sites on pRb. Furthermore, a mutant Rb protein from a human tumour cell line that carried a 35-amino-acid deletion in its C terminus failed to bind to c-myc. Our results suggest that c-myc and pRb cooperate through direct binding to control cell proliferation.	MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC ONCOL,BOSTON,MA 02150; MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02150; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	RUSTGI, AK (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC GENET,149 13TH ST,BOSTON,MA 02150, USA.			Bernards, Rene/0000-0001-8677-3423				BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PENDERGAST GC, 1991, SCIENCE, V251, P186; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	27	327	333	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					541	544		10.1038/352541a0	http://dx.doi.org/10.1038/352541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865909	Green Submitted			2022-12-24	WOS:A1991GA22600067
J	SCHAFER, DA; GELLES, J; SHEETZ, MP; LANDICK, R				SCHAFER, DA; GELLES, J; SHEETZ, MP; LANDICK, R			TRANSCRIPTION BY SINGLE MOLECULES OF RNA-POLYMERASE OBSERVED BY LIGHT-MICROSCOPY	NATURE			English	Article							TERNARY COMPLEXES; MOVEMENTS; TRACKING	THE kinetics of transcription by Escherichia coli RNA polymerase relate directly to the regulation of transcription and to the properties of processive enzymes in general 1, but analysis of RNA polymerase movement along the DNA template has so far been limited to the study of populations of enzyme molecules. The ability to view nanometre-sized particles with the light microscope 2,3 suggested a method of monitoring transcription by individual RNA polymerase molecules. We describe here the behaviour of 40-nm-diameter particles of colloidal gold attached to the ends of DNA molecules being transcribed by RNA polymerase immobilized on a glass surface. The tethered gold particles are released from the surface at times after addition of nucleoside triphosphates that are consistent with the kinetics of transcription by RNA polymerase in solution. Analysis of the brownian motion of the gold particles enabled us to measure the movement along the template DNA of individual polymerase molecules.	WASHINGTON UNIV,DEPT CELL BIOL,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Washington University (WUSTL); Washington University (WUSTL); Duke University; Brandeis University; Brandeis University				Gelles, Jeff/0000-0001-7910-3421				ALLEN RD, 1983, J MICROSC-OXFORD, V129, P3, DOI 10.1111/j.1365-2818.1983.tb04157.x; GEERTS H, 1987, BIOPHYS J, V52, P775, DOI 10.1016/S0006-3495(87)83271-X; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Press WH, 1988, NUMERICAL RECIPES C; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; YAGER TD, 1989, CELLULAR MOL BIOL, P1241	13	239	246	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					444	448		10.1038/352444a0	http://dx.doi.org/10.1038/352444a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861724				2022-12-24	WOS:A1991FZ34600070
J	LEE, B; GODFREY, M; VITALE, E; HORI, H; MATTEI, MG; SARFARAZI, M; TSIPOURAS, P; RAMIREZ, F; HOLLISTER, DW				LEE, B; GODFREY, M; VITALE, E; HORI, H; MATTEI, MG; SARFARAZI, M; TSIPOURAS, P; RAMIREZ, F; HOLLISTER, DW			LINKAGE OF MARFAN-SYNDROME AND A PHENOTYPICALLY RELATED DISORDER TO 2 DIFFERENT FIBRILLIN GENES	NATURE			English	Article							ABNORMALITIES; MICROFIBRILS; DEFECT	MARFAN Syndrome (MFS), one of the most common genetic disorders of connective tissue, is characterized by skeletal, cardiovascular and ocular abnormalities 1. The incidence of the disease is about 1 in 20,000, with life expectancy severely reduced because of cardiovascular complications. As the underlying defect is unknown, MFS diagnosis is based solely on clinical criteria. Certain phenotypic features of MFS are also shared by other conditions, which may be genetically distinct entities although part of a clinical continuum. Immunohistochemical studies have implicated fibrillin, a major component of elastin-associated microfibrils 2, in MFS aetiology 3,4. Genetic linkage analysis with random probes has independently localized the MFS locus to chromosome 15 (refs 5-7). Here we report that these two experimental approaches converge with the cloning and mapping of the fibrillin gene to chromosome 15q15-21, and with the establishment of linkage to MFS. We also isolated a second fibrillin gene and mapped it to chromosome 5q23-31. We linked this novel gene to a condition, congenital contractural arachnodactyly, that shares some of the features of MFS 1. Thus, the cosegregation of two related genes with two related syndromes implies that fibrillin mutations are likely to be responsible for different MFS phenotypes.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,1 GUSTAVE LEVY PL,NEW YORK,NY 10029; UNIV NEBRASKA,MED CTR,DEPT PEDIAT,MEYER REHABIL INST,MUNROE CTR HUMAN GENET,OMAHA,NE 68131; HOP ENFANTS LA TIMONE,INSERM,U242,F-13385 MARSEILLE,FRANCE; UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,MOLEC GENET LAB,FARMINGTON,CT 06030; TOKYO MED & DENT UNIV,MED RES INST,DEPT TISSUE PHYSIOL,TOKYO 101,JAPAN; UNIV NEBRASKA,MED CTR,DEPT PATHOL,OMAHA,NE 68131	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Connecticut; Tokyo Medical & Dental University (TMDU); University of Nebraska System; University of Nebraska Medical Center			vitale, emilia/A-5282-2011	Vitale, Emilia/0000-0003-4651-3875				BEALS RK, 1971, J BONE JOINT SURG AM, VA 53, P987, DOI 10.2106/00004623-197153050-00013; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; GODFREY M, 1990, AM J HUM GENET, V46, P652; HOLLISTER DW, 1990, NEW ENGL J MED, V323, P152, DOI 10.1056/NEJM199007193230303; INOUE S, 1986, AM J ANAT, V176, P121, DOI 10.1002/aja.1001760203; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE B, 1991, J BIOL CHEM, V266, P5256; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; MADDOX BK, 1989, J BIOL CHEM, V264, P21382; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; OTT J, 1974, AM J HUM GENET, V26, P588; PYERITZ RE, 1990, PRINCIPLES PRACTICE, P1047; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TSIPOURAS P, P NATL ACAD SCI USA, V88, P4486; WALKER BA, 1969, ANN INTERN MED, V71, P349, DOI 10.7326/0003-4819-71-2-349	19	578	600	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					330	334		10.1038/352330a0	http://dx.doi.org/10.1038/352330a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852206				2022-12-24	WOS:A1991FY28900069
J	ALBERTI, A; CHEMELLO, L; CAVALLETTO, D; TAGGER, A; DALCANTON, A; BIZZARO, N; TAGARIELLO, G; RUOL, A				ALBERTI, A; CHEMELLO, L; CAVALLETTO, D; TAGGER, A; DALCANTON, A; BIZZARO, N; TAGARIELLO, G; RUOL, A			ANTIBODY TO HEPATITIS-C VIRUS AND LIVER-DISEASE IN VOLUNTEER BLOOD-DONORS	ANNALS OF INTERNAL MEDICINE			English	Article							RECOMBINANT IMMUNOBLOT ASSAY; NON-B-HEPATITIS; NON-A; TRANSFUSION	Objective: To evaluate the specificity of antibodies to hepatitis C virus (anti-HCV) and their relation to liver disease in blood donors. Design: Case series of consecutive blood donors found positive for anti-HCV by enzyme-linked immunosorbent assay (ELISA). Patients were evaluated for antibody specificity using a recombinant immunoblotting assay (RIBA) and were evaluated for biochemical evidence of liver disease. Patients showing increased alanine aminotransferase (ALT) levels had a liver biopsy. Setting: University hospital. Participants: Fifty consecutive blood donors found to be anti-HCV positive on both an initial and repeat ELISA. Inclusion criteria were as follows: an absence of hepatitis B surface antigens and non-organ-specific autoantibodies; a daily alcohol intake of < 50 g; no history of recent hepatotoxic drug use; and normal serum levels of alpha, antitrypsin, ceruloplasmin, and copper. Main Results: Anti-HCV positivity was confirmed by RIBA in only 13 of 50 donors (26%) who had positive ELISA results. These 13 donors had an elevated ALT level and histologic evidence of chronic hepatitis, which was active in 8 patients (62%) and had already produced cirrhosis in 2 patients (15%). In contrast, the 17 donors with an intermediate RIBA pattern had only mild and often nonspecific histologic liver abnormalities. The 20 patients with a negative RIBA result had normal ALT levels. Conclusion: In blood donors, the anti-HCV RIBA is not only more specific than the anti-HCV ELISA, but is also useful in identifying patients who have an underlying chronic liver disease.	IST VIROL, MILAN, ITALY; OSPED CASTELFRANCO VENETO, CTR TRASFUS, I-31033 CASTELFRANCO VENETO, ITALY; OSPED S DONA PIAVE, S DONA PIAVE, ITALY	ULSS 2 Marca TV; Ospedale Castelfranco Veneto	ALBERTI, A (corresponding author), CLIN MED 2, VIA GIUSTINIANI 2, I-35100 PADUA, ITALY.		chemello, liliana/AAU-9414-2020; dal canton, antonio/G-4388-2013	ALBERTI, ALFREDO/0000-0001-9926-2382				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BALDI M, 1990, HEPATOLOGY, V12, P960; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; ESTEBAN JI, 1989, LANCET, V2, P294; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; SKIDMORE S, 1990, LANCET, V335, P1346, DOI 10.1016/0140-6736(90)91230-8; VANDERPOEL CL, 1990, LANCET, V336, P187, DOI 10.1016/0140-6736(90)91718-P; 1990, LANCET, V335, P1431	10	85	85	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1991	114	12					1010	1012		10.7326/0003-4819-114-12-1010	http://dx.doi.org/10.7326/0003-4819-114-12-1010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ555	1851402				2022-12-24	WOS:A1991FQ55500003
J	STRUTHERS, RS; VALE, WW; ARIAS, C; SAWCHENKO, PE; MONTMINY, MR				STRUTHERS, RS; VALE, WW; ARIAS, C; SAWCHENKO, PE; MONTMINY, MR			SOMATOTROPH HYPOPLASIA AND DWARFISM IN TRANSGENIC MICE EXPRESSING A NON-PHOSPHORYLATABLE CREB MUTANT	NATURE			English	Article							HORMONE-RELEASING FACTOR; NUCLEAR FACTOR CREB; SOMATOSTATIN GENE; PITUITARY; TRANSCRIPTION; HYPERPLASIA; BINDING; PROTEIN; CELLS	MOST of the transcriptional effects of cyclic AMP are mediated by the cAMP response element binding protein (CREB) 1, 2. After activation of cAMP-dependent protein kinase A, the catalytic subunits of this enzyme apparently mediate the phosphorylation and activation of CREB 3, 4. As cAMP serves as a mitogenic signal for anterior pituitary somatotrophic cells 5, we investigated whether CREB similarly regulates proliferation of these cells. We prepared transgenic mice expressing a transcriptionally inactive mutant of CREB (CREBM1), which cannot be phosphorylated, in cells of the anterior pituitary. If CREB activity is required for proliferation, the overexpressed mutant protein would effectively compete with wild-type CREB activity and thereby block the response to cAMP. As predicted, the CREBM1 transgenic mice exhibited a dwarf phenotype with atrophied pituitary glands markedly deficient in somatotroph but not other cell types. We conclude that transcriptional activation of CREB is necessary for the normal development of a highly restricted cell type, and that environmental cues, possibly provided by the hypothalamic growth hormone-releasing factor, are necessary for population of the pituitary by somatotrophic cells.	UNIV CALIF SAN DIEGO,GRAD PROGRAM BIOMED SCI,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,NEURONAL STRUCT & FUNCT LAB,LA JOLLA,CA 92037	University of California System; University of California San Diego; Salk Institute	STRUTHERS, RS (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BILLESTRUP N, 1987, MOL ENDOCRINOL, V1, P300, DOI 10.1210/mend-1-4-300; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BORELLI E, 1989, NATURE, V339, P593; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; GERFEN CR, 1984, BRAIN RES, V290, P219, DOI 10.1016/0006-8993(84)90940-5; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIRA SA, 1988, P NATL ACAD SCI USA, V85, P4755, DOI 10.1073/pnas.85.13.4755; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; 1986, MANIPULATING MOUSE E	21	266	268	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1991	350	6319					622	624		10.1038/350622a0	http://dx.doi.org/10.1038/350622a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH112	1826763				2022-12-24	WOS:A1991FH11200063
J	CUNNINGHAM, CC; STOSSEL, TP; KWIATKOWSKI, DJ				CUNNINGHAM, CC; STOSSEL, TP; KWIATKOWSKI, DJ			ENHANCED MOTILITY IN NIH-3T3 FIBROBLASTS THAT OVEREXPRESS GELSOLIN	SCIENCE			English	Article							MYOSIN HEAVY-CHAIN; ACTIN-FILAMENTS; CA-2+ CONTROL; DICTYOSTELIUM; BINDING; GENE; INACTIVATION; EXPRESSION; PROTEIN; CELLS	Increasing the content of the actin-binding protein gelsolin in cultured mouse fibroblasts by up to 125 percent by gene transfection proportionally enhanced the rate at which the cells migrated through porous filters toward a gradient of serum and closed a wound made on a confluent monolayer of cells in a tissue culture dish. These results provide direct evidence that gelsolin, which promotes both actin assembly and disassembly in vitro, is an important element in fibroblast locomotion and demonstrate that the manipulation of intracellular machinery can increase cell motility.			CUNNINGHAM, CC (corresponding author), MASSACHUSETTS GEN HOSP,HEMATOL ONCOL UNIT,BLDG 149,13TH ST,BOSTON,MA 02129, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07680, HL19429] Funding Source: Medline; NIAID NIH HHS [AI28465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; CHAPONNIER C, 1990, J CELL BIOL, V110, P1983; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FRANCK Z, 1990, J CELL BIOL, V111, P2478; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MEHL RE, 1988, J CELL BIOL, V106, P373; NOEGEL AA, 1988, DEV GENET, V9, P531, DOI 10.1002/dvg.1020090429; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1981, J BIOL CHEM, V256, P9693	27	276	284	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1233	1236		10.1126/science.1848726	http://dx.doi.org/10.1126/science.1848726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1848726				2022-12-24	WOS:A1991FA69100042
J	GOLDSCHMIDTCLERMONT, PJ; KIM, JW; MACHESKY, LM; RHEE, SG; POLLARD, TD				GOLDSCHMIDTCLERMONT, PJ; KIM, JW; MACHESKY, LM; RHEE, SG; POLLARD, TD			REGULATION OF PHOSPHOLIPASE-C-GAMMA-1 BY PROFILIN AND TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; BOVINE BRAIN; RECEPTOR	Epidermal growth factor and platelet-derived growth factor can stimulate the production of the second messenger inositol trisphosphate in responsive cells, but the biochemical pathway for these signaling events has been uncertain because the reactions have not been reconstituted with purified molecules in vitro. A reconstitution is described that requires not only the growth factor, its receptor with tyrosine kinase activity, and the soluble phospholipase C-gamma-1, but also the small soluble actin-binding protein profilin. Profilin binds to the substrate phosphatidylinositol 4,5-bisphosphate and inhibits its hydrolysis by unphosphorylated phospholipase C-gamma-1. Phosphorylation of phospholipase C-gamma-1 by the epidermal growth factor receptor tyrosine kinase overcomes the inhibitory effect of profilin and results in an effective activation of phospholipase C-gamma-1.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	GOLDSCHMIDTCLERMONT, PJ (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Machesky, Laura/Z-4554-2019	Machesky, Laura/0000-0002-7592-9856	NIGMS NIH HHS [GM-26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARTER HR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P119, DOI 10.1016/0167-4889(90)90213-W; GOLDSCHMIDTCLER.PJ, IN PRESS J CELL BIOL; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KIM JW, 1990, J BIOL CHEM, V265, P3940; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RHEE S, UNPUB; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, J BIOL CHEM, V262, P12511; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	29	512	515	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 8	1991	251	4998					1231	1233		10.1126/science.1848725	http://dx.doi.org/10.1126/science.1848725			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA691	1848725				2022-12-24	WOS:A1991FA69100041
J	SAWAGUCHI, T; GOLDMANRAKIC, PS				SAWAGUCHI, T; GOLDMANRAKIC, PS			D1 DOPAMINE-RECEPTORS IN PREFRONTAL CORTEX - INVOLVEMENT IN WORKING MEMORY	SCIENCE			English	Article							CEREBRAL-CORTEX; TYROSINE-HYDROXYLASE; HUMAN-BRAIN; AUTORADIOGRAPHIC DISTRIBUTION; H-3 RACLOPRIDE; RHESUS-MONKEY; D-2 RECEPTORS; SCH 23390; INNERVATION; BINDING	The prefrontal cortex is involved in the cognitive process of working memory. Local injections of SCH23390 and SCH39166, selective antagonists of the D1 dopamine receptor, into the prefrontal cortex of rhesus monkeys induced errors and increased latency in performance on an oculomotor task that required memory-guided saccades. The deficit was dose-dependent and sensitive to the duration of the delay period. These D1 antagonists had no effect on performance in a control task requiring visually guided saccades, indicating that sensory and motor functions were unaltered. Thus, D1 dopamine receptors play a selective role in the mnemonic, predictive functions of the primate prefrontal cortex.			SAWAGUCHI, T (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH044866, R37MH038546, R01MH038546] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38546, MH44866] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERGER B, 1989, Society for Neuroscience Abstracts, V15, P428; BERGER B, 1988, J COMP NEUROL, V273, P99, DOI 10.1002/cne.902730109; BISCHOFF S, 1986, EUR J PHARMACOL, V129, P367, DOI 10.1016/0014-2999(86)90449-8; BROWN RM, 1979, BRAIN RES, V168, P133, DOI 10.1016/0006-8993(79)90132-X; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CAMPS M, 1989, NEUROSCIENCE, V28, P275, DOI 10.1016/0306-4522(89)90179-6; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093; CORTES R, 1989, NEUROSCIENCE, V28, P263, DOI 10.1016/0306-4522(89)90178-4; FARDE L, 1988, PSYCHOPHARMACOLOGY, V94, P471, DOI 10.1007/BF00212840; FARDE L, 1987, PSYCHOPHARMACOLOGY, V92, P278, DOI 10.1007/BF00210831; FUNAHASHI S, 1986, Society for Neuroscience Abstracts, V12, P554; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; GASPAR P, 1989, J COMP NEUROL, V279, P249, DOI 10.1002/cne.902790208; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1990, J NEUROSCI, V10, P2125; HALL H, 1988, J NEURAL TRANSM, V73, P7, DOI 10.1007/BF01244618; KEBABIAN JW, 1986, TRENDS PHARMACOL SCI, V7, P96, DOI 10.1016/0165-6147(86)90272-5; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KOHLER C, 1985, BIOCHEM PHARMACOL, V34, P2251, DOI 10.1016/0006-2952(85)90778-6; LEVITT P, 1984, J COMP NEUROL, V225, P1; LEWIS DA, 1988, BRAIN RES, V449, P225, DOI 10.1016/0006-8993(88)91040-2; LEWIS DA, 1987, J NEUROSCI, V7, P279; LIDOW MS, 1989, P NATL ACAD SCI USA, V86, P6412, DOI 10.1073/pnas.86.16.6412; MEMO M, 1986, J NEURAL TRANSM-SUPP, V22, P19; MYERS RD, 1966, PHYSIOL BEHAV, V1, P171, DOI 10.1016/0031-9384(66)90064-3; RICHFIELD EK, 1989, J COMP NEUROL, V286, P409, DOI 10.1002/cne.902860402; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1385, DOI 10.1152/jn.1990.63.6.1385; SAWAGUCHI T, 1988, NEUROSCI RES, V5, P465, DOI 10.1016/0168-0102(88)90030-2	28	1066	1081	5	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					947	950		10.1126/science.1825731	http://dx.doi.org/10.1126/science.1825731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	1825731				2022-12-24	WOS:A1991EY62900048
J	PETERS, PJ; NEEFJES, JJ; OORSCHOT, V; PLOEGH, HL; GEUZE, HJ				PETERS, PJ; NEEFJES, JJ; OORSCHOT, V; PLOEGH, HL; GEUZE, HJ			SEGREGATION OF MHC CLASS-II MOLECULES FROM MHC CLASS-I MOLECULES IN THE GOLGI-COMPLEX FOR TRANSPORT TO LYSOSOMAL COMPARTMENTS	NATURE			English	Article							MANNOSE 6-PHOSPHATE; RECEPTORS; ANTIGEN; CHAINS; CELLS; PATHWAYS; ASIALOGLYCOPROTEIN; BIOSYNTHESIS; HEPATOCYTES; ENDOCYTOSIS	Traffic of MHC molecules dictates the source of peptides that are presented to T cells. The intracellular distribution of MHC class I and class II molecules reflects the dichotomy in presentation of antigen from endogenous and exogenous origin, respectively. In human B lymphoblastoid cells, class I molecules are present in compartments constituting the biosynthetic pathway, whereas class II molecules enter structures related to lysosomes during their biosynthesis.	NETHERLANDS CANC INST, DEPT CELLULAR BIOCHEM, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute	PETERS, PJ (corresponding author), STATE UNIV UTRECHT, SCH MED, CELL BIOL LAB, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS.		Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				ACTON SL, 1990, J CELL BIOL, V111, P1419, DOI 10.1083/jcb.111.4.1419; ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRODSKY FM, 1984, IMMUNOL TODAY, V5, P350, DOI 10.1016/0167-5699(84)90078-1; CHAIN BM, 1988, IMMUNOL REV, V106, P33, DOI 10.1111/j.1600-065X.1988.tb00772.x; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; DARNELL J, 1990, MOL CELL BIOL, P596; DAVIS JE, 1990, J IMMUNOL, V144, P990; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HAMMERLING GJ, 1990, IMMUNOL TODAY, V11, P337; HOPKINS CR, 1986, TRENDS BIOCHEM SCI, V11, P473, DOI 10.1016/0968-0004(86)90250-1; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; KLAUSNER R D, 1989, New Biologist, V1, P3; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; MACHY P, 1990, J IMMUNOL, V145, P1350; METZELAAR MJ, IN PRESS J BIOL CHEM; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NGUYEN QV, 1989, HUM IMMUNOL, V24, P153, DOI 10.1016/0198-8859(89)90056-6; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; OTTEN G, 1989, CURR OPIN IMMUNOL, V2, P204, DOI 10.1016/0952-7915(89)90189-1; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROTH J, 1984, J BIOL CHEM, V93, P350; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ AL, 1990, ANNU REV IMMUNOL, V8, P195, DOI 10.1146/annurev.immunol.8.1.195; SLOT JW, 1989, AM J ANAT, V185, P271, DOI 10.1002/aja.1001850220; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, IN PRESS J CELL BIOL; STAM NJ, 1986, J IMMUNOL, V137, P2299; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; TASSIN MT, 1990, EUR J CELL BIOL, V52, P219; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	51	628	633	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 21	1991	349	6311					669	676		10.1038/349669a0	http://dx.doi.org/10.1038/349669a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY627	1847504				2022-12-24	WOS:A1991EY62700038
J	BASHIR, ZI; ALFORD, S; DAVIES, SN; RANDALL, AD; COLLINGRIDGE, GL				BASHIR, ZI; ALFORD, S; DAVIES, SN; RANDALL, AD; COLLINGRIDGE, GL			LONG-TERM POTENTIATION OF NMDA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION IN THE HIPPOCAMPUS	NATURE			English	Article							COLLATERAL-COMMISSURAL PATHWAY; D-ASPARTATE RECEPTORS; MOUSE CENTRAL NEURONS; SPINAL-CORD NEURONS; RAT HIPPOCAMPUS; ACTIVATION; ANTAGONISTS; EXPRESSION; INDUCTION; RESPONSES	Neurotransmission at most excitatory synapses in the brain operates through two types of glutamate receptor termed alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and N-methyl-D-aspartate (NMDA) receptors; these mediate the fast and slow components of excitatory postsynaptic potentials respectively 1-3. Activation of NMDA receptors can also lead to a long-lasting modification in synaptic efficiency at glutamatergic synapses; this is exemplified in the CAl region of the hippocampus, where NMDA receptors mediate the induction of long-term potentiation (LTP) 4. It is believed that in this region LTP is maintained by a specific increase in the AMPA receptor-mediated synaptic response can undergo robust, synapse-specific LTP. This findings has implications for neuropathologies such as epilepsy and neurodegeneration, in which excessive NMDA receptor activation has been implicated 7. It adds fundamentally to theories of synaptic plasticity because NMDA receptor activation may, in addition to causing increased synaptic efficiency, directly alter the plasticity of synapses.	UNIV BRISTOL, SCH MED SCI, DEPT PHARMACOL, BRISTOL BS8 1TD, AVON, ENGLAND; UNIV BIRMINGHAM, SCH MED, DEPT PHARMACOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol; University of Birmingham; University of Bristol			collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015	Collingridge, Graham L/0000-0002-9572-5359; Randall, Andrew/0000-0001-8852-3671; Bashir, Zafar/0000-0003-3650-2136; Alford, Simon/0000-0002-0454-4246	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTOLA A, 1990, EUR J NEUROSCI, V2, P254, DOI 10.1111/j.1460-9568.1990.tb00417.x; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BINDMAN LJ, 1988, J PHYSIOL-LONDON, V406, pP176; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P283; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1985, J PHYSIOL-LONDON, V363, P35, DOI 10.1113/jphysiol.1985.sp015694; DANGELO E, 1990, NATURE, V346, P467, DOI 10.1038/346467a0; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DINGLEDINE R, 1986, J PHYSIOL-LONDON, V380, P175, DOI 10.1113/jphysiol.1986.sp016279; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; LEONARD J P, 1989, Society for Neuroscience Abstracts, V15, P535; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RANDALL AD, 1990, NEUROSCI LETT, V114, P191, DOI 10.1016/0304-3940(90)90070-P; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; SLATER NT, 1985, NEUROSCI LETT, V60, P25, DOI 10.1016/0304-3940(85)90376-3; STASHEFF SF, 1989, SCIENCE, V245, P648, DOI 10.1126/science.2569762; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	31	318	325	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 10	1991	349	6305					156	158		10.1038/349156a0	http://dx.doi.org/10.1038/349156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1846031				2022-12-24	WOS:A1991ER41800058
J	PEPIN, MC; POTHIER, F; BARDEN, N				PEPIN, MC; POTHIER, F; BARDEN, N			IMPAIRED TYPE-II GLUCOCORTICOID-RECEPTOR FUNCTION IN MICE BEARING ANTISENSE RNA TRANSGENE	NATURE			English	Article							OBESE ZUCKER RAT; MESSENGER-RNA; PROTEIN; CELLS; BRAIN; BINDING; ADRENOCORTICOTROPIN; ADRENALECTOMY; INHIBITION; EXPRESSION	GLUCOCORTICOIDS, in conjunction with their cognate receptors, exert negative-feedback effects on the hypothalamus-pituitary-adrenal axis, suppressing adrenal steroid secretions. Two types of corticosteroid receptor, distinguishable by their ability to bind corticosterone, have been identified as classical mineralocorticoid (type I) 1 and glucocorticoid (type II) 2 receptors by cloning their complementary DNAs. The type I receptor controls the basal circadian rhythm of corticosteroid secretion. Both receptor types are involved in negative feedback 3, but the type II receptor may be more important for terminating the stress response as it is the only one to be increased in animals rendered more sensitive to corticosteroid negative-feedback effects 4 . Here we create a transgenic mouse with impaired corticosteroid-receptor function by partially knocking out gene expression with type II glucocorticoid receptor antisense RNA. We use this animal to study the glucocorticoid feedback effect on the hypothalamus-pituitary-adrenal axis.	CHU LAVAL,RES CTR,DEPT PHYSIOL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; CHU LAVAL,DEPT ZOOTECHNIE,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; UNIV LAVAL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA	Laval University; Laval University; Laval University	PEPIN, MC (corresponding author), CHU LAVAL,RES CTR,MOLEC PSYCHOGENET LAB,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.							ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL BJ, 1976, ARCH GEN PSYCHIAT, V33, P1039; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FARMER SR, 1983, MOL CELL BIOL, V3, P182, DOI 10.1128/MCB.3.2.182; FLETCHER JM, 1986, BRIT J NUTR, V56, P141, DOI 10.1079/BJN19860094; FREEDMAN MR, 1986, AM J PHYSIOL, V250, pR595, DOI 10.1152/ajpregu.1986.250.4.R595; FUNDER JW, 1987, ANNU REV PHYSIOL, V49, P397; GIGUERE V, 1982, ENDOCRINOLOGY, V110, P1225, DOI 10.1210/endo-110-4-1225; GREDEN JF, 1983, ARCH GEN PSYCHIAT, V40, P493; Hogan B., 1986, MANIPULATING MOUSE E; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; KATSUKI M, 1988, SCIENCE, V241, P593, DOI 10.1126/science.2456614; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; LANGLEY SC, 1990, BRAIN RES, V533, P268, DOI 10.1016/0006-8993(90)91349-L; LINKOWSKI P, 1985, J CLIN ENDOCR METAB, V61, P429, DOI 10.1210/jcem-61-3-429; MCGARRY TJ, 1986, P NATL ACAD SCI USA, V83, P399, DOI 10.1073/pnas.83.2.399; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; PEIFFER A, 1991, PSYCHONEUROENDOCRINO, V16, P505, DOI 10.1016/0306-4530(91)90034-Q; PEPIN MC, 1989, MOL BRAIN RES, V6, P77, DOI 10.1016/0169-328X(89)90031-4; PEPIN MC, 1991, MOL CELL BIOL, V11, P1647, DOI 10.1128/MCB.11.3.1647; PROVENCHER P, 1990, J STEROID BIOCHEM, V36, P589, DOI 10.1016/0022-4731(90)90177-T; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; SVEC F, 1981, J BIOL CHEM, V256, P5984; TORNELLO S, 1982, NEUROENDOCRINOLOGY, V35, P411, DOI 10.1159/000123429; WHITE BD, 1990, J STEROID BIOCHEM, V36, P681, DOI 10.1016/0022-4731(90)90188-X	30	284	292	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					725	728		10.1038/355725a0	http://dx.doi.org/10.1038/355725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741058				2022-12-24	WOS:A1992HE60400063
J	WAWER, MJ; SERWADDA, D; MUSGRAVE, SD; KONDELULE, JK; MUSAGARA, M; SEWANKAMBO, NK				WAWER, MJ; SERWADDA, D; MUSGRAVE, SD; KONDELULE, JK; MUSAGARA, M; SEWANKAMBO, NK			DYNAMICS OF SPREAD OF HIV-I INFECTION IN A RURAL DISTRICT OF UGANDA	BRITISH MEDICAL JOURNAL			English	Article							VIRUS-INFECTION; IVORY-COAST; PREVALENCE; POPULATION; TANZANIA; REGION; AIDS	Objective - To define the geographical distribution of HIV infection and the community characteristics associated with HIV prevalence in a rural population of Uganda. Design - Seroprevalence survey and interviews of the population aged 13 years and older in 21 randomly selected clusters. Setting - Rural population of Rakai district, south west Uganda. Subjects - 1292 adults, of whom 594 men and 698 women gave a blood sample and answered the questionnaire. Main outcome measures - HIV status determined by ELISA and western blotting in relation to community characteristics. Results - The weighted seroprevalence of HIV for the district was 12.6% with prevalence by cluster varying from 1.2% to 52.8%. Seroprevalence was highest in main road trading centres (men 26%, women 47%), intermediate in rural trading villages on secondary roads (men 22%, women 29%), and lowest in rural agricultural villages (men 8%, women 9%). For both men and women, multiple regression showed a strong negative association between cluster seroprevalence and the proportion of the population employed in agriculture (beta = -0.677 for men, -0.807 for women). Among women, cluster seroprevalence increased with a higher proportion of the population reporting multiple sex partners (beta = 0.814), external travel (beta = 0.579), and injections (beta = 0.483). Conclusions - Community characteristics, particularly the proportion of the population in agriculture, are associated with HIV prevalence and can be used for targeting interventions. The seroprevalences of HIV suggest spread of infection from main road trading centres, through intermediate trading villages, to rural agricultural villages.	MULAGO HOSP,DEPT MED,KAMPALA,UGANDA; UGANDAN MINIST HLTH,RAKAI PROJECT,ENTEBBE,UGANDA; MAKERERE UNIV,DEPT MED,KAMPALA,UGANDA; MAKERERE UNIV,INST PUBL HLTH,KAMPALA,UGANDA	Mulago National Referral Hospital; Makerere University; Makerere University	WAWER, MJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,CTR POPULAT & FAMILY HLTH,NEW YORK,NY 10032, USA.			Sewankambo, Nelson/0000-0001-9362-053X	PHS HHS [R01-A129314-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARSWELL JW, 1989, AIDS, V3, P759, DOI 10.1097/00002030-198911000-00013; CARSWELL JW, 1987, AIDS, V1, P223; Cochran W. G., 1977, SAMPLING TECHNIQUES; DECOCK KM, 1989, LANCET, V2, P408; DELALLA F, 1988, AIDS, V2, P317, DOI 10.1097/00002030-198808000-00013; DENIS F, 1987, LANCET, V1, P408; DOLMANS WMV, 1989, AIDS, V3, P297, DOI 10.1097/00002030-198905000-00008; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KILLEWO J, 1990, AIDS, V4, P1081, DOI 10.1097/00002030-199011000-00005; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; NAAMARA W, 1988, 2ND P INT C AIDS AFR; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PLORDE DS, 1981, BRIT J VENER DIS, V57, P357; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; WILCOX RR, 1980, BR J VENER DIS, V56, P277	16	108	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1991	303	6813					1303	1306		10.1136/bmj.303.6813.1303	http://dx.doi.org/10.1136/bmj.303.6813.1303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT011	1747672	Green Published, Bronze			2022-12-24	WOS:A1991GT01100021
J	GRAY, JT; CELANDER, DW; PRICE, CM; CECH, TR				GRAY, JT; CELANDER, DW; PRICE, CM; CECH, TR			CLONING AND EXPRESSION OF GENES FOR THE OXYTRICHA TELOMERE-BINDING PROTEIN - SPECIFIC SUBUNIT INTERACTIONS IN THE TELOMERIC COMPLEX	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; TETRAHYMENA TRANSFER-RNASGLN; SIZED DNA-MOLECULES; MACRONUCLEAR DNA; NUCLEOPROTEIN COMPLEXES; ANTICODON MUTATIONS; CILIATE EVOLUTION; GLUTAMINE CODONS; DRAMATIC EVENTS; 3' TERMINUS	Telomeres of Oxytricha nova macronuclear chromosomes consist of a repeated T4G4 sequence, single-stranded at the 3' terminus, bound by a heterodimeric protein. The cloning of genes for the two polypeptides and their separate expression in E. coli have enabled evaluation of their individual contributions to DNA binding. The 56 kd alpha-subunit binds single-stranded DNA by itself, one polypeptide per T4G4 block; multiple subunits can coat a (T4G4)n multimer. The derived amino acid sequence of alpha does not reveal any known DNA-binding motif, so it appears to represent a novel type of DNA-binding protein. The previously cloned 41 kd beta-subunit does not by itself protect DNA from methylation, but is required along with alpha to recreate the pattern of methylation protection indicative of telomeres in vivo. The unusual ability of the protein to engage in two different interactions with the same telomeric DNA sequence might provide the versatility necessary for diverse telomere functions.			GRAY, JT (corresponding author), UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.		Gray, John T/D-2916-2016	Gray, John T/0000-0002-1888-4612; PRICE, Carolyn/0000-0002-7865-2303				AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COREN JS, 1991, MOL CELL BIOL, V11, P2282, DOI 10.1128/MCB.11.4.2282; DANCIS BM, 1979, J THEOR BIOL, V78, P211, DOI 10.1016/0022-5193(79)90265-0; DILLON JR, 1985, RECOMBINANT DNA METH; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRESLIN AF, 1989, P NATL ACAD SCI USA, V86, P6264, DOI 10.1073/pnas.86.16.6264; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HERRICK G, 1987, GENE DEV, V1, P1047, DOI 10.1101/gad.1.10.1047; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAWRENCE CB, 1988, COMPUT APPL BIOSCI, V4, P25; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIU ZP, 1991, GENE DEV, V5, P49, DOI 10.1101/gad.5.1.49; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; McClintock B, 1941, GENETICS, V26, P234; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller H.J., 1938, COLLECTING NET, V13, P181; NIELSEN H, 1986, EMBO J, V5, P2711, DOI 10.1002/j.1460-2075.1986.tb04555.x; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; Prescott D.M., 1983, Modern Cell Biology, V2, P329; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; QUIRES CH, 1988, J BIOL CHEM, V263, P16297; RAGHURAMAN MK, 1989, CELL, V59, P719, DOI 10.1016/0092-8674(89)90018-4; RAGHURAMAN MK, 1989, NUCLEIC ACIDS RES, V17, P4235, DOI 10.1093/nar/17.11.4235; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SWANTON MT, 1980, CHROMOSOMA, V77, P217, DOI 10.1007/BF00329546; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	47	142	161	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1991	67	4					807	814		10.1016/0092-8674(91)90075-A	http://dx.doi.org/10.1016/0092-8674(91)90075-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1840510				2022-12-24	WOS:A1991GQ40700017
J	OHTA, Y; STOSSEL, TP; HARTWIG, JH				OHTA, Y; STOSSEL, TP; HARTWIG, JH			LIGAND-SENSITIVE BINDING OF ACTIN-BINDING PROTEIN TO IMMUNOGLOBULIN-G FC RECEPTOR-I (FC-GAMMA-RI)	CELL			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; PERIPHERAL-BLOOD MONOCYTES; IMMUNE INTERFERON; MONOCLONAL-ANTIBODIES; TRANSIENT ACTIVATION; HUMAN-PLATELETS; CYTO-TOXICITY; CROSS-LINKING; NADPH OXIDASE; CELL-LINE	The high affinity receptor that binds the Fc domain of immunoglobulin G (IgG) subclasses 1 and 3 (Fc-gamma-RI) mediates important immune defense functions by inducing cell surface changes on human leukocytes. In this article, we document direct high affinity binding of Fc-gamma-RI to the actin filament cross-linking protein, actin-binding protein (ABP). In the absence of IgG, all Fc-gamma-RI molecules in undifferentiated cells of myeloid line U937 bound to ABP over a 9-fold range of Fc-gamma-RI expression induced by human IFN-gamma. Binding of IgG to U937 cells constitutively expressing Fc-gamma-RI or to COS cells genetically transfected to express Fc-gamma-RI rapidly decreased the avidity of Fc-gamma-RI for ABP. This finding suggests the existence of a pathway communicating a signal between a functional IgG receptor and intracellular components involved in the effector responses to Fc-gamma-RI-ligand interaction.	HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	OHTA, Y (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-19429, HL-45154] Funding Source: Medline; NIAID NIH HHS [AI-28465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERLEY WL, 1991, BLOOD, V77, P607; AKIYAMA Y, 1984, CANCER RES, V44, P5127; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1985, J BIOL CHEM, V260, P1970; GOMEZ F, 1989, BLOOD, V74, P1058; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GRAZIANO RF, 1987, J IMMUNOL, V138, P945; GUYRE PM, 1989, J IMMUNOL, V143, P1650; GUYRE PM, 1990, J CLIN INVEST, V86, P1892, DOI 10.1172/JCI114921; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; JONES DH, 1985, J CELL BIOL, V100, P558, DOI 10.1083/jcb.100.2.558; KINET JP, 1989, CELL, V57, P351, DOI 10.1016/0092-8674(89)90910-0; KURLANDER RJ, 1982, J CLIN INVEST, V69, P1, DOI 10.1172/JCI110419; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBECK MD, 1985, J IMMUNOL, V135, P1299; ODIN JA, 1990, CELLULAR MOL MECHANI; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PFEFFERKORN LC, 1989, J IMMUNOL, V143, P2640; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1976, J CELL BIOL, V68, P602, DOI 10.1083/jcb.68.3.602; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WEITZ JI, 1987, J EXP MED, V166, P1836, DOI 10.1084/jem.166.6.1836; WRIGHT SD, 1984, NATURE, V309, P359, DOI 10.1038/309359a0	38	92	93	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 18	1991	67	2					275	282		10.1016/0092-8674(91)90179-3	http://dx.doi.org/10.1016/0092-8674(91)90179-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1833070				2022-12-24	WOS:A1991GL47000007
J	ROMERO, DP; BLACKBURN, EH				ROMERO, DP; BLACKBURN, EH			A CONSERVED SECONDARY STRUCTURE FOR TELOMERASE RNA	CELL			English	Article							TERMINAL TRANSFERASE-ACTIVITY; POLYMERASE-III PROMOTER; RIBONUCLEASE-P RNA; RIBOSOMAL-RNA; U6 SNRNA; RIBONUCLEOPROTEIN ENZYME; TETRAHYMENA; DNA; GENE; TRANSCRIPTION	The RNA moiety of the ribonucleoprotein enzyme telomerase contains the template for telomeric DNA synthesis. We present a secondary structure model for telomerase RNA, derived by a phylogenetic comparative analysis of telomerase RNAs from seven tetrahymenine ciliates. The telomerase RNA genes from Tetrahymena malaccensis, T. pyriformis, T. hyperangularis, T. pigmentosa, T. hegewishii, and Glaucoma chattoni were cloned, sequenced, and compared with the previously cloned RNA gene from T. thermophila and with each other. To define secondary structures of these RNAs, homologous complementary sequences were identified by the occurrence of covariation among putative base pairs. Although their primary sequences have diverged rapidly overall, a strikingly conserved secondary structure was identified for all these telomerase RNAs. Short regions of nucleotide conservation include a block of 22 totally conserved nucleotides that contains the telomeric templating region.			ROMERO, DP (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026259, R37GM026259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; ANDREAZZOLI M, 1991, EMBO J, V10, P767, DOI 10.1002/j.1460-2075.1991.tb08008.x; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.bi.55.070186.003123; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHALLONER PB, 1986, NUCLEIC ACIDS RES, V14, P6299, DOI 10.1093/nar/14.15.6299; CHASTAIN M, 1991, PROG NUCL ACIDS RES, V41, P131; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DAGGETT PM, 1989, AM TYPE CULTURE CO S; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DRAPER DE, 1990, RIBOSOME, P160; FOX GE, 1975, NATURE, V256, P505, DOI 10.1038/256505a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENWOOD SJ, 1991, J PROTOZOOL, V38, P1, DOI 10.1111/j.1550-7408.1991.tb04783.x; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUERRIERTAKADA C, 1984, BIOCHEMISTRY-US, V23, P6327, DOI 10.1021/bi00321a006; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KATZEN AL, 1981, CELL, V24, P313, DOI 10.1016/0092-8674(81)90321-4; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LONGFELLOW CE, 1990, BIOCHEMISTRY-US, V29, P278, DOI 10.1021/bi00453a038; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1990, RIBOSOME, P73; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PREPARATA RM, 1989, J MOL EVOL, V28, P427, DOI 10.1007/BF02603078; ROIHA H, 1989, GENE, V82, P137, DOI 10.1016/0378-1119(89)90038-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SAMPSON JR, 1990, BIOCHEMISTRY-US, V29, P2523, DOI 10.1021/bi00462a014; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; SOGIN ML, 1986, EMBO J, V5, P3625, DOI 10.1002/j.1460-2075.1986.tb04691.x; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; TANI T, 1991, NUCLEIC ACIDS RES, V19, P2495, DOI 10.1093/nar/19.9.2495; Tinoco I. Jr., 1990, Nucleic Acids and Molecular Biology, V4, P205; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3451, DOI 10.1093/nar/18.12.3451; WHITE SA, 1989, BIOCHEMISTRY-US, V28, P1892, DOI 10.1021/bi00430a069; YU GL, 1990, MOL CELL BIOL, V10, P2070, DOI 10.1128/MCB.10.5.2070; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	65	216	240	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 18	1991	67	2					343	353		10.1016/0092-8674(91)90186-3	http://dx.doi.org/10.1016/0092-8674(91)90186-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GL470	1840508				2022-12-24	WOS:A1991GL47000014
J	ROMAN, C; COHN, L; CALAME, K				ROMAN, C; COHN, L; CALAME, K			A DOMINANT NEGATIVE FORM OF TRANSCRIPTION ACTIVATOR MTFE3 CREATED BY DIFFERENTIAL SPLICING	SCIENCE			English	Article							LOOP-HELIX PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING; DNA-BINDING; THYROID-HORMONE; MESSENGER-RNA; DOMAIN; CELLS; EXTRAMACROCHAETAE; DIMERIZATION; DROSOPHILA	Transcription factor E3 (mTFE3) is a murine transcription activator that binds to the intronic enhancer of the immunoglobulin heavy chain gene. A naturally occurring splice product of mTFE3 messenger RNA (mRNA) lacked 105 nucleotides that encode an activation domain; both absolute and relative amounts of long and truncated mRNAs varied in different tissues. Cells were cotransfected with complementary DNAs that encoded the two mRNA forms in amounts that corresponded to the amounts of each mRNA found in different cells. Small changes in substoichiometric amounts of the truncated form of mRNA effected trans-dominant negative modulation of mTFE3 activity. These findings identify a function for differential splicing in the regulation of transcription factor activity.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	University of California System; University of California Los Angeles; Columbia University; Columbia University; Columbia University; Columbia University					NCI NIH HHS [R01CA38571] Funding Source: Medline; NIGMS NIH HHS [R01GM28361] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038571] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KILEDJIAN M, 1990, NUCLEIC ACIDS RES, V18, P957, DOI 10.1093/nar/18.4.957; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERCOLA M, 1985, SCIENCE, V227, P266, DOI 10.1126/science.3917575; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PETERSON CL, 1989, MOL CELL BIOL, V9, P776, DOI 10.1128/MCB.9.2.776; RAMAKRISHNAN L, 1988, MOL CELL BIOL, V8, P5216, DOI 10.1128/MCB.8.12.5216; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; Roman C., UNPUB; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	33	115	117	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1991	254	5028					94	97		10.1126/science.1840705	http://dx.doi.org/10.1126/science.1840705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH605	1840705				2022-12-24	WOS:A1991GH60500035
J	VIGILANT, L; STONEKING, M; HARPENDING, H; HAWKES, K; WILSON, AC				VIGILANT, L; STONEKING, M; HARPENDING, H; HAWKES, K; WILSON, AC			AFRICAN POPULATIONS AND THE EVOLUTION OF HUMAN MITOCHONDRIAL-DNA	SCIENCE			English	Article							PAPUA-NEW-GUINEA; HUMAN ORIGINS; SEQUENCES; PRIMATES; TIME	The proposal that all mitochondrial DNA (mtDNA) types in contemporary humans stem from a common ancestor present in an African population some 200,000 years ago has attracted much attention. To study this proposal further, two hypervariable segments of mtDNA were sequenced from 189 people of diverse geographic origin, including 121 native Africans. Geographic specificity was observed in that identical mtDNA types are shared within but not between populations. A tree relating these mtDNA sequences to one another and to a chimpanzee sequence has many deep branches leading exclusively to African mtDNAs. An African origin for human mtDNA is supported by two statistical tests. With the use of the chimpanzee and human sequences to calibrate the rate of mtDNA evolution, the age of the common human mtDNA ancestor is placed between 166,000 and 249,000 years. These results thus support and extend the African origin hypothesis of human mtDNA evolution.	UNIV CALIF BERKELEY,DEPT BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV UTAH,DEPT ANTHROPOL,SALT LAKE CITY,UT 84112	University of California System; University of California Berkeley; Utah System of Higher Education; University of Utah	VIGILANT, L (corresponding author), PENN STATE UNIV,DEPT ANTHROPOL,UNIVERSITY PK,PA 16802, USA.		Klein, Richard G/B-5910-2009					AQUADRO CF, 1983, GENETICS, V103, P287; Bowcock A M, 1987, Gene Geogr, V1, P47; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BRAUER G, 1989, HUMAN REVOLUTION, P123; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CANN RL, 1987, NATURE, V329, P111, DOI 10.1038/329111c0; CANN RL, 1984, GENETICS, V106, P479; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; DARLU P, 1987, HUM EVOL, V2, P407; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; EXCOFFIER L, 1989, AM J HUM GENET, V44, P73; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P5841, DOI 10.1093/nar/16.13.5841; GAUT BS, 1991, P NATL ACAD SCI USA, V88, P2060, DOI 10.1073/pnas.88.6.2060; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927; HASEGAWA M, 1990, J MOL EVOL, V31, P113, DOI 10.1007/BF02109480; HASEGAWA M, IN PRESS NEW APSECTS; HORAI S, 1990, AM J HUM GENET, V46, P828; Howells W.W., 1980, YEARB PHYS ANTHROPOL, V23, P1, DOI DOI 10.1002/AJPA.1330230503; Kimura M, 1985, NEUTRAL THEORY MOL E; KOCHER TD, 1991, EVOLUTION OF LIFE, P391; KRUGER J, 1989, HUM GENET, V82, P308; LONG JC, 1990, AM J PHYS ANTHROPOL, V81, P113, DOI 10.1002/ajpa.1330810112; NEI M, 1982, EVOL BIOL, V14, P1; NEI M, 1991, EVOLUTION OF LIFE, P415; PRAGER EM, 1988, J MOL EVOL, V27, P326, DOI 10.1007/BF02101195; SAITOU N, 1987, NATURE, V327, P288, DOI 10.1038/327288a0; SMITH FH, 1989, YEARB PHYS ANTHROPOL, V32, P35; Sokal R. R, 1981, BIOMETRY; SPUHLER JN, 1988, YEARB PHYS ANTHROPOL, V31, P15; STONEKING M, 1990, GENETICS, V124, P717; STONEKING M, 1986, COLD SPRING HARB SYM, V51, P433, DOI 10.1101/SQB.1986.051.01.052; STONEKING M, 1989, HUMAN REVOLUTION, P17; STRINGER CB, 1989, HUMAN REVOLUTION, P232; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; Swofford David L., 1990, P411; SWOFFORD DL, 1990, PAUP VERSION 3 0; VIGILANT L, 1989, P NATL ACAD SCI USA, V86, P9350, DOI 10.1073/pnas.86.23.9350; VIGILANT L, 1990, THESIS U CALIFORNIA; WAINSCOAT JS, 1986, NATURE, V319, P491, DOI 10.1038/319491a0; Wilson A. C., 1987, HUM GENET, P158; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; WILSON AC, IN PRESS SYS ZOOL; Wolpoff M. H, 1980, PALEOANTHROPOLOGY; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62; ZUCKERKANDL EMILE, 1965, P97	49	990	1024	2	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1991	253	5027					1503	1507		10.1126/science.1840702	http://dx.doi.org/10.1126/science.1840702			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1840702				2022-12-24	WOS:A1991GG65100032
J	WIECK, A; KUMAR, R; HIRST, AD; MARKS, MN; CAMPBELL, IC; CHECKLEY, SA				WIECK, A; KUMAR, R; HIRST, AD; MARKS, MN; CAMPBELL, IC; CHECKLEY, SA			INCREASED SENSITIVITY OF DOPAMINE-RECEPTORS AND RECURRENCE OF AFFECTIVE PSYCHOSIS AFTER CHILDBIRTH	BRITISH MEDICAL JOURNAL			English	Article							HORMONE; APOMORPHINE; ESTRADIOL; DISORDERS; ESTROGEN; NEURONS	Objective - To test the hypothesis that affective psychosis after childbirth is associated with an altered sensitivity to dopaminergic stimulation. Design - Prospective study of pregnant women at high risk of developing an affective psychosis after childbirth. Clinical assessments in pregnancy and after delivery were made by using a semistructured interview (schedule for affective disorders and schizophrenia) and psychiatric illnesses were categorised according to operational criteria (research diagnostic criteria). Setting - Obstetric and psychiatric departments in and around Greater London. Subjects - 29 pregnant women with a history of bipolar or schizoaffective psychosis and 47 control pregnant women. Of these, 16 from each group participated in a growth hormone challenge test and the results for 15 women in each group were analysed. Interventions - On the fourth day postpartum women participating in the hormone challenge test were given a subcutaneous injection of a small dose (0.005 mg/kg) of the dopamine agonist apomorphine. Main outcome measures - Growth hormone secretion in response to apomorphine as an index of the functional state of hypothalamic dopamine receptors. Results - Eight of the 15 women at risk of psychosis subsequently had a recurrence of illness (five bipolar, one schizomanic, and two major depressive illnesses); these women had significantly greater growth hormone responses to apomorphine than the seven at risk women who remained well and the 15 controls, and there were no significant differences between groups in average baseline growth hormone concentrations. The mean (SD) concentrations for women with recurrence, women at risk who remained well, and control women respectively were: average baseline concentrations 1.06 (1.14), 1.44 (1.39), and 0.90 (1.34) mU/l; peak increase in concentrations 13.68 (12.95), 3.46 (4.68), and 3.40 (3.83) mU/l (between group difference p < 0.05); average increase in concentrations 6.74 (7.01), 1.78 (3.39), and 1.40 (2.05) mU/l (p < 0.05). Conclusions - The onset of affective psychosis after childbirth was associated with increased sensitivity of dopamine receptors in the hypothalamus and possibly elsewhere in the brain. Such changes may be triggered by the sharp fall in circulating oestrogen concentrations after delivery.	INST PSYCHIAT,DEPT PSYCHIAT,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT NEUROSCI,LONDON SE5 8AF,ENGLAND	University of London; King's College London; University of London; King's College London								BACKSTROM T, 1976, J STEROID BIOCHEM, V7, P469, DOI 10.1016/0022-4731(76)90114-X; BLUM M, 1987, J BIOL CHEM, V262, P817; CHECKLEY SA, 1980, PSYCHOL MED, V10, P35, DOI 10.1017/S0033291700039593; CHECKLEY SA, 1986, BIOL DEPRESSION, P100; COOKSON JC, 1985, J AFFECT DISORDERS, V8, P233, DOI 10.1016/0165-0327(85)90021-7; CORN TH, 1984, BRIT J PSYCHIAT, V144, P636, DOI 10.1192/bjp.144.6.636; DEAKIN JWF, 1988, MOTHERHOOD MENTAL IL, P113; DEAN C, 1989, PSYCHOL MED, V19, P637, DOI 10.1017/S0033291700024235; DEMAREST KT, 1984, NEUROENDOCRINOLOGY, V39, P193, DOI 10.1159/000123979; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; ETTIGI P, 1975, J CLIN ENDOCR METAB, V40, P1094, DOI 10.1210/jcem-40-6-1094; GELATO MC, 1984, J CLIN ENDOCR METAB, V59, P197, DOI 10.1210/jcem-59-2-197; HAMILTON JA, 1982, MOTHERHOOD MENTAL IL, P1; KENDELL RE, 1987, BRIT J PSYCHIAT, V150, P662, DOI 10.1192/bjp.150.5.662; KUMAR R, 1983, BRIT J PSYCHIAT, V142, P618, DOI 10.1192/bjp.142.6.618; LAL S, 1981, J NEURAL TRANSM, V50, P39, DOI 10.1007/BF01254912; MATUSSEK N, 1988, CURRENT TOPICS NEURO, V8, P141; MELTZER HY, 1980, SCHIZOPHRENIA BULL, V6, P456, DOI 10.1093/schbul/6.3.456; ROSS RJM, 1987, CLIN ENDOCRINOL, V27, P155, DOI 10.1111/j.1365-2265.1987.tb01140.x; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; VANHARTESVELDT C, 1986, NEUROSCI BIOBEHAV R, V10, P1, DOI 10.1016/0149-7634(86)90029-1; WIECK A, 1989, BAILLIERE CLIN OB GY, V3, P857, DOI 10.1016/S0950-3552(89)80069-0; WIECK A, 1989, BRIT J CLIN PHARMACO, V27, pP700	23	119	121	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1991	303	6803					613	616		10.1136/bmj.303.6803.613	http://dx.doi.org/10.1136/bmj.303.6803.613			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF675	1805821	Bronze, Green Published			2022-12-24	WOS:A1991GF67500021
J	CHUTE, CG; CHUANG, TY; BERGSTRALH, EJ; SU, WPD				CHUTE, CG; CHUANG, TY; BERGSTRALH, EJ; SU, WPD			THE SUBSEQUENT RISK OF INTERNAL CANCER WITH BOWENS DISEASE - A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL CARCINOMA; MALIGNANCY; DERMATOMYOSITIS; ROCHESTER; MINNESOTA	Objective.-To address the subsequent risk of internal cancer in a population-based cohort of patients with Bowen's disease. Design.-Incident cases of skin cancers other than malignant melanoma occurring in a defined population were classified as basal cell carcinoma, squamous cell carcinoma, or Bowen's disease. Through medical records, all patients were followed up for the development of subsequent internal cancer until they died, moved from Rochester, Minn, or January 1, 1986, whichever came first. Incidence rates of skin cancer and subsequent cancer were computed; the subsequent rate of internal cancer was compared with that prevailing in the community Patients.-Enrolled were all permanent residents in the population base of Rochester, Minn, who developed basal cell carcinoma (n = 657), squamous cell carcinoma (n = 169), or Bowen's disease (n = 71) on the basis of pathologic examination and clinical presentation from 1976 through 1984. Main Outcome Measure.-The relative risk of subsequent internal cancer among patients with Bowen's disease compared with that of the population base from which they arose was 1.1 (95% confidence limits, 0.5, 1.6). Results.-Annual incidence rates, adjusted to the 1980 US white population, were 14.9 per 100 000 for Bowen's disease, 38.8 for squamous cell carcinoma, and 146 for basal cell carcinoma. The estimated relative risk for subsequent cancer was 0.9 (95% confidence limits, 0.5, 1.6) among patients with squamous cell carcinoma and 1.0 (95% confidence limits, 0.7, 1.3) for patients with basal cell carcinoma. These risks were not significantly different for various durations of follow-up or for sun-exposed vs sun-protected sites. Conclusions.-We find no evidence in these population-based cohort data of an increased risk of subsequent internal cancer associated with Bowen's disease or other forms of nonmelanomatous skin cancer.	WRIGHT STATE UNIV,DEPT DERMATOL,4100 W 3RD ST,BLDG 307,ROOM 128,DAYTON,OH 45428; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT DERMATOL,ROCHESTER,MN 55905	Wright State University Dayton; Mayo Clinic; Mayo Clinic					NIAMS NIH HHS [AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN SL, 1973, ARCH DERMATOL, V108, P367, DOI 10.1001/archderm.108.3.367; ARBESMAN H, 1987, JAMA-J AM MED ASSOC, V257, P516, DOI 10.1001/jama.257.4.516; BARNES BE, 1976, ANN INTERN MED, V84, P68, DOI 10.7326/0003-4819-84-1-68; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; CALLEN JP, 1980, ARCH DERMATOL, V116, P422, DOI 10.1001/archderm.116.4.422; CALLEN JP, 1988, ARCH DERMATOL, V124, P675, DOI 10.1001/archderm.124.5.675; CHUANG TY, 1988, J AM ACAD DERMATOL, V19, P47, DOI 10.1016/S0190-9622(88)70150-4; CHUANG TY, 1990, J AM ACAD DERMATOL, V22, P413, DOI 10.1016/0190-9622(90)70056-N; CHUANG TY, 1990, ARCH DERMATOL, V126, P185, DOI 10.1001/archderm.126.2.185; CHUANG TY, 1990, AM J PREV MED, V6, P238, DOI 10.1016/S0749-3797(18)31010-9; EEDY DJ, 1987, BRIT J DERMATOL, V117, P715, DOI 10.1111/j.1365-2133.1987.tb07351.x; EPSTEIN E, 1960, ARCH DERMATOL, V80, P349; GRAHAM JH, 1959, ARCH DERMATOL, V80, P133, DOI 10.1001/archderm.1959.01560200001001; GRAHAM JH, 1961, ARCH DERMATOL, V83, P738, DOI 10.1001/archderm.1961.01580110026004; HAYNES HA, 1983, HARRISONS PRINCIPLES, P829; HUGO NE, 1967, PLAST RECONSTR SURG, V39, P190, DOI 10.1097/00006534-196702000-00011; ISSELBACHER KJ, 1980, HARRISONS PRINCIPLES, V1, P802; JOHNSON ML, 1982, CECIL TXB MED, P1029; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; KURLAND LT, 1973, USES EPIDEMIOLOGY PL, P164; LAKHANPAL S, 1986, MAYO CLIN PROC, V61, P645, DOI 10.1016/S0025-6196(12)62030-8; MARFING TE, 1987, DIS COLON RECTUM, V30, P782, DOI 10.1007/BF02554627; MIKI Y, 1982, J AM ACAD DERMATOL, V6, P26, DOI 10.1016/S0190-9622(82)70003-9; MYERS M, 1980, NIH802044 PUBL, P53; PETERKA ES, 1961, ARCH DERMATOL, V84, P623, DOI 10.1001/archderm.1961.01580160087015; RAGOZZINO MW, 1982, NEW ENGL J MED, V307, P393, DOI 10.1056/NEJM198208123070701; RAGOZZINO MW, 1984, MAYO CLIN P, V59, P720; REES JL, 1988, BRIT J DERMATOL, V119, P113; REYMANN F, 1988, ARCH DERMATOL, V124, P677, DOI 10.1001/archderm.124.5.677; SCHROEDER DJ, 1982, MAYO CLIN TECH REP S; Stone J L, 1986, Hawaii Med J, V45, P281; THESTRUPPEDERSEN K, 1988, ACTA DERM-VENEREOL, V68, P236	32	55	55	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					816	819		10.1001/jama.266.6.816	http://dx.doi.org/10.1001/jama.266.6.816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865520				2022-12-24	WOS:A1991GA07300033
J	LUISI, BF; XU, WX; OTWINOWSKI, Z; FREEDMAN, LP; YAMAMOTO, KR; SIGLER, PB				LUISI, BF; XU, WX; OTWINOWSKI, Z; FREEDMAN, LP; YAMAMOTO, KR; SIGLER, PB			CRYSTALLOGRAPHIC ANALYSIS OF THE INTERACTION OF THE GLUCOCORTICOID RECEPTOR WITH DNA	NATURE			English	Article							TRANSCRIPTION FACTOR-IIIA; STEROID-HORMONE RECEPTOR; TARGET GENE SPECIFICITY; ZINC-BINDING DOMAINS; MAMMARY-TUMOR VIRUS; CRYSTAL-STRUCTURE; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; AMINO-ACIDS; RESOLUTION	Two crystal structures of the glucocorticoid receptor DNA-binding domain complexed with DNA are reported. The domain has a globular fold which contains two Zn-nucleated substructures of distinct conformation and function. When it binds DNA, the domain dimerizes, placing the subunits in adjacent major grooves. In one complex, the DNA has the symmetrical consensus target sequence; in the second, the central spacing between the target's half-sites is larger by one base pair. This results in one subunit interacting specifically with the consensus target half-site and the other nonspecifically with a noncognate element. The DNA-induced dimer fixes the separation of the subunits' recognition surfaces so that the spacing between the half-sites becomes a critical feature of the target sequence's identity.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Yale University; Howard Hughes Medical Institute; Yale University; University of California System; University of California San Francisco			Otwinowski, Zbyszek/F-3665-2011	Otwinowski, Zbyszek/0000-0003-3640-8545				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BROWN RS, 1985, FEBS LETT, V186, P274; BRUNGER AT, 1988, CRYSTALLOGRAPHIC COM, V4; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FREEDMAN LP, 1988, CELL, V54, P444, DOI 10.1016/0092-8674(88)90063-3; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; PRESLEY JP, 1988, J APPL CRYSTALLOGR, V21, P572; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SAENGER W, 1984, PRINCIPLES NUCLEIC A, V120; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHEVITZ RW, 1981, ACTA CRYSTALLOGR A, V37, P669, DOI 10.1107/S0567739481001526; SCHULTZ S, IN PRESS SCIENCE; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SOMERS WA, 1991, THESIS U LEEDS; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	55	1273	1292	0	50	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					497	505		10.1038/352497a0	http://dx.doi.org/10.1038/352497a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865905				2022-12-24	WOS:A1991GA22600052
J	ORENTLICHER, D				ORENTLICHER, D			GENDER DISPARITIES IN CLINICAL DECISION-MAKING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY-BYPASS SURGERY; SEX-DIFFERENCES; LUNG-CANCER; MYOCARDIAL-INFARCTION; DETECTION BIAS; MEDICAL-CARE; WOMEN; MEN; MORTALITY; ILLNESS				ORENTLICHER, D (corresponding author), AMER MED ASSOC,COUNCIL ETH & JUDICIAL AFFAIRS,515 N STATE ST,CHICAGO,IL 60610, USA.							ARMITAGE KJ, 1979, JAMA-J AM MED ASSOC, V241, P2186, DOI 10.1001/jama.241.20.2186; BARKERBENFIELD B, 1973, AM FAMILY SOCIOHISTO; BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; BROVERMA.IK, 1970, J CONSULT CLIN PSYCH, V34, P1, DOI 10.1037/h0028797; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P106, DOI 10.2307/2136508; COLAMECO S, 1983, J FAM PRACTICE, V16, P1117; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1051, DOI 10.1001/jama.263.8.1051; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P1049, DOI 10.1001/jama.263.8.1049; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GOVE WR, 1979, AM SOCIOL REV, V44, P126, DOI 10.2307/2094822; Hamilton J, 1983, J Am Med Womens Assoc (1972), V38, P126; HAMILTON JA, 1985, WOMENS HLTH REPORT P, P2; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HIBBARD JH, 1986, WOMEN HEALTH, V11, P21, DOI 10.1300/J013v11n02_03; KARLIN BG, 1988, ANN INTERN MED, V108, P149; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND CM, 1987, NEPHRON, V45, P257, DOI 10.1159/000184160; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MARCUS AC, 1981, J HEALTH SOC BEHAV, V22, P174, DOI 10.2307/2136293; MCFARLANE MJ, 1986, ARCH INTERN MED, V146, P1695, DOI 10.1001/archinte.146.9.1695; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; NATANSON CA, 1975, SOC SCI MED, V9, P57; RASKIN A, 1974, J NERV MENT DIS, V159, P120, DOI 10.1097/00005053-197408000-00006; SAVAGE WD, 1983, MED EDUC, V17, P159, DOI 10.1111/j.1365-2923.1983.tb00656.x; SCHOENBERG JB, 1989, AM J EPIDEMIOL, V130, P688, DOI 10.1093/oxfordjournals.aje.a115390; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOBIN JN, 1988, ANN INTERN MED, V108, P149; VERBRUGGE LM, 1982, PUBLIC HEALTH REP, V97, P417; VERBRUGGE LM, 1981, MED CARE, V19, P609, DOI 10.1097/00005650-198106000-00005; WAISBERG J, 1988, WOMEN HEALTH, V14, P3, DOI 10.1300/J013v14n01_02; WELLS CK, 1988, AM J EPIDEMIOL, V128, P1016; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; WENGER NK, 1985, ANNU REV MED, V36, P285; 1985, WOMENS HLTH REPORT P, P2	37	147	148	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 24	1991	266	4					559	562						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FX021	1843800				2022-12-24	WOS:A1991FX02100032
J	COBBE, SM; REDMOND, MJ; WATSON, JM; HOLLINGWORTH, J; CARRINGTON, DJ				COBBE, SM; REDMOND, MJ; WATSON, JM; HOLLINGWORTH, J; CARRINGTON, DJ			HEARTSTART SCOTLAND - INITIAL EXPERIENCE OF A NATIONAL SCHEME FOR OUT OF HOSPITAL DEFIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY MEDICAL TECHNICIANS; AUTOMATIC EXTERNAL DEFIBRILLATOR; CARDIAC-ARREST; CLINICAL-EXPERIENCE; MANAGEMENT; RESUSCITATION; CARE	Objective - To determine the outcome of out of hospital defibrillation in Scotland during the year after the introduction of automated external defibrillators in October 1988. Design - Retrospective analysis of ambulance service reports and hospital records. Setting - Scottish Ambulance Service and acute receiving hospitals throughout Scotland. Main outcome measures - Delay from cardiac arrest to first defibrillator shock; vital state on arrival at hospital accident and emergency department; survival to hospital discharge. Results - During the study period 268 defibrillators were purchased by public subscription and 96% of the 2000 ambulance crew underwent an eight hour training programme in cardiopulmonary resuscitation and defibrillation. A total of 1111 cardiac arrests were recorded, and defibrillation was indicated and undertaken in 602 (54%) patients, mean age 63 (range 14-92) years. A spontaneous pulse was present on arrival at hospital in 180 (30%) of the defibrillated patients, and 75 (12.5%) were subsequently discharged alive. As expected, the likelihood of survival was inversely related to the delay from the onset of cardiac arrest to the time of the first shock and was greater in the case of witnessed arrest. If ventricular fibrillation occurred after the arrival of the ambulance, survival to discharge was 33%. Conclusions - An effective scheme for out of hospital defibrillation can be introduced rapidly, and with limited training implications and costs, by the use of automated external defibrillators in ambulances.	FIFE LOTHIAN & BORDERS SCOTTISH AMBULANCE SERV,EDINBURGH EH10 5SA,SCOTLAND		COBBE, SM (corresponding author), ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,SCOTLAND.							ANDERSON IWR, 1987, BRIT MED J, V294, P228, DOI 10.1136/bmj.294.6566.228; BEAGLEHOLE R, 1986, BMJ-BRIT MED J, V292, P33, DOI 10.1136/bmj.292.6512.33; COBB LA, 1986, MANAGEMENT ACUTE COR, P105; COBB LA, 1975, CIRCULATION       S3, V51, P223; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; GRAY AJ, 1987, BMJ, V295, P1133; HAMPTON JR, 1978, BRIT MED J, V1, P1118, DOI 10.1136/bmj.1.6120.1118; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P123; MACKINTOSH AF, 1978, BRIT MED J, V1, P1115, DOI 10.1136/bmj.1.6120.1115; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; PANTRIDG.JF, 1967, LANCET, V2, P271; ROWLEY JM, 1987, BRIT MED J, V295, P1387, DOI 10.1136/bmj.295.6610.1387; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; 1990, 1989 GEN REG OFF ANN; 1976, HN76204 DHSS DEP HLT; 1987, EXTENDED TRAINING AM; 1984, DA8412 DHSS DEP HLTH	25	78	78	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1517	1520		10.1136/bmj.302.6791.1517	http://dx.doi.org/10.1136/bmj.302.6791.1517			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855025	Bronze, Green Published			2022-12-24	WOS:A1991FT50500028
J	STEPHENS, LR; HUGHES, KT; IRVINE, RF				STEPHENS, LR; HUGHES, KT; IRVINE, RF			PATHWAY OF PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE SYNTHESIS IN ACTIVATED NEUTROPHILS	NATURE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; INOSITOL PHOSPHATES; BOVINE BRAIN; 4,5-BISPHOSPHATE; IDENTIFICATION; 4-PHOSPHATE; POLYPHOSPHOINOSITIDE; PHOSPHODIESTERASE; TRANSFORMATION; TRISPHOSPHATE	Neutrophils activated by the formyl peptide f-Met-LeuPhe transiently accumulate a small subset of highly polar inositol lipids. A similar family of lipids also appear in many other cells in response to a range of growth factors and activated oncogenes, and are presumed to be the direct or indirect products of 3-phosphatidylinositol kinase. The structures of these lipids are shown to be phosphatidylinositol 3-phosphate, phosphatidylinositol-(3,4)bisphosphate and phosphatidylinositol-(3,4,5)trisphosphate, and we present evidence that in intact neutrophils a phosphatidyl-inositol-(4,5)bisphosphate-3-kinase seems to be the focal point through which agonists stimulate the formation of 3-phosphorylated inositol lipids.	AMERSHAM INT PLC,CARDIFF CF4 7YT,WALES		STEPHENS, LR (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE RES STN,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND.			stephens, len/0000-0002-2771-3487				ALLEN D, 1978, BIOCHIM BIOPHYS ACTA, V508, P277; ASCOLI M, 1990, J BIOL CHEM, V265, P1718; Auger K. R., 1990, METHODS INOSITIDE RE, P159; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BENNETT JP, 1982, BIOCHEM J, V208, P801, DOI 10.1042/bj2080801; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROCKERHOFF H, 1962, J BIOL CHEM, V237, P1764; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; DOWNES P, 1982, CELL CALCIUM, V3, P467, DOI 10.1016/0143-4160(82)90031-8; ENDOMANN G, 1990, J BIOL CHEM, V265, P396; GEE NS, 1988, BIOCHEM J, V253, P777, DOI 10.1042/bj2530777; IMBODEN JB, 1987, J CLIN INVEST, V79, P1538, DOI 10.1172/JCI112986; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; IRVINE RF, 1978, BIOCHEM J, V176, P475, DOI 10.1042/bj1760475; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LETCHER AJ, 1990, METHODS INOSITIDE RE, P31; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; PALMER FBSC, 1981, J LIPID RES, V22, P1296; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SIM SS, 1990, J BIOL CHEM, V265, P10367; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; Stephens L. R., 1990, METHODS INOSITIDE RE, P9; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; STEPHENS LR, 1990, BIOCHEM J, V269, P65, DOI 10.1042/bj2690065; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; TAKAZAWA K, 1989, BIOCHEM J, V261, P483, DOI 10.1042/bj2610483; TOMLINSON R, 1961, J BIOL CHEM, V236, P1902; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VADNAL RE, 1989, BIOCHEM BIOPH RES CO, V163, P995, DOI 10.1016/0006-291X(89)92320-6; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	50	438	450	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1991	351	6321					33	39		10.1038/351033a0	http://dx.doi.org/10.1038/351033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1851250				2022-12-24	WOS:A1991FK19300049
J	WONG, YH; FEDERMAN, A; PACE, AM; ZACHARY, I; EVANS, T; POUYSSEGUR, J; BOURNE, HR				WONG, YH; FEDERMAN, A; PACE, AM; ZACHARY, I; EVANS, T; POUYSSEGUR, J; BOURNE, HR			MUTANT ALPHA-SUBUNITS OF GI2 INHIBIT CYCLIC-AMP ACCUMULATION	NATURE			English	Article							BINDING REGULATORY COMPONENT; ADENYLATE-CYCLASE; G-PROTEINS; MUTATIONS; MEMBRANES; RECEPTOR; SITE; IDENTIFICATION; DISSOCIATION; STIMULATION	ONE or more of three G(i) proteins, G(i1-3), mediates hormonal inhibition of adenylyl cyclase 1-3. Whether this inhibition is mediated by the alpha or by the beta-gamma-subunits of G(i) proteins is unclear 1,2. Mutations inhibiting the intrinsic GTPase activity of another G protein, the stimulatory regulator of adenylyl cyclase (G(s)), constitutively activate it by replacing either of two conserved amino acids in its alpha-subunit (alpha-s) 4-7. These mutations create the gsp oncogene which is found in human pituitary and thyroid tumours 5,8. In a second group of human endocrine tumours, somatic mutations in the alpha-subunit of G(i2) replace a residue cognate to one of those affected by gsp mutations 8. This implies that the mutations convert the alpha-i2 gene into a dominantly acting oncogene, called gip2 (ref. 8), and that the mutant alpha-i2 subunits are constitutively active. We have therefore assessed cyclic AMP accumulation in cultured cells which stably or transiently express exogenous wild-type alpha-i2 complementary DNA or either of two mutant alpha-i2 cDNAs. The results show that putatively oncogenic mutations in alpha-i2 constitutively activate the protein's ability to inhibit cAMP accumulation.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV NICE, FAC SCI, CNRS, CTR BIOCHIM, F-06034 NICE, FRANCE	University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur				Wong, Yung Hou/0000-0002-0123-7697				BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHANG FH, 1987, ENDOCRINOLOGY, V121, P1711, DOI 10.1210/endo-121-5-1711; EVANS T, 1987, J BIOL CHEM, V262, P176; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HILDEBRANDT JD, 1983, NATURE, V302, P706, DOI 10.1038/302706a0; HILDEBRANDT JD, 1982, J BIOL CHEM, V257, P4723; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P3178; JAKOBS KH, 1983, P NATL ACAD SCI-BIOL, V80, P3899, DOI 10.1073/pnas.80.13.3899; JAKOBS KH, 1983, NATURE, V303, P177, DOI 10.1038/303177a0; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATADA T, 1986, J BIOL CHEM, V261, P5215; KATADA T, 1984, J BIOL CHEM, V259, P3578; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; PRICE SR, 1990, ADP RIBOSYLATING TOX, P397; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	30	250	251	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1991	351	6321					63	65		10.1038/351063a0	http://dx.doi.org/10.1038/351063a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK193	1851251				2022-12-24	WOS:A1991FK19300060
J	LUBIN, I; FAKTOROWICH, Y; LAPIDOT, T; GAN, Y; ESHHAR, Z; GAZIT, E; LEVITE, M; REISNER, Y				LUBIN, I; FAKTOROWICH, Y; LAPIDOT, T; GAN, Y; ESHHAR, Z; GAZIT, E; LEVITE, M; REISNER, Y			ENGRAFTMENT AND DEVELOPMENT OF HUMAN T-CELLS AND B-CELLS IN MICE AFTER BONE-MARROW TRANSPLANTATION	SCIENCE			English	Article							DEPENDENT DIABETES-MELLITUS; COMBINED IMMUNE-DEFICIENCY; RED-BLOOD-CELLS; SCID-HU MOUSE; SOYBEAN AGGLUTININ; RESISTANCE; SUSCEPTIBILITY; RECIPIENTS; ALLOGRAFTS; GRAFTS	A model for human lymphocyte ontogeny has been developed in a normal mouse. Human bone marrow, depleted of mature T and B lymphocytes, and bone marrow from mice with severe combined immunodeficiency were transplanted into lethally irradiated BALB/c mice. Human B and T cells were first detected 2 to 4 months after transplantation and persisted for at least 6 months. Most human thymocytes (30 to 50 percent of total thymocytes) were CD3+ CD4+ CD8+. Human immunoglobulin was detected in some chimeras, and a human antibody response to dinitrophenol could be generated after primary and secondary immunization.	WEIZMANN INST SCI,DEPT BIOPHYS,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; CHAIM SHEBA MED CTR,DEPT PEDIAT,IL-62621 TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center			Lapidot, Tsvee/A-1812-2010; Reisner, Yair/AAA-4772-2019	Reisner, Yair/0000-0002-3354-6945				KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KEEVER CA, 1989, BLOOD, V73, P1340; KIESSLING R, 1977, EUR J IMMUNOL, V7, P655, DOI 10.1002/eji.1830070915; LAPIDOT T, 1989, BLOOD, V73, P2025; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NAMIKAWA R, 1990, J EXP MED, V172, P1055, DOI 10.1084/jem.172.4.1055; OREILLY RJ, 1986, PRIMARY IMMUNODEFICI, P301; REISNER Y, 1983, BLOOD, V61, P341; REISNER Y, 1978, P NATL ACAD SCI USA, V75, P2933, DOI 10.1073/pnas.75.6.2933; REISNER Y, 1981, LANCET, V2, P327; RONNINGEN KS, 1989, HUM IMMUNOL, V26, P215; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHWARTZ E, 1987, J IMMUNOL, V138, P460; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; VANBEKKUM DW, 1985, BONE MARROW TRANSPL, P311	18	87	102	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1991	252	5004					427	431		10.1126/science.1826797	http://dx.doi.org/10.1126/science.1826797			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FH103	1826797				2022-12-24	WOS:A1991FH10300039
J	KAKLAMANI, E; TRICHOPOULOS, D; TZONOU, A; ZAVITSANOS, X; KOUMANTAKI, Y; HATZAKIS, A; HSIEH, CC; HATZIYANNIS, S				KAKLAMANI, E; TRICHOPOULOS, D; TZONOU, A; ZAVITSANOS, X; KOUMANTAKI, Y; HATZAKIS, A; HSIEH, CC; HATZIYANNIS, S			HEPATITIS-B AND HEPATITIS-C VIRUSES AND THEIR INTERACTION IN THE ORIGIN OF HEPATOCELLULAR-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC NON-A; ANTIBODIES; PREVALENCE; SMOKING	Serum taken from patients in a case-control study in Athens, Greece, was used to examine the interactive roles of hepatitis B virus (HBV) and hepatitis C virus (HCV) in the origin of hepatocellular carcinoma (HCC). An enzyme immunoassay for anti-HCV was used to test serum taken from 185 cases with HCC, 35 cases with metastatic liver cancer (MLC), and 432 hospital controls. Weakly positive anti-HCV results were more strongly related to MLC than to HCC, implying that these anti-HCV results are false positive. By contrast, strongly positive anti-HCV results were significantly related to HCC (relative risk [RR], 6.3), whereas no significant association was evident for MLC (RR, 0.6). The association of anti-HCV with HCC was substantially higher among subjects whose radioimmunoassay was positive for hepatitis B surface antigen (RR, 20.0) than among those whose radioimmunoassay was negative for this marker (RR, 4.8). These findings indicate that HCV infection has an interactive role in the origin of HCC.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,677 HUNTINGTON AVE,BOSTON,MA 02115; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS,GREECE; IPPOKRATEION HOSP,ACAD DEPT MED,ATHENS,GREECE	Harvard University; Harvard T.H. Chan School of Public Health; Athens Medical School; National & Kapodistrian University of Athens								ALTER H, 1989, 1ST P INT S HEP C VI, P25; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRUIX J, 1989, LANCET, V2, P1004; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; Davis W, 1980, IARC SCI PUBL, V32, P192; ESTEBAN JI, 1989, LANCET, V2, P294; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; GRAY JJ, 1990, LANCET, V335, P609, DOI 10.1016/0140-6736(90)90398-O; GRAY JJ, 1989, SERODIAG IMMUN INF D, V3, P389, DOI 10.1016/0888-0786(89)90057-7; HIRAYAMA T, 1989, CANCER CHEMOTH PHARM, V23, pS114, DOI 10.1007/BF00647254; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MORGANCAPNER P, 1988, LANCET, V1, P1397; MUNOZ N, 1987, NEOPLASMS LIVER, P3, DOI DOI 10.1007/978-4-431-68349-0_1; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PURCELL RH, 1989, CANCER DETECT PREV, V14, P203; SIMONETTI RG, 1989, LANCET, V2, P1338; TRICHOPOULOS D, 1987, INT J CANCER, V39, P45, DOI 10.1002/ijc.2910390109; TRICHOPOULOS D, 1978, LANCET, V2, P1217; WREGHITT TG, 1990, LANCET, P789; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; 1988, IARC SCI PUBL, V44, P207	24	201	201	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1991	265	15					1974	1976		10.1001/jama.265.15.1974	http://dx.doi.org/10.1001/jama.265.15.1974			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF768	1848908				2022-12-24	WOS:A1991FF76800023
J	STROBEL, SA; DERVAN, PB				STROBEL, SA; DERVAN, PB			SINGLE-SITE ENZYMATIC CLEAVAGE OF YEAST GENOMIC DNA MEDIATED BY TRIPLE HELIX FORMATION	NATURE			English	Article							GEL-ELECTROPHORESIS; SACCHAROMYCES-CEREVISIAE; SEQUENCE; ENDONUCLEASE; RECOGNITION; SEPARATION; PROTEINS; MATURASE; BINDING	PHYSICAL mapping of chromosomes would be facilitated by methods of breaking large DNA into manageable fragments, or cutting uniquely at genetic markers of interest. Key issues in the design of sequence-specific DNA cleaving reagents are the specificity of binding, the generalizability of the recognition motif, and the cleavage yield. Oligonucleotide-directed triple helix formation is a generalizable motif for specific binding to sequences longer than 12 base pairs within DNA of high complexity 1-3. Studies with plasmid DNA show that triple helix formation can limit the operational specificity of restriction enzymes to endonuclease recognition sequences that overlap oligonucleotide-binding sites 4,5. Triple helix formation, followed by methylase protection, triple helix-disruption, and restriction endonuclease digestion produces near quantitative cleavage at the single overlapping triple helix-endonuclease site 4,5. As a demonstration that this technique may be applicable to the orchestrated cleavage of large genomic DNA, we report the near quantitative single-site enzymatic cleavage of the Saccharomyces cerevisiae genome mediated by triple helix formation. The 340-kilobase yeast chromosome III was cut uniquely at an overlapping homopurine-EcoRI target site 27 base pairs long to produce two expected cleavage products of 110 and 230 kilobases. No cleavage of any other chromosome was detected. The potential generalizability of this technique, which is capable of near quantitative cleavage at a single site in at lease 14 megabase pairs of DNA, could enable selected regions of chromosomal DNA to be isolated without extensive screening of genomic libraries.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology								ANDREADIS A, 1982, CELL, V31, P319, DOI 10.1016/0092-8674(82)90125-8; BARLOW DP, 1987, TRENDS GENET, V3, P167, DOI 10.1016/0168-9525(87)90219-8; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; KEESEY JK, 1979, J BIOL CHEM, V254, P7427; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LIPSETT MN, 1964, J BIOL CHEM, V239, P1256; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PATEL Y, 1990, NUCLEIC ACIDS RES, V18, P1603, DOI 10.1093/nar/18.6.1603; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; WEIL MD, 1989, P NATL ACAD SCI USA, V86, P51, DOI 10.1073/pnas.86.1.51; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6	27	135	142	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1991	350	6314					172	174		10.1038/350172a0	http://dx.doi.org/10.1038/350172a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB645	1848684				2022-12-24	WOS:A1991FB64500066
J	TSUKAMOTO, T; MIURA, S; FUJIKI, Y				TSUKAMOTO, T; MIURA, S; FUJIKI, Y			RESTORATION BY A 35K MEMBRANE-PROTEIN OF PEROXISOME ASSEMBLY IN A PEROXISOME-DEFICIENT MAMMALIAN-CELL MUTANT	NATURE			English	Article							RAT-LIVER PEROXISOMES; ENDOPLASMIC-RETICULUM; ZELLWEGER SYNDROME; CARBOXY TERMINUS; POLYPEPTIDE; ENVELOPE; GENOME	PEROXISOMES are among the intracellular organelles of eukaryotic cells that contain specialized sets of enzymes with specific functions 1. Little is known of membranous components involved in assembly of the intracellular compartments 2-5. We isolated two peroxisome-deficient and mutually complementary, Chinese hamster ovary cell mutants, Z65 and Z24 6, which closely resembled fibroblasts from patients with autosomal recessive, peroxisome-defective disorders such as Zellweger syndrome 1,7. These patients show characteristic dysmorphism, severe hypotonia, psychomotor retardation, and peroxisomal dysfunctions and rarely survive early childhood. Here we report what seems to be the first direct cloning and characterization of a complementary DNA encoding a peroxisomal membrane protein of relative molecular mass 35,000 (M(r) 35K) that restores the biogenesis of peroxisomes and complements the defect of peroxisomal functions in the mutant Z65.	MEIJI INST HLTH SCI,MOLEC CELL BIOL LAB,ODAWARA,KANAGAWA 250,JAPAN									AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERTHET J, 1951, BIOCHEM J, V50, P174, DOI 10.1042/bj0500174; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREITMAN ML, 1982, MOL CELL BIOL, V2, P966, DOI 10.1128/MCB.2.8.966; BRUL S, 1988, J CLIN INVEST, V81, P1710, DOI 10.1172/JCI113510; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MARSHALL M, 1972, J BIOL CHEM, V247, P1641; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MORI M, 1979, P NATL ACAD SCI USA, V76, P3719; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SONE T, 1987, J BIOL CHEM, V262, P5878; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	29	223	225	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1991	350	6313					77	81		10.1038/350077a0	http://dx.doi.org/10.1038/350077a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1750930				2022-12-24	WOS:A1991FA69300070
J	YAYON, A; KLAGSBRUN, M; ESKO, JD; LEDER, P; ORNITZ, DM				YAYON, A; KLAGSBRUN, M; ESKO, JD; LEDER, P; ORNITZ, DM			CELL-SURFACE, HEPARIN-LIKE MOLECULES ARE REQUIRED FOR BINDING OF BASIC FIBROBLAST GROWTH-FACTOR TO ITS HIGH-AFFINITY RECEPTOR	CELL			English	Article							CAPILLARY ENDOTHELIAL-CELLS; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; PLASMINOGEN-ACTIVATOR PRODUCTION; PROTEIN-TYROSINE KINASE; SULFATE; PROTEOGLYCAN; GLYCOSAMINOGLYCANS; PURIFICATION; STIMULATION; METABOLISM	The role of low affinity, heparin-like binding sites for basic fibroblast growth factor (bFGF) was investigated in CHO cells mutant in their metabolism of glycosaminoglycans. Heparan sulfate-deficient mutants transfected to express a cloned mouse FGF receptor cDNA are not able to bind bFGF. It is demonstrated that free heparin and heparan sulfate can reconstitute a low affinity receptor that is, in turn, required for the high affinity binding of bFGF. These studies suggest that the low affinity receptor is an accessory molecule required for binding of bFGF to the high affinity site. Such an obligatory interaction of low and high affinity FGF receptors suggests a physiological role for heparin-like, low affinity receptors and constitutes a novel mechanism for the regulation of growth factor-receptor interactions.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; UNIV ALABAMA,DEPT BIOCHEM,BIRMINGHAM,AL 35294; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	YAYON, A (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.			Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [P01CA045548, R01CA037329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM033063] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37329, CA 45548] Funding Source: Medline; NIGMS NIH HHS [GM 33063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZIZKHAN RG, 1980, J EXP MED, V152, P931, DOI 10.1084/jem.152.4.931; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; IMAMURA T, 1987, EXP CELL RES, V172, P92, DOI 10.1016/0014-4827(87)90096-6; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KINOSHITA S, 1979, EXP CELL RES, V123, P229, DOI 10.1016/0014-4827(79)90463-4; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LATERRA J, 1980, P NATL ACAD SCI-BIOL, V77, P6662, DOI 10.1073/pnas.77.11.6662; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NADER HB, 1984, J BIOL CHEM, V259, P1431; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PRESTA M, 1989, CANCER RES, V48, P68; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360	47	2304	2380	3	130	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					841	848		10.1016/0092-8674(91)90512-W	http://dx.doi.org/10.1016/0092-8674(91)90512-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1847668				2022-12-24	WOS:A1991EZ47800018
J	TEH, HS; GARVIN, AM; FORBUSH, KA; CARLOW, DA; DAVIS, CB; LITTMAN, DR; PERLMUTTER, RM				TEH, HS; GARVIN, AM; FORBUSH, KA; CARLOW, DA; DAVIS, CB; LITTMAN, DR; PERLMUTTER, RM			PARTICIPATION OF CD4 CORECEPTOR MOLECULES IN T-CELL REPERTOIRE SELECTION	NATURE			English	Article							ANTIGEN RECEPTOR; TRANSGENIC MICE; RECOGNITION; EXPRESSION; LINES; MOUSE; GENE	DURING thymocyte development, progenitor cells bearing both CD4 and CD8 coreceptor molecules mature into functional T lymphocytes that express these proteins in a mutually exclusive way 1. Although T-cell specificity is determined primarily by the structure of the T-cell antigen receptor (TCR) heterodimer 2, a developmentally regulated process acts to ensure that cells bearing class II-restricted TCRs are CD4+ and those bearing class I-restricted TCRs express, only CD8 (ref.3). To investigate this maturation process, we have engineered transgenic mice in which CD4 is expressed in all thymocyte subsets and in all peripheral T cells. Peripheral CD4+8+ T lymphocytes from these mice react with both class I and class II alloantigens. Moreover, expression of the CD4 transgene disrupts the positive selection of doubly transgenic thymocytes bearing a class I-restricted TCR specific for the male (H-Y) antigen. Hence the CD4 coreceptor participates directly in T-cell repertoire selection.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT IMMUNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED MED GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1W5, BC, CANADA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of British Columbia			Teh, Hung-Sia/A-5710-2008					BAILEY DW, 1971, IMMUNOGENETICS H2 SY, P155; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; CHAFFIN K, IN PRESS EMBO J; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEWIS DB, IN PRESS J EXP MED; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MCKENZIE IFC, 1979, J EXP MED, V150, P1323, DOI 10.1084/jem.150.6.1323; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STAERZ UD, 1985, J IMMUNOL, V134, P3994; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; Teh H S, 1990, Dev Immunol, V1, P1, DOI 10.1155/1990/18208; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	27	85	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					241	243		10.1038/349241a0	http://dx.doi.org/10.1038/349241a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1824796				2022-12-24	WOS:A1991ET51900056
J	FU, YH; KUHL, DPA; PIZZUTI, A; PIERETTI, M; SUTCLIFFE, JS; RICHARDS, S; VERKERK, AJMH; HOLDEN, JJA; FENWICK, RG; WARREN, ST; OOSTRA, BA; NELSON, DL; CASKEY, CT				FU, YH; KUHL, DPA; PIZZUTI, A; PIERETTI, M; SUTCLIFFE, JS; RICHARDS, S; VERKERK, AJMH; HOLDEN, JJA; FENWICK, RG; WARREN, ST; OOSTRA, BA; NELSON, DL; CASKEY, CT			VARIATION OF THE CGG REPEAT AT THE FRAGILE-X SITE RESULTS IN GENETIC INSTABILITY - RESOLUTION OF THE SHERMAN PARADOX	CELL			English	Article							HUMAN DNA; EXPRESSION	Fragile X syndrome results from mutations in a (CGG)n repeat found in the coding sequence of the FMR-1 gene. Analysis of length variation in this region in normal individuals shows a range of allele sizes varying from a low of 6 to a high of 54 repeats. Premutations showing no phenotypic effect in fragile X families range in size from 52 to over 200 repeats. All alleles with greater than 52 repeats, including those identified in a normal family, are meiotically unstable with a mutation frequency of one, while 75 meioses of alleles of 46 repeats and below have shown no mutation. Premutation alleles are also mitotically unstable as mosaicism is observed. The risk of expansion during oogenesis to the full mutation associated with mental retardation increases with the number of repeats, and this variation in risk accounts for the Sherman paradox.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,ATLANTA,GA 30322; ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS; QUEENS UNIV,DEPT CYTOGENET,KINGSTON K7L 3N6,ONTARIO,CANADA	Emory University; Howard Hughes Medical Institute; Emory University; Howard Hughes Medical Institute; Erasmus University Rotterdam; Queens University - Canada	FU, YH (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,CTR HUMAN GENOME,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Warren, Stephen T/A-2498-2012; Sutcliffe, James S/C-1348-2012	Sutcliffe, James S/0000-0001-5200-6007; Verkerk, Annemieke JMH/0000-0002-7523-3656; PIZZUTI, Antonio/0000-0003-3245-1925	NHGRI NIH HHS [HG00038] Funding Source: Medline; NICHD NIH HHS [HD20521] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN WT, 1990, AM J HUM GENET, V47, P175; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; EDWARDS A, 1991, AM J HUM GENET, V49, P746; GUSTAVSON KH, 1986, AM J MED GENET, V23, P581, DOI 10.1002/ajmg.1320230152; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD CD, 1987, GENETICS, V117, P587; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1985, HUM GENET, V69, P3289; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WEBB TP, 1986, AM J MED GENET, V23, P573, DOI 10.1002/ajmg.1320230151; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	23	1703	1764	0	67	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1047	1058		10.1016/0092-8674(91)90283-5	http://dx.doi.org/10.1016/0092-8674(91)90283-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760838				2022-12-24	WOS:A1991GX16400005
J	SCHULTZ, R; READ, AW; STRATON, JAY; STANLEY, FJ; MORICH, P				SCHULTZ, R; READ, AW; STRATON, JAY; STANLEY, FJ; MORICH, P			GENITOURINARY TRACT INFECTIONS IN PREGNANCY AND LOW-BIRTH-WEIGHT - CASE-CONTROL STUDY IN AUSTRALIAN ABORIGINAL WOMEN	BRITISH MEDICAL JOURNAL			English	Article							WESTERN-AUSTRALIA; PRETERM BIRTH; HEALTH; MEMBRANES	Objective - To investigate the association between genital and urinary tract infections in pregnant Aboriginal women and low birth weight. Design - Retrospective case-control study controlling for potential confounding variables. Setting - Western Australia from 1985 to 1987. Subjects - All Aboriginal women (n = 269) who had given birth to singleton infants weighing 2250 g or less (cases), and 269 randomly selected Aboriginal women who had given birth to singleton infants weighing 3000 g or more (controls). Main outcome measures - Proportions of women in case and control groups who had had genital and urinary tract infections; odds ratios for low birth weight when genitourinary tract infection was present; population attributable fraction of low birth weight to genitourinary tract infection. Results - At the time of delivery 51% of women in the case group (109/215) had genitourinary tract infections compared with 13% of controls (35/266). After controlling for potential confounding variables the odds ratio for giving birth to infants weighing 2250 g or less when genitourinary tract infection was present was 4.0 (95% confidence interval 2.3 to 7.0). The proportion of infants with low birth weight attributable to genitourinary tract infection in the whole population of Aboriginal women was 32% (95% confidence interval 17% to 49%). Conclusions - There was a strong association between low birth weight and the presence of genitourinary tract infections in Aboriginal women both during pregnancy and at the time of delivery. A community intervention trial of screening and treatment of genitourinary infections in this population is recommended.	WESTERN AUSTRALIAN RES INST CHILD HLTH,PERTH,WA 6001,AUSTRALIA	Telethon Kids Institute; University of Western Australia	SCHULTZ, R (corresponding author), UNIV WESTERN AUSTRALIA,DEPT PUBL HLTH,NEDLANDS,WA 6009,AUSTRALIA.							ARTURO ZC, 1989, THESIS U W AUSTR, P127; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BLAND M, 1987, INTRO MED STATISTICS; BOWER C, 1988, REPORT CONGENITAL MA; CHISWICK ML, 1986, BRIT J OBSTET GYNAEC, V93, P1236, DOI 10.1111/j.1471-0528.1986.tb07857.x; CREASY RK, 1980, OBSTET GYNECOL, V55, P692; HILL C, 1987, VALIDATION STUDY W A; HOUSTON S, 1985, MED J AUSTRALIA, V143, pS45; ILLSLEY R, 1963, PERINATAL MORTALITY, P270; KHOURY MJ, 1988, PEDIATRICS, V82, P83; KLIEWER EV, 1989, MED J AUSTRALIA, V151, P493, DOI 10.5694/j.1326-5377.1989.tb128495.x; Lee M L, 1988, J Perinat Neonatal Nurs, V2, P10; LEGER WJ, 1989, AM J PERINAT, V6, P234; MCGREGOR JA, 1988, AM J REPROD IMMUNOL, V16, P123; MOORE D, 1988, PERINATAL STATISTICS; NAEYE RL, 1980, LANCET, V1, P192; ROMERO R, 1989, OBSTET GYNECOL, V73, P576; ROMERO R, 1989, J REPROD MED, V34, P797; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817, DOI 10.1016/0002-9378(89)90409-2; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SEWARD JF, 1981, MED J AUSTRALIA, V2, P80, DOI 10.5694/j.1326-5377.1981.tb100804.x; THOMSON N, 1984, AUST NZ J MED, V14, P705, DOI 10.1111/j.1445-5994.1984.tb05038.x; THOMSON N, 1985, MED J AUSTRALIA, V143, pS46; THOMSON N, 1983, AUST ABORIG STUD, V1, P10; TOTH M, 1988, OBSTET GYNECOL, V71, P723; Wang E, 1989, EFFECTIVE CARE PREGN, P534; 1989, AM J EPIDEMIOL, V129, P1247; 1985, SAS PROCEDURES GUIDE	28	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1369	1373		10.1136/bmj.303.6814.1369	http://dx.doi.org/10.1136/bmj.303.6814.1369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760603	Bronze, Green Published			2022-12-24	WOS:A1991GU38400020
J	MONTESANO, R; MATSUMOTO, K; NAKAMURA, T; ORCI, L				MONTESANO, R; MATSUMOTO, K; NAKAMURA, T; ORCI, L			IDENTIFICATION OF A FIBROBLAST-DERIVED EPITHELIAL MORPHOGEN AS HEPATOCYTE GROWTH-FACTOR	CELL			English	Article							SCATTER FACTOR; ANGIOGENESIS INVITRO; MOLECULAR-CLONING; HEPATOPOIETIN-A; MESSENGER-RNA; PURIFICATION; CELLS; EXPRESSION; EMBRYOGENESIS; MONOLAYERS	We have previously shown that Madin-Darby canine kidney (MDCK) epithelial cells grown in collagen gels in the presence of fibroblasts or fibroblast-conditioned medium (CM) form branching tubules, instead of the spherical cysts that develop under control conditions. We now report that the fibroblast-derived molecule responsible for epithelial tubulogenesis is hepatocyte growth factor (HGF). First, addition of exogenous HGF to cultures of MDCK cells induces formation of epithelial tubules. Second, the tubulogenic activity of fibroblast CM is completely abrogated by antibodies to HGF. These results demonstrate that HGF, a polypeptide that was identified as a mitogen for cultured hepatocytes, has the properties of a paracrine mediator of epithelial morphogenesis, and suggest that it may play important roles in the formation of parenchymal organs during embryonic development.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN	Kyushu University	MONTESANO, R (corresponding author), UNIV GENEVA,MED CTR,INST HISTOL & EMBRYOL,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND.							ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAMBARD M, 1981, J CELL BIOL, V91, P157, DOI 10.1083/jcb.91.1.157; COFFER A, 1991, BIOCHEM J, V278, P35, DOI 10.1042/bj2780035; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GROBSTEIN C, 1956, ADV CANCER RES, V4, P187, DOI 10.1016/S0065-230X(08)60725-3; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; KONISHI T, 1991, IN PRESS BIOCH BIOPH; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MATSUMOTO K, 1991, IN PRESS CRIT REV ON; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1983, J CELL BIOL, V97, P935, DOI 10.1083/jcb.97.3.935; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MONTESANO R, 1991, P NATL ACAD SCI USA, V66, P697; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PRAT PM, 1991, IN PRESS INT J CANCE; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Saxen L., 1976, CELL SURFACE ANIMAL, P331; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SLACK JMW, 1989, LANCET, V1, P1312; SPORN MB, 1990, HDB EXPT PHARM, V1; SPORN MB, 1990, HDB EXPT PHARM, V2; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; UENO N, 1990, Progress in Growth Factor Research, V2, P113, DOI 10.1016/0955-2235(90)90027-H; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WOLF HK, 1991, AM J PATHOL, V138, P1035; YANG J, 1979, P NATL ACAD SCI USA, V76, P3401, DOI 10.1073/pnas.76.7.3401; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314	57	1160	1201	1	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1991	67	5					901	908		10.1016/0092-8674(91)90363-4	http://dx.doi.org/10.1016/0092-8674(91)90363-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GT755	1835669				2022-12-24	WOS:A1991GT75500009
J	MAKITA, Z; RADOFF, S; RAYFIELD, EJ; YANG, Z; SKOLNIK, E; DELANEY, V; FRIEDMAN, EA; CERAMI, A; VLASSARA, H				MAKITA, Z; RADOFF, S; RAYFIELD, EJ; YANG, Z; SKOLNIK, E; DELANEY, V; FRIEDMAN, EA; CERAMI, A; VLASSARA, H			ADVANCED GLYCOSYLATION END-PRODUCTS IN PATIENTS WITH DIABETIC NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUCOSE-MODIFIED PROTEINS; SURFACE BINDING-PROTEIN; CHRONIC-HEMODIALYSIS; HUMAN COLLAGEN; COMPLICATIONS; RECEPTOR; MELLITUS; DISEASE; TISSUE; BETA-2-MICROGLOBULIN	Background. Glucose reacts nonenzymatically with proteins in vivo, chemically forming covalently attached glucose-addition products and cross-links between proteins. The excessive accumulation of rearranged late-glucose-addition products, or advanced glycosylation end products (AGEs), is believed to contribute to the chronic complications of diabetes mellitus. Methods. To elucidate the relation of AGEs to diabetic complications, we used a radioreceptor assay to measure serum and tissue AGEs in diabetic (Types I and II) and nondiabetic patients with different levels of renal function. Serum AGEs were measured as a low-molecular-weight (less-than-or-equal-to 10 kd) peptide fraction and a high-molecular-weight (> 10 kd) protein fraction. Results. The mean (+/- SD) AGE content of samples of arterial-wall collagen from 9 diabetic patients was significantly higher than that of samples from 18 nondiabetic patients (14.5 +/- 5.2 vs. 3.6 +/- 1.5 AGE units per milligram, P < 0.001). Moreover, diabetic patients with end-stage renal disease had almost twice as much AGE in tissue as diabetic patients without renal disease (21.3 +/- 2.8 vs. 11.5 +/- 1.9 AGE units per milligram, P < 0.001). The AGE levels in both serum fractions were elevated in the patients with-diabetes, and the levels of AGE peptides correlated directly with serum creatinine (P < 0.001) and inversely with creatinine clearance (P < 0.005), suggesting that levels of AGE peptides increased with the severity of diabetic nephropathy. In six patients with diabetes who required hemodialysis, the levels of AGE peptides were five times higher than in eight normal subjects (82.8 +/- 9.4 vs. 15.6 +/- 3.4 AGE units per milliliter, P < 0.001). In another group of diabetic patients, the mean serum creatinine level decreased by 75 percent during a session of hemodialysis, whereas the level of AGE peptides decreased by only 24 percent. Serum levels of AGE peptides were normal in two patients with normal serum creatinine levels after renal transplantation. Conclusions. AGEs accumulate at a faster-than-normal rate in arteries and the circulation of patients with diabetes; the increase in circulating AGE peptides parallels the severity of renal functional impairment in diabetic nephropathy.	SUNY DOWNSTATE MED CTR HOSP, DEPT MED, DIV RENAL DISEASES, NEW YORK, NY USA; ROCKEFELLER UNIV, MED BIOCHEM LAB, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008245, R01AG006943] Funding Source: NIH RePORTER; NIA NIH HHS [AG6943, AG8245] Funding Source: Medline; NIDDK NIH HHS [DK19655] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABB AL, 1971, T AM SOC ART INT ORG, V17, P81; BERGSTROM J, 1986, REPLACEMENT RENAL FU, P354; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN M, 1989, J BIOL CHEM, V264, P20947; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CERAMI A, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0587-90; DAVIS JE, 1978, DIABETES, V27, P102, DOI 10.2337/diabetes.27.2.102; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FARMAR JG, 1988, J ORG CHEM, V53, P2346, DOI 10.1021/jo00245a039; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GEJYO F, 1986, KIDNEY INT, V30, P385, DOI 10.1038/ki.1986.196; GOLDSTEIN DE, 1986, CLIN CHEM, V32, pB64; GREENE DA, 1987, NEW ENGL J MED, V316, P599; HAMMER C, 1988, COMP BIOCHEM PHYS B, V90, P7, DOI 10.1016/0305-0491(88)90030-2; JACOBS C, 1981, P EUR DIAL TRANS, V18, P4; JEBSEN RH, 1967, NEW ENGL J MED, V277, P327, DOI 10.1056/NEJM196708172770702; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; MAKITA Z, 1990, DIABETES S, V39, pA29; MERIMEE TJ, 1990, NEW ENGL J MED, V322, P978, DOI 10.1056/NEJM199004053221406; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1988, DIABETES, V37, P867, DOI 10.2337/diabetes.37.7.867; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; NAKAYAMA H, 1987, J IMMUNOL METHODS, V99, P95; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; RADOFF S, 1990, DIABETES, V39, P1510, DOI 10.2337/diabetes.39.12.1510; RADOFF S, 1988, ARCH BIOCHEM BIOPHYS, V263, P418, DOI 10.1016/0003-9861(88)90654-6; RADOFF S, IN PRESS DIABETES; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; VISHWANATH V, 1986, DIABETES, V35, P916, DOI 10.2337/diabetes.35.8.916; VLASSARA H, 1989, J CLIN INVEST, V84, P1813, DOI 10.1172/JCI114366; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WING AJ, 1986, REPLACEMENT RENAL FU, P850; WOLFF SP, 1989, MAILLARD REACTION AG, P259	38	784	805	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					836	842		10.1056/NEJM199109193251202	http://dx.doi.org/10.1056/NEJM199109193251202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875967				2022-12-24	WOS:A1991GF61600002
J	GODDEN, JW; TURLEY, S; TELLER, DC; ADMAN, ET; LIU, MY; PAYNE, WJ; LEGALL, J				GODDEN, JW; TURLEY, S; TELLER, DC; ADMAN, ET; LIU, MY; PAYNE, WJ; LEGALL, J			THE 2.3 ANGSTROM X-RAY STRUCTURE OF NITRITE REDUCTASE FROM ACHROMOBACTER-CYCLOCLASTES	SCIENCE			English	Article							PROTEINS	The three-dimensional crystal structure of the copper-containing nitrite reductase (NIR) from Achromobacter cycloclastes has been determined to 2.3 angstrom (angstrom) resolution by isomorphous replacement. The monomer has two Greek key beta-barrel domains similar to that of plastocyanin and contains two copper sites. The enzyme is a trimer both in the crystal and in solution. The two copper atoms in the monomer comprise one type I copper site (Cu-I; two His, one Cys, and one Met ligands) and one putative type II copper site (Cu-II; three His and one solvent ligands). Although ligated by adjacent amino acids Cu-I and Cu-II are approximately 12.5 angstrom apart. Cu-II is bound with nearly perfect tetrahedral geometry by residues not within a single monomer, but from each of two monomers of the trimer. The Cu-II site is at the bottom of a 12 angstrom deep solvent channel and is the site to which the substrate (NO2-) binds, as evidenced by difference density maps of substrate-soaked and native crystals.	UNIV WASHINGTON, DEPT BIOL STRUCT SM20, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT MICROBIOL, ATHENS, GA 30602 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031770] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08268-02, GM31770] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adman E.T., 1985, METALLOPROTEINS ME 1, P1; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DENARIAZ G, 1991, BIOCHIM BIOPHYS ACTA, V1056, P225, DOI 10.1016/S0005-2728(05)80053-2; DOOLEY DM, 1988, J BIOL CHEM, V263, P14625; FENDERSON FF, 1991, BIOCHEMISTRY-US, V30, P7180, DOI 10.1021/bi00243a020; Golterman H. L., 1985, Denitrification in the nitrogen cycle, P1; HULSE CL, 1988, ANAL BIOCHEM, V172, P420, DOI 10.1016/0003-2697(88)90464-2; IWASAKI H, 1972, J BIOCHEM, V71, P645; IWASAKI H, 1975, J BIOCHEM-TOKYO, V78, P355, DOI 10.1093/oxfordjournals.jbchem.a130915; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; LIU MY, 1986, J BACTERIOL, V166, P604, DOI 10.1128/jb.166.2.604-608.1986; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; Payne W. J., 1985, Denitrification in the nitrogen cycle, P47; SHAPLEIGH JP, 1987, BIOCHIM BIOPHYS ACTA, V911, P334, DOI 10.1016/0167-4838(87)90074-4; SHAPLEIGH JP, 1985, FEMS MICROBIOL LETT, V26, P275; SOLOMON EI, 1983, COPPER COORDINATION, P1; SUZUKI S, 1989, BIOCHEM BIOPH RES CO, V164, P1366, DOI 10.1016/0006-291X(89)91820-2; Teller D C, 1973, Methods Enzymol, V27, P346; TURLEY S, 1988, J MOL BIOL, V200, P417, DOI 10.1016/0022-2836(88)90251-3; WANG BC, 1985, METHOD ENZYMOL, V115, P90	26	344	348	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					438	442		10.1126/science.1862344	http://dx.doi.org/10.1126/science.1862344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862344				2022-12-24	WOS:A1991FY28800038
J	KNIGHTON, DR; ZHENG, JH; TENEYCK, LF; XUONG, NH; TAYLOR, SS; SOWADSKI, JM				KNIGHTON, DR; ZHENG, JH; TENEYCK, LF; XUONG, NH; TAYLOR, SS; SOWADSKI, JM			STRUCTURE OF A PEPTIDE INHIBITOR BOUND TO THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE-MONOPHOSPHATE DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; ACTIVE-SITE; SECONDARY STRUCTURE; SUBSTRATE; BINDING; 3',5'-MONOPHOSPHATE; IDENTIFICATION; CONFORMATION; HOMOLOGY; DOMAINS	The structure of a 20-amino acid peptide inhibitor bound to the catalytic subunit of cyclic AMP-dependent protein kinase, and its interactions with the enzyme, are described. The x-ray crystal structure of the complex is the basis of the analysis. The peptide inhibitor, derived from a naturally occurring heat-stable protein kinase inhibitor, contains an amphipathic helix that is followed by a turn and an extended conformation. The extended region occupies the cleft between the two lobes of the enzyme and contains a five-residue consensus recognition sequence common to all substrates and peptide inhibitors of the catalytic subunit. The helical portion of the peptide binds to a hydrophobic groove and conveys high affinity binding. Loops from both domains converge at the active site and contribute to a network of conserved residues at the sites of magnesium adenosine triphosphate binding and catalysis. Amino acids associated with peptide recognition, nonconserved, extend over a large surface area.	UNIV CALIF SAN DIEGO,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; SAN DIEGO SUPERCOMP CTR,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT PHYS,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [T32CA09523] Funding Source: Medline; NCRR NIH HHS [RR01644] Funding Source: Medline; NIDDK NIH HHS [T32DK07233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BRAMSON HN, 1987, BIOCHEMISTRY-US, V26, P4466, DOI 10.1021/bi00388a042; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1989, J BIOL CHEM, V264, P14579; GRANOT J, 1981, BIOCHEMISTRY-US, V20, P602, DOI 10.1021/bi00506a024; GRANOT J, 1981, J BIOL CHEM, V255, P4569; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HJELMQUIST G, 1974, BIOCHEM BIOPH RES CO, V61, P559, DOI 10.1016/0006-291X(74)90993-0; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kemp BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; NELSON NC, 1983, J BIOL CHEM, V258, P981; PARELLO J, IN PRESS J MOL BIOL; REED J, 1984, BIOCHEMISTRY-US, V23, P1357, DOI 10.1021/bi00302a004; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; REED J, 1989, BIOCHEM J, V264, P371, DOI 10.1042/bj2640371; REED J, 1987, BIOCHEMISTRY-US, V26, P7641, DOI 10.1021/bi00398a017; ROSEVEAR PR, 1984, BIOCHEMISTRY-US, V23, P3161, DOI 10.1021/bi00309a009; SALERNO A, 1990, J BIOL CHEM, V265, P18079; SHOJI S, 1979, J BIOL CHEM, V254, P6211; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4461, DOI 10.1021/bi00388a041; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WELDON SL, 1985, J BIOL CHEM, V260, P4203; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YONEMOTO W, IN PRESS METHODS ENZ; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZOLLER MN, 1981, J BIOL CHEM, V256, P10387	42	883	946	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1991	253	5018					414	420		10.1126/science.1862343	http://dx.doi.org/10.1126/science.1862343			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862343				2022-12-24	WOS:A1991FY28800031
J	MISSIAEN, L; TAYLOR, CW; BERRIDGE, MJ				MISSIAEN, L; TAYLOR, CW; BERRIDGE, MJ			SPONTANEOUS CALCIUM RELEASE FROM INOSITOL TRISPHOSPHATE-SENSITIVE CALCIUM STORES	NATURE			English	Article							INTRACELLULAR CALCIUM; CA-2+ RELEASE; FURA-2-LOADED HEPATOCYTES; OSCILLATIONS; CELLS; 1,4,5-TRISPHOSPHATE; MITOCHONDRIA; PHOSPHATES; RETICULUM; BINDING	Inositol 1,4,5-trisphosphate (InsP3) functions as a second messenger to mobilize Ca2+ from intracellular reservoirs 1. The release mechanism displays all-or-none characteristics 2,3, that may account for other observations that the InsP3-induced mobilization of Ca2+ is quantal 4-6. Quantal release may depend on the sensitivity of the InsP3 receptor being regulated by the Ca2+ concentration in the lumen of the endoplasmic reticulum 7. We report here that the InsP3-sensitive store in hepatocytes discharges spontaneously when overloaded with Ca2+. The release, which is blocked by heparin, is preceded by an increasing sensitivity of the InsP3 receptor to endogenous InsP3, and is promoted by those sulphydryl reagents (oxidized glutathione and thimerosal) that induce Ca2+ oscillations in intact cells (ref. 8, and T. A. Rooney, D. C. Renard, E. J. Sass and A. P. Thomas, manuscript in preparation). This novel process could have a role in generating both Ca2+ oscillations and Ca2+ waves.	UNIV CAMBRIDGE, DEPT PHARMACOL, CAMBRIDGE CB2 1QJ, ENGLAND	University of Cambridge	MISSIAEN, L (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, AFRC, MOLEC SIGNALLING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BECKER GL, 1980, J BIOL CHEM, V255, P9009; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; KURTZ A, 1989, P NATL ACAD SCI USA, V86, P3423, DOI 10.1073/pnas.86.9.3423; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; OHNISHI ST, 1979, J BIOCHEM, V86, P1147, DOI 10.1093/oxfordjournals.jbchem.a132609; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PERES A, 1990, FEBS LETT, V275, P213, DOI 10.1016/0014-5793(90)81474-3; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; STUENKEL EL, 1990, AM J PHYSIOL, V258, pC289, DOI 10.1152/ajpcell.1990.258.2.C289; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1990, CELL CALCIUM, V11, P353, DOI 10.1016/0143-4160(90)90038-V; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; ZHAO H, 1990, J BIOL CHEM, V265, P14822	28	335	340	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					241	244		10.1038/352241a0	http://dx.doi.org/10.1038/352241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857419				2022-12-24	WOS:A1991FX18500066
J	SLEZAK, SE; MUIRHEAD, KA				SLEZAK, SE; MUIRHEAD, KA			RADIOACTIVE CELL-MEMBRANE LABELING	NATURE			English	Article							FLUORESCENT				SLEZAK, SE (corresponding author), ZYNAXIS CELL SCI,371 PHOENIXVILLE PIKE,MALVERN,PA 19355, USA.							GRAY G, 1991, J NUCL MED, V32, P1092; HOFER KH, 1984, BLOOD CELLS NUCL M 2, P224; HORAN PK, 1990, FLOW CYTOMETRY, V30, P469; KOPIA GA, 1990, CIRCULATION, V82, P175; MEINICOFF MJ, 1988, J LEUKOCYTE BIOL, V43, P387; OLZEWSKI WL, 1987, IN VIVO MIGRATION IM, P223; PALMER LD, 1991, FASEB J, V5, pA639; ROWLINSONBUSZA G, 1991, CANCER RES, V51, P3251; SLEZAK SE, 1989, J IMMUNOL METHODS, V117, P205, DOI 10.1016/0022-1759(89)90142-7; SLEZAK SE, 1989, BLOOD, V74, P2171; TEARE GF, 1991, CELL IMMUNOL, V134, P157, DOI 10.1016/0008-8749(91)90339-D; YUAN Y, 1990, MICROVASC RES, V40, P218, DOI 10.1016/0026-2862(90)90021-I	12	20	21	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					261	262		10.1038/352261a0	http://dx.doi.org/10.1038/352261a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857424				2022-12-24	WOS:A1991FX18500073
J	BLOOM, DE; GLIED, S				BLOOM, DE; GLIED, S			BENEFITS AND COSTS OF HIV TESTING	SCIENCE			English	Article							IMMUNODEFICIENCY VIRUS HIV; UNITED-STATES; AIDS; MEN; PREVENTION; KNOWLEDGE; IMPACT; COHORT; TRIAL	The benefits and costs of human immunodeficiency virus (HIV) testing in employment settings are examined from two points of view: that of private employers whose profitability may be affected by their testing policies and that of public policy-makers who may affect social welfare through their design of regulations related to HIV testing. The results reveal that HIV testing is clearly not cost-beneficial for most firms, although the benefits of HIV testing may outweigh the costs for some large firms that offer generous fringe-benefit packages and that recruit workers from populations in which the prevalence of HIV infection is high. The analysis also indicates that the testing decisions of unregulated employers are not likely to yield socially optimal economic outcomes and that existing state and federal legislation related to HIV testing in employment settings has been motivated primarily by concerns over social equity.	COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10027; COLUMBIA UNIV,DEPT ECON,NEW YORK,NY 10027	Columbia University; Columbia University	BLOOM, DE (corresponding author), COLUMBIA UNIV,DEPT ECON,NEW YORK,NY 10027, USA.				NICHD NIH HHS [HD25914-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025914] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANTA WF, 1989, COMPLETE HDB COMBATT; BLOOM DE, 1988, SCIENCE, V239, P604, DOI 10.1126/science.3277273; BLOOM DE, 1989, HEALTH POLICY, V11, P187, DOI 10.1016/0168-8510(89)90035-3; BODEN LI, 1986, J OCCUP ENVIRON MED, V28, P751, DOI 10.1097/00043764-198608000-00040; BOWLEG IA, 1989, SUMMARY AIDS LAWS 19; Brown Charles, 1990, EMPLOYERS LARGE SMAL; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; DECRESCE RP, 1989, DRUG TESTING WORKPLA; EDEN J, 1988, AIDS HLTH INSURANCE; FEHRS LJ, 1988, LANCET, V2, P379; GAIL MH, 1989, STAT MED, V8, P59, DOI 10.1002/sim.4780080108; GLIED S, 1990, THESIS HARVARD U; GOLDEN JA, 1989, LANCET, V1, P654; HAY JW, 1988, J ACQ IMMUN DEF SYND, V1, P466; KOTLIKOFF LJ, 1983, PENSIONS AM EC; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P1499; LEONARD AS, 1987, AIDS LAW GUIDE PUBLI, P109; LONG JE, 1982, REV ECON STAT, V64, P211, DOI 10.2307/1924300; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MIIKE L, 1987, COMMUNICATION   1019; Ostrow D G, 1989, AIDS Educ Prev, V1, P1; Parsons D. O., 1986, HDB LABOR EC, V2, P789; RATCLIFFE JM, 1986, J OCCUP  MED, V28, P907; RUTHERFORD W, 1987, DEC PRES COMM HUM IM; SCITOVSKY AA, 1987, PUBLIC HEALTH REP, V102, P5; TEWKSBURY RL, 1984, HDB EMPLOYEE BENEFIT, P678; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P23; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1355, DOI 10.2105/AJPH.79.10.1355; VANGRIENSVEN GJP, 1989, AM J EPIDEMIOL, V129, P596; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1987, MORB MORTAL WKLY REP, V38, pS6; 1990, SCIENCE, V249, P20; 1988, HLTH US 1987; 1989, PROTECTION AIDS RELA; 1990, HIV AIDS SURVEIL NOV; NIH ND2591401 GRANT; 1988, FORTUNE; 1987, HOUSEHD EC STUD P70; 1988, JAMA-J AM MED ASSOC, V260, P935; 1986, BUR LABOR STAT B, V2262; 1990, STATISTICAL ABSTRACT; 1989, MORB MORTAL WKLY REP, V38, pS4; 1987, HLTH CARE COVERAGE C	45	30	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1798	1804		10.1126/science.1829547	http://dx.doi.org/10.1126/science.1829547			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU061	1829547				2022-12-24	WOS:A1991FU06100028
J	STRAUSFELD, U; LABBE, JC; FESQUET, D; CAVADORE, JC; PICARD, A; SADHU, K; RUSSELL, P; DOREE, M				STRAUSFELD, U; LABBE, JC; FESQUET, D; CAVADORE, JC; PICARD, A; SADHU, K; RUSSELL, P; DOREE, M			DEPHOSPHORYLATION AND ACTIVATION OF A P34CDC2 CYCLIN-B COMPLEX INVITRO BY HUMAN CDC25 PROTEIN	NATURE			English	Article							M-PHASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; PERIODIC ACTIVATION; POSSIBLE MECHANISM; MITOTIC INDUCER; KINASE; PURIFICATION; STARFISH; MITOSIS	OOCYTES arrested in the G2 phase of the cell cycle contain a p34cdc2/cyclin B complex which is kept in an inactive form by phosphorylation of its p34cdc2 subunit on tyrosine, threonine and perhaps serine residues (see refs 1 and 2 for review). The phosphatase(s) involved in p34cdc2 dephosphorylation is unknown, but the product of the fission yeast cdc25+ gene 3,4, and its homologues in budding yeast 5 and Drosophila 6 are probably positive regulators of the transition from G2 to M phase. We have purified the inactive p34cdc2/cyclin B complex from G2-arrested starfish oocytes. Addition of the purified bacterially expressed product of the human homologue of the fission yeast cdc25+ gene 7 (p54CDC25H) triggers p34cdc2 dephosphorylation and activates H1 histone kinase activity in this preparation. We propose that the cdc25+ gene product directly activates the p34cdc2-cyclin B complex.	LAB ARAGO, F-66650 BANYULS SUR MER, FRANCE; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; INSERM, F-34033 MONTPELLIER, FRANCE	Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	STRAUSFELD, U (corresponding author), CNRS, BP 5051, F-34033 MONTPELLIER, FRANCE.		Fesquet, didier/M-9750-2019; labbe, jean-claude/B-2277-2009; Fesquet, Didier/A-1490-2009	Fesquet, didier/0000-0001-5657-9689; 				Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; GOULD K, 1991, NATURE, V250, P1573; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1988, DEV BIOL, V127, P157, DOI 10.1016/0012-1606(88)90197-2; LABBE JC, IN PRESS METH ENZYM; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; TONKS NK, 1988, J BIOL CHEM, V263, P6722	21	532	550	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1991	351	6323					242	245		10.1038/351242a0	http://dx.doi.org/10.1038/351242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL990	1828290				2022-12-24	WOS:A1991FL99000060
J	LOTURCO, JJ; KRIEGSTEIN, AR				LOTURCO, JJ; KRIEGSTEIN, AR			CLUSTERS OF COUPLED NEUROBLASTS IN EMBRYONIC NEOCORTEX	SCIENCE			English	Article							GAP JUNCTIONAL COMMUNICATION; MAMMALIAN CEREBRAL-CORTEX; SINGLE-CHANNEL CURRENTS; FETAL MONKEY NEOCORTEX; VISUAL-CORTEX; RECOMBINANT RETROVIRUS; CORTICAL-NEURONS; MIGRATION; TRANSPLANTATION; GUIDANCE	The neocortex of the brain develops from a simple germinal layer into a complex multilayer structure. To investigate cellular interactions during early neocortical development, whole-cell patch clamp recordings were made from neuroblasts in the ventricular zone of fetal rats. During early corticogenesis, neuroblasts are physiologically coupled by gap junctions into clusters of 15 to 90 cells. The coupled cells form columns within the ventricular zone and, by virtue of their membership in clusters, have low apparent membrane resistances and generate large responses to the inhibitory neurotransmitter gamma-aminobutyric acid. As neuronal migration out of the ventricular zone progresses, the number of cells within the clusters decreases. These clusters allow direct cell to cell interaction at the earliest stages of corticogenesis.			LOTURCO, JJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROSURG,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021223, P01NS012151, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHS [NS12151, NS07280, NS21223] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; BARFIELD J A, 1990, Society for Neuroscience Abstracts, V16, P1272; BERRY M, 1965, J ANAT, V99, P691; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLANTON MG, 1990, P NATL ACAD SCI USA, V87, P8027, DOI 10.1073/pnas.87.20.8027; CONNORS BW, 1984, J NEUROSCI, V4, P1324; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; GOODALL H, 1984, J EMBRYOL EXP MORPH, V79, P53; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; GUTNICK MJ, 1981, SCIENCE, V211, P67, DOI 10.1126/science.7444449; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; JENSEN KF, 1984, P NATL ACAD SCI-BIOL, V81, P964, DOI 10.1073/pnas.81.3.964; JONES EG, 1975, SCIENCE, V190, P572, DOI 10.1126/science.810887; KAZNOWSKI CE, 1990, SOC NEUR ABSTR, V16, P1272; KRIEGSTEIN A R, 1990, Society for Neuroscience Abstracts, V16, P57; LEE S, 1987, CELL, V51, P851, DOI 10.1016/0092-8674(87)90108-5; LOTURCO JJ, IN PRESS J NEUROSCI; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; MCCONNELL SK, 1985, SCIENCE, V229, P1268, DOI 10.1126/science.4035355; Miller M, 1988, DEV MATURATION CEREB, V7, P133; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PETERS A, 1975, J ANAT EMBRYOL, V141, P3; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1978, POSTGRAD MED J, V54, P25; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; RAKIC P, 1975, BRAIN MECHANISMS MEN, P3; ROBERTSON JD, 1963, J CELL BIOL, V19, P201, DOI 10.1083/jcb.19.1.201; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; SOMOGYI P, 1989, J NEUROSCI, V9, P2197; TURIN L, 1980, J PHYSIOL-LONDON, V300, P489, DOI 10.1113/jphysiol.1980.sp013174; VEENSTRA RD, 1986, SCIENCE, V233, P972, DOI 10.1126/science.2426781	41	277	279	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					563	566		10.1126/science.1850552	http://dx.doi.org/10.1126/science.1850552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850552				2022-12-24	WOS:A1991FJ12700046
J	HIBBS, J; PERPER, J; WINEK, CL				HIBBS, J; PERPER, J; WINEK, CL			AN OUTBREAK OF DESIGNER DRUG RELATED DEATHS IN PENNSYLVANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								3-Methylfentanyl ("China White") is a "designer" opiate that has caused more than 100 overdose deaths in California since 1979, but that has not been associated previously with deaths east of the Rocky Mountains. During 1988, 3-methylfentanyl was identified in 16 fatal overdose cases in Allegheny County, Pennsylvania, contributing to a fourfold rise in overdose mortality during October of that year. Morphine was detected in the blood of five persons (31%) and cocaine in the blood of three persons (19%) dying of 3-methylfentanyl overdoses; these were demographically similar to 99 other fatal overdose cases investigated by the county coroner from 1986 through 1988. This documents the contribution of 3-methylfentanyl to overdose mortality in an eastern city and the use of 3-methylfentanyl with other illegal drugs. Drug abusers in the northeastern United States should be considered at risk for more "designer drug" overdose outbreaks in the future.	CTR DIS CONTROL, DIV FIELD SERV, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; ALLEGHENY CTY CORONERS OFF, PITTSBURGH, PA USA; ALLEGHENY CTY DEPT LABS, PITTSBURGH, PA USA	Centers for Disease Control & Prevention - USA								AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; FROEDE RC, 1980, MICROSCOPIC DIAGNOSI, P149; GILLESPIE TJ, 1982, J ANAL TOXICOL, V6, P139, DOI 10.1093/jat/6.3.139; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Janssen P.A., 1985, OPIOIDS ANESTHESIA, P37; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; MARTIN ML, 1989, ANN EMERG MED, V18, P446; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; RUTTENBER AJ, 1984, SCIENCE, V226, P14, DOI 10.1126/science.6474188; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003	11	51	51	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					1011	1013		10.1001/jama.265.8.1011	http://dx.doi.org/10.1001/jama.265.8.1011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1867667				2022-12-24	WOS:A1991EY43200031
J	ENNALS, S				ENNALS, S			UNDERSTANDING BENEFITS - INDUSTRIAL INJURIES BENEFITS	BRITISH MEDICAL JOURNAL			English	Article											ENNALS, S (corresponding author), ESSENTIAL RIGHTS,94 CHAWORTH RD,NOTTINGHAM NG2 7AD,ENGLAND.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 16	1991	302	6773					400	401		10.1136/bmj.302.6773.400	http://dx.doi.org/10.1136/bmj.302.6773.400			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX858	1825930	Green Published, Bronze			2022-12-24	WOS:A1991EX85800032
J	ROTZLER, S; SCHRAMEK, H; BRENNER, HR				ROTZLER, S; SCHRAMEK, H; BRENNER, HR			METABOLIC STABILIZATION OF END-PLATE ACETYLCHOLINE-RECEPTORS REGULATED BY CA2+ INFLUX ASSOCIATED WITH MUSCLE-ACTIVITY	NATURE			English	Article							MAMMALIAN SKELETAL-MUSCLE; CA-2+ CHANNELS; CALCIUM CURRENTS; MEMBRANE; DEGRADATION; RYANODINE; CELLS; ENANTIOMERS; DENERVATION; FRACTION	DURING formation of the neuromuscular junction, acetylcholine receptors in the endplate membrane become matabolically stabilized under neural control, their half-life increasing from about 1 day to about 10 days (see ref. 1 for review). The metabolic stability of the receptors is regulated by the electrical activity induced in the muscle by innervation 2-4. We report here that metabolic stabilization of endplate receptors but not of extrajunctional receptors can be induced in the absence of muscle activity if muscles are treated with the calcium ionophore A23187. Acetylcholine receptor stabilization was also induced by culturing non-stimulated muscle in elevated K+ with the Ca2+ channel activator (+)-SDZ202-791. Conversely, activity-dependent receptor stabilization is prevented in muscle stimulated in the presence of the Ca2+ channel blockers (+)-PN200-110 or D-600. Treatment of muscles with ryanodine, which induces Ca2+ release from the sarcoplasmic reticulum in the absence of activity, does not cause stabilization of junctional receptors. Evidently, muscle activity induces metabolic acetylcholine receptor stabilization by way of an influx of Ca2+ ions through dihydropyridine-sensitive Ca2+ channels in the endplate membrane, whereas Ca2+ released from the sarcoplasmic reticulum is ineffective in this developmental process.	UNIV BASEL,DEPT PHYSIOL,VESALGASSE 1,CH-4051 BASEL,SWITZERLAND	University of Basel								BEAM KG, 1988, J GEN PHYSIOL, V91, P799, DOI 10.1085/jgp.91.6.799; BEAM KG, 1988, J GEN PHYSIOL, V91, P781, DOI 10.1085/jgp.91.6.781; BEVAN S, 1983, J PHYSIOL-LONDON, V336, P159, DOI 10.1113/jphysiol.1983.sp014574; BRENNER HR, 1989, J PHYSIOL-LONDON, V410, P501, DOI 10.1113/jphysiol.1989.sp017546; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P517, DOI 10.1073/pnas.83.2.517; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; FAIRHURST AS, 1970, EUR J BIOCHEM, V13, P504, DOI 10.1111/j.1432-1033.1970.tb00953.x; FAIRHURST AS, 1974, AM J PHYSIOL, V227, P1124, DOI 10.1152/ajplegacy.1974.227.5.1124; FUMAGALLI G, 1990, NEURON, V4, P563, DOI 10.1016/0896-6273(90)90114-U; HARRIS JB, 1971, ACTA PHYSIOL SCAND, V83, P382, DOI 10.1111/j.1748-1716.1971.tb05091.x; HOF RP, 1985, J CARDIOVASC PHARM, V7, P689, DOI 10.1097/00005344-198507000-00012; JENDEN DJ, 1969, PHARMACOL REV, V21, P1; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KOKUBUN S, 1986, MOL PHARMACOL, V30, P571; LEVITT TA, 1981, NATURE, V291, P239, DOI 10.1038/291239a0; LINDEN DC, 1979, NEUROSCIENCE, V4, P527, DOI 10.1016/0306-4522(79)90129-5; MCCLESKEY EW, 1985, J PHYSIOL-LONDON, V361, P231, DOI 10.1113/jphysiol.1985.sp015643; MILEDI R, 1980, J PHYSIOL-LONDON, V300, P197, DOI 10.1113/jphysiol.1980.sp013158; PAPPONE PA, 1980, J PHYSIOL-LONDON, V306, P377, DOI 10.1113/jphysiol.1980.sp013403; PEZZEMENTI L, 1981, J BIOL CHEM, V256, P2651; ROTZLER S, 1990, J CELL BIOL, V111, P655, DOI 10.1083/jcb.111.2.655; SALPETER MM, 1986, J CELL BIOL, V103, P1399, DOI 10.1083/jcb.103.4.1399; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; SCHMID A, 1984, FEBS LETT, V172, P114, DOI 10.1016/0014-5793(84)80885-6; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0	26	58	58	5	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 24	1991	349	6307					337	339		10.1038/349337a0	http://dx.doi.org/10.1038/349337a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1846230				2022-12-24	WOS:A1991EU50100055
J	TRUJILLO, KA; AKIL, H				TRUJILLO, KA; AKIL, H			INHIBITION OF MORPHINE-TOLERANCE AND DEPENDENCE BY THE NMDA RECEPTOR ANTAGONIST MK-801	SCIENCE			English	Article							ANALGESIC TOLERANCE; LOCUS COERULEUS; MECHANISMS; NEURONS; RATS	The N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor is an important mediator of several forms of neural and behavioral plasticity. The present studies examined whether NMDA receptors might be involved in the development of opiate tolerance and dependence, two examples of behavioral plasticity. The noncompetitive NMDA receptor antagonist MK-801 attenuated the development of tolerance to the analgesic effect of morphine without affecting acute morphine analgesia. In addition, MK-801 attenuated the development of morphine dependence as assessed by nalox-one-precipitated withdrawal. These results suggest that NMDA receptors may be important in the development of opiate tolerance and dependence.			TRUJILLO, KA (corresponding author), UNIV MICHIGAN, MENTAL HLTH RES INST, 205 WASHTENAW PL, ANN ARBOR, MI 48109 USA.		Trujillo, Keith/E-8427-2012	Trujillo, Keith/0000-0002-8059-6347	NIDA NIH HHS [DA05336, DA02265] Funding Source: Medline; NIMH NIH HHS [MH422251] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002265, F32DA005336] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; ANDRADE R, 1983, EUR J PHARMACOL, V91, P161, DOI 10.1016/0014-2999(83)90461-2; BAKER TB, 1985, PSYCHOL REV, V92, P78, DOI 10.1037/0033-295X.92.1.78; BLASIG J, 1973, PSYCHOPHARMACOLOGIA, V33, P19; BUCHAN A, 1990, J NEUROSCI, V10, P311; Christie M J, 1987, NIDA Res Monogr, V78, P158; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; CLOUET DH, 1975, ANNU REV PHARMACOL, V15, P49, DOI 10.1146/annurev.pa.15.040175.000405; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; CRISWELL HE, 1990, BRAIN RES, V512, P284, DOI 10.1016/0006-8993(90)90638-R; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DAFTERS R, 1989, BEHAV NEUROSCI, V103, P1082, DOI 10.1037/0735-7044.103.5.1082; FRANCIS DL, 1971, BRIT J PHARMACOL, V41, pP424; Goudie A. J., 1986, BEHAVIORAL BASIS DRU, P225; HARRIS LS, 1964, J PHARMACOL EXP THER, V143, P141; JOHNSON SM, 1989, PHARMACOL REV, V41, P435; KARLER R, 1989, LIFE SCI, V45, P599, DOI 10.1016/0024-3205(89)90045-3; LEWIS JW, 1987, BRAIN RES, V424, P65, DOI 10.1016/0006-8993(87)91193-0; NEHLS DG, 1990, BRAIN RES, V511, P271, DOI 10.1016/0006-8993(90)90172-8; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; RASMUSSEN K, 1989, BRAIN RES, V505, P346, DOI 10.1016/0006-8993(89)91466-2; RAY BA, 1988, NIDA RES MONOGR, V84; SHARP CW, 1984, NIDA RES MONOGR, V54; SIEGEL S, 1976, SCIENCE, V193, P323, DOI 10.1126/science.935870; Siegel S., 1983, RES ADV ALCOHOL DRUG, V7, P207; TIFFANY ST, 1988, BEHAV NEUROSCI, V102, P534, DOI 10.1037/0735-7044.102.4.534; TUNG CS, 1990, ACTA PHYSIOL SCAND, V138, P581, DOI 10.1111/j.1748-1716.1990.tb08888.x; WATKINS JC, 1989, NMDA RECEPTOR; WEI E, 1973, PSYCHOPHARMACOLOGIA, V28, P35, DOI 10.1007/BF00413955; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; WIKLER A, 1948, AM J PSYCHIAT, V105, P329, DOI 10.1176/ajp.105.5.329; WIKLER A, 1976, PAVLOVIAN J BIOL SCI, V11, P191	34	1065	1113	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					85	87		10.1126/science.1824728	http://dx.doi.org/10.1126/science.1824728			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1824728				2022-12-24	WOS:A1991EQ60300033
J	EMINI, EA; SCHLEIF, WA; NUNBERG, JH; CONLEY, AJ; EDA, Y; TOKIYOSHI, S; PUTNEY, SD; MATSUSHITA, S; COBB, KE; JETT, CM; EICHBERG, JW; MURTHY, KK				EMINI, EA; SCHLEIF, WA; NUNBERG, JH; CONLEY, AJ; EDA, Y; TOKIYOSHI, S; PUTNEY, SD; MATSUSHITA, S; COBB, KE; JETT, CM; EICHBERG, JW; MURTHY, KK			PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY GP120 V3 DOMAIN-SPECIFIC MONOCLONAL-ANTIBODY	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODIES; GLYCOPROTEIN GP120; ACID SEQUENCE; ENVELOPE; EPITOPE; PROTEIN; BINDING; FUSION; CELLS	THE acquired immunodeficiency syndrome (AIDS) is the late-stage clinical manifestation of long-term persistent infection with the human immunodeficiency virus type 1 (HIV-1). Immune responses directed against the virus and against virus-infected cells during the persistent infection fail to mediate resolution of the infection. As a result, a successful AIDS vaccine must elicit an immune state that will prevent the establishment of the persistent infection following introduction of the virus into the host. The third hypervariable (V3) domain of the HIV-1 gp120 envelope glycoprotein is a disulphide-linked closed loop of about 30 amino acids which binds and elicits anti-HIV-1 type-specific virus-neutralizing antibodies 1-7 . The in vitro characteristics of anti-V3 domain antibody suggest that this antibody could by itself prevent HIV-1 infection in vivo 8,9, an idea supported by chimpanzee challenge studies in which protection against the HIV-1 persistent infection seemed to correlate with the presence of anti-V3 domain antibody 10-12. Here we directly demonstrate the protective efficacy of anti-V3 domain antibody in vivo and propose that this antibody is potentially useful as both a pre- and post-exposure prophylactic agent.	CHEMOSEROTHERAPEUT RES INST,KUMAMOTO 86115,JAPAN; REPLIGEN CORP,CAMBRIDGE,MA 02139; KUMAMOTO UNIV,KUMAMOTO 860,JAPAN; SW FDN BIOMED RES,SAN ANTONIO,TX 78284	Kumamoto University; Texas Biomedical Research Institute	EMINI, EA (corresponding author), MERCK SHARP & DOHME LTD,W POINT,PA 19486, USA.		Matsushita, Shuzo/F-5782-2013					BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GOUDSMIT J, 1988, AIDS, V2, P157; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HO DD, 1987, J VIROL, V61, P2024, DOI 10.1128/JVI.61.6.2024-2028.1987; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KENEALY WR, 1989, AIDS RES HUM RETROV, V5, P173, DOI 10.1089/aid.1989.5.173; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; ROBERTSON GA, 1988, J VIROL METHODS, V20, P195, DOI 10.1016/0166-0934(88)90123-1; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988	15	493	526	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					728	730		10.1038/355728a0	http://dx.doi.org/10.1038/355728a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741059				2022-12-24	WOS:A1992HE60400064
J	GOTO, M; RUBENSTEIN, M; WEBER, J; WOODS, K; DRAYNA, D				GOTO, M; RUBENSTEIN, M; WEBER, J; WOODS, K; DRAYNA, D			GENETIC-LINKAGE OF WERNER SYNDROME TO 5 MARKERS ON CHROMOSOME-8	NATURE			English	Article							DNA; POLYMORPHISMS; CELLS	WERNER'S syndrome (WS) is a rare autosomal recessive disease in which the affected individuals display symptoms of premature ageing 1-3. The substantial phenotypic overlap between WS and normal ageing indicates that these two conditions may have pathogenetic mechanisms in common 3-5. The WS mutation has pleiotropic effects, and patients and their cells show many differences compared with normals 5. Despite extensive study of the clinical and biochemical features of this disorder, the primary genetic defect remains unknown. We have undertaken a genetic linkage study in an effort to identify the locus of the primary defect 6. Here we report close genetic linkage of the WS mutation to a group of markers on chromosome 8.	GENENTECH INC,DEPT MOLEC BIOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT SCI COMP,S SAN FRANCISCO,CA 94080; TOKYO METROPOLITAN OTSUKA HOSP,DEPT RHEUMATOL,TOKYO 170,JAPAN; MARSHFIELD FDN MED RES,MARSHFIELD,WI 54449	Roche Holding; Genentech; Roche Holding; Genentech								AOKI R, 1988, JPN J MED, V77, P125; ARAM H, 1974, CUTIS, V14, P215; BLANTON SH, 1991, GENOMICS, V11, P857, DOI 10.1016/0888-7543(91)90008-3; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CERIMELE D, 1982, HUM GENET, V62, P25, DOI 10.1007/BF00295600; CHI K, 1988, W JPN J DERMAT, V50, P824; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUJISAWA A, 1989, JPN J OPHTHALMOL, V31, P6785; GOTO M, 1978, CLIN CHIM ACTA, V85, P101, DOI 10.1016/0009-8981(78)90227-9; GOTO M, 1981, CLIN GENET, V19, P8; GOTO M, 1987, NEUROCUTANEOUS DIS, P242; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; HAYASHI N, 1985, JPN J ORTHOP, V31, P1871; KITATANI M, 1988, HUM GENET, V78, P94, DOI 10.1007/BF00291244; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LATHROP GM, 1984, AM J HUM GENET, V36, P460; MASHIYAMA S, 1988, JPN J NEUROSURG, V16, P75; MATSUMURA T, 1985, ADV EXP MED BIOL, V190, P313; MATSUNAGA I, 1975, JPN J OPHTHALMOL, V69, P743; MORI S, 1988, Japanese Journal of Geriatrics, V25, P486; OKUNO N, 1990, DIABETES, V33, P179; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; SALK D, 1982, HUM GENET, V62, P1, DOI 10.1007/BF00295598; SALK D, 1985, WERNERS SYNDROME HUM; SAMANTRAY SK, 1977, AUST NZ J MED, V7, P309, DOI 10.1111/j.1445-5994.1977.tb03695.x; SHINDO Y, 1986, Journal of Dermatology (Tokyo), V13, P396; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; THANNHAUSER SJ, 1945, ANN INTERN MED, V23, P559, DOI 10.7326/0003-4819-23-4-559; THORLEYLAWSON DA, 1977, J EXP MED, V146, P495, DOI 10.1084/jem.146.2.495; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WERNER O, 1904, THESIS U KIEL; YANGFENG TL, 1985, CYTOGENET CELL GENET, V40, P784	33	188	195	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1992	355	6362					735	738		10.1038/355735a0	http://dx.doi.org/10.1038/355735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE604	1741060				2022-12-24	WOS:A1992HE60400067
J	LEE, DK; HORIKOSHI, M; ROEDER, RG				LEE, DK; HORIKOSHI, M; ROEDER, RG			INTERACTION OF TFIID IN THE MINOR GROOVE OF THE TATA ELEMENT	CELL			English	Article							RNA POLYMERASE-II; INTEGRATION HOST FACTOR; BOX-BINDING-PROTEIN; B-DNA DODECAMER; TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; FUNCTIONAL DOMAINS; YEAST; GENE; PROMOTER	TFIID binding in the minor groove of DNA at the TATA element was demonstrated by methylation interference and hydroxyl radical footprinting assays, and by binding studies with thymine analog substituted oligonucleotides. These results provide an explanation for TFIID-dependent DNA bending at the TATA element. TFIID binding shows phosphate contacts with the same residues that were found to be essential for TFIID interactions by methylation and thymine-specific modification interference assays. Based on previous studies implicating residues conserved between the direct repeats in DNA binding, as well as models of prokaryotic DNA binding proteins, these results also suggest a model in which the direct repeats of TFIID form two basic antiparallel beta-ribbon arms that could contact DNA through the minor groove.			LEE, DK (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.							BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUN L, 1975, BIOCHEMISTRY-US, V14, P1795, DOI 10.1021/bi00679a036; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TRAVERS A, 1987, NATURE, V327, P280, DOI 10.1038/327280a0; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1982, P NATL ACAD SCI-BIOL, V79, P5470; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	60	150	151	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1241	1250		10.1016/0092-8674(91)90300-N	http://dx.doi.org/10.1016/0092-8674(91)90300-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760848				2022-12-24	WOS:A1991GX16400022
J	SHARIEF, MK; HENTGES, R				SHARIEF, MK; HENTGES, R			ASSOCIATION BETWEEN TUMOR-NECROSIS-FACTOR-ALPHA AND DISEASE PROGRESSION IN PATIENTS WITH MULTIPLE-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; STATUS SCALE EDSS; CEREBROSPINAL-FLUID; LESIONS; CYCLOPHOSPHAMIDE; PLASMAPHERESIS; ASTROCYTES; EXCHANGE; SERUM; GAMMA	Background. Cachectin, or tumor necrosis factor-alpha (TNF-alpha), is a principal mediator of the inflammatory response and may be important in the pathogenesis and progression of multiple sclerosis, an inflammatory disease of the central nervous system. Methods. In a 24-month prospective study, we used a sensitive enzyme-linked immunosorbent assay to determine levels of TNF-alpha in cerebrospinal fluid and serum in 32 patients with chronic progressive multiple sclerosis and in 20 with stable multiple sclerosis and 85 with other neurologic diseases. An attempt was made to relate TNF-alpha levels with the degree of disability of the patients with multiple sclerosis and with their neurologic deterioration during the 24 months of observation. Results. High levels of TNF-alpha were found in the cerebrospinal fluid of 53 percent of the patients with chronic progressive multiple sclerosis and in none of those with stable multiple sclerosis (P < 0.001). TNF-alpha was detected in the cerebrospinal fluid of 7 percent of the controls (P < 0.01) with other neurologic disease. In patients with chronic progressive multiple sclerosis, mean TNF-alpha levels were significantly higher in the cerebrospinal fluid than in corresponding serum samples (52.41 vs. 11.88 U per milliliter; range, 2 to 178 vs. 2 to 39; P < 0.001). In these patients, cerebrospinal fluid levels of TNF-alpha correlated with the degree of disability (r = 0.834, P < 0.001) and the rate of neurologic deterioration (r = 0.741, P < 0.001) before the start of the study. Cerebrospinal fluid levels also correlated with the increase in neurologic disability after 24 months of observation (r = 0.873, P < 0.001). Conclusions. These data provide evidence of intrathecal synthesis of TNF-alpha in multiple sclerosis and suggest that the level of TNF-alpha in cerebrospinal fluid correlates with the severity and progression of the disease. Our results suggest that TNF-alpha may reflect histologic disease activity in multiple sclerosis and could be used to monitor outcomes or responses to therapy.	FREE UNIV BRUSSELS, DEPT NEUROPSYCHIAT, B-1050 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	SHARIEF, MK (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, INST NEUROL, DEPT CLIN NEUROCHEM, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							ADAMS CWM, 1989, J NEUROL SCI, V92, P291, DOI 10.1016/0022-510X(89)90144-5; BECK J, 1988, ACTA NEUROL SCAND, V78, P318, DOI 10.1111/j.1600-0404.1988.tb03663.x; BJORVATN B, 1984, BRIT MED J, V288, P439, DOI 10.1136/bmj.288.6415.439; BROSNAN CF, 1988, J NEUROIMMUNOL, V18, P87, DOI 10.1016/0165-5728(88)90137-3; CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; CHUNG IY, 1990, J IMMUNOL, V144, P2999; EBERS GC, 1986, DIS NERV SYST, P1268; FRANCIOTTA DM, 1989, ANN NEUROL, V26, P787, DOI 10.1002/ana.410260618; GALLO P, 1991, J NEUROL SCI, V101, P227, DOI 10.1016/0022-510X(91)90050-H; GAY D, 1991, BRAIN, V114, P557, DOI 10.1093/brain/114.1.557; GOODKIN DE, 1987, ARCH NEUROL-CHICAGO, V44, P823, DOI 10.1001/archneur.1987.00520200027013; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; JAMES PB, 1989, LANCET, V1, P46; JERSILD C, 1973, LANCET, V2, P1221; KERMODE AG, 1990, BRAIN, V113, P1477, DOI 10.1093/brain/113.5.1477; KHATRI BO, 1985, NEUROLOGY, V35, P312, DOI 10.1212/WNL.35.3.312; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LUXTON RW, 1989, CLIN CHEM, V35, P1731; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MCCULLAGH P, 1983, GENERALIZED LINEAR M, P99; MCLAUGHLIN PJ, 1990, IMMUNOL CELL BIOL, V68, P51, DOI 10.1038/icb.1990.7; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MINTZ M, 1989, AM J DIS CHILD, V143, P771, DOI 10.1001/archpedi.1989.02150190021012; MUSTAFA M M, 1989, Pediatric Infectious Disease Journal, V8, P907, DOI 10.1097/00006454-198912000-00037; MUSTAFA MM, 1989, J PEDIATR-US, V115, P208, DOI 10.1016/S0022-3476(89)80067-8; NOSEWORTHY JH, 1990, NEUROLOGY, V40, P971, DOI 10.1212/WNL.40.6.971; NOSEWORTHY JH, 1991, LANCET, V337, P441; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POSER S, 1982, ACTA NEUROL SCAND, V66, P355; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; ROBERTSON B, 1988, J IMMUNOL, V140, P4300; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; TOURTELLOTTE WW, 1978, NEUROLOGY, V28, P76, DOI 10.1212/WNL.28.9_Part_2.76; TOURTELLOTTE WW, 1988, J NEUROIMMUNOL, V20, P217, DOI 10.1016/0165-5728(88)90163-4; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TROTTER JL, 1989, ANN NEUROL, V25, P172, DOI 10.1002/ana.410250211; WAKSMAN BH, 1984, P SOC EXP BIOL MED, V175, P282; WALKER RWH, 1983, J NEUROIMMUNOL, V4, P141, DOI 10.1016/0165-5728(83)90018-8; WOLINSKY JS, 1990, ANN NEUROL, V27, P591	43	710	731	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					467	472		10.1056/NEJM199108153250704	http://dx.doi.org/10.1056/NEJM199108153250704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1852181	Bronze			2022-12-24	WOS:A1991GA76300004
J	MCLELLAN, DL				MCLELLAN, DL			REHABILITATION	BRITISH MEDICAL JOURNAL			English	Article											MCLELLAN, DL (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,REHABIL RES UNIT,LEVEL C,W WING,SOUTHAMPTON S09 4XY,ENGLAND.							Alexander J. L., 1979, Evaluation of Efficacy of Medical Action, P287; BEARDSHAW V, 1988, LAST LIST COMMUNITY; CANTRELL E, 1985, PRISONERS HANDICAP; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; Cornes P, 1991, Int Disabil Stud, V13, P5; EDWARDS FC, 1990, HLTH SERVICES ADULTS; GODFREY HPD, 1988, ARCH PHYS MED REHAB, V69, P458; MCLELLAN DL, 1987, J SOC OCCUP MED, V37, P94; ROBINE JM, 1991, BMJ-BRIT MED J, V302, P457, DOI 10.1136/bmj.302.6774.457; THOMAS AP, 1989, CLIN DEV MED, V106; WILSON BA, 1988, NEUROPSYCHOL REHABIL, P69; 1989, SURVEY DISABILITY GR, V1; 1991, CM1523	13	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1991	303	6798					355	357		10.1136/bmj.303.6798.355	http://dx.doi.org/10.1136/bmj.303.6798.355			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1833005	Green Published, Bronze			2022-12-24	WOS:A1991GA60600028
J	LIAO, NS; BIX, M; ZIJLSTRA, M; JAENISCH, R; RAULET, D				LIAO, NS; BIX, M; ZIJLSTRA, M; JAENISCH, R; RAULET, D			MHC CLASS-I DEFICIENCY - SUSCEPTIBILITY TO NATURAL-KILLER (NK) CELLS AND IMPAIRED NK ACTIVITY	SCIENCE			English	Article							BONE-MARROW ALLOGRAFTS; T-CELLS; INTERFERON INDUCERS; ANTIGEN EXPRESSION; LYMPHOMA VARIANTS; MICE; REJECTION; GENE; LYSIS; TRANSFECTION	The role of major histocompatibility complex (MHC) class I expression in natural killer (NK) cell target recognition is controversial. Normal T cell blasts from MHC class I-deficient mutant mice were found to serve as target cells for NK cells in vitro, which suggests that MHC class I molecules are directly involved in NK cell recognition. Spleen cells from the mutant mice were deficient in their ability to lyse MHC class I-deficient target cells or NK-susceptible tumor targets, and mutant mice could not reject allogeneic bone marrow. Thus, class I molecules may participate in the positive selection or tolerance induction of NK cells.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	University of California System; University of California Berkeley; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Liao, Nan-Shih/ABE-7580-2020	Liao, Nan-Shih/0000-0003-3707-4145; Bix, Mark/0000-0003-4617-0497; Raulet, David/0000-0002-1257-8649	NCI NIH HHS [R35 CA44339] Funding Source: Medline; NIAID NIH HHS [R01 AI30171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CICCONE E, 1990, J EXP MED, V172, P47, DOI 10.1084/jem.172.1.47; CUDKOWICZ G, 1964, NATURE, V204, P450, DOI 10.1038/204450a0; CUDKOWICZ G, 1971, J EXP MED, V134, P1513, DOI 10.1084/jem.134.6.1513; DEGLIANTONI G, 1985, J EXP MED, V162, P1512, DOI 10.1084/jem.162.5.1512; DENNERT G, 1988, J IMMUNOL, V140, P2472; DJEU JY, 1979, J IMMUNOL, V122, P175; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; GIDLUND M, 1978, NATURE, V273, P759, DOI 10.1038/273759a0; HARELBELLAN A, 1986, P NATL ACAD SCI USA, V83, P5688, DOI 10.1073/pnas.83.15.5688; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; KRIMPENFORT P, 1987, EMBO J, V6, P1673, DOI 10.1002/j.1460-2075.1987.tb02416.x; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; LJUNGGREN HG, 1990, J IMMUNOL, V145, P380; MASON LH, 1990, J IMMUNOL, V145, P751; MURPHY WJ, 1987, J EXP MED, V166, P1499, DOI 10.1084/jem.166.5.1499; NISHIMURA MI, 1988, J IMMUNOL, V141, P4403; OHLEN C, 1989, J IMMUNOL, V142, P3336; OHLEN C, 1989, SCIENCE, V246, P666, DOI 10.1126/science.2814488; RAULET DH, 1982, J EXP MED, V155, P1766, DOI 10.1084/jem.155.6.1766; RAULET DH, 1980, J IMMUNOL, V125, P1136; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SENTMAN CL, 1989, J IMMUNOL, V142, P1847; SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306; STORKUS WJ, 1989, J IMMUNOL, V143, P3853; STURMHOFEL K, 1990, EUR J IMMUNOL, V20, P171, DOI 10.1002/eji.1830200125; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZIJLSTRA M, UNPUB	32	423	430	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					199	202		10.1126/science.1853205	http://dx.doi.org/10.1126/science.1853205			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853205				2022-12-24	WOS:A1991FW16000038
J	LIVDAHL, TP; WILLEY, MS				LIVDAHL, TP; WILLEY, MS			PROSPECTS FOR AN INVASION - COMPETITION BETWEEN AEDES-ALBOPICTUS AND NATIVE AEDES-TRISERIATUS	SCIENCE			English	Article							TREE-HOLE MOSQUITOS; NORTH-AMERICA; UNITED-STATES; CULICIDAE; DIPTERA	Competition between larval populations of the native North American treehole mosquito Aedes triseriatus and Aedes albopictus, recently introduced from Asia to North America, was assessed by comparing per capita growth rate estimates for experimental cohorts of larvae developing under a variety of initial density combinations in fluid obtained from tires or from treeholes. Estimates of carrying capacities and competition coefficients indicate that competition between the two species will result in stable coexistence in treehole communities but local extinction of A. triseriatus in tire habitats.			LIVDAHL, TP (corresponding author), CLARK UNIV,DEPT BIOL,WORCESTER,MA 01610, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI027940] Funding Source: NIH RePORTER; NIAID NIH HHS [R15AI27940] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK WC, 1989, J MED ENTOMOL, V26, P260, DOI 10.1093/jmedent/26.4.260; BRADSHAW WE, 1988, OECOLOGIA, V74, P507, DOI 10.1007/BF00380047; BRADSHAW WE, 1983, OECOLOGIA, V57, P239, DOI 10.1007/BF00379586; COPELAND RS, 1990, ANN ENTOMOL SOC AM, V83, P1063, DOI 10.1093/aesa/83.6.1063; HARD JJ, 1989, OIKOS, V54, P137, DOI 10.2307/3565259; HAWLEY WA, 1987, SCIENCE, V236, P1114, DOI 10.1126/science.3576225; HO C, 1989, J MED ENTOMOL, V26, P615; LIVDAHL TP, 1984, J ANIM ECOL, V53, P573, DOI 10.2307/4535; OMEARA G, 1990, 1990 ANN M ENT WOC A; PETERSEN JJ, 1969, MOSQ NEWS, V29, P134; SCHREIBER ET, 1988, J AM MOSQUITO CONTR, V4, P9; SHROYER DA, 1986, J AM MOSQUITO CONTR, V2, P424; SOKAL RR, 1981, BIOMETRY, P795; SPRENGER D, 1986, J AM MOSQUITO CONTR, V2, P217; WALKER ED, 1988, ENVIRON ENTOMOL, V17, P199, DOI 10.1093/ee/17.2.199; 1989, AM MOSQ CONTROL ASS, V15, P15; 1990, AM MOSQ CONTROL ASS, V16, P13; 1990, AM MOSQ CONTROL ASS, V16, P5	18	156	158	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 12	1991	253	5016					189	191		10.1126/science.1853204	http://dx.doi.org/10.1126/science.1853204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW160	1853204				2022-12-24	WOS:A1991FW16000034
J	DOERING, TL; RAPER, J; BUXBAUM, LU; ADAMS, SP; GORDON, JI; HART, GW; ENGLUND, PT				DOERING, TL; RAPER, J; BUXBAUM, LU; ADAMS, SP; GORDON, JI; HART, GW; ENGLUND, PT			AN ANALOG OF MYRISTIC ACID WITH SELECTIVE TOXICITY FOR AFRICAN TRYPANOSOMES	SCIENCE			English	Article							VARIANT SURFACE GLYCOPROTEIN; PHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; GLYCOSYL-PHOSPHATIDYLINOSITOL; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; BRUCEI; BIOSYNTHESIS; PROTEIN; IDENTIFICATION; PURIFICATION	Trypanosoma brucei, the protozoan parasite responsible for African sleeping sickness, evades the host immune response through the process of antigenic variation. The variant antigen, known as the variant surface glycoprotein (VSG), is anchored to the cell surface by a glycosyl phosphatidylinositol (GPI) structure that contains myristate (n-tetradecanoate) as its only fatty acid component. The utilization of heteroatom-containing analogs of myristate was studied both in a cell-free system and in vivo. Results indicated that the specificity of fatty acid incorporation depends on chain length rather than on hydrophobicity. One analog, 10-(propoxy)decanoic acid, was highly toxic to trypanosomes in culture although it is nontoxic to mammalian cells.	MONSANTO CO,ST LOUIS,MO 64167; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Monsanto; Washington University (WUSTL)	DOERING, TL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21210, USA.			Hart, Gerald/0000-0001-7812-4351; Raper, Jayne/0000-0002-8723-9748	NIAID NIH HHS [AI21334, AI27179] Funding Source: Medline; NIGMS NIH HHS [5T32GM07309] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, R01AI021334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITMAN C, 1990, TROP DIS RES NEWS, V31, P3; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DIXON H, 1967, T ROY SOC TROP MED H, V61, P12; DOERING TL, 1989, J BIOL CHEM, V264, P11168; DOERING TL, 1990, J BIOL CHEM, V265, P611; DOERING TL, UNPUB; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAJDUK SL, 1989, TROPICAL GEOGRAPHIC, P268; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; RABEN DM, UNPUB; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001	32	75	77	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1851	1854		10.1126/science.1829548	http://dx.doi.org/10.1126/science.1829548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1829548				2022-12-24	WOS:A1991FU06100041
J	XIAO, JH; DAVIDSON, I; MATTHES, H; GARNIER, JM; CHAMBON, P				XIAO, JH; DAVIDSON, I; MATTHES, H; GARNIER, JM; CHAMBON, P			CLONING, EXPRESSION, AND TRANSCRIPTIONAL PROPERTIES OF THE HUMAN ENHANCER FACTOR TEF-1	CELL			English	Article							UBIQUITOUS NUCLEAR PROTEINS; SIMIAN VIRUS-40 ENHANCER; FIBROBLAST GROWTH-FACTOR; HUMAN ESTROGEN-RECEPTOR; CELL TYPE-SPECIFICITY; DNA-BINDING DOMAIN; NON-AUG CODONS; SV40 ENHANCER; MESSENGER-RNA; MAMMALIAN-CELLS	We describe the cDNA encoding the SV40 transcriptional enhancer factor 1 (TEF-1) and show that its translation initiates exclusively at an AUU codon in vivo. Cloned TEF-1, which is unrelated to other known transcription factors, specifically binds the SV40 GT-IIC and Sph enhansons. Cloned TEF-1 does not activate these enhansons in lymphoid MPC11 cells where they are known to be inactive, but represses the endogenous HeLa TEF-1 activity in vivo and in vitro. Repression is also observed with chimeras where the DNA-binding domain of the GAL4 activator replaces that of TEF-1, showing that repression results from interference/squelching. Such chimeras stimulate transcription in HeLa, but not in MPC11, cells in vivo and in HeLa cell extracts in vitro. However, high concentrations result in self-interference/squelching. These results strongly suggest that the trans-activation function of TEF-1 is mediated by a highly limiting, possible cell-specific, titratable transcriptional intermediary factor(s).	FAC MED STRASBOURG,INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Davidson, Irwin/0000-0001-5533-1171				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHAMBON P, 1984, RECENT PROG HORM RES, V40, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clemens MJ, 1989, CURR OPIN CELL BIOL, V1, P1160, DOI 10.1016/S0955-0674(89)80067-5; COSMAN D, 1987, IMMUNOL TODAY, V8, P16, DOI 10.1016/0167-5699(87)90826-7; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; DAVIDSON I, 1986, NATURE, V323, P544, DOI 10.1038/323544a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUPTA KC, 1988, J BIOL CHEM, V263, P8553; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HATZOPOULOS AK, 1988, TRANSCRIPTION SPLICI, P43; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERMAN RC, 1989, TRENDS BIOCHEM SCI, V14, P219, DOI 10.1016/0968-0004(89)90030-3; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIUCHI T, 1990, J BIOL CHEM, V265, P6521; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOZAK M, 1986, ADV VIRUS RES, V31, P229, DOI 10.1016/S0065-3527(08)60265-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1979, J BIOL CHEM, V254, P4731; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGHANGUE NB, 1988, TRANSCRIPTION SPLICI, P1; LAMAIRE P, 1990, MOL CELL BIOL, V10, P3456; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MACCHI M, 1989, EMBO J, V8, P4215, DOI 10.1002/j.1460-2075.1989.tb08607.x; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; PAYRE V, 1988, FEBS LETT, V234, P245; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUSZTAI R, 1989, J VIROL, V63, P3516, DOI 10.1128/JVI.63.8.3516-3518.1989; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TOOZE J, 1982, MOL BIOL TUMOR VIR 2, P799; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREIZENBERG SJ, 1988, GENE DEV, V2, P718; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WASYLYK B, 1988, CRC CR REV BIOCH MOL, V23, P77, DOI 10.3109/10409238809088317; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZHENG XM, 1990, NATURE, V344, P556, DOI 10.1038/344556a0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	120	360	367	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 17	1991	65	4					551	568		10.1016/0092-8674(91)90088-G	http://dx.doi.org/10.1016/0092-8674(91)90088-G			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FM037	1851669				2022-12-24	WOS:A1991FM03700006
J	YAMAMURA, Y; OGAWA, H; CHIHARA, T; KONDO, K; ONOGAWA, T; NAKAMURA, S; MORI, T; TOMINAGA, M; YABUUCHI, Y				YAMAMURA, Y; OGAWA, H; CHIHARA, T; KONDO, K; ONOGAWA, T; NAKAMURA, S; MORI, T; TOMINAGA, M; YABUUCHI, Y			OPC-21268, AN ORALLY EFFECTIVE, NONPEPTIDE VASOPRESSIN-VI RECEPTOR ANTAGONIST	SCIENCE			English	Article							ARGININE-VASOPRESSIN; ADENYLATE-CYCLASE; RAT; MEMBRANES; RESPONSES; HORMONE	An orally effective, nonpeptide, vasopressin V1 receptor antagonist, OPC-21268, has been identified. This compound selectively antagonized binding to the V1 subtype of the vasopressin receptor in a competitive manner. In vivo, the compound acted as a specific antagonist of arginine vasopressin (AVP)-induced vasoconstriction. After oral administration in conscious rats, the compound also antagonized pressor responses to AVP. OPC-21268 can be used to study the physiological role of AVP and may be therapeutically useful in the treatment of hypertension and congestive heart failure.			YAMAMURA, Y (corresponding author), OTSUKA PHARMACEUT CO LTD,TOKUSHIMA INST NEW DRUG RES 2,46310 KAGASUNO KAWAUCHI CHO,TOKUSHIMA 77101,JAPAN.							ANDERSON WA, 1963, BIOCHIM BIOPHYS ACTA, V67, P674; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOCKAERT J, 1973, J BIOL CHEM, V248, P5922; GILLESPIE JS, 1967, BRIT J PHARM CHEMOTH, V30, P78, DOI 10.1111/j.1476-5381.1967.tb02114.x; KNAPE JTA, 1988, ARCH INT PHARMACOD T, V291, P142; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING M, 1981, J MED CHEM, V24, P701, DOI 10.1021/jm00138a012; MANNING M, 1977, J MED CHEM, V20, P1228, DOI 10.1021/jm00219a026; MANNING M, 1989, J LAB CLIN MED, V114, P617; NAKAHARA T, 1978, J BIOL CHEM, V253, P3211; NAKAMURA T, 1983, J BIOL CHEM, V258, P9283; SAWYER WH, 1981, SCIENCE, V212, P49, DOI 10.1126/science.7209515; TOLBERT MEM, 1980, J BIOL CHEM, V255, P1938; YAMAMURA Y, UNPUB	15	303	317	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1991	252	5005					572	574		10.1126/science.1850553	http://dx.doi.org/10.1126/science.1850553			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ127	1850553				2022-12-24	WOS:A1991FJ12700049
J	HUANG, J; SCHNEIDER, RJ				HUANG, J; SCHNEIDER, RJ			ADENOVIRUS INHIBITION OF CELLULAR PROTEIN-SYNTHESIS INVOLVES INACTIVATION OF CAP-BINDING PROTEIN	CELL			English	Article							DOUBLE-STRANDED-RNA; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; 5' NONTRANSLATED REGION; MESSENGER-RNA; INITIATION-FACTOR; VAI-RNA; TRIPARTITE LEADER; TRANSLATIONAL CONTROL; INFECTED CELLS; GENE-EXPRESSION	Adenovirus (Ad) infection results in a marked inhibition of cellular protein synthesis that initiates during the late phase of the viral infectious cycle. We show that the mechanism used for suppression of cellular protein synthesis during cell cycle progression is exploited by Ad to repress host and enhance late viral mRNA translation. Discrimination between cellular and late Ad mRNAs and inhibition of host protein synthesis are shown to involve viral-mediated underphosphorylation of cap-binding protein (CBP) and subsequent inactivation of CBP complex, a large enzymatic complex required for cap-dependent mRNA translation. Late Ad mRNAs, like those of poliovirus, possess the unique ability to translate independent of a normal cap recognition process and do not require the activity of CBP complex. Inhibition of cellular translation by these two viruses is quite similar, except that whereas CBP complex is proteolytically degraded by poliovirus, it is functionally inactivated by Ad.	NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University	HUANG, J (corresponding author), NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016, USA.				NCI NIH HHS [CA-42357] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSOCAPLEN FV, 1988, J VIROL, V62, P1606, DOI 10.1128/JVI.62.5.1606-1616.1988; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; BABICH A, 1983, MOL CELL BIOL, V3, P1212, DOI 10.1128/MCB.3.7.1212; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BELTZ GA, 1979, J MOL BIOL, V131, P353, DOI 10.1016/0022-2836(79)90081-0; BERKNER KL, 1985, NUCLEIC ACIDS RES, V13, P841, DOI 10.1093/nar/13.3.841; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; CHERNEY CS, 1979, J VIROL, V5, P533; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DERY I, 1987, TRANSLATIONAL REGULA; DOLPH PJ, 1988, J VIROL, V62, P2059, DOI 10.1128/JVI.62.6.2059-2066.1988; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FLINT SJ, 1984, COMPR VIROL, V19, P297; GINSBERG HS, 1984, J GEN VIROL, V36, P59; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HAYES BW, 1990, J VIROL, V64, P2732, DOI 10.1128/JVI.64.6.2732-2742.1990; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HUANG JT, 1990, P NATL ACAD SCI USA, V87, P7115, DOI 10.1073/pnas.87.18.7115; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KITAJEWSKI J, 1986, MOL CELL BIOL, V6, P4493, DOI 10.1128/MCB.6.12.4493; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MARAN A, 1988, VIROLOGY, V164, P106, DOI 10.1016/0042-6822(88)90625-3; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MOORE M, 1987, MOL CELL BIOL, V7, P4505, DOI 10.1128/MCB.7.12.4505; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OMALLEY RP, 1989, VIROLOGY, V168, P112, DOI 10.1016/0042-6822(89)90409-1; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PETTERSSON U, 1978, CELL, V12, P741; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SCHNEIDER RJ, 1984, CELL, V37, P291, DOI 10.1016/0092-8674(84)90325-8; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SCHNEIDER RJ, 1985, P NATL ACAD SCI USA, V82, P4321, DOI 10.1073/pnas.82.13.4321; SEN GC, 1983, J GEN VIROL, V64, P2213, DOI 10.1099/0022-1317-64-10-2213; SIEKIERKA J, 1985, P NATL ACAD SCI USA, V82, P1959, DOI 10.1073/pnas.82.7.1959; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG Y, 1989, J BIOL CHEM, V264, P10679; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	64	153	161	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1991	65	2					271	280		10.1016/0092-8674(91)90161-Q	http://dx.doi.org/10.1016/0092-8674(91)90161-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FH092	1849798				2022-12-24	WOS:A1991FH09200010
J	CHIANG, HL; SCHEKMAN, R				CHIANG, HL; SCHEKMAN, R			REGULATED IMPORT AND DEGRADATION OF A CYTOSOLIC PROTEIN IN THE YEAST VACUOLE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; CATABOLITE INACTIVATION; STRUCTURAL GENE; FRUCTOSE-1,6-BISPHOSPHATASE; TRANSLOCATION; PHOSPHORYLATION; PROTEOLYSIS; ENCODES; GLUCOSE	The key regulatory enzyme in gluconeogenesis, fructose 1,6-bisphosphatase (FBPase) is subject to glucose-stimulated proteolytic degradation in Saccharomyces cerevisiae. This process involves the regulated transfer of FBPase directly from the cytosol into the vacuole or a vacuole-related organelle. Glucose may regulate the production of an FBPase receptor or import factor that is transported to the vacuole through the secretory pathway.			CHIANG, HL (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DIV BIOCHEM & MOLEC BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA.							AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BURLINI N, 1988, BIOCHIM BIOPHYS ACTA, V972, P353, DOI 10.1016/0167-4889(88)90212-1; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; FUNAGUMA T, 1985, BIOCHEM BIOPH RES CO, V130, P467, DOI 10.1016/0006-291X(85)90440-1; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; Guerra R. de la, 1988, FEBS Letters, V242, P149, DOI 10.1016/0014-5793(88)81004-4; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOLZER H, 1980, ANNU REV BIOCHEM, V49, P63, DOI 10.1146/annurev.bi.49.070180.000431; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAMPONI S, 1987, FEBS LETT, V216, P265, DOI 10.1016/0014-5793(87)80703-2; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; SCHAFER W, 1987, BIOCHIM BIOPHYS ACTA, V925, P150, DOI 10.1016/0304-4165(87)90104-8; SEDIVY JM, 1985, J MOL BIOL, V186, P307, DOI 10.1016/0022-2836(85)90107-X; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YOSHIHISA T, 1990, J BIOL CHEM, V265; ZUBENKO GS, 1981, GENETICS, V97, P45	32	140	140	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1991	350	6316					313	318		10.1038/350313a0	http://dx.doi.org/10.1038/350313a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD838	1848921				2022-12-24	WOS:A1991FD83800082
J	BERRY, MJ; BANU, L; LARSEN, PR				BERRY, MJ; BANU, L; LARSEN, PR			TYPE-I IODOTHYRONINE DEIODINASE IS A SELENOCYSTEINE-CONTAINING ENZYME	NATURE			English	Article							SELENIUM GLUTATHIONE-PEROXIDASE; PROTEIN DISULFIDE ISOMERASE; RAT-LIVER; NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; EXPRESSION; THYROXINE; TRIIODOTHYRONINE; INHIBITION; DEFICIENCY	ALTHOUGH thyroxine (3,5,3',5'-tetraiodonthyroine, T4) is the principal secretory product of the vertebrate thyroid, its essential metabolic and developmental effects are all mediated by 3,5,3'-triiodothyronine (T3), which is produced from the prohormone by 5'-deiodination. The type-I iodothyronine deiodinase, a thiol-requiring propylthiouracil-sensitive oxidoreductase, is found mainly in liver and kidney and provides most of the circulating T3(1) but so far this enzyme has not been purified. Using expression cloning in the Xenopus oocyte, we have isolated a 2.1-kilobase complementary DNA of this deiodinase from a rat liver cDNA library. The kinetic properties of the protein expressed in transient assay systems, the tissue distribution of the messenger RNA, and its changes with thyroid status, all confirm its identity. We find that the mRNA for this enzyme contains a UGA codon for selenocysteine which is necessary for maximal enzyme activity. This explains why conversion to T4 to T3 is impaired in experimental selenium deficiency 2-6 and identifies an essential role for this trace element in thyroid hormone action.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV THYROID,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	BERRY, MJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,HOWARD HUGHES MED INST LAB,75 FRANCIS ST,BOSTON,MA 02115, USA.							ARTHUR JR, 1988, RES VET SCI, V45, P122, DOI 10.1016/S0034-5288(18)30906-8; ARTHUR JR, 1990, J INORG BIOCHEM, V39, P101, DOI 10.1016/0162-0134(90)80018-S; ARTHUR JR, 1990, CLIN CHEM ENZYMOL CO, V3, P209; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BECKETT GJ, 1987, BIOCHEM J, V248, P443, DOI 10.1042/bj2480443; BECKETT GJ, 1989, BIOCHEM J, V259, P887, DOI 10.1042/bj2590887; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BEHNE D, 1990, BIOCHIM BIOPHYS ACTA, V1033, P219, DOI 10.1016/0304-4165(90)90124-F; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; BOADO RJ, 1988, BIOCHEM BIOPH RES CO, V155, P1297, DOI 10.1016/S0006-291X(88)81282-8; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FORSTROM JW, 1978, BIOCHEMISTRY-US, V17, P2639, DOI 10.1021/bi00606a028; FRUMESS RD, 1975, METABOLISM, V24, P547, DOI 10.1016/0026-0495(75)90079-7; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; ISHIDA K, 1987, NUCLEIC ACIDS RES, V15, P10051, DOI 10.1093/nar/15.23.10051; KOHRLE J, 1990, J BIOL CHEM, V265, P6146; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; LEE BJ, 1990, MOL CELL BIOL, V10, P1940, DOI 10.1128/MCB.10.5.1940; Leonard JL, 1986, THYROID HORMONE META, P189; MENON NK, 1987, J BACTERIOL, V169, P5401, DOI 10.1128/jb.169.12.5401-5407.1987; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; OPPENHEI.JH, 1972, J CLIN INVEST, V51, P2493, DOI 10.1172/JCI107063; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS CHH, 1989, BIOCHEM BIOPH RES CO, V162, P857, DOI 10.1016/0006-291X(89)92389-9; STGERMAIN DL, 1989, J BIOL CHEM, V264, P3054; TAPPEL AL, 1984, CURR TOP CELL REGUL, V24, P87; VISSER TJ, 1983, MOL CELL ENDOCRINOL, V33, P321, DOI 10.1016/0303-7207(83)90177-6; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	31	810	846	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					438	440		10.1038/349438a0	http://dx.doi.org/10.1038/349438a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1825132				2022-12-24	WOS:A1991EV51400059
J	HSU, MC; SCHUTT, AD; HOLLY, M; SLICE, LW; SHERMAN, MI; RICHMAN, DD; POTASH, MJ; VOLSKY, DJ				HSU, MC; SCHUTT, AD; HOLLY, M; SLICE, LW; SHERMAN, MI; RICHMAN, DD; POTASH, MJ; VOLSKY, DJ			INHIBITION OF HIV REPLICATION IN ACUTE AND CHRONIC INFECTIONS INVITRO BY A TAT ANTAGONIST	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; TRANSCRIPTIONAL REGULATION; QUANTITATIVE-ANALYSIS; ZIDOVUDINE AZT; HTLV-III; SEQUENCE; TYPE-1; PROTEIN	The human immunodeficiency virus-I (HIV-1) trans-activator Tat is an attractive target for the development of antiviral drugs because inhibition of Tat would arrest the virus at an early stage. The drug Ro 5-3335 [7-chloro-S-(2-pyrryl)-3H-1,4-benzodiazepin-2(H)-one], inhibited gene expression by HIV-1 at the level of transcriptional trans-activation by Tat. The compound did not inhibit the basal activity of the promoter. Both Tat and its target sequence TAR were required for the observed inhibitory activity. Ro 5-3335 reduced the amount of cell-associated viral RNA and antigen in acutely, as well as in chronically infected cells in vitro (median inhibition concentration 0.1 to 1 micromolar). Effective inhibition of viral replication was also observed 24 hours after cells were transfected with infectious recombinant HIV-1 DNA. The compound was active against both HIV-1 and HIV-2 and against 3'-azido-3'-deoxythymidine (AZT)-resistant clinical isolates.	UNIV CALIF SAN DIEGO,VET ADM MED CTR,INFECT DIS SECT,SAN DIEGO,CA 92161; COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR,MOLEC VIROL LAB,NEW YORK,NY 10019	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Columbia University; Mount Sinai St. Luke's; Mount Sinai West	HSU, MC (corresponding author), HOFFMANN LA ROCHE INC,DEPT VIROL,NUTLEY,NJ 07110, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397, U01AI027670, R37AI029164, R01AI029164] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27670, AI 29164, AI 27397] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; CASAREALE D, 1987, VIROLOGY, V156, P40, DOI 10.1016/0042-6822(87)90434-X; CONNELL EV, COMMUNICATION; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; HAEFELY WE, COMMUNICATION; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAYES T, COMMUNICATION; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2551; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; TANNEAU F, 1990, J INFECT DIS, V162, P837, DOI 10.1093/infdis/162.4.837; TOWN C, COMMUNICATION; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOLSKY DJ, 1990, J VIROL METHODS, V28, P257, DOI 10.1016/0166-0934(90)90119-Z	39	228	245	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1799	1802		10.1126/science.1763331	http://dx.doi.org/10.1126/science.1763331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763331				2022-12-24	WOS:A1991GW31600046
J	ZHANG, K; PAPAGEORGE, AG; MARTIN, P; VASS, WC; OLAH, Z; POLAKIS, PG; MCCORMICK, F; LOWY, DR				ZHANG, K; PAPAGEORGE, AG; MARTIN, P; VASS, WC; OLAH, Z; POLAKIS, PG; MCCORMICK, F; LOWY, DR			HETEROGENEOUS AMINO-ACIDS IN RAS AND RAP1A SPECIFYING SENSITIVITY TO GAP PROTEINS	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; CATALYTIC DOMAIN; EFFECTOR DOMAIN; RAS-P21 GTPASE; P21; IDENTIFICATION; MUTANTS; PURIFICATION; STIMULATION	Guanosine triphosphatase (GTPase) activity of Ras is increased by interaction with Ras-GAP (GTPase-activating protein) or with the GAP-related domain of the type 1 neurofibromatosis protein (NF1-GRD), but Ras is not affected by interaction with cytoplasmic and membrane forms of Rap-GAP; Rap1A, whose effector function can suppress transformation by Ras, is sensitive to both forms of Rap-GAP and resistant to Ras-GAP and NF1-GRD. A series of chimeric proteins composed of portions of Ras and Rap were constructed; some were sensitive to Ras-GAP but resistant to NF1-GRD, and others were sensitive to cytoplasmic Rap-GAP but resistant to membrane Rap-GAP. Sensitivity of chimeras to Ras-GAP and cytoplasmic Rap-GAP was mediated by amino acids that are carboxyl-terminal to the effector region. Residues 61 to 65 of Ras conferred Ras-GAP sensitivity, but a larger number of Rap1A residues were required for sensitivity to cytoplasmic Rap-GAP. Chimeras carrying the Ras effector region that were sensitive only to Ras-GAP or only to cytoplasmic Rap-GAP transformed NIH 3T3 cells poorly. Thus, distinct amino acids of Ras and Rap1A mediate sensitivity to each of the proteins with GAP activity, and transforming potential of Ras and sensitivity of Ras to Ras-GAP are at least partially independent properties.	CETUS CORP,EMERYVILLE,CA 94608		ZHANG, K (corresponding author), NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCCORMICK F, 1990, MOL CARCINOGEN, V3, P185, DOI 10.1002/mc.2940030404; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; Zhang K. Y., UNPUB	43	36	39	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1630	1634		10.1126/science.1749934	http://dx.doi.org/10.1126/science.1749934			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749934				2022-12-24	WOS:A1991GV07300041
J	SOKOL, S; CHRISTIAN, JL; MOON, RT; MELTON, DA				SOKOL, S; CHRISTIAN, JL; MOON, RT; MELTON, DA			INJECTED WNT RNA INDUCES A COMPLETE BODY AXIS IN XENOPUS EMBRYOS	CELL			English	Article							MESODERM INDUCTION; GROWTH-FACTORS; AMPHIBIAN DEVELOPMENT; INT-1 PROTOONCOGENE; LAEVIS EMBRYOS; ACTIVIN-A; PATTERN; TRANSCRIPTION; EMBRYOGENESIS; EXPRESSION	Studies in Xenopus have shown that growth factors of the TGF-beta and Wnt oncogene families can mimic aspects of dorsal axis formation. Here we directly compare the inductive properties of two Wnt proteins by injecting synthetic mRNA into developing embryos. The results show that Wnt-1 and Xwnt-8 can induce a new and complete dorsal axis and can rescue the development of axis-deficient, UV-irradiated embryos. In contrast, activin mRNA injection induces only a partial dorsal axis that lacks anterior structures. These studies demonstrate that the mechanism of Wnt-induced axis duplication results from the creation of an independent Spemann organizer. The relationship between the properties of the endogenous dorsal inducer and the effects of Wnts and activins is discussed.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	SOKOL, S (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Moon, Randall/M-5605-2019; Young, Richard A/F-6495-2012; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Young, Richard A/0000-0001-8855-8647; Moon, Randall T/0000-0002-9352-1408; Sokol, Sergei/0000-0002-3963-9202				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; COOKE J, 1989, DEVELOPMENT, V107, P229; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1987, DEVELOPMENT, V99, P527; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; JONES EA, 1987, DEVELOPMENT, V101, P557; KAGEURA H, 1990, DEV BIOL, V142, P432, DOI 10.1016/0012-1606(90)90365-P; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOHUN TJ, 1984, NATURE, V311, P715; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NAKAMURA O, 1970, P JPN ACAD, V46, P546, DOI 10.2183/pjab1945.46.546; NAKAMURA O, 1978, ORG MILESTONE HALF C, P179; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V163, P298, DOI 10.1007/BF00577017; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1969, ROUX ARCH DEVEL BIOL, V62, P341; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OGI K-I, 1967, Science Reports of the Tohoku University Fourth Series (Biology), V33, P239; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PATERNO GD, 1989, DEVELOPMENT, V106, P79; Roberts AB, 1990, GROWTH FACTORS, V3, P277, DOI 10.3109/08977199009003670; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; Ruiz i Altaba A, 1989, Nature, V341, P33; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H., 1938, EMBRYONIC DEV INDUCT; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VIZE PD, 1991, XENOPUS LAEVIS PRACT; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	54	461	470	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1991	67	4					741	752		10.1016/0092-8674(91)90069-B	http://dx.doi.org/10.1016/0092-8674(91)90069-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GQ407	1834344				2022-12-24	WOS:A1991GQ40700011
J	MORIYOSHI, K; MASU, M; ISHII, T; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S				MORIYOSHI, K; MASU, M; ISHII, T; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S			MOLECULAR-CLONING AND CHARACTERIZATION OF THE RAT NMDA RECEPTOR	NATURE			English	Article							AMINO-ACID RECEPTORS; GLUTAMATE RECEPTOR; XENOPUS OOCYTES; FUNCTIONAL EXPRESSION; PROTEIN-KINASE; ACETYLCHOLINE-RECEPTOR; BRAIN; SEQUENCE; CHANNEL; KAINATE	A complementary DNA encoding the rat NMDA receptor has been cloned and characterized. The single protein encoded by the cDNA forms a receptor-channel complex that has electrophysiological and pharmacological properties characteristic of the NMDA receptor. This protein has a significant sequence similarity to the AMPA/kainate receptors and contains four putative transmembrane segments following a large extracellular domain. The NMDA receptor messenger RNA is expressed in neuronal cells throughout the brain regions, particularly in the hippocampus, cerebral cortex and cerebellum.	KYOTO UNIV,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN	Kyoto University	MORIYOSHI, K (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHANGEUX JP, 1987, TRENDS PHARMACOL SCI, V8, P459, DOI 10.1016/0165-6147(87)90039-3; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IKIN AF, 1990, BIOCHEMISTRY-US, V29, P2290, DOI 10.1021/bi00461a012; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; LY AM, 1991, BIOCHEMISTRY-US, V30, P4307, DOI 10.1021/bi00231a029; MADISON DV, 1991, REV NEUROSCI, V14, P379; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOHNO T, 1986, MOL GEN GENET, V205, P260, DOI 10.1007/BF00430437; SAITO M, 1989, BRAIN RES, V481, P16, DOI 10.1016/0006-8993(89)90480-0; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SONDERS MS, 1990, J BIOL CHEM, V265, P6776; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; VERDOORN TA, 1987, SCIENCE, V238, P1114, DOI 10.1126/science.2825347; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YOUNG AB, 1990, TRENDS PHARMACOL SCI, V11, P126, DOI 10.1016/0165-6147(90)90199-I	44	1724	1764	1	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 7	1991	354	6348					31	37		10.1038/354031a0	http://dx.doi.org/10.1038/354031a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GN829	1834949				2022-12-24	WOS:A1991GN82900048
J	PAOLINI, R; JOUVIN, MH; KINET, JP				PAOLINI, R; JOUVIN, MH; KINET, JP			PHOSPHORYLATION AND DEPHOSPHORYLATION OF THE HIGH-AFFINITY RECEPTOR FOR IMMUNOGLOBULIN-E IMMEDIATELY AFTER RECEPTOR ENGAGEMENT AND DISENGAGEMENT	NATURE			English	Article							CELL ANTIGEN RECEPTOR; NATURAL-KILLER-CELLS; FC-GAMMA RECEPTOR; IGE RECEPTOR; ZETA-CHAIN; MOLECULAR-CLONING; CD16; EXPRESSION; SUBUNIT; RIII	TRIGGERING of mast cells and basophils by immunoglobulin E (IgE) and antigen induces various biochemical signals, including tyrosine kinase activation 1,2, which lead to cell degranulation and the release of mediators of the allergic reaction. The high-affinity receptor for IgE (Fc-epsilon-RI) responsible for initiating these events is a complex structure composed of an IgE-binding alpha-chain, a beta-chain and a homodimer of gamma-chains 3. It has been assumed that beta and gamma, which have extensive cytoplasmic domains, play an important but undefined role in coupling Fc-epsilon-RI to signal transduction mechanisms. Here we show that Fc-epsilon-RI engagement induces immediate in vivo phosphorylation on beta (tyrosine and serine) and gamma (tyrosine and threonine) by at least two different non-receptor kinases. We take advantage of unique features of this receptor system to demonstrate that the phosphorylation signal is restricted to activated receptors and is immediately reversible upon receptor disengagement by undefined phosphatases. Rapid phosphorylation and dephosphorylation may be a general mechanism to couple and uncouple activated receptors to other effector molecules. This could be particularly relevant to other multimeric receptors containing Fc-epsilon-RI gamma-chains or the related-zeta and eta-chains such as the T-cell antigen receptor (TCR) 4-6 and the low-affinity receptor for immunoglobulin G (Fc-gamma-RIII, CD16) (refs 7-11).			PAOLINI, R (corresponding author), NIAID,MOLEC ALLERGY & IMMUNOL SECT,TWINBROOK II BLDG,12441 PARKLAWN DR,ROCKVILLE,MD 20852, USA.			PAOLINI, Rossella/0000-0001-7605-1531				ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CUNHAMELO JR, 1987, J BIOL CHEM, V262, P11455; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LIU FT, 1980, J IMMUNOL, V124, P2728; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PEREZMONTFORT R, 1983, BIOCHEMISTRY-US, V22, P5733, DOI 10.1021/bi00294a009; QUARTO R, 1986, MOL IMMUNOL, V23, P1215, DOI 10.1016/0161-5890(86)90154-9; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; STEPHAN V, 1991, FASEB J, V5; VIVIER E, 1991, J IMMUNOL, V146, P206; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377	28	284	287	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 31	1991	353	6347					855	858		10.1038/353855a0	http://dx.doi.org/10.1038/353855a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GM732	1834946				2022-12-24	WOS:A1991GM73200063
J	NASMYTH, K; DIRICK, L				NASMYTH, K; DIRICK, L			THE ROLE OF SWI4 AND SWI6 IN THE ACTIVITY OF G1 CYCLINS IN YEAST	CELL			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; HO GENE; FISSION YEAST; ESCHERICHIA-COLI; MATING-PHEROMONE; DNA; DIVISION; IDENTIFICATION; TRANSCRIPTION	Entry into the mitotic cycle (START) requires a protein kinase encoded by the CDC28 gene and one of three redundant G1-specific cyclins encoded by CLN1, -2, and -3. SWI4 and SWI6 are transcription factors required for the START-dependent activation of the HO endonuclease gene. They also fulfill an overlapping but essential role for cell division since cells deleted for both genes are inviable. We show that the essential role of SWI4 and SWI6 is to ensure the activity of G1-specific cyclin genes. SWI4 and SWI6 appear necessary for the transcription of CLN1 and CLN2, but not for that of CLN3. CLN3 function is, however, also dependent on SWI4 and SWI6.			NASMYTH, K (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P803; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CARTER BLA, 1980, GENETICS, V96, P561; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HABER JE, 1977, GENETICS, V87, P33; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MORTIMER RK, 1969, YEASTS, V1, P385; MURRAY AW, 1989, NATURE, V342, P14, DOI 10.1038/342014a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SOCKANATHAN S, 1991, THESIS U CAMBRIDGE C; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	46	291	296	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					995	1013		10.1016/0092-8674(91)90444-4	http://dx.doi.org/10.1016/0092-8674(91)90444-4			19	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1832338				2022-12-24	WOS:A1991GE46000017
J	SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML				SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML			TIMING OF BREAST-CANCER EXCISION DURING THE MENSTRUAL-CYCLE INFLUENCES DURATION OF DISEASE-FREE SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; MENSTRUAL CYCLE; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; FOLLICULAR PHASE	PERIPHERAL-BLOOD; SURGICAL CURE; CARCINOMA; EPIDEMIOLOGY; WOMEN	Objective: To study disease-free survival at 10 years in relation to timing of breast tumor excision during the menstrual cycle. Design: A prospective study of consecutively treated patients with primary breast cancer. Setting: Memorial Sloan-Kettering Cancer Center, New York. Patients: Two hundred and eighty-three premenopausal patients treated by mastectomy and axillary dissection. Main Results: When the tumor was excised during the follicular phase, approximated by setting the putative day of ovulation on day 14 after the onset of last menses, a higher recurrence risk (43%) was observed compared with excision later in the menstrual cycle (29%, P = 0.02). The rate peaked among patients treated between days 7 and 14 and was lowest between days 20 and 30. Multivariate analysis using the Cox regression model to control for tumor size, nodal status, estrogen receptor status, adjuvant chemotherapy, and family history indicated that the hazard rate of breast cancer recurrence after excision during the follicular phase was 1.53 (95% Cl, 1.02 to 2.29). Stratification by nodal status indicated that the effect of phase was statistically significant only among patients with positive nodes (hazard ratio, 2.10; Cl, 1.19 to 3.70). Conclusions: Our results support the hypothesis that the risk for recurrence may be affected by the hormonal milieu of the menstrual cycle; these findings must be confirmed, however, by a prospective study in which cycle phase at time of tumor excision is biochemically documented.	MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CORNELL UNIV, N SHORE UNIV HOSP, COLL MED, MANHASSET, NY 11030 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Northwell Health; North Shore University Hospital	SENIE, RT (corresponding author), CTR DIS CONTROL, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							AKSEL S, 1981, FERTIL STERIL, V36, P521; ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; AXELROD DM, 1988, CANCER INVEST, V6, P7, DOI 10.3109/07357908809077024; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BIEGLMAYER C, 1990, FERTIL STERIL, V53, P842; BROWN JB, 1989, INT J GYNECOL OBSTET, P111; CHIAZZE L, 1968, J AMER MED ASSOC, V203, P377, DOI 10.1001/jama.203.6.377; COX DR, 1972, J R STAT SOC B, V34, P187; GELBER RD, 1989, LANCET, V2, P1344; HEISE E, 1982, ONCOLOGY, V39, P340, DOI 10.1159/000225667; HRUSHESKY WJM, 1988, J NATL CANCER I, V80, P1232, DOI 10.1093/jnci/80.15.1232; HRUSHESKY WJM, 1989, LANCET, V2, P949; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LESSER ML, 1982, SURGERY, V91, P234; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; METCALF MG, 1983, NEW ZEAL MED J, V96, P645; POWLES TJ, 1989, LANCET, V2, P1343; RATAJCZAK HV, 1988, J EXP MED, V168, P73, DOI 10.1084/jem.168.1.73; ROSEN PP, 1982, CANCER, V50, P171, DOI 10.1002/1097-0142(19820701)50:1<171::AID-CNCR2820500132>3.0.CO;2-M; SENIE R T, 1990, Breast Cancer Research and Treatment, V16, P146; SENIE RT, 1981, AM J PUBLIC HEALTH, V71, P583, DOI 10.2105/AJPH.71.6.583; SENIE RT, 1980, CANCER, V46, P1705, DOI 10.1002/1097-0142(19801001)46:7<1705::AID-CNCR2820460734>3.0.CO;2-Q; SENIE RT, 1985, BREAST CANCER RES TR, V5, P301, DOI 10.1007/BF01806025; STRATTON JA, 1984, J CLIN LAB IMMUNOL, V15, P127; SULKE AN, 1985, BRIT MED J, V290, P884, DOI 10.1136/bmj.290.6472.884; TRELOAR AE, 1967, INT J FERTIL, V12, P77; VIGNON F, 1983, J CLIN ENDOCR METAB, V56, P1124, DOI 10.1210/jcem-56-6-1124; VILLE Y, 1990, BREAST CANCER RES TR, V16, P119, DOI 10.1007/BF01809296; VOGEL PM, 1981, AM J PATHOL, V104, P23; Vollman RF., 1977, MENSTRUAL CYCLE; WHITE D, 1982, BRIT J CANCER, V46, P611, DOI 10.1038/bjc.1982.245; 1989, CLIN GYNECOLOGIC END, P3	34	118	118	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					337	342		10.7326/0003-4819-115-5-337	http://dx.doi.org/10.7326/0003-4819-115-5-337			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863022				2022-12-24	WOS:A1991GC06500001
J	SIGURGEIRSSON, B; LINDELOF, B; EKLUND, G				SIGURGEIRSSON, B; LINDELOF, B; EKLUND, G			CONDYLOMATA ACUMINATA AND RISK OF CANCER - AN EPIDEMIOLOGIC-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENITAL WARTS; PAPILLOMAVIRUSES; ROCHESTER; MINN	Objective-To determine whether patients with condylomata acuminata have an increased risk o developing cancer. Design-Prospective cohort study on patients diagnosed as having condylomata acuminata. The number of malignant tumours in the cohort was compared with national incidences obtained from the Swedish Cancer Registry. Setting-Dermatology department of the Karolinska Hospital, Stockholm, Sweden. Subjects-3260 patients (2549 males and 711 females, median (range) age 23 (1-80) years) seen during 1969-84, with a mean follow up of 7.8 years. Main outcome measures-Number of malignant tumours observed in the cohort during the study period and expected number from national incidence. Results-There were 27 malignancies in the study group. There was no significant increase genital cancer in females compared with the national incidence. Only one patient had invasive cervical cancer (relative risk = 1.8; 95% confidence interval 0 to 10.1). Seventeen women had cervical carcinoma in situ (1.5; 0.9 to 2.5) compared with an expected number of 11.5; this increase was not significant. For males 22 cancers were observed at all sites (1.6; 1.0 to 2.5). The number of genitourinary cancers observed in males was almost three times higher than expected (2.6; 1.2 to 5.0). Conclusion-The results indicate that the risk of developing cervical carcinoma in situ or invasive cervical cancer after a genital human papillomavirus infection is less than previously thought. The implications of increase in the genitourinary malignancies in males are uncertain.	KAROLINSKA HOSP, DEPT CANC EPIDEMIOL, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet; Karolinska University Hospital	SIGURGEIRSSON, B (corresponding author), KAROLINSKA HOSP, DEPT DERMATOL, S-10401 STOCKHOLM 60, SWEDEN.		Sigurgeirsson, Bárður/B-6130-2011; Sigurgeirsson, Bardur/AAP-7755-2020	Sigurgeirsson, Bardur/0000-0002-9733-9742				ADAMI HO, 1989, ACTA ONCOL, V28, P463, DOI 10.3109/02841868909092251; ARMSTRONG B, 1988, LANCET, V1, P756; BAFVERSTEDT B, 1967, ACTA DERM-VENEREOL, V47, P376; BARRETT TJ, 1954, JAMA-J AM MED ASSOC, V154, P333, DOI 10.1001/jama.1954.02940380043010c; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; BREHART M, 1984, EMBO J, V3, P1151; BUNNEY MH, 1985, VIRAL WARTS THEIR BI, P22; CHUANG TY, 1984, ARCH DERMATOL, V120, P469, DOI 10.1001/archderm.120.4.469; CHUANG TY, 1984, ARCH DERMATOL, V120, P476, DOI 10.1001/archderm.120.4.476; CHUANG TY, 1987, J AM ACAD DERMATOL, V16, P376, DOI 10.1016/S0190-9622(87)70053-X; DUNN AEG, 1968, J ULTRA MOL STRUCT R, V22, P282, DOI 10.1016/S0022-5320(68)90021-X; GISSMANN L, 1982, INT J CANCER, V29, P143, DOI 10.1002/ijc.2910290205; GISSMANN L, 1986, BANBURY REPORT, V21, P217; Grisson, 1915, DERMATOL WOCHENSCHR, V60, P89; HAUSEN HZ, 1985, PROG MED VIROL, V32, P15; HAUSEN HZ, 1977, CURR TOP MICROBIOL, P1; KAPAUR TR, 1982, INDIAN J DERMATOL, V48, P23; KOVI J, 1974, AM J CLIN PATHOL, V61, P702; LYNCH PJ, 1985, CLIN OBSTET GYNECOL, V28, P142, DOI 10.1097/00003081-198528010-00017; MATTSSON B, 1984, THESIS KAROLINSKA I, P1; MCCANCE DJ, 1988, NATURE, V335, P765, DOI 10.1038/335765a0; MCNICOL PJ, 1990, J CLIN MICROBIOL, V28, P409, DOI 10.1128/JCM.28.3.409-412.1990; ORIEL JD, 1977, SEX TRANSM DIS, V4, P153, DOI 10.1097/00007435-197710000-00009; ORTH G, 1978, B CANCER, V65, P151; RAGOZZINO MW, 1984, MAYO CLIN PROC, V59, P719, DOI 10.1016/S0025-6196(12)62062-X; SHAFEEK MA, 1979, OBSTET GYNECOL, V54, P120, DOI 10.1097/00006250-197907000-00027; SIEGEL A, 1962, AM J SURG, V103, P613, DOI 10.1016/0002-9610(62)90531-7; SIGURGEIRSSON B, IN PRESS COMPUT METH; SYRJANEN KJ, 1983, OBSTET GYNECOL, V62, P617; VONKROGH G, 1982, ACTA DERM-VENEREOL, V62, P1; WALKER PG, 1983, BRIT J VENER DIS, V59, P120; 1961, CANCER INCIDENCE SWE	32	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1991	303	6798					341	344		10.1136/bmj.303.6798.341	http://dx.doi.org/10.1136/bmj.303.6798.341			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA606	1781836	Green Published, Bronze			2022-12-24	WOS:A1991GA60600021
J	RISE, ML; FRANKEL, WN; COFFIN, JM; SEYFRIED, TN				RISE, ML; FRANKEL, WN; COFFIN, JM; SEYFRIED, TN			GENES FOR EPILEPSY MAPPED IN THE MOUSE	SCIENCE			English	Article							EL MOUSE; QUANTITATIVE TRAITS; MENDELIAN FACTORS; LINKAGE MAP; MICE; PROVIRUSES; ANTICONVULSANTS; SUSCEPTIBILITY; SEIZURES; PROBES	The neurological mutant mouse strain El is a model for complex partial seizures in humans. The inheritance of epileptic seizures with seven conventional chromosomal markers and over 60 endogenous proviral markers was studied by means of backcrosses of El with two seizure-resistant strains, DBA/2J and ABP/LeJ. The major gene responsible for this epileptic phenotype (El-1) was localized to a region distal with respect to the centromere on chromosome 9. At least one other gene, El-2, linked to proviral markers on chromosome 2, also influences the seizure phenotype. In addition, a potential modifier of seizures was detected in the DBA/2J background. The location of El-1 on distal chromosome 9 may allow identification of an epilepsy candidate gene in humans on the basis of conserved synteny with human chromosome 3.	BOSTON COLL,DEPT BIOL,CHESTNUT HILL,MA 02167; TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111	Boston College; Tufts University				Seyfried, Thomas/0000-0003-1491-3989	NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023355] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA44385] Funding Source: Medline; NINDS NIH HHS [NS 23355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON VE, 1986, ADV NEUROL, P59; BARANOV VS, 1987, CHROMOSOMA, V96, P60, DOI 10.1007/BF00285885; BAUMANN RJ, 1982, GENETIC BASIS EPILEP, P11; BRIGANDE J V, 1989, Epilepsia, V30, P652; DELGADOESCUETA AV, 1983, NEW ENGL J MED, V308, P1508, DOI 10.1056/NEJM198306233082506; EYFRIED TN, 1986, ADV NEUROL, P115; FELTON J, 1974, J BIOL CHEM, V249, P3267; FRANKEL WN, 1989, J VIROL, V63, P3810, DOI 10.1128/JVI.63.9.3810-3821.1989; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FRANKEL WN, 1990, GENETICS, V124, P221; FRANKEL WN, 1989, J VIROL, V63, P1762; FRANKEL WN, 1991, MOUSE GENOME, V89, P266; FUETA Y, 1986, Journal of UOEH, V8, P417; FUKAHORI M, 1990, BRAIN RES, V529, P16, DOI 10.1016/0006-8993(90)90806-M; GLASER GH, 1977, PRACT MED, V10, P1; HAUSER WA, 1982, GENETIC BASIS EPILEP, P3; HONDA T, 1984, BRAIN DEV-JPN, V6, P22, DOI 10.1016/S0387-7604(84)80005-4; Imaizumi K., 1959, B EXP ANIM TOKYO, V8, P6; Kurokawa M, 1966, Prog Brain Res, V21, P112; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NEUMANN PE, 1990, BEHAV GENET, V20, P307, DOI 10.1007/BF01067798; NEUMANN PE, IN PRESS P NATL ACAD; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; RISE ML, UNPUB; SEARLE A G, 1987, Genomics, V1, P3, DOI 10.1016/0888-7543(87)90099-1; SEYFRIED TN, 1985, EPILEPSIA, V26, P143, DOI 10.1111/j.1528-1157.1985.tb05398.x; SEYFRIED TN, 1982, MOUSE BIOMEDICAL RES, P97; STOYE JP, 1988, J VIROL, V62, P168, DOI 10.1128/JVI.62.1.168-175.1988; SUGAYA E, 1986, EPILEPSIA, V27, P354, DOI 10.1111/j.1528-1157.1986.tb03553.x; SUZUKI J, 1976, EXPERIENTIA, V32, P336, DOI 10.1007/BF01940824; SUZUKI J, 1983, BRAIN RES, V266, P359, DOI 10.1016/0006-8993(83)90670-4	34	184	187	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1991	253	5020					669	673		10.1126/science.1871601	http://dx.doi.org/10.1126/science.1871601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871601				2022-12-24	WOS:A1991GA30400040
J	BEATTIE, KL; FOWLER, RF				BEATTIE, KL; FOWLER, RF			SOLID-PHASE GENE ASSEMBLY	NATURE			English	Editorial Material							CHEMICAL SYNTHESIS; OLIGONUCLEOTIDES; DNA		HOUSTON ADV RES CTR,THE WOODLANDS,TX 77381		BEATTIE, KL (corresponding author), BAYLOR UNIV,CTR BIOTECHNOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381, USA.							BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BEATTIE KL, 1988, BIOTECHNOL APPL BIOC, V10, P510; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; FRANK R, 1983, NUCLEIC ACIDS RES, V11, P4365, DOI 10.1093/nar/11.13.4365; HOSTOMSKY Z, 1987, NUCLEIC ACIDS RES, V15, P4849, DOI 10.1093/nar/15.12.4849; JAYARAMAN K, 1991, P NATL ACAD SCI USA, V88, P4084, DOI 10.1073/pnas.88.10.4084; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; MATTHES HWD, 1984, EMBO J, V3, P801, DOI 10.1002/j.1460-2075.1984.tb01888.x; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P245, DOI 10.1016/S0040-4039(00)81376-3; MULLIS KB, 1987, METHOD ENZYMOL, V155, P355; RIORDAN ML, 1991, NATURE, V350, P442, DOI 10.1038/350442a0; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	15	23	31	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					548	549		10.1038/352548a0	http://dx.doi.org/10.1038/352548a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865911				2022-12-24	WOS:A1991GA22600071
J	DAVIES, TF; MARTIN, A; CONCEPCION, ES; GRAVES, P; COHEN, L; BENNUN, A				DAVIES, TF; MARTIN, A; CONCEPCION, ES; GRAVES, P; COHEN, L; BENNUN, A			EVIDENCE OF LIMITED VARIABILITY OF ANTIGEN RECEPTORS ON INTRATHYROIDAL T-CELLS IN AUTOIMMUNE THYROID-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN BASIC-PROTEIN; GRAVES-DISEASE; ANTITHYROID DRUGS; CLONES; LYMPHOCYTES; ENCEPHALOMYELITIS; THYROGLOBULIN; HETEROGENEITY; TRANSCRIPTS; LINES	Background. Patients with autoimmune thyroid diseases, including Graves' disease and Hashimoto's disease, have marked lymphocytic infiltration in their thyroid glands. We examined the gene for the variable regions of the alpha-chain of the human T-cell receptor (the V-alpha gene) in intrathyroidal T cells to determine whether the infiltration is a secondary heterogeneous immune response or a more restricted, and therefore primary and presumably pathogenetic, reaction to thyroid autoantigens. Methods. We used the polymerase chain reaction to detect small numbers of T cells expressing the variable region of the V-alpha gene. Different oligonucleotides were used to amplify complementary DNA for the 18 known families of the V-alpha gene in intrathyroidal T cells from 9 patients with autoimmune thyroid disease. We compared the findings with the results in patients with nonautoimmune thyroid disease as well as those in normal subjects. Results. We found marked restriction in the expression of T-cell-receptor V-alpha genes by T cells from the thyroid tissue of patients with autoimmune thyroid disease. An average of only 5 of the 18 V-alpha genes were expressed in such samples, as compared with 17 V-alpha genes expressed in peripheral-blood T cells from the same patients. No such restriction was found in thyroid tissue from patients with nonautoimmune thyroid disease. The predominantly expressed V-alpha genes differed from patient to patient, however, with no clear association with the type of disease. Conclusions. Intrathyroidal T-cell accumulation in autoimmune thyroid disease is highly restricted and points to the primacy of T cells in causing thyroid disorders. These results present the possibility of using antibodies to the T-cell receptor for the specific inhibition of abnormal T-cell function in autoimmune thyroid disease.	CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Weizmann Institute of Science					NIDDK NIH HHS [DK28243, DK35764] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035764, R01DK028243] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENNUN A, 1991, P NATL ACAD SCI USA, V88, P2466, DOI 10.1073/pnas.88.6.2466; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; FISFALEN ME, 1988, J CLIN ENDOCR METAB, V66, P776, DOI 10.1210/jcem-66-4-776; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOODMAN MG, 1982, B LYMPHOCYTES TODAY, P63; JANSSON R, 1983, J CLIN ENDOCR METAB, V56, P1164, DOI 10.1210/jcem-56-6-1164; KIMURA H, 1991, CLIN IMMUNOL IMMUNOP, V58, P195, DOI 10.1016/0090-1229(91)90136-X; LONDEI M, 1985, SCIENCE, V228, P85, DOI 10.1126/science.3871967; MACKENZIE WA, 1987, IMMUNOLOGY, V61, P101; MACKENZIE WA, 1987, J CLIN ENDOCR METAB, V64, P818, DOI 10.1210/jcem-64-4-818; MARGOLICK JB, 1984, AM J MED, V76, P815, DOI 10.1016/0002-9343(84)90992-6; MARON R, 1983, J IMMUNOL, V131, P2316; MARTIN A, 1990, AUTOIMMUNITY, V6, P269, DOI 10.3109/08916939008998419; MOEBIUS U, 1990, EUR J IMMUNOL, V20, P889, DOI 10.1002/eji.1830200426; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; ROMAN SH, 1984, CLIN CHEM, V30, P246; ROMBALL CG, 1987, J IMMUNOL, V138, P1092; SPINELLA DG, 1987, J IMMUNOL, V138, P3991; VOLPE R, 1986, CLIN ENDOCRINOL, V25, P453, DOI 10.1111/j.1365-2265.1986.tb01712.x; WEISS I, 1981, J CLIN ENDOCR METAB, V53, P1223, DOI 10.1210/jcem-53-6-1223; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	22	212	213	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	1991	325	4					238	244		10.1056/NEJM199107253250404	http://dx.doi.org/10.1056/NEJM199107253250404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX627	1829139	Bronze			2022-12-24	WOS:A1991FX62700004
J	INOUE, I; NAGASE, H; KISHI, K; HIGUTI, T				INOUE, I; NAGASE, H; KISHI, K; HIGUTI, T			ATP-SENSITIVE K+ CHANNEL IN THE MITOCHONDRIAL INNER MEMBRANE	NATURE			English	Article							OXIDATIVE-PHOSPHORYLATION; ENERGY TRANSDUCTION; CATIONIC CHANNEL; TRANSPORT; PROTEINS; IMPORT	MITOCHONDRIA take up and extrude various inorganic and organic ions, as well as larger substances such as proteins 1-4. The technique of patch clamping should provide real-time information on such transport and on energy transduction in oxidative phosphorylation. It has been applied to detect microscopic currents from mitochondrial membranes and conductances of ion channels in the 5-1,000 pS range in the outer and inner membranes 5-10. These pores are not, however, selective for particular ions. Here we use fused giant mitoplasts prepared from rat liver mitochondria to identify a small conductance channel highly selective for K+ in the inner mitochondrial membrane. This channel can be reversibly inactivated by ATP applied to the matrix side under inside-out patch configuration; it is also inhibited by 4-aminopyridine and by glybenclamide. The slope conductance of the unitary currents measured at negative membrane potentials was 9.7 +/- 1.0 pS (mean +/- s.d., n = 6) when the pipette solution contained 100 mM K+ and the bathing solution 33.3 mM K+. Our results indicate that mitochondria depolarize by generating a K+ conductance when ATP in the matrix is deficient.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN	Tokushima University	INOUE, I (corresponding author), UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN.							ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; CHAN TL, 1970, J CELL BIOL, V45, P291, DOI 10.1083/jcb.45.2.291; CHAZOTTE B, 1985, BIOCHIM BIOPHYS ACTA, V818, P87, DOI 10.1016/0005-2736(85)90142-7; CROMPTON M, 1985, CURR TOP MEMBR TRANS, V25, P231; DIWAN JJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P155, DOI 10.1016/S0304-4173(87)80001-0; Garlid K.D., 1988, INTEGRATION MITOCHON, P259; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; HIGUTI T, 1983, BIOCHIM BIOPHYS ACTA, V725, P1, DOI 10.1016/0005-2728(83)90217-7; HIGUTI T, 1985, P NATL ACAD SCI USA, V82, P1331, DOI 10.1073/pnas.82.5.1331; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; LEHNINGER AL, 1964, MITOCHONDRION, P180; MEVES H, 1977, J PHYSIOL-LONDON, V268, P511, DOI 10.1113/jphysiol.1977.sp011869; MORAN O, 1990, J BIOL CHEM, V265, P980; Rottenberg H, 1979, Methods Enzymol, V55, P547; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1989, J BIOENERG BIOMEMBR, V21, P485, DOI 10.1007/BF00762520; STURGESS NC, 1985, LANCET, V2, P474; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x	23	632	681	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					244	247		10.1038/352244a0	http://dx.doi.org/10.1038/352244a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857420				2022-12-24	WOS:A1991FX18500067
J	LAUER, MS; ANDERSON, KM; KANNEL, WB; LEVY, D				LAUER, MS; ANDERSON, KM; KANNEL, WB; LEVY, D			THE IMPACT OF OBESITY ON LEFT-VENTRICULAR MASS AND GEOMETRY - THE FRAMINGHAM-HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AORTIC REGURGITATION; GLUCOSE-INTOLERANCE; BLOOD-PRESSURE; BODY BUILD; HYPERTROPHY; HYPERTENSION; DISEASE; CARDIOMYOPATHY; REDUCTION; CRITERIA	Objective.- To determine the relationship of varying degrees of obesity with left ventricular mass and geometry. Design.- Survey. Setting.- Population-based epidemiologic study. Participants and Methods.- M-mode echocardiograms, which were adequate for estimation of left ventricular mass, were obtained in 3922 healthy participants of the Framingham Heart Study Measured height and weight were used to calculate body-mass index, a measure of obesity. Results.- Body-mass index was strongly correlated with left ventricular mass. After adjusting for age and blood pressure, body-mass index remained a strong independent predictor of left ventricular mass, left ventricular wall thickness, and left ventricular internal dimension (P < .01 for all). Body-mass index was associated with prevalence of echocardiographic left ventricular hypertrophy, particularly in subjects with a body-mass index exceeding 30 kg/m2. Conclusions.- Obesity is significantly correlated with left ventricular mass, even after controlling for age and blood pressure. The increase in left ventricular mass associated with increasing adiposity reflects increases in both left ventricular wall thickness and left ventricular internal dimension.	BETH ISRAEL HOSP, CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BOSTON UNIV, SCH MED, DIV EPIDEMIOL & PREVENT MED, BOSTON, MA 02118 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,DEPT MED,DIV CARDIOL, THORNDIKE LAB, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Boston University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	LAUER, MS (corresponding author), NHLBI, FRAMINGHAM HEART STUDY, 5 THURBER ST, FRAMINGHAM, MA 02215 USA.		Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021; Lauer, Michael S/L-9656-2013	Levy, Daniel/0000-0003-1843-8724; Lauer, Michael S/0000-0002-9217-8177	NHLBI NIH HHS [N01-HC-38038, HL07374] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER J K, 1962, Cardiovasc Res Cent Bull, V1, P39; ALEXANDER JK, 1985, PROG CARDIOVASC DIS, V27, P325, DOI 10.1016/S0033-0620(85)80002-5; BOROW K, 1989, TXB ADULT PEDIATRIC, P108; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DEDIVITIIS O, 1981, CIRCULATION, V64, P477, DOI 10.1161/01.CIR.64.3.477; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; GARDIN JM, 1987, HYPERTENSION, V9, P36; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KATZ AM, 1990, NEW ENGL J MED, V322, P100; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MESSERLI FH, 1981, ARCH INTERN MED, V141, P81, DOI 10.1001/archinte.141.1.81; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1982, LANCET, V1, P1165; OSTLUND RE, 1990, NEW ENGL J MED, V322, P229, DOI 10.1056/NEJM199001253220404; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1990, AM J CARDIOL, V65, P371, DOI 10.1016/0002-9149(90)90304-J; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SORLIE P, 1980, JAMA-J AM MED ASSOC, V243, P1828, DOI 10.1001/jama.243.18.1828; TOBIAN L, 1978, NEW ENGL J MED, V298, P46, DOI 10.1056/NEJM197801052980110; VANDENBOSSCHE JL, 1984, J AM COLL CARDIOL, V4, P1195, DOI 10.1016/S0735-1097(84)80138-2; WILSON JR, 1980, AM J MED, V68, P664, DOI 10.1016/0002-9343(80)90252-1; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240	37	457	478	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	1991	266	2					231	236		10.1001/jama.266.2.231	http://dx.doi.org/10.1001/jama.266.2.231			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU896	1829117				2022-12-24	WOS:A1991FU89600031
J	CHITTENDEN, T; LIVINGSTON, DM; KAELIN, WG				CHITTENDEN, T; LIVINGSTON, DM; KAELIN, WG			THE T/E1A-BINDING DOMAIN OF THE RETINOBLASTOMA PRODUCT CAN INTERACT SELECTIVELY WITH A SEQUENCE-SPECIFIC DNA-BINDING PROTEIN	CELL			English	Article							E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; LARGE T-ANTIGENS; SUSCEPTIBILITY GENE; REGULATORY PROTEINS; TRANS-ACTIVATION; CELL-CYCLE; RB GENE; SV40; PROMOTER	A DNA-binding site selection and enrichment procedure revealed a sequence-specific DNA-binding activity selectively associated with glutathione S-transferase-retinoblastoma protein chimeras (GST-RB) that had been incubated with a human cell extract. Appropriate mutant forms of GST-RB, incubated in equivalent extracts, did not associate with this specific DNA-binding activity, and a peptide replica of the HPV E7 RB-binding segment selectively inhibited the association of GST-RB with the sequence-specific DNA-binding protein(s). Sequence analysis of oligonucleotides with high affinity for GST-RB complexes, as well as the results of competition binding studies, strongly suggest that RB can associate specifically with the transcription factor E2F or with a protein having closely related DNA-binding properties.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	CHITTENDEN, T (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES RE, 1990, J BIOL CHEM, V265, P12782; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Maniatis T., 1982, MOL CLONING; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PIENTENPOL JA, 1990, CELL, V61, P777; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	41	396	414	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1073	1082		10.1016/0092-8674(91)90559-H	http://dx.doi.org/10.1016/0092-8674(91)90559-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1828394				2022-12-24	WOS:A1991FR04700018
J	CONNOLLY, T; RAPIEJKO, PJ; GILMORE, R				CONNOLLY, T; RAPIEJKO, PJ; GILMORE, R			REQUIREMENT OF GTP HYDROLYSIS FOR DISSOCIATION OF THE SIGNAL RECOGNITION PARTICLE FROM ITS RECEPTOR	SCIENCE			English	Article								The signal recognition particle (SRP) directs signal sequence specific targeting of ribosomes to the rough endoplasmic reticulum. Displacement of the SRP from the signal sequence of a nascent polypeptide is a guanosine triphosphate (GTP)-dependent reaction mediated by the membrane-bound SRP receptor. A nonhydrolyzable GTP analog can replace GTP in the signal sequence displacement reaction, but the SRP then fails to dissociate from the membrane. Complexes of the SRP with its receptor containing the nonhydrolyzable analog are incompetent for subsequent rounds of protein translocation. Thus, vectorial targeting of ribosomes to the endoplasmic reticulum is controlled by a GTP hydrolysis cycle that regulates the affinity between the SRP, signal sequences, and the SRP receptor.	UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035687] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CONNOLLY T, UNPUB; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HOFFMAN KE, 1988, J BIOL CHEM, V263, P4381; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WILSON C, 1988, J CELL BIOL, V107, P69, DOI 10.1083/jcb.107.1.69	27	172	174	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	1991	252	5009					1171	1173		10.1126/science.252.5009.1171	http://dx.doi.org/10.1126/science.252.5009.1171			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN056	1851576				2022-12-24	WOS:A1991FN05600050
J	HEMPSTEAD, BL; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; CHAO, MV				HEMPSTEAD, BL; MARTINZANCA, D; KAPLAN, DR; PARADA, LF; CHAO, MV			HIGH-AFFINITY NGF BINDING REQUIRES COEXPRESSION OF THE TRK PROTOONCOGENE AND THE LOW-AFFINITY NGF RECEPTOR	NATURE			English	Article							NERVE GROWTH-FACTOR; PC12 PHEOCHROMOCYTOMA CELLS; HUMAN NEURO-BLASTOMA; HUMAN-MELANOMA CELLS; NEUROTROPHIC FACTOR; RAT PHEOCHROMOCYTOMA; MOLECULAR-CLONING; GENE-TRANSFER; EXPRESSION; BRAIN	Nerve growth factor (NGF) interacts with two different low-affinity receptors that can be distinguished by affinity crosslinking. Reconstitution experiments by membrane fusion and transient transfection into heterologous cells indicate that high-affinity NGF binding requires coexpression and binding to both the low-affinity NGF receptor and the tyrosine kinase trk gene product. These studies reveal a new growth factor receptor-mediated mechanism of cellular differentiation involving trk and the low-affinity NGF receptor.	NCI, FREDERICK CANC RES & DEV CTR, MOLEC EMBRYOL GRP, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	HEMPSTEAD, BL (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DEPT CELL BIOL & ANAT, DIV HEMATOL ONCOL, 1300 YORK AVE, NEW YORK, NY 10021 USA.		Parada, luis F/B-9400-2014	Chao, Moses/0000-0002-6969-3744				ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Berg M.D., UNPUB; BERND P, 1984, J BIOL CHEM, V259, P5509; BLOCK T, 1983, J NEUROCHEM, V40, P1654, DOI 10.1111/j.1471-4159.1983.tb08139.x; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BURTON J, 1990, P NATL ACAD SCI USA, V87, P7329, DOI 10.1073/pnas.87.18.7329; BUXSER SE, 1983, J CELL BIOCHEM, V22, P219, DOI 10.1002/jcb.240220404; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ESCANDON E, 1990, DEV BIOL, V142, P293, DOI 10.1016/0012-1606(90)90350-R; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; GROB PM, 1983, P NATL ACAD SCI-BIOL, V80, P6819, DOI 10.1073/pnas.80.22.6819; GROB PM, 1985, J BIOL CHEM, V260, P8044; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1989, RECENT PROG HORM RES, V45, P441; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1987, EMBO J, V6, P1197, DOI 10.1002/j.1460-2075.1987.tb02354.x; HOSANG M, 1985, J BIOL CHEM, V260, P655; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1987, BIOCHEM PHARMACOL, V36, P4189, DOI 10.1016/0006-2952(87)90658-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, IN PRESS SCIENCE; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLENDER EJ, 1980, J BIOL CHEM, V255, P9338; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROBB RJ, 1986, P NATL ACAD SCI USA, V83, P3992, DOI 10.1073/pnas.83.11.3992; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TANIUCHI M, 1986, J BIOL CHEM, V261, P3342; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VALE RD, 1982, J CELL BIOL, V94, P710, DOI 10.1083/jcb.94.3.710; Volonte C, 1990, GROWTH FACTORS, V2, P321; WALDEMAN TA, 1990, ANNU REV BIOCHEM, V58, P875; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAN H, IN PRESS SCIENCE; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	79	1129	1154	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1991	350	6320					678	683		10.1038/350678a0	http://dx.doi.org/10.1038/350678a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FJ130	1850821				2022-12-24	WOS:A1991FJ13000050
J	KOREN, MJ; DEVEREUX, RB; CASALE, PN; SAVAGE, DD; LARAGH, JH				KOREN, MJ; DEVEREUX, RB; CASALE, PN; SAVAGE, DD; LARAGH, JH			RELATION OF LEFT-VENTRICULAR MASS AND GEOMETRY TO MORBIDITY AND MORTALITY IN UNCOMPLICATED ESSENTIAL-HYPERTENSION	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION; HEART ENLARGEMENT; LEFT VENTRICULAR MASS AND GEOMETRY; CARDIOVASCULAR DISEASES; RISK FACTORS	BLOOD-PRESSURE; ECHOCARDIOGRAPHIC DETERMINATION; ELECTROCARDIOGRAPHIC DETECTION; SYSTEMIC HYPERTENSION; CONSCIOUS DOGS; HYPERTROPHY; CRITERIA; VALIDATION; OCCLUSION; DISEASE	Objective: To assess the prognostic significance of left ventricular mass and geometry in initially healthy persons with essential hypertension. Design: An observational study of a prospectively identified cohort. Setting: University medical center. Patients: Two hundred and eight patients with essential hypertension and pre-existing cardiac disease were evaluated using echocardiography between 1976 and 1981. Two hundred and fifty-three subjects or their family members (90%) were contacted for a follow-up interview an average of 10.2 years after the initial echocardiogram was obtained; the survival status of 27 patients lost to follow-up was ascertained using National Death Index data. Measurements and Main Results: Left ventricular mass exceeded 125 g/m2 in 69 of 253 patients (27%). Cardiovascular events occurred in a higher proportion of patients with than without left ventricular hypertrophy (26% compared with 12%; p = 0.006). Patients with increased ventricular mass were also at higher risk for cardiovascular death (14% compared with 0.5%; P < 0.001) and all-cause mortality (16% compared with 2%; P = 0.001). Electrocardiographic left ventricular hypertrophy did not predict risk. Patients with normal left ventricular geometry had the fewest adverse outcomes (no cardiac deaths; morbid events in 11%), and those with concentric hypertrophy had the most (death in 21%; morbid events in 31%). In a multivariate analysis, only age and left ventricular mass-but not gender, blood pressure, or serum cholesterol level-independently predicted all three outcome measures. Conclusions: Echocardiographically determined left ventricular mass and geometry stratify risk in patients with essential hypertension independently of and more strongly than blood pressure or other potentially reversible risk factors and may help to stratify the need for intensive treatment.	CORNELL UNIV, MED CTR,NEW YORK HOSP,DIV CARDIOL,BOX 222, 525 E 68TH ST, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital					NHLBI NIH HHS [HL 18323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1980, CARDIOLOGY REV REPOR, V1, P509; [Anonymous], 1980, LANCET, V1, P1261; BLAKE J, 1988, AM J CARDIOL, V62, P246, DOI 10.1016/0002-9149(88)90220-2; BLAKE J, 1990, AM J MED, V88, P477, DOI 10.1016/0002-9343(90)90426-E; BRESLIN DJ, 1966, CIRCULATION, V33, P87, DOI 10.1161/01.CIR.33.1.87; CASALE PN, 1985, J AM COLL CARDIOL, V6, P572, DOI 10.1016/S0735-1097(85)80115-7; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CHIKOS PM, 1977, AM J ROENTGENOL, V128, P367, DOI 10.2214/ajr.128.3.367; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; DEVEREUX RB, 1984, J AM COLL CARDIOL, V3, P82, DOI 10.1016/S0735-1097(84)80433-7; DEVEREUX RB, 1987, HYPERTENSION, V9, P97; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1984, AM J CARDIOL, V54, P592, DOI 10.1016/0002-9149(84)90255-8; DEVEREUX RB, 1983, CIRCULATION, V67, P907, DOI 10.1161/01.CIR.67.4.907; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1984, J AM COLL CARDIOL, V4, P1222, DOI 10.1016/S0735-1097(84)80141-2; DEVEREUX RB, 1987, HYPERTENSION, V9, P69; DIXON WJ, 1988, BMDP STATISTICAL SOF; FUJITA M, 1988, J AM COLL CARDIOL, V12, P1048, DOI 10.1016/0735-1097(88)90475-5; GANAU A, 1989, Journal of the American College of Cardiology, V13, p245A; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HOUGHTON JL, 1990, J AM COLL CARDIOL, V15, P43, DOI 10.1016/0735-1097(90)90173-M; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KOYANAGI S, 1982, CIRCULATION, V65, P1192, DOI 10.1161/01.CIR.65.6.1192; KOYANAGI S, 1982, CIRC RES, V50, P55, DOI 10.1161/01.RES.50.1.55; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1987, AM J CARDIOL, V59, P836, DOI 10.1016/0002-9149(87)91102-7; MacMahon S., 1989, HYPERTENSION S1, V13, P45; MESSERLI FH, 1990, CIRCULATION, V81, P1128, DOI 10.1161/01.CIR.81.3.1128; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; POLESE A, 1990, Journal of the American College of Cardiology, V15, p111A; REICHEK N, 1981, CIRCULATION, V63, P1391, DOI 10.1161/01.CIR.63.6.1391; REICHEK N, 1982, AM HEART J, V103, P202, DOI 10.1016/0002-8703(82)90493-8; REN JF, 1985, J AM COLL CARDIOL, V5, P1224, DOI 10.1016/S0735-1097(85)80029-2; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SCHMIEDER RE, 1988, CIRCULATION, V78, P951, DOI 10.1161/01.CIR.78.4.951; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; SOKOLOW M, 1961, CIRCULATION, V23, P697, DOI 10.1161/01.CIR.23.5.697; 1972, CIRCULATION, V45, P991; 1979, JAMA-J AM MED ASSOC, V242, P2572	51	1994	2078	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1991	114	5					345	352		10.7326/0003-4819-114-5-345	http://dx.doi.org/10.7326/0003-4819-114-5-345			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ174	1825164				2022-12-24	WOS:A1991EZ17400001
J	KAELIN, WG; PALLAS, DC; DECAPRIO, JA; KAYE, FJ; LIVINGSTON, DM				KAELIN, WG; PALLAS, DC; DECAPRIO, JA; KAYE, FJ; LIVINGSTON, DM			IDENTIFICATION OF CELLULAR PROTEINS THAT CAN INTERACT SPECIFICALLY WITH THE T/E1A-BINDING REGION OF THE RETINOBLASTOMA GENE-PRODUCT	CELL			English	Article							SV40 LARGE-T; SUSCEPTIBILITY GENE; DNA-BINDING; ADENOVIRUS E1A; RB GENE; SV40-TRANSFORMED CELLS; ENCODED PROTEIN; OSTEO-SARCOMA; 1A PROTEINS; EXPRESSION	The SV40 T antigen (T)/adenovirus E1A-binding domain of the retinoblastoma gene product (pRB) has been fused to S. japonicum glutathione S-transferase, and the chimera, bound to insoluble glutathione, was used to search for cellular proteins that can interact specifically with pRB. At least seven such proteins were detected in extracts of multiple human tumor cell lines. These proteins failed to bind to a family of pRB fusion proteins that harbor inactivating mutations in the T/E1A-binding domain and to the wild-type fusion protein in the presence of a peptide replica of the pRB-binding domain of T. Therefore, the binding of one or more of these proteins may contribute to the growth-suppressing function of pRB.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; NCI,USN,MED ONCOL BRANCH,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA	KAELIN, WG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.		kaye, frederic/E-2437-2011		NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HYTE P, 1989, CELL, V56, P67; JENSEN RH, 1977, J HISTOCHEM CYTOCHEM, V25, P573, DOI 10.1177/25.7.70448; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P357; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; REISSMANN PT, 1989, ONCOGENE, V4, P839; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHEN JY, 1990, CELL GROWTH DIFF, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1988, ONCOGENE, V3, P471	66	545	563	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 8	1991	64	3					521	532		10.1016/0092-8674(91)90236-R	http://dx.doi.org/10.1016/0092-8674(91)90236-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EX361	1825028				2022-12-24	WOS:A1991EX36100008
J	MEINWALD, J; THOMPSON, WR; PEARSON, DL; KONIG, WA; RUNGE, T; FRANCKE, W				MEINWALD, J; THOMPSON, WR; PEARSON, DL; KONIG, WA; RUNGE, T; FRANCKE, W			INHALATIONAL ANESTHETICS STEREOCHEMISTRY - OPTICAL RESOLUTION OF HALOTHANE, ENFLURANE, AND ISOFLURANE	SCIENCE			English	Article							GENERAL-ANESTHETICS; GAS-CHROMATOGRAPHY; STEREOISOMERS; BINDING	Halothane (I), enflurane (II), and isoflurane (III), which are among the most important inhalation anesthetics, are currently administered as racemic mixtures. The pure enantiomers have not been described, and no analytical method for resolving the commercially available racemic mixtures has been reported. Complete optical resolution of (+/-)-I and (+/-)-III on per-n-pentylated alpha-cyclodextrin (Lipodex A) and of (+/-)-II and (+/-)-III on octakis(6-O-methyl-2,3-di-O-pentyl)-gamma-cyclodextrin capillary columns has been achieved, making rapid and convenient determination of enantiomeric ratios in samples of all three of these anesthetics possible.	PARK PLAZA HOSP,DEPT ANESTHESIOL,HOUSTON,TX 77004; UNIV HAMBURG,INST ORGAN CHEM,W-2000 HAMBURG 13,GERMANY	University of Hamburg	MEINWALD, J (corresponding author), CORNELL UNIV,DEPT CHEM,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM37018] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORMAN S, 1990, CHEM ENG NEWS, V68, P9, DOI 10.1021/cen-v068n028.p009; BOUCHE J, 1968, J GAS CHROMATOGR, V6, P501, DOI 10.1093/chromsci/6.10.501; CALVERLEY RK, 1989, CLIN ANESTH, P3; Calverley RK, 1986, SURV ANESTHESIA, V29, P170; DECAMP WH, 1989, CHIRALITY, V1, P2, DOI 10.1002/chir.530010103; DLUZEWSKI AR, 1983, MOL ASPECTS MED, V6, P459, DOI 10.1016/0098-2997(83)90001-8; EVERS AS, 1987, NATURE, V328, P157, DOI 10.1038/328157a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; KENDIG JJ, 1973, ANESTHESIOLOGY, V39, P518, DOI 10.1097/00000542-197311000-00011; Konig W. A., 1990, J HIGH RES CHROMATOG, V13, P702; KONIG WA, 1983, J CHROMATOGR, V280, P135, DOI 10.1016/S0021-9673(00)91548-6; KONIG WA, 1988, ANGEW CHEM INT EDIT, V27, P979, DOI 10.1002/anie.198809791; KONIG WA, 1988, ANGEW CHEM, V100, P989; PEARSON DL, 1990, THESIS CORNELL U ITH; STEVENS WC, 1989, CLIN ANESTH, P293; SUCKLING CW, 1957, BRIT J ANAESTH, V29, P466, DOI 10.1093/bja/29.10.466; TERRELL RC, 1971, J MED CHEM, V14, P517, DOI 10.1021/jm00288a014	17	59	61	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 1	1991	251	4993					560	561		10.1126/science.1846702	http://dx.doi.org/10.1126/science.1846702			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV459	1846702				2022-12-24	WOS:A1991EV45900051
J	NERI, A; CHANG, CC; LOMBARDI, L; SALINA, M; CORRADINI, P; MAIOLO, AT; CHAGANTI, RSK; DALLAFAVERA, R				NERI, A; CHANG, CC; LOMBARDI, L; SALINA, M; CORRADINI, P; MAIOLO, AT; CHAGANTI, RSK; DALLAFAVERA, R			B-CELL LYMPHOMA-ASSOCIATED CHROMOSOMAL TRANSLOCATION INVOLVES CANDIDATE ONCOGENE LYT-10, HOMOLOGOUS TO NF-KAPPA-B P50	CELL			English	Article							HEAVY-CHAIN LOCUS; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-MYC ONCOGENE; DISTINCT PATHOGENETIC FORMS; ENHANCER-BINDING-PROTEINS; HUMAN T-CELLS; BURKITT-LYMPHOMA; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; REL ONCOGENE	A B cell lymphoma-associated chromosomal translocation, t(10;14)(q24;q32), juxtaposes the immunoglobulin C-alpha-1 locus to a novel gene, lyt-10. The normal lyt-10 cDNA codes for a 98 kd protein which displays amino-terminal homology with the rel (DNA-binding) domain of the NF-kappa-B-rel family of transcription factors and carboxy-terminal homology with the NF-kappa-B p50 precursor protein, including the putative proteolytic cleavage domain (poly-G) and the ankyrin-like repeat domains. The lyt-10 protein can bind to kappa-B sequences in vitro, although with different specificity from NF-kappa-B p50, and in vitro DNA-binding is activated by removal of the ankyrin domain. Chromosomal translocation generates an lyt-10-C-alpha-1 fusion gene coding for a protein that retains the rel effector domain, lacks the ankyrin regulatory domain, and binds kappa-B sequences in vitro, suggesting its constitutive activation in vivo. Analogous rearrangements of the lyt-10 gene have been found in an additional three cases of lymphoid neoplasia. The lyt-10 gene defines a new subfamily (rel/poly-G/ankyrin) of NF-kappa-B-rel transcription factors with potential for oncogenic activation in human cancer.	COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,INST RIC & CARATTERE SCI,IST SCI MED,SERV EMATOL,I-20122 MILAN,ITALY; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Columbia University; University of Milan; Memorial Sloan Kettering Cancer Center	NERI, A (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032, USA.		Neri, Antonino/I-9690-2014; Corradini, Paolo/N-7584-2017	Neri, Antonino/0000-0001-9047-5912; Corradini, Paolo/0000-0002-9186-1353; Critelli, Salvatore/0000-0001-7325-0228	NCI NIH HHS [CA-20194, CA-44029, CA-34775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034775, R01CA044029, P01CA020194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELL REG, V6; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROTHMAN AR, 1990, CANCER RES, V50, P3795; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1991, ORIGINS HUMAN CANCER; DUBE ID, 1986, BLOOD, V67, P1181; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GRUMONT RJ, 1988, ONCOGENE RES, V4, P1; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HAKEM R, 1989, J IMMUNOL, V142, P297; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.genet.21.1.321; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; LU D, 1991, ONCOGENE, V6, P1235; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PESCHLE C, 1984, P NATL ACAD SCI-BIOL, V81, P5514, DOI 10.1073/pnas.81.17.5514; RABBITTS TH, 1981, NUCLEIC ACIDS RES, V9, P4509, DOI 10.1093/nar/9.18.4509; RAIMONDI SC, 1988, BLOOD, V72, P1560; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	81	403	407	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 20	1991	67	6					1075	1087		10.1016/0092-8674(91)90285-7	http://dx.doi.org/10.1016/0092-8674(91)90285-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GX164	1760839				2022-12-24	WOS:A1991GX16400007
J	BUCK, J; DERGUINI, F; LEVI, E; NAKANISHI, K; HAMMERLING, U				BUCK, J; DERGUINI, F; LEVI, E; NAKANISHI, K; HAMMERLING, U			INTRACELLULAR SIGNALING BY 14-HYDROXY-4,14-RETRO-RETINOL	SCIENCE			English	Article							RETINOL-BINDING PROTEIN; RECEPTOR; ACID; PURIFICATION	In mammals, retinol is the precursor for retinoids, which affect various aspects of morphogenesis and development. However, B lymphocytes, although retinol-dependent, do not use retinoic acid as mediator. Retinol is metabolized by B lymphocytes and other cell lines to optically active 14-hydroxy-4,14-retro-retinol; it is this compound that mediates the growth control. Thus another second messenger molecule, in addition to retinoic acid and retinal, is derived from retinol.	COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Columbia University	BUCK, J (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT IMMUNOL,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA49933] Funding Source: Medline; NIAID NIH HHS [AI38351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEECHAM AF, 1971, TETRAHEDRON, V27, P5207, DOI 10.1016/S0040-4020(01)90774-4; BEUTEL RH, 1955, J AM CHEM SOC, V77, P5166, DOI 10.1021/ja01624a065; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; BUCK JD, UNPUB; FEX G, 1977, BIOCHIM BIOPHYS ACTA, V493, P410, DOI 10.1016/0005-2795(77)90197-0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GONNELLA NC, 1982, J AM CHEM SOC, V104, P3775, DOI 10.1021/ja00377a063; Goodman, 1984, RETINOIDS; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOSSWEIN L, 1976, THESIS U WURZBURG; HEILBRON I, 1958, B SOC CHIM FR, P83; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCLEAN SW, 1982, CLIN CHEM, V28, P693; NATORI S, 1974, NATURAL PRODUCTS CHE, V1, P30; ONG DE, 1978, J BIOL CHEM, V253, P828; OROSHNIK W, 1952, J AM CHEM SOC, V74, P295, DOI 10.1021/ja01122a003; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SCHRECKENBACH T, 1977, EUR J BIOCHEM, V76, P499, DOI 10.1111/j.1432-1033.1977.tb11620.x; SCHWIETER U, 1969, Pure and Applied Chemistry, V20, P365, DOI 10.1351/pac196920040365; STRAUB O, 1971, CAROTENOIDS, P772; VETTER W, 1971, CAROTENOIDS, P204; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230	25	169	174	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1991	254	5038					1654	1656		10.1126/science.1749937	http://dx.doi.org/10.1126/science.1749937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV073	1749937				2022-12-24	WOS:A1991GV07300048
J	KOCHEN, MM; HASFORD, JC; JAGER, H; ZIPPEL, S; LAGE, M; ROSENDAHL, C; FUESSL, HS; EICHENLAUB, D				KOCHEN, MM; HASFORD, JC; JAGER, H; ZIPPEL, S; LAGE, M; ROSENDAHL, C; FUESSL, HS; EICHENLAUB, D			HOW DO PATIENTS WITH HIV PERCEIVE THEIR GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; AIDS	Objective - To study the perceptions of patients with HIV of their general practitioners in terms of knowledge, abilities, confidence, and satisfaction. Design - Questionnaire survey of inpatients, outpatients, and members of a self help group. Setting - Two city hospitals, three outpatient clinics, and one AIDS self help group in Munich and Berlin, Germany. Subjects - All 402 patients available between 1 September 1988 and 31 May 1989. Main outcome measures - General practitioners' attitudes towards the patients' HIV status; patients' experience of treatment rejection; reception in the general practitioner's office; the doctor's perceived knowledge about HIV and AIDS. Results - 394 of 402 patients consented to interview; 87% were registered with a general practitioner and 91% of those indicated that the doctor was aware of their HIV diagnosis. The overwhelming majority of patients (94%) had a friendly or at least neutral reception in the general practitioner's surgery and only six patients' general practitioner changed his or her behaviour for the worse because of the HIV diagnosis. Two thirds of patients said they would consult first with their primary care doctor for a physical problem, but only 13% would do so for psychological problems. Over a third of the patients did not routinely inform other doctors or medical staff about their HIV status, but there was no significant correlation between this concealment and ever having been rejected by a doctor (7%) or a dentist (12%). Conclusion - Most patients expressed a high degree of satisfaction with their general practitioners in terms of confidential issues, attitudes, knowledge, and management.	UNIV MUNICH,GEN PRACTICE,W-8000 MUNICH 2,GERMANY; UNIV MUNICH,CHILDRENS HOSP,IMMUNE DEFICIENCY CLIN,W-8000 MUNICH 2,GERMANY; UNIV MUNICH,MED POLICLIN,W-8000 MUNICH 2,GERMANY; SCHWABINGER KRANKENHAUS,IMMUNODEFICIENCY CLIN,MUNICH,GERMANY; SCHWABINGER KRANKENHAUS,DEPT MED 4,MUNICH,GERMANY; AIDS HILFE,MUNICH,GERMANY; AUGUSTE VIKTORIA KRANKENHAUS,DEPT MED 2,BERLIN,GERMANY	University of Munich; University of Munich; University of Munich								BHUGRA D, 1989, J ROY SOC MED, V82, P603, DOI 10.1177/014107688908201013; BUCKNALL A, 1986, J ROY COLL GEN PRACT, V36, P491; GALLAGHER M, 1988, J ROY COLL GEN PRACT, V38, P414; GILLON R, 1987, BRIT MED J, V294, P1332, DOI 10.1136/bmj.294.6583.1332; HODGKIN P, 1988, BRIT MED J, V296, P516, DOI 10.1136/bmj.296.6621.516; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; KING MB, 1989, BMJ-BRIT MED J, V299, P713, DOI 10.1136/bmj.299.6701.713; NORTHFELT DW, 1988, ANN INTERN MED, V108, P773; SIBBALD B, 1988, J ROY COLL GEN PRACT, V38, P500; WOFSY CB, 1987, JAMA-J AM MED ASSOC, V257, P2074, DOI 10.1001/jama.257.15.2074; 1990, STATISTICAL YB FEDER, P355; 1988, J R COLL GEN PRACT, V38, P219; 1990, MED J AUSTRALIA, V153, P5	13	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 30	1991	303	6814					1365	1368		10.1136/bmj.303.6814.1365	http://dx.doi.org/10.1136/bmj.303.6814.1365			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU384	1760602	Green Published, Bronze			2022-12-24	WOS:A1991GU38400019
J	GOODWIN, FK				GOODWIN, FK			ANABOLIC-STEROIDS AND DEPENDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,WASHINGTON,DC, USA.							BROWER KJ, 1991, BRIT J ADDICT, V86, P759	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1619	1619						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1832194				2022-12-24	WOS:A1991GF41900007
J	POWELL, SK; CUNNINGHAM, BA; EDELMAN, GM; RODRIGUEZBOULAN, E				POWELL, SK; CUNNINGHAM, BA; EDELMAN, GM; RODRIGUEZBOULAN, E			TARGETING OF TRANSMEMBRANE AND GPI-ANCHORED FORMS OF N-CAM TO OPPOSITE DOMAINS OF A POLARIZED EPITHELIAL-CELL	NATURE			English	Article							ADHESION MOLECULE UVOMORULIN; MDCK CELLS; PROTEINS; COMPONENT; KIDNEY; CDNAS; LINE	THE calcium-independent neural cell adhesion molecule N-CAM is expressed transiently during development in many tissues, including epithelia 1. The three naturally occurring principal isoforms 2,3 of N-CAM differ in the way in which they associate with the membrane and in their cytoplasmic domains 4. These isoforms are generated by developmentally regulated alternative splicing of a single gene 4-6: the large cytoplasmic domain (ld) form (relative molecular mass 180,000 (M(r) 180K)) is specific for post-mitotic neurons; the 120K small cytoplasmic domain (ssd) and 140K small surface domain (sd) forms also occur on other cell types 7. One function of the different isoforms could be to specify cellular localization; for example, glycosyl phosphatidyl inositol (GPI)-membrane anchoring acts as a targeting signal for expression on the apical surface of polarized epithelial cells 8,9. Neurons and epithelial cells may use similar mechanisms for polarizing their plasma membrane proteins 10,11. We have therefore investigated the targeting of GPI-anchored (ssd N-CAM, 120K) and transmembrane forms of N-CAM (sd N-CAM, 140K; Id N-CAM, 180K) by comparing the expression of each after transfection of the appropriate complementary DNAs into polarized epithelial cells. We find that isoforms with alternative modes of membrane association are targeted to different surfaces of polarized epithelial cells: ssd N-CAM is expressed on the apical surface, whereas sd and ld N-CAM are expressed on the basolateral surface. These results suggest that the different isoforms of N-CAM determine their own diverse cellular destinations. They also support the hypothesis that the GPI anchor acts as an apical targeting signal in epithelia.	ROCKEFELLER UNIV,DEPT DEV & MOLEC BIOL,NEW YORK,NY 10021	Rockefeller University	POWELL, SK (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,1300 YORK AVE,NEW YORK,NY 10021, USA.							CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; CUNNINGHAM BA, 1990, MORPHOREGULATORY MOL; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; KLEIN G, 1988, DEVELOPMENT, V102, P749; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MURRAY BA, 1986, J CELL BIOL, V102, P189, DOI 10.1083/jcb.102.1.189; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737	27	105	106	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					76	77		10.1038/353076a0	http://dx.doi.org/10.1038/353076a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1831882				2022-12-24	WOS:A1991GD80500062
J	HAGELBERG, E; GRAY, IC; JEFFREYS, AJ				HAGELBERG, E; GRAY, IC; JEFFREYS, AJ			IDENTIFICATION OF THE SKELETAL REMAINS OF A MURDER VICTIM BY DNA ANALYSIS	NATURE			English	Article							POLYMERASE CHAIN-REACTION; DINUCLEOTIDE REPEAT; MINISATELLITES; POLYMORPHISMS; AMPLIFICATION	THERE is considerable anthropological and forensic interest in the possibility of DNA typing skeletal remains. Trace amounts of DNA can be recovered even from 5,500-year-old bones and multicopy human mitochondrial DNA sequences can frequently be amplified from such DNA using the polymerase chain reaction (PCR) 1,2. But given the sensitivity of PCR, it is very difficult to exclude contaminating material. We now report the successful identification of the 8-year-old skeletal remains of a murder victim, by comparative typing of nuclear microsatellite markers 3-5 in the remains and in the presumptive parents of the victim. This analysis establishes the authenticity of the bone DNA and the feasibility of bone DNA typing in forensic investigations.	UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND	University of Leicester	HAGELBERG, E (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MRC, MOLEC HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND.		Schneider, Peter M./A-6661-2011		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHAKRABORTY R, IN PRESS DNA FINGERP; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; HAGELBERG E, 1989, NATURE, V342, P485, DOI 10.1038/342485a0; HAGELBERG E, 1991, P ROY SOC B-BIOL SCI, V244, P45, DOI 10.1098/rspb.1991.0049; HOUCK CM, 1979, J MOL BIOL, V132, P289, DOI 10.1016/0022-2836(79)90261-4; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; LITT M, 1989, AM J HUM GENET, V44, P397; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2199; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	13	220	227	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					427	429		10.1038/352427a0	http://dx.doi.org/10.1038/352427a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861721				2022-12-24	WOS:A1991FZ34600063
J	HART, JT; THOMAS, C; GIBBONS, B; EDWARDS, C; HART, M; JONES, J; JONES, M; WALTON, P				HART, JT; THOMAS, C; GIBBONS, B; EDWARDS, C; HART, M; JONES, J; JONES, M; WALTON, P			25 YEARS OF CASE FINDING AND AUDIT IN A SOCIALLY DEPRIVED COMMUNITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GENERAL-PRACTICE; BLOOD-PRESSURE; DIETARY-SODIUM; INVERSE CARE; HEALTH CHECK; INEQUALITIES; HYPERTENSION; SATISFACTION; ATTENDERS	Objective - To evaluate audit and case finding (whole population care) in a community over 25 years. Design - Contemporary screening for and audits of care of chronic disease and risk factors; retrospective review of computerised practice records; and comparisons of mortality and social indices with neighbouring communities. Setting - One general practice in Glyncorrwg, West Glamorgan. Subjects - 1800 people registered with the practice in 1987 and 558 people who died from 1964 to 1987, whose records had been retained. Main outcome measures - Detection of high blood pressure, smoking, airways obstruction, obesity, diabetes, and alcohol problems in adults aged 20-79; prevalence of smoking in this population and in hypertensive and diabetic groups; age standardised mortality ratios in relation to indices of social deprivation. Results - In the population aged 20-79 (1207 patients) 249 (21%) had peak expiratory flow rate less than 50% of expected value or which improved by 15% or more with an inhaled beta-agonist, 207 (17%) had body mass index at or over 30 kg/m2, 118 (10%) had untreated mean arterial pressures greater than 159/104 mm Hg (three readings), 80 (7%) (65 (16%) men, 15 (4%) women) had recognised alcohol problems, and 35 (3%) had diabetes. The proportion of men aged 20-64 who said they smoked fell from 61% (290/476) in 1968-70 to 36% (162/456) in 1985 whereas that of women who smoked was unchanged (43%, 187/436 v 42%, 190/448 respectively). In 116 screened hypertensive patients group mean blood pressure fell from 186/110 mm Hg before treatment to 146/84 mm Hg at 1987 audit, as did the proportion of smokers (56% v 20%), but body mass index and total cholesterol concentration showed no significant change. In 34 diabetic patients mean blood pressure and the proportion of smokers fell (171/93 mm Hg v 155/81 mm Hg; 44% v 12%). The age standardised mortality ratio in 1981-6 was lower than in a neighbouring village without a developed case finding programme (actual to expected deaths < 65 = 21 to 22 in Glyncorrwg, 48 to 30 in control village). Conclusions - Whole population care through organised case finding and audit is feasible but only with a labour intensive approach combining accessibility, flexibility, and continuity, as well as a planned and structured approach, which requires substantial expansion of staff numbers and assiduous recording. It may reduce risks for at least some high risk groups. Despite their shortcomings the available data are consistent with the hypothesis that whole population care helps reduce mortality. Incentives in the new contract, which encourage the uncritical development of structured process, may diminish health outputs.	UNIV SWANSEA, DEPT GEOG, SWANSEA SA2 8PP, WALES; ABER BLAENGWYNFI HLTH CTR, BLAENGWYNFI, W GLAM, WALES; GLYNCORRWG HLTH CTR, GLYNCORRWYG, W GLAM, WALES	Swansea University	HART, JT (corresponding author), ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON W2 1PG, ENGLAND.							ALBASHIR MM, 1991, BRIT J GEN PRACT, V41, P6; AMIEL S, 1991, BRIT MED J, V302, P527, DOI 10.1136/bmj.302.6775.527; [Anonymous], 1970, JAMA, V213, P1143; BALLARD DJ, 1988, AM J PREV MED, V4, P133, DOI 10.1016/S0749-3797(18)31185-1; BOSANQUET N, 1988, BMJ-BRIT MED J, V296, P157; BUCHAN IC, 1973, SCOTTISH HLTH STUDIE, V27; CATFORD JC, 1984, BRIT MED J, V289, P1668, DOI 10.1136/bmj.289.6459.1668; Coope J, 1974, J R Coll Gen Pract, V24, P161; DAY JL, 1987, BRIT MED J, V294, P1590, DOI 10.1136/bmj.294.6587.1590; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAMILTON M, 1964, LANCET, V1, P235; Hart J T, 1974, J R Coll Physicians Lond, V8, P299; Hart J T, 1976, J R Coll Gen Pract, V26, P885; HART JT, 1987, BRIT MED J, V294, P871, DOI 10.1136/bmj.294.6576.871; HART JT, 1970, LANCET, V2, P223; HART JT, 1990, BRIT J GEN PRACT, V40, P4; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HART JT, 1982, BRIT MED J, V284, P1686, DOI 10.1136/bmj.284.6330.1686; HART JT, 1987, HYPERTENSION COMMUNI; Hart JT, 1988, PREVENTION CORONARY; HARTLAGE JA, 1984, SOAP COSMET CHEM SPE, V60, P42; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; Kark SL, 1989, PRACTICE COMMUNITY O; KAUL SA, 1988, STUDY SMALL AREA STA; LEESE B, 1989, BRIT MED J, V298, P932, DOI 10.1136/bmj.298.6678.932; LITTLEPAGE BNC, 1988, STUDY SMALL AREA STA; MAIN J, 1990, RCGP CONNECTION  SEP, P4; MARMOT MG, 1984, LANCET, V1, P1003; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; PILL R, 1988, J ROY COLL GEN PRACT, V38, P57; PRINGLE M, 1989, BRIT MED J, V299, P470, DOI 10.1136/bmj.299.6697.470; RIDSDALE L, 1989, J ROY COLL GEN PRACT, V39, P488; RIDSDALE L, 1990, BRIT MED J, V301, P455, DOI 10.1136/bmj.301.6750.455; ROBSON J, 1989, BMJ-BRIT MED J, V298, P433, DOI 10.1136/bmj.298.6671.433; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SAVAGE R, 1990, BRIT MED J, V301, P968, DOI 10.1136/bmj.301.6758.968; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; Stott N C, 1979, J R Coll Gen Pract, V29, P201; THOMAS K, 1989, J ROY COLL GEN PRACT, V39, P509; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; Townsend PP., 1988, HLTH DEPRIVATION INE; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WALLACE PG, 1987, J ROY COLL GEN PRACT, V37, P354; WALLER D, 1990, BRIT MED J, V300, P1115, DOI 10.1136/bmj.300.6732.1115; WATT GCM, 1983, LANCET, V1, P1245; WATT GCM, 1983, BMJ-BRIT MED J, V286, P432, DOI 10.1136/bmj.286.6363.432; WATT GCM, 1985, BMJ-BRIT MED J, V291, P1525, DOI 10.1136/bmj.291.6508.1525; 1980, INEQUALITIES HLTH; 1987, 7 HEARTB WAL; 1986, 24 ROYAL COLL GEN PR; 1985, 1 HEARTB WAL	54	60	59	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	1991	302	6791					1509	1513		10.1136/bmj.302.6791.1509	http://dx.doi.org/10.1136/bmj.302.6791.1509			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855023	Green Published, Bronze			2022-12-24	WOS:A1991FT50500026
J	PRENDERGAST, GC; LAWE, D; ZIFF, EB				PRENDERGAST, GC; LAWE, D; ZIFF, EB			ASSOCIATION OF MYN, THE MURINE HOMOLOG OF MAX, WITH C-MYC STIMULATES METHYLATION-SENSITIVE DNA-BINDING AND RAS COTRANSFORMATION	CELL			English	Article							MAJOR LATE PROMOTER; CASEIN KINASE-II; LEUCINE ZIPPER; TRANSCRIPTION FACTOR; EARLY REGION-1A; CELLS; PROTEINS; ONCOGENE; FOS; TRANSFORMATION	Myn, a novel murine approximately 18 kd basic/helix-loop-helix/"leucine zipper" (B/HLH/LZ) protein, forms a specific DNA-binding complex with the c-Myc oncoprotein through the HLH/LZ motif in both proteins. c-Myc/Myn recognizes a c-Myc-binding site (GACCACGTGGTC) with higher affinity than either protein by itself. CpG methylation of the recognition site greatly inhibits DNA binding, suggesting that DNA methylation may regulate the c-Myc/Myn complex in vivo. In 3T3 fibroblasts, Myn mRNA levels are induced several-fold by serum with delayed early kinetics, suggesting regulation by immediate-early gene products. Coexpression of Myn in a myc/ras rat embryo fibroblast focus formation assay specifically augmented c-myc transforming activity. We suggest that interaction of Myn with c-Myc stabilizes sequence-specific DNA binding in vivo.	NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University	PRENDERGAST, GC (corresponding author), NYU MED CTR,KAPLAN CANC CTR,HOWARD HUGHES MED INST,MSB 397,NEW YORK,NY 10016, USA.			Ziff, Edward/0000-0001-7389-8649				BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROUCH DH, 1990, ONCOGENE, V5, P433; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GIBSON TJ, 1990, DNA MAP SEQ, V1, P3; GORHAM JD, 1990, DEV BRAIN RES, V57, P235, DOI 10.1016/0165-3806(90)90049-5; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES PA, 1986, CANCER RES, V46, P461; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KERKHOFF E, 1991, IN PRESS P NATL ACAD; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULTZ WH, 1987, SCIENCE, V240, P1759; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MULLER R, 1987, ONCOGENE RES, V2, P19; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Penn L J, 1990, Semin Cancer Biol, V1, P69; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, IN PRESS EMBO J; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAJCHEL A, 1987, NUCLEIC ACIDS RES, V16, P2347; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	63	572	580	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					395	407		10.1016/0092-8674(91)90457-A	http://dx.doi.org/10.1016/0092-8674(91)90457-A			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1840505				2022-12-24	WOS:A1991FK18200006
J	WISSINGER, B; SCHUSTER, W; BRENNICKE, A				WISSINGER, B; SCHUSTER, W; BRENNICKE, A			TRANS SPLICING IN OENOTHERA MITOCHONDRIA - NAD1-MESSENGER RNAS ARE EDITED IN EXON AND TRANSSPLICING GROUP-II INTRON SEQUENCES	CELL			English	Article							GENE ORGANIZATION; PLANT-MITOCHONDRIA; NUCLEOTIDE-SEQUENCE; WHEAT MITOCHONDRIA; RIBOSOMAL-PROTEIN; CHLOROPLAST DNA; CDNA LIBRARIES; EXPRESSION; GENOME; SUBUNIT	The complete NADH dehydrogenase subunit 1 (nad1) ORF in Oenothera mitochondria is encoded by five exons. These exons are located in three distant locations of the mitochondrial genome. One genomic region encodes exon a, the second encodes exons b and c, and the third specifies exons d and e. Cis-splicing group II introns separate exons b and c and d and e, while trans-splicing reactions are required to link exons a and b and c and d. The two parts of the group II intron sequences involved in these trans-splicing events can be aligned in domain IV. Exon sequences and the maturase-related ORF in intron d/e are edited by numerous C to U alterations in the mRNA. Two RNA editing events in the trans-splicing intron a/b improve conservation of the secondary structure in the stem of domain VI. RNA editing in intron sequences may thus be required for the trans-splicing reaction.			WISSINGER, B (corresponding author), INST GENBIOL FORSCHUNG,IHNESTR 63,W-1000 BERLIN 33,GERMANY.							ADEMA GJ, 1990, NUCLEIC ACIDS RES, V18, P5365, DOI 10.1093/nar/18.18.5365; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLAND MM, 1986, MOL GEN GENET, V204, P8, DOI 10.1007/BF00330180; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BONEN L, 1987, NUCLEIC ACIDS RES, V15, P10393, DOI 10.1093/nar/15.24.10393; BRENNICKE A, 1980, PLANT PHYSIOL, V65, P1207, DOI 10.1104/pp.65.6.1207; BURGER G, 1985, ACHIEVEMENTS PERSPEC, V2, P305; CHAPDELAINE Y, 1991, CELL, V65; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; CUMMINGS DJ, 1988, CURR GENET, V14, P253, DOI 10.1007/BF00376746; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAYMERLE H, 1986, NUCLEIC ACIDS RES, V14, P8615, DOI 10.1093/nar/14.21.8615; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1987, EMBO J, V6, P29, DOI 10.1002/j.1460-2075.1987.tb04714.x; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KRAWETZ SA, 1989, NUCLEIC ACIDS RES, V17, P819, DOI 10.1093/nar/17.2.819; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; LAMATTINA L, 1989, FEBS LETT, V258, P79, DOI 10.1016/0014-5793(89)81620-5; LEAVER CJ, 1982, ANNU REV PLANT PHYS, V33, P373, DOI 10.1146/annurev.pp.33.060182.002105; LEVINGS CS, 1989, CELL, V56, P171, DOI 10.1016/0092-8674(89)90890-8; LONSDALE DM, 1989, BIOCH PLANTS COMPREH, V15, P229; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; NEWTON KJ, 1988, ANNU REV PLANT PHYS, V39, P503, DOI 10.1146/annurev.arplant.39.1.503; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; RUTLEDGE RG, 1988, GENE, V68, P151, DOI 10.1016/0378-1119(88)90607-5; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SCHUSTER W, 1987, MOL GEN GENET, V210, P44, DOI 10.1007/BF00337757; SCHUSTER W, 1990, EMBO J, V9, P263, DOI 10.1002/j.1460-2075.1990.tb08104.x; SCHUSTER W, 1988, PLANT SCI, V54, P1, DOI 10.1016/0168-9452(88)90049-0; SCHUSTER W, 1988, THESIS U TUBINGEN GE; SCHUSTER W, 1988, PLANT MOL BIOL PRACT, P79; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STERN DB, 1986, CURR GENET, V10, P857, DOI 10.1007/BF00418532; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; STERN DB, 1984, P NATL ACAD SCI-BIOL, V81, P1946, DOI 10.1073/pnas.81.7.1946; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WAHLEITHNER JA, 1990, P NATL ACAD SCI USA, V87, P548, DOI 10.1073/pnas.87.2.548; WARD BL, 1981, CELL, V25, P793, DOI 10.1016/0092-8674(81)90187-2; WISSINGER B, 1990, MOL GEN GENET, V224, P389, DOI 10.1007/BF00262433; WISSINGER B, 1988, MOL GEN GENET, V212, P56, DOI 10.1007/BF00322444; ZAITA N, 1987, FEBS LETT, V210, P153, DOI 10.1016/0014-5793(87)81326-1	50	167	172	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1991	65	3					473	482		10.1016/0092-8674(91)90465-B	http://dx.doi.org/10.1016/0092-8674(91)90465-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FK182	1850322				2022-12-24	WOS:A1991FK18200014
J	LEE, JS; RO, JY; SAHIN, AA; HONG, WK; BROWN, BW; MOUNTAIN, CF; HITTELMAN, WN				LEE, JS; RO, JY; SAHIN, AA; HONG, WK; BROWN, BW; MOUNTAIN, CF; HITTELMAN, WN			EXPRESSION OF BLOOD-GROUP ANTIGEN-A - A FAVORABLE PROGNOSTIC FACTOR IN NON-SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY-BLADDER; CARCINOMA; ABH; GLYCOSYLATION; ANTIBODIES; RECEPTOR; TUMORS	Background. New prognostic factors are needed to guide the treatment of patients with non-small-cell lung cancer. We evaluated the prognostic value of altered expression of ABH blood-group antigens, which has been implicated in the multistep process of carcinogenesis and tumor progression. Methods. The presence of blood-group antigens was assessed immunohistochemically in paraffin-embedded tumor samples from 164 patients who underwent curative surgery for non-small-cell lung cancer from 1980 through 1982. Monoclonal antibodies were used to detect the A and B antigens, and Ulex europaeus agglutinin I to detect H antigen. Results. Survival of the 28 patients with blood type A or AB who had primary tumors negative for blood-group antigen A was significantly shorter than that of the 43 patients with antigen A-positive tumors (P < 0.001) and of the 93 patients with blood type B or O (P =0.002). The respective median survival times were 15, 71, and 39 months. Disease progressed significantly earlier in the 28 patients with tumors negative for blood-group antigen A than in the antigen A-positive patients (P < 0.001). Expression of blood-group antigen B or H in tumor cells did not correlate with survival. Cox proportional-hazards regression analysis showed that expression of blood-group antigen A in tumor cells added significantly to the prediction of overall survival provided by other known prognostic factors among the patients with blood type A or AB (P = 0.004). Conclusions. Expression of blood-group antigen A in tumor cells is an important favorable prognostic factor in patients with non-small-cell lung cancer. This variable needs to be considered in the design of future trials of therapy.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC SURG, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT PATHOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	LEE, JS (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MED ONCOL, BOX 80, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.				NCI NIH HHS [CA-11672, CA-45746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, AM J CLIN PATHOL, V77, P123; BLACK MM, 1956, AM J CLIN PATHOL, V26, P250; CAREY TE, 1987, OTOLARYNG HEAD NECK, V96, P221, DOI 10.1177/019459988709600301; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; COX DR, 1972, J R STAT SOC B, V34, P187; DABELSTEEN E, 1975, ACTA PATH MICRO IM A, VA 83, P292; DABELSTEEN E, 1988, APMIS, V96, P813, DOI 10.1111/j.1699-0463.1988.tb00948.x; DABELSTEEN E, 1974, ACTA PATH MICRO IM A, VA 82, P431; DAVIDSOHN I, 1973, ARCH PATHOL, V95, P132; DAVIDSOHN I, 1972, AM J CLIN PATHOL, V57, P715; DAVIDSOHN I, 1969, AM J PATHOL, V57, P307; FINKELSTEIN DM, 1986, J CLIN ONCOL, V4, P702, DOI 10.1200/JCO.1986.4.5.702; FUJIOKA T, 1986, UROL INT, V41, P397, DOI 10.1159/000281242; GIBLETT ER, 1983, HEMATOLOGY, P1491; GOOI HC, 1985, BIOSCIENCE REP, V5, P83; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HIROHASHI S, 1984, J NATL CANCER I, V72, P1299; HONG WK, 1989, P AN M AM SOC CLIN, V8, P167; JUHL BR, 1986, CANCER, V57, P1768, DOI 10.1002/1097-0142(19860501)57:9<1768::AID-CNCR2820570910>3.0.CO;2-E; JUHL BR, 1986, CANCER, V58, P1184; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAY HE, 1961, J NATL CANCER I, V26, P1349; LEE JS, 1989, P AN M AM SOC CLIN, V8, P226; LIMAS C, 1979, CANCER, V44, P2099, DOI 10.1002/1097-0142(197912)44:6<2099::AID-CNCR2820440621>3.0.CO;2-I; MACKENZIE IC, 1977, ACTA PATH MICRO IM A, V85, P49; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; NARUKE, 1989, J THORAC CARDIOV SUR, V97, P350; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; ORNTOFT TF, 1987, CANCER, V60, P2641, DOI 10.1002/1097-0142(19871201)60:11<2641::AID-CNCR2820601112>3.0.CO;2-5; SCHOENTAG R, 1984, CANCER, V53, P503, DOI 10.1002/1097-0142(19840201)53:3<503::AID-CNCR2820530323>3.0.CO;2-J; Snedecor G.W., 1980, STAT METHODS, V7; SUMMERS JL, 1983, CANCER RES, V43, P934; YARDEN Y, 1985, J BIOL CHEM, V260, P315	34	206	216	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1991	324	16					1084	1090		10.1056/NEJM199104183241603	http://dx.doi.org/10.1056/NEJM199104183241603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FG912	1848917				2022-12-24	WOS:A1991FG91200003
J	BURTON, FH; HASEL, KW; BLOOM, FE; SUTCLIFFE, JG				BURTON, FH; HASEL, KW; BLOOM, FE; SUTCLIFFE, JG			PITUITARY HYPERPLASIA AND GIGANTISM IN MICE CAUSED BY A CHOLERA-TOXIN TRANSGENE	NATURE			English	Article							HORMONE-RELEASING-FACTOR; ADENYLATE-CYCLASE ACTIVITY; GROWTH-HORMONE; GENE; EXPRESSION; CELLS; MECHANISMS; INJECTION; ABLATION; INVITRO	CYCLIC AMP 1 is thought to act as an intracellular second messenger, mediating the physiological response of many cell types to extracellular signals 2,3. In the pituitary, growth hormone (GH)-producing cells (somatotrophs) proliferate and produce GH in response to hypothalamic GH-releasing factor 4-8, which binds a receptor that stimulates G(s) protein activation of adenylyl cyclase 3,9-12. We have now determined whether somatotroph proliferation and GH production are stimulated by cAMP alone 5,7,11,13-15, or require concurrent, non-G(s)-mediated induction of other regulatory molecules by designing a transgene to induce chronic supraphysiological concentrations of cAMP in somatotrophs. The rat GH promoter 16,17 was used to express an intracellular form of cholera toxin 18, a non-cytotoxic and irreversible activator of G(s) (ref. 19). Introduction of this transgene into mice caused gigantism, elevated serum GH levels, somatotroph proliferation and pituitary hyperplasia. These results support the direct triggering of these events by cAMP, and illustrate the utility of cholera toxin transgene as a tool for physiological engineering.	SCRIPPS RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	BURTON, FH (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ASA SL, 1984, J CLIN ENDOCR METAB, V58, P796, DOI 10.1210/jcem-58-5-796; ASA SL, 1990, P SOC EXP BIOL MED, V193, P232; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; BARTA A, 1981, P NATL ACAD SCI-BIOL, V78, P4867, DOI 10.1073/pnas.78.8.4867; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BOURNE HR, 1987, NATURE, V330, P517, DOI 10.1038/330517a0; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; HAMMER RE, 1985, NATURE, V315, P413, DOI 10.1038/315413a0; HOEFFLER JP, 1985, ENDOCRINOLOGY, V117, P187, DOI 10.1210/endo-117-1-187; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOFIELD JG, 1967, NATURE, V215, P1382, DOI 10.1038/2151382b0; SMIGEL M, 1984, ADV CYCLIC NUCL PROT, V17, P1; STEFANEANU L, 1989, ENDOCRINOLOGY, V125, P2710, DOI 10.1210/endo-125-5-2710; STRUTHERS RS, 1989, ENDOCRINOLOGY, V124, P24, DOI 10.1210/endo-124-1-24; SUTHERLAND EW, 1957, J AM CHEM SOC, V79, P3608, DOI 10.1021/ja01570a087; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0	27	179	180	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1991	350	6313					74	77		10.1038/350074a0	http://dx.doi.org/10.1038/350074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FA693	1848356				2022-12-24	WOS:A1991FA69300069
J	READ, AE; DONEGAN, E; LAKE, J; FERRELL, L; GALBRAITH, C; KURAMOTO, IK; ZELDIS, JB; ASCHER, NL; ROBERTS, J; WRIGHT, TL				READ, AE; DONEGAN, E; LAKE, J; FERRELL, L; GALBRAITH, C; KURAMOTO, IK; ZELDIS, JB; ASCHER, NL; ROBERTS, J; WRIGHT, TL			HEPATITIS-C IN PATIENTS UNDERGOING LIVER-TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article							NON-B-HEPATITIS; HEPATOCELLULAR-CARCINOMA; NON-A; VIRUS; ANTIBODIES; RECIPIENTS; PREVALENCE; ASSAY	Objective: To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) among patients undergoing liver transplantation and the relation between anti-HCV and post-transplant hepatitis. Design: Retrospective cohort. Patients: Serum samples from 128 patients who underwent liver transplantation. Sixty-six patients who had 6 months of follow-up and for whom both pretransplant and post-transplant serum samples were available were included in a study to assess the relation between anti-HCV and post-transplant hepatitis. Measurements: Sera were tested for anti-HCV using an enzyme-linked immunosorbent assay (ELISA) and, if positive, two confirmatory tests were done. Patients had a biopsy every week until two specimens showed no abnormal findings. Main Results: Only patients with chronic non-A, non-B hepatitis (15 of 30; 50%), alcoholic cirrhosis (7 of 19; 37%), and chronic hepatitis B infection (3 of 11; 27%) were anti-HCV positive. No patient with another form of chronic liver disease or with acute liver failure due to non-A, non-B hepatitis was anti-HCV positive. After transplantation, loss of anti-HCV was frequent and acquisition rare. Hepatitis developed in the graft in 17% of patients, but the incidence was similar among anti-HCV negative and anti-HCV-positive patients. Conclusions: Hepatitis C virus is a common cause of chronic liver disease in patients requiring liver transplantation, but anti-HCV is rarely found in patients with acute liver failure. Previous HCV infection, based on detection of anti-HCV, is not an independent risk factor for post-transplant hepatitis.	VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF DAVIS, DAVIS, CA 95616 USA; SACRAMENTO MED FDN, CTR BLOOD, SACRAMENTO, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Davis	READ, AE (corresponding author), UNIV CALIF SAN FRANCISCO, GASTROENTEROL UNIT 1120 HSW, SAN FRANCISCO, CA 94143 USA.			Lake, John/0000-0002-4332-0528	NIDDK NIH HHS [DK-26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1989, LANCET, V2, P1006; DEMETRIS AJ, 1986, AM J PATHOL, V125, P161; ESTEBAN JI, 1989, LANCET, V2, P294; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; PAYA CV, 1987, J CLIN MICROBIOL, V25, P755, DOI 10.1128/JCM.25.5.755-757.1987; ZELDIS JB, 1990, ANN INTERN MED, V112, P958, DOI 10.7326/0003-4819-112-12-958	8	93	93	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					282	284		10.7326/0003-4819-114-4-282	http://dx.doi.org/10.7326/0003-4819-114-4-282			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1846278				2022-12-24	WOS:A1991EX52100005
J	LUSSO, P; DEMARIA, A; MALNATI, M; LORI, F; DEROCCO, SE; BASELER, M; GALLO, RC				LUSSO, P; DEMARIA, A; MALNATI, M; LORI, F; DEROCCO, SE; BASELER, M; GALLO, RC			INDUCTION OF CD4 AND SUSCEPTIBILITY TO HIV-1 INFECTION IN HUMAN CD8+ LYMPHOCYTES-T BY HUMAN HERPESVIRUS-6	NATURE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; CELLS; VIRUS; EXPRESSION; ANTIGEN; GENE; DIFFERENTIATION; CYTOMEGALOVIRUS; INDIVIDUALS; RETROVIRUS	DURING intrathymic T-cell ontogenesis, functionally competent CD3+CD4+CD8- and CD3+CD4-CD8+ T lymphocytes develop from immature CD4-CD8- thymocytes after transiently acquiring a double-positive CD4+CD8+ phenotype 1-3. The partition between CD4+CD8- and CD4-CD8+ T cells is generally considered to be irreversible, although a small percentage of circulating CD3+ T lymphocytes coexpressing CD4 and CD8 molecules has been identified 4. It has been suggested that in CD8+ T cells the CD4 genes may be methylated and thus highly repressed 5, whereas in CD4+ T cells the CD8 genes are unmethylated 6 and their transcription can be induced by physiological stimuli such as interleukin-4 (ref. 7). Here, we demonstrate that infection with human herpesvirus 6 (HHV-6) (ref. 8), a virus proposed as a potential cofactor in AIDS (ref. 9), dramatically upregulates the expression of CD4-the receptor for human immunodeficiency virus type-1 (HIV-1) (refs 10-12)-in a human neoplastic T-cell line. More importantly, HHV-6 induces de novo expression of CD4 messenger RNA and protein in normal mature CDE8+ T lymphocytes, rendering them susceptible to infection with HIV-1. These findings demonstrate that human CD3+CD4-CD8+ T lymphocytes can reacquire CD4 in the post-thymic life and elucidate a novel mechanism-receptor regulation-through which HHV-6 may positively interact with HIV-1 in coinfected patients.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,FREDERICK,MD 21701; NIAID,IMMUNOGENET LAB,BETHESDA,MD 20892; ADV BIOSCI LABS,DEPT CELL BIOL,KENSINGTON,MD 20895	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LUSSO, P (corresponding author), NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892, USA.		de maria, andrea/F-7116-2016; Malnati, Mauro/AAN-4207-2020	de maria, andrea/0000-0001-5782-333X; Malnati, mauro/0000-0001-5355-1680				BACH MA, 1984, J IMMUNOL, V132, P735; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BIASSONI R, 1988, J IMMUNOL, V140, P1685; BLUE ML, 1986, J IMMUNOL, V137, P1202; BLUE ML, 1985, J IMMUNOL, V134, P2281; CARBONE AM, 1988, SCIENCE, V242, P1174, DOI 10.1126/science.2460926; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERSTOFT J, 1985, SCAND J IMMUNOL, V22, P463, DOI 10.1111/j.1365-3083.1985.tb01904.x; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; PAGANO JS, 1988, J VIROL METHODS, V21, P229, DOI 10.1016/0166-0934(88)90069-9; PALIARD X, 1988, NATURE, V335, P642, DOI 10.1038/335642a0; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; RICHARDSON B, 1986, J IMMUNOL, V137, P35; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SHARMA B, 1985, CLIN EXP IMMUNOL, V62, P296; SHEARER GM, 1985, J CLIN INVEST, V76, P1699, DOI 10.1172/JCI112158; SOLBACH W, 1982, J EXP MED, V156, P1250, DOI 10.1084/jem.156.4.1250; STINSKI MF, 1977, J VIROL, V23, P751, DOI 10.1128/JVI.23.3.751-767.1977; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933	30	244	246	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					533	535		10.1038/349533a0	http://dx.doi.org/10.1038/349533a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846951				2022-12-24	WOS:A1991EW57100070
J	MARRACK, P; KUSHNIR, E; KAPPLER, J				MARRACK, P; KUSHNIR, E; KAPPLER, J			A MATERNALLY INHERITED SUPERANTIGEN ENCODED BY A MAMMARY-TUMOR VIRUS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NUCLEOTIDE-SEQUENCE; EXPRESSION; GENE; REACTIVITY; TOLERANCE; PRODUCTS; REGION; MLS	A COLLECTION of superantigens, molecules which in combination with class II major histocompatibility complex (MHC) engage T cells bearing particular V-beta chains as part of their alpha-beta receptors, have recently been described 1,2. The mouse self superantigen, Mls-1a, for example, in conjunction with many MHC class II proteins, engages mouse T cells bearing V-beta-6, 7, 8.1 and 9, almost regardless of the sequences of the other variable components of the receptors on the T cells 3-5. Two types of superantigen have been identified so far: first, superantigens encoded in the mouse genome, such as mls-1a; second, superantigens produced by bacteria, such as the staphylococcal enterotoxins 1,2. Although the latter type of super-antigens are in many cases known to be proteins of about 220 amino acids 6,7, nothing is known about the structures of any of the superantigens encoded in mouse. Here we describe the properties of a new mouse superantigen. The antigen is maternally transmitted in milk and is probably encoded by a mammary tumour virus (MTV). Given the known genetic linkage between at least one of the mouse genomic superantigens and endogenous MTV integration sites 8, it is tempting to speculate that the superantigen described here and some of the endogenous mouse superantigens are encoded by MTVs.			MARRACK, P (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,HOWARD HUGHES MED INST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687				ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; Andervont HB, 1940, J NATL CANCER I, V1, P147; BETLEY MJ, 1988, J BACTERIOL, V170, P34, DOI 10.1128/jb.170.1.34-41.1988; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAPPLER JW, 1989, J EXP MED, V169, P1533, DOI 10.1084/jem.169.5.1533; KING LB, 1990, J IMMUNOL, V144, P3218; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; OLTER AD, 1988, MOL ENDOCRINOL, V2, P143; ONEILL HC, 1987, CELL, V49, P143, DOI 10.1016/0092-8674(87)90764-1; PARKS WP, 1974, SCIENCE, V184, P158, DOI 10.1126/science.184.4133.158; RINGOLD GM, 1983, CURR TOP MICROBIOL, V106, P79; SOLTER D, 1988, ANNU REV GENET, V22, P127; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; 1987, JAX430 NOT	20	345	354	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					524	526		10.1038/349524a0	http://dx.doi.org/10.1038/349524a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846947				2022-12-24	WOS:A1991EW57100066
J	MIAO, VP; COVERT, SF; VANETTEN, HD				MIAO, VP; COVERT, SF; VANETTEN, HD			A FUNGAL GENE FOR ANTIBIOTIC-RESISTANCE ON A DISPENSABLE (B) CHROMOSOME	SCIENCE			English	Article							NECTRIA-HAEMATOCOCCA; PHYTOALEXIN-DETOXIFICATION; ELECTROPHORETIC KARYOTYPE; ASPERGILLUS-NIDULANS; LARGE DNA; PISATIN; PATHOGENICITY; PLANT	A family of cytochrome P-450 (Pda) genes in the pathogenic fungus Nectria haematococca is responsible for the detoxification of the phytoalexin pisatin, an antimicrobial compound produced by garden pea (Pisum sativum L.). The Pda6 gene was mapped by electrophoretic karyotype analysis to a small meiotically unstable chromosome that is dispensable for normal growth. Such traits are typical of B chromosomes. The strains of Nectria studied here have no sequences that are homologous to the Pda family other than Pda6 and therefore demonstrate that unique, functional genes can be found on B chromosomes. Unstable B chromosomes may be one mechanism for generating pathogenic variation in fungi.	UNIV ARIZONA,DEPT PLANT PATHOL,TUCSON,AZ 85721; CORNELL UNIV,DEPT PLANT PATHOL,ITHACA,NY 14853	University of Arizona; Cornell University	VANETTEN, HD (corresponding author), UNIV ARIZONA,DEPT PLANT PATHOL,TUCSON,AZ 85721, USA.							BRODY H, 1989, P NATL ACAD SCI USA, V86, P6260, DOI 10.1073/pnas.86.16.6260; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Jones RN, 1982, B CHROMOSOMES; KISTLER HC, 1984, J GEN MICROBIOL, V130, P2595; LUCY MC, 1988, PHYSIOL MOL PLANT P, V33, P187, DOI 10.1016/0885-5765(88)90019-7; MACKINTOSH SF, 1989, MOL PLANT MICROBE IN, V2, P354, DOI 10.1094/MPMI-2-354; MATTHEWS DE, 1983, ARCH BIOCHEM BIOPHYS, V224, P494, DOI 10.1016/0003-9861(83)90237-0; MATUO T, 1972, PHYTOPATHOLOGY, V62, P731, DOI 10.1094/Phyto-62-731; MIAO VP, IN PRESS APPL ENV MI; MIAO VPW, 1991, MOL GEN GENET, V226, P214, DOI 10.1007/BF00273606; MILLS D, 1990, MOL PLANT MICROBE IN, V3, P351, DOI 10.1094/MPMI-3-351; ORBACH MJ, 1988, MOL CELL BIOL, V8, P1469, DOI 10.1128/MCB.8.4.1469; Sambrook J., 1989, MOL CLONING; SCHAFER W, 1989, SCIENCE, V246, P247, DOI 10.1126/science.246.4927.247; VANETTEN HD, 1984, PHYSIOL PLANT PATHOL, V25, P149, DOI 10.1016/0048-4059(84)90053-5; VANETTEN HD, 1989, ANNU REV PHYTOPATHOL, V27, P143, DOI 10.1146/annurev.py.27.090189.001043; VANETTEN HD, 1989, NATO ASI SERIES H, V36, P219; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WELTRING KM, 1988, GENE, V68, P335, DOI 10.1016/0378-1119(88)90036-4	19	223	231	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1991	254	5039					1773	1776		10.1126/science.1763326	http://dx.doi.org/10.1126/science.1763326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW316	1763326				2022-12-24	WOS:A1991GW31600037
J	OLNEY, JW; LABRUYERE, J; WANG, G; WOZNIAK, DF; PRICE, MT; SESMA, MA				OLNEY, JW; LABRUYERE, J; WANG, G; WOZNIAK, DF; PRICE, MT; SESMA, MA			NMDA ANTAGONIST NEUROTOXICITY - MECHANISM AND PREVENTION	SCIENCE			English	Article							CEREBROCORTICAL NEURONS; KETAMINE; PHENCYCLIDINE; DIAZEPAM	Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, including phencyclidine (PCP) and ketamine, protect against brain damage in neurological disorders such as stroke. However, these agents have psychotomimetic properties in humans and morphologically damage neurons in the cerebral cortex of rats. It is now shown that the morphological damage can be prevented by certain anticholinergic drugs or by diazepam and barbiturates, which act at the gamma-aminobutyric acid (GABA) receptor-channel complex and are known to suppress the psychotomimetic symptoms caused by ketamine. Thus, it may be possible to prevent the unwanted side effects of NMDA antagonists, thereby enhancing their utility as neuroprotective drugs.	UNIV MISSOURI,SCH OPTOMETRY,ST LOUIS,MO 63110	University of Missouri System; University of Missouri Saint Louis	OLNEY, JW (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.				NIA NIH HHS [AG 05681] Funding Source: Medline; NIDA NIH HHS [DA 53568] Funding Source: Medline; NIMH NIH HHS [MH 38894] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKAIKE N, 1987, J PHYSIOL-LONDON, V394, P85, DOI 10.1113/jphysiol.1987.sp016861; ALLEN HL, 1990, SCIENCE, V247, P221, DOI 10.1126/science.2403696; AYIM EN, 1976, E AFR MED J, V53, P377; Burke R E, 1986, Mov Disord, V1, P135, DOI 10.1002/mds.870010208; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COPPEL DL, 1973, ANAESTHESIA, V28, P293, DOI 10.1111/j.1365-2044.1973.tb00449.x; FREEDMAN SB, 1988, EUR J PHARMACOL, V156, P133, DOI 10.1016/0014-2999(88)90155-0; KORTTILA K, 1978, ACTA ANAESTH SCAND, V22, P640, DOI 10.1111/j.1399-6576.1978.tb01348.x; LABRUYERE J, 1989, Society for Neuroscience Abstracts, V15, P761; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; MACDONALD RL, 1978, SCIENCE, V200, P775, DOI 10.1126/science.205953; MAGBAGBEOLA JA, 1974, CAN ANAESTH SOC J, V21, P321, DOI 10.1007/BF03005737; MARSHALL BE, 1990, GOODMAN GILMANS PHAR, P307; OLNEY J, UNPUB; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OLNEY JW, 1986, NEUROSCI LETT, V68, P29, DOI 10.1016/0304-3940(86)90224-7; OLNEY JW, 1988, EXCITATORY AMINO ACI, P337; Paxinos G., 2004, J CHEM INF MODEL, V5th; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; SESMA MA, IN PRESS SOC NEUR AB; SHARP J W, 1990, Society for Neuroscience Abstracts, V16, P1122; STUDY RE, 1981, P NATL ACAD SCI-BIOL, V78, P7180, DOI 10.1073/pnas.78.11.7180; ZORUMSKI CF, 1991, AM J PSYCHIAT, V148, P162	25	759	795	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1991	254	5037					1515	1518		10.1126/science.1835799	http://dx.doi.org/10.1126/science.1835799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT903	1835799				2022-12-24	WOS:A1991GT90300043
J	GODLEE, F				GODLEE, F			HEALTH IMPLICATIONS OF CLIMATIC-CHANGE	BRITISH MEDICAL JOURNAL			English	Editorial Material																		[Anonymous], 1990, POLICYMAKERS SUMMARY; BROWN L, 1989, STATE WORLD 1989 WOR; Brown L.R., 1990, STATE WORLD 1990 WOR; BROWN LR, 1991, STATE WORLD 1991 WOR; HAINES A, 1991, J PUBLIC HEALTH MED, V13, P69; HANSEN J, 1988, 1ST P N AM C PREP CL, P35; Houghton J.T., 1990, CLIMATE CHANGE IPCC; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; LONGSTRETH JA, 1989, POTENTIAL EFFECTS GL; MacKenzie J. J., 1988, ILL WINDS AIRBORNE P; MCELROY MB, 1989, B AM ACADEMY ARTS SC, V42, P25; OESCHLI FW, 1970, ENVIRON RES, V3, P277; PEARCE F, 1991, NEW SCI         1122, P20; ROGOT E, 1976, AM J EPIDEMIOL, V103, P565, DOI 10.1093/oxfordjournals.aje.a112261; TITUS JG, 1989, POTENTIAL EFFECTS GL; WARRICK R, 1986, GREENHOUSE EFFECT CL; 1991, POLICY IMPLICATIONS; 1990, WORLD RESOURCES 1990, P14; 1988, 1988 POL OPT C STAT	19	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1991	303	6812					1254	1256		10.1136/bmj.303.6812.1254	http://dx.doi.org/10.1136/bmj.303.6812.1254			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747652	Green Published, Bronze			2022-12-24	WOS:A1991GQ34200033
J	CORNALL, RJ; PRINS, JB; TODD, JA; PRESSEY, A; DELARATO, NH; WICKER, LS; PETERSON, LB				CORNALL, RJ; PRINS, JB; TODD, JA; PRESSEY, A; DELARATO, NH; WICKER, LS; PETERSON, LB			TYPE-1 DIABETES IN MICE IS LINKED TO THE INTERLEUKIN-1 RECEPTOR AND LSH/ITY/BCG GENES ON CHROMOSOME-1	NATURE			English	Article							NOD MOUSE; NONOBESE; RESISTANCE; PREVENTION; DISEASE; CYCLOPHOSPHAMIDE; INSULITIS; MELLITUS; ALPHA; MAP	HUMAN type 1 (insulin-dependent) diabetes is a common autoimmune disease of the insulin-producing beta-cells of the pancreas which is caused by both genetic and environmental factors 1,2. Several features or the genetics and immunopathology of diabetes in nonobese diabetic (NOD) mice are shared with the human disease 1,3,4. Of the three diabetes-susceptibility genes, Idd-1 (refs 5-7), -3 and -4 (ref. 4) that have been mapped in mice to date, only in the case of Idd-1 is there any evidence for the identity of the gene product: allelic variation within the murine immune response I-A-beta gene and its human homologue HLA-DQB1 correlates with susceptibility, implying that I-A-beta is a component of Idd-1 (refs 5-11). We report here the mapping of Idd-5 to the proximal region of mouse chromosome 1. This region contains at least two candidate susceptibility genes, the interleukin-1 receptor gene (Il-1r1; ref. 12) and Lsh/Ity/Bcg (refs 13-19), which encodes resistance to bacterial and parasitic infections and affects the function of macrophages.	MERCK SHARP & DOHME LTD, DEPT CELLULAR & MOLEC PHARMACOL, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, AUTOIMMUNE DIS RES, RAHWAY, NJ 07065 USA	Merck & Company; Merck & Company	CORNALL, RJ (corresponding author), JOHN RADCLIFFE HOSP, NUFFIELD DEPT SURG, OXFORD OX3 9DU, ENGLAND.		Wicker, Linda S/F-7384-2010; Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148; Prins, Jan-Bas/0000-0002-1831-8522	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELL JM, IN PRESS IMMUN LETT; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; COPELAND NG, 1991, GENOMICS, V9, P44, DOI 10.1016/0888-7543(91)90219-5; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; HARADA M, 1984, DIABETOLOGIA, V27, P604, DOI 10.1007/BF00276978; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HILLYARD AL, 1991, LOCUS MAP MOUSE COMP; HOGARTH PM, 1991, J IMMUNOL, V146, P369; HUTCHINGS P, 1990, NATURE, V348, P639, DOI 10.1038/348639a0; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MALO D, 1991, ENOMICS, V10, P356; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; MOCK B, 1990, GENOMICS, V7, P57, DOI 10.1016/0888-7543(90)90518-Y; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; RISCH N, 1987, AM J HUM GENET, V40, P1; SCHURR E, 1991, IMMUNOL TODAY, V12, P42; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639; WICKER LS, 1991, FRONTIERS DIABETES R, V2, P67; WICKER LS, IN PRESS P P S BIOME; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325	30	186	187	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1991	353	6341					262	265		10.1038/353262a0	http://dx.doi.org/10.1038/353262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1832743				2022-12-24	WOS:A1991GF67400061
J	GIBBONS, IR; GIBBONS, BH; MOCZ, G; ASAI, DJ				GIBBONS, IR; GIBBONS, BH; MOCZ, G; ASAI, DJ			MULTIPLE NUCLEOTIDE-BINDING SITES IN THE SEQUENCE OF DYNEIN BETA-HEAVY CHAIN	NATURE			English	Article							SEA-URCHIN SPERM; OUTER ARM DYNEIN; PHOTOSENSITIZED CLEAVAGE; MOLECULAR-CLONING; FLAGELLA; MYOSIN; ALPHA; PROTEINS; KINESIN; ATP	AXONEMAL dyneins have two or three globular heads joined by flexible tails to a common base, with each head/tail unit consisting of a single heavy-chain polypeptide of relative molecular mass > 400,000. The sizes of the components have been deduced by electron microscopy 1-3 . The isolated-beta heavy chain of sea urchin sperm flagella, which is immunologically identical to that of the embryo cilia (data not shown; ref. 4), is of particular interest as it retains the capability for microtubule translocation in vitro 5,6. Limited proteolysis of the beta-heavy chain divides it into two fragments, A and B, which sediment separately at 12S and 6S, and possibly correspond to the head and tail domains of the molecule 7. Dynein ATPase is the energy-transducing enzyme that generates the sliding movement between tubules that underlies the beating of cilia and flagella of eukaryotes, and possibly also other large intracellular movements 8,9. Here we report that the deduced amino-acid sequence of the beta-heavy chain of axonemal dynein from embryos of the sea urchin Tripneustes gratilla has 4,466 residues and contains the consensus motifs for five nucleotide-binding sites. The probable hydrolytic ATP-binding site can be identified by its location close to or at the V1 site of vanadate-mediated photocleavage 10. The general features of the map of photocleavage and proteolytic peptides reported earlier have been confirmed, except that the map's polarity is reversed. The predicted secondary structure of the beta-heavy chain consists of an alpha/beta-type pattern along its whole length. The two longest regions of potential alpha helix, with unbroken heptad hydrophobic repeats 120 and 50 amino acids long, may be of functional importance. But dynein does not seem to contain an extended coiled-coil tail domain.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	GIBBONS, IR (corresponding author), UNIV HAWAII,PACIFIC BIOMED RES CTR,HONOLULU,HI 96822, USA.		Gibbons, Ian/B-5842-2013; Mocz, Gabor/A-7308-2009	Mocz, Gabor/0000-0001-9855-2206				CREMO CR, 1990, BIOCHEMISTRY-US, V29, P7982, DOI 10.1021/bi00486a029; CREMO CR, 1991, BIOPHYS J, V59, P513; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; FOLTZ KR, 1990, CELL MOTIL CYTOSKEL, V16, P33, DOI 10.1002/cm.970160106; GARBER AT, 1989, EMBO J, V8, P1727, DOI 10.1002/j.1460-2075.1989.tb03565.x; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GIBBONS IR, IN PRESS P NATN ACAD; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; HAYASHI M, 1972, BIOCHEMISTRY-US, V11, P2977, DOI 10.1021/bi00766a008; KING SM, 1989, J BIOL CHEM, V264, P10210; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MOCZ G, 1990, J BIOL CHEM, V265, P2917; MOCZ G, 1988, J CELL BIOL, V106, P1607, DOI 10.1083/jcb.106.5.1607; MOCZ G, 1990, BIOCHEMISTRY-US, V29, P48; MOCZ G, IN PRESS BIOCHEMISTR; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OGAWA K, 1990, CELL MOTIL CYTOSKEL, V16, P58, DOI 10.1002/cm.970160108; OGAWA K, 1991, P JPN ACAD B-PHYS, V67, P27, DOI 10.2183/pjab.67.27; OGAWA K, IN PRESS P INT ECHIN; OW RA, 1987, J BIOL CHEM, V262, P3409; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; SMITH EF, 1991, CELL MOTIL CYTOSKEL, V18, P258, DOI 10.1002/cm.970180403; TANG WJY, 1987, J BIOL CHEM, V262, P17728; VALE RD, 1987, ANNU REV CELL BIOL, V3, P347, DOI 10.1146/annurev.cb.03.110187.002023; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	34	222	225	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					640	643		10.1038/352640a0	http://dx.doi.org/10.1038/352640a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830927				2022-12-24	WOS:A1991GB21100062
J	STEDMAN, HH; SWEENEY, HL; SHRAGER, JB; MAGUIRE, HC; PANETTIERI, RA; PETROF, B; NARUSAWA, M; LEFEROVICH, JM; SLADKY, JT; KELLY, AM				STEDMAN, HH; SWEENEY, HL; SHRAGER, JB; MAGUIRE, HC; PANETTIERI, RA; PETROF, B; NARUSAWA, M; LEFEROVICH, JM; SLADKY, JT; KELLY, AM			THE MDX MOUSE DIAPHRAGM REPRODUCES THE DEGENERATIVE CHANGES OF DUCHENNE MUSCULAR-DYSTROPHY	NATURE			English	Article							SKELETAL-MUSCLE MYOPATHY; SATELLITE CELLS; RAT; PRODUCT; GROWTH; INVIVO; GENE	ALTHOUGH murine X-linked muscular dystrophy (mdx) and Duchenne muscular dystrophy (DMD) are genetically homologous and both characterized by a complete absence of dystrophin 1,2, the limb muscles of adult mdx mice suffer neither the detectable weakness nor the progressive degeneration that are features of DMD 3-8. Here we show that the mdx mouse diaphragm exhibits a pattern of degeneration, fibrosis and severe functional deficit comparable to that of DMD limb muscle, although adult mice show no overt respiratory impairment. Progressive functional changes include reductions in strength (to 13.5% of control by two years of age), elasticity, twitch speed and fibre length. The collagen density rises to at least seven times that of control diaphragm and ten times that of mdx hind-limb muscle. By 1.5 years of age, similar but less severe histological changes emerge in the accessory muscles of respiration. On the basis of these findings, we propose that dystrophin deficiency alters the threshold for work-induced injury. Our data provide a quantitative framework for studying the pathogenesis of dystrophy and extend the application of the mdx mouse as an animal model.	UNIV PENN,SCH VET MED,PHILADELPHIA,PA 19104	University of Pennsylvania	STEDMAN, HH (corresponding author), UNIV PENN,SCH MED,3800 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		panettieri, reynold/AAG-9485-2019; Sweeney, H Lee/F-1862-2010					ANDERSON JE, 1988, J MUSCLE RES CELL M, V9, P499, DOI 10.1007/BF01738755; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; DUSTERHOFT S, 1990, DIFFERENTIATION, V45, P185, DOI 10.1111/j.1432-0436.1990.tb00472.x; GRIFFITHS RI, 1987, J NEUROSCI METH, V21, P159, DOI 10.1016/0165-0270(87)90113-0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KASPER CE, 1990, J APPL PHYSIOL, V68, P533, DOI 10.1152/jappl.1990.68.2.533; KELLY AM, 1978, DEV BIOL, V65, P1, DOI 10.1016/0012-1606(78)90174-4; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; MANDEL JL, 1989, NATURE, V339, P584, DOI 10.1038/339584a0; MCCULLY KK, 1987, RESPIRATORY MUSCLES, P317; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; NEWMAN S, 1984, J APPL PHYSIOL, V56, P753, DOI 10.1152/jappl.1984.56.3.753; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; SCHMALBRUCH H, 1977, ANAT REC, V189, P169, DOI 10.1002/ar.1091890204; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; SMITH PEM, 1987, NEW ENGL J MED, V316, P1197, DOI 10.1056/NEJM198705073161906; STAHL WR, 1967, J APPL PHYSIOL, V22, P453, DOI 10.1152/jappl.1967.22.3.453; SWITZER BR, 1971, ANAL BIOCHEM, V39, P487, DOI 10.1016/0003-2697(71)90438-6; SYME DA, 1990, J PHYSIOL-LONDON, V424, P301, DOI 10.1113/jphysiol.1990.sp018068; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	25	744	754	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					536	539		10.1038/352536a0	http://dx.doi.org/10.1038/352536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865908				2022-12-24	WOS:A1991GA22600065
J	YONISHROUACH, E; RESNITZKY, D; LOTEM, J; SACHS, L; KIMCHI, A; OREN, M				YONISHROUACH, E; RESNITZKY, D; LOTEM, J; SACHS, L; KIMCHI, A; OREN, M			WILD-TYPE P53 INDUCES APOPTOSIS OF MYELOID LEUKEMIC-CELLS THAT IS INHIBITED BY INTERLEUKIN-6	NATURE			English	Article							TUMOR SUPPRESSION; C-MYC; GROWTH; DIFFERENTIATION; EXPRESSION; GENE; PROTEIN; ONCOGENE; SURVIVAL; BCL-2	WILD-TYPE p53 protein has many properties consistent with its being the product of a tumour suppressor gene 1-3. Although the normal roles of tumour suppressor genes are still largely unknown, it seems that they could be involved in promoting cell differentiation 4-6 as well as in mediating growth arrest by growth-inhibitory cytokines 7-9. Hence, the abrogation of wild-type p53 expression, which is a common feature of many tumours, could eliminate these activities. We have now tested this notion by restoring the expression of p53 in a murine myeloid leukaemic cell line that normally lacks p53. The use of a temperature-sensitive p53 mutant 10 allowed us to analyse cells in which the introduced p53 had either wild-type or mutant properties. Although there seemed to be no effect on differentiation, the introduction of wild-type p53 resulted in rapid loss of cell viability in a way characteristic of apoptosis (programmed cell death). The effect of wild-type p53 was counteracted by interleukin-6. Thus products of tumour suppressor genes could be involved in restricting precursor cell populations by mediating apoptosis.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIBACH E, 1973, P NATL ACAD SCI USA, V70, P343, DOI 10.1073/pnas.70.2.343; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARRIS H, 1989, CIBA F SYMP, V142, P199; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LOTEM J, IN PRESS BLOOD; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; PROKOCIMER M, 1986, BLOOD, V68, P113; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SACHS L, 1989, CIBA F SYMP, V142, P217; SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO;2-Y; SHABO Y, 1988, BLOOD, V72, P2070; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STANBRIDGE EJ, 1990, REV GENET, V24, P615; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	41	2157	2202	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1991	352	6333					345	347		10.1038/352345a0	http://dx.doi.org/10.1038/352345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1852210				2022-12-24	WOS:A1991FY28900074
J	DELISA, JA; JAIN, SS				DELISA, JA; JAIN, SS			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									KESSLER INST REHABIL,W ORANGE,NJ	Kessler Institute for Rehabilitation	DELISA, JA (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103, USA.							AYERS JWT, 1988, FERTIL STERIL, V49, P1089; BACH JR, 1990, CHEST, V98, P613, DOI 10.1378/chest.98.3.613; BACH JR, IN PRESS B NY ACAD M; BEJJANI FJ, 1989, J BIOMECH, V22, P439, DOI 10.1016/0021-9290(89)90204-2; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; CHANG MS, 1987, ERGONOMICS, V30, P331; COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615; Figoni S F, 1990, J Am Paraplegia Soc, V13, P33; GRESHAM GE, 1990, STROKE, V21, P1; JOHNSTON MV, IN PRESS BRAIN INJ; LINSENMEYER TA, 1991, NEUROREHABILITATION, V1, P22; PATTERSON RP, 1990, ARCH PHYS MED REHAB, V71, P340; ROBINSON LR, 1990, AM J PHYS MED REHAB, V69, P307, DOI 10.1097/00002060-199012000-00006; TRAVERS PH, 1988, OCCUP MED, V3, P271; VERVILLE RE, 1990, ARCH PHYS MED REHAB, V71, P1010	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 19	1991	265	23					3158	3160						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ770	1828273				2022-12-24	WOS:A1991FQ77000035
J	EVAVOLD, BD; ALLEN, PM				EVAVOLD, BD; ALLEN, PM			SEPARATION OF IL-4 PRODUCTION FROM TH-CELL PROLIFERATION BY AN ALTERED T-CELL RECEPTOR LIGAND	SCIENCE			English	Article							ANTIGEN-PRESENTATION; B-CELLS; ACTIVATION; EXPRESSION; INVIVO; IDENTIFICATION; HYDROLYSIS; MOLECULES; RESPONSES; PATHWAYS	In the presence of antigen presenting cells, a murine T helper (Th) cell specific for murine hemoglobin (Hb) responded to its immunogenic peptide by both cytokine (interleukin-4) secretion and proliferation. An altered Hb peptide with a single amino acid substitution induced only cytokine secretion and did not induce proliferation. Interleukin-1 costimulated and restored the Th proliferative response to normal levels. The altered peptide also supported cognate T cell-B cell interactions indicative of T cell helper function. Thus, this result suggests that the T cell receptor has the capacity of differential signaling.	WASHINGTON UNIV,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Evavold, Brian/0000-0002-3561-3494	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024157, R01AI024157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007066] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24157] Funding Source: Medline; NIEHS NIH HHS [ESO7066] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRIAN AA, 1988, P NATL ACAD SCI USA, V85, P564, DOI 10.1073/pnas.85.2.564; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; EVAVOLD BD, UNPUB; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KRZYCH U, 1982, J IMMUNOL, V128, P1529; KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774; LORENZ RG, 1989, J EXP MED, V170, P203, DOI 10.1084/jem.170.1.203; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; LORENZ RG, 1989, NATURE, V337, P560, DOI 10.1038/337560a0; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; OROURKE AM, 1990, SCIENCE, V249, P171, DOI 10.1126/science.2164711; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHIGETA M, 1986, J IMMUNOL, V136, P34; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; TITE JP, 1987, J IMMUNOL, V139, P2892; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181	22	539	566	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 31	1991	252	5010					1308	1310		10.1126/science.1833816	http://dx.doi.org/10.1126/science.1833816			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN857	1833816				2022-12-24	WOS:A1991FN85700040
J	KELLUM, R; SCHEDL, P				KELLUM, R; SCHEDL, P			A POSITION-EFFECT ASSAY FOR BOUNDARIES OF HIGHER-ORDER CHROMOSOMAL DOMAINS	CELL			English	Article							BETA-GLOBIN GENE; WHITE GENE; DROSOPHILA-MELANOGASTER; TRANSGENIC MICE; CHROMATIN; DNA; EXPRESSION; ORGANIZATION; ELEMENTS; SITES	Eukaryotic chromosomes are thought to be organized into a series of discrete higher order chromatin domains. This organization is believed to be important not only in the compaction of the chromatin fiber, but also in the utilization of genetic information. Each domain would define an independent unit of gene activity, insulated from the regulatory influences of adjacent domains. Critical to this model of chromosome organization and function are the domain boundaries: the special nucleoprotein structures that delimit each higher order domain and segregate the chromosome into units of independent gene activity. In the work reported here we have tested whether two putative domain boundaries, scs and scs', from the Drosophila 87A7 heat shock locus can establish a domain of independent gene activity in vivo and insulate against chromosomal position effects.			KELLUM, R (corresponding author), PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544, USA.							ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; ADOLPH KW, 1980, EXP CELL RES, V125, P95, DOI 10.1016/0014-4827(80)90193-7; BASLER J, 1981, BIOCHEMISTRY-US, V20, P6921, DOI 10.1021/bi00527a027; BELMONT AS, 1989, CHROMOSOMA, V98, P129, DOI 10.1007/BF00291049; BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; BOWEN BC, 1981, NUCLEIC ACIDS RES, V9, P5093, DOI 10.1093/nar/9.19.5093; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COOK PR, 1976, J CELL SCI, V22, P303; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; JUDD BH, 1976, GENETICS BIOL DROS B, V1, P767; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P325, DOI 10.1016/0022-2836(82)90332-1; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LEVIS R, 1985, EMBO J, V4, P3489, DOI 10.1002/j.1460-2075.1985.tb04108.x; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; PIRROTTA V, 1985, EMBO J, V4, P3501, DOI 10.1002/j.1460-2075.1985.tb04109.x; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; ROBERTSON HM, 1988, GENETICS, V118, P461; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SCHOLNICK SB, 1983, CELL, V34, P37, DOI 10.1016/0092-8674(83)90134-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42	32	543	568	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1991	64	5					941	950		10.1016/0092-8674(91)90318-S	http://dx.doi.org/10.1016/0092-8674(91)90318-S			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FA940	1848159				2022-12-24	WOS:A1991FA94000011
J	KAUFMAN, RH				KAUFMAN, RH			HUMAN PAPILLOMAVIRUS AND CERVICAL-CANCER - RISK TO MALE PARTNER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KAUFMAN, RH (corresponding author), BAYLOR UNIV,HOUSTON,TX 77030, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	1991	265	9					1179	1180						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EZ474	1847486				2022-12-24	WOS:A1991EZ47400038
J	WEISS, S; BOGEN, B				WEISS, S; BOGEN, B			MHC CLASS-II-RESTRICTED PRESENTATION OF INTRACELLULAR ANTIGEN	CELL			English	Article							TOXIC LYMPHOCYTES-T; B-LYMPHOMA CELLS; SOLUBLE-PROTEIN; LIGHT-CHAINS; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; PRESENTING CELLS; IMMUNOGLOBULIN; RECOGNITION; SEQUENCE	An endogenously produced immunoglobulin light chain (lambda-2(315)) is processed and presented to T cells in association with major histocompatibility complex (MHC) class II molecules. Using transfectants producing variant forms of lambda-2(315) that are neither expressed on the cell surface nor secreted, we demonstrate that intracellular lambda-2(315), which has never been exported outside of the cell, is the source of processed lambda-2(315) idiotype. This challenges the currently accepted paradigm that endogenous antigens are only presented by MHC class I molecules. Variants of lambda-2(315) protein that are retained in the endoplasmic recticulum (ER) are also presented. Variants that are expressed in the cytosol as well as those that are transported into the nucleus rather than the ER are not presented. Thus, the ER is likely to be the processing compartment.	INST IMMUNOL & RHEUMATOL,N-0172 OSLO,NORWAY		WEISS, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.							BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BIKOFF EK, 1989, EUR J IMMUNOL, V19, P1903, DOI 10.1002/eji.1830191022; BOGEN B, 1989, EMBO J, V8, P1947, DOI 10.1002/j.1460-2075.1989.tb03599.x; BOGEN B, 1990, EUR J IMMUNOL, V20, P2359, DOI 10.1002/eji.1830201030; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; BOGEN B, 1989, SCAND J IMMUNOL, V29, P273, DOI 10.1111/j.1365-3083.1989.tb01125.x; BOGEN B, 1986, EUR J IMMUNOL, V16, P1379, DOI 10.1002/eji.1830161111; BOGEN B, 1983, EUR J IMMUNOL, V13, P353, DOI 10.1002/eji.1830130502; BOGEN B, 1984, THESIS U TROMSO TROM; BOGEN B, 1988, HISTOPHYSIOLOGY IMMU, P877; BOTHWELL ALM, 1982, NATURE, V298, P380, DOI 10.1038/298380a0; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; BROWNING MJ, 1990, J IMMUNOL, V145, P985; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DICK T, 1989, P NATL ACAD SCI USA, V86, P2316, DOI 10.1073/pnas.86.7.2316; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; EAGER KB, 1989, J IMMUNOL, V143, P2328; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE P, 1988, J IMMUNOL, V140, P1063; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; ROCHE PA, 1990, NATURE, V345, P618; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAERZ UD, 1987, NATURE, V329, P449, DOI 10.1038/329449a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TAKAHASHI H, 1990, NATURE, V344, P873, DOI 10.1038/344873a0; THOMAS DB, 1990, J IMMUNOL, V144, P2789; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; WALLNY HJ, 1990, NATURE, V343, P275, DOI 10.1038/343275a0; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WEISS S, 1984, EUR J IMMUNOL, V14, P744, DOI 10.1002/eji.1830140814; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282; WINBERRY L, 1980, J IMMUNOL, V124, P1174; WINCHESTER G, 1984, IMMUNOGENETICS, V19, P487, DOI 10.1007/BF00403439; WU GE, 1982, NUCLEIC ACIDS RES, V10, P3831, DOI 10.1093/nar/10.13.3831; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YURIN VL, 1989, EUR J IMMUNOL, V79, P1685	62	273	278	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 22	1991	64	4					767	776		10.1016/0092-8674(91)90506-T	http://dx.doi.org/10.1016/0092-8674(91)90506-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	EZ478	1847667				2022-12-24	WOS:A1991EZ47800012
J	HOU, JZ; KAN, M; MCKEEHAN, K; MCBRIDE, G; ADAMS, P; MCKEEHAN, WL				HOU, JZ; KAN, M; MCKEEHAN, K; MCBRIDE, G; ADAMS, P; MCKEEHAN, WL			FIBROBLAST GROWTH-FACTOR RECEPTORS FROM LIVER VARY IN 3 STRUCTURAL DOMAINS	SCIENCE			English	Article							COMPLEMENTARY-DNA; BINDING; CELL; PURIFICATION; PROTEINS; CLONING; GENE	Changes in heparin-binding fibroblast growth factor gene expression and receptor phenotype occur during liver regeneration and in hepatoma cells. The nucleotide sequence of complementary DNA predicts that three amino-terminal domain motifs, two juxtamembrane motifs, and two intracellular carboxyl-terminal domain motifs combine to form a minimum of 6 and potentially 12 homologous polypeptides that constitute the growth factor receptor family in a single human liver cell population. Amino-terminal variants consisted of two transmembrane molecules that contained three and two immunoglobulin-like disulfide loops, as well as a potential intracellular form of the receptor. The two intracellular juxtamembrane motifs differed in a potential serine-threonine kinase phosphorylation site. One carboxyl-terminal motif was a putative tyrosine kinase that contained potential tyrosine phosphorylation sites. The second carboxyl-terminal motif was probably not a tyrosine kinase and did not exhibit the same candidate carboxyl-terminal tyrosine phosphorylation sites.	W ALTON JONES CELL SCI CTR,10 OLD BARN RD,LAKE PLACID,NY 12946									BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; HOSHI H, 1988, FASEB J, V2, P2797, DOI 10.1096/fasebj.2.12.2457532; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1988, J BIOL CHEM, V263, P11306; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	10	223	231	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 8	1991	251	4994					665	668		10.1126/science.1846977	http://dx.doi.org/10.1126/science.1846977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW399	1846977				2022-12-24	WOS:A1991EW39900043
J	WOODLAND, DL; HAPP, MP; GOLLOB, KJ; PALMER, E				WOODLAND, DL; HAPP, MP; GOLLOB, KJ; PALMER, E			AN ENDOGENOUS RETROVIRUS MEDIATING DELETION OF ALPHA-BETA T-CELLS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCLONAL-ANTIBODIES; IMPARTS REACTIVITY; I-E; TOLERANCE; DIFFERENTIATION; EXPRESSION; ANTIGENS; TRANSCRIPTS; MOLECULE	A SPECIAL class of self-antigens (endogenous superantigens) is capable of deleting many murine T cells on the basis of their expression of particular T-cell receptor V-beta gene segments. In mice that endogenously express these antigens, tolerance is mediated in part by the clonal deletion of the relevant V-beta-bearing T cells 1-17. The deletion of I-E-reactive V-beta-5.2-bearing T cells is dependent on the coexpression of an I-E tolerogenic coligand (Etc) 14 and the gene for one of these coligands, Etc-1, maps to chromosome 12, near the mouse mammary tumour viral integrant, Mtv-9. Here we report a perfect genetic linkage between Etc-1 and Mtv-9 and show that Etc-1 is also involved in the I-E-dependent deletion of T cells bearing V-beta-5.1 and V-beta-11 domains. We also demonstrate that Mtv-9 transcripts are present in B cells expressing Etc-1 and suggest that the coligand recognized by roughly 15% of all T lymphocytes is encoded by the Mtv-9 genome.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WOODLAND, DL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Gollob, Kenneth J/C-1341-2008; Gollob, Kenneth J/GPX-8434-2022	Gollob, Kenneth J/0000-0003-4184-3867; 				BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BILL J, 1989, J EXP MED, V169, P115, DOI 10.1084/jem.169.1.115; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; EICHER EM, 1990, GENETICS, V125, P431; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KING LB, 1989, P NATL ACAD SCI USA, V86, P2814, DOI 10.1073/pnas.86.8.2814; KING LB, 1990, J IMMUNOL, V144, P3218; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEE BK, 1990, J VIROL, V64, P4568, DOI 10.1128/JVI.64.9.4568-4572.1990; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; OKADA CY, 1990, J IMMUNOL, V144, P3473; OKADA CY, 1989, J EXP MED, V169, P1703, DOI 10.1084/jem.169.5.1703; PALMER E, 1989, COLD SPRING HARB SYM, V54, P135; PENNELL CA, 1985, P NATL ACAD SCI USA, V82, P3799, DOI 10.1073/pnas.82.11.3799; PETERS G, 1986, J VIROL, V59, P535, DOI 10.1128/JVI.59.3.535-544.1986; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; SHARMA S, 1988, J IMMUNOL, V141, P2510; TAYLOR BA, 1987, ORIGIN INBRED MICE, P423; TOMONARI K, 1990, IMMUNOL REV, V116, P139, DOI 10.1111/j.1600-065X.1990.tb00808.x; TOMONARI K, 1988, IMMUNOGENETICS, V28, P445, DOI 10.1007/BF00355377; VACCHIO MS, 1990, J EXP MED, V172, P802; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289	30	318	323	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 7	1991	349	6309					529	530		10.1038/349529a0	http://dx.doi.org/10.1038/349529a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EW571	1846949				2022-12-24	WOS:A1991EW57100068
J	KAWAMURA, S; MURAKAMI, M				KAWAMURA, S; MURAKAMI, M			CALCIUM-DEPENDENT REGULATION OF CYCLIC-GMP PHOSPHODIESTERASE BY A PROTEIN FROM FROG RETINAL RODS	NATURE			English	Article							OUTER SEGMENT; PHOTORECEPTOR-MEMBRANES; CGMP PHOSPHODIESTERASE; GUANYLATE-CYCLASE; PLASMA-MEMBRANE; SALAMANDER RODS; BINDING PROTEIN; ACTIVATION; CONDUCTANCE; SEQUENCE	IN vertebrate photoreceptors, light reduces cyclic GMP concentration and closes cGMP-activated channels to induce a hyperpolarizing response 1. As Ca2+ can permeate the channels and the Na+ - CA2+ exchanger continuously extrudes Ca2+, closure of the channel results in a reduction of the inter-rod Ca2+ concentration 2-4. This is believed to be one of the mechanisms of light adaptation produced by activation of guanylate cyclase 5-9. Effects of Ca2+ on the cGMP phosphodiesterase (PDE) have been reported 10-15, but their physiological significance has remained unclear. We have perfused the inside-out preparation of a frog rod outer segment (I/O ROS (ref. 16), originally termed truncated ROS (ref. 17)), and find that Ca2+ in a physiological range regulates the light-activation of PDE. Therefore, PDE regulation by Ca2+ must be involved in light-adaptation in rods. The effect is mediated by a newly found protein which binds to disk membranes at high Ca2+ concentrations and prolongs PDE activation.			KAWAMURA, S (corresponding author), KEIO UNIV,SCH MED,DEPT PHYSIOL,SHINANOMACHI 35,SHINJUKU KU,TOKYO 160,JAPAN.							BARKDOLL AE, 1989, J GEN PHYSIOL, V93, P1091, DOI 10.1085/jgp.93.6.1091; BUZDYGON BE, 1984, J BIOL CHEM, V259, P4567; DELPRIORE LV, 1983, BIOCHEM BIOPH RES CO, V113, P317, DOI 10.1016/0006-291X(83)90468-0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; HODGKIN AL, 1988, J PHYSIOL-LONDON, V403, P439, DOI 10.1113/jphysiol.1988.sp017258; KAWAMURA S, 1986, BIOCHIM BIOPHYS ACTA, V870, P256, DOI 10.1016/0167-4838(86)90230-X; KAWAMURA S, 1981, J GEN PHYSIOL, V77, P571, DOI 10.1085/jgp.77.5.571; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P649, DOI 10.1085/jgp.94.4.649; KAWAMURA S, 1989, NEUROSCI RES       S, V10, pS15; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; RATTO GM, 1988, J NEUROSCI, V8, P3240; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; TORRE V, 1986, P NATL ACAD SCI USA, V83, P7109, DOI 10.1073/pnas.83.18.7109; WAGNER R, 1989, FEBS LETT, V242, P249, DOI 10.1016/0014-5793(89)80479-X; WILSON PW, 1985, NUCLEIC ACIDS RES, V13, P8867, DOI 10.1093/nar/13.24.8867; YAMAGATA K, 1990, NEURON, V2, P469; YAMAKUNI T, 1986, NUCLEIC ACIDS RES, V14, P6768, DOI 10.1093/nar/14.16.6768; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	22	210	212	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 31	1991	349	6308					420	423		10.1038/349420a0	http://dx.doi.org/10.1038/349420a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EV514	1846944				2022-12-24	WOS:A1991EV51400053
J	ELDER, AT; JYOTHINAGARAM, SG; PADFIELD, PL; SHAW, TRD				ELDER, AT; JYOTHINAGARAM, SG; PADFIELD, PL; SHAW, TRD			HEMODYNAMIC-RESPONSE IN SOCCER SPECTATORS - IS SCOTTISH FOOTBALL EXCITING	BRITISH MEDICAL JOURNAL			English	Article							ELECTROCARDIOGRAM	Objective - To determine the effect of watching a game of Scottish football on heart rate and blood pressure. Design - Prospective study. Setting - Two Scottish Premier League football grounds. Subjects - 10 healthy men, each a supporter of one of two clubs. Main outcome measures - Systolic and diastolic blood pressure and heart rate at home, while walking, and during the match. Results - Systolic blood pressure and heart rate were significantly higher when the men were watching the match than when they were at home. While they were watching the match, heart rate was maximal immediately after a goal had been scored by the supported team. Conclusion - The emotional stress invoked by Scottish football is associated with significant increases in heart rate and systolic blood pressure.	WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	ELDER, AT (corresponding author), WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.			Elder, Andrew/0000-0003-3229-9601				CLARK S, 1991, J HUM HYPERTENSION, V5, P7; NORTHCOTE RJ, 1983, BRIT HEART J, V50, P372; PRINGLE SD, 1989, BRIT MED J, V299, P1575, DOI 10.1136/bmj.299.6715.1575; SCHIFFER F, 1976, AM J CARDIOL, V37, P41, DOI 10.1016/0002-9149(76)90497-5; TAGGART P, 1973, LANCET, V2, P341; TAGGART P, 1969, BMJ-BRIT MED J, V4, P130, DOI 10.1136/bmj.4.5676.130	6	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1991	303	6817					1609	1610		10.1136/bmj.303.6817.1609	http://dx.doi.org/10.1136/bmj.303.6817.1609			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX956	1773191	Bronze, Green Published			2022-12-24	WOS:A1991GX95600024
J	ZWI, AB; CABRAL, AJR				ZWI, AB; CABRAL, AJR			IDENTIFYING HIGH-RISK SITUATIONS FOR PREVENTING AIDS	BRITISH MEDICAL JOURNAL			English	Article							AFRICA		MINIST HLTH MAPUTO,MAPUTO,MOZAMBIQUE		ZWI, AB (corresponding author), LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,LONDON WC1E 7HJ,ENGLAND.		Zwi, Anthony/AAP-8731-2020; Zwi, Anthony/AAP-7026-2021	Zwi, Anthony/0000-0001-6902-6602				BALDO M, 1991, ACTION AIDS SO AFRIC, P34; BASSETT MT, 1991, INT J HEALTH SERV, V21, P143, DOI 10.2190/N0NJ-FKXB-CT25-PA09; EISENBERG L, 1984, AM J MED, V77, P524, DOI 10.1016/0002-9343(84)90114-1; FREUDENBERG N, 1990, INT J HEALTH SERV, V20, P589, DOI 10.2190/W70D-28M1-C62K-K60R; Freudenberg N, 1989, AIDS Educ Prev, V1, P12; FREUDENBERG N, 1981, INT J HLTH ED, V24, P1; Green LW, 1988, HLTH PROMOT, V3, P151; HUNT CW, 1989, J HEALTH SOC BEHAV, V30, P353, DOI 10.2307/2136985; JOCHELSON K, 1991, INT J HEALTH SERV, V21, P157, DOI 10.2190/11UE-L88J-46HN-HR0K; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; McKeown Thomas, 1979, ROLE MED; NABARRO D, 1989, AIDS, V3, pS265, DOI 10.1097/00002030-198901001-00037; PACKARD RM, 1991, SOC SCI MED, V33, P771, DOI 10.1016/0277-9536(91)90376-N; PIOT P, 1988, TROPICAL GEOGRAPHICA, P894; ROSENFIELD PL, 1988, TROPICAL GEOGRAPHICA, P197; SANDERS D, 1991, HEALTH POLICY PLANN, V6, P157, DOI 10.1093/heapol/6.2.157; WILSON D, 1990, SOC SCI MED, V31, P609, DOI 10.1016/0277-9536(90)90097-C; Zwi A., 1990, Health Policy and Planning, V5, P316, DOI 10.1093/heapol/5.4.316; 1986, HLTH PROMOTION, V1, P3	19	53	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 14	1991	303	6816					1527	1529		10.1136/bmj.303.6816.1527	http://dx.doi.org/10.1136/bmj.303.6816.1527			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV476	1782498	Bronze, Green Published			2022-12-24	WOS:A1991GV47600030
J	EDIDIN, M; KUO, SC; SHEETZ, MP				EDIDIN, M; KUO, SC; SHEETZ, MP			LATERAL MOVEMENTS OF MEMBRANE-GLYCOPROTEINS RESTRICTED BY DYNAMIC CYTOPLASMIC BARRIERS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEINS; DIFFUSION; MOBILITY; PARTICLES; ANTIGENS; SURFACE	Cell membranes often are patchy, composed of lateral domains. These domains may be formed by barriers within or on either side of the membrane bilayer. Major histocompatibility complex (MHC) class 1 molecules that were either transmembrane- (H-2D(b)) or glycosylphosphatidylinositol (GPI)-anchored (Qa2) were labeled with antibody-coated gold particles and moved across the cell surface with a laser optical tweezers until they encountered a barrier, the barrier-free path length (BFP). At room temperature, the BFPs of Qa2 and H-2D(b) were 1.7 +/- 0.2 and 0.6 +/- 0.1 (micrometers +/- SEM), respectively. Barriers persisted at 34-degrees-C, although the BFP for both MHC molecules was fivefold greater at 34-degrees-C than at 23-degrees-C. This indicates that barriers to lateral movement are primarily on the cytoplasmic half of the membrane and are dynamic.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Duke University; Johns Hopkins University					NIGMS NIH HHS [GM 36277] Funding Source: Medline; PHS HHS [AL14584] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036277] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENNETT GV, 1990, CURR OPIN CELL BIOL, V2, P51; Block S, 1990, NONINVASIVE TECHNIQU, V9, P375; DEBRABANDER M, 1991, J CELL BIOL, V112, P111, DOI 10.1083/jcb.112.1.111; EDIDIN M, 1991, J CELL BIOL, V112, P1143, DOI 10.1083/jcb.112.6.1143; EDIDIN M, IN PRESS STRUCTURE C; GHOSH RN, 1990, BIOPHYS J, V57, pA286; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; NIGG EA, 1980, P NATL ACAD SCI-BIOL, V77, P4702, DOI 10.1073/pnas.77.8.4702; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V125, P2473; PETERS R, 1988, FEBS LETT, V234, P1, DOI 10.1016/0014-5793(88)81290-0; SAXTON MJ, 1990, BIOPHYS J, V58, P1303, DOI 10.1016/S0006-3495(90)82470-X; SHEETZ MP, 1983, SEMIN HEMATOL, V20, P175; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; STROYNOWSKI I, 1987, CELL, V50, P759, DOI 10.1016/0092-8674(87)90334-5; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441	19	222	222	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1991	254	5036					1379	1382		10.1126/science.1835798	http://dx.doi.org/10.1126/science.1835798			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR777	1835798				2022-12-24	WOS:A1991GR77700057
J	CROSS, SJ; LEE, HS; RAWLES, JM; JENNINGS, K				CROSS, SJ; LEE, HS; RAWLES, JM; JENNINGS, K			SAFETY OF THROMBOLYSIS IN ASSOCIATION WITH CARDIOPULMONARY-RESUSCITATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN, DEPT MED & THERAPEUT, ABERDEEN AB9 1FX, SCOTLAND	University of Aberdeen	CROSS, SJ (corresponding author), ABERDEEN ROYAL INFIRM, DEPT CARDIAC, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1988, LANCET, V2, P349; DEBONO D, 1990, PRACTICAL CORONARY T, P28; DUBOIS C, 1986, EUR HEART J, V7, P945, DOI 10.1093/oxfordjournals.eurheartj.a061999; PASTERNAK RC, 1988, HEART DISEASE TXB CA, P1222; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465	5	24	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1991	303	6812					1242	1242		10.1136/bmj.303.6812.1242	http://dx.doi.org/10.1136/bmj.303.6812.1242			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GQ342	1747647	Bronze, Green Published			2022-12-24	WOS:A1991GQ34200026
J	DINNING, G; DOUGHTY, RW; REID, MM; LLOYD, HL				DINNING, G; DOUGHTY, RW; REID, MM; LLOYD, HL			POTASSIUM CONCENTRATIONS IN IRRADIATED BLOOD	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; REG TRANSFUS CTR,NEWCASTLE TYNE NE2 4NQ,ENGLAND	Newcastle University - UK								BUTTON LN, 1981, TRANSFUSION, V21, P419, DOI 10.1046/j.1537-2995.1981.21481275998.x; LEITMAN SF, 1985, TRANSFUSION, V25, P293, DOI 10.1046/j.1537-2995.1985.25485273804.x; RAMIREZ AM, 1987, TRANSFUSION, V27, P444, DOI 10.1046/j.1537-2995.1987.27587320546.x; RIVET C, 1989, TRANSFUSION, V29, P185, DOI 10.1046/j.1537-2995.1989.29289146841.x; 1989, LANCET, V1, P529	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1991	303	6810					1110	1110		10.1136/bmj.303.6810.1110	http://dx.doi.org/10.1136/bmj.303.6810.1110			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GN209	1747580	Bronze, Green Published			2022-12-24	WOS:A1991GN20900024
J	TUNIS, SR; BASS, EB; STEINBERG, EP				TUNIS, SR; BASS, EB; STEINBERG, EP			THE USE OF ANGIOPLASTY, BYPASS-SURGERY, AND AMPUTATION IN THE MANAGEMENT OF PERIPHERAL VASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-LUMINAL ANGIOPLASTY; LIMB-THREATENING ISCHEMIA; CORONARY HEART-DISEASE; INTERMITTENT CLAUDICATION; BALLOON DILATATION; SURGICAL PRACTICE; FRAMINGHAM; MORTALITY; IMPACT	Background. Percutaneous transluminal angioplasty has been adopted widely as a treatment for patients with peripheral vascular disease of the lower extremities. However, the effect of this procedure on the overall management of peripheral vascular disease and on the outcomes of patients has not been clearly delineated. In particular, it is not known whether angioplasty has replaced other treatments for peripheral vascular disease. Methods. To assess the extent to which angioplasty is used and the associated changes in the surgical management of peripheral vascular disease of the lower extremities, we used data on hospital discharges in Maryland to identify all angioplasty procedures, peripheral bypass operations, and lower-extremity amputations performed for peripheral vascular disease in Maryland hospitals between 1979 and 1989. Results. We estimate that from 1979 to 1989 the annual rate of percutaneous transluminal angioplasty for peripheral vascular disease of the lower extremities, adjusted for age and sex, rose from 1 to 24 per 100,000 Maryland residents (P < 0.0001 by linear regression). Despite this increase in the use of angioplasty, the adjusted annual rate of peripheral bypass surgery also rose substantially, from 32 to 65 per 100,000 (P < 0.001), whereas the adjusted annual rate of lower-extremity amputation remained stable at about 30 per 100,000. Total charges for hospitalizations during which a peripheral revascularization procedure was performed increased from $14.7 million in 1979 (in 1989 dollars) to $30.5 million in 1989. Conclusions. In Maryland, the adoption of percutaneous transluminal angioplasty for peripheral vascular disease of the lower extremities has been associated with an increase in the use of peripheral bypass surgery and with no decline in lower-extremity amputations. These results could be due to increased diagnosis of peripheral vascular disease, expanded indications for procedural interventions; or an increased number of repeat procedures performed in patients with peripheral vascular disease of the lower extremities.	JOHNS HOPKINS PROGRAM MED TECHNOL & PRACTICE ASSES, 1830 E MONUMENT ST, RM 8068, BALTIMORE, MD 21205 USA	Johns Hopkins University				Bass, Eric/0000-0001-9106-527X	NHLBI NIH HHS [2 T32 HL07180] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAR R, 1989, J VASC SURG, V10, P57, DOI 10.1067/mva.1989.vs0100057; ANDERSON GM, 1988, AM J PUBLIC HEALTH, V78, P251, DOI 10.2105/AJPH.78.3.251; ANDERSON JB, 1986, BRIT J SURG, V73, P17, DOI 10.1002/bjs.1800730108; ASCER E, 1990, J VASC SURG, V11, P576, DOI 10.1067/mva.1990.18640; BECKER GJ, 1989, RADIOLOGY, V170, P921, DOI 10.1148/radiology.170.3.2521745; BILD DE, 1989, DIABETES CARE, V12, P24, DOI 10.2337/diacare.12.1.24; BLAIR JM, 1989, J VASC SURG, V9, P698, DOI 10.1067/mva.1989.vs0090698; CASARELLA WJ, 1986, CURR PROB CARDIOLOGY, V11, P138; CINTORA I, 1988, ANN SURG, V208, P625, DOI 10.1097/00000658-198811000-00014; CODD JE, 1979, AM J SURG, V138, P770, DOI 10.1016/0002-9610(79)90294-0; CUMBERLAND DC, 1988, CLIN RADIOL, V39, P573, DOI 10.1016/S0009-9260(88)80043-6; DAGOSTINO RB, 1989, INT J EPIDEMIOL, V18, pS67; DALEN JE, 1990, AM HEART J, V119, P502, DOI 10.1016/S0002-8703(05)80271-6; DAVIS PK, 1989, ANN THORAC SURG, V47, P493, DOI 10.1016/0003-4975(89)90422-0; DOUBILET P, 1984, NEW ENGL J MED, V310, P95, DOI 10.1056/NEJM198401123100206; EICKHOFF JH, 1980, ACTA CHIR SCAND, P181; ERNST CB, 1987, J VASC SURG, V6, P611, DOI 10.1067/mva.1987.avs0060611; FEINLEIB M, 1989, CIRCULATION, V79, P13; FRY SM, 1990, INVEST RADIOL, V25, P93, DOI 10.1097/00004424-199001000-00023; GALLINO A, 1984, CIRCULATION, V70, P619, DOI 10.1161/01.CIR.70.4.619; HOLLIER LH, 1989, J VASC SURG, V9, P627, DOI 10.1067/mva.1989.vs0090627; HOLLMAN J, 1988, INT J CARDIOL, V20, P193, DOI 10.1016/0167-5273(88)90263-X; JEANS WD, 1986, BRIT J RADIOL, V59, P453, DOI 10.1259/0007-1285-59-701-453; JEANS WD, 1990, RADIOLOGY, V177, P559, DOI 10.1148/radiology.177.2.2145608; JEANS WD, 1986, BRIT J RADIOL, V59, P457, DOI 10.1259/0007-1285-59-701-457; JOHNSTON KW, 1987, ANN SURG, V206, P403, DOI 10.1097/00000658-198710000-00002; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KANNEL WB, 1970, CIRCULATION, V41, P875, DOI 10.1161/01.CIR.41.5.875; MAINI BS, 1978, ARCH SURG-CHICAGO, V113, P1297; SAMSON RH, 1984, ANN SURG, V199, P234, DOI 10.1097/00000658-198402000-00017; SHEINER NM, 1985, CAN J SURG, V28, P193; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TAYLOR LM, 1990, J VASC SURG, V11, P193, DOI 10.1067/mva.1990.17235; Veith F J, 1990, Ann Vasc Surg, V4, P85, DOI 10.1007/BF02042697; VEITH FJ, 1990, ANN SURG, V212, P402, DOI 10.1097/00000658-199010000-00003; VEITH FJ, 1990, ACTA CHIR SCAND, P139; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C; WIDLUS DM, 1989, JAMA-J AM MED ASSOC, V261, P3148, DOI 10.1001/jama.261.21.3148; Wilson S E, 1990, Ann Vasc Surg, V4, P351, DOI 10.1007/BF02000498; ZARINS CK, 1989, JAMA-J AM MED ASSOC, V261, P416, DOI 10.1001/jama.261.3.416; 1985, SAS USERS GUIDE STAT; 1988, HOSPITAL REPORT CLIN; 1990, CODING CLIN ICD9CM, P16; 1990, STATISTICAL ABSTRACT, P99	44	221	226	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					556	562		10.1056/NEJM199108223250806	http://dx.doi.org/10.1056/NEJM199108223250806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857391				2022-12-24	WOS:A1991GB44700006
J	OGAWA, K				OGAWA, K			4 ATP-BINDING SITES IN THE MIDREGION OF THE BETA-HEAVY CHAIN OF DYNEIN	NATURE			English	Article							URCHIN SPERM FLAGELLA; PHOTOSENSITIZED CLEAVAGE; TAU-PROTEIN; FRAGMENT-A; OUTER ARM; SEQUENCE; IRRADIATION; SUBUNITS; ENZYMES; MOTOR	THE 'motor' proteins of eukaryotic cells contain specialized domains that hydrolyse ATP to produce force and movement along a cytoskeletal polymer (actin in the case of the myosin family; microtubules in the case of the kinesin family and dyneins). There are motor-protein superfamilies in which each member has a conserved force-generating domain joined to a different 'tail' which conveys specific attachment properties (see ref. 1 for a review). The minus-end-directed microtubule motors, the dyneins 2, may also constitute a superfamily of force-generating proteins with distinct attachment domains 3. Axonemal outer-arm dynein from sea urchin spermatozoa is a multimeric protein consisting of two heavy chains (alpha and beta) with ATPase activity. three intermediate chains and several light chains 4. Here I report the sequence of cloned complementary DNA encoding the beta-heavy chain of a dynein motor molecule. The predicted amino-acid sequence reveals four ATP-binding consensus sequences in the central domain. The dynein beta-heavy chain is thought to associate transiently with a microtubule during ATP hydrolysis 5, but the ATP-dependent microtubule-binding sequence common to the kinesin superfamily is not found in the dynein beta-heavy chain. These unique features distinguish the dynein beta-heavy chain from other motor protein superfamilies and may be characteristic of the dynein superfamily.			OGAWA, K (corresponding author), NATL INST BASIC BIOL, DEPT CELL BIOL, OKAZAKI, AICHI 444, JAPAN.							GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NISHIKAWA K, 1986, J BIOCHEM-TOKYO, V100, P1043, DOI 10.1093/oxfordjournals.jbchem.a121783; NISHIKAWA K, 1991, METHOD ENZYMOL, V202, P31; OGAWA K, 1975, J BIOL CHEM, V250, P6476; OGAWA K, 1987, EUR J CELL BIOL, V43, P3; OGAWA K, 1990, CELL MOTIL CYTOSKEL, V16, P58, DOI 10.1002/cm.970160108; OGAWA K, 1991, P JPN ACAD B-PHYS, V67, P27, DOI 10.2183/pjab.67.27; OW RA, 1987, J BIOL CHEM, V262, P3409; PFISTER KK, 1984, J BIOL CHEM, V259, P8499; SALE WS, 1988, J CELL BIOL, V107, P1793, DOI 10.1083/jcb.107.5.1793; SALE WS, 1985, J CELL BIOL, V101, P1400, DOI 10.1083/jcb.101.4.1400; TANG WJY, 1982, J BIOL CHEM, V257, P508; TANG WJY, 1987, J BIOL CHEM, V262, P17728; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	21	173	176	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					643	645		10.1038/352643a0	http://dx.doi.org/10.1038/352643a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1830928				2022-12-24	WOS:A1991GB21100063
J	DIXON, DA; KOWALCZYKOWSKI, SC				DIXON, DA; KOWALCZYKOWSKI, SC			HOMOLOGOUS PAIRING INVITRO STIMULATED BY THE RECOMBINATION HOTSPOT, CHI	CELL			English	Article							ESCHERICHIA-COLI RECA; HOT SPOT ACTIVITY; BACTERIOPHAGE-LAMBDA; GENERALIZED RECOMBINATION; STRAND EXCHANGE; RECBCD ENZYME; GENETIC-RECOMBINATION; BINDING-PROTEIN; PHAGE-LAMBDA; DNA	Genetic recombination in Escherichia coli is stimulated at DNA sequences known as Chi sites, 5'-GCTGGTGG-3'. We describe the in vitro formation of homologously paired joint molecules that is dependent upon this recombination hotspot. Chi-dependent joint molecule formation requires RecA, RecBCD, and SSB proteins and a Chi site in the donor linear dsDNA. The donor dsDNA is unwound by RecBCD enzyme, and the invasive strand is generated by nicking at Chi. This Chi-dependent invading strand must contain homology to the recipient supercoiled DNA substrate at its newly formed 3' end for efficient joint molecule formation. Action at Chi generates invasive ssDNA from the 5' but not the 3' side of Chi, suggesting that the nuclease activity of RecBCD enzyme is attenuated upon encountering a Chi site. These results support the view that RecBCD enzyme action can precede RecA protein action and reconcile the seemingly opposing degradative and recombination functions of RecBCD enzyme.			DIXON, DA (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA.				NIGMS NIH HHS [GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Berger S. L., 1987, GUIDE MOL CLONING TE; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CHENG KC, 1989, GENETICS, V123, P5; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; GLASSBERG J, 1979, J BACTERIOL, V140, P14, DOI 10.1128/JB.140.1.14-19.1979; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KOWALCZYKOWSKI SC, 1987, TRENDS BIOCHEM SCI, V12, P141, DOI 10.1016/0968-0004(87)90070-3; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; KOWALCZYKOWSKI SC, 1990, UCLA S MOL CELLULAR, P357; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LOVETT ST, 1988, GENETICS, V120, P37; MACKAY V, 1976, J BIOL CHEM, V251, P3716; MACKAY V, 1974, J BIOL CHEM, V249, P4286; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; ROMAN LJ, 1989, J BIOL CHEM, V264, P18340; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1984, COLD SPRING HARB SYM, V49, P485, DOI 10.1101/SQB.1984.049.01.055; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; SMITH GR, 1990, NUCL ACIDS MOL BIOL, P78; SMITH JV, 1981, SCOT EDUC REV, V13, P25; STAHL FW, 1979, ANNU REV GENET, V13, P7, DOI 10.1146/annurev.ge.13.120179.000255; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1990, GENETICS, V126, P519; STAHL FW, 1975, MOL GEN GENET, V140, P29, DOI 10.1007/BF00268986; STAHL FW, 1980, GENETICS, V94, P235; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; Telander-Muskavitch K.M, 1981, ENZYMES, P233; Thaler D.S., 1988, MECH CONSEQUENCES DN, P413; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; WANG TCV, 1989, MOL GEN GENET, V216, P315, DOI 10.1007/BF00334370; WEST SC, 1988, TRENDS GENET, V4, P8, DOI 10.1016/0168-9525(88)90121-7; WIEGAND RC, 1977, J MOL BIOL, V116, P805, DOI 10.1016/0022-2836(77)90272-8; WILLIAMS JGK, 1981, J BIOL CHEM, V256, P7573	57	150	151	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 26	1991	66	2					361	371		10.1016/0092-8674(91)90625-9	http://dx.doi.org/10.1016/0092-8674(91)90625-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855256				2022-12-24	WOS:A1991FY71200016
J	LECHLEITER, J; GIRARD, S; CLAPHAM, D; PERALTA, E				LECHLEITER, J; GIRARD, S; CLAPHAM, D; PERALTA, E			SUBCELLULAR PATTERNS OF CALCIUM RELEASE DETERMINED BY G-PROTEIN-SPECIFIC RESIDUES OF MUSCARINIC RECEPTORS	NATURE			English	Article							SUBTYPES; CELL; HYDROLYSIS	CALCIUM release from intracellular stores is a point of convergence for a variety of receptors involved in cell signalling 1. Consequently, the mechanism(s) by which cells differentiate between individual receptor signals is central to transmembrane communication 2-5. There are significant differences in timing and magnitude of Ca2+ release stimulated by the m2 and m3 muscarinic acetylcholine receptors 6-11. The m2 receptors couple to a pertussis toxin-sensitive G protein to activate phosphatidyl inositol hydrolysis weakly and to stimulate small, delayed and oscillatory chloride currents. In contrast, m3 receptors potently activate phosphatidyl inositol hydrolysis and stimulate large, rapid and transient chloride currents by a pertussis toxin-insensitive G protein pathway. Using confocal microscopy, we now show that the m2- and m3-coupled Ca2+ release pathways can also be spatially distinguished. At submaximal acetylcholine concentrations, both receptors stimulated pulses of Ca2+ release from discrete foci in random, periodic and frequently bursting patterns of activity. But maximal stimulation of m2 receptors increased the number of focal release sites, whereas m3 receptors invariably evoked a Ca2+ wave propagating rapidly just beneath the plasma membrane surface. Analysis of pertussis toxin sensitivity and hybrid m2-m3 muscarinic acetylcholine receptors confirmed that these Ca2+ release patterns represent distinct cell signalling pathways.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University	LECHLEITER, J (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHARMACOL,200 1ST ST SW,ROCHESTER,MN 55905, USA.		Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1989, TRENDS PHARM SCI S4, V10, P34; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; ROONEY TA, 1990, J BIOL CHEM, V265, P10792	15	153	155	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1991	350	6318					505	508		10.1038/350505a0	http://dx.doi.org/10.1038/350505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FG143	1849616				2022-12-24	WOS:A1991FG14300053
J	SKOLNIK, EY; MARGOLIS, B; MOHAMMADI, M; LOWENSTEIN, E; FISCHER, R; DREPPS, A; ULLRICH, A; SCHLESSINGER, J				SKOLNIK, EY; MARGOLIS, B; MOHAMMADI, M; LOWENSTEIN, E; FISCHER, R; DREPPS, A; ULLRICH, A; SCHLESSINGER, J			CLONING OF PI3 KINASE ASSOCIATED P85 UTILIZING A NOVEL METHOD FOR EXPRESSION CLONING OF TARGET PROTEINS FOR RECEPTOR TYROSINE KINASES	CELL			English	Article							PHOSPHOLIPASE C-II; PHOSPHATIDYLINOSITOL KINASE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; CATALYTIC DOMAINS; PHOSPHORYLATION; TRANSFORMATION; ELEMENTS	A novel method has been developed to allow cloning of protein targets for receptors with tyrosine kinase activity. By utilizing the carboxy-terminal tail of EGF receptor (EGFR) as a probe to screen lambda-gt11 expression libraries, several EGFR-binding proteins have been cloned; two have been analyzed and contain unique SH2 and SH3 domains. One gene (GRB-1) has been fully sequenced, is expressed in various tissues and cell lines, and has a molecular mass of 85 kd. Interestingly, GRB-1 encodes the human counterpart of the PI3 kinase-associated protein p85. Advantages of this technique include the ease of cloning tyrosine kinase receptor targets present at low levels and the ability to identify proteins that are related in their capacity to bind activated receptors but contain no significant DNA sequence homology. This method, termed CORT (for cloning of receptor targets), offers a general approach for the identification and cloning of various receptor targets.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society	SKOLNIK, EY (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.		Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001927] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK01927] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS G, 1990, EMBO J, V9, P4375; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OTSU M, 1991, CELL; PAWSON T, 1988, ONCOGENE, V3, P491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V335, P90; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; [No title captured]	42	596	646	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 5	1991	65	1					83	90		10.1016/0092-8674(91)90410-Z	http://dx.doi.org/10.1016/0092-8674(91)90410-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1849461	hybrid			2022-12-24	WOS:A1991FF77300011
J	VARKI, A; HOOSHMAND, F; DIAZ, S; VARKI, NM; HEDRICK, SM				VARKI, A; HOOSHMAND, F; DIAZ, S; VARKI, NM; HEDRICK, SM			DEVELOPMENTAL ABNORMALITIES IN TRANSGENIC MICE EXPRESSING A SIALIC-ACID SPECIFIC 9-O-ACETYLESTERASE	CELL			English	Article							INFLUENZA-C VIRUS; MELANOMA-ASSOCIATED GANGLIOSIDE; DE-ORTHO-ACETYLATION; CELL-SURFACE; O-ACETYLATION; MEMBRANE-FUSION; GERMINAL CELLS; RAT RETINA; LOW-PH; HEMAGGLUTININ	9-O-acetylation of sialic acids is tissue specific and developmentally regulated. We have selectively destroyed these O-acetyl groups during murine embryogenesis by expressing the 9-O-acetyl-sialic acid-specific esterase of influenza C. DNA constructs driven by the metallothionein promoter arrested development at the 2-cell stage and gave a markedly decreased yield of live mice. A similar construct driven by the phenylethanolamine-N-methyltransferase promoter did not cause this block, but gave transgenic mice with selective expression of esterase in the retina and the adrenal gland. These organs showed variable abnormalities in organization, while all other tissues examined appeared normal. The ganglioside 9-O-acetyl-G(D3) was selectively destroyed in target tissues. Thus, 9-O-acetylated sialic acids may play an role in murine development at the 2-cell stage and in certain differentiated tissues.	UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	VARKI, A (corresponding author), UNIV CALIF SAN DIEGO, SAN DIEGO CANC CTR, LA JOLLA, CA 92093 USA.		Hedrick, Stephen M/E-9171-2010	Hedrick, Stephen/0000-0002-6345-8751	NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032373, R01GM035880, R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [CA23100] Funding Source: Medline; NIGMS NIH HHS [GM35880, GM32373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BECH K, 1969, ACTA PATHOL MIC SC, V76, P391; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BOUHOURS D, 1983, J BIOL CHEM, V258, P299; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; CHANEY W, 1986, J BIOL CHEM, V261, P551; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CHOU DKH, 1989, J BIOL CHEM, V264, P3409; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; DEKAN G, 1990, AM J PATHOL, V137, P913; DENT AL, 1990, NATURE, V343, P714, DOI 10.1038/343714a0; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; EISENLOHR LC, 1988, J IMMUNOL, V141, P1870; ELS MC, 1989, VIROLOGY, V170, P346, DOI 10.1016/0042-6822(89)90394-2; FARQUHAR MG, 1991, IN PRESS INTRACELLUL; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FORMANOWSKI F, 1990, J GEN VIROL, V71, P1181, DOI 10.1099/0022-1317-71-5-1181; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; GENDEL S, 1983, J BACTERIOL, V156, P148, DOI 10.1128/JB.156.1.148-154.1983; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; Hogan B., 1986, MANIPULATING MOUSE E; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; IWAKURA Y, 1988, EMBO J, V7, P3757, DOI 10.1002/j.1460-2075.1988.tb03259.x; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1982, CIBA F SYMP, V92, P138; LEVINE JM, 1984, J NEUROSCI, V4, P820; LEVINE JM, 1986, DEV BRAIN RES, V27, P211, DOI 10.1016/0165-3806(86)90247-6; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MENDEZOTERO R, 1988, J NEUROSCI, V8, P564; MONK M, 1987, MAMMALIAN DEV; MORAHAN G, 1989, P NATL ACAD SCI USA, V86, P3782, DOI 10.1073/pnas.86.10.3782; MORRISON TG, 1989, VIROLOGY, V171, P10, DOI 10.1016/0042-6822(89)90505-9; MUCHMORE EA, 1987, FASEB J, V1, P229, DOI 10.1096/fasebj.1.3.3623000; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; NAKADA S, 1984, J VIROL, V50, P118, DOI 10.1128/JVI.50.1.118-124.1984; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; NISHIMURA H, 1988, J GEN VIROL, V69, P2545, DOI 10.1099/0022-1317-69-10-2545; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PFEIFER JB, 1984, VIRUS RES, V1, P281, DOI 10.1016/0168-1702(84)90017-0; REID PE, 1984, HISTOCHEM J, V16, P235, DOI 10.1007/BF01003608; REITMAN ML, 1982, J BIOL CHEM, V257, P357; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; Rutishauser U, 1990, Adv Exp Med Biol, V265, P179; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SCHACHTER H, 1988, BIOCHIMIE, V70, P1701, DOI 10.1016/0300-9084(88)90309-4; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SCHLOSSHAUER B, 1988, J NEUROSCI, V8, P580; SERONFERRE M, 1981, ANNU REV PHYSIOL, V43, P141, DOI 10.1146/annurev.ph.43.030181.001041; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; STEGMANN T, 1987, J BIOL CHEM, V262, P17744; STEVENS ME, 1989, EXP CELL RES, V183, P319, DOI 10.1016/0014-4827(89)90392-3; THEILER K, 1974, Z ANAT ENTWICKLUNGS, V144, P195, DOI 10.1007/BF00519775; THURIN J, 1985, J BIOL CHEM, V260, P4556; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; VAN MEER G, 1985, BIOCHEMISTRY-US, V24, P3593, DOI 10.1021/bi00335a030; VARKI A, 1983, J BIOL CHEM, V258, P2465; VLASAK R, 1989, J VIROL, V63, P2056, DOI 10.1128/JVI.63.5.2056-2062.1989; VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4; WARING H, 1936, J MICROSC SCI, V78, P329; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	82	124	124	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1991	65	1					65	74		10.1016/0092-8674(91)90408-Q	http://dx.doi.org/10.1016/0092-8674(91)90408-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FF773	1826463	Bronze			2022-12-24	WOS:A1991FF77300009
J	HIGASHIYAMA, S; ABRAHAM, JA; MILLER, J; FIDDES, JC; KLAGSBRUN, M				HIGASHIYAMA, S; ABRAHAM, JA; MILLER, J; FIDDES, JC; KLAGSBRUN, M			A HEPARIN-BINDING GROWTH-FACTOR SECRETED BY MACROPHAGE-LIKE CELLS THAT IS RELATED TO EGF	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FACTOR FAMILY; FACTOR-ALPHA; EXPRESSION; AFFINITY; DNA; ATHEROSCLEROSIS; PURIFICATION; AMPHIREGULIN	Macrophage-like U-937 cells secrete a 22-kilodalton heparin-binding growth factor that is mitogenic for BALB-3T3 fibroblasts and smooth muscle cells, but not endothelial cells. The amino acid sequence predicted from complementary DNA clones indicates that the mitogen is a new member of the epidermal growth factor (EGF) family. This heparin-binding EGF-like growth factor (HB-EGF) binds to EGF receptors on A-431 epidermoid carcinoma cells and smooth muscle cells, but is a far more potent mitogen for smooth muscle cells than is EGF. HB-EGF is also expressed in cultured human macrophages and may be involved in macrophage-mediated cellular proliferation.	CHILDRENS HOSP MED CTR,DEPT SURG RES,BOSTON,MA 02115; CALIF BIOTECHNOL INC,MT VIEW,CA 94043; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037392, P01CA045548, R37CA037392, R56CA037392] Funding Source: NIH RePORTER; NCI NIH HHS [CA45548, CA37392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQEL NM, 1985, J PATHOL, V146, P197, DOI 10.1002/path.1711460306; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GREGORY H, 1975, NATURE, V257, P235; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HIGASHIYAMA S, UNPUB; IBERG N, 1989, J BIOL CHEM, V264, P19951; KIMBALL ES, 1984, BIOCHIM BIOPHYS ACTA, V771, P82, DOI 10.1016/0005-2736(84)90113-5; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MINTA JO, 1985, AM J PATHOL, V119, P111; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SINGH JP, 1987, METHOD ENZYMOL, V147, P13; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	39	1075	1142	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 22	1991	251	4996					936	939		10.1126/science.1840698	http://dx.doi.org/10.1126/science.1840698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EY629	1840698				2022-12-24	WOS:A1991EY62900044
J	SILVA, LR; AMITAI, Y; CONNORS, BW				SILVA, LR; AMITAI, Y; CONNORS, BW			INTRINSIC OSCILLATIONS OF NEOCORTEX GENERATED BY LAYER-5 PYRAMIDAL NEURONS	SCIENCE			English	Article							RAT CEREBRAL-CORTEX; CAT VISUAL-CORTEX; HIPPOCAMPAL SLICE; N-METHYLASPARTATE; INVITRO; RESPONSES; RECEPTOR; TRANSMITTERS; POTENTIALS; CELLS	Rhythmic activity in the neocortex varies with different behavioral and pathological states and in some cases may encode sensory information. However, the neural mechanisms of these oscillations are largely unknown. Many pyramidal neurons in layer 5 of the neocortex showed prolonged, 5- to 12-hertz rhythmic firing patterns at threshold. Rhythmic firing was due to intrinsic membrane properties, sodium conductances were essential for rhythmicity, and calcium-dependent conductances strongly modified rhythmicity. Isolated slices of neocortex generated epochs of 4- to 10-hertz synchronized activity when N-methyl-D-aspartate receptor-mediated channels were facilitated. Layer 5 was both necessary and sufficient to produce these synchronized oscillations. Thus, synaptic networks of intrinsically rhythmic neurons in layer 5 may generate or promote certain synchronized oscillations of the neocortex.	BROWN UNIV,DIV BIOL & MED,NEUROBIOL SECT,PROVIDENCE,RI 02912	Brown University			Connors, Barry/AAX-1975-2020; Amitai, Yael/G-2791-2013	Amitai, Yael/0000-0001-6664-8705; Connors, Barry/0000-0002-3739-3157				AGMON A, 1989, NEUROSCI LETT, V99, P137, DOI 10.1016/0304-3940(89)90278-4; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; ALVING BO, 1968, J GEN PHYSIOL, V51, P29, DOI 10.1085/jgp.51.1.29; ANDERSON WW, 1986, BRAIN RES, V398, P215, DOI 10.1016/0006-8993(86)91274-6; ARMSTRONGJAMES M, 1988, BRAIN RES, V451, P189, DOI 10.1016/0006-8993(88)90763-9; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; CHAGNACAMITAL Y, 1990, J COMP NEUROL, V296, P598, DOI 10.1002/cne.902960407; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CONNORS BW, 1984, NATURE, V310, P685, DOI 10.1038/310685a0; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FREEMAN WJ, 1985, BRAIN RES REV, V10, P147, DOI 10.1016/0165-0173(85)90022-0; FREEMAN WJ, 1988, BRAIN RES, V422, P627; GETTING PA, 1989, METHODS NEURONAL MOD, P171; GORMAN ALF, 1982, J PHYSIOL-LONDON, V333, P681, DOI 10.1113/jphysiol.1982.sp014475; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRILLNER S, 1987, TRENDS NEUROSCI, V10, P34, DOI 10.1016/0166-2236(87)90123-8; GUTNICK MJ, 1982, J NEUROPHYSIOL, V48, P1321, DOI 10.1152/jn.1982.48.6.1321; HAGIWARA S, 1983, TRENDS NEUROSCI, V6, P189, DOI 10.1016/0166-2236(83)90084-X; HEGSTAD E, 1989, EPILEPSY RES, V3, P174, DOI 10.1016/0920-1211(89)90046-6; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; JONES KA, 1988, J NEUROSCI, V8, P3522; Kooi K., 1978, FUNDAMENTALS ELECTRO; KRISTIANSEN K, 1949, ELECTROEN CLIN NEURO, V1, P265, DOI 10.1016/0013-4694(49)90191-1; LLINAS R, 1989, Society for Neuroscience Abstracts, V15, P660; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Lopes da Silva F.H., 1978, ARCHITECTONICS CEREB, P319; LOTURCO JJ, 1990, NEUROSCI LETT, V114, P265, DOI 10.1016/0304-3940(90)90574-S; MASON A, 1990, J NEUROSCI, V10, P1415; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; SCHWINDT PC, 1989, J NEUROPHYSIOL, V61, P233, DOI 10.1152/jn.1989.61.2.233; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; STANTON PK, 1987, EPILEPSY RES, V1, P53, DOI 10.1016/0920-1211(87)90051-9; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; SUTOR B, 1987, PFLUG ARCH EUR J PHY, V410, P102, DOI 10.1007/BF00581902; SUTOR B, 1989, J NEUROPHYSIOL, V61, P621, DOI 10.1152/jn.1989.61.3.621; THOMSON AM, 1986, J PHYSIOL-LONDON, V370, P531, DOI 10.1113/jphysiol.1986.sp015949; THOMSON AM, 1985, NATURE, V313, P479, DOI 10.1038/313479a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; YAROM Y, 1989, EXPT BRAIN RES SERIE, V17, P209	43	535	540	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 25	1991	251	4992					432	435		10.1126/science.1824881	http://dx.doi.org/10.1126/science.1824881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU504	1824881				2022-12-24	WOS:A1991EU50400042
